{"nugget_id":"doc_6940fe2eb68d_chunk_0000_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Крупные частные сделки: объявлены mega private deals суммарно более $800M; значительная часть связана с лицензированием China assets.","text_en":"Large private financings: mega private deals totaling over $800M; several tied to licensing China assets.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0000","quote":"There were a bunch of mega private deals announced, in fact, for which were amounted to over 800 million."},{"chunk_id":"doc_6940fe2eb68d_chunk_0000","quote":"Three of those four were a China play of licensing China assets"}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0000_n2","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Фарма усиливает присутствие в венчурной экосистеме через поддержку независимых фондов (пример: сотрудничество Lilly и A16Z по новому фонду).","text_en":"Pharma is increasing involvement in venture via backing independent funds (e.g., Lilly and A16Z collaborating on a new fund).","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0000","quote":"Lilly and A16Z collaborated on a new fund"},{"chunk_id":"doc_6940fe2eb68d_chunk_0000","quote":"a sign of kind of the way pharma is looking at getting better play into the venture world"}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0000_n3","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"Широкий рынок biotech демонстрирует заметную недоходность относительно tech и S&P за последние годы, что делает пассивные инвестиции в biotech менее привлекательными.","text_en":"Broad biotech has underperformed versus tech and the S&P over recent years, making passive biotech exposure less attractive.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0000","quote":"the theme was basically just biotech's underperformance."},{"chunk_id":"doc_6940fe2eb68d_chunk_0000","quote":"over the last five years. Biotech is down 5%. Tech is up almost 200%, and the S&P is up 80%."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0001_n1","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"Биотех/сектор существенно недопроизводит и не выигрывает от снижения ставок, в отличие от tech, несмотря на длинные таймлайны индустрии.","text_en":"Biotech/sector has significantly underperformed and hasn’t benefited from falling rates unlike tech, despite long industry timelines.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0001","quote":"But our underperformance has been significant."},{"chunk_id":"doc_6940fe2eb68d_chunk_0001","quote":"rates were one of the big things that have held our industry back because our timelines are so long."},{"chunk_id":"doc_6940fe2eb68d_chunk_0001","quote":"as rates have come down... tech outperformance and it really hasn't, we really haven't benefited from that at all."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0001_n2","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Рост роли Китая в биотех-индустрии: значимая доля in-licensing новых молекул у big pharma и рост upfronts в пользу китайских компаний по сравнению с нулём 5 лет назад.","text_en":"China’s growing impact: big pharma in-licensing and upfronts shifting toward China vs. near-zero five years ago.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0001","quote":"last year, big pharma in licensing new molecules, one third of them came from China. Compared to zero five years ago."},{"chunk_id":"doc_6940fe2eb68d_chunk_0001","quote":"Over the last year, the number of upfronts that went to China companies was six billion"}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0001_n3","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Если тренд усиления Китая продолжится, небольшие биотехи и discovery-работа в США окажутся «в большой беде», с влиянием на рабочие места и деньги; уже упоминаются layoffs в США.","text_en":"If the China trend continues, smaller biotechs and discovery work in the US are in trouble, impacting jobs and capital; layoffs are being seen.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0001","quote":"We've also seen layoffs from US companies over the last week."},{"chunk_id":"doc_6940fe2eb68d_chunk_0001","quote":"smaller, that discovery work and smaller biotech companies are in big trouble if this trend continues."},{"chunk_id":"doc_6940fe2eb68d_chunk_0001","quote":"It will have a real impact on jobs and money."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0002_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Растёт публичное обсуждение и вовлечённость вокруг темы (судя по «off the charts» engagement на твитах), и всё больше людей начинают воспринимать это как проблему.","text_en":"Public discussion and engagement around the issue is rising, with “off the charts” engagement indicating many people are starting to feel and think about it as a problem.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0002","quote":"\"The engagement on those tweets is off the charts, so it's clear that this is an issue that uh A lot of people are.\""}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0002_n2","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Появляются политические/регуляторные ограничения на взаимодействие с Китаем: обсуждается запрет клинических исследований в военных госпиталях Китая и ожидается, что партнёриться с китайскими компаниями станет сложнее.","text_en":"Political/regulatory constraints on China interactions are emerging, including calls to avoid trials at Chinese military hospitals and expectations that partnering with Chinese companies will get harder.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0002","quote":"\"there was a a letter today from Congress people saying that the U. S. biotech sector shouldn't do clinical trials at military hospitals in China.\""},{"chunk_id":"doc_6940fe2eb68d_chunk_0002","quote":"\"it's going to be really hard to partner with China companies\""}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0002_n3","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Наблюдается активность сделок/лицензирования в DLL3 (ADC и другие модальности), включая сделки с участием активов из Китая.","text_en":"There is active deal/licensing activity in DLL3 (ADCs and other modalities), including recent deals involving assets from China.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0002","quote":"\"We did see a couple of deals. Both on DLL3.\""},{"chunk_id":"doc_6940fe2eb68d_chunk_0002","quote":"\"people are going out there and licensing these assets.\""},{"chunk_id":"doc_6940fe2eb68d_chunk_0002","quote":"\"some of it, the latest ones came from China.\""}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0003_n1","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Высокие ставки (5–6%) делают безрисковую доходность привлекательной и оттягивают капитал из рискованных активов, включая biotech.","text_en":"High interest rates (5–6%) make low-risk returns attractive, pulling capital away from risky assets including biotech.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0003","quote":"rates are at 5%, 6%. That's a very easy way to just park your money and not put it into risky assets."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0003_n2","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Регуляторное давление на цены усиливается: IRA вводит гос. price setting, что создаёт структурный «headwind» для индустрии.","text_en":"Pricing/regulatory pressure is increasing: the IRA introduces government price setting, creating a structural headwind for the industry.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0003","quote":"we had the Inflation Reduction Act. Unprecedented— the first time ever that price setting from at least from the government standpoint has entered the picture."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0003_n3","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Появился новый конкурентный фактор: Китай как «world competitor», который, по словам спикера, делает discovery быстрее и дешевле.","text_en":"A new competitive factor has emerged: China as a world competitor reportedly doing discovery faster and cheaper.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0003","quote":"we have this world competitor that's apparently doing things faster and cheaper than we're able to do on a discovery side."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0004_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Появился новый фактор конкуренции: Китай как мировой конкурент в discovery, который делает быстрее и дешевле, чем «мы».","text_en":"A new competitive factor: China as a global discovery competitor doing things faster and cheaper than “we” can.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0004","quote":"we have this world competitor that's apparently doing things faster and cheaper than we're able to do on a discovery side."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0004_n2","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"В биотехе отмечают встречный ветер: недостаток M&A, что снижает оптимизм и поддержку оценок.","text_en":"A headwind in biotech: lack of M&A, which reduces optimism and support for biotech valuations.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0004","quote":"one other headwind: on this is the lack of M&A."},{"chunk_id":"doc_6940fe2eb68d_chunk_0004","quote":"that is usually a bolster of people getting a little bit more sanguine and excited about valuations in biotech."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0004_n3","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"AI находится на ранней стадии влияния (включая drug discovery), и биотех конкурирует за капитал с техом, где деньги могут делаться быстрее.","text_en":"AI’s impact is still early (including on drug discovery), and biotech competes for capital with tech where money may be made faster.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0004","quote":"we're only at the very beginnings of the impact of AI on anything, even including drug discovery."},{"chunk_id":"doc_6940fe2eb68d_chunk_0004","quote":"our sector competes for money with others."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0005_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"На ближайшем JPM ожидают мало сделок/мегасделок, а IPO продолжают сдвигаться.","text_en":"For the upcoming JPM, few deals/mega-deals are expected, and IPOs keep getting pushed out.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0005","quote":"We're not expecting a lot of deals. We're not expecting mega deals. And the IPOs have all been— you know, getting pushed out."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0005_n2","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"Рынок реагирует так, что акции падают даже при наличии данных, независимо от того, позитивные они или негативные.","text_en":"The market is such that stocks go down even when data is released, regardless of whether it’s positive or negative.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0005","quote":"Where if you have data, the stock goes down, and it doesn't matter if the data is positive or negative."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0005_n3","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Сектор находится под стрессом, когда под вопросом доступ (access); также нужно «пережить» ближайшие 1–2 года из‑за процентных ставок.","text_en":"The sector is under stress when access is questioned; it also needs to get through the next 1–2 years due to interest rates.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0005","quote":"Typically, when access is questioned, the sector is under stress"},{"chunk_id":"doc_6940fe2eb68d_chunk_0005","quote":"We just need to deal with the next year or two on interest rates."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0006_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Ожидания по M&A в секторе ниже: в этом году ожидается отсутствие M&A, и Exelixis, по мнению спикера, не будет приобретена.","text_en":"Lower M&A expectations: speaker expects no M&A this year and believes Exelixis will not be acquired.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0006","quote":"Exelixis, which is expected to get, it was hoped to get acquired. We don't think they'll get acquired."},{"chunk_id":"doc_6940fe2eb68d_chunk_0006","quote":"Last year, we're probably not expecting the same strength, absence of M &A. This year."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0006_n2","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"Конкуренция и ценовое давление осложняют продажи Skytropha (еженедельный гормон роста).","text_en":"Competition and pricing pressure are hurting Skytropha (weekly growth hormone).","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0006","quote":"last year, year was a tough year for that brand because the competition from Novo and a lot of pricing pressures."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0006_n3","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Сроки получения данных по исследованию зависят от выживаемости; на ClinicalTrials.gov указаны данные в 2026, но это не гарантировано.","text_en":"Trial readout timing depends on survival; ClinicalTrials.gov lists 2026 data but it’s uncertain.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0006","quote":"CT . gov talks about data in 2026, but it depends on survival, obviously, in that study."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0007_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Крупная фарма в этом году ощутит заметный финансовый эффект от IRA/Part D redesign; Pfizer публично оценил удар по выручке.","text_en":"Large pharma will feel a notable IRA/Part D redesign impact this year; Pfizer publicly quantified the hit to revenue.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0007","quote":"This is the year that large pharma is going to get it squarely in the face with regards to the impact on the Part D redesign."},{"chunk_id":"doc_6940fe2eb68d_chunk_0007","quote":"So that's a 1. 6% hit to the top line. So that's from the Part D redesign."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0007_n2","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Большинство других фармкомпаний, вероятно, не будут раскрывать детальную оценку влияния Part D redesign, что усложнит внешнюю оценку эффекта.","text_en":"Most other pharma companies likely won’t disclose granular Part D redesign impact, making external assessment harder.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0007","quote":"our expectation is actually not that they'll— but that most of them will not tell us how much."},{"chunk_id":"doc_6940fe2eb68d_chunk_0007","quote":"they've told us we don't think we're going to go to the same granularity as Pfizer did."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0007_n3","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Есть неопределённость/вариативность в том, насколько процесс выбора препаратов в рамках IRA может зависеть от смены администрации и политических назначенцев.","text_en":"Uncertainty/variability exists in how IRA drug selection may be influenced by administration change and political appointees.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0007","quote":"Do we know how much of that process can be influenced, either positively or negatively, by political appointees?"},{"chunk_id":"doc_6940fe2eb68d_chunk_0007","quote":"there is a process of selecting the drugs—right? ... there is a choice that's made that needs to be brokered."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0008_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Наблюдается волна уходов из FDA на уровне senior-позиций (включая комиссара FDA и главу CDER), что участники обсуждения внимательно отслеживают.","text_en":"There appears to be a wave of senior-level departures from the FDA (including the FDA commissioner and head of CDER), which participants are closely tracking.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0008","quote":"it's beginning to feel like this is not a good cadence of exits out of the FDA. At the senior positions."},{"chunk_id":"doc_6940fe2eb68d_chunk_0008","quote":"the FDA commissioner and the head of CDER are leaving."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0008_n2","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"В FDA отмечаются «inefficiency, inconsistencies, uncertainty» и постоянное напряжение между иерархией/политикой и дивизионами, влияющее на принятие решений.","text_en":"The FDA is described as having inefficiency, inconsistencies, and uncertainty, with ongoing tension between hierarchy/policy and divisions affecting decisions.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0008","quote":"I don't think that anybody would agree that there's not some inefficiency, some inconsistencies, uncertainty"}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0008_n3","doc_id":"doc_6940fe2eb68d","kind":"buyer_signal","text_ru":"Компании с долгим горизонтом до данных (например, «end of 27») могут быть наказаны рынком, особенно если «presumably will need to raise money».","text_en":"Markets may penalize companies with long timelines to data (e.g., end of 2027), especially if they presumably need to raise money.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0008","quote":"they're not going to have data until probably the end of 27."},{"chunk_id":"doc_6940fe2eb68d_chunk_0008","quote":"any company that, then, presumably will need to raise money gets penalized."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0009_n1","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"В текущем рынке компании, которым нужно привлекать капитал и у которых данные не дифференцированы/есть задержка, могут сильно наказываться рынком (падение акций).","text_en":"In the current market, companies needing to raise capital with non-differentiated data/lagging timelines can be heavily punished by the market (stock drops).","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0009","quote":"\"we're just in a tough market right now where, you know, companies are probably gonna think twice. Do they really need to raise?\""},{"chunk_id":"doc_6940fe2eb68d_chunk_0009","quote":"\"the bottom line there is that they're not differentiated.\""},{"chunk_id":"doc_6940fe2eb68d_chunk_0009","quote":"\"that stock is down 60%, even though the data, I would say, would look in line.\""}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0009_n2","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Длительные сроки запуска исследования (4–6 месяцев) и позднее получение данных (до конца 2027) создают временной барьер и могут приводить к штрафу со стороны рынка для компаний, которым нужно финансирование.","text_en":"Long study start timelines (4–6 months) and late data readouts (likely end of 2027) create a timing constraint and can lead to market penalties for companies needing funding.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0009","quote":"\"Know it takes four to six months to start a study\""},{"chunk_id":"doc_6940fe2eb68d_chunk_0009","quote":"\"they're not going to have data until probably the end of 27.\""},{"chunk_id":"doc_6940fe2eb68d_chunk_0009","quote":"\"any company that, then, presumably will need to raise money gets penalized.\""}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0009_n3","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Компании могут откладывать публикацию данных, если нет юридической обязанности, из‑за рыночной реакции/волатильности.","text_en":"Companies may delay releasing data unless legally required, due to market reaction/volatility.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0009","quote":"\"Do they need to really release data if they have, unless they, you know, obviously legally obligated to do so, they might as well wait.\""}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0010_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Растёт конкуренция в кардиометаболическом/анти-ожирительном сегменте, рынок активно наблюдают.","text_en":"Competition is heating up in the cardiometabolic/anti-obesity segment, and the market is being closely watched.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0010","quote":"\"just a fascinating market sector to watch, especially with the competition heating up.\""}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0010_n2","doc_id":"doc_6940fe2eb68d","kind":"buyer_signal","text_ru":"Есть потребительский спрос на препараты для снижения веса/контроля веса (люди обсуждают, стоит ли начать принимать препараты после набора веса).","text_en":"There is consumer demand for weight-loss/weight-control drugs (people discuss starting them after weight gain).","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0010","quote":"\"I've been having some emails from friends telling me after Christmas, Sam, do you think we should go on to Zeb Barons or we go V?\""}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0010_n3","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Структура опционного лицензионного/коллаборационного соглашения с Gilead могла затруднять Galapagos продвижение проектов дальше фазы 1 и заключение сделок.","text_en":"The option/license/collaboration structure with Gilead may have made it difficult for Galapagos to progress beyond Phase 1 and do deals.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0010","quote":"\"it became very difficult for them to do anything. In anything beyond phase one\""}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0011_n1","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"Инвесторы негативно восприняли CAR‑T приобретение Galapagos и недовольны тем, что это стало первым крупным M&A и операционным фокусом компании.","text_en":"Investors disliked Galapagos’ CAR‑T acquisition and were unhappy it became the first major acquisition and operational focus.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0011","quote":"I think that investors hated the CAR T acquisition."},{"chunk_id":"doc_6940fe2eb68d_chunk_0011","quote":"investors were not wild that that was like the first major acquisition of that company and that it's been the focus operationally"}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0011_n2","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Модель персонализированного производства CAR‑T в больницах требует масштабирования до национального и глобального уровня, что является существенным барьером.","text_en":"Hospital-based personalized CAR‑T manufacturing requires national and global scale-out, a major constraint.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0011","quote":"The idea is to do kind of personalized manufacturing at hospitals and in cities."},{"chunk_id":"doc_6940fe2eb68d_chunk_0011","quote":"it's going to require like a a huge, literally national and global scale out."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0011_n3","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"CAR‑T сейчас «не в фаворе» у стартапов/рынка, что указывает на временное снижение интереса к сектору.","text_en":"CAR‑T is currently out of favor among startups/market sentiment, indicating reduced interest in the sector.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0011","quote":"CAR T is just kind of out of favor right now in terms of startups."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0012_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Структурные изменения/разделение компании рассматриваются как способ привлечь разные базы инвесторов, но эффект может быть незначительным.","text_en":"Company splits/structural changes are seen as a way to attract different investor bases, though impact may be limited.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0012","quote":"sometimes these are just. Uh structure changes that don't have a real big impact, but sometimes there's always the hope that it will uh to be able to attract different investor bases."}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0012_n2","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Рынок резко реагирует на ранние данные: акции Janix упали более чем на 30% от пика после первоначального ажиотажа вокруг данных.","text_en":"Market reacts sharply to early data: Janix shares are down just over 30% from the post-data excitement peak.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0012","quote":"Janix's share price, which is down about just over 30% from the peak that it was at after the excitement for the data"}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0012_n3","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Сравнение эффективности между программами masked T-cell engager затруднено из‑за ранней стадии и малых выборок; идёт эскалация доз.","text_en":"Efficacy comparisons between masked T-cell engager programs are hard due to early stage and small numbers; dose escalation is ongoing.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0012","quote":"There's still dose escalation going on."},{"chunk_id":"doc_6940fe2eb68d_chunk_0012","quote":"these are very difficult comparisons to make on such small numbers."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0013_n1","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Сравнения данных/графиков на малых выборках трудно интерпретировать.","text_en":"Comparisons on small numbers are difficult to interpret.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0013","quote":"these are very difficult comparisons to make on such small numbers."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0013_n2","doc_id":"doc_6940fe2eb68d","kind":"pain","text_ru":"Есть вопросы/неопределённость по безопасности при более высоких дозах (вплоть до 2 мг/кг) для CD3 engager: нужно ли повышать дозу и сохранится ли безопасность.","text_en":"Uncertainty about safety at higher dosing (up to 2 mg/kg) for a CD3 engager: why such high dose and whether safety holds.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0013","quote":"when you get to that higher end, are you going to have the same safety? Lots of questions"}],"confidence":"medium"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0013_n3","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"По H5N1 отмечено: мутаций, позволяющих передачу от человека к человеку, очень мало, и нет доказательств такой передачи.","text_en":"For H5N1: mutations enabling human-to-human transmission are very low frequency, and there is no evidence of such transmission.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0013","quote":"the frequency of H5N1 virus that had any kind of mutation that would allow it to transmit from human to human was very, very low."}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0014_n1","doc_id":"doc_6940fe2eb68d","kind":"trend","text_ru":"Фарма-компании активно занимаются внешними инновациями и ищут ранние инвестиции; модель сотрудничества с венчурными фирмами может масштабироваться.","text_en":"Pharma companies are pursuing external innovation and early-stage investments; partnering with venture firms may become a broader model.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0014","quote":"there's been a lot of pharma companies doing external innovation and trying to find early-stage investments."},{"chunk_id":"doc_6940fe2eb68d_chunk_0014","quote":"Lilly and maybe other pharma companies might follow that type of model to work with a firm"}],"confidence":"high"}
{"nugget_id":"doc_6940fe2eb68d_chunk_0014_n2","doc_id":"doc_6940fe2eb68d","kind":"constraint","text_ru":"Существует риск (и надежда его избежать) появления передачи H5N1 от человека к человеку.","text_en":"There is concern about potential human-to-human transmission of H5N1, with hope it does not occur.","evidence":[{"chunk_id":"doc_6940fe2eb68d_chunk_0014","quote":"fingers crossed that we never see human-to-human transmission from this H5N1 virus."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0000_n1","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"Сентимент в биотехе/среди клиентов и компаний оценивается как умеренно слабый; акции были сильно под давлением, несмотря на M&A.","text_en":"Biotech sentiment among clients/companies is middling-weak; stocks have been hit hard despite M&A.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0000","quote":"I felt sentiment amongst... the client base there and companies... was uh about a five out of ten."},{"chunk_id":"doc_6c015dd8786f_chunk_0000","quote":"stocks were hit pretty hard going into December and into January... But despite the M&A... it was pretty rough."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0000_n2","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"Окно IPO описывается как «довольно жёсткое/тяжёлое», и ожидается, что пройдёт время, прежде чем IPO начнут успешно прайситься и торговаться после размещения.","text_en":"The IPO window is described as tough; it may take a while before IPOs price and perform well post-market.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0000","quote":"I've been hearing it's pretty tough and that... It's going to be a while until we see a bunch of IPOs price and do well"}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0000_n3","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Частные биотех-компании чаще продаются (M&A) вместо выхода на IPO, что связывается с трудными условиями на рынке капитала.","text_en":"Private biotechs are being acquired instead of going public, linked to tough capital market conditions.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0000","quote":"two private biotech get taken out on Sunday... trying to go public... given the state of the conditions... get acquired instead."},{"chunk_id":"doc_6c015dd8786f_chunk_0000","quote":"a number of private companies... were getting acquired over the last six months... the capital market is a little tough."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0001_n1","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"За последние ~6 месяцев наблюдалась волна M&A: ряд частных компаний приобретались, что связывают с «тяжёлым» рынком капитала.","text_en":"Over the last ~6 months, multiple private companies were acquired, attributed to a tough capital market.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0001","quote":"\"a number of private companies... were getting acquired over the last six months. As a reflection of the fact that the capital market is a little tough.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0001_n2","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"Рынок капитала остаётся сложным и «дискриминирующим» до появления лучшей видимости по процентным ставкам; неопределённость политики также влияет на настроения.","text_en":"Capital markets remain tough/discriminatory until there’s better visibility on interest rates; policy uncertainty affects sentiment.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0001","quote":"\"it's been a tough capital market environment, and it will almost certainly remain discriminatory until we get better visibility on interest rates\""},{"chunk_id":"doc_6c015dd8786f_chunk_0001","quote":"\"a lot of uncertainty around the policy environment\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0001_n3","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"Участники рынка и клиентская база продолжают искать индикатор/индекс, который адекватно отражает сектор biotech; существующие корзины/индексы (например, XBI) считаются несовершенными.","text_en":"Market participants/clients are looking for a better biotech sector indicator; existing baskets/indexes (e.g., XBI) are not great.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0001","quote":"\"we and our client base continue to look for a great indicator that well reflects the biotech sector. There are not great\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_nugget_0001","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"На конференции наблюдалась сильная поляризация динамики акций («haves and have-nots»): много победителей и много проигравших, что в сумме дало около +1% по XBI.","text_en":"At the conference, stock performance was highly polarized (“haves and have-nots”): many winners and many losers, netting to about +1% for XBI.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0002","quote":"\"It was definitely a a bunch of baskets of haves and have-nots. There were great numbers of winners... but also a ton of losers.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_nugget_0002","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Снижение/негатив по акциям связывают с даунгрейдами и гайденсом (упомянуты Moderna и Lilly), что «dragged a whole bunch of stocks down».","text_en":"Stock weakness/negative sentiment is attributed to downgrades and guidance (Moderna and Lilly mentioned), which “dragged a whole bunch of stocks down.”","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0002","quote":"\"on the back of the downgrades and the guidance... was Moderna and then Lilly, which didn't help and it dragged a whole bunch of stocks down.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_nugget_0003","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"Макроусловия (\"higher for longer\" ставки) и состав участников торгов (в основном биотех-фонды/хедж-фонды, меньше «больших денег») ограничивают устойчивый рост: сделки были, но «no follow through».","text_en":"Macro conditions (“higher for longer” rates) and trading dominated by biotech funds/hedge funds (less “bigger money”) limit sustained upside: deals happened but there was “no follow through.”","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0002","quote":"\"higher for longer interest rate environment... the macro has the steering wheel.\""},{"chunk_id":"doc_6c015dd8786f_chunk_0002","quote":"\"there was no follow through.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_nugget_0001","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Снижение ожиданий M&A/«takeout» в биотехе: компании, которые считались кандидатами на поглощение, заметно упали, потому что поглощения не произошло.","text_en":"Lower M&A/takeout expectations in biotech: companies thought to be takeouts traded down significantly when takeouts didn’t happen.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0003","quote":"a number of companies that were quote unquote supposed to be takeouts. All traded significantly down because, oh, I guess they're not getting taken out."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_nugget_0002","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"Недостаток поддержки со стороны generalist-инвесторов: рынок/капитал больше сфокусирован на tech, а не на biotech.","text_en":"Lack of generalist investor support: market attention/capital is more focused on tech than biotech.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0003","quote":"the lack of generalist support—has continued to be much more focused on tech... and much less focused on biotech."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_nugget_0003","doc_id":"doc_6c015dd8786f","kind":"opportunity","text_ru":"Возможность для небольших компаний в ожирении/GLP-1: успешное продвижение препарата в Phase 2/3 может создать ценность, но чувствительным фактором будет стартовая оценка/valuation.","text_en":"Opportunity for small obesity/GLP-1 companies: successful Phase 2/3 progress can create value, but initial valuation is highly sensitive.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0003","quote":"if a small company with the GLP-1... have a successful drug that moves forward to phase two and phase three. then that will create value."},{"chunk_id":"doc_6c015dd8786f_chunk_0003","quote":"It's just all going to come down to... What is the valuation to start?"}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0004_n1","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Наблюдается, что многие люди/коллеги используют новые препараты от ожирения (заметно по упоминаниям и изменению веса).","text_en":"People/colleagues are increasingly using new obesity medications, noticeable via mentions and weight loss.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0004","quote":"a lot of their colleagues have looked like they've lost weight and have mentioned that they're on some of these new obesity meds."}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0004_n2","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"В CNS/нейронауках за последний год было несколько многомиллиардных M&A сделок; обсуждаемая сделка — крупнейшая со времён Karuna BMS.","text_en":"CNS/neuroscience has seen multiple multi-billion M&A deals in the last year; this deal is the largest since Karuna BMS.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0004","quote":"This would be the largest acquisition of a biotech company since the Karuna BMS deal and the fourth multi-billion-dollar acquisition of a CNS drug developer in the last year or so."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0004_n3","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"2024 год для нейро/нейронаучных компаний описывается как «американские горки»: позитив по M&A/одобрениям и интересу фармы, но были и неудачи по данным.","text_en":"2024 was a roller coaster for neuroscience companies: positive M&A/approvals and pharma interest, but also data setbacks.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0004","quote":"2024 was a bit of a roller coaster for companies in the neuroscience space."},{"chunk_id":"doc_6c015dd8786f_chunk_0004","quote":"interest by pharma companies being very positive, juxtaposed with some setbacks with regard to data"}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0005_n1","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"Клинические исследования в нейропсихиатрии описываются как очень сложные: проблемы с отбором пациентов, подбором дозы, плацебо-ответом и комплаенсом.","text_en":"Clinical studies in neuropsychiatry are described as very difficult: issues with patient selection, dose selection, placebo response, and compliance.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0005","quote":"clinical studies in this space are very difficult. They're challenging."},{"chunk_id":"doc_6c015dd8786f_chunk_0005","quote":"patient selection must make sure that you have patients that actually have depression"},{"chunk_id":"doc_6c015dd8786f_chunk_0005","quote":"Dose selection is a huge issue... you're going to get higher placebo response"}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0005_n2","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"Указывается очень высокий уровень неудач при переходе от доклиники к клиническому proof of concept в этой области.","text_en":"A very high failure rate is cited from preclinical to clinical proof of concept in this area.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0005","quote":"Something like 93% failure goes from preclinical to clinical proof of concept."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0005_n3","doc_id":"doc_6c015dd8786f","kind":"opportunity","text_ru":"Отмечается, что ряд препаратов продвинут и могут сильно помочь пациентам, но имеют проблему, которую теперь можно решить с помощью современных технологий; также упоминается пример Xenomalin и CARX-T.","text_en":"Some advanced drugs could make a major difference but have an issue that can now be solved with today’s technology; Xenomalin and CARX-T are cited as an example.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0005","quote":"could make a major difference for patients. But have some issue that we can now solve with today's technology."},{"chunk_id":"doc_6c015dd8786f_chunk_0005","quote":"Xenomalin was a perfect example that, with the advancement of CARX-T"}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0006_n1","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"IPO-рынок в биотехе выглядит «challenged», поэтому компании, которые могли бы выйти на IPO, чаще выбирают выход через M&A; pharma активно этим пользуется.","text_en":"The biotech IPO market is described as challenged, so companies that might have IPO’d are opting for M&A exits; pharma is actively taking advantage.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0006","quote":"\"the IPO market is a little bit challenged. And therefore they look to the exit of M &A. And pharma has been all over this.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0006_n2","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Pharma смещается к меньшим «tuck-in» сделкам с частными компаниями, поскольку публичные M&A-таргеты всем известны и воспринимаются как переоценённые.","text_en":"Pharma is shifting toward smaller tuck-in deals with private companies because public M&A targets are well-known and seen as overvalued.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0006","quote":"\"Everybody knows the M&A targets and they're all overvalued.\""},{"chunk_id":"doc_6c015dd8786f_chunk_0006","quote":"\"they ended up going smaller, tuck in.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0006_n3","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"За последние 3–6 месяцев усилился тренд на China-formed компании/активы: их находят/лицензируют и переносят в US или в pharma-структуры.","text_en":"Over the last 3–6 months, there’s been a trend of China-formed companies/assets being found or licensed and brought to the US or into pharma structures.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0006","quote":"\"a whole lot of China-formed companies\""},{"chunk_id":"doc_6c015dd8786f_chunk_0006","quote":"\"that is definitely a big trend that's happened in the last, say, three to six months.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0007_n1","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Фарма всё активнее лицензирует/сourcing внешние молекулы из Китая; это стало заметным трендом в последние месяцы и усилило конкуренцию.","text_en":"Pharma is increasingly sourcing/licensing external molecules from China; this has become a notable recent trend and increased competition.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0007","quote":"Pharma is now sourcing nearly a third of external molecules from China."},{"chunk_id":"doc_6c015dd8786f_chunk_0007","quote":"that is definitely a big trend that's happened in the last, say, three to six months."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0007_n2","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"Регуляторный барьер: FDA отклонила препарат из-за критики данных только из Китая, что создало негативные последствия для компаний/сделок.","text_en":"Regulatory barrier: FDA rejection due to criticism of China-only data, creating negative fallout for companies/deals.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0007","quote":"rejected by FDA due to FDA criticism of China only data"}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0007_n3","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"Опасения из‑за быстрых «fast follower» конкурентов из Китая; звучит рекомендация скрывать данные и быть неоднозначными в патентах для защиты.","text_en":"Concern about fast-follower Chinese competitors; advice to avoid publishing data and keep patent filings ambiguous for protection.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0007","quote":"warning companies not to publish any data on new mechanism drugs and be very ambiguous in patent filings"}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0008_n1","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Китай много лет заявляет цель стать мировым центром компетенций в биотехнологиях; при этом США с союзниками продолжают лидировать, но подчёркивается необходимость сохранять и наращивать лидерство.","text_en":"China has long stated its intent to become the world’s biotech center of excellence; the U.S. and allies still lead but must maintain and advance that lead.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0008","quote":"China has stated, now for many years, that they intend to become the world's center of excellence in biotechnology."},{"chunk_id":"doc_6c015dd8786f_chunk_0008","quote":"The United States, together with our allies, continues to lead in biotech."},{"chunk_id":"doc_6c015dd8786f_chunk_0008","quote":"But we have to maintain and advance our lead."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0008_n2","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"Законопроект BioSecure, вероятно, получит сильную двухпартийную поддержку в Палате представителей, но Сенат рассматривается как «roadblock», и принятие закона может зависеть от присоединения к оборонным ассигнованиям в конце года.","text_en":"BioSecure may have strong bipartisan support in the House, but the Senate is seen as a roadblock; passage may depend on being attached to year-end defense appropriations.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0008","quote":"I would expect again to see pretty strong, overwhelming bipartisan support. In the House, the Senate is much more of a challenge"},{"chunk_id":"doc_6c015dd8786f_chunk_0008","quote":"it seems with respect to the biosecure law that the Senate will still be a roadblock."},{"chunk_id":"doc_6c015dd8786f_chunk_0008","quote":"The only likelihood of it actually becoming law... is if it gets tacked on to, probably, a year-end defense appropriation."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0008_n3","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Отмечается стратегическое преимущество Китая в скорости запуска, набора и завершения клинических исследований.","text_en":"China is described as having a strategic advantage in the speed of starting, enrolling, and completing clinical studies.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0008","quote":"the pace at which they can begin, they can enroll, and they can complete their clinical studies. It's really remarkable."},{"chunk_id":"doc_6c015dd8786f_chunk_0008","quote":"And it's a major strategic advantage for them."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0009_n1","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"С точки зрения политики в первые дни сложно существенно ограничить рост биотехнологий в Китае; возможности ограничены.","text_en":"From a policy standpoint early on, there’s limited ability to curb the growth of biotechnology in China.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0009","quote":"\"it's relatively limited in terms of what we can do from a policy standpoint in the early days to limit the growth of biotechnology in China.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0009_n2","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"Текущая клиническая/регуляторная парадигма делает разработку лекарств слишком дорогой, долгой и неопределённой (по мнению 100+ CEO).","text_en":"The current clinical trial/regulatory paradigm makes drug development too expensive, slow, and uncertain (per 100+ emerging company CEOs).","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0009","quote":"\"it simply costs too much money, takes too much time, it's too uncertain to develop our medicines.\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0009_n3","doc_id":"doc_6c015dd8786f","kind":"opportunity","text_ru":"Есть запрос на переосмысление клинических испытаний и реформы процессов (сокращение сроков набора, IRB/университетские контракты, роль CRO, снижение бюрократии в FDA).","text_en":"Opportunity to reimagine clinical trials and reform processes (shorten enrollment timelines, address IRBs/university contracting, CRO role, reduce FDA bureaucracy).","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0009","quote":"\"we have to reimagine the clinical trial. regulatory paradigm.\""},{"chunk_id":"doc_6c015dd8786f_chunk_0009","quote":"\"Condensing enrollment timelines? How do we think about IRBs, university contracting? What's the role of the CRO industry here?\""},{"chunk_id":"doc_6c015dd8786f_chunk_0009","quote":"\"How do we strengthen leadership? How do we reduce bureaucracy?\""}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0010_n1","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"Научные и медицинские разработки компаний опережают способность FDA переваривать/оценивать технологии, из‑за чего система становится медленной и громоздкой.","text_en":"Company science/medicine has outpaced FDA’s ability to evaluate technologies, defaulting to a slow, cumbersome system.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0010","quote":"our science and our medicine coming out of our companies has leapfrogged the FDA's ability to digest and process and evaluate our technologies. And it's defaulted to a very slow and cumbersome system."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0010_n2","doc_id":"doc_6c015dd8786f","kind":"opportunity","text_ru":"Есть запрос на переосмысление клинических испытаний и ускорение разработки через биомаркеры, accelerated approval и адаптивные дизайны (в т.ч. Bayesian).","text_en":"Opportunity to rethink trials and speed development using biomarkers, accelerated approval, and adaptive (Bayesian) trial designs.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0010","quote":"When is it appropriate? To use biomarkers, accelerated approval, adaptive clinical designs, Bayesian statistics"}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0010_n3","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Ожидаются политико‑регуляторные изменения: Конгресс будет пересматривать IRA и проводить слушания по «9 verses 13» для orphan cures; также обсуждается крупный налоговый билль и R&D tax credit.","text_en":"Policy/regulatory activity: Congress to revisit IRA with hearings on “9 verses 13” for orphan cures; large tax bill and R&D tax credit discussed.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0010","quote":"Congress now is going to look at the IRA. I'm confident we're going to have hearings on 9 verses 13. on orphan cures."},{"chunk_id":"doc_6c015dd8786f_chunk_0010","quote":"There's going to be a very large tax bill this year... I do believe that we can address the R&D tax credit."}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0011_n1","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Люди лицензируют активы (например, CAR-T, ADC) из Китая из‑за более высокой скорости получения ранних клинических данных.","text_en":"People are licensing assets (e.g., CAR-Ts, ADCs) from China due to faster generation of early clinical data.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0011","quote":"folks have gone to China for some of the assets that they're licensing, CAR-Ts or ADCs, et cetera, is because of the speed with which they can generate some early clinical data."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0011_n2","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"Скорость проведения клинических испытаний в США отстаёт от других стран (упоминается Китай), особенно для ранних фаз/поиска сигнала.","text_en":"Clinical trial speed in the US lags other countries (China mentioned), especially for early-phase signal-finding studies.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0011","quote":"the speed at which we can do some of these clinical trials... is way ahead of what we're seeing here."},{"chunk_id":"doc_6c015dd8786f_chunk_0011","quote":"speed up the early phase signal finding studies"}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0011_n3","doc_id":"doc_6c015dd8786f","kind":"opportunity","text_ru":"Есть возможность/инициативы ускорять ранние клинические исследования в США через более риск-ориентированный подход, сохраняя выравнивание с регуляторными стандартами США.","text_en":"Opportunity/initiatives to accelerate early clinical trials in the US via a more risk-based approach while aligning with US regulatory standards.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0011","quote":"I think there are some initiatives that are going on... to try and address that in the US."},{"chunk_id":"doc_6c015dd8786f_chunk_0011","quote":"take a look at more of a risk-based approach to really speed up the early phase signal finding studies."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"Ранние signal-finding исследования (в т.ч. cell & gene therapy) в США могут занимать около двух лет, из‑за чего ранние биотехи/академия проигрывают по скорости странам вроде Китая.","text_en":"Early signal-finding studies (incl. cell & gene therapy) in the US can take ~2 years, putting early biotechs/academia behind faster countries like China.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0012","quote":"a cell and gene therapy trial. Signal finding study out of Penn would take about two years"},{"chunk_id":"doc_6c015dd8786f_chunk_0012","quote":"in that time, as an early stage biotech or as an academic, you've got 20 companies that have already done that trial in China"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_6c015dd8786f","kind":"opportunity","text_ru":"Возможность ускорить ранние фазы за счёт переноса части регуляторной нагрузки на локальный review/IRB-процесс и сжатия таймлайнов, ориентируясь на практики других стран.","text_en":"Opportunity to speed early phases by shifting some regulatory burden to local review/IRB processes and condensing timelines, learning from other countries’ systems.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0012","quote":"can we shift some of that regulatory burden of early phase signal finding studies onto more of a local review process that may be much accelerated"},{"chunk_id":"doc_6c015dd8786f_chunk_0012","quote":"There's a role for looking outside the US at other systems and what works, and then bringing that in and modifying our system."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Отмечаются крупные upfront-платежи за доклинические активы (пример: обсуждение «высокого» upfront для preclinical), включая сделки с не‑US компаниями.","text_en":"Noted large upfront payments for preclinical assets, including deals with non-US companies (discussion of a “high” upfront for preclinical).","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0012","quote":"250 million dollars up front for a pre-clinical asset"},{"chunk_id":"doc_6c015dd8786f_chunk_0012","quote":"the 125 is definitely a high number for preclinical"}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0013_n1","doc_id":"doc_6c015dd8786f","kind":"pain","text_ru":"На рынке нет хороших пероральных препаратов (таблеток) для псориаза или атопического дерматита, поэтому все хотят такие решения.","text_en":"There are no great oral pills for psoriasis or atopic dermatitis, so there is strong demand for them.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0013","quote":"everybody wants an oral psoriasis or atopic dermatitis pill because there are not great ones at all."}],"confidence":"high"}
{"nugget_id":"doc_6c015dd8786f_chunk_0013_n2","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Компании заключают сделки с китайскими компаниями (пример: J&J) и сравнивают стоимость/условия таких сделок.","text_en":"Companies are doing deals with Chinese companies (e.g., J&J), with attention to deal size/terms.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0013","quote":"J and J did a deal with the Chinese company for the oral stat six."},{"chunk_id":"doc_6c015dd8786f_chunk_0013","quote":"J and J went to China to do theirs."}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0013_n3","doc_id":"doc_6c015dd8786f","kind":"buyer_signal","text_ru":"Штаты/регионы в США активно хотят развивать у себя биотех и заинтересованы в росте отрасли на своей территории.","text_en":"US states/regions are actively seeking biotech growth in their state.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0013","quote":"Everybody wants biotech in their state."},{"chunk_id":"doc_6c015dd8786f_chunk_0013","quote":"They want it to grow."}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0014_n1","doc_id":"doc_6c015dd8786f","kind":"opportunity","text_ru":"Возможность для emerging biotech компаний демонстрировать свою работу членам Конгресса через визиты в детские больницы и компании в разных городах/штатах.","text_en":"Opportunity for emerging biotech companies to showcase their work to members of Congress via visits to children’s hospitals and companies across cities/states.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0014","quote":"We're going to go to children's hospitals. We're going to go to member companies, you know, emerging biotech companies with members of Congress"}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0014_n2","doc_id":"doc_6c015dd8786f","kind":"trend","text_ru":"Позитивное общественное восприятие биотеха/лекарств, которые спасают жизни (люди хотят «больше» таких лекарств, а не ненавидят компании).","text_en":"Positive public sentiment toward biotech/medicines that save lives (people want more of it rather than hating the company).","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0014","quote":"I rarely hear anybody ever say, 'If ever'—that God, I hate that biotech company. That made that medicine that saved my kid's life."},{"chunk_id":"doc_6c015dd8786f_chunk_0014","quote":"They need more of it. And they want more of it."}],"confidence":"medium"}
{"nugget_id":"doc_6c015dd8786f_chunk_0014_n3","doc_id":"doc_6c015dd8786f","kind":"constraint","text_ru":"Есть политические/регуляторные вызовы и вещи, которые нужно исправить, включая IRA.","text_en":"There are policy/regulatory challenges and things to fix, including in the IRA.","evidence":[{"chunk_id":"doc_6c015dd8786f_chunk_0014","quote":"while we'll have challenges, no doubt. On the policy front and things we need to fix, like in the IRA."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0000_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Рынок/инвесторы сильно реагируют на ранние данные по next-gen препаратам от ожирения (рост акций Novo после анонса данных).","text_en":"Markets react strongly to early data from next-gen obesity programs (Novo shares rose after announcing data).","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0000","quote":"They were pretty big this morning, up about 7. 5% right now. Almost 10% at the Open."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0000_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Ранние данные по Amicretin показывают 22% снижение веса к 36 неделям при эскалации до 20 мг; это воспринимается как более быстрый темп, чем в предыдущих исследованиях.","text_en":"Early Amicretin data shows 22% weight loss at 36 weeks at 20 mg; perceived as faster than prior studies.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0000","quote":"by 36 weeks, those who have escalated to 20– 20 milligrams and stayed on treatment saw a 22% weight loss."},{"chunk_id":"doc_db621c04b3de_chunk_0000","quote":"the headline number, looks to be the fastest that we've seen in studies so far."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0000_n3","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Ограничение интерпретации результатов: данные представлены «as treated» (только для соблюдавших схему без прекращений) и без значимых данных по переносимости.","text_en":"Interpretation constraint: results are 'as treated' (only those who followed dosing without discontinuations) and lacked meaningful tolerability data.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0000","quote":"this is really as an as treated result— this is only considering results for people who followed the planned dosing schedule"},{"chunk_id":"doc_db621c04b3de_chunk_0000","quote":"there really wasn't any meaningful tolerability data presented."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0001_n1","doc_id":"doc_db621c04b3de","kind":"pain","text_ru":"В результатах по снижению веса не учитывают выбывших (discontinuations), из‑за чего эффективность и переносимость могут быть искажены; ITT/консервативная импутация может снизить заявленный эффект.","text_en":"Weight-loss results exclude discontinuations, potentially overstating efficacy and obscuring tolerability; ITT/conservative imputation could reduce the reported effect.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0001","quote":"the discontinuations aren't counted in these results— any meaningful rate of discontinuation has implications for both the tolerability and efficacy side."},{"chunk_id":"doc_db621c04b3de_chunk_0001","quote":"If you were to do a true ITT analysis... that 22% weight loss is very likely to be overstated."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0001_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"На рынке ожирения ценность «гонки» за более высоким процентом снижения веса снижается; важнее снижение веса без тошноты/рвоты и GI‑проблем переносимости.","text_en":"In obesity, chasing marginally higher weight-loss percentages is seen as less valuable; demand shifts toward weight loss without nausea/vomiting and GI tolerability issues.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0001","quote":"i don't know that chasing raw weight loss improvements at this point in the market is of huge value"},{"chunk_id":"doc_db621c04b3de_chunk_0001","quote":"people are interested in getting this weight loss without the nausea and the vomiting and the gi tolerability issues"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0001_n3","doc_id":"doc_db621c04b3de","kind":"pain","text_ru":"В safety/tolerability исследовании не дали комментариев по безопасности и переносимости, что затрудняет оценку и сравнение профиля побочек/выбываний.","text_en":"A safety/tolerability study provided no safety/tolerability commentary, limiting assessment and comparison of side effects/discontinuations.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0001","quote":"this was a safety and tolerability study. And we didn't get any safety and tolerability comments."},{"chunk_id":"doc_db621c04b3de_chunk_0001","quote":"the comparative analysis of discontinuation rates and side effect profile... is not possible. because we haven't got enough data or any data to compare to."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0002_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"В публичных биотех-рынках после JPM наблюдается слабый аппетит инвесторов к сделкам (wall cross/PIPE), несмотря на M&A; общий сентимент «не отличный».","text_en":"Post-JPM public biotech markets show investor reluctance for capital markets activity (wall cross/PIPE) despite M&A; overall sentiment is not great.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0002","quote":"\"what you hear is a great reluctance to participate in sort of basic activities involving the capital markets\""},{"chunk_id":"doc_db621c04b3de_chunk_0002","quote":"\"So fortunately, for better or for worse, sentiment is not great.\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0002_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Рост XBI за последнюю неделю может быть техническим (short covering), а не результатом притока свежих денег.","text_en":"The recent XBI uptick may be technical (short covering) rather than driven by fresh inflows.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0002","quote":"\"apparently there's a fund or two that are actually under significant pressure right now. that are engage very heavy short covering.\""},{"chunk_id":"doc_db621c04b3de_chunk_0002","quote":"\"this is not... A rally... caused by... a giant inflow of fresh money\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0002_n3","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Несмотря на слабый сентимент, IPO и follow-on рынок частично функционируют: «good IPOs get done», а некоторые follow-on сделки апсайзятся.","text_en":"Despite weak sentiment, IPO and follow-on markets are still functioning: good IPOs are getting done and some follow-ons are being upsized.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0002","quote":"\"we're seeing good IPOs get done\""},{"chunk_id":"doc_db621c04b3de_chunk_0002","quote":"\"the follow-on market has been functioning pretty well\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0003_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"В венчурном рынке сохраняется оптимизм и «dry powder», но усилилась требовательность к эффективности использования капитала и выбору клинических/регуляторных стратегий.","text_en":"VC market remains optimistic with dry powder, but is becoming more discerning about capital efficiency and clinical/regulatory strategies.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"there's always been a lot of dry powder on the VC front\""},{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"a better lens of efficiency of capital deployment\""},{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"more discernment on, you know, the right targets and the right clinical and regulatory strategies\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0003_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"В VC стало меньше «mega rounds»; инвесторы больше ищут новую инновацию и более «novel» компании, но интерес по-прежнему смещён к клинической стадии из-за осторожности к риску.","text_en":"Fewer mega rounds; more interest in new innovation/novel companies, but preference still leans toward clinical-stage due to risk aversion.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"There are less mega rounds.\""},{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"People are actually looking for new innovation and making investments into more novel companies.\""},{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"there is interest mostly in the clinical stage companies because, again, investors are wary of risk\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0003_n3","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Фокус инвесторов смещается обратно в онкологию после повышенного внимания к ожирению и части нейро; интерес к онкологии сочетается с предпочтением клинических активов для снижения риска.","text_en":"Investor focus is shifting back to oncology after heightened attention to obesity and some neuro; oncology interest is paired with clinical-stage assets to de-risk.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"people are turning back to oncology\""},{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"too much focus last year on obesity and some neuro\""},{"chunk_id":"doc_db621c04b3de_chunk_0003","quote":"\"partnering that oncology interest together with with clinical stage assets to de-risk the investments\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0004_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Интерес инвесторов/рынка смещается обратно в онкологию после повышенного фокуса на ожирение и часть нейро-направлений в прошлом году.","text_en":"Market/investor attention is turning back to oncology after last year’s heavy focus on obesity and some neuro.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0004","quote":"there was too much excitement, too much focus last year on obesity and some neuro. So people are turning back to oncology."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0004_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"M&A и licensing deal flow описывается как находящийся на историческом максимуме; фарма активна по рынку.","text_en":"M&A and licensing deal flow is described as at a historic high; pharma is active across the market.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0004","quote":"Our M &A and licensing deal flow right now is at a historic high."},{"chunk_id":"doc_db621c04b3de_chunk_0004","quote":"Pharma is active. Across the board"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0004_n3","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Крупные сделки ($10B+) редки по определению и не должны ожидаться часто.","text_en":"Large ($10B+) deals are, by definition, relatively rare and shouldn’t be expected frequently.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0004","quote":"I do think by definition, sort of $10 billion plus deals are relatively rare."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0005_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Участники ожидают рост M&A и активность сделок (в т.ч. крупные транзакции) с продолжением в 2025; число сделок с upfront > $75M выросло с 2023 к 2024 и прогнозируется выше уровня 2020.","text_en":"Participants expect increased M&A activity continuing into 2025; deals with >$75M upfront rose from 2023 to 2024 and are projected to exceed 2020 levels.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"I agree with everyone here in terms of the increase in M &A, and it certainly will continue in 2025.\""},{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"deals with upfront of over 75 million that rose from just, we had only six in 2023, to 17 last year.\""},{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"Four or five billion-dollar. Type plus transactions... that are in the works at the moment.\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0005_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Отмечается высокая активность сделок/лицензирования с китайскими биотехами; Q4 был самым «busy» по таким сделкам, и некоторые из крупнейших upfront были за китайские активы.","text_en":"High deal/licensing activity with Chinese biotechs is noted; Q4 was the busiest, and some of the largest upfronts were for Chinese assets.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"the fourth quarter was that was the busiest in terms of um deals with Chinese biotechs.\""},{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"some of the biggest deals were for Chinese assets when they were licensed.\""},{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"we calculate about 9% of all agreements.\""}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0005_n3","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Упоминается риск/барьер: возможное блокирование сделок (в контексте китайских сделок) и нетипичная «freeze» активности NIH (нет встреч, поездок и т.п.) при новой администрации.","text_en":"Potential constraint: possible blocking of deals (re China-related deals) and an atypical NIH freeze (no meetings/travel) under the new administration.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"they're going to start blocking these.\""},{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"the freeze on pretty much everything... no more, no meetings, no travel, nothing is.\""},{"chunk_id":"doc_db621c04b3de_chunk_0005","quote":"\"isn't typical; it's a bit beyond the level of what you would expect during a transition.\""}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0006_n1","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Заморозка/блокировка активности вокруг NIH: отменены поездки и консультативные встречи, «no meetings, no travel».","text_en":"NIH activity freeze/block: travel and advisory meetings canceled; effectively no meetings/travel.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0006","quote":"\"this block that's been put on any activity, all travel has been cancelled, advisory meetings have been cancelled\""},{"chunk_id":"doc_db621c04b3de_chunk_0006","quote":"\"no more, no meetings, no travel, nothing\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0006_n2","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Упоминается FDA hiring freeze, из‑за которого приходится отзывать/останавливать подготовленные офферы.","text_en":"FDA hiring freeze mentioned; prepared offers may need to be rescinded/paused.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0006","quote":"\"especially related to the FDA hiring freeze\""},{"chunk_id":"doc_db621c04b3de_chunk_0006","quote":"\"even people who might have had offers prepared, they have to rescind those\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0006_n3","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Выход/блокирование поддержки ВОЗ ставит в «limbo» программы (например, eradication polio, tetanus, flu work) и затрагивает обмен информацией по инфекционным заболеваниям.","text_en":"WHO withdrawal/support blocking puts programs (polio eradication, tetanus, flu work) in limbo and affects infectious-disease information sharing.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0006","quote":"\"it ties in with the WHO withdrawal\""},{"chunk_id":"doc_db621c04b3de_chunk_0006","quote":"\"a lot of the activity that was being supported by the US was on polio eradication, tetanus, flu work\""},{"chunk_id":"doc_db621c04b3de_chunk_0006","quote":"\"Will be in limbo at the minute\""}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0007_n1","doc_id":"doc_db621c04b3de","kind":"pain","text_ru":"Биотех-компании, которые обсуждают вопросы с FDA, испытывают задержки/тишину в коммуникации: «не слышат в ответ» или ощущают, что на них не обращают внимания.","text_en":"Biotech companies in discussions with the FDA are experiencing communication delays: not hearing back or feeling ignored.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0007","quote":"Those biotech companies that are in discussions with the FDA, they're actually not hearing back from the FDA"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0007_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"В конце года FDA ускоряла многие ревью/обсуждения (в конце декабря перед рождественским перерывом).","text_en":"At year-end, the FDA expedited many reviews/conversations (late December before the Christmas break).","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0007","quote":"FDA has expedited a lot of their reviews at the end of the year"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0007_n3","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Пауза в процессах/приоритизации затрагивает и NIH-гранты: упоминается, что NIH review был поставлен на паузу.","text_en":"A pause in reprioritization is affecting NIH grants as well: NIH review has been paused.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0007","quote":"I understand that that has been paused."}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0008_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"NIH и академические институты остаются ключевыми источниками финансирования базовой науки; внутри large pharma базовой науки делается мало.","text_en":"NIH and academia remain key funders of basic science; large pharma does relatively little basic science internally.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0008","quote":"\"It's unlikely that people inside large pharma companies right now are doing a ton of basic science. So most of that gets funded. Through the academic institutions and the NIH\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0008_n2","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Отмена NIH study sections рассматривается как неудобный/негативный фактор для индустрии в текущий момент.","text_en":"Cancellation of NIH study sections is described as an inconvenient moment for the industry.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0008","quote":"\"But it is, you know. An inconvenient moment to have cancellation of NIH study sections and so on.\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0008_n3","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Отмечается рост инноваций в Китае на фоне более капиталистической среды и ориентации на науку.","text_en":"China is described as becoming more science-focused and capitalistic, with a large amount of innovation emerging.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0008","quote":"\"China's all about science and they've created a much more capitalistic environment... we're seeing a huge amount of innovation coming out of it.\""}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0009_n1","doc_id":"doc_db621c04b3de","kind":"pain","text_ru":"FDA воспринимается индустрией как не оптимизированная и неэффективно настроенная, с проблемами структуры и непоследовательной обратной связью для биотехов/спонсоров.","text_en":"The FDA is seen by industry as not optimized/efficiently tuned, with structural issues and inconsistent feedback to biotechs/sponsors.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0009","quote":"most of us who've been in the industry for a long time recognize where the FDA is— not optimized and is not efficiently tuned."},{"chunk_id":"doc_db621c04b3de_chunk_0009","quote":"the inconsistent feedback on [to], you know, biotechs and sponsors right along the way."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0009_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Обсуждаются возможные изменения в FDA при McCary; есть ожидание потенциальных улучшений, хотя допускается, что может стать хуже.","text_en":"Potential FDA changes under McCary are being discussed; there is expectation of possible improvements, though it could get worse.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0009","quote":"it'll be interesting to see what you know, changes McCary might implement"},{"chunk_id":"doc_db621c04b3de_chunk_0009","quote":"it could go in the other direction. It could get worse. But... there is a possibility that we could see some improvements"}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0009_n3","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Миелома стала одной из крупнейших индикаций и приносит очень крупные продажи (Carvykti и Darzalex), что отражает масштаб коммерческого рынка в этой индикации.","text_en":"Myeloma has become one of the largest indications, driving very large sales (Carvykti and Darzalex), indicating a large commercial market.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0009","quote":"myeloma has impressively become one of the largest indications out there"},{"chunk_id":"doc_db621c04b3de_chunk_0009","quote":"they reported $3. 34 billion in carbon. These sales"},{"chunk_id":"doc_db621c04b3de_chunk_0009","quote":"quarterly sales of Darcel X that were reported to be over 3 billion"}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0010_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Растёт интерес к более раннему применению биспецифических терапий; они «off-the-shelf» и проще для использования вне крупных центров.","text_en":"Growing interest in moving bispecific therapies earlier; they are off-the-shelf and easier to use outside major centers.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0010","quote":"there is a lot of interest in pushing those by specifics earlier. They're off the shelf, you can take them to a two-patient community center without much worry."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0010_n2","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Рынок множественной миеломы сложно моделировать из‑за множества комбинаций и разных линий терапии.","text_en":"The multiple myeloma market is hard to model due to many combinations and different lines of therapy.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0010","quote":"it's one of the toughest markets to model. Because of the combinations, endless combinations you can have and different lines of therapy."}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0010_n3","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"CAR‑T в миеломе становится более «usable» и смещается в сторону амбулаторного применения.","text_en":"CAR-T in myeloma is becoming more usable and shifting toward outpatient use.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0010","quote":"an interesting world of CAR-T where it has become more and more usable and outpatient, etc."}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0011_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"В индустрии регулярно звучат «визионерские»/громкие заявления, которые могут преувеличивать сложность биологии и обещать нереалистичные сроки.","text_en":"The industry repeatedly hears visionary/grandiose claims that may overstate biology’s complexity and promise unrealistic timelines.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0011","quote":"throughout my career, I've sort of heard this recurrent visionary claim many times"},{"chunk_id":"doc_db621c04b3de_chunk_0011","quote":"grandiose statements that are likely... overstating the complexity of biology"},{"chunk_id":"doc_db621c04b3de_chunk_0011","quote":"it's not going to happen at the speed um that that is being promised here"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0011_n2","doc_id":"doc_db621c04b3de","kind":"opportunity","text_ru":"Тех-CEO могут быть особенно полезны в задачах работы с «massive data sets» в здравоохранении (данные, imaging, диагностика), ускоряя анализ таких данных.","text_en":"Tech CEOs may add value in handling massive healthcare datasets (imaging/diagnostics) and speeding up analysis.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0011","quote":"how do you deal with massive metadata? data sets or massive data sets, such as healthcare data, imaging data"},{"chunk_id":"doc_db621c04b3de_chunk_0011","quote":"they will have a much better view as to what technology can do in speeding up analyzing that stuff"}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0011_n3","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Есть ограничение на применимость «тех»-взгляда: в drug discovery/биологии разговор, по мнению спикера, должен быть у людей с близким отношением к проведению работ (химия и т. п.).","text_en":"A constraint: for drug discovery/biology, the speaker suggests the conversation should be led by those close to the work (chemistry, etc.).","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0011","quote":"When it comes to drug discovery, biology. I think they should really leave that particular conversation to folks"}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0012_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"В биотехе активно обсуждают AI/ML, но звучат более «трезвые» оценки: AI — инструмент для распознавания паттернов и не заменит опытных разработчиков лекарств.","text_en":"Biotech is heavily discussing AI/ML, but more sober views emphasize it as a pattern-recognition tool that won’t replace experienced drug developers.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0012","quote":"he admits that they use it as a tool... He says it can help with pattern recognition... it's not going to replace good drug developers"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0012_n2","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Ограничение AI в drug discovery: нужны опыт и контекстуализация выходов моделей; обсуждаются «какие вопросы можем ответить» и «какие ограничения».","text_en":"AI limitation in drug discovery: outputs require experience and contextualization; discussion focuses on what questions can be answered and what the limitations are.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0012","quote":"you need the right experience and contextualization of these data outputs"},{"chunk_id":"doc_db621c04b3de_chunk_0012","quote":"what questions can we answer. With AI and what are the limitations?"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0012_n3","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"mRNA-вакцины против рака тестируются в комбинации с checkpoint inhibitors; ключевой вопрос — улучшат ли они response rate и PFS/выживаемость.","text_en":"mRNA cancer vaccines are being tested with checkpoint inhibitors; the key question is whether they improve response rate and PFS/survival.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0012","quote":"whether an mRNA vaccine can genuinely help in increasing the response rate... or progression-free survival to a checkpoint inhibitor"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0013_n1","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Agentic AI уже принят во многих индустриях и «приходит» в biotech/life sciences; ожидается рост специализированных агентов для задач drug discovery.","text_en":"Agentic AI is already adopted in other industries and is coming to biotech/life sciences; specialized agents for drug discovery are expected to emerge.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0013","quote":"\"Agentic AI is something that's already been embraced by many other industries. It is coming to biotech and life sciences.\""},{"chunk_id":"doc_db621c04b3de_chunk_0013","quote":"\"this is the year where we'll start creating agents that are specialized um in tasks that are relevant for drug discovery.\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0013_n2","doc_id":"doc_db621c04b3de","kind":"opportunity","text_ru":"Появляется возможность использовать внешних поставщиков AI-агентов (например, NVIDIA), а создание собственных агентов может дифференцировать компанию и сформировать IP.","text_en":"Opportunity to use external AI-agent providers (e.g., NVIDIA), while building in-house agents can differentiate a company and create IP.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0013","quote":"\"JP Morgan did announce that they will be providing AI agents. So it's not something that you have to do as part of your own company.\""},{"chunk_id":"doc_db621c04b3de_chunk_0013","quote":"\"Although if you can, that will actually differentiate you and create your own IP.\""}],"confidence":"medium"}
{"nugget_id":"doc_db621c04b3de_chunk_0013_n3","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"Регуляторные и юридические ограничения/риски (ответственность, liability) при автономных решениях AI в клинике (диагноз/назначения) требуют guardrails и safeguards.","text_en":"Regulatory and legal constraints/risks (accountability, liability) for autonomous AI decisions in clinical settings require guardrails and safeguards.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0013","quote":"\"how. Like the regulatory constraints, you know, stay on top of it.\""},{"chunk_id":"doc_db621c04b3de_chunk_0013","quote":"\"where's the accountability, where's the liability?\""}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0014_n1","doc_id":"doc_db621c04b3de","kind":"constraint","text_ru":"При внедрении AI, который заменяет человеческий выбор/решение, возникает вопрос ответственности и юридической ответственности; нужны guardrails и safeguards.","text_en":"When AI removes human choice/decision, accountability and liability become concerns; guardrails and safeguards are needed.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0014","quote":"“even if AI is better, where's the accountability, where's the liability? ... make sure that we put the right guardrails and safeguards around that.”"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0014_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Biogen объявляет стратегические сдвиги в R&D: возможны сокращения персонала, фокус на «prioritized preclinical portfolio» и больший акцент на external innovation (в т.ч. M&A).","text_en":"Biogen is shifting R&D strategy: potential staffing cuts, focus on a prioritized preclinical portfolio, and greater emphasis on external innovation (incl. M&A).","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0014","quote":"“It sounds like there's going to be staffing cuts.”"},{"chunk_id":"doc_db621c04b3de_chunk_0014","quote":"“focusing on a new footprint that will match the needs of a prioritized preclinical portfolio.”"},{"chunk_id":"doc_db621c04b3de_chunk_0014","quote":"“It does seem to come with a greater emphasis on external innovation.”"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0014_n3","doc_id":"doc_db621c04b3de","kind":"pain","text_ru":"Проблема трансляции из доклиники в клинику: сильные доклинические данные/модели могут не приводить к клинической эффективности; это связано с pipeline failures.","text_en":"Bench-to-bedside translation issue: strong preclinical work/models may not translate into clinical efficacy, contributing to pipeline failures.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0014","quote":"“pipeline failures ... really great pre-clinical research behind it and just never materialized in the same sort of clinical efficacy”"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0015_n1","doc_id":"doc_db621c04b3de","kind":"pain","text_ru":"У компании есть проблема: нужно найти замену для «тающего кубика льда» — их самого успешного, но уже зрелого франчайза; пока не нашли близкую по времени линию продаж, которая бы его заменила.","text_en":"The company struggles to replace its most successful but maturing franchise; it hasn’t found a near-term sales line to displace it.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0015","quote":"generate um a replacement for for the melting ice cube that is their most successful franchise"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0015_n2","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"Наблюдается тренд: компании рассматривают сокращение внутреннего R&D и покупку «de-risked» продуктов через сделки/приобретения, фактически аутсорся инновации в biotech.","text_en":"Trend: companies consider cutting internal R&D and acquiring de-risked products to feed the pipeline, effectively outsourcing innovation to biotech.","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0015","quote":"cutting internal R&D? ... acquire products that are de-risked to feed the pipeline"}],"confidence":"high"}
{"nugget_id":"doc_db621c04b3de_chunk_0015_n3","doc_id":"doc_db621c04b3de","kind":"trend","text_ru":"В Nature Medicine (20 января) по GLP-1 агонистам: сообщается о «40 positive events» против «18 negative», с вопросом о механизме (снижение веса vs GLP-1 агонизм).","text_en":"Nature Medicine (Jan 20) on GLP-1 RAs reports “40 positive events” vs “18 negative,” with uncertainty about mechanism (weight loss vs GLP-1 agonism).","evidence":[{"chunk_id":"doc_db621c04b3de_chunk_0015","quote":"Summary, 40 positive events... 40 positive benefits versus 18 negative"}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0000_n1","doc_id":"doc_e74ba96b9fc8","kind":"constraint","text_ru":"Инвесторы не понимают, будет ли администрация про‑фарма или анти‑фарма; высокая неопределённость и непредсказуемость политики.","text_en":"Investors face uncertainty on whether the administration will be pro- or anti-pharma; policy unpredictability is a constraint.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0000","quote":"we're all kind of um honestly sitting on our hands and waiting for some sign or direction around whether this administration is going to be. Pro-pharma or anti-pharma"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0000_n2","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Обсуждается усиление/«добавление зубов» к IRA и фокус на политике снижения цен на лекарства.","text_en":"Discussion suggests strengthening the IRA and a renewed focus on drug pricing policy.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0000","quote":"I was hearing that he is going to put some teeth back into the IRA or maybe add teeth to the IRA."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0000","quote":"President Trump tweeted in all caps, 'America first' drug prices."}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0000_n3","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Возвращается идея международного референсного ценообразования: устанавливать цены относительно других стран.","text_en":"The idea of international reference pricing (setting prices relative to other countries) is resurfacing.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0000","quote":"we might go back to the idea of looking at setting prices relative to other countries."}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0001_n1","doc_id":"doc_e74ba96b9fc8","kind":"constraint","text_ru":"Потенциальные изменения в Vaccine Injury Compensation Program (ICP) и/или составе ACIP могут открыть производителей вакцин для судебных исков, что снижает их готовность работать на рынке США.","text_en":"Potential changes to the Vaccine Injury Compensation Program (ICP) and/or ACIP composition could expose vaccine makers to lawsuits, reducing willingness to operate in the US market.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0001","quote":"changing the ICP, the vaccine injury compensation program, so that such that vaccine makers become open to uh uh to being sued"},{"chunk_id":"doc_e74ba96b9fc8_chunk_0001","quote":"If you're open to being sued for random science... then why would you be in that game?"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0001_n2","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Слушания воспринимаются как «театр» и дают мало ясности о том, как кандидат будет управлять и мыслить о политике FDA/NIH.","text_en":"Hearings are seen as “theater” and provide little clarity on how the candidate would govern and think about FDA/NIH policy.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0001","quote":"I didn't watch every minute of the hearings, but enough to say that this is theater."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0001","quote":"there was very little about how he would govern in the role and how right—uh—he— he thinks about the FDA or NIH"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0001_n3","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Индустрия потеряла доверие общественности (особенно в COVID-годы) и нужно восстановление доверия к «pro-science» голосам.","text_en":"The industry has lost public trust (especially during COVID years) and needs to restore trust in pro-science voices.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0001","quote":"we have to realize that uh, there are a lot of people we've lost, a lot of trust, right?"},{"chunk_id":"doc_e74ba96b9fc8_chunk_0001","quote":"A lot of this was during the COVID years, but uh, I think we need to figure out how do we get back and restore that trust."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0002_n1","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Падение доверия к медицине и вакцинам; ощущение, что «битва» за доверие проигрывается и может стать хуже.","text_en":"Eroding trust in medicines and vaccines; sense that the trust battle is being lost and could worsen.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0002","quote":"there are some benefits that could come out of—restoring, you know, half the population to believe, in medicines and vaccines... because I think we're losing that"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0002_n2","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Фигуры с MD/PhD и большой аудиторией в соцсетях формируют повестку, даже если индустрия с ними не согласна.","text_en":"MD/PhD figures with large social followings are shaping the narrative regardless of industry agreement.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0002","quote":"there are those who have MD and PhD credentials that a lot of the country is following, whether we agree with it or not"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0002_n3","doc_id":"doc_e74ba96b9fc8","kind":"opportunity","text_ru":"Запрос на восстановление доверия через прозрачность: «почистить» VAERS и проводить проспективные исследования по детскому календарю вакцинации.","text_en":"Opportunity to rebuild trust via transparency: improve VAERS and run prospective studies on childhood vaccine schedules.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0002","quote":"if he says, 'Hey, we're to clean up the VAERS system,' right? We're going to do prospective studies that look at the entire childhood vaccine schedule"}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0003_n1","doc_id":"doc_e74ba96b9fc8","kind":"opportunity","text_ru":"Запрос на проспективные исследования, сравнивающие полный детский календарь вакцинации при модифицированном графике vs отсутствие вакцинации, с акцентом на данные и прозрачность.","text_en":"Call for prospective studies comparing the full childhood vaccine schedule (modified schedule vs no vaccine), emphasizing data and transparency.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0003","quote":"do prospective studies that look at the entire childhood vaccine schedule with a modified child vaccine schedule versus no vaccine."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0003","quote":"let's get the data and let's get transparency."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0003_n2","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Обсуждается, что эффект IRA на цены/«haircut» от CMS оказался «не так плох», как ожидали, и есть ожидание, что при Трампе не станет хуже.","text_en":"Perception that IRA/CMS additional price cuts were not as bad as expected, and expectation that Trump won’t make it worse.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0003","quote":"the additional haircut, right? The additional trim off of the already discounted CMS prices wasn't as bad as we thought."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0003","quote":"I don't think people are thinking Trump's going to make it worse."}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0003_n3","doc_id":"doc_e74ba96b9fc8","kind":"opportunity","text_ru":"Видится возможность при «pro-business» Конгрессе исправить/модифицировать IRA и в целом «сделать проще» продвижение лекарств (drug development).","text_en":"Seen opportunity with a pro-business Congress to fix/modify IRA and generally make it easier for drugs to move forward.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0003","quote":"focus on while there is a unified, you know, Congress. That pro-business of getting what needs to be fixed about IRA"},{"chunk_id":"doc_e74ba96b9fc8_chunk_0003","quote":"Let's make it easier for drugs to move forward."}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0004_n1","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Обсуждается возможное сокращение сроков разработки/вывода лекарств (\"nine years versus 13 years\") и ожидание, что это можно быстро отрегулировать на уровне администрации/Конгресса.","text_en":"They discuss potentially shortening drug development timelines (\"nine years versus 13 years\") and expect it could be adjusted by the administration/Congress.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0004","quote":"I was thinking more of the nine years versus 13 years."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0004","quote":"That should be an easy fix right now. I don't know why that would not be adjusted with this administration and this Congress."}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0004_n2","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Сообщается об одобрении Vertex Jurnavix (Nav1.8) как первого одобрения и для взрослых с умеренной/сильной острой болью.","text_en":"They report Vertex’s Jurnavix (Nav1.8) approval as a first approval, indicated for adults with moderate to severe acute pain.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0004","quote":"Vertex announces the approval of Jurnavix."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0004","quote":"it's the first approval. So it's approved for adults with moderate to severe acute pain."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0004_n3","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Разработка обезболивающих/психоактивных препаратов сталкивается с высокой сложностью: трудно отделить аддиктивность от эффективности (сделать лучше без формирования зависимости).","text_en":"Developing pain/mood/anxiety drugs faces a high hurdle: it’s hard to decouple addictiveness/liking from efficacy (make patients feel better without addiction).","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0004","quote":"it's a really, really high hurdle for something like pain or mood or anxiety"},{"chunk_id":"doc_e74ba96b9fc8_chunk_0004","quote":"decouple addictiveness or likeness from efficacy"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0005_n1","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Сложно создать препарат, который улучшает состояние (психологическое/неврологическое) без формирования зависимости.","text_en":"It’s very challenging to make a drug that improves how someone feels psychologically/neurologically without making it addictive.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0005","quote":"to make someone who psychologically or neurologically feels bad feel better, but do that in a way that doesn't actually make the drug addictive."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0005_n2","doc_id":"doc_e74ba96b9fc8","kind":"buyer_signal","text_ru":"В хронической боли есть готовность платить высокую цену за лечение (упоминается pricing > $10k/год) из‑за слабой эффективности альтернатив.","text_en":"In chronic pain, there is willingness to pay high annual pricing (>$10k/year) because many alternatives don’t work well.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0005","quote":"with chronic treatment, a pricing of over $10, 000 a year"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0005_n3","doc_id":"doc_e74ba96b9fc8","kind":"constraint","text_ru":"Запуски в acute care для не жизнеспасающих терапий часто идут плохо и медленно, что усложняет коммерциализацию.","text_en":"Acute care launches for non-life-saving treatments often perform poorly and ramp slowly, making commercialization hard.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0005","quote":"acute care launches for non-life-saving treatments, they tend not to go well. curve is so slow."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0006_n1","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Ожидался «вал» IPO в начале 2025, но рынок не поддержал; IPO выходят медленно, «по капле».","text_en":"A deluge of IPOs was expected in early 2025, but markets didn’t cooperate; IPOs are coming out slowly (drip).","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0006","quote":"at one point it seemed like we were going to get a deluge of IPOs in early 2025... But clearly, the markets have not cooperated."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0006","quote":"So I think we'll get a few more dripping out."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0006_n2","doc_id":"doc_e74ba96b9fc8","kind":"buyer_signal","text_ru":"Со стороны клиентов/инвесторов нет готовности «обнимать» IPO-рынок; часть инвесторов не хочет слышать про IPO roadshow в ближайшее время.","text_en":"Clients/investors are not ready to embrace the IPO market; some don’t want to hear about IPO roadshows soon.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0006","quote":"we're just not hearing from our clients that they are ready to embrace the IPO market"},{"chunk_id":"doc_e74ba96b9fc8_chunk_0006","quote":"There's a cohort of investors that just doesn't want to hear about an IPO roadshow anytime soon."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0006_n3","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Инвесторы ощущают проблему: лучшие частные компании могут быть «подобраны» через M&A до IPO, из-за чего публичные инвесторы не успевают в них инвестировать.","text_en":"Investors feel a problem: top private names may get acquired via M&A before IPO, limiting public investors’ access.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0006","quote":"a lot of dual tracking going on of IPOs with private M&A discussions going on behind the scenes."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0006","quote":"some of the better private names are being picked off before they have a chance to come to the market"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0007_n1","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"В биотех-инвестировании наблюдается «defensive investing»: инвесторы прячутся и действуют оборонительно, особенно в large/mid cap; в small cap интерес нишевый и «бинарный».","text_en":"Biotech investing is trending toward defensive positioning: hiding/defensive investing in large/mid caps; small caps are niche and binary.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0007","quote":"\"what I'm seeing from a risk-taking perspective, is a lot of hiding and a lot of defensive investing.\""},{"chunk_id":"doc_e74ba96b9fc8_chunk_0007","quote":"\"the way I would sort of say it in large cap and mid cap is it's like defensive investing.\""}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0007_n2","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"В obesity-сегменте, по словам спикера, нет «major shortage» способов/компаний, чтобы «play obesity» — рынок переполнен вариантами.","text_en":"In obesity, the speaker says there is no major shortage of ways/companies to play the theme—many options exist.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0007","quote":"\"there isn't really a major shortage of obesity ways or ways to play obesity.\""}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0007_n3","doc_id":"doc_e74ba96b9fc8","kind":"buyer_signal","text_ru":"IPO Metzera прошло с повышением цены и ростом на торгах (по Bloomberg), что может быть сигналом спроса инвесторов на историю в obesity.","text_en":"Metzera’s IPO priced higher and traded up (per Bloomberg), suggesting investor demand for an obesity story.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0007","quote":"\"They sold in the end 15. 3 million shares instead of the original offering of 17. 2, which is is great because they got a higher price.\""},{"chunk_id":"doc_e74ba96b9fc8_chunk_0007","quote":"\"Bloomberg just reported that they're trading at $28. 80.\""}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0008_n1","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"В ранних данных по препаратам для снижения веса часто не раскрывают подробные профили безопасности/переносимости и побочных эффектов — сообщают в основном только снижение веса.","text_en":"Early weight-loss drug readouts often lack detailed safety/tolerability and side-effect profiles, focusing mainly on weight loss.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0008","quote":"where are the efficacy, side effects, and and and safety and tolerability profile? Well, I've scoured the S1 and I couldn't find any more detail."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0008","quote":"they just told us how much people lost weight, rather than to actually tell us what the detailed safety tolerated was."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0008_n2","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Интерес/ставка на пероральные терапии ожирения смещается в сторону пероральных пептидов; есть скепсис, что малые молекулы (GLP) сработают для пероральной терапии.","text_en":"Interest in oral obesity therapies is leaning toward oral peptides; skepticism remains that small-molecule GLPs will work for oral therapy.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0008","quote":"they're focused on doing oral peptides."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0008","quote":"I'm not sure that small molecules like GLPs are going to work out. I think it's going to take something like an oral peptide"}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0008_n3","doc_id":"doc_e74ba96b9fc8","kind":"buyer_signal","text_ru":"Сильные клинические данные в MASH/NASH могут поддерживать крупные раунды финансирования; также отмечается, что рынок внимательно отслеживается фармой из‑за размера возможности и нехватки собственных активов.","text_en":"Strong MASH/NASH clinical data can enable large financings; pharma is watching closely due to market size and limited internal programs.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0008","quote":"One company I think had some really stellar data and was able to raise 400 million off of it."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0008","quote":"this is also almost certainly a market that pharma is watching very closely because of the innovation and the size of the opportunity"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0009_n1","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"У F4 NASH/MASH пациентов очень высокая неудовлетворённая медицинская потребность: при F4 ожидаемая продолжительность жизни около 5 лет.","text_en":"F4 NASH/MASH patients have a very high unmet need: life expectancy around five years.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0009","quote":"if you're an F4 NASH-MASH patient, you have a life expectancy only about five years. So the unmet medical need here is almost oncology-like."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0009_n2","doc_id":"doc_e74ba96b9fc8","kind":"constraint","text_ru":"GLP-1 препараты не показали пользы по фиброзу у F4 пациентов, что ограничивает их применимость для этой подгруппы.","text_en":"GLP-1s have not shown fibrosis benefit in F4 patients, limiting their relevance for this subgroup.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0009","quote":"GLP-1s have not shown any fibrosis benefit in F4 patients."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0009_n3","doc_id":"doc_e74ba96b9fc8","kind":"buyer_signal","text_ru":"Если препарат снижает фиброз, возможна премиальная цена; также отмечается, что многие пациенты уже диагностированы и находятся под наблюдением.","text_en":"If a drug reduces fibrosis, premium pricing is possible; many patients are already diagnosed and in care.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0009","quote":"when you have a drug that can reduce fibrosis, you can charge a premium pricing. And a lot of these patients, of course, are already diagnosed"}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0010_n1","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Ожирение/метаболические заболевания (MASH/NASH/NAFLD) за последние годы стали восприниматься всерьёз; раньше тема казалась «смешной», а теперь «смотрим, где мы сегодня».","text_en":"Obesity/metabolic diseases (MASH/NASH/NAFLD) have become taken seriously over recent years; previously it was dismissed, but now the field has progressed.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0010","quote":"most people would have laughed at me if you talked about obesity five years ago, MASH, NASH, NAFLD"}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0010_n2","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Сложность интерпретации эффективности в педиатрических исследованиях: дети растут, и в первый год улучшения могут быть и у плацебо, что требует оговорок при оценке эффекта.","text_en":"Difficulty interpreting efficacy in pediatric trials: kids are growing and placebo patients can improve in year one, requiring caveats about true drug effect.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0010","quote":"these kids are younger and they're still growing and you have to kind of caveat. some of the improvements because we see placebo. patients improve in that first year."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0010_n3","doc_id":"doc_e74ba96b9fc8","kind":"constraint","text_ru":"Регуляторный барьер/контроверзность: препарат был одобрен несмотря на недостижение первичной конечной точки; часть «FDA clinical trial purists» была недовольна, упоминается override review staff.","text_en":"Regulatory constraint/controversy: the drug was approved despite missing its primary endpoint; some FDA clinical trial purists were unhappy and review staff was overridden.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0010","quote":"remember it didn't hit its primary endpoint and it was a controversial approval. And got the review staff got overridden"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0011_n1","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Сектор cell & gene therapy «нуждается в хороших новостях» и уже переживает разочарования; провал Cargo стал «трудным развитием» для поля.","text_en":"Cell & gene therapy is in need of good news and has already faced disappointment; Cargo’s failure was a difficult development for the field.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0011","quote":"\"really difficult development for the field of cell and gene therapy, which as a subsector is really in need of good news.\""},{"chunk_id":"doc_e74ba96b9fc8_chunk_0011","quote":"\"It's really already from disappointment.\""}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0011_n2","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"В CAR-T исследованиях отмечается высокая частота HLH как серьёзного побочного эффекта, который «всё чаще» появляется в таких исследованиях.","text_en":"CAR-T studies are seeing a high incidence of HLH, a very serious side effect that is increasingly cropping up.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0011","quote":"\"there was a high incidence of HLH... a very serious side effect that we are seeing increasingly crop up in these CAR T-cell studies.\""}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0011_n3","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"Проблема неэффективного использования капитала: менеджмент и советы директоров «перекатывают» деньги из одного провала в следующий актив пайплайна, что неэффективно для «очень ценных» денежных резервов.","text_en":"Capital allocation issue: management/boards roll capital from one failure to the next pipeline asset, which is inefficient use of precious cash reserves.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0011","quote":"\"real problem with management and boards just kind of rolling their capital. One failure into whatever is up next in their pipeline.\""},{"chunk_id":"doc_e74ba96b9fc8_chunk_0011","quote":"\"This is not an efficient way to use... very precious cash reserves in in our industry.\""}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0012_n1","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"В CAR-T наблюдается сдвиг от нацеливания на один антиген к инженерии мульти-специфичных/мульти-антигенных продуктов; это воспринимается как «будущее» технологии, хотя и сложное и рискованное.","text_en":"CAR-T is shifting from single-antigen targeting toward engineered multi-antigen/multi-specific products; seen as the future, though complex and risky.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0012","quote":"“these CAR-T cells are now becoming like Swiss Army knives with multi-tools.”"},{"chunk_id":"doc_e74ba96b9fc8_chunk_0012","quote":"“to be able to engineer in multi antigens into one CAR T product, I think is really exciting. And complicated for sure and risky”"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0012_n2","doc_id":"doc_e74ba96b9fc8","kind":"constraint","text_ru":"Мульти-антигенные CAR-T продукты описываются как «сложные» и «рискованные», что указывает на технологический/разработческий барьер.","text_en":"Multi-antigen CAR-T products are described as complicated and risky, indicating a development/technology barrier.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0012","quote":"“And complicated for sure and risky”"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0012_n3","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"По данным спикера, значительная доля M&A сделок (без учета лицензирования) приходится на компании, домицилированные в США, в период 2019–2024.","text_en":"According to the speaker’s data, 80% of (non-licensing) M&A deals are US-domiciled in 2019–2024.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0012","quote":"“80% of M &A deals are US domiciled. In the 2019 to 2024 range.”"}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0013_n1","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"В 2019–2024 около 80% M&A-сделок (в выборке) были с US-домицилем.","text_en":"In 2019–2024, about 80% of M&A deals (in their dataset) were US-domiciled.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0013","quote":"\"forgetting the licensing side, 80% of M &A deals are US domiciled. In the 2019 to 2024 range.\""}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0013_n2","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"В 2024 крупная фарма чаще покупала частные компании: 68% сделок против «чуть больше половины» в среднем за 2019–2024.","text_en":"In 2024, large pharma acquired private companies more often: 68% of deals vs just over half on average in 2019–2024.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0013","quote":"\"private companies were definitely more popular in 2024 versus the average over the 2019-24.\""},{"chunk_id":"doc_e74ba96b9fc8_chunk_0013","quote":"\"Average over 2019-24 was just over half the deals.\""},{"chunk_id":"doc_e74ba96b9fc8_chunk_0013","quote":"\"Last year, according to our data, 68%.\""}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0013_n3","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"VC-фонды всё ещё способны закрываться; отмечается наличие «dry powder» и больше частного капитала для продолжения инвестиций.","text_en":"VC funds can still close; there is “dry powder” and more private capital to keep fueling investments.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0013","quote":"\"VC funds are still uh able to close\""},{"chunk_id":"doc_e74ba96b9fc8_chunk_0013","quote":"\"there's more private capital, a lot of dry powder, to continue to fuel investments.\""}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0014_n1","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Упоминается рост частного капитала/«dry powder» для продолжения инвестиций (в т.ч. намерение собрать фонд на $1B).","text_en":"More private capital/dry powder to keep fueling investments (incl. intent to raise a $1B fund).","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0014","quote":"did a filing suggesting that they want to, uh, aim for a, a billion dollar fund. So, just the idea that there's more private capital, a lot of dry powder"}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0014_n2","doc_id":"doc_e74ba96b9fc8","kind":"pain","text_ru":"23andMe описывается как компания с быстрым исчерпанием кэша и рядом проблем (включая утечки данных, уходы из совета), что подсвечивает сложности бизнес-моделей в этой сфере.","text_en":"23andMe is described as running out of cash and having issues (data breaches, board resignations), highlighting business-model challenges in the space.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0014","quote":"they're running out of cash quickly. They announced a strategic sale. This has been a company that's really had a lot of issues, data breaches, board resignations."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0014","quote":"it's not easy to be multiple business models here. The consumerization got more commoditized."}],"confidence":"high"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0014_n3","doc_id":"doc_e74ba96b9fc8","kind":"constraint","text_ru":"Отмечается ограниченный охват 23andMe по числу генетических образцов (около 15 млн), что удивляет и указывает на трудность масштабирования сбора генетических данных.","text_en":"23andMe’s reach is described as limited (about 15M genetic samples), suggesting difficulty scaling genetic data collection.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0014","quote":"The fact that they only got about 15 million genetic samples, to me, was surprising. How little reach they actually had"}],"confidence":"medium"}
{"nugget_id":"doc_e74ba96b9fc8_chunk_0015_n1","doc_id":"doc_e74ba96b9fc8","kind":"trend","text_ru":"Продолжается «obesity theme» в биотехе; ожидается дальнейшее развитие событий/новостей в области ожирения.","text_en":"The obesity theme in biotech continues, with expectations of further developments/news in the obesity space.","evidence":[{"chunk_id":"doc_e74ba96b9fc8_chunk_0015","quote":"Ozempic got another indication. And so this obesity theme continues."},{"chunk_id":"doc_e74ba96b9fc8_chunk_0015","quote":"I'm sure we'll see more and more develop as we talked about in the obesity space"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0000_n1","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Инвесторские настроения в биотехе с начала января стали «менее негативными», но это ещё не «позитив».","text_en":"Investor sentiment in biotech has shifted from very negative in early January to “less negative,” but not truly positive.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0000","quote":"Things were like really negative at the start of January and that seems to be shifting."},{"chunk_id":"doc_5b3a95aa371e_chunk_0000","quote":"I would just say that things were less negative. I hesitate to use the phrase 'positive.'"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0000_n2","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Рынок остаётся в режиме defensive/risk-off: инвесторы менее готовы брать риск, а интерес к «супер бинарным» high-science малым компаниям генерировать сложнее.","text_en":"The market remains defensive/risk-off; investors are less willing to take risk, and it’s harder to generate interest in small, highly binary high-science companies.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0000","quote":"there's more like defensive investing than um, then really wanting to take on risk."},{"chunk_id":"doc_5b3a95aa371e_chunk_0000","quote":"there's still a lot of small companies that have interesting science, but are more speculative, where it's harder to generate a lot of interest"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0000_n3","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Часть участников рынка связывает улучшение настроений с «комфортом» от hearing RFK, возможным смягчением тарифной риторики и ожиданиями снижения доходности 10-летних трежерис (что воспринимается как хорошая новость для биотеха).","text_en":"Some market participants attribute improved sentiment to comfort from RFK’s confirmation hearing, possible tariff pullback, and expectations of lower 10-year Treasury yields (seen as good for biotech).","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0000","quote":"A lot of people talked about RFKs. confirmation hearing as being somewhat comforting."},{"chunk_id":"doc_5b3a95aa371e_chunk_0000","quote":"Trump is now talking about. um, kind of pulling back a little bit on these tariffs."},{"chunk_id":"doc_5b3a95aa371e_chunk_0000","quote":"the new treasury secretary said, I'd like to see the 10 year. treasury yield to come down. So that's obviously very good news for biotech."}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0001_n1","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Инвесторы в секторе ведут себя более осторожно (risk-off), предпочитая защитные бумаги; при этом сектор отстаёт от S&P.","text_en":"Investors are more risk-off, favoring defensive names; the sector is still lagging the S&P.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0001","quote":"Investors are trying to keep their head down, trying to do a little bit more risk off."},{"chunk_id":"doc_5b3a95aa371e_chunk_0001","quote":"dividend-paying stocks, large caps are performing pretty well"},{"chunk_id":"doc_5b3a95aa371e_chunk_0001","quote":"we're still, you know, trailing the S&P by twelve percent."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0001_n2","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Недостаток интереса со стороны generalist-инвесторов; обсуждаются «глубокие проблемы» устройства сектора, которые их отпугивают.","text_en":"Lack of generalist investor interest; there are “deep issues” in how the sector works that keep generalists away.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0001","quote":"one of the issues we have right now is that the lack of generalist interest."},{"chunk_id":"doc_5b3a95aa371e_chunk_0001","quote":"there are a set of relatively deep issues with how our sector works that are keeping generalists away."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0001_n3","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Доступ к капиталу для многих компаний зависит от specialist-инвесторов и PIPE-сделок с дисконтом/условиями; практики вроде wall-cross PIPE могут иметь негативные последствия и воспринимаются как потенциально неэтичные.","text_en":"Many companies’ access to capital depends on specialist investors and PIPEs with discounts/terms; wall-cross PIPE practices may have downsides and be seen as borderline unethical.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0001","quote":"a lot of companies are able to access capital. Because of specialist investors."},{"chunk_id":"doc_5b3a95aa371e_chunk_0001","quote":"we want to do it with a pipe with this discount or this particular twist or turn."},{"chunk_id":"doc_5b3a95aa371e_chunk_0001","quote":"these practices, like the wall cross pipes, were borderline unethical and that the SEC should look into them."}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0002_n1","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Генералистам сложно возвращаться в малые biotech из‑за высокой сложности данных/катализаторов; «колода сложена» против них.","text_en":"Generalist investors struggle to return to small biotechs due to complexity of data/catalysts; the deck is stacked against them.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0002","quote":"\"first of all, data you have to really understand the data you have to understand the catalyst.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0002","quote":"\"there's so much complexity in the industry that it seems like the decks are sort of stacked against any generalist investor.\""}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0002_n2","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Качество раскрытия информации у публичных biotech низкое: важные для инвесторов вещи (взаимодействие с FDA/научные данные) раскрываются плохо, а SEC‑требования часто нерелевантны.","text_en":"Disclosure quality in public biotech is poor: what investors care about (FDA interactions/science/data) is not well disclosed; SEC requirements can be irrelevant.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0002","quote":"\"biotech companies that are public are subject to all sorts of SEC disclosure requirements.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0002","quote":"\"That are probably not that relevant. To what investors actually care about.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0002","quote":"\"the quality of disclosure about what really matters\""}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0002_n3","doc_id":"doc_5b3a95aa371e","kind":"opportunity","text_ru":"Улучшение раскрытия «того, что реально важно» может повысить доступ/интерес генералистов, снизив информационное преимущество специалистов.","text_en":"Improving disclosure of what truly matters could increase generalist access/interest by reducing specialists’ information edge.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0002","quote":"\"Generalist access would be to take away some of the edge. That specialists have\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0002","quote":"\"But the quality of disclosure, I think, could be better.\""}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0003_n1","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"В biotech качество раскрытия информации и управленческих комментариев воспринимается как недостаточное; из‑за субъективности интерпретаций данных/регуляторной обратной связи компании могут делать вводящие в заблуждение заявления без последствий.","text_en":"In biotech, disclosure quality is seen as lacking; due to subjective interpretations of data/regulatory feedback, companies can make misleading statements with little consequence.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0003","quote":"\"But the quality of disclosure, I think, could be better.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0003","quote":"\"companies have said something that's misleading and. There's no consequence to it\""}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0003_n2","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Интерес generalist-инвесторов к biotech описывается как цикличный и driven by FOMO; они подключаются в основном при outperformance сектора.","text_en":"Generalist investor interest in biotech is described as cyclical and FOMO-driven, mainly appearing when the sector outperforms.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0003","quote":"\"generalist interests largely become cyclical, right? And there's an element of like FOMO.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0003","quote":"\"it's really only when you get that outperformance do you sort of force that interest to occur.\""}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0003_n3","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"По комментариям крупных pharma ожидаются M&A, но скорее в формате меньших add-on сделок, а не крупных $10B+ транзакций.","text_en":"Large pharma commentary suggests M&A this year but skewing toward smaller add-on deals rather than $10B+ transactions.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0003","quote":"\"we'll be doing M &A this year, but think of more like smaller add-on type deals.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0003","quote":"\"don't expect us to do other 10 billion dollar deals\""}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0004_n1","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Крупные фармкомпании публично сигнализируют о готовности к M&A; ожидается сильный год для M&A в 2025.","text_en":"Large pharma signal readiness for M&A; expectation of a strong M&A year in 2025.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0004","quote":"\"it's going to be a strong year for M&A in 2025.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0004","quote":"\"Pfizer said that they've got $10 billion plus to do M &A this year.\""}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0004_n2","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Психоделики в депрессии становятся более «институционализированными»: меньше неопределённости по FDA-пути, более опытные команды, больше данных из рандомизированных контролируемых исследований.","text_en":"Psychedelics in depression are becoming more institutionalized: less FDA-path uncertainty, more experienced teams, and more RCT data.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0004","quote":"\"five years ago... there was still uncertainty around the FDA path of these things\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0004","quote":"\"we're seeing more experienced drug developers join the C-suite of these companies.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0004","quote":"\"we've had data now from multiple randomized controlled trials\""}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0004_n3","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"В исследованиях психоделиков исторически не хватало качественных данных: ранее по GH были только open-label данные, а не RCT.","text_en":"Historically, psychedelic programs lacked high-quality data: for GH, previously only open-label data existed rather than RCTs.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0004","quote":"\"we only had open label data before it.\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0004","quote":"\"a lot of the historical data was open label, or cases, or anecdotes.\""}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0005_n1","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"В психоделических RCT есть риск функционального «разослепления» (functional unblinding), особенно при отсутствии ответа в placebo-руке.","text_en":"Psychedelic RCTs can suffer from functional unblinding, especially when the placebo arm shows no improvement.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0005","quote":"there was, I think, pretty obvious functional unblinding in this study, given that the placebo arm just didn't improve at all."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0005_n2","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Изменение/замена медицинского устройства для введения в будущих исследованиях и наличие clinical hold FDA создают риск; инвесторы захотят PK-данные для «бриджа» между исследованиями.","text_en":"Changing the administration device plus an FDA clinical hold adds risk; investors will want PK data to bridge to the next study.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0005","quote":"GH is ultimately changing the medical device... they have a clinical hold with the FDA on this device"},{"chunk_id":"doc_5b3a95aa371e_chunk_0005","quote":"investors are going to want to see pharmacokinetic data. shows that you can really bridge these data into the next study."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0005_n3","doc_id":"doc_5b3a95aa371e","kind":"buyer_signal","text_ru":"Есть сигнал коммерческой жизнеспособности: Spravato (эскетамин J&J) при требовании 2-часового визита раз в две недели «annualizing» на $1.2B.","text_en":"Commercial viability signal: J&J’s Spravato annualizes at $1.2B despite requiring a two-hour visit every other week.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0005","quote":"Spravato, J &J's esketamine drug. requires a two-hour patient visit every other week."},{"chunk_id":"doc_5b3a95aa371e_chunk_0005","quote":"it's annualizing at $1. 2 billion, right?"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0006_n1","doc_id":"doc_5b3a95aa371e","kind":"opportunity","text_ru":"Рынок мигрени описывается как большой и недообслуженный; есть пространство для новых/улучшающих терапий, т.к. CGRP не закрывают потребности всех пациентов.","text_en":"Migraine is described as a large, underserved market; there is room for new/improved therapies since CGRPs don’t meet all patients’ needs.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0006","quote":"My view on the migraine market is it is still a large and underserved market."},{"chunk_id":"doc_5b3a95aa371e_chunk_0006","quote":"it still seems to be that CGRPs aren't meeting the needs for all patients."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0006_n2","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Доступ/аптейк терапии будет сильно зависеть от payer dynamics и step-through через триптаны; это выступает «gatekeeper» для uptake.","text_en":"Uptake/access is constrained by payer dynamics and step-through requirements via triptans, acting as a major gatekeeper.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0006","quote":"there's a payer dynamic that the market is going to wait to see, to see how access will evolve for a drug for most patients that have to step through triptans."},{"chunk_id":"doc_5b3a95aa371e_chunk_0006","quote":"payer dynamics are going to be a major gatekeeper to the uptake of this drug"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0006_n3","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Запуск/коммерческий тезис зависит от будущих данных; «one of the challenges is going to be the dataset», ожидается дополнительный датасет позже в году.","text_en":"Launch/commercial thesis depends on forthcoming data; “one of the challenges is going to be the dataset,” with another dataset expected later this year.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0006","quote":"one of the challenges is going to be the dataset."},{"chunk_id":"doc_5b3a95aa371e_chunk_0006","quote":"another data set that's coming at the end of this year that may open up the market further"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0007_n1","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"У Neurocrine по Ingrezza наблюдается усиление сопротивления со стороны плательщиков: больше прямых отказов вместо административных барьеров для врачей.","text_en":"Neurocrine is seeing increased payer pushback for Ingrezza, with more outright denials rather than added physician hurdles.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0007","quote":"they're seeing greater payer pushback."},{"chunk_id":"doc_5b3a95aa371e_chunk_0007","quote":"plans have been pushing back more... There have been more, a greater number of outright 'no's,' right?"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0007_n2","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"С 2024 года (по оценке спикера) планы чаще отказывают в доступе к препарату, хотя существенных изменений в контрактинге/формулярной стратегии не отмечается.","text_en":"Since sometime in 2024, plans have been issuing more denials despite no significant change in contracting dynamics/formulary strategy.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0007","quote":"Without really a significant change in contracting dynamics in their market"},{"chunk_id":"doc_5b3a95aa371e_chunk_0007","quote":"we don't know exactly when this trend started, but let's say, sometime in 2024, plans have been pushing back more"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0007_n3","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Изменения в Medicare Part D по IRA увеличивают финансовую ответственность плательщиков в катастрофическом покрытии (с 15% до 60%), что может усиливать давление на управление доступом к дорогим specialty-препаратам.","text_en":"IRA changes in Medicare Part D increase payer liability in catastrophic coverage (from 15% to 60%), potentially tightening management of expensive specialty drugs.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0007","quote":"under the IRA, for Part D drugs... payers used to eat 15% of that catastrophic portion. Now it's 60%."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0008_n1","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Из‑за IRA/редизайна Part D резко меняется распределение ответственности за «catastrophic coverage»: доля payers выросла с 15% до 60%, что меняет payer dynamics для некоторых продуктов.","text_en":"IRA/Part D redesign shifts catastrophic coverage liability: payers’ share rises from 15% to 60%, changing payer dynamics for certain products.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0008","quote":"payers used to eat 15% of that catastrophic portion. Now it's 60%."},{"chunk_id":"doc_5b3a95aa371e_chunk_0008","quote":"payer dynamics changing this year for certain types of products?"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0008_n2","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Есть «payer pushback» на фоне изменений в catastrophic coverage, что создает давление/неопределенность для компаний с экспозицией к этим затратам.","text_en":"There is payer pushback around catastrophic coverage changes, creating pressure/uncertainty for exposed companies.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0008","quote":"clearly, there are there's payer pushback with this catastrophic coverage."}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0008_n3","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Неопределенность: компании не готовы публично «коммититься» к росту utilization и описывать краткосрочный удар по выручке vs. возможный последующий сдвиг в utilization из‑за снижения out-of-pocket.","text_en":"Uncertainty: few companies commit publicly to utilization increases and the near-term revenue hit vs. potential later utilization shift from lower out-of-pocket.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0008","quote":"there's not many companies are really committing to saying oh yeah like utilization will really increase"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0009_n1","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Инвесторы жалуются на отсутствие «катализаторов» у компаний (вплоть до 2026), что на фоне сокращения баланса может приводить к «death spiral».","text_en":"Investors complain companies lack catalysts (out to 2026), and shrinking balance sheets can lead to a “death spiral.”","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0009","quote":"one of the big problems that I hear talking to investors is they just don't have catalysts. 2026"},{"chunk_id":"doc_5b3a95aa371e_chunk_0009","quote":"we've seen sort of these companies that see balance sheets dwindle quarter to quarter, they really get in kind of this death spiral"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0009_n2","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Крупное follow-on финансирование может быть практически недостижимо по текущей цене акции; также упоминаются ограничения на сильное размывание (near 100% dilution).","text_en":"A large follow-on financing may be infeasible at the current share price; restrictions on near-100% dilution are mentioned.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0009","quote":"if they try to do anywhere near this size of a financing through a follow on offering, I mean, there's no way they could do it"},{"chunk_id":"doc_5b3a95aa371e_chunk_0009","quote":"I think there would be restrictions on on 100 you know, near 100 pollution"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0009_n3","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Ожидается «довольно интересный год» для M&A; M&A описывается как «pretty robust».","text_en":"M&A is described as “pretty robust,” with expectations of an “interesting year” for M&A.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0009","quote":"I commented before that I saw M&A. being pretty robust."},{"chunk_id":"doc_5b3a95aa371e_chunk_0009","quote":"it's going to be a pretty interesting year for M&A, based on what I'm seeing."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_nugget_001","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Ожидается «интересный год» для M&A; собеседник видит усиление активности сделок.","text_en":"An “interesting year” for M&A is expected; the speaker is seeing increased deal activity.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0010","quote":"\"it's going to be a pretty interesting year for M&A, based on what I'm seeing.\""}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_nugget_002","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Биосимиляр Amgen на ILEA (path blue) успешно получил одобрение и запустился после юридического решения; это влияет на динамику рынка и воспринимается как угроза для Regeneron.","text_en":"Amgen’s ILEA biosimilar (path blue) achieved approval and launched after a legal decision; it’s affecting market dynamics and is seen as a threat to Regeneron.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0010","quote":"\"it's really the only one that's successful in getting an approval and then subsequent launch. After a legal decision\""},{"chunk_id":"doc_5b3a95aa371e_chunk_0010","quote":"\"it certainly seems, even from a Regeneron standpoint, that they're a bit threatened by the Amgen-Papleau launch.\""}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_nugget_003","doc_id":"doc_5b3a95aa371e","kind":"buyer_signal","text_ru":"Amgen сообщает о продажах биосимиляра path blue: около $31 млн за 9 недель после запуска, что выглядит как сильный ранний коммерческий сигнал.","text_en":"Amgen reports about $31M in path blue sales within 9 weeks of launch, a strong early commercial signal.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0010","quote":"\"Amgen reported 31 million in pap blue that's in nine weeks into launch\""}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0011_n1","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Ожидается, что рынок ILEA станет более конкурентным в ближайшие пару лет, на фоне входа успешных биосимиляров.","text_en":"The ILEA market is expected to become more competitive over the next couple of years, amid successful biosimilar entry.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0011","quote":"The product, so biosimilar entry that is successful, is a big deal."},{"chunk_id":"doc_5b3a95aa371e_chunk_0011","quote":"We should expect to see the idea market become ever more competitive in the next couple of years."}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0011_n2","doc_id":"doc_5b3a95aa371e","kind":"opportunity","text_ru":"Политика возмещения (ASP+8) может создавать сильные стимулы для офтальмологов переключаться на биосимиляры при правильном ценообразовании.","text_en":"Reimbursement policy (ASP+8) can create strong incentives for ophthalmologists to switch to biosimilars if pricing is set correctly.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0011","quote":"make biosimilars reimbursement ASP plus eight."},{"chunk_id":"doc_5b3a95aa371e_chunk_0011","quote":"if you keep get your pricing right, you can actually create strong incentives for ophthalmologists to switch"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0011_n3","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Для компаний сложен переход от R&D-стадии к коммерческой: нужно уметь эффективно давать коммерческий guidance, учитывая факторы вроде доступа к возмещению и изменения политики/законодательства.","text_en":"Transitioning from R&D to commercial stage is challenging: teams must guide commercially while accounting for reimbursement access and shifting policy/legislation.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0011","quote":"one of the biggest challenges... as they go from R &D companies to commercial stage companies."},{"chunk_id":"doc_5b3a95aa371e_chunk_0011","quote":"reimbursement access that you're partly in control of, but we also know that legislation, policy, et cetera, can shift beneath you."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0012_n1","doc_id":"doc_5b3a95aa371e","kind":"opportunity","text_ru":"Класс мускариновых препаратов рассматривается как большая возможность для пациентов и большой рыночный шанс.","text_en":"Muscarinics as a class are viewed as a big opportunity for patients and a large market opportunity.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0012","quote":"“Muscarinics as a class were more important... a huge opportunity for patients and a huge market opportunity.”"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0012_n2","doc_id":"doc_5b3a95aa371e","kind":"buyer_signal","text_ru":"Инвесторы/аналитики ценят менеджмент, который готов отвечать на сложные вопросы и демонстрирует уверенность через готовность к взаимодействию.","text_en":"Investors/analysts value management teams that engage on hard questions; willingness to engage signals confidence.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0012","quote":"“the company's willingness to engage really reflected their confidence in what they were doing.”"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0012_n3","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"В CNS-сфере проведение клинических испытаний воспринимается как сложное.","text_en":"Clinical trial conduct in the CNS space is considered difficult.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0012","quote":"“especially when we talk about the CNS space where trial conduct is so hard”"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0013_n1","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Компании/CEO часто воспринимают жёсткие вопросы как атаку «скептических хедж-фондов/шортов» и «создание нарративов», вместо того чтобы видеть их как часть нормальной проверки.","text_en":"Companies/CEOs often interpret tough questions as attacks by skeptical hedge funds/shorts or narrative-building, rather than normal diligence.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0013","quote":"I hear too often, companies kind of almost like blindly blaming this concept of skeptical hedge funds... as a reason for tough questions"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0013_n2","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"В биотехе даже инвесторы, которым нравится акция, не чувствуют высокой уверенности; подход — думать о вероятностях и риске, а не о 90–100% уверенности.","text_en":"In biotech, even investors who like a stock rarely feel very certain; they think in probabilities and risk rather than 90–100% confidence.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0013","quote":"In biotech, I mean, it's hard. It's hard to love a stock and still and never feel 100%, right, or even 90%"}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0013_n3","doc_id":"doc_5b3a95aa371e","kind":"opportunity","text_ru":"Возможность для CEO/компаний: лучше готовиться к «nuanced questions» и уметь обсуждать bull case и bear case, чтобы «getting them over that hump» с инвесторами проходило легче.","text_en":"Opportunity for CEOs/companies: prepare for nuanced investor questions and discuss both bull and bear cases to get investors over the hump.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0013","quote":"presents the bull case, the bear case, and has a good handle on on all of those dynamics"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0014_n1","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Инвесторская база требует от компаний ответов на «нюансированные» вопросы, что создает давление на менеджмент и коммуникации.","text_en":"The investor base wants nuanced questions answered, creating pressure on management communications.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0014","quote":"the entire investor base really wants to have all these nuanced questions answered."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0014_n2","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Построение доверия/взаимопонимания между менеджментом и sell-side аналитиками/инвесторами требует времени.","text_en":"Building understanding/relationship between management and sell-side analysts/investors takes time.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0014","quote":"that takes time, both the management team building, you know, the right rapport within the team"},{"chunk_id":"doc_5b3a95aa371e_chunk_0014","quote":"the relationship that is built with you know uh sell side analysts investors really understanding the management team"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0014_n3","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"В индустрии наблюдается скепсис к «compounded market», который «crept up» вокруг инкретинов.","text_en":"There is industry skepticism toward the compounded market that has crept up in incretins.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0014","quote":"most people in our industry are pretty skeptical of this compounded market that's crept up in these incretins."}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0015_n1","doc_id":"doc_5b3a95aa371e","kind":"constraint","text_ru":"Сектор описывается как «высоко регулируемый», вопреки представлению о «гаражных» продавцах без оглядки на правила.","text_en":"The sector is described as highly regulated, contrary to the idea of garage sellers operating without regard for rules.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0015","quote":"The reality is it's not only a highly regulated sector."}],"confidence":"high"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0015_n2","doc_id":"doc_5b3a95aa371e","kind":"trend","text_ru":"Компаунинг/онлайн-доступ к препаратам рассматривается как заметное развитие: пациенты впервые в значимом масштабе получают доступ к лекарствам онлайн самостоятельно.","text_en":"Compounding/online access is framed as a notable development enabling patients to access drugs online on their own at scale.","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0015","quote":"compounding has been one of the more interesting developments because it's allowed patients to... get access to drugs online on their own"}],"confidence":"medium"}
{"nugget_id":"doc_5b3a95aa371e_chunk_0015_n3","doc_id":"doc_5b3a95aa371e","kind":"pain","text_ru":"Есть напряжение из‑за того, что компании инвестируют годы и большие суммы в R&D, а другие могут «выигрывать» через временную «лазейку» (в контексте компаундинга).","text_en":"Tension exists where companies invest years and large sums in R&D while others may benefit via a temporary loophole (in the compounding context).","evidence":[{"chunk_id":"doc_5b3a95aa371e_chunk_0015","quote":"a company will be investing years and millions— even close to a billion dollars— in R &D. Other companies could benefit through kind of this loophole."}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0000_n1","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Негативный рыночный сентимент в биотехе: «долгий slog», мало оптимизма, высокие ставки.","text_en":"Negative biotech market sentiment: a long slog, few signs of optimism, high interest rates.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0000","quote":"\"it's been a long slog over the last several years and we're not really seeing major signs of optimism. Interest rates remain high.\""}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0000_n2","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Перенасыщение публичного биотех-рынка: слишком много компаний вышло на IPO; многие торгуются ниже кэша, что воспринимается как признак нездорового рынка.","text_en":"Overcrowded public biotech market: too many IPOs; many trade below cash, seen as an unhealthy market sign.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0000","quote":"\"we just took too many biotech companies public\""},{"chunk_id":"doc_af75dee37a48_chunk_0000","quote":"\"200 or so are trading below cash\""}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0000_n3","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Резкий разворот настроений инвесторов: от «all-time high enthusiasm» к «winter's here»; звучат тезисы, что «VC venture model is broken».","text_en":"Sharp investor sentiment reversal: from all-time high enthusiasm to “winter's here”; claims that the VC venture model is broken.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0000","quote":"\"by the end of last year into the election, we were at an all-time high enthusiasm.\""},{"chunk_id":"doc_af75dee37a48_chunk_0000","quote":"\"The centimometer is now back to winter's coming, winter's here, and it reversed drastically.\""},{"chunk_id":"doc_af75dee37a48_chunk_0000","quote":"\"The VC venture model is broken.\""}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0001_n1","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Сильный пессимизм в биотех-секторе из‑за слабой динамики секторального индекса (XBI) на фоне роста широкого рынка.","text_en":"Strong pessimism in biotech due to flat sector performance (XBI) versus broad market gains.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0001","quote":"\"It's correct. It's exactly five years of nothing. And at the same time, the S&P 500 has doubled.\""}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0001_n2","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Обсуждается высокая макро- и политическая неопределённость (инфляция/ставки, первые 100 дней новой администрации), влияющая на сентимент.","text_en":"High macro/political uncertainty (inflation/rates, first 100 days of new administration) affecting sentiment.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0001","quote":"\"we're almost near peak uncertainty right now with the first hundred days of the new administration.\""}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0001_n3","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Есть опасения из‑за возможных кадровых изменений в FDA и у руководителей офисов, что может создавать регуляторную неопределённость.","text_en":"Concerns about potential leadership changes at the FDA creating regulatory uncertainty.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0001","quote":"\"There's concerns now that he's asking for resignations of the FDA and office heads.\""}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0002_n1","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"У биотех-хеджфондов/фондов, делающих PIPE и берущих варранты, возникает проблема ликвидности: варранты могут быть очень прибыльными, но они неликвидны, и при резких редемпшенах непонятно, как их обслуживать.","text_en":"Biotech hedge funds doing PIPEs and taking warrants face liquidity constraints: warrants can be very profitable but illiquid, creating issues when redemptions spike.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0002","quote":"they do pipes and they take a lot of warrants... but they're illiquid. And so the issue when you suddenly have all these redemptions, what do you do?"}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0002_n2","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Обсуждается динамика оттоков капитала из биотеха (люди забирают деньги), что воспринимается как небуллиш-сигнал, хотя может быть специфично для одного фонда.","text_en":"Outflows from biotech (people pulling money out) are discussed as a not-bullish sign, possibly fund-specific.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0002","quote":"the idea of outflows and people taking money out of biotech, that's not a bullish sign, but it might be specific to this fund."}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0002_n3","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Несмотря на «difficult markets», спикер утверждает, что идёт «innovation cycle», и ряд mid/large-cap биотех-компаний «turning profitable» в ближайшие годы.","text_en":"Despite difficult markets, the speaker claims an innovation cycle with several mid/large-cap biotech companies turning profitable soon.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0002","quote":"We've been talking about difficult markets... there is an unbelievable amount of innovation going on... companies... are turning profitable this year."}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0003_n1","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Биотех-компании испытывают давление, потому что больше не могут бесконечно привлекать капитал.","text_en":"Biotech companies face pressure because they can’t keep raising money indefinitely anymore.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0003","quote":"But I think there's just a lot of pressure because companies can't continue to raise money forever anymore."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0003_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Для запуска важно, чтобы FDA приняло подачу (filing) в текущем квартале.","text_en":"A launch depends on FDA accepting a filing planned for this quarter.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0003","quote":"They'll file that this quarter. It'll be important for FDA to accept that."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0003_n3","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Ранние данные по кандидату Zanza пока не показывают достаточной дифференциации относительно Cabo, из‑за чего акция «зависла».","text_en":"Early Zanza data hasn’t shown enough differentiation versus Cabo, leaving the stock hovering.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0003","quote":"The early data so far has not ample differentiation against Cabo. And so the stock is kind of in a hover."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0004_n1","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"У биотех-компаний усилилось давление: «нельзя продолжать привлекать деньги бесконечно».","text_en":"Biotech companies face increased pressure because they can’t keep raising money indefinitely.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0004","quote":"there's just a lot of pressure because companies can't continue to raise money forever anymore."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0004_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Клинический холд на вакцину от норовируса у Moderna вызвал путаницу/неопределённость у рынка.","text_en":"A clinical hold on Moderna’s norovirus vaccine created confusion/uncertainty for the market.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0004","quote":"the elements that really got people a bit confused today was this thing: a clinical hold on the norovirus vaccine."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0004_n3","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Регуляторный барьер: для COVID+flu combo вакцины может потребоваться дождаться данных фазы 3 по гриппу, прежде чем пройти регуляторов.","text_en":"Regulatory barrier: a COVID+flu combo vaccine may need Phase 3 flu data before getting through regulators.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0004","quote":"they may need to wait for the phase three data for their flu vaccine data to come through before they can get that through the regulators."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0005_n1","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Для Moderna есть риск/сомнение в эффективности адъювантной терапии меланомы (cancer vaccine): ожидавшийся позитивный эффект не подтвердился, и это влияет на ожидания перед ближайшими данными.","text_en":"There is uncertainty/risk around Moderna’s adjuvant melanoma (cancer vaccine) efficacy: expected positive impact didn’t materialize, affecting expectations ahead of upcoming data.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0005","quote":"And it didn't work out. So you have that same situation now for Moderna."},{"chunk_id":"doc_af75dee37a48_chunk_0005","quote":"this is a trial that I think most people expected to see some positive impact from."}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0005_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"GSK называет рынок RSV-вакцин «рынком двух игроков», что (со слов спикера) связано с разговорами с плательщиками и создаёт дополнительное давление/барьер для Moderna.","text_en":"GSK frames the RSV vaccine market as a “two-player market,” reportedly based on payer conversations, creating added pressure/barrier for Moderna.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0005","quote":"They refer to the RSV vaccine market as a two-player market."},{"chunk_id":"doc_af75dee37a48_chunk_0005","quote":"that comment is based on the kind of conversations they're having with payers at the minute."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0005_n3","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"На IPO-рынке биотеха в целом выходят более зрелые компании (часто с данными, фаза 2), но даже «landmark IPOs» с конца прошлого года без новостей показали сильное падение.","text_en":"In biotech IPOs, companies going public are generally more mature (often with Phase 2 data), yet landmark IPOs from late last year have fallen sharply even without news.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0005","quote":"Companies in general... have gone tremendously better... they're in phase two, more innovative."},{"chunk_id":"doc_af75dee37a48_chunk_0005","quote":"The landmark IPOs from the end of last year, without any news, have all have done really poorly."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0006_n1","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Рынок сейчас наказывает биотех-компании без катализаторов/конкурентных данных, которым ещё предстоит привлекать капитал.","text_en":"The market is currently penalizing biotech companies with no catalysts/competitive data that will need to raise capital later.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0006","quote":"Anybody that has no catalysts or any inkling of competitive data who will raise money later on is absolutely getting penalized right now."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0006_n2","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Инвесторы обеспокоены тем, что большинству биотех-компаний придётся привлекать «сотни миллионов долларов» в ближайшие 5 лет, что усиливает давление на оценки.","text_en":"Investors worry most biotech companies will need to raise hundreds of millions over the next five years, increasing valuation pressure.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0006","quote":"they're going to have to raise hundreds of millions of dollars between now and five years from now.' And they start getting worried."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0006_n3","doc_id":"doc_af75dee37a48","kind":"buyer_signal","text_ru":"В IPO важен объём привлечённых средств: «хорошие» компании, по мнению спикера, привлекают достаточно, чтобы дойти до катализатора до потенциального разводнения по более низкой оценке.","text_en":"IPO buyers focus on whether companies raise enough to reach a catalyst before potential dilution at a lower valuation.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0006","quote":"are they raising enough money in the IPO where they can get to a catalyst event before diluting at a lower valuation potentially?"}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0007_n1","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Для нишевых/редких ожирительных показаний M&A маловероятны, пока нет «жёстких» качественных данных по ожирению; текущие данные слишком ранние и нужен значимый trial.","text_en":"M&A for niche/rare obesity indications is unlikely until there is hard, high-quality obesity data; current data is very early and a meaningful trial is needed.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0007","quote":"\"I just can't see an easy way for these to become M &A targets until they've got some really hard, good quality obesity data.\""},{"chunk_id":"doc_af75dee37a48_chunk_0007","quote":"\"their approach is, when you look at the data that they've got, it's very early.\""},{"chunk_id":"doc_af75dee37a48_chunk_0007","quote":"\"The issue is that you need a meaningful trial to prove it.\""}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0007_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Для прохождения разработки требуются «сотни миллионов долларов», а средств IPO может не хватить, чтобы дойти до конца раунда.","text_en":"Development may require hundreds of millions of dollars, and IPO proceeds may be insufficient to reach the end of the round.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0007","quote":"\"talking about the hundreds of million dollars that are required\""},{"chunk_id":"doc_af75dee37a48_chunk_0007","quote":"\"certainly not enough from the IPO to get through to the end of their round.\""}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0007_n3","doc_id":"doc_af75dee37a48","kind":"buyer_signal","text_ru":"Есть слухи и подтверждение, что Merck KGaA ведёт обсуждения по SpringWorks; ожидается возможное объявление сделки перед отчётом.","text_en":"Rumors and confirmation that Merck KGaA has been in discussions about SpringWorks; a deal announcement is anticipated ahead of earnings.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0007","quote":"\"there's been rumors and Merck KGa confirmed that they have been in discussions.\""},{"chunk_id":"doc_af75dee37a48_chunk_0007","quote":"\"we anticipate a deal is going to get announced probably Tuesday or Wednesday ahead of that.\""}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0008_n1","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Публичные biotech-компании могут торговаться «ниже кэша/с отрицательным EV», при этом рынок может «не заботиться», но сделки с крупной фармой всё равно возможны и вызывают резкие движения цены.","text_en":"Public biotechs can trade below cash/with negative EV and be ignored by the market, yet still land big-pharma deals that move the stock sharply.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"Talking about companies trading below cash and nobody caring, etc. It doesn't mean they don't have anything interesting."},{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"when they announced the deal, the share price went up like 117%."},{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"an interesting example of a negative enterprise value company that managed to get a deal with a meaningful farmer."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0008_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Даже после сделки компания может иметь короткий runway (кэш только до 1Q26), что означает необходимость нового раунда финансирования и потребность в новостях/катализаторах для привлечения инвесторов.","text_en":"Even after a deal, runway may be short (cash only through 1Q26), implying another raise and a need for news/catalysts to attract investors.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"they only have now cash for first quarter 26."},{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"that means that they're going to have to raise again."},{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"that would clearly need some news or some reason for investors to be. to be wanting to go in."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0008_n3","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Есть обсуждение возможного «ренессанса» masked T-cell engagers, но участники не готовы делать выводы без более длительного follow-up и подтверждения, что более высокие дозы дают более высокую эффективность.","text_en":"A possible 'renaissance' of masked T-cell engagers is being discussed, but conclusions are deferred pending longer follow-up and evidence that higher dosing improves efficacy.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"are we at the beginning of a of a renaissance of the mass t cell engager world?"},{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"I don't want to make pronounce your pronouncements like that until we see updated from Janix and Veer with longer duration follow-up"},{"chunk_id":"doc_af75dee37a48_chunk_0008","quote":"see whether higher dosing can give them higher efficacy."}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0009_n1","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Вокруг данных по RA (Anaptis) было много сомнений и вопросов: участники обсуждения в чате и аналитики на колле сомневались, достаточно ли данные хороши, и их смутил участок между 12 и 14 неделями.","text_en":"There was significant doubt and questioning around the RA data (Anaptis), including confusion about what happened between weeks 12 and 14.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0009","quote":"a lot of people were questioning it and whether it was good enough"},{"chunk_id":"doc_af75dee37a48_chunk_0009","quote":"The thing that really confused people is what happened between week 12 and week 14 of the trial."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0009_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Подход PD-1 агониста для RA воспринимается как потенциально рискованный/тревожный принципиально, т.к. он «приглушает» T-клеточный ответ и создаёт иммуносупрессивную среду.","text_en":"A PD-1 agonist approach in RA is viewed as concerning/risky in principle because it dampens T-cell response and creates an immunosuppressive environment.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0009","quote":"Anaptis drug is essentially a PD-1 agonist, which immediately scares the bejesus out of me a little bit."},{"chunk_id":"doc_af75dee37a48_chunk_0009","quote":"you're basically creating an immune suppressive environment with a PD-1 agonist."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0009_n3","doc_id":"doc_af75dee37a48","kind":"opportunity","text_ru":"RA остаётся сложной I&I-индикацией с большим неудовлетворённым спросом и «огромной возможностью» для best-in-class решений.","text_en":"RA remains an elusive I&I indication with substantial unmet need and a huge opportunity for best-in-class therapies.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0009","quote":"RA has been one of the more elusive I &I indications and still has a lot of unmet need and huge opportunity"}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0010_n1","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Ожидаются шаги по onshore-переносу фармпроизводства в США в ближайший год.","text_en":"Moves toward onshoring pharmaceutical manufacturing in the U.S. are expected over the coming year.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0010","quote":"\"I think we'll see a lot of moves in the coming year for companies to um onshore a lot of pharmaceutical manufacturing.\""}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0010_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Ожидаемая эрозия кадрового состава и морального состояния в FDA (сокращения, ограничения найма, return-to-office), что может ухудшить способность агентства выполнять сроки PDUFA.","text_en":"Expected FDA staffing erosion and morale issues (cuts, hiring limits, return-to-office) may impair ability to meet PDUFA deadlines.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0010","quote":"\"There's going to be an erosion. In staffing\""},{"chunk_id":"doc_af75dee37a48_chunk_0010","quote":"\"There's just a tremendous amount of anxiety and lack of and poor morale at FDA right now\""},{"chunk_id":"doc_af75dee37a48_chunk_0010","quote":"\"erode its ability to function even to meet PDUFA deadlines\""}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0010_n3","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Высокая неопределённость вокруг возможных реформ FDA (включая комиссию по реформам) и потенциального возрождения политики most favored nation (international reference pricing).","text_en":"High uncertainty around potential FDA reforms (including a reform commission) and possible revival of most-favored-nation international reference pricing.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0010","quote":"\"there's likely to be some kind of commission that's going to be created to recommend reforms at FDA\""},{"chunk_id":"doc_af75dee37a48_chunk_0010","quote":"\"We don't know whether Trump will revive the most favored nation international reference pricing policy proposal\""}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0011_n1","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Неопределённость вокруг возможного введения international reference pricing / most favored nation policy, которая может «висеть» всю администрацию.","text_en":"Uncertainty around a potential international reference pricing / most favored nation policy that may hang over the whole administration.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0011","quote":"uncertainty that's going to be hanging out there for the whole administration."}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0011_n2","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Взаимодействие с FDA сопровождается задержками и ограничением коммуникации (запросы на встречи, только письменные ответы, задержки).","text_en":"FDA interactions involve delays and limited communication (meeting requests, written responses only, delays).","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0011","quote":"meeting requests, getting written responses only, getting delays."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0011_n3","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Ожидаются сокращения в FDA; если уйдёт часть review staff, это может привести к срыву PDUFA deadlines и серьёзным проблемам для биофармы.","text_en":"FDA cutbacks are expected; if review staff leave, PDUFA deadlines could be missed, causing serious issues for biopharma.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0011","quote":"it's clear that FDA is going to experience cutbacks."},{"chunk_id":"doc_af75dee37a48_chunk_0011","quote":"If you have 10% of the review staff leaving, that would mean that you would start missing PDUFA deadlines"}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0012_n1","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Риск снижения эффективности FDA при сокращениях: непонятно, кто будет гарантировать performance агентства после принудительного увольнения сотрудников.","text_en":"Risk to FDA performance under forced layoffs: unclear who guarantees agency performance after staff cuts.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0012","quote":"When the president's going to force FDA to shed whatever number of people... who's still gonna guarantee the performance of that agency?"},{"chunk_id":"doc_af75dee37a48_chunk_0012","quote":"And that's the problem."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0012_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Долгий онбординг/обучение ревьюеров FDA: по словам сотрудников, они становятся продуктивными только через ~2 года, поэтому последствия сокращений быстро не исправить.","text_en":"Long onboarding/training for FDA reviewers: reportedly not productive until ~2 years, so impacts of layoffs can’t be reversed quickly.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0012","quote":"it takes a very long time to train a reviewer."},{"chunk_id":"doc_af75dee37a48_chunk_0012","quote":"they're really not productive. Until they've been there for two years"}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0012_n3","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"FDA воспринимается как слишком медленная и бюрократическая в процессе review; есть признание, что агентство могло бы работать быстрее и лучше.","text_en":"FDA is perceived as too slow and bureaucratic in drug review; acknowledged it could be faster and better.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0012","quote":"is the FDA too slow, too bureaucratic, too regimented in the way they review drugs?"},{"chunk_id":"doc_af75dee37a48_chunk_0012","quote":"Are they too bureaucratic? Are they too slow? Absolutely, they could be faster."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0013_n1","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"FDA воспринимается как бюрократичная и медленная организация; есть признание, что она могла бы работать быстрее и лучше.","text_en":"FDA is perceived as bureaucratic and slow; there’s acknowledgment it could be faster and better.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0013","quote":"Are they too bureaucratic? Are they too slow? Absolutely, they could be faster. Absolutely, they could be better."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0013_n2","doc_id":"doc_af75dee37a48","kind":"trend","text_ru":"Обсуждается продвижение идеи отдельного регуляторного стандарта для крайне редких заболеваний, потому что текущая «регуляторная гибкость» не работает.","text_en":"There’s push for a different regulatory standard for ultra-rare diseases because the current flexibility paradigm isn’t working.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0013","quote":"pushing hard to persuade Congress and to persuade the FDA to create a different standard for extremely rare diseases"}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0013_n3","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Сокращение штата FDA может иметь непредвиденные последствия и не обязательно экономит деньги налогоплательщиков, так как многие сотрудники drug review оплачиваются user fees индустрии.","text_en":"Cutting FDA staff may have unintended consequences and may not save taxpayer money since many drug review staff are funded by industry user fees.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0013","quote":"It's the idea that. That. is likely going to have unintended consequences."},{"chunk_id":"doc_af75dee37a48_chunk_0013","quote":"most of the drug review staff are paid for by industry user fees"}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0014_n1","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Фрустрация индустрии из‑за качества/пропускной способности NIH и ощущение неэффективности использования бюджета.","text_en":"Industry frustration with NIH quality/throughput and perceived inefficiency in how its budget is used.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0014","quote":"have been a little frustrated with the quality and the throughput that NIH puts out."},{"chunk_id":"doc_af75dee37a48_chunk_0014","quote":"most people would say, 'Wow, there is a lot of inefficiency there.'"}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0014_n2","doc_id":"doc_af75dee37a48","kind":"opportunity","text_ru":"Запрос на более эффективный формат «партнёрства с индустрией», чтобы направлять использование NIH-грантов/долларов.","text_en":"Desire for an industry partnership model to help drive/guide NIH spending and grant use.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0014","quote":"I wish there was a better way to have almost like an industry partnership to drive and guide that use of dollars."}],"confidence":"medium"}
{"nugget_id":"doc_af75dee37a48_chunk_0014_n3","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Неопределённость и риск сокращений/дестабилизации NIH: возможные cutbacks, disruption коллабораций с индустрией и влияние на доступ к SBIR для малых биотехов.","text_en":"Uncertainty and risk of NIH cutbacks/disruption: potential funding reductions, disrupted industry collaborations, and impacts on SBIR access for small biotechs.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0014","quote":"there's a lot of concern. That there are going to be moves... damage the ability of the NIH to fund cutting-edge research"},{"chunk_id":"doc_af75dee37a48_chunk_0014","quote":"disrupting relationships, research relationships, collaborations that industry has with NIH"},{"chunk_id":"doc_af75dee37a48_chunk_0014","quote":"Perhaps it might change the ability of industry to get SBIR funding, which is really important for some of the small biotechs"}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0015_n1","doc_id":"doc_af75dee37a48","kind":"pain","text_ru":"Есть опасения, что изменения могут нарушить исследовательские отношения/коллаборации индустрии с NIH и NIH-funded исследователями.","text_en":"Concerns that changes could disrupt industry research relationships/collaborations with NIH and NIH-funded researchers.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0015","quote":"impact would be disrupting relationships, research relationships, collaborations that industry has with NIH, with NIH-funded researchers."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0015_n2","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Есть риск изменения доступа индустрии к SBIR funding, что особенно важно для небольших биотехов.","text_en":"Risk that industry access to SBIR funding may change, which is especially important for small biotechs.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0015","quote":"Perhaps it might change the ability of industry to get SBIR funding, which is really important for some of the small biotechs especially."}],"confidence":"high"}
{"nugget_id":"doc_af75dee37a48_chunk_0015_n3","doc_id":"doc_af75dee37a48","kind":"constraint","text_ru":"Неопределённость вокруг будущего FDA user fee reauthorization: может пойти вперёд, быть улучшено или «blown up» и вызвать реальные проблемы.","text_en":"Uncertainty around FDA user fee reauthorization: it may proceed, be improved, or be blown up and cause real problems.","evidence":[{"chunk_id":"doc_af75dee37a48_chunk_0015","quote":"what's going to happen with the user fee reauthorization is that going to go forward... or is it going to get blown up and cause real problems."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0000_n1","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Заметная доля публичных биотех-компаний торгуется с отрицательной enterprise value (стоимость equity ниже кэша на балансе), формируя «армию зомби-биотехов».","text_en":"A notable share of public biotech companies trade at negative enterprise value (equity valued below cash on the balance sheet), forming an 'army of zombie biotechs'.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0000","quote":"I track about 700... public biotech companies and about 200. of those trade at a negative EV in some form or another."},{"chunk_id":"doc_51bff68de235_chunk_0000","quote":"companies that trade at a negative enterprise value... the equity in the company is worth less than the cash."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0000_n2","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"После клинических/пайплайновых неудач компании могут оказаться в состоянии «зомби» (отрицательная EV), и возникает проблема: что делать с оставшимся кэшем и почему такие компании продолжают существовать.","text_en":"After clinical/pipeline setbacks, companies can become 'zombies' (negative EV), raising the problem of what to do with remaining cash and why such companies keep existing.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0000","quote":"that situation arises when companies have... significant setbacks, right? Clinical trial, clinical setback, setbacks with their pipelines."},{"chunk_id":"doc_51bff68de235_chunk_0000","quote":"what to do with these companies and why they continue to exist"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0000_n3","doc_id":"doc_51bff68de235","kind":"opportunity","text_ru":"Инвесторы ищут компании, которые выглядят «зомби», но могут «трансформироваться», что рассматривается как источник интересных инвестиционных возможностей.","text_en":"Investors look for companies that appear to be 'zombies' but can transform, creating interesting investment opportunities.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0000","quote":"As an investor, we are always looking to find companies that look like zombies but aren't, because those can create pretty interesting opportunities."},{"chunk_id":"doc_51bff68de235_chunk_0000","quote":"we've seen some incredible kind of zombie transformations."}],"confidence":"medium"}
{"nugget_id":"doc_51bff68de235_chunk_0001_n1","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Инвесторы сегодня часто быстро списывают компании как «зомби», хотя при внимательном анализе данных они могут такими не быть.","text_en":"Investors today often write off companies as “zombies” too quickly, even though closer data review may show they aren’t.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0001","quote":"many investors are just very quick today to write off companies that. If they actually looked hard enough and looked at the data"}],"confidence":"medium"}
{"nugget_id":"doc_51bff68de235_chunk_0001_n2","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"В индустрии в целом «в агрегате» много денег тратится впустую из‑за управленческих и мотивационных факторов (аррогантность, жадность, нежелание уходить с позиций).","text_en":"In aggregate, the industry wastes a lot of money due to management/motivation issues (arrogance, greed, unwillingness to give up positions).","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0001","quote":"when you look in the aggregate, there is a lot of money that is wasted, whether that's because of arrogance, because of greed"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0001_n3","doc_id":"doc_51bff68de235","kind":"buyer_signal","text_ru":"Крупные акционеры могут требовать закрытия компании после провала ключевого эксперимента, если именно это они финансировали и не заинтересованы в дальнейших пивотах.","text_en":"Large shareholders may push to shut down a company after a key experiment fails if that’s what they funded and they’re not interested in pivots.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0001","quote":"the company's largest shareholders and they want the company to be shut down because they said this is what we funded it didn't work"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0002_n1","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Инвесторов раздражают резкие «пивоты»/смена фокуса компании: они вкладывались в одно, а компания тратит деньги на другое, из которого крупным инвесторам сложно выйти.","text_en":"Investors get upset by hard pivots: they invested for one focus, but the company uses capital for something else, and large investors can’t easily exit.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0002","quote":"“It's like I invested in you to do this, and now you've taken your investment dollars... And now you're doing something that I'm totally not interested in.”"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0002_n2","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Озвучена потребность в консолидации на публичном рынке из‑за «редундантности»: много компаний делают одно и то же и делают это плохо.","text_en":"Call for public-market consolidation due to redundancies: many companies try to do the same thing and do it poorly.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0002","quote":"“we just have so many redundancies... so many companies who are trying to do sort of the same thing similarly and doing them badly.”"},{"chunk_id":"doc_51bff68de235_chunk_0002","quote":"“we need some consolidation, I think, at least on the public side.”"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0002_n3","doc_id":"doc_51bff68de235","kind":"opportunity","text_ru":"Возможность/механика для «проверки мандата инвесторов»: предложить акционерам выбор — выкуп/возврат денег за акцию или остаться в «следующем путешествии» с большей долей; аналогично практикам в некоторых reverse mergers (дивиденд/байбек для держателей оболочки).","text_en":"Opportunity/mechanism to test investor mandate: offer shareholders a choice—buyback/cash-out per share or stay for the next strategy with a larger stake; similar to some reverse-merger practices.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0002","quote":"“what if you do something where you basically say... we'll give you x dollars per share or you can stay... those who stay get a larger stake”"},{"chunk_id":"doc_51bff68de235_chunk_0002","quote":"“some reverse merge companies are doing now... existing holders of the shell... can get a dividend or your shares bought back”"}],"confidence":"medium"}
{"nugget_id":"doc_51bff68de235_chunk_0003_n1","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Компании недостаточно думают о своих акционерах; из‑за агентских причин менеджменту сложно/невыгодно возвращать кэш акционерам.","text_en":"Companies don’t spend enough time thinking about shareholders; agency issues make returning cash to shareholders difficult/unattractive.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0003","quote":"Companies definitely don't spend enough time thinking about their shareholders, and there's obvious agency reasons for that."},{"chunk_id":"doc_51bff68de235_chunk_0003","quote":"it's very hard for them. to say hey we want to return cash. because it's so hard to get cash."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0003_n2","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"За последние 2–3 года спикер не смог убедить ни одну компанию добровольно вернуть кэш акционерам; делают это только под сильным давлением.","text_en":"In the last 2–3 years, the speaker couldn’t get any company to voluntarily return cash to shareholders; they do it only under strong pressure.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0003","quote":"I have been completely unsuccessful in getting a company in the last two or three years to voluntarily agree to return cash to shareholders."},{"chunk_id":"doc_51bff68de235_chunk_0003","quote":"They will do it with a gun to their head."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0003_n3","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Упоминается сделка: Stoke заключила с Biogen «rest of world» партнёрство по программе Dravet (права вне США/Северной Америки).","text_en":"Deal mentioned: Stoke signed a rest-of-world partnership with Biogen for the Dravet program (rights ex-U.S./ex-North America).","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0003","quote":"Stoke. Signed a rest of world deal with Biogen on their Dravet program."},{"chunk_id":"doc_51bff68de235_chunk_0003","quote":"they struck a partnership with Biogen for, you know, for basically ex-U. S. rights, ex-North American rights."}],"confidence":"medium"}
{"nugget_id":"doc_51bff68de235_chunk_0004_n1","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Компании (пример: Stoke) испытывают давление из‑за необходимости финансировать дорогостоящие Phase 3 исследования; ожидание такого рейза может «давить» на акцию.","text_en":"Companies (e.g., Stoke) face pressure from needing to fund costly Phase 3 trials; anticipation of a raise can depress the stock.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0004","quote":"they needed to raise money to fund the phase three study, and um, it was one of the reasons why this talk had been depressed"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0004_n2","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"Партнёрство/продажа части коммерческих прав может восприниматься рынком как «обременение» актива и снижать привлекательность для инвесторов/покупателей.","text_en":"Partnering/selling part of commercial rights can be seen as encumbering the asset, reducing attractiveness to investors/acquirers.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0004","quote":"some people who thought that it wasn't the idea that this is now an encumbered asset"}],"confidence":"medium"}
{"nugget_id":"doc_51bff68de235_chunk_0004_n3","doc_id":"doc_51bff68de235","kind":"buyer_signal","text_ru":"Инвесторы, ориентированные на M&A, могут продавать после объявления партнёрства вместо поглощения, что отражает предпочтение buyout-сценария.","text_en":"M&A-focused investors may sell after a partnership announcement instead of an acquisition, indicating preference for a buyout outcome.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0004","quote":"whenever you sign a partnership rather than getting acquired though those types of investors you know sell and move on"}],"confidence":"medium"}
{"nugget_id":"doc_51bff68de235_chunk_0005_n1","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Биотех-компании (в т.ч. в gene therapy) заранее «конфиденциально» договариваются с банкирами и несколькими институционалами и фиксируют раунд до публичного раскрытия данных.","text_en":"Biotech companies (incl. gene therapy) may confidentially line up bankers and a few institutions to lock in a raise before publicly releasing data.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0005","quote":"in the days leading up to announcing this news, they confidentially got together with bankers and like a handful of institutional investors and locked in a raise"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0005_n2","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Слабый рынок биотеха (особенно gene therapy) делает реакцию акций на хорошие новости непредсказуемой, из‑за чего компании не могут «рассчитывать на хороший stock reaction».","text_en":"In a weak biotech market (especially gene therapy), stock reactions to good news are unreliable, making it hard to count on a positive move.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0005","quote":"Biotech has been terrible lately, especially in the gene therapy space. And you can't count on a good stock reaction sometimes"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0005_n3","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"У generalist и retail инвесторов есть опасения по поводу справедливости, когда институционалы получают ранний доступ к данным и возможность инвестировать по низкой цене.","text_en":"Generalist and retail investors have fairness concerns when institutions get early data access and can invest at a low price.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0005","quote":"generalist and retail investors have, I think, valid concerns about the fairness of our industry"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0006_n1","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Инвесторы конкурируют между собой и при высоком спросе «разгоняют» цену/акции, что регулярно происходит в финансированиях.","text_en":"Investors compete and, when demand is high, bid up price/stock; this happens regularly in financings.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0006","quote":"when there is a lot of demand... you just see investors bidding up... bidding up the stock."},{"chunk_id":"doc_51bff68de235_chunk_0006","quote":"We see that continuing to happen on financings on a pretty regular basis."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0006_n2","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Компаниям сложно привлекать капитал; из‑за этого они оказываются в невыгодном положении и «на милости» инвесторов/фондов.","text_en":"Companies find it difficult to raise money, putting them at a disadvantage and at the mercy of investors/funds.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0006","quote":"companies have to raise money. They are sort of at a disadvantage because it's difficult to raise money."},{"chunk_id":"doc_51bff68de235_chunk_0006","quote":"they are sort of at the mercy of the of investors and funds."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0006_n3","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"В многих биотехах трудно набрать значимую позицию на открытом рынке из‑за низких объёмов торгов; институционалам часто нужен раунд/рефинансирование, чтобы построить позицию.","text_en":"In many biotechs, low trading volume makes it hard to build a meaningful open-market position; institutions often need a financing/refinancing to build one.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0006","quote":"it is actually very difficult to build a meaningful position on the open market in many biotechs simply because of volume"}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0007_n1","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"У биотех-компаний сохраняется «pricing tension» и риск неверно оценить ценовую чувствительность при переговорах/сделках.","text_en":"Biotech companies face ongoing pricing tension and risk misjudging pricing sensitivity in negotiations/deals.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0007","quote":"\"I think that pricing tension really continues to uh you know really continues to exist uh you know for companies.\""}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0007_n2","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Компании «тестируют» рынок, публикуя данные и смотря на реакцию, чтобы использовать это для привлечения финансирования; при «более грязных» данных могут тестировать заранее, чтобы понять, есть ли путь вперёд.","text_en":"Companies test the market by releasing data and gauging reaction to raise money; with messier data they may test earlier to see if there’s a path forward.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0007","quote":"\"I'm going to put data out, I'm going to see how the market reacts, and I'm going to use that to raise money.\""},{"chunk_id":"doc_51bff68de235_chunk_0007","quote":"\"particularly, I think, when data is, you know, maybe a little bit messier.\""}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0007_n3","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"Розничные инвесторы не могут эффективно оценивать ограниченное число datapoints у биотех-компаний, что влияет на динамику PIPE/дисконтов.","text_en":"Retail investors can’t effectively evaluate a small number of datapoints at biotech companies, shaping PIPE/discount dynamics.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0007","quote":"\"retail investors can't come in and look at four data points or whatever at some biotech company.\""}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0008_n1","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Сложно превратить научные прорывы в генотерапии в устойчиво прибыльный бизнес; бизнес-кейс для таких продуктов «очень трудный».","text_en":"Turning gene-therapy scientific breakthroughs into a successful, profitable business is very difficult; the business case is hard.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0008","quote":"\"how do you turn these breakthrough scientific achievements—um— ... into a successful business venture and you know it turns out that it's very difficult\""}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0008_n2","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"У компании были серьёзные финансовые ограничения: сложные условия по займам/ковенантам и ощущение, что варианты привлечения денег были исчерпаны.","text_en":"Severe financial constraints: loans/loan covenants and reportedly exhausting other fundraising options.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0008","quote":"\"they had you know loans uh loan covenants\""},{"chunk_id":"doc_51bff68de235_chunk_0008","quote":"\"they had sort of exhausted all other options to uh to raise money\""}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0008_n3","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"В разработке и выводе генотерапии возникали научные «hiccups and setbacks» и производственные проблемы; также отмечается чрезмерный расход денег.","text_en":"Gene-therapy development faced scientific hiccups/setbacks and manufacturing issues; also noted heavy spending.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0008","quote":"\"they had sort of some scientific hiccups and setbacks\""},{"chunk_id":"doc_51bff68de235_chunk_0008","quote":"\"and they had manufacturing\""},{"chunk_id":"doc_51bff68de235_chunk_0008","quote":"\"they just spent so much money\""}],"confidence":"medium"}
{"nugget_id":"nugget_0001","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Сложно сделать генную терапию работающим бизнесом; это упоминается как фактор, способствующий краху компании.","text_en":"It is difficult to make gene therapy work as a business; cited as a factor contributing to a company’s demise.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0009","quote":"\"this difficulty of making gene therapy work as a business.\""}],"confidence":"high"}
{"nugget_id":"nugget_0002","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Упоминается кейс, где китайская конкуренция стала фактором, «вымывшим» компанию; это подаётся как ранний/первый исторический пример такого эффекта.","text_en":"A case is described where Chinese competition helped wipe out a company; framed as an early/first historical example of this dynamic.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0009","quote":"\"one of the first companies ever, in part, to be wiped out by Chinese competition.\""}],"confidence":"medium"}
{"nugget_id":"nugget_0003","doc_id":"doc_51bff68de235","kind":"opportunity","text_ru":"Возможность строить биотех-компании более эффективно (вплоть до команды ~15 человек) и конкурировать «на эффективности», чтобы лучше противостоять китайским игрокам.","text_en":"Opportunity to run biotech more efficiently (even with ~15 people) and compete on efficiency to better outcompete Chinese players.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0009","quote":"\"for biotech companies to start to compete on efficiency.\""},{"chunk_id":"doc_51bff68de235_chunk_0009","quote":"\"starting the next Bluebird with 15 people\""}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0010_n1","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"В биотехе возможны неожиданные клинические побочные эффекты (пример: значимый билирубин как сайд-эффект), что является риском разработки.","text_en":"Biotech development can face unexpected clinical side effects (e.g., significant bilirubin side effect), a core risk of drug development.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0010","quote":"they discovered that they had a significant bilirubin side effect with one of their drugs."},{"chunk_id":"doc_51bff68de235_chunk_0010","quote":"small molecule drug development is really hard. And until you see it in the clinic, there's a lot that you don't know."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0010_n2","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Растёт число компаний, у которых вскоре после IPO происходят негативные события; несколько IPO «blown up» в течение ~6 месяцев после выхода на биржу.","text_en":"A growing number of companies face negative events shortly after IPO; multiple IPOs have “blown up” within ~6 months of going public.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0010","quote":"a growing list of companies that, you know, shortly after IPO has seen some kind of talks."},{"chunk_id":"doc_51bff68de235_chunk_0010","quote":"at least the second, maybe even third IPO to have blown up. In the last you know six months since going public"}],"confidence":"medium"}
{"nugget_id":"doc_51bff68de235_chunk_0010_n3","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Сентимент в биотехе сейчас очень плохой; инвесторы/клиенты теряют деньги, что «casts a pall over the industry».","text_en":"Biotech sentiment is very poor; investors/clients are losing money, casting a pall over the industry.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0010","quote":"The sentiment out there is terrible right now in biotech"},{"chunk_id":"doc_51bff68de235_chunk_0010","quote":"people are crowding into the same set of names and seemingly you know, losing money hand over fist"}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"По наблюдению автора, после «credible announcement» о слиянии примерно в половине случаев сделка закрывается и акция растёт, а в половине — не закрывается и акция падает.","text_en":"After a credible merger announcement, about half the time the deal happens and the stock rises; about half the time it doesn’t and the stock falls.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0011","quote":"About half the time, the merger happens, and this stock goes up. And about half the time the merger doesn't happen and of course the stock goes down."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"Процесс после объявления M&A обычно занимает 2–4 месяца, так как банкиры «шопят» компанию, чтобы получить лучший оффер.","text_en":"Post-announcement M&A process usually takes 2–4 months because bankers shop the company to secure the best offer.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0011","quote":"It usually takes two to four months. And the reason is that The bankers are probably going to keep shopping SpringWorks"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"Крупная фарма в целом сфокусирована на больших онкологических показаниях, поэтому активы SpringWorks «вероятно» не будут подобраны крупной фармой, так как компания нацелена на средние и малые показания.","text_en":"Large pharma generally focuses on big oncology indications, so SpringWorks’ assets may be less likely to be acquired by large pharma given its mid/smaller indication focus.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0011","quote":"large pharma are in general focused on big indications in oncology and SpringWorks is going after mid-size and smaller indications."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Наблюдается тренд: небольшие биотехи всё чаще успешно коммерциализируют препараты самостоятельно, хотя исторически это было сложно.","text_en":"Trend: smaller biotechs are increasingly able to commercialize drugs on their own, historically a difficult task.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0012","quote":"this speaks to a broader trend, you know, companies being able to commercialize on their own, right? And that's something that's, you know, traditionally been really hard."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Успешные запуски (особенно превзошедшие консенсус) часто приводят к M&A: такие компании обычно «замечают» и покупают.","text_en":"Successful launches (beating consensus) often lead to M&A: such companies tend to get noticed and acquired.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0012","quote":"in almost every case, company that has a good launch gets spotted."},{"chunk_id":"doc_51bff68de235_chunk_0012","quote":"companies that you know that had launches that beat consensus, and that didn't get bought. Not many."}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"В оценке данных по ожирению рынок/аналитики чрезмерно фокусируются на проценте снижения веса (вплоть до различий 20% vs 21–22%), игнорируя важные факторы вроде переносимости и удобства.","text_en":"Obesity data evaluation is overly fixated on percent weight loss (e.g., 20% vs 21–22%), underweighting tolerability and convenience.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0012","quote":"every time a new data set— phase one or phase two— comes out... the first thing people do is go toward that. Percent weight loss"},{"chunk_id":"doc_51bff68de235_chunk_0012","quote":"treat a 20% reduction in body mass quite differently from a 21% or 22% reduction."},{"chunk_id":"doc_51bff68de235_chunk_0012","quote":"tolerability is very important. The other thing that's very important, of course, is convenience."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0013_n1","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"В сегменте препаратов для снижения веса конкуренция/«победители и проигравшие» вероятно будут определяться больше переносимостью и удобством (частотой инъекций), чем различиями в эффективности (проценты снижения массы).","text_en":"In weight-loss drugs, winners/losers may be determined more by tolerability and convenience (injection frequency) than small efficacy differences.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0013","quote":"it'll be probably much more on those two latter points— tolerability and convenience— than it'll be on efficacy."},{"chunk_id":"doc_51bff68de235_chunk_0013","quote":"I think patients know whether they're. Injecting themselves on a weekly or monthly or maybe even future quarterly basis."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0013_n2","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"Регуляторное/правовое давление: Lilly и Novo подали иски, чтобы FDA объявило об отсутствии дефицита и остановило распространение GLP-1 через компаундинговые аптеки; если решение FDA финальное, продавать препараты от компаундеров нельзя.","text_en":"Regulatory/legal constraint: Lilly and Novo sued to push FDA to end shortage status and stop GLP-1 distribution via compounding pharmacies; if FDA decision is final, they can’t keep selling compounded drugs.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0013","quote":"Lili and Novo have filed lawsuits. To force the FDA to declare that there is no longer shortage and to stop distribution of GLP-1s by compounding pharmacies."},{"chunk_id":"doc_51bff68de235_chunk_0013","quote":"They can't continue selling drugs from compounders."}],"confidence":"high"}
{"nugget_id":"doc_51bff68de235_chunk_0013_n3","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"Бизнес-модель Hims сместилась к «customized compounding» и быстрому квалифицированию пациента как «non-responder» к доступным дозам; ожидаемая проблема — патентная сторона.","text_en":"Hims shifted to “customized compounding” and quickly qualifies patients as non-responders to available doses; expected issue is patents.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0013","quote":"it will very rapidly try to qualify you as a non-responder to currently available doses."},{"chunk_id":"doc_51bff68de235_chunk_0013","quote":"their business model shifted about two months ago to what they call customized compounding."},{"chunk_id":"doc_51bff68de235_chunk_0013","quote":"The issue that they're going to run into is going to be on the patent side."}],"confidence":"medium"}
{"nugget_id":"nugget_001","doc_id":"doc_51bff68de235","kind":"constraint","text_ru":"Попытки обходить правила компаундинга через «альтернативные дозировки» могут привести к патентным искам и рискам на стороне патентов.","text_en":"Using alternative dosing to dodge compounding rules may trigger patent lawsuits and patent-side risk.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0014","quote":"if they're, you know, using dosing rules to essentially dodge compounding regulations, they may find themselves in in a lawsuit"}],"confidence":"high"}
{"nugget_id":"nugget_002","doc_id":"doc_51bff68de235","kind":"trend","text_ru":"В obesity-направлении крупная фарма готова заранее производить большие объёмы препарата до появления данных, принимая на себя риск по запасам.","text_en":"In obesity, big pharma is willing to manufacture large drug supply before data readout, taking inventory risk.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0014","quote":"Eli Lilly has already apparently produced like 500 million dollars worth of their their oral therapy... that's before the data."}],"confidence":"medium"}
{"nugget_id":"nugget_003","doc_id":"doc_51bff68de235","kind":"pain","text_ru":"Малым биотехам сложно конкурировать в obesity-сегменте из‑за масштаба инвестиций и риска, который могут позволить себе крупные компании.","text_en":"Smaller biotechs struggle to match the investment scale and risk tolerance needed to compete in obesity.","evidence":[{"chunk_id":"doc_51bff68de235_chunk_0014","quote":"That's a. a tough thing for smaller biotech companies to do."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0000_n1","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Рынок IPO в биотехе фактически остановился, и большинство компаний из IPO-класса 2024 торгуются ниже цены размещения (с сильным медианным падением).","text_en":"The biotech IPO market is at a standstill, and most 2024 IPOs trade below issue price (with a large median drop).","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0000","quote":"The IPO market is also at a standstill. The 2024 IPO class has 16 out of 18 companies trading below IPO price. And a median drop of 61%."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0000_n2","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Фонды биотеха/здравоохранения закрываются из‑за слабой доходности и редемпшенов, что вынуждает их продавать активы без разбора.","text_en":"Some biotech/healthcare funds are shutting down due to poor performance and redemptions, forcing indiscriminate selling.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0000","quote":"Some biotech and healthcare funds have been shutting down due to poor performance and redemptions, forcing them to sell indiscriminately."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0000_n3","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"Компании с фундаментальным прогрессом стали дешевле, что формирует «богатый» набор возможностей для инвесторов, готовых размещать капитал (публично и приватно).","text_en":"Companies with strong fundamental progress have become cheaper, creating a rich opportunity set for investors deploying capital (public and private).","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0000","quote":"companies that have made a lot of great fundamental progress are cheaper than they were a few months ago"}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0001_n1","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"В текущем рынке внимание инвесторов смещено к M&A, потому что «в зелёной зоне» оказываются в основном компании, которые покупают; создаётся ощущение, что заработать можно только через M&A.","text_en":"In the current market, investor attention is heavily on M&A because the stocks that perform are often those being acquired; it feels like the only way to get paid is via M&A.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0001","quote":"\"the focus on M &A is probably as substantial as it's ever been.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0001","quote":"\"the only way I'm getting paid is through M&A.\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0001_n2","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Для независимых biotech после успешного запуска препарата быстро возникает давление со стороны рынка: требуется показать «что дальше», долгосрочную стратегию и как избежать будущего patent cliff.","text_en":"Independent biotechs face rapid post-launch pressure to show “what’s next,” a long-term strategy, and how they will avoid a future patent cliff.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0001","quote":"\"there's this intense focus on, okay, what are you going to do for me next?\""},{"chunk_id":"doc_97a8a85455c7_chunk_0001","quote":"\"How are you going to prevent? Having a patent cliff\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0001_n3","doc_id":"doc_97a8a85455c7","kind":"opportunity","text_ru":"M&A рассматривается как «выход» для компаний, которые идут в коммерциализацию самостоятельно, на фоне более жёсткого/скептического инвестиционного отношения к таким компаниям.","text_en":"M&A is viewed as an exit path for go-it-alone companies amid a harsher/more skeptical investment outlook for them.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0001","quote":"\"the investment outlook for these go-it-alone companies is more severe or more skeptical than it's ever been.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0001","quote":"\"And M&A seems like a great way out for those companies\""}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0002_n1","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Коммерциализация/запуск препарата для biotech сложны и могут быть разрушительными для стоимости; до запуска оценка компании остаётся «story stock».","text_en":"Commercialization/drug launch is hard for biotech and can be value-destructive; pre-launch valuation is ambiguous (“story stocks”).","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0002","quote":"\"the most value destructive thing a biotech company can do is is launch a drug\""},{"chunk_id":"doc_97a8a85455c7_chunk_0002","quote":"\"commercializing drugs is really hard\""},{"chunk_id":"doc_97a8a85455c7_chunk_0002","quote":"\"these stocks are all story stocks until that day\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0002_n2","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"На конференции отмечали плохой сентимент и фокус компаний на продлении runway: обсуждают, как «растянуть кэш» и какие программы сокращают.","text_en":"Conference sentiment was poor; companies focused on extending runway—talking about stretching cash and cutting programs.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0002","quote":"\"Sentiment, as we said, was poor.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0002","quote":"\"companies are talking about how much they can stretch their cash and how many programs they're cutting\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0002_n3","doc_id":"doc_97a8a85455c7","kind":"opportunity","text_ru":"Есть возможность консолидации онкологических активов, готовых к запуску или в фазе 3, которые ожидаются нишевыми и «торгуются на уровне кэша».","text_en":"Opportunity to consolidate oncology assets near launch or in phase 3 expected to be niche, many trading at cash.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0002","quote":"\"There are a lot of oncology assets that are ready to launch products or in phase three\""},{"chunk_id":"doc_97a8a85455c7_chunk_0002","quote":"\"products that are expected to be niche-y. And someone probably needs to consolidate them.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0002","quote":"\"They're all trading at cash.\""}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0003_n1","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"В вакцинах у компании мало BD-возможностей из‑за сильного внутреннего пайплайна; в онкологии после приобретения Cgen потребность во внешних инновациях ограничена (кроме небольших, комбинируемых с ADC).","text_en":"In vaccines there are few BD opportunities due to a robust internal pipeline; in oncology post-Cgen acquisition they need limited external innovation (except small assets combinable with an ADC).","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0003","quote":"In vaccines, they really don't see a lot of BD opportunities. They have a fairly robust internal pipeline."},{"chunk_id":"doc_97a8a85455c7_chunk_0003","quote":"In ontology, obviously, they just acquired Cgen... They don't need a lot of external innovation, other than smaller that can be combinable with an ADC."}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0003_n2","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"INI/иммунология названы «огромной темой»: рынки в ряде показаний растут, появляются конкуренты и «много новой биологии», включая новые модальности и ингаляционные биологики.","text_en":"INI/immunology is described as a huge theme: markets in several indications are growing, competitors are emerging, and there is lots of new biology, including new modalities and inhaled biologics.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0003","quote":"INI is obviously a huge theme for for us and many people. There's so much going on now."},{"chunk_id":"doc_97a8a85455c7_chunk_0003","quote":"these markets are really growing... multiple competitors now, but all new biology."},{"chunk_id":"doc_97a8a85455c7_chunk_0003","quote":"Also, new modalities and inhaled biologics."}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0003_n3","doc_id":"doc_97a8a85455c7","kind":"constraint","text_ru":"Для Chimerix ключевым ограничением/барьером было согласование с FDA стратегии ускоренного одобрения; значимым событием стало выравнивание с FDA на подачу по данным фазы 2 и получение priority review.","text_en":"A key barrier for Chimerix was aligning with the FDA on an accelerated approval strategy; a major milestone was filing based on phase 2 data and receiving priority review.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0003","quote":"the FDA was able to encourage them, or at least they gained alignment with the FDA on an accelerated approval strategy"},{"chunk_id":"doc_97a8a85455c7_chunk_0003","quote":"encouraged or aligned with the FDA to file for approval based on phase two data. They subsequently received priority review"}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0004_n1","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"В сделках M&A в биофарме Jazz описывается как покупатель, ориентированный на «singles and doubles», а не на «home runs».","text_en":"Jazz is described as pursuing an acquisition strategy focused on “singles and doubles” rather than “home runs.”","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0004","quote":"jazz really has been built on. an acquisition strategy where they're looking for singles and doubles and not necessarily home runs."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0004_n2","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"AbbVie заходит в ожирение с отличающимся подходом: не через GLP-1, а «lead with an amylin», с акцентом на длинный half-life и потенциально более редкое дозирование.","text_en":"AbbVie is entering obesity with a different approach: leading with an amylin (not GLP-1), highlighting long half-life and potentially less frequent dosing.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0004","quote":"it's taking a very different approach... companies are really leading. with a GLP-1... And Abby chose to lead with an amylin."},{"chunk_id":"doc_97a8a85455c7_chunk_0004","quote":"a half-life that's that's pretty long, about uh, you know, 270 hours. So that can you know, enable perhaps less frequent dosing."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0004_n3","doc_id":"doc_97a8a85455c7","kind":"opportunity","text_ru":"В ожирении фокус возможностей смещается от роста эффективности к улучшению переносимости, «muscle sparing» и другим параметрам; это описывается как «big biotech opportunity».","text_en":"In obesity, opportunity is shifting from increasing efficacy to improving tolerability, muscle sparing, and other attributes; described as a big biotech opportunity.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0004","quote":"I think that continues to be a big biotech opportunity. even with good products on the market."},{"chunk_id":"doc_97a8a85455c7_chunk_0004","quote":"the opportunity is shifted towards. tolerability, muscle sparing and other areas as opposed to increasing efficacy."}],"confidence":"high"}
{"nugget_id":"nugget_0001","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"Фокус возможностей в obesity-сегменте смещается от повышения эффективности к улучшению переносимости, сохранению мышечной массы и другим параметрам.","text_en":"In obesity, opportunity focus is shifting from increasing efficacy to tolerability, muscle sparing, and other attributes.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0005","quote":"the opportunity is shifted towards. tolerability, muscle sparing and other areas as opposed to increasing efficacy."}],"confidence":"high"}
{"nugget_id":"nugget_0002","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"В секторе много компаний с отрицательной NPV/enterprise value: рынок оценивает их так, будто активы не имеют ценности, а кэш будет «сожжён».","text_en":"Many biotechs trade at negative NPV/enterprise value, implying the market values their assets at zero and expects cash burn.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0005","quote":"upwards of, I think, at 1. 200 names that were negative NPV"},{"chunk_id":"doc_97a8a85455c7_chunk_0005","quote":"shareholders are valuing the company as if the cash that it has in the bank is just going to be invested to be a zero"}],"confidence":"high"}
{"nugget_id":"nugget_0003","doc_id":"doc_97a8a85455c7","kind":"buyer_signal","text_ru":"Растёт давление со стороны акционеров на принятие cash-deals и снижается терпимость к reverse mergers/ожиданию реализации тезисов.","text_en":"Shareholder pressure is increasing to accept cash deals, with less patience for reverse mergers or waiting for theses to play out.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0005","quote":"there's more pressure from shareholders to take these types of cash deals, and less patience for reverse mergers"}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Клинические испытания при IPF особенно трудно проводить; заболевание в целом «очень тяжёлое».","text_en":"IPF is a very tough disease and clinical trials are particularly difficult to run.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0006","quote":"IPF has been a very tough disease. Overall and clinical trials here have been particularly difficult to run."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_97a8a85455c7","kind":"constraint","text_ru":"В IPF наблюдается ограниченное число механизмов, которые демонстрировали эффективность.","text_en":"There are only a few mechanisms that have been seen to work in IPF.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0006","quote":"there are really just a few mechanisms that we have seen work in IPF"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_97a8a85455c7","kind":"opportunity","text_ru":"Есть пространство для улучшения переносимости уже одобренных препаратов для IPF.","text_en":"There is room to improve the tolerability profile of currently approved IPF drugs.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0006","quote":"there's a lot of room to improve, primarily on the tolerability profile of some of the drugs that are currently approved for IPF."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0007_n1","doc_id":"doc_97a8a85455c7","kind":"constraint","text_ru":"При большом числе параллельных программ компании сложно регулярно обновлять статус каждой по отдельности; поэтому дают агрегированные, общие апдейты сразу по нескольким программам.","text_en":"With many concurrent programs, it’s hard to provide individual program updates; companies may resort to broad, multi-program updates.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0007","quote":"\"they're, you know, at any given time, they're running like 15 or 16 different programs. Um, so updating individual programs is very hard.\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0007_n2","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"В разработке для биполярного расстройства (острая мания) у KB7-активатора не было достаточной доклинической/клинической базы ожидать эффекта, и исследование не достигло первичной конечной точки.","text_en":"For bipolar acute mania, there wasn’t much preclinical/clinical evidence KB7 would work, and the study missed the primary endpoint.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0007","quote":"\"they had a bipolar disorder study that they announced did not hit the primary endpoint.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0007","quote":"\"there really wasn't a lot of preclinical or clinical evidence that KB7 would have an impact here.\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0007_n3","doc_id":"doc_97a8a85455c7","kind":"opportunity","text_ru":"Есть рыночная/продуктовая возможность для подходов, которые быстрее и сильнее снижают IgG по сравнению с существующими FcRn, но ценность небольшого улучшения (5–10% относительного) под вопросом, особенно при выходе на рынок позже конкурентов.","text_en":"Opportunity for approaches that lower IgG faster/more than existing FcRn, but the value of a small (5–10%) relative improvement is questioned, especially if coming to market later.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0007","quote":"\"they're sort of trying to go uh head to head with uh the FCRNs out there\""},{"chunk_id":"doc_97a8a85455c7_chunk_0007","quote":"\"is maybe a five ten percent uh relative improvement in IGG reductions, is it gonna be meaningful now?\""}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0008_n1","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"Ожидается рост интереса и новостей по программам деградации внеклеточных белков; упоминаются как публичные, так и частные игроки с сильной поддержкой.","text_en":"More attention and news are expected around extracellular protein degrader programs, with both public and well-backed private players mentioned.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0008","quote":"I think you're going to hear more and more about these extracellular protein degrader programs."},{"chunk_id":"doc_97a8a85455c7_chunk_0008","quote":"there are a number of other ones that are private that have very strong backing."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0008_n2","doc_id":"doc_97a8a85455c7","kind":"constraint","text_ru":"В GMG отмечают рост placebo-эффекта, из‑за чего сокращается разница между активным лечением и плацебо; также нет обязательной линейности между снижением IgG и клиническими исходами, что усложняет интерпретацию и дизайн исследований.","text_en":"In GMG, rising placebo effects shrink active-vs-placebo deltas; IgG reduction is not necessarily linear with clinical outcomes, complicating interpretation and trial design.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0008","quote":"there is no necessarily linearity between IgG reduction and clinical outcomes because these are complicated disorders."},{"chunk_id":"doc_97a8a85455c7_chunk_0008","quote":"the placebo effect has gone up in GMG. So the delta, you know, between active and placebo is shrinking"}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0008_n3","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Для MRTX113 (G12D ингибитор) ключевой проблемой оказались фармакокинетика и формуляция: изначально IV с «challenging» PK, затем липосомальная форма, попытка перейти на oral закончилась неудачей из‑за PK.","text_en":"For MRTX113 (a G12D inhibitor), pharmacokinetics and formulation were major issues: initially IV with challenging PK, liposomal formulation, and an oral version failed due to PK.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0008","quote":"it was originally IV and the PK was fairly challenging"},{"chunk_id":"doc_97a8a85455c7_chunk_0008","quote":"they made it into a liposomal formulation"},{"chunk_id":"doc_97a8a85455c7_chunk_0008","quote":"into an oral. And it failed. ... it failed because of PK"}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Сделка M&A/приобретение оказалось разочаровывающим на коммерческой стороне, несмотря на ожидания победы на рынке.","text_en":"An acquisition has been commercially disappointing despite expectations of market success.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0009","quote":"\"that acquisition is disappointed a little bit, certainly on the commercial side\""}],"confidence":"medium"}
{"nugget_id":"n2","doc_id":"doc_97a8a85455c7","kind":"constraint","text_ru":"M&A описывается как сложный процесс; покупка более позднего актива может быть дорогой по сравнению с более ранним принятием клинического риска.","text_en":"M&A is described as complicated; buying later-stage assets can be expensive versus taking clinical risk earlier.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0009","quote":"\"M &A, as we know, is complicated.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0009","quote":"\"advise going earlier and taking clinical risk as opposed to buying something later\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"Публичные сообщения о вакцинации со стороны RFK воспринимаются как «про-вакцинные» в заголовках, но с «смешанными»/неопределёнными формулировками при чтении текста.","text_en":"Public vaccine messaging from RFK is seen as pro-vaccine in headlines but mixed/less definitive in the full text.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0009","quote":"\"the headlines looked very positive\""},{"chunk_id":"doc_97a8a85455c7_chunk_0009","quote":"\"it was a little wishy-washy\""}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0010_n1","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"Обсуждается, что CDC планирует крупное исследование связи вакцин и аутизма, несмотря на мнение части индустрии, что связь уже опровергнута; это создает резонансные заголовки.","text_en":"CDC is discussed as planning a large study on vaccines-autism link, despite industry belief it’s already debunked, generating headline noise.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0010","quote":"\"the CDC is planning a large study into the link between vaccines and autism, a link that many of us believe has already been completely debunked.\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0010_n2","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"FDA описывается как агентство с низкой моралью, которое чувствует, что его «подавляли» и «деприоритизировали», что является проблемой для нового руководства.","text_en":"FDA is described as a low-morale agency that feels pushed around and deprioritized, creating a leadership challenge.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0010","quote":"\"he's going to inherit some troubles, right? A low morale agency that feels like it's been pushed around and deprioritized.\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0010_n3","doc_id":"doc_97a8a85455c7","kind":"constraint","text_ru":"Публичные «напоминания» о важности вакцинации часто происходят только на фоне ухудшения общественного здоровья (например, вспышек), что ограничивает возможность улучшений без негативных событий.","text_en":"Public reminders of vaccine importance tend to come only at the expense of public health (e.g., outbreaks), limiting improvement without negative events.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0010","quote":"\"those reminders tend to come at the expense of public health at some point.\""}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0011_n1","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Переход топ-чиновников из FDA в Big Pharma вызывает критику и PR-негатив из‑за восприятия «revolving door» и риска конфликта интересов.","text_en":"Senior FDA-to-pharma moves trigger criticism and PR backlash over the perceived “revolving door” and conflict-of-interest risk.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0011","quote":"\"the move sparked some mixed feedback, including criticism on the, quote, revolving door between the FDA and Big Pharma.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0011","quote":"\"just seems like really bad PR\""},{"chunk_id":"doc_97a8a85455c7_chunk_0011","quote":"\"if you are looking for a job at Pfizer, are you going to cozy up too much\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0011_n2","doc_id":"doc_97a8a85455c7","kind":"opportunity","text_ru":"Спрос на экс‑FDA экспертизу/консалтинг для понимания ожиданий регулятора (дизайн КИ, эндпоинты) и повышения шансов успеха программ.","text_en":"Demand for ex-FDA expertise/consulting to understand regulator expectations (trial design, endpoints) and improve program success odds.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0011","quote":"\"I use consultants who are ex-FDA people. They do very well.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0011","quote":"\"I want to understand what is the FDA thinking\""},{"chunk_id":"doc_97a8a85455c7_chunk_0011","quote":"\"you want to know what the regulators want in terms of clinical trial design\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0011_n3","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"Вокруг «cross-pollination» между регулятором и индустрией наблюдается поляризация: одновременно звучит критика «revolving door» и аргументы о ценности обмена экспертизой.","text_en":"Polarized reactions to regulator–industry “cross-pollination”: criticism of the “revolving door” alongside arguments for the value of expertise exchange.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0011","quote":"\"The move sparked some mixed feedback\""},{"chunk_id":"doc_97a8a85455c7_chunk_0011","quote":"\"positive feedback from others who note the importance of cross-pollination.\""}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0012_n1","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"Обсуждается (как вероятность) сценарий радикального изменения регуляторной системы США: возможная ликвидация FDA и передача регулирования индустрии.","text_en":"A speculative scenario is discussed: radical change in US regulation, potentially eliminating the FDA and shifting regulation to industry.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0012","quote":"there's probably at least a 20% chance that in the next six months, we hear that the FDA is going to be completely eliminated."},{"chunk_id":"doc_97a8a85455c7_chunk_0012","quote":"Pfizer will just handle regulatory regulation of drugs. from here on out."}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0012_n2","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Жёсткая трактовка конфликта интересов (например, «увольнять онколога, если он получал деньги от фармы») может исключить ведущих онкологов, участвующих в клинических исследованиях, и подорвать клинические испытания/сотрудничество.","text_en":"Overly strict conflict-of-interest views (e.g., firing oncologists who took pharma money) could remove top trial-participating oncologists and undermine trials/collaboration.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0012","quote":"'If your oncologist has ever taken any money from pharma, you should fire them and find another oncologist.'"},{"chunk_id":"doc_97a8a85455c7_chunk_0012","quote":"that would essentially be removing the most highly regarded oncologists who participate in clinical trials"}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0012_n3","doc_id":"doc_97a8a85455c7","kind":"constraint","text_ru":"Существуют строгие правила/ограничения для бывших сотрудников FDA по взаимодействию с FDA после ухода (например, запрет «аутрича» и влияния на review team).","text_en":"There are strict post-employment rules limiting former FDA officials’ outreach and ability to influence FDA review teams.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0012","quote":"there's very strict rules about like her ability to like outreach to people on the FDA."},{"chunk_id":"doc_97a8a85455c7_chunk_0012","quote":"there's actual rules that says she's not allowed to do that."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0013_n1","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Есть недоверие/предвзятость к культуре науки; после COVID наблюдается «blowback» и восприятие научного сообщества как dismissive/arrogant.","text_en":"There is distrust/bias against science culture; post-COVID blowback includes perceptions of the scientific community as dismissive/arrogant.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0013","quote":"there seems to be, in some circles, distrust is underlying."},{"chunk_id":"doc_97a8a85455c7_chunk_0013","quote":"there's a lot of blowback from everything that happened in COVID."},{"chunk_id":"doc_97a8a85455c7_chunk_0013","quote":"perceptions of the scientific community being dismissive and also a little bit arrogant"}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0013_n2","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Людям сложно «break into the biotech industry», поэтому молодые специалисты часто пишут с запросами на нетворкинг.","text_en":"Breaking into biotech is difficult, leading younger people to frequently reach out for networking.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0013","quote":"how difficult it is to break into the biotech industry."},{"chunk_id":"doc_97a8a85455c7_chunk_0013","quote":"get pinged on social media or email or other channels. All the time, probably with requests from younger people to network."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0013_n3","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"По мере занятости у людей снижается интерес к «networking for the sake of networking»; ценятся конкретные и прямые запросы при интро.","text_en":"As people get busier, interest in networking for its own sake declines; specific, straightforward asks are preferred for introductions.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0013","quote":"as you get busier, there's less of an interest for networking for the sake of networking."},{"chunk_id":"doc_97a8a85455c7_chunk_0013","quote":"be very straightforward and specific about what you want when getting introduced."}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0014_n1","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Интро к «высокопоставленному» контакту (например, в Big Pharma), которое воспринимается как низкоценное, может повредить отношениям и будущим возможностям нетворкинга.","text_en":"Low-value intros to high-powered contacts (e.g., Big Pharma) can damage relationships and future networking ability.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0014","quote":"every time you introduce someone to another party—and if that party, like let's just say it's somebody at Big Pharma, if they view that introduction as uninteresting or low value— you've now taken an ax to your relationship"}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0014_n2","doc_id":"doc_97a8a85455c7","kind":"opportunity","text_ru":"Практика dual opt-in (сначала спросить принимающую сторону, ок ли интро) помогает снизить риск неловкого отказа и сохранить отношения.","text_en":"Dual opt-in intros (ask the recipient first) can reduce awkward rejections and preserve relationships.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0014","quote":"There's other best practices like the dual opt-in, meaning you ask the receiving party if it's okay to make the intro"}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0014_n3","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Людям бывает сложно сформулировать, что именно они хотят от нетворкинга; без ясной мотивации и контекста интро/разговоры становятся менее эффективными.","text_en":"People often struggle to articulate what they want from networking; without clear motivation/context, intros and conversations are less effective.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0014","quote":"What can be hard is people who maybe aren't quite sure what they're looking for yet"}],"confidence":"medium"}
{"nugget_id":"doc_97a8a85455c7_chunk_0015_n1","doc_id":"doc_97a8a85455c7","kind":"buyer_signal","text_ru":"При холодном нетворкинге/аутриче более конкретные, персонализированные запросы (с демонстрацией ресёрча) повышают вероятность, что человек согласится на встречу.","text_en":"In cold outreach/networking, specific, personalized asks that show research increase the likelihood someone will take the meeting.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0015","quote":"\"when they say something very specific... When they show an effort and an interest... that might lead people to be more intent to take the meeting.\""},{"chunk_id":"doc_97a8a85455c7_chunk_0015","quote":"\"do some research... if you do a little bit more research, you're more likely to get good results.\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0015_n2","doc_id":"doc_97a8a85455c7","kind":"trend","text_ru":"Обсуждается новость о планах NASDAQ перейти на 24-часовую торговлю.","text_en":"There is discussion of news that NASDAQ plans to move to 24-hour trading.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0015","quote":"\"I just heard that NASDAQ is announcing plans to move to 24-hour trading.\""}],"confidence":"high"}
{"nugget_id":"doc_97a8a85455c7_chunk_0015_n3","doc_id":"doc_97a8a85455c7","kind":"pain","text_ru":"Ожидаются неудобства для участников рынка/сервисных команд из‑за возможных ночных обращений клиентов при 24-часовой торговле.","text_en":"24-hour trading may create operational pain via overnight client calls/questions.","evidence":[{"chunk_id":"doc_97a8a85455c7_chunk_0015","quote":"\"looking forward to the 3 a. m. call from a client asking, 'Why is stock XXXX up 10 right now?\""}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0000_n1","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"В фокусе инвесторов/рынка слишком сильная фиксация на одном показателе (проценте снижения веса), что может искажать оценку продуктов.","text_en":"Investment focus is overly fixated on single headline numbers (weight-loss %), which can distort product assessment.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0000","quote":"There's just too much investment focus on singular numbers."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0000_n2","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Дифференциация препаратов для снижения веса смещается от абсолютной величины снижения веса к удобству, переносимости и безопасности.","text_en":"Differentiation in weight-loss drugs is shifting from absolute weight-loss magnitude to convenience, tolerability, and safety.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0000","quote":"differentiated on in the marketplace itself which isn't the absolute magnitude of weight loss but things like convenience and tolerability and safety."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0000_n3","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"В некоторых текущих исследованиях пациенты теряют вес слишком быстро и плохо это переносят, из‑за чего приходится снижать дозу.","text_en":"In some ongoing trials, patients are losing weight too quickly and not tolerating it well, requiring dose reductions.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0000","quote":"people are losing so much weight so quickly that they're They're not managing and they're having to dose down."}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0001_n1","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"Разработка лекарств занимает слишком много времени, стоит слишком дорого, результаты/процессы непоследовательны и неопределённы; индустрии нужна более быстрая и понятная система, дающая определённость для решений по активам.","text_en":"Drug development takes too long, costs too much, is inconsistent and uncertain; the industry needs a faster, clearer system to decide whether to advance or stop assets.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0001","quote":"It just takes too long, costs way too much money. is inconsistent even within therapeutic areas. It is uncertain."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0001","quote":"We need a system that provides certainty faster. And oftentimes more clearly."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0001_n2","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Звучит сильный двухпартийный консенсус в США, что биотехнологии — критически важный стратегический актив (в администрации и на Капитолийском холме).","text_en":"There is a strong bipartisan consensus in the US that biotechnology is a critical strategic asset (across the administration and Capitol Hill).","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0001","quote":"there is a strong consensus, bipartisan, that biotechnology is a critical strategic asset for the United States."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0001","quote":"That view is widely held in the administration... but also on Capitol Hill among Democrats and Republicans."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0001_n3","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"В отрасли отмечаются «неопределённость» и «хаос», усложняющие управление; предлагается различать риторику/«пробные шары»/экспромтные комментарии и даже executive orders.","text_en":"The sector faces uncertainty and chaos; a suggested constraint is the need to separate rhetoric/trial balloons/extemporaneous comments and even executive orders from signal.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0001","quote":"I get all the uncertainty, the chaos, and trying to manage through all of that."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0001","quote":"You need to distinguish between what are trial balloons, what is rhetoric... what are even executive orders."}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0002_n1","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Высокая неопределённость: заявления/исполнительные указы могут быть отозваны или заблокированы судами, поэтому важно отличать риторику от реальной политики.","text_en":"High uncertainty: statements/executive orders may be withdrawn or blocked by courts, so rhetoric must be distinguished from actual policy.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0002","quote":"You need to distinguish between what are trial balloons, what is rhetoric... what are even executive orders."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0002","quote":"That may likely not survive or succeed. They may be withdrawn. They may be blocked by the courts."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0002_n2","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Ожидаются изменения в FDA; обсуждаются реформы/модернизация и устранение бюрократии, включая изменения клинической парадигмы.","text_en":"Changes at the FDA are expected; reforms/modernization and reducing regulatory bureaucracy are being discussed, including beyond to the clinical trial paradigm.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0002","quote":"There will be change at the FDA."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0002","quote":"addressing redundancies and bureaucracies in the regulatory process. In fact, even beyond that to the clinical trial paradigm."}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0002_n3","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"Риск снижения доверия к данным и науке в контексте вакцинации; на это реагируют кампанией по продвижению вакцин.","text_en":"Risk of declining trust in data and science around vaccination; they are responding with a pro-vaccine campaign.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0002","quote":"this gets to the broader issue of trust. In data and trust in science"},{"chunk_id":"doc_85b3acc0f1e3_chunk_0002","quote":"Bio continues to be a strong advocate for the importance of vaccines. We have a very large campaign that we're going to be launching shortly."}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0003_n1","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Спикер отмечает более позитивную политическую среду для biotech/biopharma и отсутствие риторики про «злые фармкомпании»/цены на лекарства в президентском обращении.","text_en":"Speaker senses a more positive policy environment for biotech/biopharma, noting absence of drug-price/anti-pharma rhetoric in the president’s address.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0003","quote":"\"The one thing that we'd never heard drug prices. We didn't hear about evil pharmaceutical companies.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0003","quote":"\"I am sensing that there is a much more positive environment. From a policy standpoint.\""}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0003_n2","doc_id":"doc_85b3acc0f1e3","kind":"opportunity","text_ru":"Обсуждается намерение «сломать» регуляторные барьеры для продвижения исследований стволовых клеток, что указывает на окно возможностей для ускорения/поддержки stem cell R&D.","text_en":"Intent to break down regulatory barriers to advance stem cell research suggests an opportunity to accelerate/support stem cell R&D.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0003","quote":"\"to talk about how do we break down regulatory barriers to advance stem cell research.\""}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0003_n3","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"Тарифы рассматриваются как угроза: они могут ухудшить доступ к лекарствам, повысить цены и подчеркнуть зависимость отрасли от зарубежной (особенно европейской) цепочки поставок.","text_en":"Tariffs are framed as a threat: may harm access, raise medicine prices, and expose dependence on overseas (especially European) supply chains.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0003","quote":"\"significant tariffs on our industry will harm access to medicines.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0003","quote":"\"Could potentially raise the prices of medicines.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0003","quote":"\"how dependent we are on an overseas supply chain, particularly in Europe.\""}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0004_n1","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Зависимость от зарубежной (в т.ч. европейской) цепочки поставок рассматривается как существенная угроза для инновационной среды и доступа.","text_en":"Dependence on overseas (especially European) supply chains is seen as a major threat that could harm the innovation environment and access.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0004","quote":"just how dependent we are on an overseas supply chain, particularly in Europe. So those are some major threats"}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0004_n2","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Растёт вероятность реформы PBM/«посредников»; в Белом доме есть ощущение неэффективности системы и того, что «middlemen» не продвигают интересы пациентов и общественного здоровья.","text_en":"Likelihood of PBM/middlemen reform is increasing; the White House senses system inefficiencies and that middlemen don’t advance patient/public health interests.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0004","quote":"there is an increasing likelihood this year that we are going to see real reform of the PBMs and the middlemen."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0004","quote":"there are inefficiencies in the system, that the middlemen... are not advancing the interests of patients"}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0004_n3","doc_id":"doc_85b3acc0f1e3","kind":"opportunity","text_ru":"Продвижение priority review voucher для педиатрических заболеваний рассматривается как близкая возможность: есть сильная двухпартийная поддержка и работа над альтернативными законодательными «vehicle».","text_en":"Priority review voucher for pediatric diseases is a near-term opportunity: strong bipartisan support and work on alternative legislative vehicles.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0004","quote":"Another opportunity that we continue to work through and is really frustrating is the priority review voucher. In the pediatric diseases."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0004","quote":"there is very, very strong bipartisan support for it. It's almost like the perfect program."}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"Недоинвестирование и недостаточный фокус индустрии на женском здоровье на фоне выраженных диспропорций (Альцгеймер, аутоиммунные, ССЗ).","text_en":"Women’s health is underinvested and lacks industry focus despite major disparities (Alzheimer’s, autoimmune, cardiovascular impacts).","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0005","quote":"We have to address the disparities in women's health... We've been underinvested there tremendously. And as an industry, we've not had the focus"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"В cell & gene therapy «модель сломана».","text_en":"In cell and gene therapy, “the entire model is broken.”","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0005","quote":"Secondly, cell and gene therapy, where in many ways the entire model is broken."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Есть «реальный аппетит» в администрации к переосмыслению FDA и парадигмы клинических исследований.","text_en":"There is real appetite in the administration to reimagine the FDA and the clinical trial paradigm.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0005","quote":"The other important part on innovation is going to be reimagining again the FDA and the clinical trial paradigm. There is a real appetite"}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"Доступ к продвинутым терапиям (например, CAR-T) упирается в решения страховщиков через prior authorizations, step edits и utilization management, что становится крупной проблемой.","text_en":"Access to advanced therapies (e.g., CAR-T) is constrained by insurer decisions via prior authorizations, step edits, and utilization management, becoming a major issue.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0006","quote":"\"it's a recommendation that goes to the insurance company to decide. And when we look at these prior authorizations, step edits\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0006","quote":"\"the broad utilization management. And it's certainly within the Medicare Advantage programs\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"В биотехе стало больше идей и технологий, но значительная часть текущих вызовов связана с политикой и «рукотворными» факторами (включая финансирование базовых исследований).","text_en":"Biotech has more ideas and tools now, but many current challenges are policy-driven/manmade (including basic research funding).","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0006","quote":"\"Now there's so many ideas, so many tools, technologies.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0006","quote":"\"But most of our challenges now are manmade.\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Ожидаются конкретные политические предложения по биотеху в контексте национальной безопасности из отчёта National Security Commission on Emerging Biotechnology (неделя 7 апреля).","text_en":"Specific biotech policy proposals tied to national security are expected from the National Security Commission on Emerging Biotechnology report (week of April 7).","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0006","quote":"\"First week in April, the week of April 7th, will be a very important week.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0006","quote":"\"their report is going to come out\""}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0007_n1","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Ожидается выход конгрессовского отчёта с конкретными политическими предложениями по biotech (производство, FDA, клинические испытания) с целью «сломать барьеры», и предполагается, что рекомендации будут внедряться.","text_en":"A Congressional report with specific biotech policy proposals (manufacturing, FDA, clinical trials) is expected, aiming to break down barriers, and the recommendations are expected to be implemented.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0007","quote":"\"The critical importance of biotech for our national security. And I think you'll see these will be very specific policy proposals.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0007","quote":"\"Around manufacturing, around the FDA, around clinical trials, looking at a whole bunch of areas where we can break down barriers\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0007","quote":"\"Because these reports don't sit on a shelf. They are implemented.\""}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0007_n2","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"В CDC наблюдается нестабильность кадров: людей увольняли и затем нанимали обратно; есть желание уходить из-за давления вокруг исследования «вакцины и аутизм» и восприятия «антинаучности».","text_en":"CDC workforce instability: people were let go and rehired; some want to leave due to pressure around a vaccines-and-autism study and perceived anti-science sentiment.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0007","quote":"\"I've just been talking to somebody from the CDC, and it was one of those folks who was let go and then rehired.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0007","quote":"\"there's a lot of people who are wanting to leave\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0007","quote":"\"they don't want to be involved in doing a a study looking at vaccines and autism\""}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0007_n3","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Риск для инноваций из‑за потери ключевых людей/таланта в FDA при «разрушительном» подходе к изменениям; это рассматривается как барьер, требующий бдительности и вовлечённости.","text_en":"Risk to innovation from losing key people/talent at the FDA due to a “wrecking ball” approach to changes; seen as a constraint requiring vigilance and engagement.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0007","quote":"\"You can't go in with a wrecking ball. You lose key people, you lose key talent.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0007","quote":"\"No, you're going to harm innovation.\""}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0008_n1","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Нельзя «резко сокращать»/ломать кадровый состав FDA: потеря ключевых людей и таланта приведёт к ошибкам и навредит инновациям и пациентам.","text_en":"You can’t aggressively cut FDA workforce; losing key talent leads to mistakes and harms innovation and patients.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0008","quote":"You can't go in with a wrecking ball. You lose key people, you lose key talent."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0008","quote":"No, you're going to harm innovation."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0008","quote":"You're gonna harm patients."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0008_n2","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"В контексте biosecurity нельзя «отрезать доступ» к ключевым партнёрам, особенно производственным: это замедлит биомедицинские исследования и навредит пациентам.","text_en":"Biosecurity efforts can’t cut off access to key partners, especially manufacturing partners, or it will slow research and harm patients.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0008","quote":"you can't cut off access to some of these key partners, particularly the manufacturing partners."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0008","quote":"Because again, you'll slow biomedical research, you'll harm patients."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0008_n3","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Biosecure Act, по мнению спикера, стал «водянистым/беззубым», не прошёл и всё менее вероятно станет законом; при этом он поднял важность темы biosecurity, связанной с устойчивостью цепочек поставок.","text_en":"The Biosecure Act became watered down/toothless, didn’t pass and is increasingly unlikely to become law; it elevated biosecurity focus tied to supply chain resiliency.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0008","quote":"it didn't pass. It wasn't included in the national defense authorization at the end of the year."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0008","quote":"it's in a form right now that's largely ineffective or toothless."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0008","quote":"a lot of it again is grounded in supply chain resiliency."}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0009_n1","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Китай быстро продвигается в биотехе; есть ощущение, что США могут достичь паритета (или хуже) с Китаем в ближайшие пару лет.","text_en":"China is moving very fast in biotech; there’s a sense the U.S. could reach parity (or worse) with China within a couple of years.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0009","quote":"\"There's some incredible science going on in China. And they're moving in.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0009","quote":"\"very, very fast. I think in some ways we've got a couple of years. Till we're at parity. or worse with China.\""}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0009_n2","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Подход «наказывать/запрещать» (стики) через Biosecure Act для ограничения инвестиций/партнёрств описывается как неэффективный.","text_en":"A punitive/prohibitive approach (sticks) via the Biosecure Act to restrict investments/partnerships is described as not working well.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0009","quote":"\"You're going to prohibit activities. You're going to penalize somehow investment or partnerships, the sticks, if you will. That doesn't work really well.\""}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0009_n3","doc_id":"doc_85b3acc0f1e3","kind":"buyer_signal","text_ru":"В секторе obesity/GLP-1 крупные сделки с большими upfront-платежами; пример — сделка Zealand–Roche с upfront $1.65B (всего $5.6B).","text_en":"In the obesity/GLP-1 space there are large deals with big upfront payments; e.g., the Zealand–Roche deal with a $1.65B upfront (total $5.6B).","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0009","quote":"\"I think it's $5. 6 billion altogether. Roche made a huge upfront payment\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0009","quote":"\"So just to give you a sense, the upfront was $1. 65 billion.\""}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0010_n1","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Для GLP-1/пептидов критичным ограничением является доступ к производству API и производственным мощностям; это «проблема, которую нужно было решить».","text_en":"Manufacturing capacity / API access is a key constraint for GLP-1/peptides; it’s described as a problem that needed solving.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0010","quote":"Either way, you do need to get API."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0010","quote":"A lot of people talk about the manufacturing capacity for these peptides."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0010","quote":"this is a problem that needed to be solved."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0010_n2","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Рынок/эра GLP-1 и смежных подходов становится более конкурентной: «a lot going on» и перечисляются новые игроки.","text_en":"The GLP-1 (and related) space is becoming more competitive, with multiple entrants mentioned.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0010","quote":"But this era is going to become very competitive."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0010","quote":"there's Amgen coming in. There's Metzera. There's Kylera. There's a lot going on."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0010_n3","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"У небольших биотехов остаются вопросы по самостоятельной разработке и финансированию (в т.ч. «how do you finance?»), что давит на акции.","text_en":"Small biotechs face questions about developing alone and financing, which can pressure the stock.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0010","quote":"the big question was, you know, how are you going to develop it by yourself?"},{"chunk_id":"doc_85b3acc0f1e3_chunk_0010","quote":"there's still a question, then, how do you finance?"},{"chunk_id":"doc_85b3acc0f1e3_chunk_0010","quote":"that stock obviously is facing those questions and in general has also been under pressure."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0011_n1","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"Маленьким биотех-компаниям сложно конкурировать по исполнению/экзекьюшену; активу «лучше» быть у партнёра/крупного игрока.","text_en":"Small biotechs struggle to compete on execution; assets may be better in a partner/bigger company’s hands.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0011","quote":"the inability of a smaller company like Viking to really compete on an execution standpoint"}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0011_n2","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Наблюдается волна M&A в small-cap oncology; ожидается продолжение, в т.ч. из-за оценок компаний на уровне/ниже кэша.","text_en":"A wave of small-cap oncology M&A is occurring and expected to continue, partly because many trade at or below cash.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0011","quote":"we did see a couple of M&A transactions this week... small cap oncology acquisitions"},{"chunk_id":"doc_85b3acc0f1e3_chunk_0011","quote":"many small cap oncology companies... They're trading at or below cash. So I'd expect that type of trend to continue."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0011_n3","doc_id":"doc_85b3acc0f1e3","kind":"buyer_signal","text_ru":"Есть сигнал потенциальной сделки: Merck KGaA заявляла об «advanced discussions» по приобретению SpringWorks, но процесс затягивается и обновлений нет.","text_en":"Potential deal signal: Merck KGaA said it was in “advanced discussions” to acquire SpringWorks, but it’s taking a long time with no updates.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0011","quote":"Merck KGA put out a press release... saying they're in advanced discussions."},{"chunk_id":"doc_85b3acc0f1e3_chunk_0011","quote":"the latest there is that there is no update."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"В сегменте I&I/GMG рынок продолжает расти; упоминается как «growth market» около $6B и растущий.","text_en":"The I&I/GMG market is described as continuing to grow; cited as a growth market around $6B and growing.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0012","quote":"\"it's about six billion and growing right now in GMG.\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0012","quote":"\"these I &I markets, they just keep growing and growing\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_85b3acc0f1e3","kind":"opportunity","text_ru":"Oplinza может занять роль в GMG: потенциально заменить C5-антагонисты (безопаснее, дешевле, удобнее), использоваться у пациентов, не ответивших на VivGuard, или как поддерживающая терапия.","text_en":"Oplinza may find a role in GMG: potentially replacing C5 antagonists (safer, cheaper, more convenient), for VivGuard failures, or as maintenance therapy.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0012","quote":"\"Oplinsa is going to find a role, maybe to replace C5 antagonists\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0012","quote":"\"it's cheaper and more convenient, or in patients that fail VivGuard\""}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Клинически «CD19 premise» для данного подхода, по словам спикера, «не играет» (не подтверждается клиническими данными).","text_en":"The speaker says the CD19 premise is not playing out clinically (a clinical limitation).","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0012","quote":"\"the whole CD19 premise is not really playing out clinically.\""}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0013_n1","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Вакцинный бизнес подвержен списаниям запасов из‑за ежегодного обновления вакцины и риска непроданных доз.","text_en":"Vaccine business faces inventory write-downs due to annual vaccine changes and risk of unsold doses.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0013","quote":"\"a few hundred million dollar write down in inventory\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0013","quote":"\"especially in a world where the vaccine changes every year\""}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0013_n2","doc_id":"doc_85b3acc0f1e3","kind":"pain","text_ru":"Инвесторы/рынок больше фокусируются на прогнозе (outlook), чем на факте, что 2024 «в линии», что создает давление на ожидания.","text_en":"Investors/market focus more on outlook than on 2024 being in line, creating pressure on expectations.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0013","quote":"\"2024 was in line, and but nobody seems to care about that. Everybody cares about the outlook\""}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0013_n3","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"В онкологии ожидается поток обновлений данных по выживаемости (в т.ч. small cell lung cancer) в ближайшие месяцы, что станет ключевым для оценки класса препаратов.","text_en":"Near-term flow of survival data updates (incl. small cell lung cancer) over the next months will be key to assess the drug class.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0013","quote":"\"there's going to be a lot of data now coming between them and Summit over the next three months\""},{"chunk_id":"doc_85b3acc0f1e3_chunk_0013","quote":"\"we're going to see the small cell lung cancer data\""}],"confidence":"medium"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0014_n1","doc_id":"doc_85b3acc0f1e3","kind":"constraint","text_ru":"Производство/поставки BCMA CAR-T (Carvykti) ограничены мощностями: компании не могли произвести достаточно и находятся в состоянии capacity constraint.","text_en":"BCMA CAR-T (Carvykti) supply is constrained by manufacturing capacity; they couldn’t make enough and are capacity constrained.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0014","quote":"J &J and Legend just couldn't make enough. And they're totally capacity constraint."}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0014_n2","doc_id":"doc_85b3acc0f1e3","kind":"trend","text_ru":"Идёт активное наращивание производственных мощностей CAR-T (новые/расширенные площадки, контрактное производство), с целью примерно удвоить глобальную мощность в этом году.","text_en":"CAR-T manufacturing capacity is being expanded (new/expanded sites, contract manufacturing) aiming to roughly double global capacity this year.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0014","quote":"they've now opened essentially two to three new facilities... Novartis is a contract manufacturer"},{"chunk_id":"doc_85b3acc0f1e3_chunk_0014","quote":"So they're going to double capacity this year"}],"confidence":"high"}
{"nugget_id":"doc_85b3acc0f1e3_chunk_0014_n3","doc_id":"doc_85b3acc0f1e3","kind":"buyer_signal","text_ru":"Ожидается значимый поток данных/вех (milestones) по PD1/VEGF биспецификам в ближайшие месяцы, что вызывает интерес и активность в акциях.","text_en":"Upcoming PD1/VEGF bispecific milestones/data over the next months are driving interest and stock activity.","evidence":[{"chunk_id":"doc_85b3acc0f1e3_chunk_0014","quote":"a number of milestones that are upcoming from these PD1 VEGF by specifics"},{"chunk_id":"doc_85b3acc0f1e3_chunk_0014","quote":"a lot of action in the stocks for sure upcoming"}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0000_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Обсуждаются планы HHS по сокращению федерального финансирования программ по ВИЧ в США; на этом фоне просели акции некоторых компаний в ВИЧ-сегменте.","text_en":"HHS is reportedly weighing cuts to domestic HIV federal funding; some HIV-space companies’ share prices were hit.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0000","quote":"HHS, was weighing plans to cut federal government funding for domestic HIV funding."},{"chunk_id":"doc_6407e054e017_chunk_0000","quote":"share prices of a couple of companies that are involved in the HIV space did get hit."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0000_n2","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"Инвесторы отмечают высокую неопределённость из‑за новой администрации и возможных изменений политики (в т.ч. по ВИЧ‑профилактике и рекомендациям CDC).","text_en":"Investors report high uncertainty under the new administration, including potential shifts in HIV prevention policy and CDC recommendations.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0000","quote":"what I hear from investors across the board is just the uncertainty of the introduction of the new Trump administration"},{"chunk_id":"doc_6407e054e017_chunk_0000","quote":"there's a lot of questions around how the CDC is going to issue recommendations or change recommendations."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0000_n3","doc_id":"doc_6407e054e017","kind":"opportunity","text_ru":"Дважды в год инъекционная PrEP (lenacapavir) воспринимается как более удобная и эффективная альтернатива ежедневным схемам, что может поддержать крупный запуск.","text_en":"Twice-yearly injectable PrEP (lenacapavir) is seen as a more convenient and highly efficacious alternative to daily regimens, supporting a big launch.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0000","quote":"The data from their phase three studies have looked really good, effectively superior to the prep options that are out there."},{"chunk_id":"doc_6407e054e017_chunk_0000","quote":"forced compliance of two injections per year versus taking the drug on a daily basis"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0001_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Обсуждались сообщения о возможных существенных сокращениях усилий по профилактике ВИЧ со стороны HHS, что создало неопределённость вокруг будущего финансирования и рекомендаций.","text_en":"Reports discussed potential substantial cuts to HHS HIV (and other) prevention efforts, creating uncertainty around future funding and recommendations.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0001","quote":"\"the Wall Street Journal report said that HHS was looking to substantially cut HIV and other prevention efforts\""},{"chunk_id":"doc_6407e054e017_chunk_0001","quote":"\"the CDC spends about $1. 3 billion on HIV prevention each year\""}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0001_n2","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Политика и изменения/неопределённость в рекомендациях и руководствах (CDC/ACIP) рассматриваются как фактор, влияющий на финансирование и решения плательщиков.","text_en":"Policy and uncertainty/changes in CDC/ACIP guidelines are described as affecting funding and downstream payer decisions.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0001","quote":"\"the guidelines and recommendations that have downstream effects on payers, too\""},{"chunk_id":"doc_6407e054e017_chunk_0001","quote":"\"it's a pity that policy gets in the way of what is clearly good for patients\""}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0001_n3","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Заседание ACIP по иммунизационным практикам, ожидавшееся в конце февраля, было отменено, но затем снова поставлено в повестку на середину апреля.","text_en":"An ACIP meeting expected in late February was canceled, then put back on the schedule for mid-April.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0001","quote":"\"meeting that was expected on the 26th and 28th... of February... was cancelled\""},{"chunk_id":"doc_6407e054e017_chunk_0001","quote":"\"announcement that's going to be on the 15th and 16th of April\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0002_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"В обсуждаемом кейсе, несмотря на высокую долю шорта в акции, «pod funds» не проявили интереса к встречам после анонса данных.","text_en":"In this case, despite heavy short interest, pod funds showed no interest in meetings after the data announcement.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0002","quote":"\"Immunovant is a very heavily shorted stock... 20% of the float was short\""},{"chunk_id":"doc_6407e054e017_chunk_0002","quote":"\"The number is zero. Zero pods took a meeting.\""},{"chunk_id":"doc_6407e054e017_chunk_0002","quote":"\"Basically, zero pods asked for a meeting.\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0002_n2","doc_id":"doc_6407e054e017","kind":"buyer_signal","text_ru":"После публикации данных компания провела 25 встреч с инвесторами за день, что указывает на высокий интерес инвесторов к обсуждению данных/стратегии.","text_en":"After releasing data, the company held 25 investor meetings in a day, indicating strong investor interest in discussing the data/strategy.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0002","quote":"\"So we did 25 meetings on Wednesday.\""},{"chunk_id":"doc_6407e054e017_chunk_0002","quote":"\"you email all your investors... and then you wind up filling your day with meetings\""}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0003_n1","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"Компания не получает обратной связи от части рынка (шорт-сайд/дейтракторы), что затрудняет позиционирование и понимание происходящего.","text_en":"The company gets no feedback from the short-side/detractors, making it hard to position and understand what’s going on.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0003","quote":"\"it makes it very hard to sort of position and figure out what to do. You don't get that feedback.\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0003_n2","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Описывается краткосрочность на рынке: инвесторов может интересовать только ближайшая веха/милстоун.","text_en":"Short-termism in the market: investors may only care about the next milestone.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0003","quote":"\"there's this short-termism in the marketplace where, all a pawn shop investor cares about, is the next milestone.\""}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0003_n3","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Снижение IgG через ингибирование неонатального Fc-рецептора теоретически может повышать склонность к болезням, что является потенциальным ограничением/риском механизма.","text_en":"Lowering IgG via neonatal Fc receptor inhibition could, in theory, increase susceptibility to illness—an inherent mechanism risk/constraint.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0003","quote":"\"you lower the overall level of IgG antibodies in the body, which could, in theory, make you more prone to illness\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0004_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Лидер рынка в FcRn/anti-IgG терапии (упомянутый как Gen X) уже коммерциализировал препарат и запустил его в показаниях myasthenia gravis и CIDP.","text_en":"A market leader (referred to as Gen X) has already commercialized a drug and launched it in myasthenia gravis and CIDP.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0004","quote":"\"The undisputed leader in this field right now is going to call our Gen X... a very successful drug called F-cartigimide. That has launched in both myasthenia gravis and CIDP.\""}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0004_n2","doc_id":"doc_6407e054e017","kind":"opportunity","text_ru":"Возможность для next-generation анти-FcRn/anti-IgG антител: формулировка для низкодозной подкожной инъекции и более глубокое подавление IgG по сравнению с F-cartesimide.","text_en":"Opportunity for next-gen anti-FcRn/anti-IgG antibodies: low-dose subcutaneous formulation and deeper IgG suppression vs F-cartesimide.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0004","quote":"\"they're formulatable in a well-concentrated, relatively low-dose subcutaneous injection\""},{"chunk_id":"doc_6407e054e017_chunk_0004","quote":"\"they both suppress IgG more deeply in our studies generally than we see with F-cartesimide.\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0004_n3","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Ограничение для некоторых FcRn-антител: вмешательство в связывание альбумина с FcRn может снижать уровень альбумина в крови и приводить к неожиданным последствиям (упомянуто повышение LDL).","text_en":"Constraint for some FcRn antibodies: interfering with albumin binding to FcRn can reduce blood albumin and have unexpected consequences (LDL elevation mentioned).","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0004","quote":"\"interrupts albumin binding to fcrn and so it reduces blood albumin levels.\""},{"chunk_id":"doc_6407e054e017_chunk_0004","quote":"\"one unexpected consequence of that is it significantly elevates LDL.\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0005_n1","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"Кандидат botoclumab/Patokamab вызывает неблагоприятные лабораторные изменения (повышает LDL и снижает альбумин), что мешает его использованию/запуску несмотря на клинический эффект.","text_en":"Botoclumab/Patokamab causes adverse lab changes (raises LDL, lowers albumin), hampering launch despite clinical benefit.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0005","quote":"\"it drives up LDL cholesterol and lowers albumin.\""},{"chunk_id":"doc_6407e054e017_chunk_0005","quote":"\"it is both hampered by its placebo-adjusted Delta and more importantly hampered by. this lab abnormality\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0005_n2","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Сложно конкурировать с уже одобренным сильным продуктом (VivGuard), поэтому запуск Patokamab маловероятен.","text_en":"Competing against a strong approved product (VivGuard) makes launching Patokamab unlikely.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0005","quote":"\"it was unlikely we were going to launch Patokamab.\""},{"chunk_id":"doc_6407e054e017_chunk_0005","quote":"\"VivGuard is such a great approved product. It was going to be hard to compete.\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0005_n3","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Инвесторы воспринимают пространство IGG-lowering как «переполненное» (много игроков/агентов).","text_en":"Investors perceive the IgG-lowering space as crowded with many agents.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0005","quote":"\"one thing we always hear from investors is just how crowded the IGG lowering space is\""},{"chunk_id":"doc_6407e054e017_chunk_0005","quote":"\"it seems like they're a dime a dozen these days.\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0006_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Инвесторы воспринимают пространство снижения IgG как «переполненное» (много игроков/подходов).","text_en":"Investors perceive the IgG-lowering space as crowded (many players/approaches).","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0006","quote":"one thing we always hear from investors is just how crowded the IGG lowering space is"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0006_n2","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"FcRn — сложная мишень: нужно избегать альбумина и учитывать pH, поэтому антитела создавать труднее.","text_en":"FcRn is a difficult target: you must avoid albumin and consider pH, making antibodies harder to create.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0006","quote":"Fcrn is a difficult target. You have to avoid albumin, you have to think about pH and other things."},{"chunk_id":"doc_6407e054e017_chunk_0006","quote":"It's just been harder to create these antibodies."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0006_n3","doc_id":"doc_6407e054e017","kind":"opportunity","text_ru":"Есть большой пул пациентов/индикаций под «IgG/B-cell/immune reset» подходы, включая Graves с неудачей всех доступных терапий (кроме тиреоидэктомии) и «кардиальные индикации», которые ещё не преследуются.","text_en":"Large patient/indication pool for IgG/B-cell/immune reset approaches, including Graves patients who failed all available therapies (except thyroid removal) and cardiac indications not yet pursued.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0006","quote":"There's 330,000 prevalent Graves patients who have failed. All available therapeutic options, other than surgical removal of their thyroid"},{"chunk_id":"doc_6407e054e017_chunk_0006","quote":"there's a bunch of cardiac indications that are not even yet being pursued."}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0007_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Рынок терапии гидраденита суппуративного (HS) ещё молодой: первые препараты одобрены 4–5 лет назад, и сейчас появляются новые классы/механизмы, многие в разработке.","text_en":"HS market is still young (first approvals 4–5 years ago) and is moving into new agent classes/mechanisms with many in development.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0007","quote":"We only got the first couple of drugs approved for Hydrodinitis superativa four or five years ago"},{"chunk_id":"doc_6407e054e017_chunk_0007","quote":"now we're heading into brand new classes of agents, and there are many in development"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0007_n2","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"Даже при статистически значимых данных по POVOCITINIB реакция рынка негативная из‑за «so-so» силы эффекта и вопросов по конкуренции (в т.ч. RENVOQ).","text_en":"Despite statistically significant POVOCITINIB data, market reaction was negative due to so-so strength and competition concerns (incl. RENVOQ).","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0007","quote":"I think it's very, very, very likely that Oversitneb is going to be approved, and yet... the stock was down."},{"chunk_id":"doc_6407e054e017_chunk_0007","quote":"the data were just so-so on BOVO. They weren't particularly strong."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0007_n3","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Коммерческий апсайд для POVO ограничен позиционированием как 3-я линия после TNF и IL-17, а также риском, что RENVOQ с брендом и ресурсами AbbVie «украдёт гром».","text_en":"POVO upside is constrained by third-line positioning after TNF/IL-17 and risk that AbbVie’s branded, well-resourced RENVOQ could take share.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0007","quote":"designed to be maybe a third-line therapy here after TNFs and IL-17s."},{"chunk_id":"doc_6407e054e017_chunk_0007","quote":"whether RENVOQ won't come in and steal their thunder here."}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0008_n1","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"В пространстве DMD произошло «sad news» из‑за смерти пациента Sarepta.","text_en":"In the DMD space there was “sad news” due to a Sarepta patient death.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0008","quote":"the sad news in this, Muscular Dystrophy space, which came from, of course, the Sarepta patient death"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0008_n2","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Новые экзон-скипперы показывают существенно более высокий уровень полноразмерного дистрофина (10–25%) по сравнению с первым поколением (1–3%), что описывается как «sea change».","text_en":"New exon skippers show much higher full-length dystrophin (10–25%) vs first generation (1–3%), described as a “sea change.”","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0008","quote":"creating full-length dystrophin up in the 10 to even as high as 25% range"},{"chunk_id":"doc_6407e054e017_chunk_0008","quote":"first generation exon skippers were— we're potentially producing full-length dystrophin closer to one two three percent"},{"chunk_id":"doc_6407e054e017_chunk_0008","quote":"So we've got a sea change going on here."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0008_n3","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Есть спор о пригодности CK как биомаркера повреждения мышц в DMD; исторически «никто не мог» стабильно сильно снижать CK у всех пациентов.","text_en":"There is debate about CK as a DMD muscle-damage biomarker; historically no one could consistently reduce it strongly across all patients.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0008","quote":"there's been a lot of debate in the DMD community around CK as a biomarker and whether it's even a good biomarker"},{"chunk_id":"doc_6407e054e017_chunk_0008","quote":"nobody has been able to hit it consistently in all patients like the ability data are showing"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0009_n1","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"Для системной AAV-генной терапии одной из самых устойчивых проблем безопасности является печёночная токсичность/повреждение печени, включая случаи смерти от печёночной недостаточности; текущие протоколы профилактики не всегда достаточны.","text_en":"A consistent safety issue in systemic AAV gene therapy is liver toxicity/damage, including deaths from hepatic failure; current prophylaxis protocols are not always sufficient.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0009","quote":"controlling for liver inflammation and liver damage is one of the most consistent safety issues for this systemic gene therapy space."},{"chunk_id":"doc_6407e054e017_chunk_0009","quote":"all of them prophylactically using high doses of corticosteroids prior to treatment"},{"chunk_id":"doc_6407e054e017_chunk_0009","quote":"But clearly, it isn't enough."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0009_n2","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Экзон-скиппинг терапии для DMD адресуют всё более малые подгруппы пациентов, из-за чего препараты приходится разрабатывать заново для всё меньших популяций.","text_en":"Exon-skipping therapies in DMD target increasingly small patient subgroups, requiring repeated redesign for smaller populations.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0009","quote":"Exxon 51 amenable patients only make up 13% of DMD, and that's the largest subgroup."},{"chunk_id":"doc_6407e054e017_chunk_0009","quote":"these drugs need to be designed again and again, again, to go into increasingly small patient populations"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0009_n3","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Отмечается отсутствие успешных рандомизированных клинических исследований для disease-modifying терапий в этом контексте, что рассматривается как «headwind» для группы dystrophin replacement терапий.","text_en":"There have not been successful randomized clinical studies for these disease-modifying therapies here, seen as a headwind for dystrophin replacement therapies.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0009","quote":"we've never seen randomized clinical studies uh succeed really for any of these disease-modifying therapies here"},{"chunk_id":"doc_6407e054e017_chunk_0009","quote":"a bit of a headwind to this entire group of dystrophin replacement. Therapies"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0010_n1","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"После смерти пациента на фоне генной терапии усиливается спор об эффективности и о балансе риск–польза, что вызывает вопросы к регуляторному решению FDA.","text_en":"A patient death intensifies controversy over gene therapy efficacy and the risk–benefit balance, raising questions about FDA’s regulatory decision.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0010","quote":"\"it really cements of something real where the efficacy of this gene therapy is controversial. So it raises the question of the risk-benefit balance here.\""},{"chunk_id":"doc_6407e054e017_chunk_0010","quote":"\"people Struggle with okay, what is did the FDA doing? The right thing, does the FDA now have to act to do something to reverse course?\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0010_n2","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Регуляторный путь описан как нетипичный: проваленные исследования и критика review division, но ускоренное/полное одобрение было получено после adcom и внутренних разногласий в FDA.","text_en":"The regulatory path is described as atypical: failed trials and review-division criticism, yet accelerated/full approval proceeded after an adcom and internal FDA disagreement.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0010","quote":"\"it failed a randomized, placebo-controlled phase two study\""},{"chunk_id":"doc_6407e054e017_chunk_0010","quote":"\"A Phase III study then also failed to achieve the primary endpoint\""},{"chunk_id":"doc_6407e054e017_chunk_0010","quote":"\"Peter Marks, essentially made the decision over the objections of a good portion of the review team.\""}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0010_n3","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Есть устойчивое давление со стороны пациентов/адвокации на ускорение доступа к потенциально полезным терапиям, параллельно с опасениями о возможном «net harm».","text_en":"There is ongoing pressure from patients/advocacy to speed access to potentially beneficial therapies, alongside concerns about net harm.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0010","quote":"\"people really want access to potentially beneficial therapeutics faster\""},{"chunk_id":"doc_6407e054e017_chunk_0010","quote":"\"we have a lot of advocacy groups pushing for for faster development, cutting through red tape quicker.\""}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0011_n1","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"Неясно, имеет ли уровень/тип дистрофина (микро-дистрофин vs почти полноразмерный при exon skipping) клиническое значение для пациентов; хорошая экспрессия не обязательно даёт функциональный эффект.","text_en":"It’s unclear whether dystrophin level/type (micro-dystrophin vs near full-length from exon skipping) translates into patient function; strong expression may not yield functional benefit.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0011","quote":"whether micro dystrophin is really something that matters to patients."},{"chunk_id":"doc_6407e054e017_chunk_0011","quote":"Good microdistributive expression... with both the Sarepta and Pfizer gene therapies. Neither has really amounted to much functionally."},{"chunk_id":"doc_6407e054e017_chunk_0011","quote":"The Pfizer drug missed all of its endpoints, despite. extremely good micro dystrophin expression."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0011_n2","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Отсутствуют надёжные рандомизированные плацебо-контролируемые данные, определяющие пороги/эквивалентность уровней дистрофина; компании действуют в условиях неопределённости.","text_en":"There’s a lack of randomized placebo-controlled evidence defining dystrophin thresholds/equivalence; companies operate under significant uncertainty.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0011","quote":"it's never really been truly determined in randomized placebo-controlled studies."},{"chunk_id":"doc_6407e054e017_chunk_0011","quote":"Right now, we don't know what level of dystrophin"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0011_n3","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"Короткие (например, годовые) исследования трудно интерпретировать из‑за высокой гетерогенности и влияния внешних факторов на функциональные метрики; нужен более длительный фоллоу‑ап.","text_en":"Short (e.g., one-year) studies are hard to interpret due to heterogeneity and confounders affecting functional endpoints; longer follow-up is needed.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0011","quote":"I just honestly don't even think a one-year study is really going to prove it out."},{"chunk_id":"doc_6407e054e017_chunk_0011","quote":"there is so much heterogeneity in how a patient is going to look"},{"chunk_id":"doc_6407e054e017_chunk_0011","quote":"you need a lot more patience and a longer follow-up."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0012_n1","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"Недостаток клинических доказательств: вне биологической правдоподобности из доклиники пока неизвестно, работают ли гипотезы в клинических исследованиях.","text_en":"Lack of clinical proof: beyond preclinical biological plausibility, it’s not yet known whether these hypotheses work in clinical studies.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0012","quote":"we just don't really know outside of what's decent bio plausibility from preclinical models that any of these things could work."},{"chunk_id":"doc_6407e054e017_chunk_0012","quote":"We just really don't know that it does work as hypothesized in clinical studies yet."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0012_n2","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"В биотехе наблюдается «flight to safety»: приток капитала в крупные стабильные earnings-driven компании и отток из small-cap более рискованных non-earnings-driven.","text_en":"Biotech is seeing a “flight to safety”: inflows to larger stable earnings-driven companies and outflows from small-cap higher-risk non-earnings-driven names.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0012","quote":"what we've really been seeing over the last couple of weeks in biotech, is a flight to safety."},{"chunk_id":"doc_6407e054e017_chunk_0012","quote":"Any larger, stable, earnings-driven organization... has seen an influx of funding and... any smit cap... has seen an exodus of funding."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0012_n3","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Рынок ATTR описывается как быстро растущий и достаточно большой, чтобы вместить многих игроков.","text_en":"The ATTR market is described as rapidly growing and large enough for many players.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0012","quote":"This ATTR marketplace is an interesting one. First of all, it's enormous, it's rapidly growing, and certainly there's room for many, many players."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0013_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Рынок (в обсуждаемом терапевтическом пространстве) описывается как очень большой и быстро растущий; ожидается сосуществование нескольких игроков без явных «проигравших».","text_en":"The market is described as very large and rapidly growing, with multiple players expected to coexist and no clear losers.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0013","quote":"this is a very large market that is growing at a very, very rapid pace. And I don't think there are any losers of the space."}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0013_n2","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"CAR-T терапия воспринимается как обременительная из-за необходимости лимфодеплеции, длительного производства и управления CRS.","text_en":"CAR-T is seen as burdensome due to lymphodepletion, long manufacturing times, and CRS management.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0013","quote":"cut quite a lot of the burdensome aspects of CAR T therapy out of the equation."},{"chunk_id":"doc_6407e054e017_chunk_0013","quote":"you need to go through lymphodepletion."},{"chunk_id":"doc_6407e054e017_chunk_0013","quote":"then manufacture them, however long it takes, two weeks, three weeks, four weeks, five weeks"}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0013_n3","doc_id":"doc_6407e054e017","kind":"opportunity","text_ru":"In vivo (лентивирусная) «off-the-shelf» альтернатива CAR-T позиционируется как способ убрать часть ключевых обременяющих этапов стандартной CAR-T.","text_en":"In vivo (lentiviral) off-the-shelf approaches are positioned to remove key burdensome steps of standard CAR-T.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0013","quote":"It's an in vivo cell therapy company, so lentiviral."},{"chunk_id":"doc_6407e054e017_chunk_0013","quote":"The hope of all of these companies is to um, cut quite a lot of the burdensome aspects of CAR T therapy out of the equation."},{"chunk_id":"doc_6407e054e017_chunk_0013","quote":"you've got something that you could truly use as an off-the-shelf product."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0014_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Наблюдается сильный разрыв между тем, сколько big pharma платит за частные ранние активы, и оценками публичного рынка biotech.","text_en":"There is a strong disconnect between what big pharma pays for private early-stage assets and public biotech valuations.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0014","quote":"The money that's pharma is willing to shell out for. Private assets is a strong disconnect to what's happening in public valuations."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0014_n2","doc_id":"doc_6407e054e017","kind":"pain","text_ru":"Ранние (phase 1) и непроверенные активы в публичном секторе могут оцениваться крайне низко, вплоть до отсутствия положительной enterprise value.","text_en":"Phase 1, unproven assets in public markets may be valued extremely low, potentially with no positive enterprise value.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0014","quote":"So they're both phase one. They're both unproven assets."},{"chunk_id":"doc_6407e054e017_chunk_0014","quote":"There's a good chance that neither of these companies would have a positive enterprise value right now"}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0014_n3","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"За последние ~18 месяцев big pharma активно делает сделки на $400–800M по активам (ранняя стадия/из Китая/от небольших компаний) вместо альтернативных стратегий (например, покупки).","text_en":"Over the last ~18 months, big pharma has been doing many $400–800M asset deals (earlier-stage/out of China/smaller companies) instead of other approaches (e.g., buying).","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0014","quote":"the last 18 months. Which is to me like"},{"chunk_id":"doc_6407e054e017_chunk_0014","quote":"What we've seen an enormous amount of is big pharma companies doing deals like this, right? Four to $800 million asset deals"}],"confidence":"medium"}
{"nugget_id":"doc_6407e054e017_chunk_0015_n1","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Big pharma всё чаще делает сделки по покупке более ранних активов за сотни миллионов (в т.ч. из Китая/у небольших компаний) вместо покупки поздних активов за миллиарды.","text_en":"Big pharma is increasingly doing deals for earlier-stage assets (incl. from China/smaller companies) for hundreds of millions instead of late-stage assets for billions.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0015","quote":"big pharma companies doing deals like this, right? Four to $800 million asset deals, either an earlier stage or out of China or out of smaller companies."},{"chunk_id":"doc_6407e054e017_chunk_0015","quote":"pharma companies are now looking to buy earlier stage assets for hundreds of millions of dollars instead of late stage assets for billions of dollars."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0015_n2","doc_id":"doc_6407e054e017","kind":"trend","text_ru":"Сдвиг в структуре M&A может снижать ценность поздних активов и повышать ценность ранних активов.","text_en":"This M&A shift may make late-stage assets less valuable and early-stage assets more valuable.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0015","quote":"It's going to make the late stage assets less valuable. And the early stage assets more valuable."}],"confidence":"high"}
{"nugget_id":"doc_6407e054e017_chunk_0015_n3","doc_id":"doc_6407e054e017","kind":"constraint","text_ru":"В сегменте in vivo CAR-T большинство компаний частные; это упрощает переговоры о цене по сравнению с публичными компаниями, где нужно договариваться о цене акций/оценке.","text_en":"In in vivo CAR-T, most companies are private, making price negotiation easier than negotiating share price/valuation for public companies.","evidence":[{"chunk_id":"doc_6407e054e017_chunk_0015","quote":"in VivoCart, most of the companies are private. So if you wanted to play there, it's easier to go and negotiate a price"}],"confidence":"medium"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0000_n1","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Биотех-сектор в этом году показывает слабую динамику; XBI снижается, и у инвесторов низкое желание покупать биотех на марже.","text_en":"Biotech has been underperforming this year; XBI is down and marginal demand to buy biotech is weak.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0000","quote":"\"biotech just has not been performing well. This year.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0000","quote":"\"the desire of people at the margin to buy by tech has not been good.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0000_n2","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"На рынок влияет макро-неопределённость вокруг намерений администрации Трампа и её последствий для экономики и биотех-экосистемы.","text_en":"Macro uncertainty about the Trump administration’s intentions and implications for the economy and biotech ecosystem is affecting the market.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0000","quote":"\"there's just been tremendous uncertainty about the Trump administration and what their intentions are.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0000","quote":"\"What it all means for the economy and for the biotech ecosystem. Specifically.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0000_n3","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Есть признаки давления со стороны LP: фондам сложно удерживать LP, ходят слухи о переходе некоторых фондов в режим распродаж; крупные LP (эндаументы/суверенные фонды) не оптимистичны по ожидаемой доходности.","text_en":"Signs of LP pressure: funds struggling to keep LPs; rumors of some funds in selling mode; large LPs not optimistic about prospective returns.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0000","quote":"\"there are certain funds that are struggling to keep their LPs in line.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0000","quote":"\"rumors... That certain funds are sort of for selling mode.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0000","quote":"\"are in general not that optimistic about. The perspective returns.\""}],"confidence":"medium"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0001_n1","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"В биотехе/через XBI наблюдается длительное отставание от S&P, из‑за чего биотех-аллокация стала «тормозом» доходности для фондов, бенчмаркующихся к S&P, и это ведёт к сдвигу аллокаций.","text_en":"Biotech (via XBI) has lagged the S&P over multi-year periods, making biotech allocations a drag for S&P-benchmarked funds and prompting allocation shifts.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0001","quote":"The S&P has outperformed by like 10,000 basis points."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0001","quote":"whatever biotech allocation you have, has been to drag on your returns. And so you're seeing a lot of folks shifting their allocations"}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0001_n2","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"В публичном биотех-рынке «zombie biotechs» могут долго существовать, торгуясь на уровне или ниже цены IPO; слабая пост-IPO динамика — повторяющаяся проблема.","text_en":"In public biotech markets, “zombie biotechs” can persist while trading at or below IPO price; weak post-IPO performance is a recurring issue.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0001","quote":"these IPOs from 1991, which in 2010 were essentially trading at or below their IPO prices, but were still around."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0001","quote":"The IPO class of 2005-6-7 they were almost universally trading below their IPO prices"}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0001_n3","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"При ликвидациях фондов из‑за запросов LP на вывод средств может не хватать покупателей, чтобы поглотить поток продаж, что усиливает давление на рынок.","text_en":"When funds liquidate due to LP redemption requests, there may be insufficient buyers to absorb the selling flow, increasing market pressure.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0001","quote":"those guys are getting hit with requests from their LPs to take money out."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0001","quote":"there's just not enough buyers in the market to absorb that flow."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0002_n1","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Резко сократилось число новых биотех-компаний, получающих первое финансирование: с пика 2021 до ~50 в 1 квартале сейчас.","text_en":"The number of new biotech companies getting first financings has sharply contracted: from the 2021 peak to ~50 in Q1 now.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0002","quote":"\"back in 18 and 19, there were roughly 100 brand new companies getting financed... spiked to about 180... in 2021... it's at 50 right now\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0002","quote":"\"there has been a huge contraction in the number of new companies getting formed.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0002_n2","doc_id":"doc_05fc73e3e0e0","kind":"opportunity","text_ru":"Периоды рыночных сокращений описываются как хорошее время для запуска новых инновационных компаний при дисциплине и капитальной эффективности.","text_en":"Market contractions are described as a good time to start new innovative companies if built with discipline and capital efficiency.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0002","quote":"\"when those contractions happen is actually a great time to start companies.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0002","quote":"\"this is a great time to start new, innovative companies if you can build them with discipline and capital efficiency.\""}],"confidence":"medium"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0002_n3","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"Есть «узкое место» с выходом на публичный рынок: компании, которые предпочли бы привлекать публичный капитал, вынуждены поднимать частные раунды.","text_en":"There is a bottleneck to going public: companies that would prefer public equity are stuck raising private rounds.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0002","quote":"\"you have a constraint and a bottleneck around getting public.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0002","quote":"\"this huge backlog of companies that would much rather be raising public equity are stuck raising private rounds.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0003_n1","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Сложно привлекать капитал: компании, которые предпочли бы публичный рынок, вынуждены поднимать частные раунды из‑за «бэклога» и узкого места с выходом на биржу.","text_en":"Raising capital is challenging: companies that would prefer public equity are stuck raising private rounds due to a backlog and bottleneck to going public.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0003","quote":"this huge backlog of companies that would much rather be raising public equity are stuck raising private rounds."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0003_n2","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Венчурных раундов стало значительно меньше, при этом средний размер раунда вырос — инвестиции концентрируются в меньшем числе компаний.","text_en":"Venture rounds are down significantly while average round size is up, indicating investment is concentrating into fewer companies.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0003","quote":"the number of just venture rounds— that are happening this year... is down quite significantly."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0003","quote":"you're seeing a dramatic increase in concentration of investment."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0003_n3","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"PIPE-сделки воспринимаются как «legal insider trading»: основная прибыль делается между получением конфиденциальной информации и её публичным раскрытием, что подрывает доверие.","text_en":"PIPEs are perceived as “legal insider trading”: most profits occur between receiving confidential info and its public release, undermining trust.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0003","quote":"most of the money that the funds are making are between the moment that they receive confidential information, and then the moment at which that confidential information is released"}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0004_n1","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"В текущем «down market» многим биотех-компаниям не хватает денежного запаса на 3+ года; рынок «really tough».","text_en":"In the current down market, many biotechs lack 3+ years of cash; conditions are really tough.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0004","quote":"\"have at least three years of cash. So many do not have that. We're in this down market where things are really tough.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0004_n2","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"По PIPE-инвестициям среднее может быть положительным, но медиана отрицательная; «two-thirds of the pipes didn't work out».","text_en":"For PIPE investments, the mean may be positive but the median is negative; two-thirds didn’t work out.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0004","quote":"\"if you looked at the median, it was negative. So, like, two-thirds of the pipes didn't work out.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0004_n3","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"Сокращения в HHS/FDA (включая добровольные уходы) могут привести к резкому уменьшению численности FDA, при этом FDA выполняет широкий спектр функций помимо ревьюеров.","text_en":"HHS/FDA cuts (including voluntary reductions) could sharply reduce FDA headcount, while FDA has broad responsibilities beyond reviewers.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0004","quote":"\"So that means the FDA is going from 19,700 people to 12,200 people. That's a huge reduction.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0004","quote":"\"the FDA inspects all of the plants around the world that make drugs, the FDA inspects food supplies.\""}],"confidence":"medium"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0005_n1","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Ожидается значительное сокращение персонала FDA, что вызывает опасения по последствиям для сроков и качества взаимодействия с агентством.","text_en":"A significant FDA headcount reduction is expected, raising concerns about consequences for timelines and engagement quality.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0005","quote":"\"somewhere along the way, there's going to be a significant change in the number of personnel\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0005","quote":"\"it's hard to imagine that it won't have real consequences on timelines, quality of engagement\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0005_n2","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Для ранних клинических работ многие компании не начинают в США, потому что регуляторы в Австралии/Европе/Великобритании более коллаборативны и позволяют быстрее получить клинические данные; FDA воспринимается как более «жёсткий» регулятор.","text_en":"Many companies avoid starting early clinical work in the US because Australia/Europe/UK regulators are more collaborative and enable faster clinical data; FDA is seen as tougher.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0005","quote":"\"the vast majority, do not start their clinical work in the United States\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0005","quote":"\"those regulatory agencies are more collaborative, very early on, and enable us to get to clinical data faster\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0005","quote":"\"The FDA has been the toughest group in the world for that\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0005_n3","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Отмечается рост конкуренции США с Китаем в drug discovery и development; при этом Китай, по словам спикера, инвестирует в фарм-инфраструктуру и ускоряет набор пациентов/получение ранних данных.","text_en":"US faces rising competition from China in drug discovery/development; China is described as investing in pharma infrastructure and accelerating patient access/early data generation.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0005","quote":"\"the first time the U. S. is facing real competition in drug discovery and development from China\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0005","quote":"\"In China, where they're investing in their their pharmaceutical infrastructure\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0005","quote":"\"Their FDA is working aggressively to allow Chinese companies to get the patients really fast\""}],"confidence":"medium"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0006_n1","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"FDA описывается как наиболее жёсткий регулятор в мире в части раннего клинического тестирования; консервативная позиция может ограничивать эскалацию дозы и усложнять ранние safety-исследования в США.","text_en":"FDA is described as the toughest regulator for early clinical testing; conservative stances can limit dose escalation and make early safety studies in the US challenging.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0006","quote":"The FDA has been the toughest group in the world for that, for sure."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0006","quote":"as soon as you run into a conservative stance or they don't let you dose escalate... it really. Can be a challenge"}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0006_n2","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Генералистам сложно инвестировать в biotech: чтобы понять сделки, нужно «wall crossing», и проще купить акции cash-flow компаний, чем разбираться, что покупать в biotech.","text_en":"Generalist investors find biotech hard to invest in; deals require 'wall crossing' to understand, and it’s easier to buy cash-flow companies than figure out biotech picks.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0006","quote":"a generalist... looking at all these pipe deals, thinking, '...this is obviously something that needs wall crossing to understand.'"},{"chunk_id":"doc_05fc73e3e0e0_chunk_0006","quote":"It's so much easier just to go into another cash flow... than try and figure out what biotech to buy."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0006_n3","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"В EGFR+ NSCLC сформировался сильный стандарт лечения (Tegviso), из‑за чего некоторые компании прекращали разработку EGFR ингибиторов, считая, что его невозможно превзойти.","text_en":"A strong standard of care (Tegviso) in EGFR+ NSCLC led some companies to stop developing EGFR inhibitors, believing it couldn’t be beaten.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0006","quote":"when it succeeded, I've heard some companies had some EGFR inhibitors in development and decided no point carrying on. We can't possibly beat this."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0006","quote":"Tegviso is the standard of care for treating non-small cell lung cancer, which is driven by EGFR mutations."}],"confidence":"medium"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0007_n1","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Побочные эффекты являются ключевой проблемой для комбинационной терапии J&J; особенно проблемны кожные нарушения, что требует дальнейшей работы компании.","text_en":"Side effects are a key issue for J&J’s combo therapy; skin disorders are particularly troublesome and require further work.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0007","quote":"\"it's side effects.' Side effects is one of the main issues.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0007","quote":"\"The one that's troublesome is the skin disorders that it causes.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0007_n2","doc_id":"doc_05fc73e3e0e0","kind":"opportunity","text_ru":"Переход с IV на подкожное введение ribavant рассматривается как способ улучшить профиль побочных эффектов и повысить конкурентоспособность против ежедневного перорального препарата.","text_en":"Switching ribavant from IV to subcutaneous is positioned as a way to improve side-effect profile and compete better versus a daily oral drug.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0007","quote":"\"switching to subcutaneous ribavant from IV\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0007","quote":"\"the subcutaneous switch is going to address some of the side effect profiles.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0007_n3","doc_id":"doc_05fc73e3e0e0","kind":"buyer_signal","text_ru":"Снижение ожидаемой общей частоты ответов (с ~60% до 42%) по данным BNT327 вызвало обеспокоенность у части клиентов/участников рынка.","text_en":"A drop in expected overall response rate (~60% to 42%) for BNT327 data unnerved some clients/market participants.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0007","quote":"\"decline in the um overall response rate... around the 60% before to down to 42%.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0007","quote":"\"given what I've heard from a few clients, that's something that unnerved folks.\""}],"confidence":"medium"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0008_n1","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Клиентов обеспокоило снижение общего ответа (ORR) с ожидаемых ~60% до 42%.","text_en":"Clients were unnerved by the drop in overall response rate (ORR) from ~60% expected to 42%.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0008","quote":"a decline in the um overall response rate... around the 60% before to down to 42%."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0008","quote":"given what I've heard from a few clients, that's something that unnerved folks."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0008_n2","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"В данных (spider plot) видно, что многие пациенты прогрессируют довольно быстро (через 2–4 месяца после начала терапии).","text_en":"The spider plot suggests many patients progress quickly (2–4 months after therapy start).","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0008","quote":"There are lots of patients who are progressing quite quickly— early on, two months, four months"}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0008_n3","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Растёт роль Китая в фарма-сделках: много кроссбордерных сделок, доля молекул large pharma из Китая выросла с 31% до 41%, а по upfront долларам — ещё выше.","text_en":"China’s importance in pharma dealmaking is rising: many cross-border deals; share of large pharma molecules from China increased from 31% to 41%, even higher by upfront dollars.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0008","quote":"There's a lot of China cross-border deals this year."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0008","quote":"31% of all large pharma molecules... were from China"},{"chunk_id":"doc_05fc73e3e0e0_chunk_0008","quote":"This year, the number is 41%. And if you look at the dollars... upfront dollars, it's even higher."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0009_n1","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Китайские VC и компании начинают выходить «впереди» в новых технологических областях (пример: IgG extracellular/ASGPR degraders), а не только в «by specifics».","text_en":"Chinese VCs/companies are moving to lead in emerging tech areas (e.g., IgG extracellular/ASGPR degraders), not just “by specifics.”","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0009","quote":"\"some of the conversations about the new codes that are being formed by Chinese VCs\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0009","quote":"\"this is like an emerging technology area where a Chinese company is going to be out in front.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0009_n2","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Функциональное излечение ВИЧ остаётся сложной задачей: CAR-T имеет технические проблемы, а квази-«спящие» (quiescent) инфицированные клетки трудно обнаружить.","text_en":"A functional HIV cure remains hard: CAR-T has technical issues, and quiescent infected cells are difficult to track down.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0009","quote":"\"a functional cure for HIV is something we've all been looking for for a long time.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0009","quote":"\"he went through all the technical problems with CAR-T.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0009","quote":"\"these cells that have the virus become quiescent are very hard to hunt down.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0009_n3","doc_id":"doc_05fc73e3e0e0","kind":"opportunity","text_ru":"Есть возможность для in vivo подходов к клеточной терапии (in vivo cell therapy) для функционального излечения ВИЧ; упоминается, что китайский исследователь показывает данные по такому подходу.","text_en":"Opportunity for in vivo cell therapy approaches toward a functional HIV cure; a Chinese scientist is described as showing data on this approach.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0009","quote":"\"he described it in vivo approach.\""},{"chunk_id":"doc_05fc73e3e0e0_chunk_0009","quote":"\"using in vivo cell therapy and started to show me data that he's doing it.\""}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Венчурным инвесторам важно учитывать Китай как источник инноваций; ожидается рост вклада Китая в глобальные биоинновации.","text_en":"VC investors need to consider China as an innovation source; China’s contribution to global biotech innovation is expected to grow.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0010","quote":"if you're a venture investor today and you're not thinking about china and sourcing innovation from china... you're missing the ball"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Компании могут смещаться к меньшей прозрачности: больше конфиденциальных trade secrets, меньше ранних патентных подач и более позднее раскрытие целей/таргетов (вплоть до клиники).","text_en":"Companies may become less transparent: more confidential trade secrets, less early patent filing, and later disclosure of targets (even until back in clinic).","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0010","quote":"companies will keep a lot more as confidential trade secrets. There'll be less early filing."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0010","quote":"you're going to wait until the last moment... back in the clinic and dosing before you disclose the targets"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"В AI-гонке Китай ограничен доступом к Nvidia-чипам и оборудованию ASML для литографии, что затрудняет самостоятельное производство передовых чипов.","text_en":"In the AI race, China is constrained by limited access to Nvidia chips and ASML lithography equipment needed to make advanced chips.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0010","quote":"China has suffered from in the AI race... their lack of access to... the nvidia type chips"},{"chunk_id":"doc_05fc73e3e0e0_chunk_0010","quote":"you need an access to the sort of uh machines that asml produces"}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0011_n1","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Рынок разработок препаратов от ожирения быстро расширяется: упоминается рост числа компаний и молекул в разработке, значимая доля — из Китая.","text_en":"Obesity drug development is rapidly expanding: more companies and assets in development, with a significant share coming from China.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0011","quote":"There are more than 100 drug makers that are after obesity with 160 drugs in development."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0011","quote":"over 40% of them are in phase two, and a whole bunch of them come from China."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0011_n2","doc_id":"doc_05fc73e3e0e0","kind":"buyer_signal","text_ru":"Сделки по активам в ожирении включают крупные авансы и значимые суммы за ранние стадии, что сигнализирует о готовности платить за доступ к активам/правам.","text_en":"Deals in obesity include large upfronts and meaningful payments for early-stage assets, signaling willingness to pay for access/rights.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0011","quote":"a $200 million upfront and up to $2 billion in terms of total contingencies"},{"chunk_id":"doc_05fc73e3e0e0_chunk_0011","quote":"$75 million from Novo Nordisk as an upfront for a preclinical asset."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0011_n3","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"При схожих механизмах действия в ожирении дифференциация по эффективности ограничена; ключевой вопрос — производство, доставка пациентам и завоевание доли рынка.","text_en":"With similar mechanisms in obesity, efficacy differentiation is limited; key challenges are manufacturing, getting drugs to patients, and capturing market share.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0011","quote":"if you have the same mechanisms, you're going to get the same efficacy."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0011","quote":"So the question is, how are you going to manufacture them, get them to patients, and cut yourself a market share"}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0012_n1","doc_id":"doc_05fc73e3e0e0","kind":"buyer_signal","text_ru":"Компания Seleno сообщила прайсинг для Prader-Willi: около $0.5M на пациента (средний вес) при weight-based dosing; также озвучены projected peak sales ~$2B.","text_en":"Seleno communicated pricing for Prader-Willi at about $0.5M per average-weight patient (weight-based dosing) and projected peak sales of ~$2B.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0012","quote":"\"they've communicated the pricing... about a half a million dollars for the average weight of a patient with Prader-Willi. And their projected peak sales is about $2 billion.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0012_n2","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"FDA-аппрувалы в rare disease могут быстро катализировать рост стоимости компании; пример — после одобрения акция выросла с ~$4–5 до >$70.","text_en":"FDA approvals in rare disease can rapidly catalyze company value; example given of stock moving from ~$4–5 to >$70 after approval.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0012","quote":"\"was trading at... four to five bucks a share about 18 months ago, and today is trading over $70 a share.\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0012_n3","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"Для DMD обсуждается регуляторная неопределённость: небольшое open-label исследование с сравнением с historical controls; вопрос, будет ли FDA/AdCom по-прежнему открыта к таким аппрувалам на малых датасетах.","text_en":"Regulatory uncertainty in DMD: small open-label study vs historical controls; question whether FDA/AdCom will remain open to approvals on small datasets.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0012","quote":"\"It was an open-label and they compared to historical controls... Are they still open to these types of approvals on small data sets?\""}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0013_n1","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Сложно сравнивать данные между программами в NMIBC из‑за различий в исходных характеристиках пациентов (carcinoma in situ vs papillary и т.п.).","text_en":"Comparing NMIBC program data is complicated by differences in patient baseline characteristics (carcinoma in situ vs papillary, etc.).","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0013","quote":"there are differences in the background of the patients in terms of carcinoma in situ or papillary, etc. So that complicates the comparison."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0013_n2","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"Локальная терапия, доставляемая в мочевой пузырь, не может быть доставлена системно, что ограничивает применение за пределами пузыря.","text_en":"A bladder-delivered local therapy cannot be delivered systemically, limiting use beyond the bladder.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0013","quote":"you don't want to go beyond the bladder into systemic, because you can't deliver this systemically."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0013_n3","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"Конкуренция с Johnson & Johnson воспринимается как серьёзный барьер; для конкуренции нужны значимые партнёрства или выкуп.","text_en":"Competing against Johnson & Johnson is seen as a major barrier; meaningful partnerships or acquisition would be needed to compete.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0013","quote":"The problem for all of these folks is who wants to go up against Johnson & Johnson? So they'd need meaningful partnerships"}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"Несмотря на большое число научных публикаций по биологии старения, в индустрии biotech очень мало мейнстрим-инвестиций в старение из‑за восприятия, что наука ещё не готова к трансляции.","text_en":"Despite many aging-science papers, there are very few mainstream biotech investments in aging due to a view that the science isn’t translationally ready.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0014","quote":"There are hundreds of thousands of research papers on aging science. And yet... There are actually very few mainstream investments made in the field of aging."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0014","quote":"there's a widespread view that the science is not translationally ready."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_05fc73e3e0e0","kind":"opportunity","text_ru":"Выделяются три терапевтические стратегии в старении: удаление сенесцентных клеток, перепрограммирование клеток к «молодому» фенотипу и замещение/трансплантация клеток.","text_en":"Three therapeutic strategies in aging are highlighted: removing senescent cells, reprogramming cells to a younger phenotype, and replacing/transplanting cells.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0014","quote":"a sense of three therapeutic strategies."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0014","quote":"One of those strategies is to remove senescent cells."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0014","quote":"Another strategy is to reprogram cells to a younger phenotype... and a third strategy... is to actually replace cells"}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"Компании сталкиваются с трудностями привлечения капитала (вплоть до wind down, увольнений и банкротства), включая невозможность собрать деньги на pivotal trial.","text_en":"Companies are facing fundraising challenges, including wind-downs, layoffs, and bankruptcy; inability to raise for pivotal trials is mentioned.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0014","quote":"they announced their kind of wind down they couldn't raise money for their schizophrenia pivotal trial."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0014","quote":"Encarta, Elevate that announced double-digit layoffs."},{"chunk_id":"doc_05fc73e3e0e0_chunk_0014","quote":"23andMe... they've officially declared bankruptcy, couldn't find the buyer or the investor to come in."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0015_n1","doc_id":"doc_05fc73e3e0e0","kind":"trend","text_ru":"В отрасли наблюдаются сокращения персонала (упоминаются «double-digit layoffs» у некоторых брендов).","text_en":"The industry is seeing layoffs (mentions “double-digit layoffs” at some brands).","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0015","quote":"rand names like Encarta, Elevate that announced double-digit layoffs."}],"confidence":"medium"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0015_n2","doc_id":"doc_05fc73e3e0e0","kind":"pain","text_ru":"23andMe официально объявила банкротство и не смогла найти покупателя или инвестора.","text_en":"23andMe officially declared bankruptcy and couldn’t find a buyer or investor.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0015","quote":"they've officially declared bankruptcy, couldn't find the buyer or the investor to come in."}],"confidence":"high"}
{"nugget_id":"doc_05fc73e3e0e0_chunk_0015_n3","doc_id":"doc_05fc73e3e0e0","kind":"constraint","text_ru":"Отмечается сложность сценария, когда CEO пытается выкупить компанию после того, как не удалось привлечь инвесторов.","text_en":"It’s portrayed as difficult for a CEO to buy back the company after failing to attract investors.","evidence":[{"chunk_id":"doc_05fc73e3e0e0_chunk_0015","quote":"that's a tough road if you couldn't find the investors."}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0000_n1","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"Ожидается введение тарифов на фармацевтику в США; вопрос в сроках и размере.","text_en":"US pharma tariffs are expected; timing and magnitude are uncertain.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0000","quote":"\"it's also pretty clear that there's going to be tariffs on pharmaceuticals. It's just a matter of. When and how much\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0000_n2","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Непрозрачность структуры межфирменных транзакций и размещения IP затрудняет оценку влияния тарифов на компании.","text_en":"Opaque intercompany transactions and IP location make it hard to assess tariff impact.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0000","quote":"\"it's so hard is to tease out what the impact is\""},{"chunk_id":"doc_576b38e3c826_chunk_0000","quote":"\"it's really not that transparent to us. So we're all going to be a little bit in the dark\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0000_n3","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"Индустрия выстраивала значимые производственные мощности за рубежом (например, в Ирландии) из-за низких налогов и зарплат; обсуждаемые тарифы нацелены на возврат производства в США.","text_en":"Industry built significant manufacturing abroad (e.g., Ireland) for low taxes/wages; tariffs aim to bring manufacturing back to the US.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0000","quote":"\"Our industry has built so much, especially manufacturing capacity in places like Ireland, where there's both low taxes and low wages.\""},{"chunk_id":"doc_576b38e3c826_chunk_0000","quote":"\"The goal of the tariffs is going to be... to bring manufacturing home.\""}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0001_n1","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Низкая прозрачность межфирменных транзакций и перемещения маржи вокруг IP, из‑за чего участники «в темноте» по реальному влиянию.","text_en":"Low transparency of intercompany transactions and margin shifting around IP, leaving stakeholders in the dark about true impact.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0001","quote":"\"it's really not that transparent to us. So we're all going to be a little bit in the dark\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0001_n2","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"У индустрии значимая PR‑проблема: общественность и политики хотят, чтобы отрасль была меньше и зарабатывала меньше; это «центральный headwind».","text_en":"The industry has a significant PR problem; public and politicians want it smaller and less profitable—seen as a central headwind.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0001","quote":"\"every politician out there wishes that our industry was smaller\""},{"chunk_id":"doc_576b38e3c826_chunk_0001","quote":"\"we have a significant PR problem\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0001_n3","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"Тарифы рассматриваются как фактор, который может вызвать хаос и отвлечь фокус/инвестиции от discovery и R&D из‑за краткосрочной ориентированности отрасли.","text_en":"Tariffs are seen as potentially causing chaos and distracting focus/investment from discovery and R&D due to short-term industry mindset.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0001","quote":"\"going to cause chaos\""},{"chunk_id":"doc_576b38e3c826_chunk_0001","quote":"\"that's going to be a huge distraction—I think to uh focus and investment on discovery, R&D\""}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0002_n1","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"Фокус обсуждений/звонков в индустрии сместился к опасениям по поводу FDA (регуляторной неопределённости) больше, чем к тарифам или cost of goods.","text_en":"Industry discussions/calls are more focused on FDA-related concerns than on tariffs or cost of goods.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0002","quote":"\"My call volume is more slated to the FDA concern than to tariffs at this stage.\""},{"chunk_id":"doc_576b38e3c826_chunk_0002","quote":"\"for my conversations this week, it's been much more around the FDA.\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0002_n2","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Инвесторам сложно делать высококонвикшн ставки/определять размер позиций из‑за риска внезапных изменений со стороны FDA и неопределённости вокруг кадров/процессов.","text_en":"Investors struggle to make high-conviction bets/position sizing due to risk of sudden FDA changes and uncertainty around staffing/processes.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0002","quote":"\"how can I have the ability to really make high conviction bets or investments here or size investments here?\""},{"chunk_id":"doc_576b38e3c826_chunk_0002","quote":"\"there could be another shooter drop with the FDA, like any time\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0002_n3","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Риск организационных изменений в FDA (уходы сотрудников, пропуск дедлайнов, изменения политики, layoffs) воспринимается как существенный оверхенг для многих акций.","text_en":"Potential FDA organizational disruption (departures, missed deadlines, policy changes, layoffs) is seen as a major overhang for many stocks.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0002","quote":"\"Are more people going to leave? Are they going to miss deadlines over time?\""},{"chunk_id":"doc_576b38e3c826_chunk_0002","quote":"\"FDA is subject to broad layoffs\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0003_n1","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Неопределённость для biotech из‑за отсутствия ясности, станет ли FDA более строгим или менее строгим, и отсутствия политических ориентиров.","text_en":"Uncertainty for biotech due to lack of clarity on whether FDA will become more or less stringent, and lack of policy guidance.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0003","quote":"\"the biggest issue is we don't know whether FDA is going to get more stringent or less stringent.\""},{"chunk_id":"doc_576b38e3c826_chunk_0003","quote":"\"there really no policy guidance on literally which direction, left or right, things are going?\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0003_n2","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"FDA подвергается широким сокращениям, включая уход более старших сотрудников; увольнения происходят внезапно (люди узнают, что потеряли работу, проснувшись).","text_en":"FDA is undergoing broad layoffs, including senior departures; layoffs are happening abruptly (people wake up to find they lost their job).","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0003","quote":"\"FDA is subject to broad layoffs\""},{"chunk_id":"doc_576b38e3c826_chunk_0003","quote":"\"people are waking up and finding out that they lost their job.\""},{"chunk_id":"doc_576b38e3c826_chunk_0003","quote":"\"we've seen more senior people leave\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0003_n3","doc_id":"doc_576b38e3c826","kind":"buyer_signal","text_ru":"Компании (особенно developmental stage biotech) начинают регулярно проверять, остаются ли их взаимодействия с FDA последовательными, что указывает на острую потребность в понимании статуса и направления регуляторных коммуникаций.","text_en":"Companies (especially developmental-stage biotech) are repeatedly checking whether their FDA interactions remain consistent, signaling acute need for clarity on regulatory communications.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0003","quote":"\"people are going to be asking all of their companies on a week-by-week basis... have your FDA conversations been consistent?\""}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0004_n1","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Неопределённость и отсутствие ясного «мастер-плана» (в т.ч. в FDA) вызывают критическую обеспокоенность; рынки не любят неопределённость и задержки.","text_en":"Uncertainty and lack of an overarching master plan (incl. at FDA) are a critical concern; markets dislike uncertainty and delays.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0004","quote":"the lack of an overarching master plan across many, many fronts right now, but certainly at the FDA is a critical concern."},{"chunk_id":"doc_576b38e3c826_chunk_0004","quote":"the markets hate uncertainty, but we also hate delays."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0004_n2","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Уход опытных сотрудников FDA создаёт риск потери институциональной памяти/истории, что осложняет лидерство и работу с растущей сложностью (новые модальности, биомаркеры/суррогаты).","text_en":"Departures of experienced FDA staff risk loss of institutional memory, making it harder to lead amid increasing complexity (novel modalities, biomarkers/surrogates).","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0004","quote":"the fear I have is the loss of that institutional memory and history and how to lead in the context of that complexity."},{"chunk_id":"doc_576b38e3c826_chunk_0004","quote":"taking time to build up the technical acumen to deal with novel modalities, more complex conditions."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0004_n3","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Из-за неопределённости и «flux» после увольнений становится трудно нанимать людей; есть опасения значительных задержек и «backtracking» в инновациях.","text_en":"Uncertainty/flux after layoffs makes recruiting difficult; there are worries about significant delays and backtracking in innovation.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0004","quote":"it's difficult to recruit into organizations that have undergone a lot of uncertainty and flux"},{"chunk_id":"doc_576b38e3c826_chunk_0004","quote":"I worry that we're going to have significant delays and some real backtracking in places of innovation"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0005_n1","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"В FDA отмечают текучку, потерю информации/экспертизы и дефицит лидерства, что требует исправления.","text_en":"At the FDA there is turnover, lost information/know-how, and a lack of leadership that needs correction.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0005","quote":"We've certainly got. lot of turnover that we need to correct. We've got a lot of lost information and know-how. We've got a dearth of leadership"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0005_n2","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"Ожидается «огромное культурное изменение» в FDA из‑за «тона сверху», который описывается как политически мотивированный и антинаучный.","text_en":"A major cultural change is expected at the FDA due to a top-down tone described as politically driven and anti-science.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0005","quote":"There is this tone from the top that... is politically driven and anti-science in its agenda."},{"chunk_id":"doc_576b38e3c826_chunk_0005","quote":"I think we're in for, unfortunately, a huge cultural change"}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0005_n3","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"В ряде редких генетических программ пытаются получить (ускоренное/условное) одобрение на основе биомаркера в области, где исторически требовались клинические данные и плацебо‑контролируемые исследования.","text_en":"Some rare genetic programs are seeking approval based on a biomarker in an area where historically clinical data and placebo-controlled trials were needed.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0005","quote":"being filed for excluded approval based on a biomarker"},{"chunk_id":"doc_576b38e3c826_chunk_0005","quote":"where historically you've largely needed clinical data to get FDA approval, placebo-controlled clinical trials"}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0006_n1","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"В США за последние годы наблюдается возрождение кори, связанное с ростом вакцинной нерешительности и глобальными поездками; текущие случаи превышают прошлогодние.","text_en":"The US has seen a measles resurgence in recent years tied to rising vaccine hesitancy and global travel; current cases exceed last year’s.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0006","quote":"in the last couple of years, we've seen a resurgence because of the growing incidence of vaccine hesitancy combined with global travel"},{"chunk_id":"doc_576b38e3c826_chunk_0006","quote":"this is twice as many cases and significantly more morbidity than we had all of last year"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0006_n2","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Официальные данные по кори могут существенно недооценивать реальное число случаев из‑за неполного подтверждения (viral titer) и неучёта контактных/экспонированных.","text_en":"Official measles counts may substantially underestimate true cases due to incomplete confirmation (viral titer) and uncounted exposed contacts.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0006","quote":"about 500 cases confirmed cases of measles, which is a gross underestimation"},{"chunk_id":"doc_576b38e3c826_chunk_0006","quote":"people who don't actually get virally titred wouldn't be counted in these CDC data"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0006_n3","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Публичные заявления руководства HHS с дезинформацией о рисках вакцины могут усиливать вакцинную нерешительность, что усугубляет проблему вспышек.","text_en":"Public misinformation from HHS leadership about vaccine risks may further increase vaccine hesitancy, worsening outbreaks.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0006","quote":"went on Hannity to say that the vaccine is very risky"},{"chunk_id":"doc_576b38e3c826_chunk_0006","quote":"which is concerning misinformation and potentially contributes further to vaccine hesitancy"}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0007_n1","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"В HHS происходят быстрые изменения в разных подразделениях, но они не скоординированы и без понятного плана по реорганизации и укомплектованию штата, что может иметь долгосрочные последствия.","text_en":"Rapid changes across HHS divisions are uncoordinated and lack a clear staffing/reorg plan, with potential long-term implications.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0007","quote":"there's a lot of change happening really quickly... And it's not coordinated at all. And there's no— doesn't seem to be a plan"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0007_n2","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Опасения из‑за вспышек кори/вакцинной динамики: это повышает стресс и снижает качество жизни у обычных людей, включая родителей маленьких детей.","text_en":"Concerns about measles/vaccine dynamics increase stress and reduce quality of life for everyday people, including parents of young children.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0007","quote":"the vaccine stuff spooks me... it can reduce quality of life and increase stress"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0007_n3","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Для биосектора критична предсказуемая и научно-обоснованная регуляторика FDA; без надежного регулирования «сектора не будет».","text_en":"The sector depends on predictable, science-driven FDA regulation; without reliable regulation, the sector doesn’t function.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0007","quote":"we want it to be super predictable and science-driven... without that, we don't really have a sector"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0008_n1","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Отсутствие координации и «мастер-плана» по «новой реальности» вызывает обеспокоенность.","text_en":"Lack of coordination and a “master plan” for the “new reality” is causing concern.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0008","quote":"I think what we need to see is some kind of coordination, right? And some kind of a master plan"},{"chunk_id":"doc_576b38e3c826_chunk_0008","quote":"In the absence of it, it's concerning."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0008_n2","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Биофарма испытывает репутационную проблему: низкая «моральная авторитетность», из-за чего публичные заявления могут не дать эффекта и даже вызвать критику.","text_en":"Biopharma has a reputational problem; low “moral authority” makes speaking up unlikely to help and may trigger criticism.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0008","quote":"The pharma industry has zero moral authority right now— like less than zero."},{"chunk_id":"doc_576b38e3c826_chunk_0008","quote":"speaking up, is going to score any points or accomplish anything."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0008_n3","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Есть восприятие недостаточно активной публичной позиции/лоббирования индустрии; отмечается удивление отсутствием более громкого протеста по поводу финансирования NIH.","text_en":"Perception that the industry is not vocal enough; surprise at the lack of louder outcry about NIH funding.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0008","quote":"He called us cowards, he said, 'you know, we're not doing our job to to try and enact change"},{"chunk_id":"doc_576b38e3c826_chunk_0008","quote":"I'm surprised at lack of a louder outcry about NIH funding to our research institutions"}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0009_n1","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"Покупатели (buy side) в индустрии занимают выжидательную позицию из‑за неопределённости вокруг тарифов и регуляторного руководства.","text_en":"The buy side is staying on the sidelines due to uncertainty around tariffs and agency leadership.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0009","quote":"there is an element of, regarding the industry and the the buy side, sitting a little bit on the sidelines"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0009_n2","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Неопределённость по тарифам, руководству агентства и возможным побочным эффектам на PDUFA даты (упомянуто: «mostly not, except vaccines») затрудняет выбор сообщений и действий.","text_en":"Uncertainty about tariffs, agency leadership, and potential collateral effects on PDUFA dates makes it hard to decide on messaging and actions.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0009","quote":"How much of tariffs... What is the organizational leadership of the agency going to be? Are there going to be collateral effects on Bidufa dates or not?"},{"chunk_id":"doc_576b38e3c826_chunk_0009","quote":"So far, mostly not, except vaccines?"}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0009_n3","doc_id":"doc_576b38e3c826","kind":"opportunity","text_ru":"Возможность для индустрии и финансов «lean in»: укреплять доверие к науке/медицине, объяснять индустрию (включая supply chains) и инвестировать в навыки для возвращения производства в США.","text_en":"Opportunity for industry and finance to lean in by building trust in science/medicine, educating about the industry (including supply chains), and investing in skills to bring manufacturing back to the US.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0009","quote":"The drumbeat of building and maintaining trust in science... to educate about our industry, including our supply chains"},{"chunk_id":"doc_576b38e3c826_chunk_0009","quote":"make visible investments in the skill base that's needed to bring more manufacturing back stateside"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0010_n1","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"В HCM-препаратах есть «impediments to use» из‑за необходимости эхокардиографического мониторинга в реальной практике (на примере Mavacamten).","text_en":"In HCM drugs, real-world echocardiographic monitoring requirements are impediments to use (e.g., with Mavacamten).","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0010","quote":"\"echocardiograph monitoring in the real world that are impediments to use with MAVA.\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0010_n2","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"В HCM формируется линейка follow-on/«next-generation» препаратов, где тезис — последующие поколения становятся безопаснее и снижают потребность в мониторинге.","text_en":"In HCM, follow-on/next-generation drugs are emerging with a thesis that later generations are safer and reduce monitoring needs.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0010","quote":"\"as you go across the spectrum, the thesis in each of these follow-on drugs is they get safer and safer\""}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0010_n3","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"В педиатрической популяции «tough environment» публиковать негативные данные.","text_en":"In pediatrics, it’s a tough environment to report negative data.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0010","quote":"\"in the pediatric, uh, you know, population— certainly a tough environment to report negative data out on.\""}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0011_n1","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Высокий барьер по безопасности и консервативная позиция FDA требуют большого объёма данных; на маленьком датасете сложно «опровергнуть негатив» по safety.","text_en":"High safety bar and conservative FDA stance require lots of data; small datasets make it hard to rule out safety concerns.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0011","quote":"the safety hurdle is really high... it was a small data set and it's hard to disprove the negative on a safety regulatory thing in a small data set."},{"chunk_id":"doc_576b38e3c826_chunk_0011","quote":"the FDA... is very conservative on safety, and you need a lot of data to disprove the negative."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0011_n2","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Даже при оптимальной терапии статинами и снижении холестерина сохраняется независимый риск крупных сердечных событий из‑за Lp(a), что указывает на неудовлетворённую потребность.","text_en":"Even with best statin/cholesterol-lowering management, Lp(a) can drive independent risk of major cardiac events, indicating unmet need.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0011","quote":"even with kind of best statin management, cholesterol lowering, you can still see independent risk for major cardiac events."},{"chunk_id":"doc_576b38e3c826_chunk_0011","quote":"So there is an unmet need."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0011_n3","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"siRNA/нуклеиновые препараты против Lp(a) показывают сильное клиническое снижение показателя и быстро переходят в фазу 3 с фокусом на outcomes (MACE).","text_en":"Nucleic-acid/siRNA drugs targeting Lp(a) show strong lowering and are moving into phase 3 with outcomes (MACE) focus.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0011","quote":"it has shown a dramatic lowering in phase one"},{"chunk_id":"doc_576b38e3c826_chunk_0011","quote":"a dramatic 93. 5% lowering of LP little a... they triggered off their phase three study, which is now enrolling."},{"chunk_id":"doc_576b38e3c826_chunk_0011","quote":"phase three is kicking off... cardiovascular outcomes... looking at MACE"}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0012_n1","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"Сдвиг программ по Lp(a) в сторону первичной профилактики (несколько компаний планируют/запускают исследования в primary prevention).","text_en":"Lp(a) programs are moving toward primary prevention (multiple companies planning/starting primary-prevention studies).","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0012","quote":"with LePo they're going into primary prevention... Amgen said they're going to start a primary prevention study this year."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0012_n2","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"В Horizon события накапливаются медленнее ожидаемого, из‑за чего сдвигаются сроки достижения первичной конечной точки CVOT.","text_en":"In Horizon, events are accruing slower than expected, pushing out timing for the CVOT primary endpoint readout.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0012","quote":"they said that events are happening slower than expected. So it's going to be next year in the first half."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0012_n3","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Структурный конкурентный/модальный риск для ASO в печени: даже при наличии «shots on goal» может возникать «competitive overhang» из‑за потенциально лучших препаратов на горизонте.","text_en":"Structural competitive/modality risk for liver ASOs: even with multiple shots on goal, there can be immediate competitive overhang from potentially better drugs on the horizon.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0012","quote":"there could be a better drive on the horizon... the structural challenge for ASOs in the liver."}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0013_n1","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Вывод на рынок и масштабирование таких препаратов может занимать много времени из‑за необходимости получить возмещение (reimbursement).","text_en":"Time-to-scale can be long because reimbursement takes time.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0013","quote":"it's going to take a long time for these drugs to be big because it's going to take time to get reimbursement."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0013_n2","doc_id":"doc_576b38e3c826","kind":"pain","text_ru":"Кардиологи не любят модель оплаты/закупки «buy and bill».","text_en":"Cardiologists dislike the “buy and bill” model.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0013","quote":"cardiologists don't love this buy and bill model."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0013_n3","doc_id":"doc_576b38e3c826","kind":"buyer_signal","text_ru":"Есть сигнал предпочтения пациентов: «люди любят» автоинжектор (удобство применения).","text_en":"Buyer signal: people/patients love the autoinjector (preference for this delivery format).","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0013","quote":"what we're hearing a lot out there is that people love the autoinjector"}],"confidence":"medium"}
{"nugget_id":"doc_576b38e3c826_chunk_0014_n1","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"Кроссоверные/tech-diversified фонды активнее пишут чеки в AI в healthcare (в т.ч. pharma, service delivery, decision support).","text_en":"Crossover/tech-diversified funds are increasingly investing in AI in healthcare (including pharma, service delivery, decision support).","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0014","quote":"We've seen more crossover or tech-diversified funds playing more in AI in healthcare, whether it's in the pharma side or in you know, service delivery or decision support."},{"chunk_id":"doc_576b38e3c826_chunk_0014","quote":"Thrive and Sequoia have been two, you know, major leading check writers."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0014_n2","doc_id":"doc_576b38e3c826","kind":"constraint","text_ru":"Риск для регуляторных сроков/процессов: возможные «major structural change of the agency» могут помешать FDA делать всё вовремя.","text_en":"Regulatory timing risk: a “major structural change of the agency” could inhibit the FDA from doing things on time.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0014","quote":"barring any sort of major structural change of the agency that inhibits the FDA from doing things on time."}],"confidence":"high"}
{"nugget_id":"doc_576b38e3c826_chunk_0014_n3","doc_id":"doc_576b38e3c826","kind":"trend","text_ru":"По обсуждению, FDA по late-stage кейсам выглядит «on top of it» и укладывается в сроки (в т.ч. PDUFA), что воспринимается как обнадёживающее.","text_en":"In this discussion, the FDA appears on top of late-stage items and meeting timelines (incl. PDUFA), which is seen as encouraging.","evidence":[{"chunk_id":"doc_576b38e3c826_chunk_0014","quote":"at least it sounds like things that are late stage, they're very much on top of it. That's encouraging."},{"chunk_id":"doc_576b38e3c826_chunk_0014","quote":"Fingers crossed that we continue to see a functional FDA in terms of hitting their PDUFA dates"}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_nugget_0001","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Инвесторы в биотехе смещают фокус с конкретных компаний/данных на макро-факторы.","text_en":"Biotech investors are shifting focus from specific companies/data to macro factors.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0000","quote":"All of our incoming calls, uh, from biotech investors, had very little to do with specific companies... They had everything to do with the macro"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_nugget_0002","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"В биотехе ожидаются/наблюдаются крупные внешние изменения и неопределённость: возможные тарифы, риск экономического спада, недостаток финансирования NIH, изменения в FDA.","text_en":"Biotech faces major external shifts/uncertainty: potential tariffs, economic downturn risk, lack of NIH funding, and a changing FDA.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0000","quote":"The FDA is going to be very, very different... We've got potential for tariffs... potential for economic downturn. We're seeing lack of funding at the NIH."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_nugget_0003","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Участникам рынка приходится выходить за пределы своей экспертизы из‑за резких макроизменений, что вызывает дискомфорт.","text_en":"Market participants are forced outside their expertise due to abrupt macro shifts, creating discomfort.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0000","quote":"Everyone is suddenly had to put their their macro caps on... We're all doing things that are probably way outside of our swim lanes"}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0001_n1","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"На фоне «sea change» на Уолл-стрит часть фондов и компаний может не выжить; индустрия, вероятно, сокращается.","text_en":"Amid a Wall Street “sea change,” some funds and companies may not survive; the industry is likely shrinking.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0001","quote":"this sea change that is happening on Wall Street is going to leave certain funds unable to continue, certain companies unable to raise capital."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0001","quote":"This industry is probably shrinking as we. we see it right now."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0001_n2","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Сильные рыночные колебания делают инвестирование «очень сложным» и не связаны с фундаменталом компаний.","text_en":"Large market swings make investing very challenging and are not tied to company fundamentals.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0001","quote":"How hard it is to be an investor right now."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0001","quote":"It's just the market swings, I think, are making it really, really challenging for people."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0001","quote":"obviously, it has nothing to do with fundamental companies."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0001_n3","doc_id":"doc_53a13a5b7f6b","kind":"buyer_signal","text_ru":"Инвесторы становятся более строгими к small-cap: хотят «data catalyst», который опровергает bear cases и реально создаёт ценность; чувствительны к компаниям с высокими cash needs и риском дилюции.","text_en":"Investors are becoming more stringent on small caps: want a data catalyst that disproves bear cases and creates value; more sensitive to high cash-need/dilution-risk names.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0001","quote":"there's going to be certain types of criteria that investors are going to be more stringent on with with small stocks."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0001","quote":"that's got to be a data catalyst in this market that really disproves one or two bear cases and is truly value creating."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0001","quote":"I'm finding investors being more sensitive to those types of names."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0002_n1","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Рынок/инвесторы почти не прощают даже небольшие «путаницы» в данных, что вызывает у компаний тревожность и усложняет коммуникацию результатов.","text_en":"The market/investors have little tolerance for even minor confusing points in data, creating anxiety for companies and complicating data communication.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0002","quote":"There's very little forgiveness for even any like, minor kind of like confusing point in data."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0002","quote":"that could understandably create a lot of anxiety for companies about, like, oh, my gosh"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0002_n2","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Компании смещаются от быстрого выпуска данных на уровне отдельных пациентов к публикации более полных и «robust» датасетов с контекстом.","text_en":"Companies are shifting from rapid individual patient-level releases to publishing fuller, more robust datasets with proper context.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0002","quote":"our days of kind of like individual patient level data coming out in quick succession, that would not play well, in this market"},{"chunk_id":"doc_53a13a5b7f6b_chunk_0002","quote":"companies being in a position to, ideally, release, you know, pretty full, robust data sets"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0002_n3","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"На венчурной стороне оценка компаний «reverse engineer» и привязана к публичным компам; улучшение публичных оценок биотехов является ограничивающим фактором.","text_en":"On the venture side, valuations are reverse-engineered and pegged to public-market comparables; healthier public biotech valuations are a limiting factor.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0002","quote":"on the venture side, we have to reverse engineer on valuation. And you really are pegged to comparables in the public markets."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0002","quote":"until we start to see the public valuations of biotechs get healthier."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Венчурным инвесторам сложно «обратно» посчитать экономику и путь к доходности, когда публичные оценки биотехов нездоровые и IPO-окно слабое/закрыто.","text_en":"VCs struggle to reverse-engineer returns when public biotech valuations are unhealthy and the IPO window is weak/closed.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0003","quote":"\"we have to reverse engineer on valuation. And you really are pegged to comparables in the public markets.\""},{"chunk_id":"doc_53a13a5b7f6b_chunk_0003","quote":"\"It's hard to reverse engineer. You know, how is everybody going to make money along the way\""},{"chunk_id":"doc_53a13a5b7f6b_chunk_0003","quote":"\"With the IPO window closed\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Роялти-компании (включая mid/small) сейчас активно рассматриваются как источник финансирования: их «телефоны разрываются», и они готовы брать часть девелопмент-риска на ранних стадиях.","text_en":"Royalty companies are seeing strong inbound demand and are willing to take some development risk by investing earlier-stage assets for future royalties.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0003","quote":"\"their phones are ringing off the hook right now.\""},{"chunk_id":"doc_53a13a5b7f6b_chunk_0003","quote":"\"there's a lot of these royalty companies that will take some development risk and invest in an asset early on\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_53a13a5b7f6b","kind":"opportunity","text_ru":"Для небольших биотех-компаний, особенно при закрытом IPO-окне и без big pharma сделки, появляется практическая опция привлечения капитала через роялти-финансирование на ранних стадиях.","text_en":"Smaller biotechs can pursue early-stage royalty financing as an alternative when IPOs are closed and big pharma deals aren’t available.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0003","quote":"\"if you're not getting like a big pharma deal, another option for smaller companies\""},{"chunk_id":"doc_53a13a5b7f6b_chunk_0003","quote":"\"if I was a smaller company trying to exhaust all options, I would look at that too.\""}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0004_n1","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Ожидается рост числа объявлений/сделок на стороне royalty в ближайшие 12–18 месяцев.","text_en":"More royalty-side announcements/deals are expected over the next 12–18 months.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0004","quote":"I think we're going to be seeing a lot of those types of announcements over the next year, year and a half."}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0004_n2","doc_id":"doc_53a13a5b7f6b","kind":"opportunity","text_ru":"Royalty-компании могут эффективно «чистить» рынок от «zombie companies»: приобретать компании, распределять кэш акционерам и затем лицензировать оставшиеся ранние активы.","text_en":"Royalty companies may efficiently clean up “zombie companies” by acquiring them, returning cash to shareholders, and later licensing remaining early assets.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0004","quote":"they all need to get cleaned up, and the royalty companies can do that very efficiently"},{"chunk_id":"doc_53a13a5b7f6b_chunk_0004","quote":"acquire them, distribute the cash to the shareholder base"},{"chunk_id":"doc_53a13a5b7f6b_chunk_0004","quote":"they have something to eventually license out if anybody wants to"}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0004_n3","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"Структура некоторых royalty-сделок (особенно у крупных игроков, совмещающих их с debt) может быть устроена так, что «компания проигрывает», но всё равно должна вернуть выплаты, что требует внимательного разбора нюансов.","text_en":"Some royalty deals (especially from big players also doing debt) can be structured so the company still must pay back even if it “loses,” requiring careful attention to nuances.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0004","quote":"it's so important to think through the nuances or understand the nuances of them"},{"chunk_id":"doc_53a13a5b7f6b_chunk_0004","quote":"the royalty deal is basically dead, right?"},{"chunk_id":"doc_53a13a5b7f6b_chunk_0004","quote":"the company loses. They still got to pay back"}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0005_n1","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Вокруг FDA наблюдаются заметные кадровые/политические изменения и публичная критика со стороны бывших лидеров агентства после увольнения Питера Маркса.","text_en":"Notable leadership/political changes and public criticism around the FDA following Peter Marks’ dismissal.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0005","quote":"the FDA discussion that arose and came to the fore last week with Peter Marks' dismissal."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0005","quote":"we saw a number of former FDA leaders, including Janet Woodcock, come out very vociferously against the change."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0005_n2","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Инвестсообщество испытывает тревожность и неопределённость из‑за возможного ущерба и политизации независимого процесса рассмотрения лекарств в FDA.","text_en":"The investment community is anxious/uncertain due to perceived damage and politicization risks to the FDA’s independent drug review process.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0005","quote":"we're still very anxious here we think the FDA is for the most part hanging in the balance."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0005","quote":"a majority of us do think that there is severe damage that's been inflicted on the FDA."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0005","quote":"unwilling to stand up for an independent drug review process."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0005_n3","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Разработческие biotech-компании заметно «торгуются» вверх/вниз на восприятии регуляторной гибкости; есть ожидания, что FDA может стать более «либертарианским» для не-вакцинных компаний.","text_en":"Development-stage biotech stocks move with perceived regulatory flexibility; some expect the FDA could be more libertarian for non-vaccine companies.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0005","quote":"development stage biotech companies sort of trade up and down on the perception of regulatory."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0005","quote":"maybe there's an argument that, you know, this FDA could be even more libertarian for those types of companies."}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0006_n1","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Фрустрация из‑за FDA guidance: сложно «двигать программы вперёд», есть ощущение перегруза требованиями (в т.ч. по animal tox) и это «across divisions».","text_en":"Frustration with FDA guidance: difficulty moving programs forward, perceived overweighting of requirements (incl. animal tox), across divisions.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0006","quote":"\"we've been very, very frustrated with FDA guidance.\""},{"chunk_id":"doc_53a13a5b7f6b_chunk_0006","quote":"\"the inability to just move forward with programs\""},{"chunk_id":"doc_53a13a5b7f6b_chunk_0006","quote":"\"This is not unique to one division. It's across divisions.\""}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0006_n2","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Больше компаний рассматривают получение клинических данных вне США (вопрос «Should we get clinical data outside of the U. S.?» звучит всё чаще).","text_en":"More companies are considering generating clinical data outside the U.S. (increasingly asking whether to get clinical data outside the U.S.).","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0006","quote":"\"More and more companies are saying, 'Should we get clinical data outside of the U. S.?'\""}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0006_n3","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"FDA коммуницирует про «phasing out animal testing» и «relying on other means», включая использование клинических данных; это воспринимается как возможный сигнал большей прагматичности, но непонятно, когда будет полностью внедрено.","text_en":"FDA communication about phasing out animal testing and relying on other means (incl. clinical data) is seen as a possible signal of more pragmatism, with unclear implementation timing.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0006","quote":"\"a small communication around phasing out animal testing, relying on other means.\""},{"chunk_id":"doc_53a13a5b7f6b_chunk_0006","quote":"\"Including a statement about using clinical data.\""},{"chunk_id":"doc_53a13a5b7f6b_chunk_0006","quote":"\"who knows when this will be fully implemented.\""}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0007_n1","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"FDA исторически демонстрировала открытость/гибкость по требованиям к animal testing, но без конкретного руководства, из‑за чего компании действуют по «классическому» сценарию и делают привычный пакет работ.","text_en":"FDA has shown openness/flexibility on animal testing requirements but without specific guidance, pushing companies to follow the traditional, conservative package of work.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0007","quote":"the FDA has historically expressed openness and some flexibility on animal testing requirements, but without really specific guidance about what is required."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0007","quote":"bring us the package and we'll let you know if it's okay."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0007_n2","doc_id":"doc_53a13a5b7f6b","kind":"opportunity","text_ru":"Есть возможность модернизировать регуляторный процесс и выпустить guidance в областях, где путь разработки может стать более эффективным, но для этого нужны сильное управление и опытные люди.","text_en":"Opportunity to modernize and issue guidance to make development paths more efficient, but it requires strong management and experienced people.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0007","quote":"there's a real opportunity here to. know, bring in great talent. you know, try and modernize, you know, bring out guidance in."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0007","quote":"that opportunity needs. strong, you know, strong. a talented place to manage it and experience people."}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0007_n3","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"Сокращения персонала в FDA вызывают опасения, потому что даже если «reviewers» не увольняют, они зависят от критических ролей в других департаментах; также упоминаются опасения по PDUFA/финансированию.","text_en":"FDA staff cuts are concerning because reviewers depend on critical roles in other departments; there are also concerns mentioned about PDUFA/its funding triggers.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0007","quote":"some of the people cuts, I think are concerning."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0007","quote":"those people who are doing reviews, they rely on you know, pretty critical roles in other departments"},{"chunk_id":"doc_53a13a5b7f6b_chunk_0007","quote":"there were these concerns about defunding of PDUFA"}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_nugget_0001","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Опасения, что сокращения/кадровые изменения в FDA (в т.ч. project managers) ухудшат роль «liaison» со спонсорами и усложнят получение разъяснений между встречами.","text_en":"Concerns that FDA staffing changes/cuts (incl. project managers) may weaken the sponsor liaison function and make it harder to get clarifications between meetings.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0008","quote":"the rumors that project managers might have been part of the cuts—those are a real glue for sponsors to get clarification"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_nugget_0002","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Компании слышат, что «senior reviewers» отсутствуют, остаются junior reviewers, из-за чего обратная связь становится конфликтующей и сложнее эскалировать вопросы из‑за нехватки опытных людей.","text_en":"Reports that senior reviewers are gone, leaving junior reviewers; feedback becomes conflicting and escalation is harder due to lack of experienced staff.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0008","quote":"the senior reviewers aren't there anymore, right? We just have junior reviewers"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_nugget_0003","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Есть случаи, когда руководство FDA не присутствует на встречах, что мешает быстро разрешать недопонимания после длительной подготовки к FDA meetings.","text_en":"Instances where FDA leadership failed to attend meetings, reducing the ability to quickly resolve misunderstandings after extensive meeting prep.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0008","quote":"we've talked about other companies where leadership failed to attend meetings"}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0009_n1","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Из‑за нехватки (особенно senior) сотрудников в FDA ухудшаются качество обратной связи/взаимодействия и возможность эскалации несогласий.","text_en":"FDA short-staffing (especially senior) is challenging feedback quality, interactions, and the ability to escalate disagreements.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0009","quote":"The quality of feedback, the quality of interaction. The ability to do things like escalate... are all being challenged in a very short-staffed environment"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0009_n2","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"FDA может отказывать в pre-IND встречах и предлагать рассмотреть вопросы только вместе с IND.","text_en":"FDA may refuse pre-IND meetings and instead review issues with the IND.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0009","quote":"private company that didn't even have a pre-IND meeting and the FDA refused."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0009","quote":"The pre-IND meeting request and said, 'We'll review it with the IND.'"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0009_n3","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Инвесторам сложно понять, как инвестировать с учётом тарифов: трудно моделировать влияние, больше фокус на волатильности рынка.","text_en":"Investors struggle to invest around tariffs: hard to model impact; focus shifts to market volatility.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0009","quote":"All the investors that I talk to don't really know how to invest. Within this issue."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0009","quote":"beyond how to model that, I think it's tricky."}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0010_n1","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Высокая неопределённость и волатильность вокруг тарифов/политики затрудняет планирование для компаний и защитную стратегию для инвесторов.","text_en":"High uncertainty and volatility around tariffs/policy makes company planning and investor defensive strategy difficult.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0010","quote":"I feel like the top line is just more uncertainty, more volatility."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0010","quote":"But if you're a company, I mean, how do you plan, right? I mean, I think no one knows."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0010_n2","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"Нефункционирующий/неэффективный FDA является критическим барьером для биотеха, особенно для небольших инновационных компаний.","text_en":"A dysfunctional FDA is a critical barrier for biotech, especially smaller innovative companies.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0010","quote":"If the FDA doesn't get its act together and isn't able to function, you know, we're in biotech."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0010","quote":"Especially smaller, innovative companies, we're dead in the water, right?"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0010_n3","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Крупные фармкомпании, вместо переноса производств, скорее «выжидают» и оптимизируют налоговый/производственный учёт (в т.ч. через географию IP) из‑за неясности по тарифам.","text_en":"Large pharma companies are more likely to wait and optimize tax/manufacturing accounting (incl. IP geography) given tariff uncertainty, rather than relocate manufacturing.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0010","quote":"they're much more likely to wait it out the next three or four years, not knowing what might happen"},{"chunk_id":"doc_53a13a5b7f6b_chunk_0010","quote":"I think a lot of them are looking closely at their tax accounting in particular."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0010","quote":"either shifting IP to different geographies"}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0011_n1","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"В секторе дженериков наблюдаются дефициты/shortages, которые усугубляются ценовым давлением и зависимостью от производства вне США; сбои цепочки поставок приводят к ущербу пациентам.","text_en":"Generic drugs face shortages, worsened by price pressure and ex-US manufacturing; supply chain disruptions can harm patients.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0011","quote":"there's been a lot of shortages over time... so much price pressure and so much... ex-US manufacturing, that any kind of... supply chain snafu, can really create shortages"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0011_n2","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"Тарифы как инструмент возврата производства в США плохо подходят для дженериков из‑за очень низких маржин.","text_en":"Tariffs may be ineffective for reshoring generic manufacturing because margins are very slim.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0011","quote":"Tariffs are probably... not necessarily the way... bringing manufacturing back to the generic sector, simply because the margins are so slim."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0011_n3","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"Публичные объявления о многомиллиардных инвестициях в производство в США могут быть частично PR; фактическая реализация таких анонсов под вопросом.","text_en":"Announcements of multibillion-dollar US manufacturing investments may be partly PR; whether they actually happen is uncertain.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0011","quote":"I think it's a smart, intelligent way to curry favor. Whether they actually happen is going to be another question."}],"confidence":"medium"}
{"nugget_id":"nugget_001","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"Перенос производства в США не решает проблему IP, размещённого в других странах; «размотать» такую структуру IP очень дорого и сложно.","text_en":"Moving manufacturing to the US doesn’t solve IP held abroad; unwinding legacy IP structures is very expensive and difficult.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0012","quote":"It is incredibly expensive and difficult to unwind all of this IP stuff that's really from another point in time."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0012","quote":"moving manufacturing over the U. S. would help... but it doesn't solve the whole problem."}],"confidence":"high"}
{"nugget_id":"nugget_002","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"Пациенты с гипоталамическим ожирением (часто после опухолей мозга/повреждения гипоталамуса) не отвечают на GLP-1, что делает популяцию сложной для лечения.","text_en":"Hypothalamic obesity patients (often post brain cancer/hypothalamic damage) don’t respond to GLP-1s, making the population hard to treat.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0012","quote":"most of these diagnosed patients had brain cancer and tissue damage to the hypothalamus. And as a result, they don't respond to GLP-1s."}],"confidence":"high"}
{"nugget_id":"nugget_003","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"В генотерапии по фридрейховой атаксии биомаркеры шумные (вариабельные базовые уровни, дозозависимость), а FDA guidance/согласования по эндпоинтам сейчас дисконтируются из‑за неопределённости в FDA.","text_en":"For Friedreich’s ataxia gene therapy, biomarkers are noisy (variable baselines, dose dependence), and FDA guidance/endpoint agreements are being discounted due to FDA uncertainty.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0012","quote":"the biomarkers in this indication have noise."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0012","quote":"a lot of this FDA guidance is getting discounted by people right now because of uncertainty at the FDA."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0013_n1","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"Участники считают, что из‑за неопределённости в FDA люди «дисконтируют» FDA guidance, что создаёт регуляторную неопределённость для эндпоинтов/пивоталов.","text_en":"Perceived FDA uncertainty is leading people to discount FDA guidance, creating regulatory uncertainty around endpoints/pivotal studies.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0013","quote":"a lot of this FDA guidance is getting discounted by people right now because of uncertainty at the FDA."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0013_n2","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"В cell/gene therapy описывают «overhang» и инвесторский «shoot first, ask questions later», с фокусом на коммерческую модель и жизнеспособность компаний.","text_en":"Cell/gene therapy is described as having an investor overhang and a “shoot first, ask questions later” dynamic, with scrutiny on commercial models and viability.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0013","quote":"there's been more of an investor reckoning and a little bit of a shoot first, ask questions later across the gene therapy space"}],"confidence":"medium"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0013_n3","doc_id":"doc_53a13a5b7f6b","kind":"pain","text_ru":"В обсуждаемом RCT по Alzheimer’s результаты в целом не были статистически значимыми; даже в pre-specified subgroup отмеченная сепарация по CDR-SB тоже не достигла значимости, что усложняет решение о продолжении.","text_en":"In the discussed Alzheimer’s RCT, overall results were not statistically significant; even the pre-specified subgroup separation on CDR-SB was not statistically significant, complicating go-forward decisions.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0013","quote":"the results were not statistically significant."},{"chunk_id":"doc_53a13a5b7f6b_chunk_0013","quote":"They did see a separation in CDR sum of boxes in that pre-specified subgroup, I think it wasn't statistically significant."}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0014_n1","doc_id":"doc_53a13a5b7f6b","kind":"constraint","text_ru":"В коммерчески доступных анти-бета-амилоидных препаратах ограничением для uptake являются частота ARIA, требующая мониторинга и способная вызывать серьёзные симптомы у части пациентов.","text_en":"Uptake of commercially available anti–beta-amyloid drugs is constrained by ARIA rates that require monitoring and can cause serious symptoms in a subset of patients.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0014","quote":"commercially available beta amyloid drugs have seen less uptake... because of these rates of ARIA that require a lot of monitoring"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0014_n2","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"После ужесточения критериев включения (после случая церебрального кровоизлияния) больше таких случаев не наблюдали.","text_en":"After tightening enrollment criteria following a cerebral hemorrhage case, no further such cases were observed.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0014","quote":"since tightened the criteria for enrollment, and as a result, didn't see any more of those"}],"confidence":"high"}
{"nugget_id":"doc_53a13a5b7f6b_chunk_0014_n3","doc_id":"doc_53a13a5b7f6b","kind":"trend","text_ru":"По Uplizna в миастении гравис при более длительном наблюдении эффект по MGADL продолжил улучшаться (к 52 неделям).","text_en":"For Uplizna in myasthenia gravis, longer follow-up showed continued improvement in MGADL at 52 weeks.","evidence":[{"chunk_id":"doc_53a13a5b7f6b_chunk_0014","quote":"They came out with longer follow-up. And that score continues to improve. And so at 52-week, it got to-2. 8."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0000_n1","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"После дна 7 апреля биотех-индексы отскочили (XBI ~+15%, BBC ~+30%), хотя по году остаются в минусе.","text_en":"Biotech indices rebounded since the April 7 bottom (XBI ~+15%, BBC ~+30%), though still down YTD.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0000","quote":"Since bottoming on April 7th, the XBI is up about 15%, and the BBC... is up 30%. Though these indices are still down"}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0000_n2","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Сектор биотеха годами недопоказывает, последние месяцы были очень тяжёлыми; XBI долго остаётся вялым.","text_en":"Biotech has underperformed for years; recent months have been very tough; XBI has been sluggish for a long time.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0000","quote":"the sector has underperformed for years, and the last few months have been very tough."},{"chunk_id":"doc_0c5e763379b2_chunk_0000","quote":"it's hard to be overly... optimistic... in the context of an XBI that's been so sluggish for so long"}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0000_n3","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Есть силы, которые ограничивают расходы на биофарму, что снижает интерес инвесторов; также упоминаются неопределённость и сокращения в FDA.","text_en":"Forces are constraining biopharma spending, reducing investor interest; uncertainty and FDA cuts are also mentioned.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0000","quote":"there are powerful forces that are acting to constrain spending on biopharmaceuticals, which in turn act to constrain investor interest"},{"chunk_id":"doc_0c5e763379b2_chunk_0000","quote":"An FDA that's gone through some cuts"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0001_n1","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"В биотехе за последнюю неделю улучшился риск-аппетит: лучше торгуются даже микрокэпы, а интерес инвесторов расширяется за пределы нескольких «de-risked» имён.","text_en":"Risk appetite improved in biotech over the last week: even microcaps traded better, and investor interest is broadening beyond a few de-risked names.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0001","quote":"\"the big difference in the last week is just some of the names that have been trading better in the space\""},{"chunk_id":"doc_0c5e763379b2_chunk_0001","quote":"\"a lot of the microcap names we've got some that are up 40–50\""},{"chunk_id":"doc_0c5e763379b2_chunk_0001","quote":"\"It feels like the interest is broadening a bit.\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0001_n2","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Озвучены планы ускорить одобрение лекарств в США: сократить сроки, потенциально требовать только одно РКИ с последующим усиленным постмаркетинговым надзором на базе EHR-данных.","text_en":"Plans were described to speed up US drug approvals: shorten timelines, potentially require only one RCT followed by intensive post-marketing surveillance using EHR data.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0001","quote":"\"a commitment to expediting the drug approval process\""},{"chunk_id":"doc_0c5e763379b2_chunk_0001","quote":"\"requiring only one randomized controlled trial, and then following that with intense post-marketing surveillance based on EHR data\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0001_n3","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Использование EHR-данных для постмаркетингового надзора упирается в вопросы приватности, которые нужно будет решать.","text_en":"Using EHR data for post-marketing surveillance faces privacy issues that need to be addressed.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0001","quote":"\"He also acknowledged that there's privacy issues which they're going to address.\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0002_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"У части biotech-компаний наблюдаются задержки во взаимодействии с FDA; ситуация неоднородная, «всё по-разному» после изменений/реорганизации.","text_en":"Some biotech companies are seeing FDA delays; the situation is uneven/variable after changes/reorg.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0002","quote":"Some companies that are experiencing delays are, in contrast, others are even experiencing accelerated responses."},{"chunk_id":"doc_0c5e763379b2_chunk_0002","quote":"it's a bit all over the place right now."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0002_n2","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"FDA признала, что задержка по апелляции (Vanda CRL appeal) была связана с кадровыми вопросами и недавней реорганизацией/дисрапшеном.","text_en":"FDA acknowledged an appeal delay (Vanda CRL appeal) was related to staffing and recent reorg/disruption.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0002","quote":"The FDA themselves said that the nature of the appeal delay was related to staffing and the recent reorg and recent disruption."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0002_n3","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Угроза pharma tariffs рассматривается как «headwind» и остаётся неопределённой; обсуждается как фактор, влияющий на инвестиции в производство в США и прогнозы выручки/прибыли.","text_en":"Threat of pharma tariffs is an uncertain headwind; discussed as affecting US manufacturing investments and earnings/revenue guidance.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0002","quote":"the threat of pharma tariffs, which remains uncertain."},{"chunk_id":"doc_0c5e763379b2_chunk_0002","quote":"announcements from big pharma companies about expanded investments in U. S. manufacturing sites"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0003_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Задержки в рассмотрении заявок в FDA связаны с тем, что значимая доля ревьюеров (упомянуто 25%) самоотстраняется от ревью после требования работать в офисе 5 дней в неделю, что бьёт по компаниям.","text_en":"FDA review delays are linked to a reported 25% of reviewers recusing themselves after a 5-days-in-office requirement, impacting companies.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0003","quote":"“The reason that 25% of FDA reviewers essentially recuse themselves from reviewing things... is because they were told that they needed to be in the office five days a week.”"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0003_n2","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Сообщается о быстром изменении морали и условий работы в FDA: допускается работа в офисе 3 дня в неделю вместо 5, и «люди возвращаются к работе».","text_en":"Reported rapid shift in FDA morale and work policy: 3 days/week in-office instead of 5, and people returning to work.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0003","quote":"“people are coming back to work. The first thing Bakari said is, 'You don't actually have to be in the office five days a week. You can come in. three days a week'”"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0003_n3","doc_id":"doc_0c5e763379b2","kind":"opportunity","text_ru":"Ожидается, что в ближайшие 2–3 недели компании начнут получать одобрения на основе относительно небольших датасетов, если данные «decisive» в редких заболеваниях.","text_en":"Expectation that within 2–3 weeks companies may get approvals with relatively small datasets if decisive in rare disease settings.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0003","quote":"“next two or three weeks... companies um that are going to be getting approvals with relatively small data sets as long as those data sets are decisive in involved rare disease situations.”"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0004_n1","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Растёт оптимизм среди KOL, что психоделики/психиатрические препараты — «реальные» лекарства, несмотря на осторожность и скепсис инвесторов.","text_en":"KOLs show increasing optimism that psychedelics/psych are “real drugs,” even as investors remain cautious and skeptical.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0004","quote":"\"there is just a lot more optimism that psychedelics and psych are real drugs\""},{"chunk_id":"doc_0c5e763379b2_chunk_0004","quote":"\"investors are looking at a lot of the companies in this space with real caution and real skepticism\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0004_n2","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Spravato описывается как сложный в использовании продукт (режим, диссоциация, необходимость стационарного мониторинга), при «окей» эффективности.","text_en":"Spravato is described as challenging to use (dosing cadence, dissociation, inpatient monitoring) with only “okay” efficacy.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0004","quote":"\"Spravato is a really challenging product to use. It's an every-other-week antidepressant. There's dissociation, inpatient monitoring.\""},{"chunk_id":"doc_0c5e763379b2_chunk_0004","quote":"\"the efficacy of it is okay\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0004_n3","doc_id":"doc_0c5e763379b2","kind":"buyer_signal","text_ru":"Есть признаки реального спроса/принятия: на Spravato уже около 50,000 пациентов, и использование растёт; J&J инвестирует в инфраструктуру.","text_en":"Signals of real adoption: ~50,000 patients on Spravato and growing; J&J investing in infrastructure.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0004","quote":"\"there's 50,000 people on it. Right. And it's growing.\""},{"chunk_id":"doc_0c5e763379b2_chunk_0004","quote":"\"J &J has made a lot of investments in building out the infrastructure.\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0005_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Адъювантные (комбинационные) клинические исследования в шизофрении «довольно сложно проводить», и исход может быть близок к «50-50».","text_en":"Adjunctive (combination) schizophrenia trials are “pretty hard to run,” with outcomes potentially close to a “50-50 coin flip.”","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0005","quote":"\"why wouldn't the probability of success for this trial be more like a 50-50 coin flip, since these studies are pretty hard to run?\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0005_n2","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"В реальной практике Cobenfi ожидается к применению в комбинации с традиционными антипсихотиками (до их постепенной отмены).","text_en":"In real-world use, Cobenfi is expected to be used in combination with traditional antipsychotics (before tapering them off).","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0005","quote":"\"since in the real world this is how the drug will be used. In combination before the traditional antipsychotic is tapered off.\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0005_n3","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Значимая доля пациентов с шизофренией уже получает комбинацию из двух атипичных антипсихотиков, несмотря на перекрывающиеся побочные эффекты и механизмы.","text_en":"A substantial share of schizophrenia patients are already on two atypical antipsychotics despite overlapping side effects and mechanisms.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0005","quote":"\"about a third of patients with schizophrenia are on two atypical antipsychotics.\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0006_n1","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Генная терапия «вышла из фавора»: инвесторы становятся более скептичными к модели коммерческого запуска таких продуктов.","text_en":"Gene therapy is out of favor; investors are becoming more skeptical about the launch model for these products.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0006","quote":"Gene therapy has been out of favor for a variety of reasons. One being... investors who are still or becoming more skeptical of... the launch model"}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0006_n2","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Сравнение Phase 1–2 с natural history может быть ограничено слабой «сепарацией» на 1-м году (медленное прогрессирование/ограниченная возможность улучшения).","text_en":"Phase 1–2 vs natural history comparisons may be constrained by limited separation at year one (slow progression/limited room for improvement).","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0006","quote":"there wasn't much separation... it might be because... Huntington's patients progressed pretty slowly in year one"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0006_n3","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"После ухода Питера Маркса рынок сильнее дисконтирует «регуляторные выравнивания/гибкость» для генной терапии; при этом breakthrough от FDA после его ухода воспринимается как сигнал, что гибкость может сохраняться.","text_en":"After Peter Marks left, the market discounted gene-therapy regulatory alignments more; FDA breakthrough after his departure is seen as a signal flexibility may persist.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0006","quote":"The street was pretty heavily discounting this after Peter Marks left... more confident that... the regulatory flexibility bull case may still be on."}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0007_n1","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"В 2024 у specialist-фондов снизились net biotech holdings: лонги упали, число фондов выросло, AUM в целом не изменился — специалисты стали заметно более short.","text_en":"In 2024, specialist funds’ net biotech holdings fell: long positions decreased, fund count rose, AUM stayed roughly flat—specialists went more short.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0007","quote":"as of last year, so this is 2024, that the the net biotech holdings of specialist funds went down."},{"chunk_id":"doc_0c5e763379b2_chunk_0007","quote":"the long positions went down, but the number of funds actually went up. And the assets under management of those funds was essentially unchanged."},{"chunk_id":"doc_0c5e763379b2_chunk_0007","quote":"specialists went a lot more short last year."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0007_n2","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Фонды с long/short или multi-strat в среднем удержали или нарастили AUM в 2024, тогда как более long-only фонды в среднем теряли AUM.","text_en":"Long/short or multi-strat funds on average held or grew AUM in 2024, while more long-only funds on average lost AUM.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0007","quote":"the funds that we're able to do long/short, or were able to do multi-strat, either stayed the same or gained assets on average last year"},{"chunk_id":"doc_0c5e763379b2_chunk_0007","quote":"whereas the funds that were longer only— not surprisingly— on average lost assets."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0007_n3","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Несмотря на ощущение «экзистенциального момента», на стороне asset managers сектор biotech «делает всё нормально»; при этом на specialist стороне заметен уклон в шорты.","text_en":"Despite an “existential moment” feeling, biotech is “doing just fine” on the asset manager side; specialists show a tilt toward shorting.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0007","quote":"it feels like, gosh, we're in this existential moment. Is biotech viable? Actually, our sector is doing just fine on the asset manager side."},{"chunk_id":"doc_0c5e763379b2_chunk_0007","quote":"It's just a lot of folks on the specialist side, let's be short."}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0008_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Биотех-сектор описывается как сложный, волатильный, с высокой долей неудач, постоянно потребляющий капитал и редко возвращающий его акционерам; устойчивые бизнес-модели редки.","text_en":"Biotech is described as complex, volatile, failure-prone, capital-consuming, and rarely returning capital to shareholders; sustainable business models are rare.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0008","quote":"The sector is very complex. It's very volatile. It's full of failure. It consumes a never-ending amount of capital... It almost never returns that capital to shareholders."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0008_n2","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Отмечается, что XBI «не двигался» пять и более лет, а многие компании торгуются ниже кэша.","text_en":"XBI is said to have gone nowhere for five+ years, and many companies trade below cash.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0008","quote":"there is there is] a reason why The XBI hasn't gone anywhere in five or more years, and there's a reason why many companies trade below. cash"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0008_n3","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Практики финансирования вроде wall cross pipes (когда финансирование происходит до данных) усложняют понимание сектора для generalist-инвесторов и снижают вероятность «большого» роста акции.","text_en":"Financing practices like wall cross pipes (financing before data) make it harder for generalist investors to understand biotech and reduce chances of big stock appreciation.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0008","quote":"practices like the wall cross pipes... make it even harder for generalists to to understand the industry... if... the financing happens before the data, you don't get... big stock appreciation"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0009_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Wall-cross PIPEs и тайминг финансирования относительно данных ухудшают динамику акций (меньше апсайда/появляется даунсайд) и усложняют понимание индустрии для generalists.","text_en":"Wall-cross PIPEs and financing timing vs. data can reduce upside/create downside in stocks and make the industry harder for generalists to understand.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0009","quote":"if a wall cross pipe happens and the financing happens before the data, you don't get that sort of big stock appreciation"},{"chunk_id":"doc_0c5e763379b2_chunk_0009","quote":"the financing would happen after the data. And that also creates, you know, some downside once the financing is announced."},{"chunk_id":"doc_0c5e763379b2_chunk_0009","quote":"the wall cross pipes, which I think tend to make it even harder for generalists to to understand the industry"}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0009_n2","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Обсуждаются/наблюдаются правительственные действия в отношении университетов, академических исследовательских институтов и даже научных журналов, что может иметь последствия для индустрии.","text_en":"Government actions toward universities, academic research institutions, and even research journals are being reported, with potential implications for the industry.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0009","quote":"news reports of government actions toward universities like... Harvard"},{"chunk_id":"doc_0c5e763379b2_chunk_0009","quote":"we're now even seeing reports... of actions toward venerable research journals like the New England Journal of Medicine."}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0009_n3","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Есть опасение, что такие действия могут повлиять на конкурентоспособность и научное лидерство США в средне- и долгосрочной перспективе, поскольку академическое финансирование — «верх воронки» инноваций для биотех-компаний.","text_en":"Concern that these actions could affect U.S. competitiveness/scientific excellence in the medium/long term because academic funding is the top of the innovation funnel for biotech.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0009","quote":"I am worried about these actions... having an implication on U. S. competitiveness, U. S. scientific excellence."},{"chunk_id":"doc_0c5e763379b2_chunk_0009","quote":"academic funding is the top of the funnel for all of our companies' innovation, for the most part."},{"chunk_id":"doc_0c5e763379b2_chunk_0009","quote":"there are certainly medium and longer term impacts of this"}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0010_n1","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Биотех-индустрия исторически выросла вокруг академических институтов; ключевые экосистемы (Бостон, Сан-Франциско) связаны с ведущими университетами как источниками инноваций.","text_en":"Biotech historically grew around academic institutions; major ecosystems (Boston, San Francisco) trace back to leading universities as innovation sources.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0010","quote":"our industry grew up around academic institutions."},{"chunk_id":"doc_0c5e763379b2_chunk_0010","quote":"those institutions are ground zero for our industry and continue to be important sources of innovation."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0010_n2","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Обсуждаемые сокращения NIH могут быть «глубоко вредными» для индустрии, так как NIH-исследования — место, где стартует много биотех-проектов.","text_en":"Discussed NIH cuts could be profoundly harmful because NIH research is where many biotech efforts get started.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0010","quote":"there are a lot of discussions about NIH cuts."},{"chunk_id":"doc_0c5e763379b2_chunk_0010","quote":"those could be profoundly harmful to our industry. Because NIH research is kind of where a lot of biotech get started."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0010_n3","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Элитные университеты (например, Harvard) принимают крупное иностранное финансирование с «ограниченной прозрачностью», что рассматривается как стратегическое влияние на идеологию.","text_en":"Elite universities (e.g., Harvard) accept large foreign government funding with limited transparency, framed as strategic ideological influence.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0010","quote":"these elite academic institutions like Harvard have been accepting large sums of foreign funding from governments such as Qatar and China. With limited transparency."},{"chunk_id":"doc_0c5e763379b2_chunk_0010","quote":"these funds aren't purely academic in nature, but they're actually strategic investments to shape ideology."}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0011_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Сообщается о серьёзной проблеме антисемитизма в университетах (в т.ч. Harvard), которая нормализуется в кампусной среде и вызывает ощущение небезопасности у еврейских студентов.","text_en":"Reported severe antisemitism at universities (incl. Harvard), becoming normalized on campus and leaving Jewish students feeling unsafe.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0011","quote":"\"It's being normalized in classrooms, student organizations and faculty circles.\""},{"chunk_id":"doc_0c5e763379b2_chunk_0011","quote":"\"It acknowledges how horrible antisemitism has been on its campus.\""},{"chunk_id":"doc_0c5e763379b2_chunk_0011","quote":"\"if you went and asked Jewish students at Harvard if they feel safe and protected now... they would still say no.\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0011_n2","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Университеты, как ключевые институты для биомедицинских исследований, рискуют потерять государственное финансирование из‑за ситуации на кампусе; это воспринимается как угроза «деконструкции/децимации» академии.","text_en":"Universities central to biomedical research risk losing government funding due to campus issues; this is framed as a threat of decimating academia.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0011","quote":"\"we must get through this without decimation of... the amazing institutions of... the academy\""},{"chunk_id":"doc_0c5e763379b2_chunk_0011","quote":"\"so that they can not only keep the $6 billion of annual funding they still get from the government\""},{"chunk_id":"doc_0c5e763379b2_chunk_0011","quote":"\"the extra $2 billion that was stripped away\""}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0011_n3","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Утверждается, что еврейская доля/численность поступающих в Harvard снижается до «почти исторических минимумов».","text_en":"Claim that Jewish enrollment at Harvard is falling to near all-time lows.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0011","quote":"\"Jewish enrollment in Harvard is plummeting to near all-time lows\""}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0012_n1","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Сравнение эффективности (12-месячный complete response) между TAR-200 и продуктом CG Oncology осложнено «apples to oranges», потому что наборы данных разной зрелости, из‑за чего год идёт интенсивный спор.","text_en":"Comparing 12-month complete response between TAR-200 and CG Oncology is an apples-to-oranges issue due to different data maturity, fueling a year-long debate.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0012","quote":"\"it was a bit of an apples to oranges comparison. Because one data set was much more mature than the other.\""},{"chunk_id":"doc_0c5e763379b2_chunk_0012","quote":"\"for the last year since last AUA has been a topic of intense debate. Who's got the higher CR rate?\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0012_n2","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"У пациентов с NMIBC есть «very vast unmet medical need»: им нужны множественные варианты терапии, чтобы как можно дольше сдерживать болезнь до необходимости инвазивной резекции мочевого пузыря.","text_en":"NMIBC patients have a very large unmet need: multiple options are needed to keep disease at bay before invasive bladder resection surgery.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0012","quote":"\"the very vast unmet medical need. That these patients have.\""},{"chunk_id":"doc_0c5e763379b2_chunk_0012","quote":"\"They do need multiple options to keep their disease at bay for as long as possible before they wind up requiring a bladder resection surgery\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0012_n3","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Сейчас «really tough time to be a CEO in biotech» — сложная среда для руководителей биотех-компаний.","text_en":"It’s a really tough time to be a CEO in biotech.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0012","quote":"\"It's a really tough time to be a CEO in biotech.\""}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0013_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Биотех-CEO сейчас сложно проходить период с «очень сложными» рынками капитала и турбулентностью.","text_en":"It’s a tough time for biotech CEOs, with very challenging capital markets and turbulence.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0013","quote":"It's a really tough time to be a CEO in biotech."},{"chunk_id":"doc_0c5e763379b2_chunk_0013","quote":"getting through this current environment with capital markets being very challenging."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0013_n2","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Изменение supply chain — это крупная инвестиция, требующая времени и вызывающая дисрупцию; при этом неопределённость по тарифам усложняет решение, насколько сильно перестраиваться.","text_en":"Supply chain changes are a large, time-consuming, disruptive investment, and tariff uncertainty complicates how far to go.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0013","quote":"changing your supply chain is a massive investment that takes time and is disruptive."},{"chunk_id":"doc_0c5e763379b2_chunk_0013","quote":"maybe you don't want to go overboard if you don't think. Tariffs are going to be durably in place."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0013_n3","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Крупные биофарма-компании активно думают о повышении уверенности в цепочках поставок и, вероятно, существенно инвестируют в их укрепление на фоне геополитических рисков.","text_en":"Large biopharma companies are focusing on supply chain confidence and likely investing meaningfully amid geopolitical risks.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0013","quote":"the larger companies like Denel Nyalum, Vertex, Regeneron, those companies are thinking a lot about how they need to. secure greater confidence in their supply chains"},{"chunk_id":"doc_0c5e763379b2_chunk_0013","quote":"they're probably investing meaningfully in securing that."}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0014_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"В текущем рынке инвесторы «наказывают» компании за публикацию данных, которые не снижают риски и не отвечают на ключевой инвестиционный вопрос, особенно если ожидается последующий раунд.","text_en":"In the current market, investors punish companies for releasing data that doesn’t de-risk or answer a key investment question, especially if a raise is expected afterward.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0014","quote":"This is a market that is punitive for data that doesn't really de-risk anything when investors think that a company might raise in the back of it"}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0014_n2","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"Компаниям приходится ставить часть операционных планов «на паузу» и искать финансирование через партнёрства, фокусируясь на сохранении баланса и ключевых активностях.","text_en":"Companies may need to pause some operational plans and finance them via partnerships, focusing on balance sheet preservation and highest-value activities.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0014","quote":"you need to be super focused on. balance sheet preservation"},{"chunk_id":"doc_0c5e763379b2_chunk_0014","quote":"You probably have to put some of your, you know, operational plans on hold for a little bit"}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0014_n3","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"На фоне конкуренции с Китаем ожидается, что US/European biotech-компании будут становиться заметно более эффективными; при этом встречаются бюджеты, которые выглядят чрезмерными (пример: $55M до IND для одной молекулы).","text_en":"With China competition, US/European biotechs are expected to become more efficient; yet some budgets still appear excessive (e.g., $55M to IND for one molecule).","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0014","quote":"with the China competition is that US and European companies can and probably should become much more efficient"},{"chunk_id":"doc_0c5e763379b2_chunk_0014","quote":"to get to an IND, they were going to spend 55 million dollars"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0015_n1","doc_id":"doc_0c5e763379b2","kind":"pain","text_ru":"Высокие затраты на доведение даже одного молекулярного кандидата до IND (упоминается $55M от SART до IND).","text_en":"High cost to advance even a single molecule to IND (mentions $55M from SART to IND).","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0015","quote":"to get to an IND, they were going to spend 55 million dollars"},{"chunk_id":"doc_0c5e763379b2_chunk_0015","quote":"They knew the target, and it's $55 million from SART to an IND."},{"chunk_id":"doc_0c5e763379b2_chunk_0015","quote":"I mean, they have one molecule."}],"confidence":"high"}
{"nugget_id":"doc_0c5e763379b2_chunk_0015_n2","doc_id":"doc_0c5e763379b2","kind":"trend","text_ru":"Отмечается волатильность периода и «позитивные» изменения, связанные с FDA и другими изменениями.","text_en":"A volatile period with some positive developments regarding the FDA and other changes is noted.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0015","quote":"it's a very volatile time."},{"chunk_id":"doc_0c5e763379b2_chunk_0015","quote":"There are some positive. Things happening with regard to the FDA and other changes"}],"confidence":"medium"}
{"nugget_id":"doc_0c5e763379b2_chunk_0015_n3","doc_id":"doc_0c5e763379b2","kind":"constraint","text_ru":"В сообществе biotech в США, по мнению спикера, требуется существенная «подстройка/адаптация».","text_en":"The speaker says the U.S. biotech community still needs significant adjustment/adaptation.","evidence":[{"chunk_id":"doc_0c5e763379b2_chunk_0015","quote":"There's still a lot of adjustment that needs to happen in the U. S. biotech community"}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_chunk_0000_n1","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Отмечается улучшение настроений и отскок XBI: индекс растёт уже три недели и держится после минимума начала апреля.","text_en":"Sentiment appears to be improving with XBI up for three straight weeks and holding after the early-April low.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0000","quote":"I think it's now three straight weeks. The XBI moving in the right direction."},{"chunk_id":"doc_bfffc763b19e_chunk_0000","quote":"we're seeing that there's been a nice rebound. In the XBI off the you know kind of the early April low"}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0000_n2","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Сильные запуски препаратов и более позитивные Q1 earnings воспринимаются как фактор улучшения ситуации в индустрии.","text_en":"Strong drug launches and generally more good than bad Q1 earnings are seen as contributing to improving conditions.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0000","quote":"Some good, really strong drug launches."},{"chunk_id":"doc_bfffc763b19e_chunk_0000","quote":"generally speaking, I thought there was more. More good than bad in the earnings."}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_chunk_0000_n3","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Сохраняется обеспокоенность регуляторной неопределённостью: FDA воспринимается как «прекариозный» фактор, который «висит на балансе».","text_en":"Ongoing concern about regulatory uncertainty: the FDA is viewed as being in a precarious balance.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0000","quote":"my greater concern in the back of my mind is still, honestly, the FDA."},{"chunk_id":"doc_bfffc763b19e_chunk_0000","quote":"the FDA continues to hang in a balance that's very precarious at this point in time."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0001","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Участники рынка сталкиваются с высокой неопределённостью вокруг регуляторных и макро-факторов (в т.ч. возможная реорганизация FDA, тарифы, ценовые контролы).","text_en":"The market faces high uncertainty around regulatory and macro factors (e.g., potential FDA reorg, tariffs, price controls).","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0001","quote":"The problem I think that we're all facing is just uncertainty."},{"chunk_id":"doc_bfffc763b19e_chunk_0001","quote":"nobody's ever tried to dismantle... to throw tariffs and most favored nation price controls and reorganizing the FDA."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0002","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"В период рыночного стресса наблюдался «flight to safety» в фарма-акции: инвесторы уходили в pharma как в защитный сектор.","text_en":"During market stress, investors rotated into pharma stocks as a flight to safety.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0001","quote":"investors flock to pharma stocks... when the market started to fall apart and that there was a flight to safety."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0003","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Фарма-компании продолжают рассматривать лицензирование/доступ к активам (в т.ч. «assets there that we like») как подход к конкуренции/источникам инноваций.","text_en":"Pharma companies continue to talk about licensing or accessing assets they like (incl. from China).","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0001","quote":"there's assets there that we like, and then we're going to go and license them or access them."}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_nugget_0001","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"Участники рынка сталкиваются с высокой неопределённостью, которая может двигать рынки и меняется «день ото дня».","text_en":"Market participants face high uncertainty that can move markets and changes day by day.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0002","quote":"The problem I think that we're all facing is just uncertainty."},{"chunk_id":"doc_bfffc763b19e_chunk_0002","quote":"Things can change. As we've seen, things can change day by day."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0002","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Неопределённость вокруг FDA/HHS и политики по вакцинам (включая покрытие и одобрения) рассматривается как фактор риска/барьер.","text_en":"Uncertainty around FDA/HHS and vaccine policy (coverage and approvals) is seen as a risk/barrier.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0002","quote":"The uncertainties around FDA, HHS, coverage of vaccines, what vaccines you're going to be approving or not"}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0003","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Вакцины описываются как «особая зона хаоса» в FDA; обсуждается риск требований плацебо-контроля там, где это может быть неэтично и не соответствовать клинической практике.","text_en":"Vaccines are described as a special area of chaos at FDA; there’s concern about placebo-control requirements where it may be unethical and misaligned with clinical practice.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0002","quote":"I think that vaccine seems to be to be a special area of chaos at the FDA."},{"chunk_id":"doc_bfffc763b19e_chunk_0002","quote":"it would be completely unethical to run a true placebo. That's not scientific. That's not in alignment with clinical practice."}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_nugget_0001","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Опасение, что для обновляемых вакцин (грипп/ковид) могут потребовать новые/плацебо-контролируемые исследования перед одобрением, что сделает невозможным своевременно обновлять вакцины и поднимает этические вопросы.","text_en":"Concern that updated vaccines (flu/COVID) may be required to run new/pre-approval or placebo-controlled trials, making timely updates difficult and raising ethical issues.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0003","quote":"\"I hope that, for example, we're not going to see flu vaccines... have to go through new trials\""},{"chunk_id":"doc_bfffc763b19e_chunk_0003","quote":"\"If they require a pre-approval trial, then you're not going to be able to really keep up with COVID straight changes\""},{"chunk_id":"doc_bfffc763b19e_chunk_0003","quote":"\"placebo controlled studies for vaccines... it's unethical in a lot of ways to do that\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0002","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"Участники видят «хаос» и «турбулентность» вокруг FDA (сокращения, текучка, культура), что вызывает тревогу у компаний.","text_en":"Participants perceive chaos/turmoil at the FDA (workforce reductions, turnover, culture), creating anxiety for companies.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0003","quote":"\"I honestly can't wait till we're done with this phase\""},{"chunk_id":"doc_bfffc763b19e_chunk_0003","quote":"\"Turmoil, the potential for delays, the turnover, the staff culture.\""}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_nugget_0003","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"По опросу MassBio после сокращений в FDA: у части компаний уже изменились регуляторные взаимодействия — встречи сдвигаются, сроки работ удлиняются.","text_en":"MassBio survey after FDA workforce reductions suggests regulatory interactions are already changing—meetings pushed out and timelines extended for some companies.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0003","quote":"\"MassBio did a survey just a few weeks after the FDA workforce reductions.\""},{"chunk_id":"doc_bfffc763b19e_chunk_0003","quote":"\"a full 50% of the respondents said that they had experienced some... change in their regulatory discussion\""},{"chunk_id":"doc_bfffc763b19e_chunk_0003","quote":"\"meetings had been pushed out or work. Timelines had been extended\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0001","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Крупные фармкомпании заявляют, что не видят изменений во взаимодействиях/обсуждениях с FDA, несмотря на сообщения о сдвигах у меньших компаний.","text_en":"Large pharma companies report no change in their discussions/interactions with the FDA, despite reports of delays among smaller companies.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0004","quote":"\"pretty much all the large pharma companies. And frankly, every single one of them said, 'No, we're not seeing any change in our discussion or interactions with the FDA.'\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0002","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Оценка проблем во взаимодействиях с FDA затруднена: многие респонденты не имели недавних контактов с FDA, поэтому их ответы «проблем нет» могут быть нерелевантны текущей ситуации.","text_en":"Assessing FDA interaction issues is hard because many respondents had no recent FDA interactions, making 'no problem' answers potentially irrelevant to the current situation.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0004","quote":"\"Most people hadn't. So the fact that they would say, 'I haven't had a problem with the FDA,' it's like, 'well, yeah, if you talked to him three months ago\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0003","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"На фоне разговоров о тарифах компании заявляют, что могут «поглотить» их и готовят/перенастраивают производство, чтобы при необходимости переключиться на США.","text_en":"Amid tariff discussions, companies say they can absorb tariffs and are preparing manufacturing to switch to the US if needed.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0004","quote":"\"the tariffs is not the right way to do things, but we can absorb it. And we're all preparing our manufacturing so that we can switch into the US\""}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_chunk_0005_n1","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"У части компаний с недавними взаимодействиями с FDA возникали проблемы: вопросы требовали участия старших сотрудников, и встречи отменялись, потому что не было доступных людей, способных ответить.","text_en":"Some companies with recent FDA interactions reported issues: matters required senior staff, meetings were canceled, and they couldn’t schedule someone who could answer.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0005","quote":"\"We needed an issue that required a senior person to resolve it, and they just canceled the meeting.\""},{"chunk_id":"doc_bfffc763b19e_chunk_0005","quote":"\"We don't think we can schedule with anybody that can answer this question.\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0005_n2","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Есть барьер публичного высказывания: люди боятся быть «targeted», поэтому готовы говорить с журналистами в основном только off the record.","text_en":"Public speaking is constrained by fear of being targeted; people are mostly willing to talk to journalists only off the record.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0005","quote":"\"Everybody's worried about being targeted.\""},{"chunk_id":"doc_bfffc763b19e_chunk_0005","quote":"\"At the very least, speak off the record.\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0005_n3","doc_id":"doc_bfffc763b19e","kind":"buyer_signal","text_ru":"Сенатору (Cassidy) нужны конкретные, публично оформленные примеры проблем как «инструмент», который можно распространять — запрос на структурированную доказательную базу.","text_en":"Senator Cassidy asked for specific, publicly shareable examples as a “tool” to share—demand for structured evidence of what’s going wrong.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0005","quote":"\"I need specific examples. I need to know what exactly is going on.\""},{"chunk_id":"doc_bfffc763b19e_chunk_0005","quote":"\"I need a tool that's out there that I can share with others.\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0001","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"Нет фундаментального решения международных диспропорций цен на лекарства; попытки вроде тарифов лишь «покупают время».","text_en":"There is no fundamental solution to international drug price disparities; measures like tariffs only “buy time.”","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0006","quote":"We need a fundamental solution to international drug price disparities and either get America to realize"}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0002","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Тарифы могут по-разному ударить по компаниям из‑за структуры IP/производства и трансфертного ценообразования; у мультинационалов с IP вне США риск «massive tariff».","text_en":"Tariffs may impact companies differently due to IP/manufacturing location and transfer pricing; multinationals with IP outside the US risk a “massive tariff.”","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0006","quote":"If you're a multinational and you've stashed your IP in Ireland... you're going to have a massive tariff on your transfer price"}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0003","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"В индустрии есть тенденция «downplay» влияние тарифов, хотя, по словам спикера, есть количественный эффект (удар по NPV/цене M&A).","text_en":"Industry tends to downplay tariff impact, though the speaker claims there is a quantitative effect (hit to NPVs/M&A pricing).","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0006","quote":"a lot of people want to say, 'Hey, I'll survive this.' And so they downplay this."}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_nugget_0001","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Ограниченная видимость проблем у big pharma: они могут быть «последними», кто признает наличие проблем, что затрудняет сбор достоверных данных через опросы.","text_en":"Limited visibility into big pharma issues: they may be the last to admit problems, making it hard to gather reliable survey data.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0007","quote":"I have no visibility into what big pharma is, but I would imagine that they're going to be the last ones to admit that they've got problems anywhere."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0002","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"В Европе проблемой называют скорость/время вывода продукта на рынок и риск не получить одобрение или health technology assessments даже для «явно позитивного» препарата.","text_en":"In Europe, a pain point is time-to-market and the risk of not getting approval or health technology assessments even for a clearly positive drug.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0007","quote":"the speed with which or time that it takes to get product to market. and even not getting approval or not getting the any of the health technology assessments"}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_nugget_0003","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Отмечается, что biotech испытывает «strong launches» в первом квартале.","text_en":"Biotech is experiencing strong launches in the first quarter.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0007","quote":"you had already flagged in your tweet the strong launches that biotech is experiencing."}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_chunk_0008_n1","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Сильные запуски препаратов в биотехе продолжаются; обсуждаются «очень сильные» результаты Q1 по Atruby/Truby и «довольно хорошие» цифры у Magical.","text_en":"Strong biotech drug launches are continuing; Q1 for Atruby/Truby is described as very strong and Magical also posted a pretty good number.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0008","quote":"\"it's a kind of more of a continuation of a trend\""},{"chunk_id":"doc_bfffc763b19e_chunk_0008","quote":"\"Q1 for Truby, which you know they did it was very strong\""},{"chunk_id":"doc_bfffc763b19e_chunk_0008","quote":"\"Magical obviously put up a pretty good number, too.\""}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_chunk_0008_n2","doc_id":"doc_bfffc763b19e","kind":"opportunity","text_ru":"Результаты Q1 по Truby/Atruby подтверждают, что в популяции есть значимое число недиагностированных или нелеченных пациентов, и рынок может быть более широким, чем считалось ранее.","text_en":"Q1 results for Truby/Atruby suggest many patients are undiagnosed or untreated, implying the market could be larger than previously thought.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0008","quote":"\"there were. a relatively large number of patients who are undiagnosed or untreated\""},{"chunk_id":"doc_bfffc763b19e_chunk_0008","quote":"\"it looks like that could be a much more expansive market than had previously been thought.\""}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_chunk_0008_n3","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Alnylam не планирует раскрывать продажи Amvutro по показаниям (polyneuropathy vs cardiomyopathy), что ограничивает возможность сравнения с конкурентом по CM и снижает прозрачность метрик запуска.","text_en":"Alnylam plans not to break out Amvutro sales by indication, limiting comparability (especially on CM) and reducing launch-metric transparency.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0008","quote":"\"they were not going to do that, that the plan right now is to just report and group the sales in totality\""},{"chunk_id":"doc_bfffc763b19e_chunk_0008","quote":"\"not break out by indication\""},{"chunk_id":"doc_bfffc763b19e_chunk_0008","quote":"\"that's not going to at least be possible from a reporting standpoint.\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0009_n1","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"У Regeneron в Q1 отмечены проблемы: конкурентное давление, списания запасов и сокращение финансирования copay foundations.","text_en":"Regeneron faced Q1 issues: competitive pressure, inventory write-downs, and reduced funding for copay foundations.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0009","quote":"it has a whole range of things that is— dealing with which is the competitive pressure, inventory, write downs, and this reduced funding for copay foundations."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0009_n2","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Для Eylea (prefilled syringe) упомянут ещё один CRL, при этом нет ясности, как он будет решён.","text_en":"Another CRL was called out for Eylea pre-filled syringe, with no clarity on how it will be resolved.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0009","quote":"They called out a Another CRL. for pre-filled syringe this time for Eylea and that's There was no real clarity on how that might get resolved."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0009_n3","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Наблюдается политико-регуляторное давление на mRNA-вакцинации: в штатах вносятся законопроекты о запрете mRNA-вакцин.","text_en":"There is political/regulatory pressure on mRNA vaccination: bills are being introduced in states to ban mRNA vaccinations.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0009","quote":"You see these bills being introduced. across state legislators, you know, banning mRNA vaccinations."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0010_n1","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Политическое/регуляторное давление: в штатах вводятся законопроекты о запрете mRNA-вакцинаций, что создаёт барьер для mRNA-направления.","text_en":"Political/regulatory pressure: state bills are being introduced to ban mRNA vaccinations, creating a barrier for mRNA efforts.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0010","quote":"\"You see these bills being introduced. across state legislators, you know, banning mRNA vaccinations.\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0010_n2","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"Недоверие и враждебность к mRNA из-за дезинформации (например, утверждения, что mRNA «может изменить геном»), что усиливает общественный скепсис.","text_en":"Distrust/hostility toward mRNA driven by misinformation (e.g., claims that mRNA can alter your genome), increasing public skepticism.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0010","quote":"\"there's so much hostility... against mRNA.\""},{"chunk_id":"doc_bfffc763b19e_chunk_0010","quote":"\"one of the congressmen we met with was citing some report he had read that mRNA can alter your genome.\""}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0010_n3","doc_id":"doc_bfffc763b19e","kind":"buyer_signal","text_ru":"В онкологии врачи проявляют интерес, но требуют клинических доказательств: ключевой запрос — «покажите данные».","text_en":"In oncology, physicians are interested but demand clinical proof: the key ask is “show me the data.”","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0010","quote":"\"most of the physicians you speak to are all say the same thing. Show me, show me the data.\""},{"chunk_id":"doc_bfffc763b19e_chunk_0010","quote":"\"the proof will be in the clinical data\""}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"Индустрия сталкивается с проблемой коммуникации: общественность может «свернуть не туда» и отвергать пользу научной работы/вакцин, а новости о побочках используются для подрыва доверия к целым направлениям.","text_en":"Industry messaging problem: the public may reject benefits of the work/vaccines, and side effects can be used to dismantle trust in whole scientific trends.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0011","quote":"we continue to discover that the public has ways of taking a left turn and denying itself the benefits of what we do."},{"chunk_id":"doc_bfffc763b19e_chunk_0011","quote":"when these kinds of side effects come up, they're not used to completely dismantle you know, an entire scientific trend."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_bfffc763b19e","kind":"opportunity","text_ru":"Возможность для R&D/продуктов в области маркетинговых коммуникаций: итеративно тестировать сообщения для разных сегментов общественности, чтобы «мостить» доверие к биотеху/мРНК и удерживать аудиторию.","text_en":"Opportunity for R&D/products in marketing communications: iteratively test messages across public segments to bridge trust in biotech/mRNA and retain audiences.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0011","quote":"we do have to figure out how, as an industry, we're going to iterate on the marketing communications messages with all these different pockets of the public"}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Барьер в оценке cost-effectiveness: NICE, по словам спикера, сознательно не учитывает долгосрочную динамику (в т.ч. переход в дженерики), чтобы лекарства выглядели менее cost-effective и сохранялась возможность не платить/платить низкие цены.","text_en":"Constraint in cost-effectiveness assessment: NICE allegedly omits long-term dynamics (incl. post-generic period) so drugs look less cost-effective, preserving ability to not pay/pay low prices.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0011","quote":"you're only looking at the price of the drug when it launches?"},{"chunk_id":"doc_bfffc763b19e_chunk_0011","quote":"Then it would make drugs look more cost-effective, and you know we wouldn't have an excuse not to not to pay for them."},{"chunk_id":"doc_bfffc763b19e_chunk_0011","quote":"we do this so that we pay, you know, low prices."}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_chunk_0012_n1","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Рынок «очень unforgiving» к компаниям с высокими оценками, если они не повышают прогноз/гайденс даже при хорошем квартале.","text_en":"Markets are unforgiving at high valuations if guidance isn’t raised even after a good quarter.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0012","quote":"They had an 8% EPS beat, but they didn't raise... When you're sitting at those kind of valuations... the market's very unforgiving."}],"confidence":"high"}
{"nugget_id":"doc_bfffc763b19e_chunk_0012_n2","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Наблюдается ценовое давление/«price fight» в сегменте (упоминается снижение цены до $499/мес и нежелание входить в ценовую войну).","text_en":"Price pressure/price-fight dynamics are emerging (price cut to $499/month; reluctance to enter a price war).","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0012","quote":"Nova dropped their price to whatever it is, $499 a month."},{"chunk_id":"doc_bfffc763b19e_chunk_0012","quote":"we are not going to go into this price fight because we've seen it happen before"}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_chunk_0012_n3","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Есть опасения, что реальный размер рынка может быть меньше ожиданий; для «реально большого рынка» могут потребоваться снижения цен, появление оральных форм и/или дженериков.","text_en":"Concerns exist that the market may be smaller than expected; a truly large market may require price drops, orals, and/or eventual generics.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0012","quote":"continuing worries... Is this market as big as everybody thinks?"},{"chunk_id":"doc_bfffc763b19e_chunk_0012","quote":"for the real big market to come, you do need these price drops and maybe some of the orals... to go generic"}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_bfffc763b19e","kind":"pain","text_ru":"Есть неопределённость/страх у участников рынка, как «созреют» результаты по выживаемости и как данные из Китая будут транслироваться на США.","text_en":"Market uncertainty/fear about how survival results will mature and how China data will translate to the US.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0013","quote":"fear right now in the marketplace about how the survival result will mature"},{"chunk_id":"doc_bfffc763b19e_chunk_0013","quote":"fear about how these data will translate into the US setting"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_bfffc763b19e","kind":"constraint","text_ru":"Риск интерпретации данных из-за несоответствия стандарту лечения: в исследовании Keytruda монотерапия включала пациентов <49% PD-L1, где «должно быть» Keytruda+химио; стандарт в Китае может отличаться.","text_en":"Data interpretation risk due to standard-of-care mismatch: Keytruda monotherapy included <49% PD-L1 patients where Keytruda+chemo is expected; China standard may differ.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0013","quote":"it included patients below 49%, where you're supposed to have Keytruda plus chemo"},{"chunk_id":"doc_bfffc763b19e_chunk_0013","quote":"that's not necessarily standard care in China"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"В non-muscle invasive bladder cancer появляются новые опции; ожидаются улучшения и потенциальные одобрения в ближайшие месяцы/годы.","text_en":"New options emerging in non-muscle invasive bladder cancer; expectation of improvements and approvals in coming months/years.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0013","quote":"for non-muscle invasive bladder cancer, there is great options coming up"},{"chunk_id":"doc_bfffc763b19e_chunk_0013","quote":"bladder cancer is going to see some more much better. improvements in the next few months, years"}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_nugget_001","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Ожидаются улучшения в ближайшие месяцы/годы по части одобрений (approvals) на фоне уже увиденных данных по EV Pembro при muscle-invasive, но static disease.","text_en":"Expectations of improvements in approvals over the next months/years, building on what’s already been seen with EV Pembro in muscle-invasive but static disease.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0014","quote":"improvements in the next few months, years, in terms of approvals on the back of what we've already seen with EV Pembro"}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_nugget_002","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"У Arteos (UK biotech) есть «очень интересные» и «очень многообещающие» данные по ATR inhibitor; датасет выглядит «очень хорошо».","text_en":"Arteos (a UK biotech) has “very interesting” and “very promising” data with an ATR inhibitor; the dataset “looks very good.”","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0014","quote":"A UK biotech had some very interesting data with an ATR inhibitor, and that's Arteos."},{"chunk_id":"doc_bfffc763b19e_chunk_0014","quote":"this data set actually looks very good... it did look very, very promising."}],"confidence":"medium"}
{"nugget_id":"doc_bfffc763b19e_nugget_003","doc_id":"doc_bfffc763b19e","kind":"trend","text_ru":"Настроения инвесторов в последние ~2+ месяца были «депрессивными», но сейчас виден небольшой разворот и стабилизация.","text_en":"Investor sentiment over the past ~2+ months was “depressing,” but there’s now a small turn and stabilization.","evidence":[{"chunk_id":"doc_bfffc763b19e_chunk_0014","quote":"For a good two months or more... every conversation I would have with investors... was... Just so depressing."},{"chunk_id":"doc_bfffc763b19e_chunk_0014","quote":"it's good to see... a little bit of a turn and stabilization."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0000_n1","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Политические решения/назначения в FDA создают «неопределённость и волатильность» для индустрии.","text_en":"Policy moves/appointments are creating uncertainty and volatility for the industry.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0000","quote":"policy issues that are really top of mind for everyone in the industry and creating a lot of uncertainty and volatility."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0000_n2","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Назначение Винай Прасада директором CBER вызвало заметную негативную реакцию рынка (падение XBI).","text_en":"Vinay Prasad’s appointment as CBER director triggered a notable negative market reaction (XBI drop).","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0000","quote":"the decision to appoint Vinay Prasad as the next director of CBER... drove the XBI down by 7% in the first day"}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0000_n3","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"После первых опасений из‑за критики FDA, в первом обращении к сотрудникам Прасад занял более примирительный и открытый тон, что стало неожиданностью.","text_en":"After initial concerns due to his FDA criticism, Prasad’s first staff speech was more conciliatory/open, surprising people.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0000","quote":"his first speech to staff... he really struck a more conciliatory, open tone"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0001_n1","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Реакция инвесторов на назначения затронула не только компании под CBER, но и «accelerated approval» акции вне юрисдикции CBER.","text_en":"Investor reaction to appointments affected not only CBER-related companies but also accelerated-approval stocks outside CBER’s purview.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0001","quote":"it wasn't just CBIR stocks that were down... It was also accelerated approval stocks that aren't within CBER's purview."}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0001_n2","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Есть неопределённость: «data-oriented» подход может как быть разумным, так и усложнить коммерциализацию вакцин.","text_en":"Uncertainty: a “data-oriented” approach could be reasonable or could make vaccine commercialization difficult.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0001","quote":"being data-oriented can include... reasonable things and can also include... make it really difficult for vaccines to be commercialized"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0001_n3","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"FDA недавно заявила, что минимальная/измеримая остаточная болезнь (MRD) может быть конечной точкой для подачи; компании адаптируют дизайн испытаний под это.","text_en":"FDA recently said minimal/measurable residual disease (MRD) can be a filing endpoint; companies are adjusting trials accordingly.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0001","quote":"the FDA has recently said that a minimal or measurable residual disease can be an endpoint for filing"},{"chunk_id":"doc_da8741faa7f7_chunk_0001","quote":"Arcelix... or Gilead said, that they'd moved one of their trials to have MRD as a um— as an endpoint"}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0002_n1","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Есть регуляторная неопределённость: MRD как конечная точка может перестать быть приемлемой (особенно для CAR-T под CBER), что вынудит менять endpoints.","text_en":"Regulatory uncertainty: MRD as an endpoint may become unacceptable (esp. for CAR-T under CBER), forcing companies to change endpoints.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0002","quote":"Is that going to result in CBER saying... that endpoint is not acceptable anymore? And therefore, companies have to change their endpoints"}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0002_n2","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Если MRD перестанет приниматься, клинические исследования могут стать «чрезвычайно долгими» по сравнению с быстрым измерением MRD.","text_en":"If MRD is no longer accepted, trials may become extremely long compared with faster MRD measurement.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0002","quote":"companies have to change their endpoints, in which case it makes some clinical trials extremely long to do"}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0002_n3","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Для COVID-19 бустеров проведение рандомизированных исследований с клиническими конечными точками затруднено, потому что штамм может измениться к моменту завершения trial.","text_en":"For COVID-19 boosters, RCTs with clinical endpoints are hard because the strain may change by the time the trial is done.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0002","quote":"by the time you've done it, your strain would have changed. So we end up in a situation where I don't see how these companies are going to be able to do that"}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0003_n1","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Руководство FDA (в лице Dr. Macari) публично продвигает ускорение рассмотрения заявок и обсуждает внедрение AI в процесс ревью.","text_en":"FDA leadership (Dr. Macari) is publicly pushing to speed reviews and discussing AI incorporation into the review process.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0003","quote":"Dr. Macari most recently has been very, very open... around wanting to speed drug approvals... press release... on uh AI, uh incorporation into the review process"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0003_n2","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Есть восприятие, что в разработке лекарств иногда происходит «game playing» для одобрения и коммерциализации, включая возможное завышение ценности для пациентов.","text_en":"There is a perception of occasional “game playing” in drug development to get approvals/commercialization, potentially overstating patient value.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0003","quote":"We see from time to time some game playing around drug development to get drugs approved and commercialized, perhaps... overstating their value to patients."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0003_n3","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Ожидается, что в CBER может быть повышен порог требований: меньше терпимости к препаратам без «meaningful benefit» для пациентов.","text_en":"CBER may raise the bar, with less tolerance for drugs lacking meaningful patient benefit.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0003","quote":"It seems clear that he's going to raise the bar. At Seabird... not sure Vinay is going to be as sympathetic for drugs that haven't really shown a meaningful benefit"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0004_n1","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Ожидается, что регуляторная «планка» будет повышаться, а оценка научных данных станет более строгой/более «бинарной» (в т.ч. в контексте COVID-вакцин и сравнения с терапиями, имеющими survival data).","text_en":"Regulatory bar is expected to be ratcheted up, with more stringent/scientific evaluation and more bifurcation (e.g., COVID vaccines; comparisons to therapies with survival data).","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0004","quote":"\"the bar is going to get ratcheted up.\""},{"chunk_id":"doc_da8741faa7f7_chunk_0004","quote":"\"given that some of the other therapeutics in the class have survival data.\""},{"chunk_id":"doc_da8741faa7f7_chunk_0004","quote":"\"with Novavax, that things are going to become a little bit more bifurcated.\""}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0004_n2","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Изменения в FDA и добавленные неопределённости делают жизнь участников индустрии «более сложной».","text_en":"Changes at the FDA and added uncertainties are making industry participants’ lives more complicated.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0004","quote":"\"that's probably going to make our life a little bit more complicated.\""},{"chunk_id":"doc_da8741faa7f7_chunk_0004","quote":"\"I'm a little bit more concerned about the overall change at FDA\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0004_n3","doc_id":"doc_da8741faa7f7","kind":"buyer_signal","text_ru":"События по безопасности (в т.ч. смерть пациента) могут снижать назначаемость генной терапии врачами, влияя на коммерческий запуск.","text_en":"Safety events (including a patient death) can reduce physician prescribing of a gene therapy, impacting commercial launch.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0004","quote":"\"safety events, you know, certainly did have an impact on the prescribing of some physicians.\""},{"chunk_id":"doc_da8741faa7f7_chunk_0004","quote":"\"the really unfortunate patient death.\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0005_n1","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"В запуске генной терапии на назначение влияют не только safety-события, но и внешние факторы (например, сезон гриппа) и общая сложность/«execution issues».","text_en":"Gene therapy launches are complex; prescribing is affected not only by safety events but also external factors (e.g., flu season) and execution issues.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0005","quote":"\"gene therapy launches, there's a lot of complexity\""},{"chunk_id":"doc_da8741faa7f7_chunk_0005","quote":"\"safety events, you know, certainly did have an impact on the prescribing of some physicians.\""},{"chunk_id":"doc_da8741faa7f7_chunk_0005","quote":"\"But there was also flu season.\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0005_n2","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Топ-назнающие врачи полностью загружены и не имеют мощности администрировать препарат большему числу пациентов, что ограничивает рост.","text_en":"Top prescribers are fully booked and lack capacity to administer the drug to more patients, constraining growth.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0005","quote":"\"their top physicians are fully booked and don't have any capacity to administer a drug to more patients.\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0005_n3","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Вокруг FDA отмечается неопределённость из‑за вакансий (особенно в руководстве) и возможных изменений процесса при новом руководстве HHS; некоторые публичные даты не были соблюдены.","text_en":"There is uncertainty around the FDA due to staffing vacancies (especially leadership) and potential process changes with new HHS leadership; some high-profile dates were missed.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0005","quote":"\"uncertainty, not only around what's happening with specific staffing vacancies, especially in leadership positions\""},{"chunk_id":"doc_da8741faa7f7_chunk_0005","quote":"\"potential changes that may come into play with new leadership at HHS\""},{"chunk_id":"doc_da8741faa7f7_chunk_0005","quote":"\"some few dates that that have been high profile that have not been met\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0006_n1","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Неопределённость регуляторного решения по Novavax: PDUFA прошла, решения нет; возможное требование согласовать phase four commitment; риск из‑за заявлений руководства FDA о пересмотре процесса одобрения COVID-вакцин.","text_en":"Regulatory uncertainty for Novavax: PDUFA passed with no decision; possible need to align on a phase four commitment; risk from FDA leadership comments about rethinking COVID vaccine approvals.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0006","quote":"The PDUFA date earlier this month... came and went. And still no word."},{"chunk_id":"doc_da8741faa7f7_chunk_0006","quote":"once they agree with the FDA staffers on a phase four commitment, can move forward here and get this drug approved."},{"chunk_id":"doc_da8741faa7f7_chunk_0006","quote":"We need to rethink the approval process for COVID vaccines."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0006_n2","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Обсуждается возможный сдвиг позиции FDA: требование рандомизированных клинических испытаний для одобрения COVID-вакцин и критика «single antigen vaccines», что может затронуть все текущие платформы.","text_en":"Possible FDA stance shift: requiring randomized clinical trials for COVID vaccine approvals and criticism of single-antigen vaccines, potentially affecting all current vaccine platforms.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0006","quote":"not in favor of approving COVID vaccines without a randomized clinical trial and not liking single antigen vaccines"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0006_n3","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Риск политизации регуляторного решения по COVID-вакцинам: решение может быть «политическим», а не научным, что повышает непредсказуемость одобрений.","text_en":"Risk of politicization in COVID vaccine regulatory decisions: approvals may become political rather than scientific, increasing unpredictability.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0006","quote":"This is not really a scientific judgment call. This is unfortunately. A political call."}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0007_n1","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Регуляторный подход к вакцинам становится более «бинарным/разделённым»: вероятна авторизация next-gen mRNA вакцин, но с более строгой маркировкой и повышением планки требований.","text_en":"Vaccine regulation appears increasingly bifurcated: next-gen approved mRNA vaccines may be authorized, potentially with a stricter label and a raised bar.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0007","quote":"\"on vaccine... it's getting very bifurcated\""},{"chunk_id":"doc_da8741faa7f7_chunk_0007","quote":"\"probably will be authorized.\""},{"chunk_id":"doc_da8741faa7f7_chunk_0007","quote":"\"potentially with a stricter label\""}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0007_n2","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Компании могут не пытаться выводить новые вакцины для более молодых возрастных групп (упоминается «under 50»), что указывает на сужение целевого рынка/популяции.","text_en":"Developers may not pursue new vaccines for younger age groups (\"under 50\"), indicating a narrowing target population/market.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0007","quote":"\"they're not even going to bother going for a new vaccine in the under 50.\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0007_n3","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"В более сложных регуляторных обзорах возможны задержки PDUFA и появление «question marks» даже при опубликованных датасетах; если это станет паттерном, это будет более тревожно.","text_en":"For more complex reviews, PDUFA delays and new questions can arise even with published datasets; if it becomes a pattern, it’s more concerning.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0007","quote":"\"not necessarily worried yet about a PDUFA date for something perhaps more complex being delayed\""},{"chunk_id":"doc_da8741faa7f7_chunk_0007","quote":"\"even for... kind of published data sets... we've seen question marks come up throughout the approval process\""},{"chunk_id":"doc_da8741faa7f7_chunk_0007","quote":"\"if we see that happen as a pattern... it would start getting more concerning.\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0008_n1","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Повышается планка требований к вакцинам (в т.ч. из‑за недостаточно высокой продемонстрированной эффективности).","text_en":"The bar for vaccines is being raised (partly due to inability to show strong efficacy).","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0008","quote":"\"the bar inevitably is going to get raised for vaccines\""},{"chunk_id":"doc_da8741faa7f7_chunk_0008","quote":"\"they couldn't show up great efficacy\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0008_n2","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Обсуждение политики most favored nation (привязка выплат Medicaid к самым низким ценам в других богатых странах) воспринимается как потенциально разрушительное для индустрии и инноваций.","text_en":"The proposed most-favored-nation policy (tying Medicaid payments to lowest prices in other wealthy countries) is viewed as potentially disastrous for the industry and innovation.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0008","quote":"\"the goal was to tie Medicaid drug payments to the lowest prices paid in other wealthy countries\""},{"chunk_id":"doc_da8741faa7f7_chunk_0008","quote":"\"which of course would be a huge disaster for the industry\""},{"chunk_id":"doc_da8741faa7f7_chunk_0008","quote":"\"It would have huge impact on negative impact on innovation.\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0008_n3","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Сообщается о «очень реальном страхе», что MFN может быть введён через исполнительный указ уже на следующей неделе.","text_en":"There is reported fear that MFN could be addressed via an executive order as soon as next week.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0008","quote":"\"there is very real fear reported by a number of sources\""},{"chunk_id":"doc_da8741faa7f7_chunk_0008","quote":"\"there would probably be an executive order broadly addressing this as soon as next week\""}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0009_n1","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Политики MFN для Medicare/Medicaid (с учетом «best price» и 340B) могут существенно снизить цены в США и повлиять на стимулы/инвестиции в разработку лекарств.","text_en":"MFN policies for Medicare/Medicaid (via best price and 340B) could materially impact US drug prices and incentives/investment.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0009","quote":"either MFN for Medicare or Medicaid, would have a very substantial impact on price... it would have a very substantial impact on incentives."},{"chunk_id":"doc_da8741faa7f7_chunk_0009","quote":"Best price has flowed through to so many other things, including 340B, which has totally exploded"}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0009_n2","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"MFN может снижать NPV и «opportunity size» для многих препаратов, из-за чего компании могут перестать инвестировать в разработку.","text_en":"MFN may reduce NPV and opportunity size for many drugs, leading companies to stop investing.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0009","quote":"shifts that NPV and you no longer want to invest in that drug."},{"chunk_id":"doc_da8741faa7f7_chunk_0009","quote":"MFN would be a policy that greatly contributes to that and really lowers the opportunity size"}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0009_n3","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Комбинация MFN и тарифов создает сложную ситуацию для фармкомпаний, включая неопределенность для финансовых/IR команд перед отчетностью.","text_en":"MFN combined with tariffs creates a challenging setup for pharma, adding uncertainty for finance/IR teams ahead of earnings.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0009","quote":"MFN combined with tariffs. Really creates a challenging."},{"chunk_id":"doc_da8741faa7f7_chunk_0009","quote":"I feel incredibly sympathetic for any Finance/Investor Relations departments"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0010_n1","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Политика MFN/референс-ценообразования может привести к тому, что компании будут запускать препараты только в США, что уменьшит зарубежные доходы и снизит стимулы к инновациям.","text_en":"MFN/reference pricing policy could push companies to launch only in the US, shrinking overseas revenue and reducing incentives to innovate.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0010","quote":"instituting policy that would cause companies to solely launch in the US."},{"chunk_id":"doc_da8741faa7f7_chunk_0010","quote":"that is going to cause less drugs to be innovated and be created in the first place because the pie is just smaller"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0010_n2","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Обсуждается использование торговых переговоров/сделок как более практичного инструмента для давления на страны, чтобы они платили больше (GDP-adjusted) за лекарства.","text_en":"Trade negotiations/deals are discussed as a more practical lever to push countries to pay more (GDP-adjusted) for drugs.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0010","quote":"there's better ways to do it related to. related to trade policy."},{"chunk_id":"doc_da8741faa7f7_chunk_0010","quote":"a key objective in light of all of these trade deals that are going to be happening"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0010_n3","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Нет прозрачности по net prices: фармкомпании не публикуют чистые цены, из-за чего сравнения цен между США и Европой затруднены.","text_en":"Lack of net price transparency: pharma doesn’t publish net prices, making US vs Europe price comparisons difficult.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0010","quote":"The problem pharma has is that they don't publish their net prices."},{"chunk_id":"doc_da8741faa7f7_chunk_0010","quote":"we have no transparency on it."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0011_n1","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Нет прозрачности по «net prices» (чистым ценам) на лекарства: фармкомпании их не публикуют, и участники обсуждения считают это проблемой.","text_en":"Lack of transparency on drug net prices: pharma doesn’t publish net prices, seen as a problem.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0011","quote":"The problem pharma has is that they don't publish their net prices."},{"chunk_id":"doc_da8741faa7f7_chunk_0011","quote":"we have no transparency on it."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0011_n2","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Высокие премии и большие co-pays (в т.ч. на жизненно важные препараты) и барьеры доступа (step edits) вызывают фрустрацию у пациентов и подпитывают популизм/негатив к фарме.","text_en":"High premiums and copays (including for life-saving drugs) plus access barriers (step edits) frustrate patients and fuel populism/anti-pharma sentiment.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0011","quote":"The fact that we have co-pays for life-saving drugs is egregious, right?"},{"chunk_id":"doc_da8741faa7f7_chunk_0011","quote":"we're putting in place all these step edits so people are rightfully frustrated."},{"chunk_id":"doc_da8741faa7f7_chunk_0011","quote":"when people have to pay huge prices, premiums and huge copays, that's what's driving it."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0011_n3","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Программа 340B, по словам спикера, «egregiously being abused»: вместо помощи тем, кто не может позволить лекарства, она стала источником прибыли для крупных госпитальных центров, что усложняет реформы из‑за политической поддержки.","text_en":"340B is described as being abused: instead of helping those who can’t afford drugs, it became a profit line for large hospital centers, complicating reform due to political support.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0011","quote":"we've got 340B, which is also egregiously being abused."},{"chunk_id":"doc_da8741faa7f7_chunk_0011","quote":"it's turned into a profit line for big hospital centers"},{"chunk_id":"doc_da8741faa7f7_chunk_0011","quote":"their congressional leaders support it."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0012_n1","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Референсное ценообразование/индексация упирается в то, что непубличные цены конфиденциальны и считаются proprietary, поэтому доступ к ним (например, для правительства США) проблематичен и может требовать политического решения.","text_en":"Reference pricing/indexing is constrained because non-published prices are confidential/proprietary; access (e.g., by the US government) is difficult and may require a political solution.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0012","quote":"The non-published price, frankly, I believe is proprietary and is confidential."},{"chunk_id":"doc_da8741faa7f7_chunk_0012","quote":"I don't know how the US government gets access to that to then reference it."},{"chunk_id":"doc_da8741faa7f7_chunk_0012","quote":"it's probably going to require some kind of potential political solution."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0012_n2","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Автологичное CAR-T производство создаёт «целый набор» проблем/сложностей, которые пытаются обойти новые подходы (например, in vivo CAR-T).","text_en":"Autologous CAR-T manufacturing has a host of issues/complexities that new approaches (e.g., in vivo CAR-T) aim to avoid.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0012","quote":"It avoids all the issues that you have to deal with when it comes to current allogeneic CAR-T manufacturing."},{"chunk_id":"doc_da8741faa7f7_chunk_0012","quote":"Sorry, autologous CAR-T manufacturing."},{"chunk_id":"doc_da8741faa7f7_chunk_0012","quote":"everybody is excited about in vivo CAR T as the next real big leap in CAR T therapy, because it will avoid a whole host of stuff, including manufacturing issues, preconditioning"}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0012_n3","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Huntington’s disease описывается как крайне сложная для разработки терапий область с высоким неудовлетворённым спросом.","text_en":"Huntington’s disease is described as very hard to crack with high unmet need.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0012","quote":"this is a disease area that's just been incredibly, incredibly hard to crack, very high unmet needs."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0013_n1","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"В функциональных исходах у пациентов стадии 3 на высокой дозе наблюдалось ухудшение, что усложняет интерпретацию эффективности.","text_en":"Functional outcomes were challenging, with stage 3 patients worsening on the high dose, complicating efficacy interpretation.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0013","quote":"in the stage three patients, we actually saw, you know, a fair bit of worsening for, you know, patients on the high dose drug."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0013_n2","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Неопределённость регуляторного пути: может потребоваться более крупное исследование, либо возможен путь на текущих данных.","text_en":"Regulatory path uncertainty: may require a larger trial, or there may be a path with existing data.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0013","quote":"What the regulatory path could look like and if that's going to take a bigger trial or if there's a potential path with what they have."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0013_n3","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Из-за IRA Part D redesign наблюдается сдвиг от IV к sub-Q, что влияет на экономику (в т.ч. 20% copay для дорогих препаратов).","text_en":"IRA Part D redesign is driving a shift from IV to sub-Q, affecting economics (including 20% copay for expensive drugs).","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0013","quote":"what we're seeing now is a flux away from IV towards sub-Q because it's much better for the patients."},{"chunk_id":"doc_da8741faa7f7_chunk_0013","quote":"for those who are very expensive drugs, then they have to pay the 20% copay."}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0014_n1","doc_id":"doc_da8741faa7f7","kind":"pain","text_ru":"Компании в biotech испытывают трудности с тем, чтобы рынок признавал ценность ранних программ, что повышает стоимость капитала и осложняет инвестиции в early-stage.","text_en":"Biotech companies struggle to get value recognition for early-stage programs, which can raise cost of capital and hinder early-stage investment.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0014","quote":"\"how challenging it can be for companies to get any value recognition for earlier stage programs\""},{"chunk_id":"doc_da8741faa7f7_chunk_0014","quote":"\"it can affect the cost of capital and their ability to invest in earlier stage programs\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0014_n2","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"Компании вынуждены продолжать вкладывать значительный капитал в ранние программы, понимая, что некоторое время рынок не будет «давать кредит» за эти инвестиции.","text_en":"Companies must keep investing significant capital into early-stage programs despite not getting market credit for some time.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0014","quote":"\"Companies have to continue to invest higher capital dollars into those programs, knowing they're not going to get any credit for them for some time\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0014_n3","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Crystal Biotech объявляет новую индикацию: HSV gene therapy в формате глазных капель для лечения neurotrophic keratitis.","text_en":"Crystal Biotech is announcing a new indication: an HSV gene-therapy eye drop to treat neurotrophic keratitis.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0014","quote":"\"They're announcing a new indication, basically an HSV gene therapy eyedrop to treat neurotrophic keratitis\""}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0015_n1","doc_id":"doc_da8741faa7f7","kind":"constraint","text_ru":"При высокой оценке компании требуется постоянно «бить ожидания» или привлекать раунды, что создаёт давление на регулярные результаты/фандрайзинг.","text_en":"At a high valuation, the company must consistently beat expectations or raise capital, creating pressure for continual performance/fundraising.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0015","quote":"High valuation you need to deliver constant beats or raises."}],"confidence":"high"}
{"nugget_id":"doc_da8741faa7f7_chunk_0015_n2","doc_id":"doc_da8741faa7f7","kind":"trend","text_ru":"Ожидается, что влияние компаундинговых аптек будет «вымыться» из запасов только во второй половине года, снижая эффект на инвентарь со временем.","text_en":"The impact of compounding pharmacies is expected to wash through inventory only by the second half of the year, reducing over time.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0015","quote":"it would take until the through the second half of the year for the impact of the compounding pharmacies to wash through their inventory to reduce."}],"confidence":"medium"}
{"nugget_id":"doc_da8741faa7f7_chunk_0015_n3","doc_id":"doc_da8741faa7f7","kind":"buyer_signal","text_ru":"Компания ожидает важные данные по двум направлениям (Alzheimer’s и сравнение Cagri-Semmer vs Zepp Bound), и позитивный результат рассматривается как критически важный.","text_en":"The company is awaiting key data (Alzheimer’s and Cagri-Semmer vs Zepp Bound), and positive results are seen as very important.","evidence":[{"chunk_id":"doc_da8741faa7f7_chunk_0015","quote":"they've got two bits of data coming in... One is the Alzheimer's and the other one is their Cagri-Semmer versus Zepp Bound"},{"chunk_id":"doc_da8741faa7f7_chunk_0015","quote":"which could be interesting to see if they turn out to be positive. That obviously is very important for the company."}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0000_n1","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"В США снова активизировалась повестка снижения цен на лекарства через исполнительный указ, что вызвало заметную волатильность акций фармкомпаний.","text_en":"US drug-pricing policy is resurfacing via an executive order, driving notable pharma stock volatility.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0000","quote":"We started the week with the executive order from President Trump. Essentially around the drug pricing story"},{"chunk_id":"doc_9e717ee38cc3_chunk_0000","quote":"Share prices sold off really strongly. Um and um, then they jumped back up again"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0000_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Исполнительный указ описан как расплывчатый и неспецифичный, что ограничивает его практическую применимость/предсказуемость для рынка.","text_en":"The executive order is described as vague and non-specific, limiting practical clarity/predictability for the market.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0000","quote":"it was a very vague, very general, um, very non-specific, um, set of, you know, process-related steps"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0000_n3","doc_id":"doc_9e717ee38cc3","kind":"buyer_signal","text_ru":"Инвестсообщество и компании проявляли повышенную тревожность и активно обсуждали возможные последствия до публикации указа.","text_en":"The investment community and companies showed heightened anxiety and active discussion ahead of the order’s release.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0000","quote":"people were very anxious about this the prior week"},{"chunk_id":"doc_9e717ee38cc3_chunk_0000","quote":"there was a lot of chatter that I was getting from my colleagues in the investment community. and in companies"}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0001_n1","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Исполнительный указ по MFN воспринимается рынком как старт переговоров и долгого процесса с неопределённым исходом; «худшие страхи» не реализовались, сектор испытал облегчение.","text_en":"The MFN executive order is seen as the start of negotiations and a long, uncertain process; worst fears didn’t materialize and the sector felt relief.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0001","quote":"\"it's the start of a negotiation... It's the start of a long process and where it ultimately goes remains uncertain\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0001","quote":"\"there was nothing about what happened on Monday that fulfilled people's worst fears.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0001","quote":"\"the sector has breathed a big sigh of relief\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0001_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Для индустрии проблемный факт/ограничение в дискуссии по MFN: цены на лекарства в США сильно отличаются от цен в других странах, и администрация «в каком-то фундаментальном смысле права».","text_en":"A key constraint in the MFN debate: U.S. drug prices differ greatly from other countries, and the administration is “right” at a fundamental level.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0001","quote":"\"it is a bad fact for the industry... that prices are so different here versus other places.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0001","quote":"\"at some fundamental level, the administration is right.\""}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0001_n3","doc_id":"doc_9e717ee38cc3","kind":"buyer_signal","text_ru":"Угроза MFN/тарифов/прочих мер используется как рычаг, чтобы «посадить фарму за стол»; в ответ заявлены крупные обязательства по инвестициям в производство и R&D в США, но компании могут торговаться, увязывая инвестиции с послаблениями.","text_en":"MFN/tariffs/other measures are used to force pharma to the table; pharma has committed large U.S. manufacturing/R&D investments but may negotiate them for relief.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0001","quote":"\"force pharma's hand to the table\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0001","quote":"\"$100 billion of committed U. S. investment into manufacturing and R&D\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0001","quote":"\"maybe we won't make those investments in favor of tariff relief or reduced MFN\""}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0002_n1","doc_id":"doc_9e717ee38cc3","kind":"pain","text_ru":"Стратегии и оценки в индустрии сильно «дергаются» из‑за US drug pricing; ощущение зависимости от публичных заявлений/твитов отдельных людей.","text_en":"Industry strategy and valuations swing heavily due to US drug pricing; a sense of being at the mercy of individual public statements/tweets.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0002","quote":"massive gyrations in strategy and value based on US drug pricing"},{"chunk_id":"doc_9e717ee38cc3_chunk_0002","quote":"we are at the whims of one person's tweets, mostly because US drug pricing is so disconnected"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0002_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Есть риск, что в переговорах по ценообразованию будут доминировать big pharma и крупные коммерческие организации, а biotech будет недостаточно представлена, хотя интересы отличаются.","text_en":"Negotiations may be dominated by big pharma and large commercial orgs, with biotech underrepresented despite differing interests.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0002","quote":"I'm a little bit worried biotech won't be as represented at that negotiating table and that our interests are slightly different."},{"chunk_id":"doc_9e717ee38cc3_chunk_0002","quote":"it'll likely be with the larger companies... But it will mostly be with the larger companies where there's money."}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0002_n3","doc_id":"doc_9e717ee38cc3","kind":"pain","text_ru":"Существенные расхождения цен в США vs остальной мир характерны не только для лекарств, но и для процедур/диагностики; в целом healthcare costs в США выше.","text_en":"Large US vs rest-of-world price discrepancies extend beyond drugs to procedures/diagnostics; overall US healthcare costs are higher.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0002","quote":"discrepancies in many cases between U. S and foreign drug prices"},{"chunk_id":"doc_9e717ee38cc3_chunk_0002","quote":"this happens up and down the healthcare system... US versus rest of world, vastly different prices, much more expensive."}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0003_n1","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Обсуждается возможный сдвиг к модели, где фармкомпании заключают менее прозрачные сделки на других рынках, чтобы максимизировать gross-to-net (аналогия с Medicaid и высокими ребейтами).","text_en":"A possible shift toward less transparent pharma contracting in other markets to maximize gross-to-net (Medicaid-like with high effective rebates).","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0003","quote":"we might go to a model where pharma is cutting deals with other markets with confidence. Contracts and other obscurities"}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0003_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Сомнение, что фармкомпании смогут скрывать от правительства США реальные условия скидок/ребейтов на других рынках; для US-domicile производителей правительство получает всю информацию.","text_en":"Doubt that pharma can keep foreign rebate/discount information from the U.S. government; for U.S.-domiciled manufacturers the government gets all information.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0003","quote":"I'm a little bit dubious that pharma companies are going to successfully manage to keep information from the U. S. government"},{"chunk_id":"doc_9e717ee38cc3_chunk_0003","quote":"especially for U. S. domicile manufacturers where the government gets all the information"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0003_n3","doc_id":"doc_9e717ee38cc3","kind":"pain","text_ru":"Роль PBM, их скидок и ребейтов рассматривается как фактор, усиливающий расхождение цен на лекарства между США и остальным миром.","text_en":"PBMs’ discounts and rebates are cited as a factor increasing drug price discrepancies between the U.S. and the rest of the world.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0003","quote":"the role of PBMs and the discounts that they command and the rebates that they command"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0004_n1","doc_id":"doc_9e717ee38cc3","kind":"pain","text_ru":"В США почти нет участников системы здравоохранения, которые реально заинтересованы в снижении цен; даже страховщики при ACA имеют стимул к росту затрат.","text_en":"In the US, few healthcare participants are incentivized to keep prices low; under the ACA insurers are incentivized by rising costs.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0004","quote":"no participant who has any control also wants prices low."},{"chunk_id":"doc_9e717ee38cc3_chunk_0004","quote":"the only way an insurance company can go profit under the Affordable Care Act is increasing direct health care costs."}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0004_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Правительство США как крупный покупатель ограничено в возможности вести переговоры по ценам на лекарства.","text_en":"The US government, as a major buyer, is heavily restricted in its ability to negotiate drug prices.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0004","quote":"the government— is at least as far as drug prices are concerned heavily restricted in its actual ability to negotiate"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0004_n3","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Ожидаются «поверхностные» переговоры/жесты со стороны big pharma (в т.ч. в obesity), чтобы смягчить или отсрочить более жёсткие изменения политики и ценовое давление.","text_en":"Big pharma is expected to make superficial negotiations/gestures (including in obesity) to forestall worse policy change amid coming pricing pressure.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0004","quote":"there will be superficial negotiations by big pharma companies trying to forestall worse policy change"},{"chunk_id":"doc_9e717ee38cc3_chunk_0004","quote":"in the obesity space, I think we'll see a series of negotiated compromises"}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0005_n1","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Путь через executive order для MFN/ценовой политики выглядит малореалистичным: CMMI demo уже предлагали и он провалился; внедрение займёт много времени и будет оспариваться юридически.","text_en":"Executive-order path for MFN/pricing policy seems unlikely: a CMMI demo was proposed and failed; implementation would take long and face legal challenges.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"the only executive order path would be through a CMMI demonstration project with Medicare\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"was challenged and failed, mostly due to process reasons\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"it would take a lot of time to implement it\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0005_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Сомнения в возможности через торговые сделки заставить Европу повышать цены на лекарства: «нет механизма», «нет рычага».","text_en":"Doubts that trade deals can force Europe to raise drug prices: “no mechanism” and “no lever.”","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"There's no mechanism by which the US can put... into a trade deal because it's not actual trade.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"Can't really force Europe to raise its prices.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"there is no lever\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0005_n3","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Ожидание, что прямой реформы цен не будет, но усилятся «broader business pressures» (анти-инновационные) и давление на P&L биофармы; возможна PBM-реформа в бюджете.","text_en":"Expectation of no outright price reform, but increased broader anti-innovation business pressures on biopharma P&L; possible PBM reform in the final budget.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"outright price reform is unlikely to come\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"there will be broader business pressures that are anti-innovation\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0005","quote":"\"maybe there will be some PBM... reform... in a final budget\""}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0006_n1","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Реимпорт лекарств рассматривается скорее как переговорный рычаг, чем как реальное решение, хотя его могут угрожать применить в переговорах.","text_en":"Drug reimportation is seen more as a negotiating cudgel than a real solution, though it may be threatened in negotiations.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0006","quote":"\"just much more likely to be. A negotiating cudgel than an actual solution\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0006","quote":"\"reasonably likely to be threatened as a part of the negotiation\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0006_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Для реимпорта ключевое ограничение — доступный объём: производители могут ограничивать поставки, а страны могут ограничивать экспорт ради обеспечения собственного снабжения.","text_en":"A key constraint for reimportation is available volume: manufacturers may cut supply and countries may restrict exports to ensure adequate local supply.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0006","quote":"\"you'd cut off supply for Europe\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0006","quote":"\"European countries could restrict exports because they want adequate supply\""}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0006_n3","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Direct-to-consumer продажи со стороны фармы/биотеха маловероятны из‑за барьеров: необходимость управления цепочкой поставок и направления пациентов на назначение, а также нежелание «практиковать медицину» и риск конфликта при назначении собственных препаратов.","text_en":"Pharma/biotech direct-to-consumer sales are seen as unlikely due to supply chain and prescribing/referral needs, plus reluctance to practice medicine and conflict risk in prescribing own drugs.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0006","quote":"\"I think it's fairly unlikely.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0006","quote":"\"there is a supply chain management that needed to be resolved\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0006","quote":"\"I don't see a trend of biotechs or a pharma wanting to be in the business of practicing medicine\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0007_n1","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Не наблюдается тренда, что биотехи/фарма хотят заниматься практикой медицины и брать на себя риск конфликта интересов при назначении собственных препаратов.","text_en":"No trend of biotechs/pharma wanting to practice medicine and take on conflict risk of prescribing their own drugs.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0007","quote":"I don't see a trend of biotechs or a pharma wanting to be in the business of practicing medicine and taking on the potential conflict risk"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0007_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Предсказуемость включения положений в текущие законодательные процессы низкая; утверждается, что предсказать это невозможно.","text_en":"Low predictability of what gets included in current legislative proceedings; claimed impossible to predict.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0007","quote":"I think anybody who tells you they can predict inclusion in current government legislative proceedings is lying."}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0007_n3","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Есть популистская и конгрессная поддержка реформ PBM: запрет spread pricing и требование большей отчетности по ребейтам, структурам ценообразования и контрактам.","text_en":"Populist and congressional support for PBM reform: banning spread pricing and requiring more reporting on rebates, pricing structures, and contracts.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0007","quote":"there is some populist as well as congressional support for banning spread pricing and requiring more reporting of rebate amounts"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0008_n1","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Растёт политическая поддержка реформ PBM: запрет spread pricing, больше раскрытия rebate/контрактов и ограничения на steerage.","text_en":"Growing political support for PBM reform: banning spread pricing, more rebate/contract reporting, and restrictions on steerage.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0008","quote":"there is some populist as well as congressional support for banning spread pricing and requiring more reporting of rebate amounts"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0008_n2","doc_id":"doc_9e717ee38cc3","kind":"pain","text_ru":"Конфликт интересов: интегрированный payer-PBM может направлять пациентов в свою mail order pharmacy, которая может быть не самым дешёвым источником.","text_en":"Conflict of interest: an integrated payer-PBM can steer to its own mail-order pharmacy, which may not be the lowest-cost source.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0008","quote":"ability of an integrated payer PBM to be able to steer to their own, for example, mail order pharmacy, which may not be the lowest cost source"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0008_n3","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Неопределённость политики/регуляторики: исключение orphan drugs из переговоров IRA ещё не закон; также реализация подходов зависит от того, как решат внедрять Macri и Prasad.","text_en":"Policy/regulatory uncertainty: exempting orphan drugs from IRA negotiations is not yet law; implementation depends on how Macri and Prasad decide to implement.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0008","quote":"to exempt orphan drugs from the Inflation Reduction Act negotiations."},{"chunk_id":"doc_9e717ee38cc3_chunk_0008","quote":"It's not yet law, but it feels like it's got good bipartisan support."},{"chunk_id":"doc_9e717ee38cc3_chunk_0008","quote":"time will tell to see how Macri and Prasad decide to implement."}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0009_n1","doc_id":"doc_9e717ee38cc3","kind":"pain","text_ru":"Риск снижения cash flow у фармкомпаний (в контексте мер/тарифов), что ставит под вопрос способность финансировать ранее объявленные инвестиции в США.","text_en":"Risk of reduced cash flow (in context of policy/tariffs), putting previously announced U.S. investments in question.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0009","quote":"\"Roche's ability to fund the significant investments previously announced in the U. S. will be in question.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0009","quote":"\"it's simply saying you're going to dwindle my cash flow. How can I do it?\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0009_n2","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Компании рассматривают AI/роботизацию как способ повысить производительность и управлять маржой; это может не приводить к росту занятости даже при возвращении производств в США.","text_en":"Companies look to AI/robotization for productivity and margin management; this may not increase employment even if factories return to the U.S.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0009","quote":"\"companies can manage their margins if this really hits hard is through productivity gains.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0009","quote":"\"one way of gaining productivity gains... is through AI.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0009","quote":"\"many factories, if they ever come back to the US, will probably be... by robots.\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0009_n3","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Для AI drug discovery/разработки лекарств ключевым ограничением является необходимость глубокой интеграции и доступа к данным; при высоком burn rate и крупной организации возникает вопрос масштабируемости в текущем рынке.","text_en":"AI drug discovery/development is constrained by the need for deep integration and data access; high burn and large orgs raise scalability questions in the current market.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0009","quote":"\"huge, huge power in the models also predicated on tremendous integration and access to data.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0009","quote":"\"in this market, can you continue to do it at a scale where your burn rate is that high\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0010_n1","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Масштабирование AI-моделей требует «tremendous integration and access to data», а также многократного рекурсивного применения моделей; при этом возникает вопрос устойчивости при высоком burn rate и большой организации.","text_en":"Scaling AI models depends on major integration and data access plus repeated recursive use; sustainability is questioned given high burn rate and large org size.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0010","quote":"predicated on tremendous integration and access to data... can you continue to do it at a scale where your burn rate is that high"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0010_n2","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"AI в фарме воспринимается как обязательная тема, но одновременно это «buzzword» и «hype word», что мешает продуктивному прогрессу.","text_en":"In pharma, AI is seen as something companies feel obligated to talk about, but it’s also a buzzword/hype word that can hinder productive progress.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0010","quote":"pharma companies talking about use of AI is... a thing they feel obligated to do"},{"chunk_id":"doc_9e717ee38cc3_chunk_0010","quote":"it is like both a buzzword and a set of tools. And I think they kind of get in each other's way"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0010_n3","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Технологически индустрия «very far away» от сценария, где можно ввести болезнь и получить из компьютера структуру малой молекулы-«cure».","text_en":"The industry is still very far from a push-button workflow that outputs a small-molecule cure from a disease input.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0010","quote":"we're far away from being able to push... a button and have a small molecule structure emerge... that is the cure"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0011_n1","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Регуляторно сложно одновременно доказывать FDA биоэквивалентность IV и SC форм и затем утверждать для возмещения/IRA Part B, что это «не тот же» препарат.","text_en":"Regulatory tension: hard to argue bioequivalence to FDA for IV-to-SC reformulation while later claiming it’s not the same drug for reimbursement/IRA Part B.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0011","quote":"you spend quite a lot of time to convince the FDA that actually it's the same drug as the IV."},{"chunk_id":"doc_9e717ee38cc3_chunk_0011","quote":"And then you go to IRA part B guy and say, 'Actually, it's not the same drug.'"}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0011_n2","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Есть риск, что регулятор потребует полноценное рандомизированное исследование вместо пути 505(b)(2) для подобных разработок.","text_en":"Regulatory risk: programs may be pushed away from 505(b)(2) and required to run a full randomized trial.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0011","quote":"we got pushed back and told that this was not, uh, amenable to a 505(b) 2 and had to go a full-on, um, randomized, randomized trial"}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0011_n3","doc_id":"doc_9e717ee38cc3","kind":"opportunity","text_ru":"Озвучена идея отдельной категории «super generics» с премией к IV-дженерику для продуктов, повышающих удобство и снижающих нагрузку/стоимость, но не как NCE.","text_en":"Proposed opportunity: a “super generics” category with some premium over IV generics for convenience/cost-reducing products, but not priced/treated as NCE.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0011","quote":"I think this is where we could use a category of super generics."},{"chunk_id":"doc_9e717ee38cc3_chunk_0011","quote":"There should still be some sort of premium to an IV generic"}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_9e717ee38cc3","kind":"pain","text_ru":"Кэш в публичных биотех-компаниях может быть «заперт» из‑за обязательств/структуры, что усложняет использование капитала продуктивно.","text_en":"Cash in public biotech companies can become ‘trapped’ due to obligations/structure, making productive use difficult.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0012","quote":"it still has all of these obligations that render it complex."},{"chunk_id":"doc_9e717ee38cc3_chunk_0012","quote":"a whole bunch of cash that could be used productively. Trapped in a sort of interstitial zone"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Публичные рынки в последние годы неблагосклонны к компаниям с cell therapy программами.","text_en":"Public markets have been unfriendly for a while to companies with cell therapy programs.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0012","quote":"The public markets. It has not been friendly to companies of that kind for a while"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Ужесточение регуляторной позиции по cell therapy (в т.ч. по surrogate markers для approvals) может снижать привлекательность таких компаний как независимых публичных игроков.","text_en":"A stricter regulatory stance on cell therapy (incl. surrogate markers for approvals) can reduce attractiveness of such companies as independent public entities.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0012","quote":"new head of CBER announcement... questions about cell therapy and particularly about using surrogate markers"},{"chunk_id":"doc_9e717ee38cc3_chunk_0012","quote":"the stance on cell therapy gets even stricter and at a minimum is going to make this company even less popular"}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0013_n1","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Ужесточение позиции по клеточной терапии может снижать привлекательность компании как независимой публичной.","text_en":"A stricter stance on cell therapy may reduce a company’s attractiveness as an independent public company.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0013","quote":"the stance on cell therapy gets even stricter and at a minimum is going to make this company even less popular as an independent public company"}],"confidence":"medium"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0013_n2","doc_id":"doc_9e717ee38cc3","kind":"buyer_signal","text_ru":"Позитивные данные по EPCAM-направленному ADC привели к росту акции и позволили компании сразу привлечь $100 млн.","text_en":"Positive data for an EPCAM-directed ADC drove the stock up and enabled the company to raise $100M immediately.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0013","quote":"Because of relatively positive data that came out of this, and they immediately, at the back of it, raised $100 million."}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0013_n3","doc_id":"doc_9e717ee38cc3","kind":"pain","text_ru":"Сильно предлеченный CRC остаётся крайне сложной областью: «не видим почти ничего».","text_en":"Heavily pretreated CRC remains very difficult: “we’re not seeing much of anything.”","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0013","quote":"heavily pretreated CRC has been such a bear, and we're not seeing much of anything."}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0014_n1","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"MASH снова становится «модной» терапевтической областью после периода, когда она была сильно не в фаворе; обсуждаются коммерческий потенциал и появляются «exciting assets» (FGF21, RNAi).","text_en":"MASH is becoming a hot area again after being disfavored; commercial potential is being highlighted and exciting assets (FGF21, RNAi) are emerging.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0014","quote":"\"MASH is becoming a new black all of a sudden after being very disfavored.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0014","quote":"\"the magical success has been uh illuminating the commercial potential in the space\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0014_n2","doc_id":"doc_9e717ee38cc3","kind":"buyer_signal","text_ru":"Крупная сделка AbbVie с частной 8RX по RNAi/siRNA: $335 млн upfront, мульти-таргет по нескольким терапевтическим областям (immunology/oncology/neurology).","text_en":"Large AbbVie partnership with private 8RX in RNAi/siRNA: $335M upfront, multi-target across immunology/oncology/neurology.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0014","quote":"\"they did a deal, $335 million upfront, with AbbVie.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0014","quote":"\"a multi-target deal... across multiple areas, immunology, oncology, neurology\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0014_n3","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"По второй сделке (Arzinomics, Южная Корея) детали неясны: по пресс-релизу «unclear», а финансовые условия «masked».","text_en":"Second deal (Arzinomics, South Korea) lacks clarity: press release is unclear and financial details are masked.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0014","quote":"\"It seems to be around RNA editing, but unclear, I must say.\""},{"chunk_id":"doc_9e717ee38cc3_chunk_0014","quote":"\"A lot of the financial details were masked in that.\""}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0015_n1","doc_id":"doc_9e717ee38cc3","kind":"constraint","text_ru":"Финансовые детали сделки в пресс-релизе скрыты/непрозрачны (неясен upfront), из-за чего сложно оценить размер сделки.","text_en":"Deal financials in the press release are masked/unclear (e.g., upfront), making it hard to assess deal size.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0015","quote":"A lot of the financial details were masked in that."},{"chunk_id":"doc_9e717ee38cc3_chunk_0015","quote":"It's unclear what the upfront was, for example, and so forth."}],"confidence":"high"}
{"nugget_id":"doc_9e717ee38cc3_chunk_0015_n2","doc_id":"doc_9e717ee38cc3","kind":"trend","text_ru":"Отмечается активность по заключению сделок «по всей индустрии», особенно в R&A.","text_en":"Deal-making is happening across the industry, particularly in the R&A world.","evidence":[{"chunk_id":"doc_9e717ee38cc3_chunk_0015","quote":"it's good to see this deal making happening across the industry."},{"chunk_id":"doc_9e717ee38cc3_chunk_0015","quote":"I'm always happy when it's happening in the R &A world."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"В обсуждаемом исследовании не достигли статистической значимости по overall survival (OS), что ставит компанию в «трудное положение» с точки зрения требований FDA к OS.","text_en":"The trial missed statistical significance on overall survival (OS), creating a tough FDA decision given OS requirements.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0000","quote":"they missed their statistical significance on OS, but just barely. Like, it was 0.0575."},{"chunk_id":"doc_5516ea805144_chunk_0000","quote":"they're pretty clear that they do require OS."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_5516ea805144","kind":"buyer_signal","text_ru":"Спикер прямо говорит, что был бы готов платить за препарат и заинтересован в нём как пациент.","text_en":"A speaker explicitly says they would pay money to take the drug and would be interested as a patient.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0000","quote":"Would you pay money to take this drug? The answer is, heck yeah."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Ожидание, что VEGF PD-1 станет «backbone standard of care» в онкологии, и дальнейшая эволюция будет в комбинациях с emerging ADCs.","text_en":"Expectation that VEGF PD-1 becomes a backbone standard of care in oncology, with evolution via combinations with emerging ADCs.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0000","quote":"VEGF PD-1 is going to become the backbone standard of care and oncology."},{"chunk_id":"doc_5516ea805144_chunk_0000","quote":"how does this new backbone therapy get used in combination with various types of emerging ADCs"}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0001_n1","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Крупные M&A/большие сделки в биотехе за последние несколько лет были «анемичными» и ожидаемая волна M&A не материализовалась.","text_en":"Large biotech M&A/big deals have been anemic for several years and the expected M&A wave hasn’t materialized.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0001","quote":"\"over the last several years. M &A and these bigger deals has been pretty anemic\""},{"chunk_id":"doc_5516ea805144_chunk_0001","quote":"\"you start to see more M &A, but that hasn't. really materialized\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0001_n2","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Макро- и политическая неопределённость (в т.ч. «Liberation Day», MFN, тарифные разговоры) сдерживает фарму от активного расходования баланса на M&A.","text_en":"Macro/political uncertainty (incl. “Liberation Day”, MFN, tariff talks) is making pharma hesitant to deploy balance sheets for M&A.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0001","quote":"\"Liberation Day plus MFN plus, you know, overall uncertainty in the macro environment\""},{"chunk_id":"doc_5516ea805144_chunk_0001","quote":"\"has caused pharma to say, 'Hey, wait a minute, this is not the time to go take, you know, our balance sheet.'\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0001_n3","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"В M&A есть искажения из‑за завышенных прогнозов выручки: в сделках прогнозы покупателей выше консенсуса, а сам консенсус выше реальности, что создаёт «issues and distortions».","text_en":"M&A is distorted by inflated revenue projections: acquirers’ projections exceed consensus, and consensus exceeds reality, creating “issues and distortions.”","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0001","quote":"\"Those tend to be about. 25 above the sell-side consensus\""},{"chunk_id":"doc_5516ea805144_chunk_0001","quote":"\"those sell-side consensus numbers tend to be 25% above. Reality\""},{"chunk_id":"doc_5516ea805144_chunk_0001","quote":"\"the firm is on on average paying or or attributing 50% too much success\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0002_n1","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Нет заметной «волны» M&A, которая бы существенно влияла на сектор; сделки выглядят как редкие исключения для «нескольких счастливчиков».","text_en":"There hasn’t been a substantial M&A wave impacting the sector broadly; acquisitions seem limited to a lucky handful each year.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0002","quote":"I can't even remember the last time M&A occurred in such a substantial wave as to impact the sector more broadly"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0002_n2","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Слишком много компаний, подходящих под типичный профиль M&A-цели (онкология, small molecule, late stage), поэтому трудно предсказать, кого купят.","text_en":"There are too many companies fitting the typical M&A target profile, making it hard to anticipate which will be acquired.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0002","quote":"there are just too many of those companies out there to go and anticipate which one is going to be bought"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0002_n3","doc_id":"doc_5516ea805144","kind":"opportunity","text_ru":"«Светлое пятно» — сделки на более ранних стадиях (вплоть до pre-clinical proof of concept) как стратегия «land grab» для усиления раннего пайплайна; венчур ожидает таких выходов до клинических readout.","text_en":"A bright spot is earlier-stage deals (even preclinical PoC) as a land-grab strategy to bolster early pipeline; venture hopes for exits before clinical readouts.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0002","quote":"the bright spot is that looking at deals that are earlier. Maybe even pre-clinical proof of concept"}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0003_n1","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Финансирование Phase 2–3 остаётся сложным: длинные сроки и большой объём капитала, при этом рынки капитала жёсткие, кроссоверы ушли, IPO-окно фактически закрыто.","text_en":"Financing Phase 2–3 remains difficult: long timelines and large capital needs, with tough capital markets, crossover investors gone, and the IPO window effectively closed.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0003","quote":"phase two and phase three are still not the easiest... it's a long timeline and it's a large nut"},{"chunk_id":"doc_5516ea805144_chunk_0003","quote":"the capital markets are so tough, where the crossovers have basically left the early clinical to preclinical space"},{"chunk_id":"doc_5516ea805144_chunk_0003","quote":"the IPO window is, for all intents and purposes, closed"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0003_n2","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"M&A-сделки смещены в сторону коммерческой стадии: покупатели предпочитают покупать коммерческие активы/компании, а не Phase 2.","text_en":"M&A is skewed toward commercial-stage: buyers prefer acquiring commercial assets/companies rather than Phase 2.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0003","quote":"I'm working on a record volume of M &A deals... They're all commercial stage."},{"chunk_id":"doc_5516ea805144_chunk_0003","quote":"why would you buy the phase two when you can go and buy the commercial asset?"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0003_n3","doc_id":"doc_5516ea805144","kind":"opportunity","text_ru":"Для pharma возникает возможность «value shopping»: покупать недооценённые коммерческие активы/компании и «tuck-in» в существующую коммерческую инфраструктуру.","text_en":"Pharma has a value-shopping opportunity: acquire undervalued commercial assets/companies and tuck them into existing commercial infrastructure.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0003","quote":"They're just not trading it very. Good prices."},{"chunk_id":"doc_5516ea805144_chunk_0003","quote":"it's also a nice value, a de-risked value shopping opportunity for pharma."},{"chunk_id":"doc_5516ea805144_chunk_0003","quote":"Ways to amortize, obviously, existing commercial infrastructure with nice little tuck-ins."}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0004_n1","doc_id":"doc_5516ea805144","kind":"opportunity","text_ru":"Недооценённые (в т.ч. de-risked) активы на стадии post-POC/phase 2 могут быть «выгодной покупкой» для pharma.","text_en":"Undervalued, de-risked post-POC/phase 2 assets can be a value-shopping opportunity for pharma.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0004","quote":"\"So it's also a nice value, a de-risked value shopping opportunity for pharma.\""}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0004_n2","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Наблюдается активность в коммерческих M&A; проводится параллель с периодом 1982–1988, когда было много коммерческих приобретений.","text_en":"Commercial M&A activity is picking up; compared to 1982–1988 when there were many commercial acquisitions.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0004","quote":"\"what you saw from like 1982 to 1988 was a ton of commercial acquisitions.\""}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0004_n3","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Рыночные настроения и доступ к финансированию в biotech оцениваются как худшие за историю опроса: VC-инвестиции, IPO/фоллоу-оны и оценки компаний воспринимаются как очень слабые.","text_en":"Biotech market sentiment and financing access are described as the worst in the survey’s history: VC flow, IPO/follow-ons, and valuations seen as very weak.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0004","quote":"\"they were the worst sentiments around the market financing environment than they have had in their history\""},{"chunk_id":"doc_5516ea805144_chunk_0004","quote":"\"94% said the state of biotech IPOs and follow-on markets is poor\""},{"chunk_id":"doc_5516ea805144_chunk_0004","quote":"\"almost 90% said it was low or very low in terms of valuation\""}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"На рынке biotech наблюдается «shakeout»: часть публичных компаний предпочитает сворачиваться и возвращать кэш акционерам, а не искать M&A/стратегические опции.","text_en":"Biotech is experiencing a shakeout: some public companies are winding down and returning cash to shareholders rather than pursuing M&A/strategic options.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0005","quote":"we're also going through now is a bit of a shakeout."},{"chunk_id":"doc_5516ea805144_chunk_0005","quote":"they decided to actually wind down the company and dividend out that cash"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Инвесторы и участники рынка «очень нервничают» и настроены «bearish» из‑за регуляторной среды (FDA/CBER).","text_en":"Investors/market participants are very nervous and bearish about the regulatory environment (FDA/CBER).","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0005","quote":"people definitely have been quite bearish on the regulatory environment."},{"chunk_id":"doc_5516ea805144_chunk_0005","quote":"people are very nervous about the environment."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Было профинансировано много biotech-компаний «без достаточного субстрата» для построения долгосрочно устойчивого бизнеса; есть «crowding around targets» и сложно «picking a winner».","text_en":"Many biotech companies were funded without enough substrate for long-term sustainability; there is crowding around targets and difficulty picking winners.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0005","quote":"an awful lot of companies that got funded. With perhaps not enough substrate to build long-term sustainable companies"},{"chunk_id":"doc_5516ea805144_chunk_0005","quote":"the crowding around targets and the challenges... around picking a winner."}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0006_n1","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Рынок PIPE для сделок (в т.ч. reverse merger) фактически «не был», из‑за чего не хватает уверенности/интереса инвесторов и сделки не закрываются.","text_en":"The PIPE market hasn’t been available/there’s been no interest, undermining conviction and preventing reverse-merger deals from getting done.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0006","quote":"\"That pipe market hasn't been there. There hasn't been any interest in that piece.\""},{"chunk_id":"doc_5516ea805144_chunk_0006","quote":"\"there's not been a conviction in the pipe.\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0006_n2","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Есть настроение, что «сейчас не здорово быть публичной компанией», при этом в private equity рынках есть «dry powder» для поддержки правильных программ.","text_en":"Sentiment is that it’s not great to be public right now, while private equity has dry powder to back the right programs.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0006","quote":"\"there's also this sentiment that it's not. Great to be public right now.\""},{"chunk_id":"doc_5516ea805144_chunk_0006","quote":"\"there's a lot of dry powder in the private equity markets that can support the right program.\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0006_n3","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"В биотехе «crowding» вокруг таргетов может означать десятки/сотни программ, но клиническая дифференциация и понимание, кто победит, занимает гораздо больше времени, чем в tech.","text_en":"In biotech, crowding around targets can mean 100–150 programs, and it takes much longer than tech to learn which will differentiate clinically.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0006","quote":"\"You're going to take a lot longer to figure out if the excitement around certain targets are going to play out in the clinic\""},{"chunk_id":"doc_5516ea805144_chunk_0006","quote":"\"literally 100, 150 programs that are going on. And not all of those are going to be winners.\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0007_n1","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Наблюдается сильная «скученность» вокруг одних и тех же биомишеней: по отдельным таргетам одновременно идут десятки/сотни программ, и не все станут победителями.","text_en":"There is heavy crowding around the same targets: some targets have 100–150 programs, and not all will win.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0007","quote":"specific targets where there's, you know, literally 100, 150 programs that are going on. And not all of those are going to be winners."}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0007_n2","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Для некоторых таргетов актив рассматривается как «обязательная комбинация» и не ожидается эффективность в монотерапии (ограничение для разработки/позиционирования).","text_en":"For some targets, the asset is viewed as obligate combination and not expected to work as monotherapy (a development/positioning constraint).","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0007","quote":"it's an obligate combination asset, it's not expected to have mono therapy efficacy"}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0007_n3","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Политические/регуляторные сигналы (HHS, рекомендации по COVID-вакцинам, NIH funding, фокус регуляторов) заметно влияют на сентимент generalist и public market по биотеху.","text_en":"Policy/regulatory actions (HHS, COVID vaccine recommendations, NIH funding, regulator focus) are influencing generalist and public market sentiment toward biotech.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0007","quote":"policy stuff... speaks to... NIH funding available for early stage research, the regulators focus"},{"chunk_id":"doc_5516ea805144_chunk_0007","quote":"obviously also influences the sort of the generalist sentiment and public market sentiment"}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0008_n1","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Новые FDA guardrails для COVID/flu вакцин: запрос на плацебо-контролируемые исследования для коммерциализации у <65 лет, что вызывает вопросы о реализуемости таких trials в здоровых/минимально симптомных популяциях.","text_en":"New FDA guardrails for COVID/flu vaccines: desire for placebo-controlled trials for commercialization in under-65s, raising feasibility questions in healthy/minimally symptomatic populations.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0008","quote":"wanting to see placebo-controlled trials for vaccines that would be commercialized to the under 65"},{"chunk_id":"doc_5516ea805144_chunk_0008","quote":"this begs a lot of questions about how you will do placebo-controlled trials in healthy and minimally symptomatic flu and COVID individuals"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0008_n2","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"FDA делает акцент на клинически значимых endpoints (госпитализации и смерти), а не на surrogate/симптоматических метриках, как обоснование профилактической вакцинации в этих популяциях.","text_en":"FDA emphasis on clinically meaningful endpoints (hospitalizations and deaths) over surrogate/symptom measures as justification for prophylactic vaccination in these populations.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0008","quote":"The other emphasis is looking at endpoints of relevance"},{"chunk_id":"doc_5516ea805144_chunk_0008","quote":"actual hospitalization and deaths— as being sort of the only real prophylactic justification"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0008_n3","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Отмечается «crisis in replication» в научных данных: значимая доля исследований не воспроизводится, что ведёт к mis-/disinformation.","text_en":"A noted replication crisis in scientific data: much research cannot be reproduced, contributing to mis-/disinformation.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0008","quote":"the crisis in replication in in scientific data"},{"chunk_id":"doc_5516ea805144_chunk_0008","quote":"how much research actually cannot be reproduced and that leads to mis-and disinformation"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0009_n1","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Текущий COVID отличается от периода разработки первых вакцин/бустеров; фокус смещается на актуальные циркулирующие варианты/патоген.","text_en":"Current COVID differs from when original vaccines/boosters were developed; focus is shifting to what’s most relevant for circulating variants/pathogen.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0009","quote":"The COVID that we're dealing with now is very different than the COVID when the original vaccines and boosters were developed."}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0009_n2","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Вакцинная часть biotech «под осадой», и командам (например, Moderna) будет сложно принимать R&D/капитальные решения и «навигацировать» ситуацию; ожидаются сложности для новых вакцин.","text_en":"Vaccines in biotech are “under siege,” making it difficult for teams (e.g., Moderna) to navigate and make R&D/capital allocation decisions; new vaccines may face increased difficulty.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0009","quote":"the vaccines part... is definitely under siege."},{"chunk_id":"doc_5516ea805144_chunk_0009","quote":"It's going to continue to be very difficult for the Moderna team and others to navigate that"}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0009_n3","doc_id":"doc_5516ea805144","kind":"buyer_signal","text_ru":"PDUFA-даты, проходящие успешно, рассматриваются как позитивный сигнал; без движения по PDUFA «трудно инвестировать».","text_en":"Successful PDUFA dates are viewed as a positive signal; it’s hard to invest if PDUFA progress isn’t happening.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0009","quote":"PDUFA dates going well are a good thing and says that we're along the right track."},{"chunk_id":"doc_5516ea805144_chunk_0009","quote":"It's pretty hard to invest if you can't even get the PDUFA dates going."}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0010_n1","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Есть риск задержек/ограничений со стороны FDA из‑за ресурсов/«headcount»; важно, чтобы не было задержек по PDUFA.","text_en":"Risk of FDA delays/resource constraints; PDUFA timing is a key concern.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0010","quote":"We want to make sure that there's no FDA delays, resources, or otherwise, right? A lot of headcount and doge concerns."}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0010_n2","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Беспокойство о достаточности базы безопасности/постмаркетинговой (phase four) безопасности для крупного рынка; опасения редких сигналов безопасности, которые могут проявиться позже.","text_en":"Concern about adequacy of safety database/Phase IV safety for a large market; worry about late-emerging safety signals.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0010","quote":"Where do we have enough safety? Do we have enough phase four safety? What does the safety database look like"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0010_n3","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Moderna сталкивается с необходимостью принимать «тяжёлые решения» из‑за высокого burn rate; инвесторы отмечают, что компания сжигает много кэша.","text_en":"Moderna faces tough decisions due to high cash burn; investors note significant burn rate.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0010","quote":"they got to make some tough decisions, right because they're burning a lot of cash"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0011_n1","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Аутизм — «очень consequential disease», но в индустрии ему уделяют мало внимания и о нём мало говорят.","text_en":"Autism is described as a consequential disease but gets little attention and discussion in the industry.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0011","quote":"\"autism is, as was pointed out in the Maha report, a very consequential disease. doesn't get a ton of attention from our industry.\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0011_n2","doc_id":"doc_5516ea805144","kind":"opportunity","text_ru":"Ожидается, что текущий фокус на аутизме может привести к росту инвестиций в это направление.","text_en":"The current focus on autism may drive more investment into the field.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0011","quote":"\"I would hope that maybe all of this will cause more investment to go into that field.\""}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0011_n3","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Компании боятся публично давать конструктивную обратную связь FDA/NIH из-за риска, что это «вернётся и укусит позже».","text_en":"Companies are hesitant to give on-the-record constructive feedback to FDA/NIH due to fear of future repercussions.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0011","quote":"\"we as an industry... are very shy to go on the record with constructive criticism or feedback. To the agency.\""},{"chunk_id":"doc_5516ea805144_chunk_0011","quote":"\"Because there is a fear that that might be taken down as a note and come back and bite you later.\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0012_n1","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Пост‑hoc subgroup analysis в Phase 3 может приводить к повторным провалам при попытке «переиграть» исследование на основе найденной подгруппы.","text_en":"Post-hoc subgroup analysis in Phase 3 can lead to repeated failures when a study is redone based on a later-found subgroup.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0012","quote":"\"they found a subgroup analysis years later, redid the study again based on the subgroup, and here again, failed again.\""},{"chunk_id":"doc_5516ea805144_chunk_0012","quote":"\"bit us again when you do a subgroup analysis post hoc.\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0012_n2","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Инвестиции в антибиотики (особенно для госпитального рынка) сложны из‑за трудного market access через hospital formularies, что ухудшает ROI для венчура.","text_en":"Antibiotic investing (especially for hospital markets) is constrained by difficult market access via hospital formularies, hurting venture ROI.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0012","quote":"\"it's been a really big challenge to invest in that area as venture\""},{"chunk_id":"doc_5516ea805144_chunk_0012","quote":"\"hospital formularies make market access so challenging. That the ROI for a venture investment is tough\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0012_n3","doc_id":"doc_5516ea805144","kind":"buyer_signal","text_ru":"Партнёрство с GSK и milestone $150M после успешного Phase 3 readout указывает на коммерческий интерес/готовность платить за актив в anti-infectives.","text_en":"A GSK partnership and a $150M milestone after a successful Phase 3 readout indicate commercial interest/willingness to pay for an anti-infective asset.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0012","quote":"\"they had a phase three data readout and a GSK deal.\""},{"chunk_id":"doc_5516ea805144_chunk_0012","quote":"\"GSK will owe them $150 million milestone\""}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0013_n1","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"В анти-инфективах/антибиотиках венчурные инвесторы часто видят барьер: мало «естественных» M&A-покупателей и слабые IPO-компсы, что снижает готовность инвестировать даже при сильной технологии.","text_en":"In anti-infectives/antibiotics, VCs see a barrier: few natural M&A acquirers and weak IPO comps, reducing willingness to invest even with strong tech.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0013","quote":"the odds of not having many natural acquirers and not having great comps on the IPO market weigh in the decision not to invest"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0013_n2","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Высокая неудовлетворённая потребность в новых антиинфекционных терапиях: тяжёлые/упорные инфекции требуют смены 2–3 антибиотиков, перехода с перорального на IV и иногда госпитализации.","text_en":"High unmet need in anti-infectives: intractable infections can require 2nd/3rd antibiotics, switching from oral to IV, and sometimes hospitalization.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0013","quote":"go through second and third antibiotic and go from oral to IV and maybe even from outpatient to inpatient"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0013_n3","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"Отмечаются инициативы по большей гибкости FDA в критериях superiority vs non-inferiority, а также период значимого финансирования BARDA для поддержки разработки.","text_en":"Initiatives noted to make FDA more flexible on superiority vs non-inferiority, and a period of significant BARDA funding to support development.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0013","quote":"initiative historically to make the FDA more flexible on superiority versus non-inferiority margins"}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_5516ea805144","kind":"buyer_signal","text_ru":"Модель возмещения, где услуги pain-центра и препарат упакованы в один платёж, создаёт для центров возможность «захватывать прибыльность», что связано с коммерческим успехом препарата.","text_en":"A reimbursement model bundling services and the drug into one payment lets pain centers capture profitability, linked to strong drug uptake.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0014","quote":"\"The way the reimbursement works on the J &J drug... packaged into one payment. And so that provides those centers a way of capturing profitability\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_5516ea805144","kind":"pain","text_ru":"Пациенты эмпирически проходят через несколько пероральных препаратов и ждут недели, чтобы понять, есть ли эффект.","text_en":"Patients empirically cycle through multiple oral agents and wait weeks to see benefit.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0014","quote":"\"you don't have patients... going through a number of different oral agents waiting... a couple weeks to see if they get benefit\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Индустрия описывается как одна из самых регулируемых; важна прозрачная коммуникация регулятора о том, каким будет «framework» для индустрии.","text_en":"The industry is described as highly regulated; transparent regulator communication about the industry framework matters.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0014","quote":"\"this is one of the most regulated industries... speaking about how the framework is going to be for the industry\""}],"confidence":"medium"}
{"nugget_id":"doc_5516ea805144_chunk_0015_n1","doc_id":"doc_5516ea805144","kind":"trend","text_ru":"В Конгрессе обсуждается законопроект, который добавляет защиты для потребителей с генетическими данными (в т.ч. на депозите у 23andMe) на случай банкротства, чтобы защитить идентифицируемую информацию.","text_en":"A bill in Congress seeks incremental protections for consumers with genetic data (e.g., at 23andMe) in bankruptcy to protect identifiable information.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0015","quote":"there's a writer in a bill in Congress that's seeking to provide incremental protections to consumers who may have genetic data on deposit with 23andMe"}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0015_n2","doc_id":"doc_5516ea805144","kind":"constraint","text_ru":"Приватность и генетическая информация — системная проблема: «всё в sequence потенциально идентифицируемо», поэтому требуется защита персональных данных (имя, дата рождения, адрес и т.п.).","text_en":"Privacy/genetic data is a field-wide constraint: anything in sequence may be identifiable, requiring protection of personal identifiers (name, DOB, address, etc.).","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0015","quote":"Isn't just about anything in sequence potentially identifiable in today's day and age."}],"confidence":"high"}
{"nugget_id":"doc_5516ea805144_chunk_0015_n3","doc_id":"doc_5516ea805144","kind":"buyer_signal","text_ru":"Озвучена поддержка стратегии Regeneron по выявлению новых мишеней на основе де-идентифицированной генетики и фенотипических датасетов, с ожиданием продолжения этого подхода с 23andMe.","text_en":"Expressed support for Regeneron’s approach of finding novel targets from de-identified genetics and phenotypic datasets, hoping to continue with 23andMe.","evidence":[{"chunk_id":"doc_5516ea805144_chunk_0015","quote":"They've really done a nice job of identifying novel targets from de-identified genetics."}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0000_n1","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"Крупные M&A-сделки в биотехе в последнее время были редкими; участники отмечают, что M&A «не хватало» с января.","text_en":"Big biotech M&A has been scarce recently; speakers note M&A has been “lacking” since January.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0000","quote":"it's always nice when we get M&A. It's been. You know, lacking, at least in a big way, ever since January"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0000_n2","doc_id":"doc_a29db6495933","kind":"buyer_signal","text_ru":"Есть запрос/ожидание M&A-сделок со стороны участников рынка, но реакция неоднозначна: маленькие сделки считают «слишком маленькими», а большие — как потерю потенциальных будущих «Amgen».","text_en":"There is demand/expectation for M&A, but sentiment is conflicted: small deals are dismissed as too small, big deals seen as losing potential future “Amgens.”","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0000","quote":"We ask for M &A deals. And when the little ones get done, we go, 'Oh, well, that's too little.'"}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0000_n3","doc_id":"doc_a29db6495933","kind":"pain","text_ru":"Системный мастоцитоз был малоизвестным заболеванием для многих, хотя существует значимое число пациентов, страдающих от него (в т.ч. в продвинутой и индолентной формах).","text_en":"Systemic mastocytosis was unfamiliar to many, despite many patients suffering from it (including advanced and indolent forms).","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0000","quote":"not very many of us had ever even heard of the diseases they were going after"}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0001_n1","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"С начала года в базе насчитали 11 M&A-сделок; обсуждаются крупные сделки (в т.ч. Lilly/Scorpion).","text_en":"They counted 11 M&A deals since the beginning of the year; large deals are being discussed (incl. Lilly/Scorpion).","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0001","quote":"I've counted 11 deals on our database. M&A deals since the beginning of the year."},{"chunk_id":"doc_a29db6495933_chunk_0001","quote":"the next larger one was the Lilly's acquisition of Scorpion Therapeutics."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0001_n2","doc_id":"doc_a29db6495933","kind":"buyer_signal","text_ru":"Sanofi платит $9.1B за актив, который, по консенсусу, может стать $2B препаратом к 2030; структура включает CVR за development и regulatory milestones.","text_en":"Sanofi is paying $9.1B for an asset that consensus suggests could be a $2B drug by 2030; deal includes CVRs tied to development and regulatory milestones.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0001","quote":"It gives them a possible, if consensus is right, $2 billion drug by 2030. You know, you're paying $9. 1 billion."},{"chunk_id":"doc_a29db6495933_chunk_0001","quote":"It's $129 per share in the $2 CVR for development milestones and $4 CVR for regulatory milestones."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0001_n3","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Ключевой риск для PD-1/VEGF биспецификов: переносимость результатов из китайских исследований на популяцию США не гарантирована из‑за различий в генетике/онкогенетике.","text_en":"Key risk for PD-1/VEGF bispecifics: translation of China-trial results to the US population isn’t assured due to genetic/cancer-genetic differences.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0001","quote":"All of the Big key studies have been done in China."},{"chunk_id":"doc_a29db6495933_chunk_0001","quote":"Chinese patients have different genetics, different cancer genetics in particular."},{"chunk_id":"doc_a29db6495933_chunk_0001","quote":"The translation from a China population to US population cannot be assured."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0002_n1","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Переносимость (translation) данных из китайской популяции на американскую не гарантирована из‑за различий в генетике/генетике рака.","text_en":"Translation of data from a China population to a US population isn’t assured due to genetic differences.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0002","quote":"Chinese patients have different genetics, different cancer genetics in particular. And the translation from a China population to US population cannot be assured."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0002_n2","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Компания признаёт риск невозможности подачи на FDA из-за промаха по общей выживаемости; p-value не станет статистически значимым, так как «alpha» уже израсходована.","text_en":"Potential inability to file for FDA approval after missing the overall survival endpoint; p-value won’t become statistically significant because alpha is spent.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0002","quote":"The company acknowledged that it may not be able to submit for FDA approval because they've barely missed their overall survival endpoint"},{"chunk_id":"doc_a29db6495933_chunk_0002","quote":"They've spent all of their alpha at this time point, so the p-value will never be statistically significant"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0002_n3","doc_id":"doc_a29db6495933","kind":"pain","text_ru":"Нет убедительной гипотезы/механистического объяснения, почему биспецифик/комбинация должна работать и давать OS; это остаётся существенным риском.","text_en":"Lack of a conclusive hypothesis for why the bispecific/combination should work and deliver OS remains a material risk.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0002","quote":"there's still no real like conclusive hypothesis of why this combo in a bispecific should work."},{"chunk_id":"doc_a29db6495933_chunk_0002","quote":"Without a clear hypothesis of why one is better than two things together and nobody actually hitting on OS yet"}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0003_n1","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"По биспецифическим препаратам остаётся много неизвестного, что усложняет оценку и дебаты вокруг них.","text_en":"There is still a lot unknown about bispecific drugs, complicating evaluation and debate.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0003","quote":"There's just so much that we don't yet know about these drugs, these bispecifics."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0003_n2","doc_id":"doc_a29db6495933","kind":"opportunity","text_ru":"Партнёрство с Bristol и доступ к денежным средствам создают возможность попробовать комбинацию PD-L1 VEGF с PD-1 (комбо-терапию).","text_en":"Partnering with Bristol and having cash creates an opportunity to try a PD-L1 VEGF plus PD-1 combination.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0003","quote":"partnered with Bristol, taking some of that cash, $3. 5 billion, pretty much guaranteed to 2028, to possibly do a combo with a PD-1."}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0003_n3","doc_id":"doc_a29db6495933","kind":"pain","text_ru":"Есть опасение, что PD-L1 VEGF может в итоге пойти по пути «других PD-L1», что воспринимается как риск для актива.","text_en":"There is concern that PD-L1 VEGF may ultimately follow the path of other PD-L1s, seen as a risk for the asset.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0003","quote":"it always made me worried that in the background, people are going to eventually find that this ends up going down the road of other PD-L1s."}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0004_n1","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"По биспецифическим препаратам остаётся много неизвестного; требуется терпение и время, чтобы данные «выиграли».","text_en":"There is still a lot unknown about these bispecific drugs; patience is needed and data will ultimately decide.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0004","quote":"\"There's just so much that we don't yet know about these drugs, these bispecifics.\""},{"chunk_id":"doc_a29db6495933_chunk_0004","quote":"\"we're going to need to be a little bit patient.\""},{"chunk_id":"doc_a29db6495933_chunk_0004","quote":"\"over time data will win.\""}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0004_n2","doc_id":"doc_a29db6495933","kind":"buyer_signal","text_ru":"Есть выраженный интерес к этим данным/молекулам со стороны крупных фармкомпаний (Merck, Bristol, Pfizer и др.).","text_en":"There is strong interest in these assets/data from large pharma (Merck, Bristol, Pfizer, etc.).","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0004","quote":"\"that's why there is all this interest, whether it's from Merck or Bristol or Pfizer or others.\""}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0004_n3","doc_id":"doc_a29db6495933","kind":"pain","text_ru":"В оценке VEGF-сигнала в таких испытаниях вызывают беспокойство AEs вроде протеинурии и гипертензии; отмечается 17% grade 3 (без протеинурии).","text_en":"VEGF-signal AEs like proteinuria and hypertension are a concern in these trials; 17% grade 3 is noted (no proteinuria).","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0004","quote":"\"one thing I do worry about is I always look at proteinuria and hypertension in these trials\""},{"chunk_id":"doc_a29db6495933_chunk_0004","quote":"\"And it's not low, 17% grade three, no proteinuria, but 17% grade three.\""}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0005_n1","doc_id":"doc_a29db6495933","kind":"pain","text_ru":"IgA-нефропатия десятилетиями считалась по сути нетерапируемой: стандарт лечения — симптоматический, без модификации болезни и без замедления прогрессирования.","text_en":"IgA nephropathy has been largely untreatable for decades; standard care is symptomatic/non–disease-modifying and doesn’t slow progression.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0005","quote":"it's been sort of an untreatable disease for decades. Standard of care is essentially symptomatic management or non-disease modifying therapies"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0005_n2","doc_id":"doc_a29db6495933","kind":"buyer_signal","text_ru":"Ключевая потребность/критерий ценности для врачей и пациентов — стабильность функции почек во времени (а не только снижение протеинурии).","text_en":"What patients and doctors care about is long-term stability of kidney function, not just lower protein in urine.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0005","quote":"what kidney patients care about and what doctors care about isn't whether you have lower protein in the urine."},{"chunk_id":"doc_a29db6495933_chunk_0005","quote":"It's whether over time your disease is more stable in terms of downward progression of kidney function."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0005_n3","doc_id":"doc_a29db6495933","kind":"opportunity","text_ru":"Рынок терапии IgA-нефропатии описывается как «огромный», достаточный минимум для двух игроков; ожидается широкое принятие новых терапий.","text_en":"IgA nephropathy is described as a huge market, big enough for at least two players, with therapies likely to be widely adopted.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0005","quote":"these are both going to be, I think, very quickly embraced and widely embraced therapies for IGAM patients."},{"chunk_id":"doc_a29db6495933_chunk_0005","quote":"This Igan space certainly big enough for two players."}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0006_n1","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"В нефрологии за последние пару лет было много сделок; это зона повышенного фокуса крупных фармкомпаний.","text_en":"Nephrology has seen many deals over the last couple of years and is an increased focus area for large pharma.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0006","quote":"there's been a lot of deals in the nephrology space over the last couple of years. It's definitely an area of increased focus for the larger companies."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0006_n2","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"Биспефический сегмент (PD-1 x VEGF) становится «новой технологией», которая вызывает интерес в biotech.","text_en":"The bispecific space (PD-1 x VEGF) is becoming a new technology that biotech is getting excited about.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0006","quote":"one thing that biotech always needs is like a new technology to get really excited about."},{"chunk_id":"doc_a29db6495933_chunk_0006","quote":"I think the PD-1 by VEGF and just like the whole bispecific space is turning into that."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0006_n3","doc_id":"doc_a29db6495933","kind":"opportunity","text_ru":"Protein degradation рассматривается как ранняя, но перспективная модальность, потенциально позволяющая делать простую пероральную терапию (например, once-daily) для воспалительных заболеваний.","text_en":"Protein degradation is an early but promising modality, potentially enabling simple oral (once-daily) therapies for inflammatory diseases.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0006","quote":"One new technology that I'm really excited about, if you think about it, like really in the first inning, is protein degradation."},{"chunk_id":"doc_a29db6495933_chunk_0006","quote":"have like a new modality that you can especially make, you know, potentially simple oral therapy. So the idea here is like. a once daily world."}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0007_n1","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"Протеин-деградация рассматривается как ранняя, но перспективная технология, способная «добавить возбуждения» сектору biotech в ближайшие годы и стать основой будущей разработки лекарств.","text_en":"Protein degradation is viewed as an early but promising technology that could energize biotech in coming years and become a cornerstone of future drug development.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0007","quote":"I think that protein degradation... is going to be a technology that could add some real excitement to the biotech sector over the coming years. It's very early."},{"chunk_id":"doc_a29db6495933_chunk_0007","quote":"So it is absolutely, I think it's going to be a cornerstone of future drug development."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0007_n2","doc_id":"doc_a29db6495933","kind":"opportunity","text_ru":"Протеин-деградация открывает «новый набор» мишеней, которые могут быть не поддающимися стандартному ингибированию ферментов, при условии правильного дизайна молекулы и фармакологии.","text_en":"Protein degradation opens a new set of targets not amenable to standard enzyme inhibition, assuming correct molecule design and pharmacology.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0007","quote":"it gives you a whole new – set of targets to work with that may not be amenable to standard enzyme inhibition"},{"chunk_id":"doc_a29db6495933_chunk_0007","quote":"it just opens such a big window of opportunity, assuming you get the molecule design right. And the pharmacology right."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0007_n3","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"На ASCO отмечается продолжающаяся инновация (особенно в small-cap и ранних данных) и рост ожидаемых уровней эффективности: в некоторых опухолях 20–40% ответов уже воспринимаются как менее впечатляющие по сравнению с прошлым.","text_en":"At ASCO, ongoing innovation (notably in small-cap and earlier-stage datasets) and rising efficacy expectations: in some tumors, 20–40% response rates are now less impressive than before.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0007","quote":"the real theme here was just how much innovation was ongoing, maybe a lot of that in small cap biotech"},{"chunk_id":"doc_a29db6495933_chunk_0007","quote":"now in some of these tumor types... we're kind of sticking our nose up at response rates in the 20s, 30s, even 40% on occasion."}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0008_n1","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"На ASCO обсуждаются новые молекулы и «эволюционирующие данные» (в т.ч. по KRAS), а также расширение клинических испытаний на опухоли с исторически низкой удачей (например, панкреатический рак).","text_en":"At ASCO, new molecules and evolving data (incl. KRAS) are discussed, and trials are moving into historically hard-to-treat tumors (e.g., pancreatic cancer).","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0008","quote":"we all come back with all these new molecules... the evolving data for the KRAS... trials that are going into tumors... pancreatic being one of them"}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0008_n2","doc_id":"doc_a29db6495933","kind":"buyer_signal","text_ru":"Есть сильный позитивный «KOL sentiment» и ожидания вокруг Phase III кандидата (энтузиазм, KOLs «raving»).","text_en":"Strong positive KOL sentiment and excitement around a candidate’s Phase III.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0008","quote":"there's a lot of excitement enthusiasm for their Phase III. All of the Kols were really raving about this candidate"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0008_n3","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Масштабирование и «ускорение» развития/коммерциализации крупного онко-актива может быть недоступно для небольшой компании.","text_en":"Taking a major oncology asset and accelerating it may be infeasible for a smaller company.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0008","quote":"I don't think a smaller company could have done that."}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0009_n1","doc_id":"doc_a29db6495933","kind":"pain","text_ru":"В поле TIGIT в последнее время много разочарований: крупные неудачи и закрытие/дивестирование программ.","text_en":"The TIGIT field has seen many recent disappointments, including major failures and program divestments/shutdowns.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"the whole Tidget field and all of the disappointments that we've seen there lately.\""},{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"A lot of companies have divested of their programs.\""},{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"We just had ITOs literally close shop.\""}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0009_n2","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Есть опасение по поводу Fc-активности у молекул, связывающих T-клетки: потенциально нежелательная цитотоксичность против T-клеток и вопросы по побочным эффектам.","text_en":"Concern about Fc-active molecules that bind T cells: potential unwanted cytotoxicity against T cells and side-effect considerations.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"When I think about having an FC active on a molecule that binds to a T cell, it just worries me a little bit.\""},{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"why would I want anti-antibody directed cytotoxicity against the T cell?\""},{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"maybe you can also manage the side effects a bit better if you didn't have the FC active.\""}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0009_n3","doc_id":"doc_a29db6495933","kind":"buyer_signal","text_ru":"Astra активно инвестирует в TIGIT-программу: 10 фаз III исследований (~8,000 пациентов), что указывает на уверенность/готовность тратить значимые бюджеты при наличии сигнала.","text_en":"Astra is heavily investing in a TIGIT program: 10 Phase III trials (~8,000 patients), indicating willingness to spend significant budgets based on a signal.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"they're really putting their money where their mouth is. They've got 10 trials.\""},{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"this adds up to about 8,000 patients, all phase III, right? 10 trials.\""},{"chunk_id":"doc_a29db6495933_chunk_0009","quote":"\"So they have seen a signal\""}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0010_n1","doc_id":"doc_a29db6495933","kind":"pain","text_ru":"В раке головы и шеи чекпойнт-ингибиторы в монорежиме дают очень низкие ответы, поэтому нужно что-то новое.","text_en":"In head and neck cancer, checkpoint inhibitors alone have very low response rates, so something new is needed.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0010","quote":"head and neck cancer, which traditionally is a very difficult cancer to treat, and the checkpoint inhibitors by themselves have very low response rates"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0010_n2","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Комбинации с Trop2 могут приводить к появлению новых нежелательных явлений; в обсуждаемом исследовании стоматит был значимым (53).","text_en":"Trop2 combinations can bring new adverse events; in the discussed trial, stomatitis was notable (53).","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0010","quote":"as soon as you put trop2 in there a whole bunch of new adverse events come along stomachitis being the one that really upsets people 53"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0010_n3","doc_id":"doc_a29db6495933","kind":"opportunity","text_ru":"HIF-2 Alpha рассматривается как «огромный рынок» и «огромная возможность»; даже будучи вторым и сопоставимым продуктом, это может быть большой возможностью.","text_en":"HIF-2 Alpha is described as a huge market and opportunity; even being second and comparable could still be a big opportunity.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0010","quote":"it's potentially such a huge market that, if they're second and even just comparable, I think it's a huge market and a huge opportunity"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0011_n1","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"Есть «реальный разрыв» между тем, что говорят врачи, и тем, что говорят инвесторы, в оценке конкурирующих молекул.","text_en":"There is a “real disconnect” between what doctors say and what investors say when assessing competing molecules.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0011","quote":"There's a real disconnect here between what the doctors are saying and what investors are saying."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0011_n2","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"Врачи становятся более склонны рассматривать head & neck cancer как два разных заболевания: HPV-positive и HPV-negative.","text_en":"Physicians increasingly view head and neck cancer as two distinct diseases: HPV-positive and HPV-negative.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0011","quote":"physician experts these days increasingly think about it as you just parsed out, HPV positive and negative disease."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0011_n3","doc_id":"doc_a29db6495933","kind":"buyer_signal","text_ru":"Обсуждается крупный рынок frontline head & neck cancer (оценка $3–4B), что указывает на значимый коммерческий интерес к решениям в этом сегменте.","text_en":"Frontline head & neck cancer is described as a large market ($3–4B), indicating meaningful commercial interest in solutions for this segment.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0011","quote":"frontline head and neck cancer marketplace, which is a big market, probably a three or four billion market."}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0012_n1","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"Эксперты всё чаще рассматривают рак головы и шеи как два разных заболевания: HPV-позитивное и HPV-негативное, которые сильно отличаются.","text_en":"Experts increasingly view head and neck cancer as two distinct diseases: HPV-positive and HPV-negative, which differ substantially.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0012","quote":"physician experts these days increasingly think about it as you just parsed out, HPV positive and negative disease"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0012_n2","doc_id":"doc_a29db6495933","kind":"opportunity","text_ru":"Сегментация терапии/рынка по HPV-статусу (не «one-size-fits-all») может быть важной, так как активность молекул может различаться между HPV-негативными и HPV-позитивными пациентами.","text_en":"Therapy/market segmentation by HPV status may be important (not one-size-fits-all), as molecule activity may differ between HPV-negative and HPV-positive patients.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0012","quote":"probably not going to be a one-size-fits-all market"}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0012_n3","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Есть неопределённость по позиции FDA в отношении некоторых новых технологий генной терапии, что создаёт регуляторный риск/барьер.","text_en":"Uncertainty about FDA’s stance on some emerging gene therapy technologies creates regulatory risk/constraint.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0012","quote":"everyone is wondering... what the FDA's stance is going to be on some of those types of emerging technologies"}],"confidence":"medium"}
{"nugget_id":"doc_a29db6495933_chunk_0013_n1","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Есть опасения по поводу кадров и ресурсов FDA; позитивные заявления нужно подкрепить реальными действиями.","text_en":"Concerns remain about FDA staffing/resourcing; positive talk needs follow-through.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0013","quote":"talk is cheap. We still need to see the follow through, and there are still, in my opinion, some concerns about staff and resourcing"}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0013_n2","doc_id":"doc_a29db6495933","kind":"trend","text_ru":"FDA начинает серию встреч с CEO компаний индустрии в разных регионах, что может дать больше ясности по взаимодействию и обратной связи.","text_en":"FDA is starting a series of meetings with industry CEOs across regions, potentially clarifying industry-regulator interaction and feedback.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0013","quote":"The FDA also had their first— they're trying to meet with the CEOs of— companies in the industry."},{"chunk_id":"doc_a29db6495933_chunk_0013","quote":"I know they're headed to the Bay Area and San Diego. Around bio time they're going to have one here in Boston as well."}],"confidence":"high"}
{"nugget_id":"doc_a29db6495933_chunk_0013_n3","doc_id":"doc_a29db6495933","kind":"constraint","text_ru":"Над индустрией «висит» неопределённость по тарифам (232 investigation) и MFN, особенно по тому, как MFN будет реализован.","text_en":"Uncertainty hangs over the industry regarding tariffs (232 investigation) and MFN, especially how MFN will be implemented.","evidence":[{"chunk_id":"doc_a29db6495933_chunk_0013","quote":"we're also all holding our breaths... On the tariff front"},{"chunk_id":"doc_a29db6495933_chunk_0013","quote":"a 232 investigation... might take several months"},{"chunk_id":"doc_a29db6495933_chunk_0013","quote":"the MFN is the bigger one, and how it gets implemented."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0000_n1","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"В индустрии ощущение, что новостей слишком много, и их невозможно полностью охватить.","text_en":"Sense that there is too much industry news to cover comprehensively.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0000","quote":"I don't think we can cover all of it. There's too much going on."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0000_n2","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Есть «растущая школа мысли» среди инвесторов: в therapeutics стоит «покупать просадки» на макро/политических новостях, т.к. напряжение со временем спадает.","text_en":"Growing investor view that therapeutics should be bought on dips around macro/political news as things later ease.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0000","quote":"there's some. There's a growing school of thought that therapeutics has played out the same way"}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0000_n3","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Наблюдаются признаки улучшения рынка: успешные запуски без покупателя, рекапитализация малых компаний, M&A с более скромными премиями; также ощущение, что FDA «open for business».","text_en":"Signs of improving market: successful launches without a buyer, small-company recapitalizations, M&A with more modest premiums; FDA perceived as open for business.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0000","quote":"it feels like the FDA is really open for business."},{"chunk_id":"doc_1e52caf91715_chunk_0000","quote":"We've seen. companies without a buyer successfully launch drugs really, really well."},{"chunk_id":"doc_1e52caf91715_chunk_0000","quote":"We've seen M&A with premiums that are more modest"}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_nugget_0001","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"В индустрии наблюдается сильный позитивный фундаментальный новостной поток (конференции, данные, неожиданный FDA approval), который поддерживает сектор.","text_en":"The industry is seeing strong positive fundamental news flow (conferences, data, a surprise FDA approval) supporting the sector.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0001","quote":"we're just seeing good. fundamental news flow... the data sets coming from those meetings is really favorable."},{"chunk_id":"doc_1e52caf91715_chunk_0001","quote":"We had an FDA approval... that no one expected to happen this week, that it was kind of surprise approval."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_nugget_0002","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Неопределённость вокруг MFN воспринимается как риск: часть страхов уже «в цене», но влияние на отдельные акции остаётся «wild card» с диапазоном исходов.","text_en":"Uncertainty around MFN is seen as a risk: some fears are priced in, but single-stock impact remains a wild card with a range of outcomes.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0001","quote":"I feel like there's definitely fears... priced in... the single stock impact to me is still kind of the wild card here."},{"chunk_id":"doc_1e52caf91715_chunk_0001","quote":"the single stock impact, like, there's a range of outcomes."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_nugget_0003","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Ожидается улучшение настроений по M&A в биотехе.","text_en":"M&A sentiment in biotech is expected to improve.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0001","quote":"We're seeing M&A sentiments only going to get better."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0002_n1","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Опасения, что MFN/политика администрации негативно повлияет на drug pricing и создаст «slippery slope», а отрасль уже «на обороне».","text_en":"Concern that MFN/administration policy will negatively impact drug pricing, putting the industry on a slippery slope; the industry is on the defensive.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0002","quote":"There's no doubt that drug pricing will be impacted in a negative way by MFS."},{"chunk_id":"doc_1e52caf91715_chunk_0002","quote":"Our industry is on the defensive and we better be careful"}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0002_n2","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Плохой дизайн фазы 3 (в т.ч. control arm) привёл к проблемам на ODAC и неблагоприятному голосованию 5–4.","text_en":"Poor Phase 3 trial design (incl. control arm) led to trouble at ODAC and an unfavorable 5–4 panel vote.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0002","quote":"They didn't do a great phase three trial design."},{"chunk_id":"doc_1e52caf91715_chunk_0002","quote":"control arm of substance in that design so that got him in some trouble at ODAC last month."},{"chunk_id":"doc_1e52caf91715_chunk_0002","quote":"the ODAC panel vote went against them five to four."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0002_n3","doc_id":"doc_1e52caf91715","kind":"buyer_signal","text_ru":"Озвучено ценообразование UGN102: около $21k за дозу, потенциально $100k+ за курс терапии.","text_en":"UGN102 pricing mentioned: about $21k per dose, potentially $100k+ per course of therapy.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0002","quote":"They priced this drug at about $21,000 per dose."},{"chunk_id":"doc_1e52caf91715_chunk_0002","quote":"it could be as much as a hundred thousand dollars plus per. per course of therapy."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0003_n1","doc_id":"doc_1e52caf91715","kind":"opportunity","text_ru":"Sudhuri позиционируется как опция для пациентов, которые не переносят операцию (пожилые) или с высокорецидивирующим течением; упоминается большой рынок в MIBC.","text_en":"Sudhuri is positioned for patients who can’t tolerate surgery (elderly) or have highly recurrent disease; a large MIBC market is cited.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0003","quote":"will probably be best suited for those patients who either are elderly and can't really tolerate surgery, or have a highly recurrent nature to their disease."},{"chunk_id":"doc_1e52caf91715_chunk_0003","quote":"There are, I think, 59,000 total patients with low-grade intermediate risk in MIBC, so it's certainly a large market."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0003_n2","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Высказывается мнение, что FDA продолжает проявлять гибкость, несмотря на «narrowly negative adcom», и в целом это похоже на «business as usual».","text_en":"A view is expressed that the FDA remains flexible despite a narrowly negative adcom, and overall it feels like business as usual.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0003","quote":"it shows the FDA is continuing to be flexible, right? It was a narrowly negative adcom"},{"chunk_id":"doc_1e52caf91715_chunk_0003","quote":"it, in many ways, feels like, for the most part, business as usual."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0003_n3","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Обсуждается риск/дестабилизация в вакцинной сфере из‑за изменений вокруг ACIP (замена состава, наличие «vaccine skeptics»), что воспринимается как «disaster» и потенциально ведёт к кризису общественного здравоохранения.","text_en":"Risk/disruption in vaccines is discussed due to ACIP changes (committee replacement, vaccine skeptics), seen as a disaster and potentially leading to a public health crisis.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0003","quote":"RFK Jr. tearing to shreds the ACIP committee. and replacing them with a mishmash"},{"chunk_id":"doc_1e52caf91715_chunk_0003","quote":"Seems like a disaster, doesn't it?"},{"chunk_id":"doc_1e52caf91715_chunk_0003","quote":"Most likely that something is going to be a public health crisis."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0004_n1","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Отмечается продолжающийся рост инвесторского активизма против советов директоров (письма/борьба с бордами).","text_en":"A continued rise in investor activism against boards is being observed (letters/battles with boards).","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0004","quote":"we're starting to see, you know, a continued amount of investor activism against boards."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0004_n2","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"После провала лидирующего актива публичные компании могут тратить оставшийся капитал на проекты, которые не были исходной причиной привлечения денег, что вызывает напряжение с инвесторами.","text_en":"After a lead asset fails, public companies may spend remaining capital on projects that weren’t the original basis for raising money, creating investor tension.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0004","quote":"The lead asset fails and they've got you know excess of capital and they're you know going to ultimately spend that capital on projects that weren't really the premise"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0004_n3","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"При «размотке»/закрытии компании реальный объём доступных денег меньше балансового из‑за обязательств, контрактов и необходимости страховок (в т.ч. из-за риска судебных исков).","text_en":"When unwinding/shutting down a company, available cash is less than the balance sheet due to commitments, contracts, and required insurance (incl. litigation risk).","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0004","quote":"A hundred million is never a hundred million"}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0005_n1","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Быстро стал «почти обычным» сценарий: после провала главного проекта компании с большим кэшем возвращают капитал или их «подбирают» другие.","text_en":"It has quickly become common for cash-rich biotechs after a lead-program blow-up to return capital or be taken over.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0005","quote":"\"now, today, it's almost commonplace... either waves the white flag and says, 'OK, we're going to return capital' or— where someone scoops in\""}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0005_n2","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Отсутствие IPO-рынка ограничивает выходы и подталкивает к использованию «оболочек» компаний для следующих сделок.","text_en":"A lack of an IPO market constrains exits and pushes the use of company shells for subsequent deals.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0005","quote":"\"given the lack of an IPO market\""}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0005_n3","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"Многие компании торгуются значительно ниже кэша и не смогли убедить инвесторов, что их планы имеют смысл.","text_en":"Many companies trade well below cash and have failed to convince investors their plans make sense.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0005","quote":"\"too many companies trading well below their cash balance who failed at convincing the investment public\""}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_nugget_0001","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"Оценка вероятности успеха препарата субъективна и носит вероятностный характер, что усложняет принятие решений и согласование позиций между менеджментом/советом и инвесторами.","text_en":"Drug success prediction is subjective/probabilistic, complicating decision-making and alignment between management/boards and investors.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0006","quote":"so much of this is subjective, right? probabilistic analysis that we do to to predict the likelihood of a drug succeeding"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_nugget_0002","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"В психоделиках остаются ключевые барьеры: требования FDA по безопасности и дизайну исследований, а также вопрос коммерческой жизнеспособности продуктов.","text_en":"Key barriers in psychedelics include FDA requirements for safety/trial design and uncertainty about commercial viability.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0006","quote":"One being the FDA regulatory hurdle and what they're going to want for safety and trial design. Two, are these products even commercially viable?"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_nugget_0003","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Интерес к психоделикам усилился; спикер стал заметно более позитивно настроен, отмечая прогресс пространства со времени выхода Compass на биржу.","text_en":"Interest/optimism in psychedelics has increased; the speaker is more positive, citing how far the space has come since Compass went public.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0006","quote":"this is a space I've become so much more excited about... because the space has come a tremendously long way"}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0007_n1","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"Spravato (эскетамин) коммерчески успешен, но неудобен в применении и с невыдающейся эффективностью.","text_en":"Spravato (esketamine) sells well but is inconvenient to administer and has unimpressive efficacy.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0007","quote":"It's not an easy drug to use. It's two hours inpatient. It's given every every other week. The efficacy is not amazing."},{"chunk_id":"doc_1e52caf91715_chunk_0007","quote":"it only worked in two out of four of its clinical trials"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0007_n2","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Психоделики воспринимаются как валидированный и более «регуляторно зрелый» рынок: после Spravato и регуляторных обсуждений ожидается формирование коммерческого класса препаратов.","text_en":"Psychedelics are seen as a validated, more regulatorily mature market, trending toward a real commercial drug class.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0007","quote":"it feels like the market has been validated. It feels like the FDA has become a lot more on board with this space"}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0007_n3","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"В плацебо-контролируемых исследованиях психоделиков есть проблема «functional unblinding», а также высокая вариабельность плацебо-ответа, что усложняет интерпретацию эффекта.","text_en":"Psychedelic placebo-controlled trials face functional unblinding and highly variable placebo response, complicating effect interpretation.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0007","quote":"in any placebo-controlled study of a psychedelic, you have some level of functional unblinding."},{"chunk_id":"doc_1e52caf91715_chunk_0007","quote":"the magnitude of placebo response is just like enormously variable"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0008_n1","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Есть практический барьер: непонятно, где (в каких помещениях/клиниках) физически организовать доставку/проведение такой терапии пациентам.","text_en":"Practical delivery constraint: unclear where (what rooms/clinics) to physically deliver this care to patients.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0008","quote":"\"who's going to figure out how to deliver this, right?\""},{"chunk_id":"doc_1e52caf91715_chunk_0008","quote":"\"Where on earth are you going to find— a room or suite of rooms— to deliver this care to patients.\""}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0008_n2","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Наблюдается рост/появление специализированных клиник (интервенционная психиатрия/behavioral health), что указывает на «самостроящуюся» инфраструктуру вокруг терапии.","text_en":"Emerging build-out of specialized interventional psychiatry/behavioral health clinics, suggesting infrastructure is “building itself.”","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0008","quote":"\"it's building itself,' it's building itself. And lo and behold, it's absolutely building itself.\""},{"chunk_id":"doc_1e52caf91715_chunk_0008","quote":"\"what used to be a convenience store, and now it's an interventional psychiatry behavioral health clinic.\""}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0008_n3","doc_id":"doc_1e52caf91715","kind":"buyer_signal","text_ru":"Есть сигнал коммерческой жизнеспособности: центры/больницы смогли сделать Spravato «драйвером выручки», а терапия при сложном администрировании всё равно быстро растёт.","text_en":"Commercial signal: centers/hospitals turned Spravato into a revenue driver, and it grew rapidly despite administration burden.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0008","quote":"\"they figured out, you know, how to turn bravado, as I understand it, like into a into a revenue driver.\""},{"chunk_id":"doc_1e52caf91715_chunk_0008","quote":"\"it's grown like a weed.\""}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0009_n1","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"FSHD — прогрессирующее заболевание без одобренных терапий, что создаёт высокий unmet medical need.","text_en":"FSHD is progressive with no approved therapies, indicating high unmet medical need.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0009","quote":"This is obviously a disease that has no approved therapies."},{"chunk_id":"doc_1e52caf91715_chunk_0009","quote":"It is quite progressive, so lots of unmet medical need here."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0009_n2","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Для ускоренного одобрения по FSHD FDA «открыта», но компании ещё нужно доработать/собрать поддерживающие датасеты для подачи по Dux4 biomarker endpoint.","text_en":"FDA is open to accelerated approval in FSHD, but supportive datasets for a Dux4 biomarker endpoint are still needed.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0009","quote":"the fda is open to a potential accelerated approval pathway, though maybe there's some still some work that needs to be done there."},{"chunk_id":"doc_1e52caf91715_chunk_0009","quote":"still kind of working out some of the supportive data sets that it needs to file on a Dux4 biomarker endpoint."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0009_n3","doc_id":"doc_1e52caf91715","kind":"opportunity","text_ru":"В pulmonary hypertension есть продуктовая возможность в более удобном режиме дозирования: once-a-day ингаляционный простацеклиновый аналог vs Tyveso 3 раза в день.","text_en":"In pulmonary hypertension, there’s an opportunity for more convenient dosing: once-daily inhaled prostacyclin analog vs Tyveso three times daily.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0009","quote":"Delivered as a once-a-day administration, in contrast to United Therapeutics' blockbuster Tyveso, which is three times a day."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0010_n1","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"Высокая частота и длительность ингаляционных сессий (до 10 минут каждая) — нагрузка на пациента; снижение кратности может давать сильное конкурентное преимущество.","text_en":"High frequency and duration of inhalation sessions (up to 10 minutes each) burden patients; reducing frequency can be a strong competitive advantage.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0010","quote":"for these inhaled therapies, that can take up to 10 minutes for each session to to inhale"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0010_n2","doc_id":"doc_1e52caf91715","kind":"opportunity","text_ru":"Возможность для ингаляционных терапий: уменьшить число ежедневных ингаляций, чтобы усилить захват доли рынка.","text_en":"Opportunity in inhaled therapies: reduce daily inhalation frequency to help capture market share.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0010","quote":"the ability to reduce the number of times that a patient has to do that. Can be very powerful in terms of claiming market share."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0010_n3","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Оценка биотех-акций часто опирается не на DCF, а на более «ручные» подходы (peak sales, мультипликаторы, comps), и вероятность M&A влияет на дискуссию о valuation.","text_en":"Biotech valuation often relies less on DCF and more on heuristic methods (peak sales, multiples, comps), with M&A probability affecting valuation discussions.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0010","quote":"stocks in this space are not really valued on DCF... peak sales, multiple comps, things like that."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0011_n1","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"DCF-оценка биотех-компаний воспринимается как слишком субъективная/ненадёжная: разные подходы, высокая чувствительность к ставке дисконтирования и допущениям.","text_en":"DCF valuation in biotech is seen as overly subjective/unreliable due to differing methods and high sensitivity to discount rate and assumptions.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0011","quote":"everybody does a DCF in a different way... there's so much subjectivity that I think DCF is so challenging."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0011_n2","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Для development-stage компаний звучит тезис, что «valuation is a fool's game», и фокус смещают с финансовых моделей на due diligence по вероятности, что препарат сработает.","text_en":"For development-stage companies, valuation is framed as futile, shifting focus from financial models to diligence on whether the drug works.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0011","quote":"for these development stage companies at least, I think valuation is a fool's game."},{"chunk_id":"doc_1e52caf91715_chunk_0011","quote":"We should spend a lot less time as a community working out models that are fictitious. A lot more time doing due diligence on what's going to work."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0011_n3","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"В данных Ascendus по комбинации Transcon CNP с их growth hormone отсутствовал контроль, поэтому приходилось опираться на исторические контроли.","text_en":"Ascendus combo data lacked a control arm, requiring reliance on historical controls.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0011","quote":"There was no control, so we had to look at historical controls"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0012_n1","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Для одобрения терапии FDA может потребовать 2-летние данные (как ранее по Voxzogo), что создаёт регуляторную неопределённость по длительности исследования.","text_en":"FDA may require 2-year data (as with Voxzogo), creating regulatory uncertainty about required study duration.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0012","quote":"FDA said, 'We really want to see your two-year data to get you approved.'"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0012_n2","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"Ежедневные инъекции для детей воспринимаются как значимая проблема для пациентов и родителей.","text_en":"Daily injections for kids are seen as a significant burden for patients and parents.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0012","quote":"they lament that it's a daily injection, and it's a daily injection for kids."},{"chunk_id":"doc_1e52caf91715_chunk_0012","quote":"Who don't want any injections, nor do parents ever want to have to inject their kid with a needle."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0012_n3","doc_id":"doc_1e52caf91715","kind":"buyer_signal","text_ru":"По результатам опросов специалистов отмечается низкий энтузиазм и «недовольство/безразличие» к Voxzogo из-за ежедневных инъекций и воспринимаемой недостаточной эффективности.","text_en":"Specialist checks suggest limited enthusiasm for Voxzogo due to daily injections and perceived underwhelming efficacy.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0012","quote":"we hear—um, you know— not not that much enthusiasm, a little nonplussed for Voxelgo"},{"chunk_id":"doc_1e52caf91715_chunk_0012","quote":"they're a little underwhelmed with the efficacy that they're seeing with Vox Sogo."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0013_n1","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"Ежедневные инъекции детям — нежелательны для детей и родителей; инъекционный формат воспринимается как существенный минус.","text_en":"Daily injections for kids are undesirable for both children and parents; injection delivery is seen as a major drawback.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0013","quote":"Who don't want any injections, nor do parents ever want to have to inject their kid with a needle."},{"chunk_id":"doc_1e52caf91715_chunk_0013","quote":"and it's a daily injection for kids."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0013_n2","doc_id":"doc_1e52caf91715","kind":"buyer_signal","text_ru":"По результатам опросов/«checks» отмечается высокий энтузиазм врачей/рынка к Fagratinib/Bridges при условии безопасности и конкурентной эффективности, особенно как к пероральной опции для детей.","text_en":"Channel checks indicate high enthusiasm for Bridges and Fagratinib if safety and efficacy are competitive, especially as an oral option for kids.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0013","quote":"we certainly picked up— a high degree of enthusiasm for Bridges and Fagratinib, assuming that it stays safe and competitive on its efficacy profile."},{"chunk_id":"doc_1e52caf91715_chunk_0013","quote":"As an oral option for kids."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0013_n3","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Пероральные варианты терапии воспринимаются как предпочтительные и могут расширять рынок, приводя новых пациентов на терапию при появлении новых опций.","text_en":"Oral therapy options are viewed as preferable and new options may expand the market by bringing more patients onto therapy.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0013","quote":"If you could have a pill instead, in many cases, that actually, from a patient's perspective, would be preferable."},{"chunk_id":"doc_1e52caf91715_chunk_0013","quote":"How introduction of new options into a field can potentially expand the field by bringing more patients onto therapy."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0014_n1","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"IP/патентные споры вокруг блокирования конкурента трудно оценивать и «блокировать» в США очень сложно.","text_en":"IP/patent blocking disputes are hard to handicap, and blocking in the US is very difficult.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"I feel like IP stuff is so hard."},{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"it's always so hard to handicap."},{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"blocking is really, really hard. In the US"}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0014_n2","doc_id":"doc_1e52caf91715","kind":"trend","text_ru":"Priority review для Ascendus интерпретируется как сигнал, что FDA может не требовать двухлетние данные и не рассматривает продукт как «просто удобство».","text_en":"Ascendus’ priority review is interpreted as a signal FDA may not require two-year data and may not view it as merely a convenience product.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"I was really surprised that Ascendus got priority review"},{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"we've been talking about whether Ascendus is going to need the two-year data for approval, and instead they get priority review."},{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"FDA is comfortable with this mechanism and that they're not going to require two-year data."}],"confidence":"medium"}
{"nugget_id":"doc_1e52caf91715_chunk_0014_n3","doc_id":"doc_1e52caf91715","kind":"constraint","text_ru":"Для cell therapy компаний есть «порочный круг»: необходимость тратиться на производство и проблемы с капиталом/разводнением из-за привлечения средств по низкой оценке.","text_en":"Cell therapy companies face a vicious cycle: manufacturing spend needs plus capital constraints and dilution from raising at low valuations.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"it's because of the capital issue"},{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"take in $100 million at a fairly low valuation, and that's going to... be very dilutive"},{"chunk_id":"doc_1e52caf91715_chunk_0014","quote":"a vicious cycle right now for all these cell therapy companies. Knowing that they're going to need to spend in manufacturing."}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0015_n1","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"У компаний в cell therapy «порочный круг»: нужно тратить на производство и дорогие исследования, чтобы дойти до рынка и начать зарабатывать.","text_en":"Cell therapy companies face a vicious cycle: they must spend on manufacturing and expensive studies to reach market and start generating revenue.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0015","quote":"\"it's it's a little bit like a vicious cycle right now for all these cell therapy companies. Knowing that they're going to need to spend in manufacturing.\""},{"chunk_id":"doc_1e52caf91715_chunk_0015","quote":"\"They're going to need to spend in expensive studies\""}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0015_n2","doc_id":"doc_1e52caf91715","kind":"pain","text_ru":"В миозите есть выраженная неудовлетворённая медицинская потребность.","text_en":"There is significant unmet medical need in myositis.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0015","quote":"\"can certainly attest to the unmet need in myositis\""}],"confidence":"high"}
{"nugget_id":"doc_1e52caf91715_chunk_0015_n3","doc_id":"doc_1e52caf91715","kind":"opportunity","text_ru":"Есть возможность для «sleeper programs»: ранний proof-of-concept может быть сильным, но инвесторы фокусируются на более поздних программах и упускают шанс.","text_en":"Opportunity for sleeper programs: early proof-of-concept may be exciting while investors focus on later-stage programs and miss a big opportunity.","evidence":[{"chunk_id":"doc_1e52caf91715_chunk_0015","quote":"\"trying to find those potential sleeper programs where you know maybe there is some early exciting proof of concept\""},{"chunk_id":"doc_1e52caf91715_chunk_0015","quote":"\"investors are just preoccupied with other later stage programs and missing a big opportunity.\""}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0000_n1","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Рыночный сентимент в биотехе улучшился: сейчас он «mixed to positive», при этом сильно зависит от типа фонда/инвестора.","text_en":"Biotech market sentiment has improved to “mixed to positive” and varies significantly by fund/investor type.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0000","quote":"I would say today's sentiment is mixed to positive. And specifically what you'll see is it depends very much on the fund."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0000_n2","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"IPO и follow-on размещения стали хорошо работать; средний IPO этого года вырос примерно на 50–60% после «Liberation Day».","text_en":"IPOs and follow-ons are performing well; the average IPO from earlier this year is up ~50–60% since “Liberation Day.”","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0000","quote":"both IPOs and follow-ons are performing well... since liberation day, the average IPO stock... is up like 50– 60"}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0000_n3","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Частным VC сейчас сложно привлекать капитал: «really hard to raise money as a private VC right now».","text_en":"Private VCs are struggling to raise capital right now.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0000","quote":"it's really hard to raise money as a private VC right now."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0001_n1","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"На private venture стороне боль из‑за сложности дойти до liquidity event/exit в текущей среде.","text_en":"Pain on the private venture side due to difficulty reaching liquidity events/exits in the current environment.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0001","quote":"\"there's so much that is hard to get to a liquidity event or an exit—uh— in this current environment.\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0001_n2","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"В Китае наблюдается рост интереса/сделок: звучат слухи о $500M+ сделках, и ожидается больше таких сделок в ближайшие недели и месяцы.","text_en":"In China, excitement and deal activity: rumors of $500M+ deals and expectation of more in coming weeks/months.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0001","quote":"\"we just keep hearing more and more rumors of, like, these 500 million dollar plus deals coming for China.\""},{"chunk_id":"doc_2c1539ac5770_chunk_0001","quote":"\"we're going to see more of those coming in the weeks and months ahead.\""}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0001_n3","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Китайский biotech воспринимается как большая проблема для small/mid US biotechs: copycat-активы быстро продвигаются, а big pharma может купить их за «фракцию» цены США; инвесторы дисконтируют такие области.","text_en":"Chinese biotech seen as a major problem for small/mid US biotechs: fast copycat advancement, big pharma buys at a fraction of US price; investors apply big discounts where China threat is real.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0001","quote":"\"Chinese biotech is a huge problem for small and mid-sized biotechs in the U. S.\""},{"chunk_id":"doc_2c1539ac5770_chunk_0001","quote":"\"in China, they can quickly move a copycat asset forward\""},{"chunk_id":"doc_2c1539ac5770_chunk_0001","quote":"\"investors are applying a huge discount in areas where the China threat is real.\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0002_n1","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Политические приоритеты США (America First/негатив к Китаю) могут привести к стимулам за сделки с US biotech и штрафам за продвижение китайских активов, создавая риск для China-deals.","text_en":"US policy priorities (America First/negative sentiment toward China) may create incentives for US-biotech deals and penalties for advancing China assets, increasing risk for China deals.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0002","quote":"\"incentives for doing deals with US biotechs and also penalties for advancing China assets.\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0002_n2","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"В секторе ощущается «capital drought» (частный и публичный), а также неопределённость и «looming threats» (MFN pricing, tariffs, China) и потребность в ясности/последовательности от FDA.","text_en":"The sector faces a capital drought (private and public) plus uncertainty and looming threats (MFN pricing, tariffs, China) and a need for FDA clarity/consistency.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0002","quote":"\"The capital drought, which was mentioned here, both private and public, being a major overhang\""},{"chunk_id":"doc_2c1539ac5770_chunk_0002","quote":"\"threats like most favored nation or MFN pricing, tariffs, China, and a need for clarity and consistency from FDA.\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0002_n3","doc_id":"doc_2c1539ac5770","kind":"opportunity","text_ru":"Администрация заявляет приоритеты ускорения вывода на рынок и снятия «red tape»; также упоминается новый FDA «national priority voucher», но критерии/процесс пока неясны.","text_en":"The administration prioritizes faster time-to-market and removing red tape; a new FDA “national priority voucher” is mentioned, but criteria/process are unclear.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0002","quote":"\"Their stated priorities: increased speed to market, removing red tape.\""},{"chunk_id":"doc_2c1539ac5770_chunk_0002","quote":"\"FDA Commissioner McCary announced this new national priority voucher\""},{"chunk_id":"doc_2c1539ac5770_chunk_0002","quote":"\"we need to better understand the criteria, considerations, and process for granting and using vouchers.\""}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0003_n1","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Спонсоры сталкиваются с недостатком ясности и длительным бюрократическим процессом взаимодействия с FDA, из‑за чего компании «сжигают» деньги, ожидая ответов.","text_en":"Sponsors face lack of clarity and a long, cumbersome FDA process, causing companies to burn cash while waiting for answers.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0003","quote":"\"lack of clarity sponsors sometimes experience in the long, cumbersome, and bureaucratic process to get answers while companies burn in cash\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0003_n2","doc_id":"doc_2c1539ac5770","kind":"opportunity","text_ru":"Возможность внедрить механизм быстрого запроса/эскалации (\"one-card or two-card system\") для получения немедленного ответа или разъяснения от FDA во время взаимодействия.","text_en":"Opportunity to implement a fast escalation mechanism (\"one-card or two-card system\") to get immediate FDA responses/clarifications during interactions.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0003","quote":"\"They're calling it a one-card or two-card system where each sponsor has a card they can use to request an immediate response or clarification\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0003_n3","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Ресурсные ограничения в FDA могут приводить к срыву PDUFA goal date (пример: FDA уведомила, что не уложится в срок).","text_en":"FDA resource constraints can lead to missing the PDUFA goal date (example: FDA notified it would not meet the deadline).","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0003","quote":"\"they're not going to meet their PDUFA goal date because of resource constraints\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0004_n1","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Ресурсные ограничения могут приводить к срыву PDUFA goal date.","text_en":"Resource constraints can cause missing the PDUFA goal date.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0004","quote":"they're not going to meet their PDUFA goal date because of resource constraints."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0004_n2","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"У инвесторов есть беспокойство о возможном влиянии политики на решения FDA и субъективности предстоящих регуляторных обзоров.","text_en":"Investors are uneasy about potential politics at the FDA and the subjectivity of upcoming regulatory reviews.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0004","quote":"it does raise the concern around politics at the FDA, right?"},{"chunk_id":"doc_2c1539ac5770_chunk_0004","quote":"there still is a little bit of an unease as we head into maybe, you know, a year and a half of a bunch of important regulatory reviews"}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0004_n3","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Ограниченная/неофициальная коммуникация (анонимные источники, «inferential data») затрудняет понимание регуляторной ситуации без формальных сообщений компании или FDA.","text_en":"Anonymous sources and inferential data make it hard to assess regulatory situations without formal company/FDA communication.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0004","quote":"I'm always a little skeptical with anonymous sources and kind of inferential data without the company and what they can formally communicate or what the FDA is formally communicating."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0005_n1","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Недоверие к анонимным источникам и «инферентным» данным без официальной коммуникации компании или FDA.","text_en":"Skepticism toward anonymous sources and inferential data without formal communication from the company or FDA.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0005","quote":"I'm always a little skeptical with anonymous sources and kind of inferential data without the company... or what the FDA is formally communicating."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0005_n2","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Внутри FDA описывается длительный конфликт между дивизионами и «высшей иерархией», где политика иерархии не всегда совпадает с позицией дивизионов.","text_en":"A longstanding internal conflict between FDA divisions and higher hierarchy, where hierarchy policy doesn’t always align with divisions.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0005","quote":"there's been a longstanding, decades-long battle between the divisions and the higher hierarchy."},{"chunk_id":"doc_2c1539ac5770_chunk_0005","quote":"The hierarchy policy doesn't always align with the divisions or specific divisions"}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0005_n3","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Ожидается период неопределённости в работе FDA при новой администрации, с возможным ростом прямого вмешательства, хотя оно «не common».","text_en":"A period of uncertainty in FDA operations under a new administration, with potentially more direct intervention even though it’s not common.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0005","quote":"direct intervention is not common. But I think, in this period and stage, that the new administration... are trying to work out."},{"chunk_id":"doc_2c1539ac5770_chunk_0005","quote":"I would expect a little bit of this uncertainty. How's it gonna work out, division by division?"}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0006_n1","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Внутренние дебаты в FDA при принятии решений по IND/NDA и возможному CRL «живы и здоровы»; решения формируются на основе противоречивых внутренних мнений.","text_en":"Internal FDA debates influence IND/NDA decisions and potential CRLs; decisions reflect countervailing internal views.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0006","quote":"\"internal debates. At the FDA are alive and well.\""},{"chunk_id":"doc_2c1539ac5770_chunk_0006","quote":"\"he's probably hearing countervailing views. That he's gotta consider.\""}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0006_n2","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Описывается конкурентная динамика на рынке препаратов для ожирения/метаболических заболеваний: Zepbound/Lilly опережают Wegovy/Novo по росту рецептов в приведённом примере.","text_en":"Competitive dynamics in obesity/metabolic drugs: Zepbound/Lilly outpacing Wegovy/Novo in prescription growth in the cited example.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0006","quote":"\"Novo has gone from 230,000 prescriptions for Wegovy... to 246,000\""},{"chunk_id":"doc_2c1539ac5770_chunk_0006","quote":"\"Z-bounds have gone from 160,000 to 366,000.\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0006_n3","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"По данным обсуждения, у Novo (CagriSema) ожидания по перераспределению потери веса в сторону жира (vs мышца) не подтвердились; отмечено, что профиль оказался хуже, чем у Zepbound (без head-to-head).","text_en":"Novo’s CagriSema did not meet expectations for fat-vs-muscle weight loss; described as worse than Zepbound (not head-to-head).","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0006","quote":"\"the weight loss was not as favorable in terms of how much fat you're losing versus muscle.\""},{"chunk_id":"doc_2c1539ac5770_chunk_0006","quote":"\"it turned out to be worse than what we've seen for Z-Bound, but this wasn't a head-to-head.\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0007_n1","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Остаются нерешённые вопросы по дозированию (в т.ч. при переходе в Phase 3) для комбинации GLP-1+амилин в одной молекуле (amicretin).","text_en":"There are still unanswered dosing questions (even as it moves into Phase 3) for a GLP-1+amylin single-molecule combo (amicretin).","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0007","quote":"\"that's moving directly into phase three, but we have questions on the dosing that still continue to be essentially unanswered\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0007_n2","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Высокие показатели желудочно-кишечных побочных эффектов и вопросы по безопасности/ЧСС у некоторых кандидатов затмевают данные по снижению веса.","text_en":"High GI side-effect rates and safety/heart-rate questions for some candidates are overshadowing weight-loss data.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0007","quote":"\"The rates of gastrointestinal side effects from migrating were high. I mean, high.\""},{"chunk_id":"doc_2c1539ac5770_chunk_0007","quote":"\"rate increases that were seen beyond what's been seen for Zipband and Wegovy\""},{"chunk_id":"doc_2c1539ac5770_chunk_0007","quote":"\"The tolerability concerns continue to eclipse. The weight loss data.\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0007_n3","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Регуляторная неопределённость: FDA в руководстве по ожирению не считает потерю мышечной массы на GLP-1 доказанной проблемой/неудовлетворённой потребностью на данный момент.","text_en":"Regulatory uncertainty: FDA obesity guidance says there’s currently nothing indicating muscle loss on GLP-1s is an issue/unmet need.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0007","quote":"\"the FDA in their guidance was really saying that at this point in time, there isn't anything that indicates that it's an issue.\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0008_n1","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"FDA в руководстве по ожирению не признаёт проблему потери мышц как unmet need: «нет ничего, что указывает, что это проблема» на текущий момент.","text_en":"FDA obesity guidance does not currently indicate muscle loss is an issue/unmet need.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0008","quote":"the FDA in their guidance was really saying that at this point in time, there isn't anything that indicates that it's an issue."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0008_n2","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Есть опасения по потере мышечной массы у некоторых пациентов на GLP-1 (например, у «frail» популяций).","text_en":"Concerns about muscle loss in certain patient populations taking GLP-1s (e.g., frail patients).","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0008","quote":"particularly in certain patient populations... who are taking GLP-1s... if it's a frail patient population... there may be greater concerns about muscle loss."}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0008_n3","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Проблема переносимости: в данных отмечены «pretty high» мышечные спазмы и акне; остаётся вопрос, каков будет профиль переносимости при другом дозировании/пути введения.","text_en":"Tolerability issues: high rates of muscle spasms and acne; tolerability with different dosing/route remains a key question.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0008","quote":"There were some side effects that looked not particularly pleasant. So there was a pretty high rate of muscle spasms. There was also pretty high acne."},{"chunk_id":"doc_2c1539ac5770_chunk_0008","quote":"The big questions remain: what will the tolerability profile look like with this different dosing?"}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0009_n1","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Побочные эффекты (например, акне, мышечные спазмы) могут стать проблемой для коммерческого использования препаратов для снижения веса, если их не удастся контролировать.","text_en":"Side effects (e.g., acne, muscle spasms) may hinder commercial adoption of weight-loss drugs unless managed.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0009","quote":"I don't know if it's going to be as easy as that when it comes to actual commercial. Use unless they manage it somehow."}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0009_n2","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"В пространстве препаратов для ожирения наблюдаются высокая активность, продолжающиеся инвестиции и попытки комбинированных подходов; рынок воспринимается как очень большой.","text_en":"Obesity drug space shows high activity, continued investment, and attempts at combination approaches; the market is seen as very large.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0009","quote":"why there's so much activity in this space and continued investment and interest"}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0009_n3","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Риск нелегитимных/поддельных версий Wegovy в DTC-каналах: Novo прекратила доступность Wegovy на HIMSS, заявив о продаже «knockoff» версий, угрожающих безопасности пациентов.","text_en":"Risk of illegitimate/knockoff Wegovy in DTC channels: Novo stopped making Wegovy available on HIMSS, citing knockoffs that risk patient safety.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0009","quote":"HIMSS selling illegitimate knockoff versions of Wegovy that put patient safety at risk."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0010_n1","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Direct-to-consumer (DTC) движение в препаратах от ожирения заметно выросло; продажи через прямой сайт производителя могут быть существенно выше ожиданий.","text_en":"Direct-to-consumer (DTC) obesity-drug movement has grown; sales via a manufacturer’s direct website can be much larger than expected.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0010","quote":"this direct-to-consumer movement with obesity drugs has just gotten very big"},{"chunk_id":"doc_2c1539ac5770_chunk_0010","quote":"sales off of the Lilly direct website are much larger than one might, at least much larger than I would have expected."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0010_n2","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Продажа неурегулированных compounded GLP-1 и обход IP через регуляторные лазейки воспринимаются как проблема/барьер для инновационных компаний.","text_en":"Unregulated compounded GLP-1s and perceived IP circumvention via regulatory loopholes are seen as a barrier/problem for innovators.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0010","quote":"they're pushing. these unregulated compounded drugs and kind of circumventing IP protection through regulatory loopholes."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0010_n3","doc_id":"doc_2c1539ac5770","kind":"opportunity","text_ru":"Есть рыночная возможность для профилактики гриппа/«универсальной» вакцины: отмечается, что «universal flu vaccine still has a play here in the market».","text_en":"There is market opportunity for flu prevention / a “universal flu vaccine”: it’s stated that it still has a place in the market.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0010","quote":"The universal flu vaccine still has a play here in the market."}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0011_n1","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Инвесторы из‑за регуляторной среды проявляют скепсис и меньше инвестируют в вакцинное направление.","text_en":"Due to the regulatory environment, many investors are skeptical and are doing less in the vaccine space.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0011","quote":"\"there is a lot of skepticism and many investors have, you know, really, as a result of the regulatory environment, are not doing a whole lot in the vaccine space\""}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0011_n2","doc_id":"doc_2c1539ac5770","kind":"opportunity","text_ru":"Возможность для противогриппозного решения с «универсальной защитой» (в отличие от вакцин, нацеленных на варианты).","text_en":"Opportunity for a flu solution offering “universal protection” versus variant-targeted vaccines.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0011","quote":"\"the opportunity for universal protection, right, versus the kind of flu variants\""}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0011_n3","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"В психоделиках (psilocybin COMP360) обсуждаемая проблема: эффект в фазе 3 оказался меньше, чем ожидали, и рынок отреагировал падением.","text_en":"In psychedelics (COMP360 psilocybin), a key issue is phase 3 effect size being smaller than expected, with a negative market reaction.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0011","quote":"\"the effect size was just not as big as people expected\""},{"chunk_id":"doc_2c1539ac5770_chunk_0011","quote":"\"the stock traded off a lot. I think something like 40%\""}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"Сложно сравнивать эффект-сайзы между психоделическими исследованиями из‑за различий в таймпойнтах и популяциях.","text_en":"It’s hard to compare effect sizes across psychedelic studies due to differences in timepoints and populations.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0012","quote":"it's really hard to compare across these studies because of the time point differences."},{"chunk_id":"doc_2c1539ac5770_chunk_0012","quote":"MyMed different population, it's not driven resistant depression"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Инвесторы, по мнению спикера, переоценивают эффективность/эффект-сайзы в психиатрии, и эти субъективные шкалы не определяют назначения.","text_en":"Investors (per speaker) overrate efficacy/effect sizes in psychiatry, and subjective scales don’t drive prescribing decisions.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0012","quote":"investors grossly overrate efficacy and effect sizes on these scales that are really subjective"}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Есть восприятие, что психоделические компании — менее вероятные M&A-цели из-за уникальности, что может ограничивать интерес консервативной фармы.","text_en":"There’s a perception psychedelic companies are lower-probability M&A targets due to uniqueness, potentially limiting conservative pharma interest.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0012","quote":"there's a perception that these psychedelics companies are lower probability m a targets because they're just so unique"}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0013_n1","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Появились данные, что у Nektar (ResPeg) значимый эффект в Phase 2B при атопическом дерматите, что может создать конкуренцию Dupixent и резко двинуло акцию.","text_en":"Nektar’s ResPeg showed a strong Phase 2B effect in atopic dermatitis, potentially competing with Dupixent and driving a sharp stock move.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0013","quote":"ResPeg, had a huge Phase 2B win this week in atopic dermatitis."},{"chunk_id":"doc_2c1539ac5770_chunk_0013","quote":"think that Dupixent may have a new competitor."},{"chunk_id":"doc_2c1539ac5770_chunk_0013","quote":"Nectar stock was up like 200%."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0013_n2","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"После второй смерти у Sarepta FDA собирается внимательно рассматривать ситуацию; остановлены поставки в неамбулаторную популяцию из‑за того, что обе смерти были в этой группе.","text_en":"After a second death at Sarepta, FDA scrutiny increased and shipments to the non-ambulatory population were stopped because both deaths occurred there.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0013","quote":"a second death and They really saw their stock drop precipitously."},{"chunk_id":"doc_2c1539ac5770_chunk_0013","quote":"The FDA has said they're going to look closely at this."},{"chunk_id":"doc_2c1539ac5770_chunk_0013","quote":"There's been a stopping of shipments to the non-ambulatory population because both deaths occurred in the non-ambulatory."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0013_n3","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"Есть риск, что кейс Sarepta повлияет на обсуждаемую «регуляторную гибкость» для cell & gene therapies/ультра-орфанных заболеваний.","text_en":"There is concern the Sarepta case could affect the discussed regulatory flexibility for cell & gene therapies/ultra-orphan diseases.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0013","quote":"wonder whether this will at all impact the newfound regulatory flexibility that they are talking about with regards to cell and gene therapies."}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0014_n1","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Растёт важность multiomics и спрос на такие приложения; это подтверждается сделками и интересом крупных игроков.","text_en":"Multiomics is becoming increasingly important and demand is rising, evidenced by deals and large players’ interest.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0014","quote":"this is just testament to the increasing importance of multiomics, if you like. So the demand for that application is on the rise."},{"chunk_id":"doc_2c1539ac5770_chunk_0014","quote":"And there's a handful of smaller deals that have happened here."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0014_n2","doc_id":"doc_2c1539ac5770","kind":"constraint","text_ru":"В редких заболеваниях/ДМД остаются спорные датасеты и неоднозначная интерпретация FDA, что создаёт неопределённость вокруг решений (в т.ч. отмена adcom).","text_en":"In rare disease/DMD, controversial datasets and FDA interpretation create uncertainty around decisions (including adcom cancellation).","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0014","quote":"controversial data sets if you will uh arguments on both sides"},{"chunk_id":"doc_2c1539ac5770_chunk_0014","quote":"there's mixed feelings on whether this is a positive move. versus a negative."},{"chunk_id":"doc_2c1539ac5770_chunk_0014","quote":"you can kind of draw a line through the DMD uh experiences of you know controversial data sets uh and how the FD is interpreting it."}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0014_n3","doc_id":"doc_2c1539ac5770","kind":"buyer_signal","text_ru":"Инвесторы рассматривают решение по Capricor как индикатор (барометр) регуляторной гибкости FDA.","text_en":"Investors are watching the Capricor decision as a barometer of FDA regulatory flexibility.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0014","quote":"this is one of the decisions that investors are looking to as a barometer of FDA flexibility, right?"}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0015_n1","doc_id":"doc_2c1539ac5770","kind":"pain","text_ru":"У многих компаний наблюдается нехватка капитала, что воспринимается как наиболее тревожный фактор.","text_en":"Many companies face a lack of capital, seen as the most concerning issue.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0015","quote":"the thing that seemed to be the most concerning is the fact the lack of capital for a lot of companies."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0015_n2","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Bayer закрыла R&D-лабораторию BlueRock и сократила около 50 человек, при этом Phase 3 по Паркинсону не остановили.","text_en":"Bayer shut down BlueRock’s R&D lab and let go ~50 people, while not stopping the Phase 3 Parkinson’s trial.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0015","quote":"Bayer shut down the Blue Rock R&D lab last week with the effect of essentially letting go about 50 people."},{"chunk_id":"doc_2c1539ac5770_chunk_0015","quote":"they didn't stop the phase three trial of their Parkinson's drug."}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0015_n3","doc_id":"doc_2c1539ac5770","kind":"buyer_signal","text_ru":"Royalty Pharma объявила о $2 млрд инвестиции/сделке с Revolution Medicines (структура с роялти и долгом) для их RAS inhibitor pipeline.","text_en":"Royalty Pharma announced a $2B investment/deal with Revolution Medicines (royalty + debt structure) for its RAS inhibitor pipeline.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0015","quote":"Royalty Pharma's meeting to announce this $2 billion deal, creative structure, part royalty, part debt deal for their RAS inhibitor pipeline."},{"chunk_id":"doc_2c1539ac5770_chunk_0015","quote":"Royalty Pharma announced a um A $2 billion investment in Revolution Medicines"}],"confidence":"high"}
{"nugget_id":"doc_2c1539ac5770_chunk_0016_n1","doc_id":"doc_2c1539ac5770","kind":"buyer_signal","text_ru":"Кто-то сообщает, что «ждут подходящую возможность», чтобы вернуться (войти обратно).","text_en":"Someone says they are waiting for the right opportunity to get back in.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0016","quote":"they said they're waiting for the right opportunity to get back in."}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0016_n2","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Утверждается, что рост капитализации big pharma был обусловлен Lilly.","text_en":"It is stated that big pharma market cap growth has been driven by Lilly.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0016","quote":"all of the market cap growth across big pharma has been driven by Lily."}],"confidence":"medium"}
{"nugget_id":"doc_2c1539ac5770_chunk_0016_n3","doc_id":"doc_2c1539ac5770","kind":"trend","text_ru":"Отмечается сравнение: капитализация NVIDIA больше, чем у топ-10 фармкомпаний вместе взятых.","text_en":"A comparison is noted: NVIDIA’s market cap is greater than the top 10 pharma companies combined.","evidence":[{"chunk_id":"doc_2c1539ac5770_chunk_0016","quote":"the market cap of NVIDIA is it's actually greater than the top 10 pharma companies combined"}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"В 2025 году темпы и объём biotech M&A выше, чем в 2024: число сделок почти сравнялось, а суммарная стоимость уже превысила прошлогоднюю.","text_en":"In 2025, biotech M&A pace and total value are higher than 2024: deal count is close and total value already exceeds last year.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0000","quote":"there are now... as many takeouts thus far in 2025, 18 in total... in all of 2024, 20 total, and the value... in 2025 is already eclipsing"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Долгое время не хватало сделок, где покупают «науку» (ранние активы), но появляются признаки возвращения таких сделок (пример: Capstan).","text_en":"For a long time, deals where buyers acquire early-stage “science” were missing, but there are signs they’re returning (e.g., Capstan).","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0000","quote":"What's been missing in action for a long time is companies buying science, so to speak."},{"chunk_id":"doc_7994e5031b34_chunk_0000","quote":"I think it's a positive sign that you're starting to see. Pharma companies start to do those types of deals again"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_7994e5031b34","kind":"buyer_signal","text_ru":"Инвесторы (в т.ч. в XBI/XDI) ожидают, что сделки по покупке «науки»/ранних компаний будут драйвером настроений и могут поддержать широкий сектор.","text_en":"Investors (e.g., XBI/XDI) look for early-stage “science” acquisitions as a sentiment driver that could lift the broader sector.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0000","quote":"people who invest in like XDI type stocks hope to start seeing because that's the vast majority of biotech companies out there."},{"chunk_id":"doc_7994e5031b34_chunk_0000","quote":"Verona is not going to lift like the XBI... But... when you see companies start buying... a gene editing company... dozens of other gene editing companies out there that might benefit"}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0001_n1","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"После периода неопределённости из‑за тарифов Трампа и обсуждений MFN фарма «возвращается в бизнес», и M&A выглядит как нормализующийся процесс на год.","text_en":"After uncertainty from Trump tariffs and MFN talks, pharma is “back in business,” and M&A is normalizing for the year.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0001","quote":"the Trump tariff moves and also the MFN conversations have just created tremendous uncertainty. And now that that uncertainty has cleared... pharma is sort of back in business."},{"chunk_id":"doc_7994e5031b34_chunk_0001","quote":"We're headed for what I would describe as a normal. In a year."}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0001_n2","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Надвигающиеся «patent cliffs»/LOE создают сильное давление на фарму: нужно компенсировать выпадающую выручку, а органического роста часто недостаточно.","text_en":"Upcoming patent cliffs/LOE pressure pharma to replace revenue; organic growth is often insufficient.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0001","quote":"How severe the upcoming patent cliffs are. So pharma has no choice. I mean, they've got to go out and do inorganic expansion."},{"chunk_id":"doc_7994e5031b34_chunk_0001","quote":"survival means keeping your revenue in place... but most companies in our industry don't have enough. of growth to get there."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0001_n3","doc_id":"doc_7994e5031b34","kind":"buyer_signal","text_ru":"Есть явный спрос на M&A со стороны фармы; покупки (например, в gene editing) рассматриваются как позитивный сигнал и могут подтолкнуть интерес к другим компаниям в той же категории.","text_en":"There is explicit M&A demand; acquisitions (e.g., in gene editing) are seen as a positive sign and may spur interest in other similar companies.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0001","quote":"there's a lot of blatant M &A demand."},{"chunk_id":"doc_7994e5031b34_chunk_0001","quote":"when you see companies start buying, like, a gene editing company... there's dozens of other gene editing companies out there that might benefit from it."}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0002_n1","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"У большинства компаний в индустрии недостаточно органического роста, поэтому для выживания приходится опираться на M&A/покупку выручки.","text_en":"Most companies lack enough organic growth, so survival often relies on M&A/buying revenue.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0002","quote":"most companies in our industry don't have enough. of growth to get there."},{"chunk_id":"doc_7994e5031b34_chunk_0002","quote":"survival means keeping your revenue in place. And that means M&A or some type of organic growth"}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0002_n2","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Покупатели сейчас фокусируются на M&A коммерческих активов; это описывается как «рынок покупателя».","text_en":"Buyers are focusing on M&A for commercial-stage assets; described as a buyer’s market.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0002","quote":"It's all commercial. So buyers are shopping commercial now."},{"chunk_id":"doc_7994e5031b34_chunk_0002","quote":"And so it's a buyer's market."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0002_n3","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Публичные рынки воспринимаются как сложные: звучит мнение, что многомиллиардная оценка ранней клинической компании в публичном рынке была бы маловероятна.","text_en":"Public markets are seen as challenging; a multi-billion valuation for a recently clinical company is viewed as unlikely in public markets.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0002","quote":"I think that says a lot about how challenging the public markets are. Are right now."},{"chunk_id":"doc_7994e5031b34_chunk_0002","quote":"That would not be the case if it was a public company, for sure."}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0003_n1","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Рынок M&A в биотехе описывается как «рынок покупателя»: обычно один претендент на сделку, низкие премии, и выросло число доступных целей (коммерческая стадия/биотех) за последние 3–4 года из‑за притока капитала.","text_en":"Biotech M&A is described as a buyer’s market: typically one bidder per deal, low premiums, and a larger target universe over the last 3–4 years due to capital inflows.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0003","quote":"it's a buyer's market."},{"chunk_id":"doc_7994e5031b34_chunk_0003","quote":"there's one bidder. So that you know the median number of bidders is one; it's not like six."},{"chunk_id":"doc_7994e5031b34_chunk_0003","quote":"the population of targets has just grown so much over the last three or four years."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0003_n2","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Большинство компаний получают очень мало предложений о покупке (часто ни одного или 1–2 за десятилетие), поэтому при обращении покупателя советам директоров приходится «обращать внимание».","text_en":"Most companies receive very few acquisition approaches (often none or 1–2 per decade), so boards need to pay attention when approached.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0003","quote":"how many times have you been approached in the last decade? The answer often is never or maybe once or twice."},{"chunk_id":"doc_7994e5031b34_chunk_0003","quote":"boards learn that when you get approached, you need to pay attention"}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0003_n3","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"У многих коммерческих фармкомпаний недостаточно продуктов; их P&L не показывает устойчивого выхода в EBITDA+, что подталкивает к приобретениям и консолидации (крупная организация может распределять накладные расходы на несколько продуктов).","text_en":"Many commercial-stage pharma companies lack enough products; their P&Ls don’t show a clear path to sustained EBITDA+, driving acquisitions and consolidation.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0003","quote":"most commercial stage pharmaceutical companies don't have enough products."},{"chunk_id":"doc_7994e5031b34_chunk_0003","quote":"you don't see so many like a blueprint where the company just is going to go into EBITDA positive territory forever."},{"chunk_id":"doc_7994e5031b34_chunk_0003","quote":"a larger organization that can amortize overhead expenses over more than one product."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0004_n1","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Конструкция IRA создавала дезинцентив для разработки orphan-препаратов, особенно малых молекул для нескольких orphan-индикаций.","text_en":"The IRA’s structure created a disincentive for orphan drug development, especially small-molecule orphan drugs for multiple orphan indications.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0004","quote":"The construction of the IRA was creating a disincentive for orphan drug development, especially small molecule orphan drug development for multi-orphan indications."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0004_n2","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"В «большом красивом билле» изменили/уточнили правило освобождения редких заболеваний от переговоров по ценам: при нескольких одобренных индикациях для редкой популяции теперь сохраняется освобождение.","text_en":"The new bill adjusted the rare-disease exemption from IRA drug price negotiations so that multiple approved indications for a rare-disease population are now exempt.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0004","quote":"Rectified that, so now if you have multiple approved indications for, like, a rare disease type patient population, you're now exempt."}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0004_n3","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Обсуждаются потенциальные фарм-тарифы, которые могут вырасти до 200%.","text_en":"Potential pharma tariffs were discussed, possibly increasing up to 200%.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0004","quote":"Trump brought up tariffs, talked about pharma tariffs, you know, potentially going up to 200 percent."}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0005_n1","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Окно 1–1,5 года для переноса фармпроизводства в США описывается как недостаточное для техтрансфера и переноса процессов.","text_en":"A 1–1.5 year window to move pharma manufacturing to the U.S. is described as insufficient for tech transfer and process relocation.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0005","quote":"One to 1. 5 years is like, that is not enough time to like do tech transfer and move a lot of these processes over to the US."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0005_n2","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Обсуждается тренд усиления M&A: «много M&A» и тезис, что год будет слабым по M&A, по мнению спикера, уже опровергнут.","text_en":"M&A activity is described as strong; the idea that this would be a weak M&A year is said to be disproven.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0005","quote":"So we're seeing a lot of M &A lately. And I think the thesis that this might not be a great M &A year has sort of been disproven"}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0005_n3","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Детали spending bill могут негативно влиять на биофарму через меньшее покрытие Medicaid (для здравоохранения и фармпрепаратов).","text_en":"Spending bill details could negatively affect biopharma via reduced Medicaid coverage (for healthcare and pharmaceuticals).","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0005","quote":"the spending bill details too, which did have potential... to negatively influence the biopharmaceutical industry in terms of a lesser coverage in Medicaid"}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0006_n1","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Обсуждаются ожидаемые изменения в правилах MFN: по слухам, решение будет через Medicaid/Medicare и скорее «carrot rather than stick».","text_en":"Expected MFN rule changes are being discussed: rumored to be resolved via Medicaid/Medicare with a “carrot rather than stick” approach.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0006","quote":"the approach to resolving MFN is going to mainly take place through the Medicaid system."},{"chunk_id":"doc_7994e5031b34_chunk_0006","quote":"Medicare system and that it will be carrot rather than stick."}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0006_n2","doc_id":"doc_7994e5031b34","kind":"opportunity","text_ru":"FDA объявила потенциальный стимул: если сделать препарат более доступным, могут рассмотреть выдачу ваучера для ускорения одобрения.","text_en":"FDA announced a potential incentive: making a drug more affordable may be considered for a voucher to speed up approval.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0006","quote":"if you make your drug more affordable.' We may consider granting you a voucher to speed up your approval"}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0006_n3","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Сектор биотеха недавно был крайне депрессивно оценён из‑за опасений (в т.ч. по ценообразованию), что мешает нормальным инвестициям и ведению бизнеса.","text_en":"Biotech was recently priced extremely pessimistically amid concerns (incl. pricing backlash), hindering normal investment and business operations.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0006","quote":"our industry, like four months ago, was literally priced for Armageddon."},{"chunk_id":"doc_7994e5031b34_chunk_0006","quote":"everyone bashing us on pricing and all of this stuff."},{"chunk_id":"doc_7994e5031b34_chunk_0006","quote":"so that at least segments of our industry can invest and run normal businesses."}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0007_n1","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Риск-аппетит на рынках влияет на раннюю биотех; ожидается постепенное улучшение, но это многолетний процесс.","text_en":"Market risk appetite affects early-stage biotech; improvement may come gradually, but it’s a multi-year process.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0007","quote":"We should start to see early-stage biotech pick up, but that's a multi-year process."}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0007_n2","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Дефицитные расходы и потенциальный рост тарифов рассматриваются как факторы, ухудшающие ставки/инфляцию и, как следствие, условия для биотеха.","text_en":"Deficit spending and potential tariff increases are seen as worsening rates/inflation and thus conditions for biotech.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0007","quote":"deficit spending is not good for rates at all. And so that's not good for biotech."},{"chunk_id":"doc_7994e5031b34_chunk_0007","quote":"if tariffs went up, that's going to be highly inflationary, most likely. And that would be definitely bad for rates. And that would be definitely bad for biotech."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0007_n3","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Внезапная публикация FDA большого массива CRL выявила, что многие компании (включая big pharma) не раскрывали рынку получение CRL.","text_en":"FDA’s sudden release of many CRLs revealed that many companies (including big pharma) did not disclose receiving CRLs to the market.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0007","quote":"publish out of the blue, you know, 200 complete response letters"},{"chunk_id":"doc_7994e5031b34_chunk_0007","quote":"A lot of companies were clearly not transparent with the markets as to what was going on."},{"chunk_id":"doc_7994e5031b34_chunk_0007","quote":"some of these big pharma companies were getting CRLs that they never mentioned to the market."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0008_n1","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Некоторые крупные фармкомпании получали CRL и не сообщали об этом рынку, что указывает на проблему прозрачности/честности коммуникаций.","text_en":"Some big pharma companies received CRLs and did not disclose them to the market, indicating a transparency/communication problem.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0008","quote":"some of these big pharma companies were getting CRLs that they never mentioned to the market."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0008_n2","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"FDA начала публиковать CRL, но пока только для препаратов, которые в итоге были одобрены; обсуждается расширение на все CRL, включая не одобренные препараты.","text_en":"FDA started releasing CRLs, but so far only for drugs that ultimately got approved; there’s discussion about expanding to all CRLs including unapproved drugs.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0008","quote":"they've only made Publix. CRLs for drugs that ultimately ended up getting approved."},{"chunk_id":"doc_7994e5031b34_chunk_0008","quote":"Getting the, you know, the CRLs for unapproved drugs is ultimately what would have a bigger impact"}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0008_n3","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"В FDA упоминаются внутренние проблемы: «internal turmoil», «challenges», «low morale» и «groups have really been overturned», что может быть барьером для устойчивой работы.","text_en":"FDA is described as having internal turmoil, staff challenges, low morale, and groups being overturned, which may constrain sustainable operations.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0008","quote":"some of the internal turmoil and challenges that staff is experiencing"},{"chunk_id":"doc_7994e5031b34_chunk_0008","quote":"groups have really been overturned and just how low morale and everything is."}],"confidence":"medium"}
{"nugget_id":"nugget_0001","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Есть признаки низкой морали, текучести и нехватки персонала/ухода старших ревьюеров в FDA, что может ухудшать качество обратной связи для компаний.","text_en":"Signs of low morale, turnover, and loss of senior FDA reviewers may reduce the quality of feedback companies receive.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0009","quote":"\"I've heard in several instances of just senior reviewers being gone, and so maybe not having the quality of feedback\""},{"chunk_id":"doc_7994e5031b34_chunk_0009","quote":"\"he may have some issues with regard to staffing and turnover and morale\""}],"confidence":"high"}
{"nugget_id":"nugget_0002","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Компании не уверены, что взаимодействие с FDA будет «гладким», и не могут позволить себе риск; поэтому продолжают работать и с другими регуляторными агентствами.","text_en":"Companies lack confidence that FDA processes will remain smooth and can’t afford the risk, so they continue working with other regulatory agencies too.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0009","quote":"\"companies are going to continue to just. work with other regulatory agencies as well\""},{"chunk_id":"doc_7994e5031b34_chunk_0009","quote":"\"companies can't afford to. take that risk\""}],"confidence":"high"}
{"nugget_id":"nugget_0003","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Упоминается «очень неудачный» кейс: заявка Capricor по DMD получила CRL; данные описываются как «marginal» на входе.","text_en":"An “unfortunate” case is mentioned: Capricor’s DMD filing received a CRL; the data going in was described as marginal.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0009","quote":"\"very unfortunate case of Capricor\""},{"chunk_id":"doc_7994e5031b34_chunk_0009","quote":"\"got the CRL because like the data was like marginal going into this\""}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0010_n1","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Решения по одобрению могут упираться в «тонкие/маргинальные» данные по эффективности, что приводит к CRL и спорам вокруг адкома.","text_en":"Approval decisions can hinge on thin/marginal efficacy data, leading to CRLs and controversy around holding an AdCom.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0010","quote":"\"got the CRL because like the data was like marginal going into this.\""},{"chunk_id":"doc_7994e5031b34_chunk_0010","quote":"\"There's no way we're approving this, like, based off of the you know the this indication and the existing data that they have.\""}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0010_n2","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Позитивный mid-cycle review не гарантирует одобрение: финальное решение зависит от полного рассмотрения доказательств и соответствия «statutory requirement for efficacy».","text_en":"A positive mid-cycle review doesn’t guarantee approval; the final decision depends on full evidence review and meeting the statutory efficacy requirement.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0010","quote":"\"we had a mid-cycle review and everything was fine.\""},{"chunk_id":"doc_7994e5031b34_chunk_0010","quote":"\"we have not met the statutory requirement for efficacy.\""}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0010_n3","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"В кейсах accelerated approval ожидается более быстрое получение данных из крупных/confirmatory исследований (вплоть до «в ближайшие 30 дней»), а не годы ожидания.","text_en":"In accelerated approval contexts, there can be rapid upcoming data from large/confirmatory trials (as soon as “next 30 days”), rather than years of waiting.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0010","quote":"\"we're gonna to know a lot more about this exact same therapy within like the next 30 days.\""},{"chunk_id":"doc_7994e5031b34_chunk_0010","quote":"\"accelerated approval and we're not gonna know, like, for years and years\""}],"confidence":"medium"}
{"nugget_id":"doc_7994e5031b34_chunk_0011_n1","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Регуляторные сроки/правила (PDUFA) могут вынуждать FDA принимать решение до получения ключевых данных, что, по мнению спикера, хуже служит медицине.","text_en":"Regulatory timelines/rules (PDUFA) can force FDA decisions before key data are available, which the speaker argues serves medicine poorly.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0011","quote":"you have to follow these, you know, PDUFA rules, and I don't think that serves medicine, as well as it should."},{"chunk_id":"doc_7994e5031b34_chunk_0011","quote":"they had to get a decision by such and such date, and they were going to have this key data a month later."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0011_n2","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Компании могут сталкиваться с «турбулентностью» из‑за смены/перестановок в FDA и последовательных разных review staff, что влияет на траекторию к одобрению.","text_en":"Companies may face turbulence from FDA staff turnover and sequential review teams, affecting the path toward approval.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0011","quote":"they, in their opinion, have kind of been dealing with two FDA's, two sequential review staffs."},{"chunk_id":"doc_7994e5031b34_chunk_0011","quote":"it is a little bit unfair that the companies had to go through this turmoil in staff and turnover in staff."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0011_n3","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Появилось одобрение первой пероральной терапии для купирования HAE-атак (вместо IV/инъекционных вариантов).","text_en":"Approval of the first oral therapy for treating HAE attacks (vs IV/injected options).","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0011","quote":"It's the first ever oral drug period for HAE attacks. There's IV drugs and there's injected drugs."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0012_n1","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Высокая цена PRN/«экстренной» терапии ставит пациентов в сложное положение и может снижать использование из‑за финансовых последствий.","text_en":"High pricing of PRN/emergency therapy puts patients in a difficult spot and may reduce use due to financial consequences.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0012","quote":"I think that puts patients in a tricky situation."},{"chunk_id":"doc_7994e5031b34_chunk_0012","quote":"you might use it a lot less, or you might think twice about using something"}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0012_n2","doc_id":"doc_7994e5031b34","kind":"opportunity","text_ru":"Возможность внедрить подписочную модель оплаты для PRN-терапий (годовой платеж независимо от числа доз), чтобы снизить страх финансовых последствий.","text_en":"Opportunity for a subscription pricing model for PRN therapies (annual fee regardless of doses) to reduce worry about financial consequences.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0012","quote":"it'd be interesting if a company like that in the future is somehow able to have, like, a subscription model."},{"chunk_id":"doc_7994e5031b34_chunk_0012","quote":"where you maybe pay an annual fee."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0012_n3","doc_id":"doc_7994e5031b34","kind":"pain","text_ru":"Хроническая болезнь почек — сложная для лечения индикация: мало препаратов были успешны в лечении.","text_en":"Chronic kidney disease is a challenging indication with few drugs that have been successful in treating it.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0012","quote":"Chronic kidney disease, really, really challenging indication to treat, right? Not a whole lot of drugs."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0013_n1","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Оценка biotech-акций сильно зависит от интерпретации данных: инвесторы переоценивают компании исходя из того, что означают данные для стоимости препарата, а не из прошлой цены акций.","text_en":"Biotech stock valuation is driven by how investors interpret the data (what it implies for drug value), not prior trading price.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0013","quote":"It really is just a function of like, what are your data? And investors will kind of bid you up to what they think that... data means"}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0013_n2","doc_id":"doc_7994e5031b34","kind":"constraint","text_ru":"Есть ограничения/неопределённости в интерпретации Phase 2 данных (open-label, сравнение с placebo, влияние SGLT2, нюансы тайминга), и ясность ожидается только в Phase 3.","text_en":"Phase 2 data interpretation is constrained by open-label design and other nuances; clarity is expected in Phase 3.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0013","quote":"there's a lot of debates... what these phase two data mean... this is open label. How would this look compared to placebo?"},{"chunk_id":"doc_7994e5031b34_chunk_0013","quote":"we'll ultimately really find out in the phase three."}],"confidence":"high"}
{"nugget_id":"doc_7994e5031b34_chunk_0013_n3","doc_id":"doc_7994e5031b34","kind":"trend","text_ru":"Рынок obesity стал менее «открытым»: конкурировать с Lilly будет сложнее, а ожидаемая дженеризация semaglutide около 2030 может сделать эффективный препарат очень дешёвым.","text_en":"The obesity market is becoming less open: competing with Lilly is harder, and semaglutide generics around ~2030 may be very inexpensive.","evidence":[{"chunk_id":"doc_7994e5031b34_chunk_0013","quote":"I think it's going to be much tougher for them to compete against Lilly."},{"chunk_id":"doc_7994e5031b34_chunk_0013","quote":"semaglutide is going to be generic, presumably sometime around 2030... generic semaglutide is going to be very inexpensive"}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0000_n1","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Сектор biotech воспринимается как имеющий проблему доверия/подотчётности, из‑за чего его игнорирует более широкое инвестиционное сообщество.","text_en":"Biotech is seen as having a credibility/accountability problem, leading broader investors to ignore the sector.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0000","quote":"I think the sector has a serious credibility and accountability problem."},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0000","quote":"This is an industry, unfortunately, which is going to be mostly um ignored. by the larger investment community."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0000_n2","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Высокая волатильность small/mid-cap biotech и дополнительные риски/неопределённость, связанные с FDA, делают инвестиции сложными.","text_en":"High volatility in small/mid-cap biotech plus added FDA-related concerns make investing difficult.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0000","quote":"the smaller and mid-careerly volatile. We have obviously more concerns with FDA."},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0000","quote":"It's tough. It's volatile. I mean, this is not for the faint of heart."}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0000_n3","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Восприятие стагнации: сектор (по словам спикера) «не двигался» около десяти лет, что является вызовом для привлечения инвесторов.","text_en":"Perceived stagnation: the sector “has not really moved in ten years,” hurting investor appeal.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0000","quote":"this sector. has not really moved in ten years."}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0001_n1","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Сектор, по мнению спикеров, не показал прогресса/доходности за ~10 лет, из‑за чего инвесторам сложно оправдать аллокацию капитала.","text_en":"The sector is seen as not having progressed/delivered returns for ~10 years, making it hard for investors to justify allocating capital.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0001","quote":"I think that is one of the biggest challenges we have is just this sector. has not really moved in ten years."},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0001","quote":"How can you justify putting a lot of capital to work in this sector when it just hasn't delivered?"}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0001_n2","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Высокие процентные ставки выступают барьером для привлечения/размещения капитала в секторе.","text_en":"High interest rates are a barrier to deploying capital into the sector.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0001","quote":"Especially with interest rates that remain high."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0001_n3","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Фрустрация из‑за «self-inflicted» проблем/ошибок в индустрии, которые «не должны происходить», но происходят постоянно и требуют «cleaned up».","text_en":"Frustration with recurring self-inflicted issues in the industry that shouldn’t happen and need to be cleaned up.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0001","quote":"I just think it's the self-inflicted wounds that are so frustrating."},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0001","quote":"it's the self-inflicted stuff— it's the stuff that just doesn't need to happen. That keeps happening all the time."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0002_n1","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Проблема доверия к менеджменту/компании, когда на звонках с аналитиками избегают прямых вопросов о безопасности (воспринимается как «ложь умолчанием»).","text_en":"Credibility issue when management avoids direct safety questions on analyst calls (seen as a “lie by omission”).","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0002","quote":"when someone asks you whether there were any safety issues... and you don't say— you basically avoid the question, so it's a lie by omission."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0002_n2","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Ограничение: компания не раскрыла информацию о смерти; без журналистских расследований раскрытия могло бы не быть.","text_en":"Constraint: the company did not disclose the death; without reporters pursuing it, there might have been no disclosure.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0002","quote":"So the company did not disclose this. And unless there were reporters out there pursuing these kinds of stories, there wouldn't have been a disclosure here."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0002_n3","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Регуляторная неопределённость: внутри FDA есть «raging debates» и смена руководителей дивизиона может резко менять решения.","text_en":"Regulatory uncertainty: internal FDA debates and division leadership changes can reverse decisions.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0002","quote":"The FDA is not a monolith... Raging debates... three different division directors... an interim director that came in, that kind of reversed all of that decisions."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0003_n1","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Недостаток прозрачности/раскрытия информации (в т.ч. по безопасности) подрывает доверие к менеджменту и воспринимается как проблема для индустрии и пациентов.","text_en":"Lack of transparency/disclosure (incl. safety) undermines trust in management and is seen as a problem for the industry and patients.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0003","quote":"\"I think the transparency is the issue.\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0003","quote":"\"lack of disclosures, lack of integrity, cost the industry, and cost patients\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0003","quote":"\"We need more disclosure.' You know, we're putting our kids at risk.\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0003_n2","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Публичное раскрытие регуляторных документов (например, CRL) ограничено необходимостью редактирования из-за конфиденциальности и юридических причин; решения зависят от риск-аппетита руководства/совета/юристов.","text_en":"Public disclosure of regulatory documents (e.g., CRLs) is constrained by confidentiality/legal redactions; decisions depend on management/board/legal risk appetite.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0003","quote":"\"there's going to be an element of information that's going to have to be redacted for confidentiality for legal reasons\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0003","quote":"\"It's all a question of how much risk does the management and the board and the GC want to take\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0003_n3","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Появляется практика/движение к публичному размещению CRL (complete response letters), и участники считают это сильно необходимым.","text_en":"There is a move toward publicly posting CRLs (complete response letters), and participants say it’s badly needed.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0003","quote":"\"now beginning to post the CRLs publicly.\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0003","quote":"\"We need that badly.\""}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0004_n1","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"В пациентском сообществе Дюшенна возникают проблемы с открытой дискуссией: критические выступления могут приводить к травле и цензуре (вплоть до редактирования видео по запросу компании).","text_en":"In the Duchenne community, open debate can be undermined: critical comments may lead to harassment and censorship (including video edits at a company’s request).","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0004","quote":"\"is it kind of harassed afterwards and then her comments are censored.\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0004","quote":"\"at Sarepta's request, the video was edited and her comments were edited out.\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0004_n2","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Пост-бариатрическая гипогликемия описывается как недооценённое осложнение бариатрической хирургии, требующее очень ограничительной диеты и создающее значимую нагрузку для пациентов.","text_en":"Post-bariatric hypoglycemia is described as an underappreciated complication requiring a very restrictive diet, creating significant patient burden.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0004","quote":"\"As a very underappreciated potential complication of bariatric surgery\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0004","quote":"\"patients actually struggle with significant hypoglycemia that requires a very restrictive diet\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0004_n3","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Регуляторная повестка (Вашингтон и FDA) стала заметно чаще попадать в новости, причём звучат «смешанные сигналы» о происходящем в агентстве.","text_en":"Regulatory news (Washington and the FDA) is appearing much more frequently, with “mixed messages” about what’s happening at the agency.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0004","quote":"\"it feels like Washington and the FDA is in the news every single week.\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0004","quote":"\"And it feels like a little mixed messages.\""}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0005_n1","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Звучат «смешанные сигналы» о состоянии FDA: публично говорят, что «всё ок», но есть признаки падения морали и замедления одобрений из‑за стресса в агентстве.","text_en":"Mixed signals about the FDA: leadership says things are fine, but there are signs morale is worse and approvals may be slowing due to agency stress.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0005","quote":"mixed messages... messages from the top telling us everything's okay... Maybe morale's not quite as good... maybe drug approval process is being slowed down"}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0005_n2","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Бюрократические/логистические требования (пример: число температурных датчиков в контейнере) могут становиться причиной CRL и задержек, даже без клинических проблем.","text_en":"Bureaucratic/logistical requirements (e.g., number of temperature probes in a shipping container) can trigger CRLs and delays even without clinical issues.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0005","quote":"there was a disagreement about the number of thermometer probes... They've got like five. And the FDA wanted seven. And that's one of the reasons why this thing got rejected."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0005_n3","doc_id":"doc_2cd6f3fc87a7","kind":"opportunity","text_ru":"Есть запрос на устранение «roadblocks/hurdles» (например, по ассаям и «common sense» требованиям) для ускорения вывода препаратов на рынок; если руководство FDA уберёт препятствия, индустрия будет довольна.","text_en":"Opportunity to remove roadblocks/hurdles (assays and other “common sense” requirements) to streamline getting drugs to market; industry would be pleased if FDA leadership does it.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0005","quote":"People have called for... common sense things where it seems like you could eliminate some of these roadblocks... streamlining drug rules"}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0006_n1","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Регуляторные «мелочи»/споры по CMC (например, стерилизация, разработка assays) могут существенно задерживать одобрение генной терапии (вплоть до 2026), что критично по времени для пациентов.","text_en":"Regulatory/C MC minutiae (e.g., sterilization, assay development) can materially delay gene therapy approvals (even to 2026), which is time-critical for patients.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0006","quote":"\"why are we wasting our time? Like, debating whether or not, you know, this thing is like, should be sterilized this way or sterilized another way.\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0006","quote":"\"may not be approved until 2026\""}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0006_n2","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Описывается сдвиг внутри FDA: потенциальный уход от биомаркера (Heparin sulfate) как основы accelerated approval в сторону нейрокогнитивной конечной точки.","text_en":"A shift at FDA is described: potentially moving away from a biomarker (Heparin sulfate) toward a neurocognitive endpoint for accelerated approval.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0006","quote":"\"there is a move now to. not to use Heparin sulfate potentially is the biomarker\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0006","quote":"\"but rather the neurocognitive endpoint.\""}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0006_n3","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Есть ощущение страха «репрессий»/риска «высовываться» при публичной критике FDA/руководства, на фоне упоминаний «ousters» и уходов внутри организации.","text_en":"There is perceived fear of retribution for speaking out against FDA/leadership, with mentions of internal ousters/departures.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0006","quote":"\"Do you think there's more fear of retribution than in the past\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0006","quote":"\"wow, are you going to stick your neck out?\""}],"confidence":"low"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0007_n1","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"ODAC/FDA не удовлетворены соотношением риск–польза и переносимостью (в т.ч. из‑за дозирования) для BCMA ADC (Blenrep), что мешает одобрению/возврату на рынок США.","text_en":"ODAC/FDA are not satisfied with the risk–benefit and tolerability (incl. dosing) for the BCMA ADC (Blenrep), constraining US approval/return to market.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0007","quote":"the ODAC panel isn't thrilled with the risk-benefit profile of the product. I think, in particular, some of the ocular toxin."},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0007","quote":"we don't believe that they've got the dosing right. We don't believe that the tolerability profile, which is related to the dosing, is right"}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0007_n2","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Низкая доля пациентов из США в клинических исследованиях (около 5%) поднимается как проблема при запросе одобрения для применения в США.","text_en":"Low US patient representation in trials (~5%) is raised as an issue when seeking approval for US use.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0007","quote":"they had a big problem with lack of U. S patients"},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0007","quote":"5% of patients came from the US and said, 'look,' and you're asking us to approve the drug here for use in the US."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0007_n3","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Отмечается «новая позиция» FDA/ODAC: в онкологии регуляторы становятся менее снисходительными, даже при превосходстве в исследованиях.","text_en":"A “new posture” from FDA/ODAC is noted: regulators in oncology are becoming less lenient, even when trials show superiority.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0007","quote":"we're beginning to see definitely a new posture from PASDA and ODAC, right? Historically, oncology, I don't want to have been more lenient."},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0007","quote":"DREAM7 and DREAM8 actually showed superiority."}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0008_n1","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"FDA отклоняет заявки/выдаёт CRL, если в исследовании использован устаревший контрольный рукав и/или слишком мало пациентов, что ставит под сомнение клиническую значимость результатов.","text_en":"FDA may reject/issue CRL when trials use outdated control arms and/or enroll too few patients, making clinical relevance questionable.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0008","quote":"FDA rejected Columbia for second line DLBCL... because the control arm was outdated. And again, very few patients were in there."},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0008","quote":"companies are running outdated standard of care arms... the clinical importance of that is totally questionable"}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0008_n2","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"В biotech есть проблема с доверием/кредибилити: компании, по словам спикера, управляют риском вместо инноваций и не делают по-настоящему трансформирующие препараты, оправдывающие цену.","text_en":"Biotech credibility issue: companies manage risk rather than innovate and don’t make truly transformative drugs worth the price.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0008","quote":"what's the issue with biotech. A lot of the issues in biotech is that companies are not really trying to innovate. They're trying to manage risk"}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0008_n3","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Стандарт лечения при миеломе существенно изменился/«полностью трансформировался», что повышает риск устаревания контрольных рукавов в исследованиях.","text_en":"Standard of care in myeloma has “completely transformed,” increasing the risk that trial control arms become outdated.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0008","quote":"the standard of care in myeloma has completely transformed."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0009_n1","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Стало очень сложно привлекать ранние раунды (seed/Series A) для новых биофарма-компаний; в Q2 сместился аппетит инвесторов в сторону Series B+.","text_en":"Raising early rounds (seed/Series A) for new biopharma companies has become very hard; in Q2 investor appetite shifted toward Series B+.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0009","quote":"\"it's really, really hard to take a new company and get that seed to series A round\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0009","quote":"\"in Q2 where you really saw series B and later rounds dwarfing more than 2x the amount that went into seed\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0009_n2","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"В Q2 не было IPO, при этом M&A выросло.","text_en":"In Q2 there were no IPOs, while M&A increased.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0009","quote":"\"we saw no IPOs in Q2. We did see M&A tick up\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0009_n3","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Инвесторский фокус в терапевтических областях диверсифицируется: тренд на онкологию снижается, растёт интерес к более широкому набору направлений (neuro/CNS, офтальмология, cardiometabolic, respiratory).","text_en":"Therapeutic-area focus is diversifying: oncology is declining, with broader interest (neuro/CNS, ophthalmology, cardiometabolic, respiratory).","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0009","quote":"\"oncology... That trend is dropping\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0009","quote":"\"there does seem to be an embrace of a broader array of therapeutic areas\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0010_n1","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Во 2 квартале не было IPO, при этом активность M&A выросла.","text_en":"No IPOs in Q2, while M&A activity increased.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0010","quote":"\"we saw no IPOs in Q2. We did see M&A tick up.\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0010_n2","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"В сделках M&A (по крупной biopharma) в 1 полугодии было меньше сделок, чем годом ранее, но суммарная стоимость была значительно выше.","text_en":"In large biopharma M&A in H1, there were fewer deals than last year, but total value was much higher.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0010","quote":"\"the numbers of deals... was fewer than the same equivalent time last year. So 12 deals in the first half. The value was a lot higher\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0010_n3","doc_id":"doc_2cd6f3fc87a7","kind":"buyer_signal","text_ru":"Для многих компаний M&A рассматривается как «лучший выход» (exit), и есть стремление быть целью для поглощения.","text_en":"Many view M&A as the best exit and want to be an acquisition target.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0010","quote":"\"everybody wants their companies... to be a target for M &A... as the best exit for them\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0011_n1","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"В венчуре по-прежнему есть «dry powder», и ожидается продолжение частных инвестиций, потому что фондам нужно развернуть капитал в рамках инвестиционного периода.","text_en":"Venture still has significant dry powder, and private investing is expected to continue because VCs must deploy capital within their investment period.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0011","quote":"venture, there's still a lot of dry powder on the sidelines... VCs have to use that capital... they have an investment period."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0011_n2","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Без IPO и «здоровых» публичных оценок публичных биотехов сложно улучшать ситуацию на рынке (\"climb up that mountain\").","text_en":"Without IPOs and healthy public biotech valuations, it’s hard to improve market conditions (“climb up that mountain”).","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0011","quote":"until we see IPOs and healthy valuations and public biotechs. I think it's really hard to climb up that mountain."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0011_n3","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Сектор воспринимается как слишком волатильный и сложный, чтобы привлекать «generalists», что ставит под вопрос достаточность спроса/ликвидности без них.","text_en":"The sector is seen as too volatile and complex to attract generalist investors, raising questions about whether it can work without them.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0011","quote":"Is the sector just too volatile and complex? To really attract generalists, and can it work if you don't get generalists"}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0012_n1","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Разработка и проведение клинических исследований при преэклампсии/у беременных затруднены, в том числе из‑за проблем с набором пациентов на фоне опасений по поводу «нового или экспериментального».","text_en":"Developing and running trials in preeclampsia/pregnant women is difficult, including recruitment challenges due to concerns about novel/experimental interventions.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0012","quote":"\"it can be very very difficult to develop\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0012","quote":"\"challenges that there can be when it comes to enrolling patients with pre-eclampsia or really any pregnant women\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0012","quote":"\"something novel or experimental can lead to recruitment challenges\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0012_n2","doc_id":"doc_2cd6f3fc87a7","kind":"opportunity","text_ru":"Есть значимая неудовлетворённая медицинская потребность и ограниченная инновация в терапии состояний, затрагивающих беременных (например, преэклампсия), что создаёт пространство для новых программ/подходов.","text_en":"There is significant unmet need and limited innovation in conditions affecting pregnant women (e.g., preeclampsia), creating room for new programs/approaches.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0012","quote":"\"significant unmet medical need\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0012","quote":"\"there is such limited innovation for anything that may affect pregnant women\""}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0012_n3","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"В опросе по НМРЛ низкая «familiarity» и ограниченная представленность исследования в небольшом числе центров в США могут снижать ожидания/оценку перспективности (барьер распространения/узнаваемости).","text_en":"In the NSCLC survey, low familiarity and limited presence at only a few US centers may reduce perceived impact (a dissemination/awareness constraint).","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0012","quote":"\"didn't score very highly, but I think that's because currently it's only not like five or six or seven US centers\""},{"chunk_id":"doc_2cd6f3fc87a7_chunk_0012","quote":"\"Familiarity is an issue.\""}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0013_n1","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Для одобрения FDA требуется 52 недели дозирования на целевой дозе, а в текущем режиме эскалации дозы до этого ещё далеко.","text_en":"FDA requires 52 weeks of dosing at the target dose, and with current dose escalation they are not close to that yet.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0013","quote":"the FDA requires 52 weeks of dosing at the target dose. They're not even close to that."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0013_n2","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Масштабные клинические программы требуют большого капитала; компании, вероятно, понадобится партнёр/дополнительный капитал.","text_en":"Large clinical programs have massive capital requirements; the company will likely need a partner/additional capital.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0013","quote":"they're cognizant of the massive capital requirements for for what they're planning on doing and at some point likely need that partner."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0013_n3","doc_id":"doc_2cd6f3fc87a7","kind":"trend","text_ru":"Отмечается «ещё один» признак сильных инноваций, выходящих из Китая.","text_en":"They note another sign of strong innovation coming out of China.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0013","quote":"another sign of great innovation coming out of China, too."}],"confidence":"medium"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0014_n1","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Неопределённость вокруг тарифов: на вопросы о том, что будет с тарифами, «нет ответов», идут лишь «конструктивные разговоры» с администрацией.","text_en":"Uncertainty around tariffs: questions about what will happen with tariffs have “no answers,” only “constructive conversations” with the administration.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0014","quote":"The questions were, of course, asked: what's going to happen with tariffs? ... there's no answers, right? Everybody's having constructive conversations with the administration."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0014_n2","doc_id":"doc_2cd6f3fc87a7","kind":"pain","text_ru":"Проблема с возмещением/реимбурсацией: отмечены «reimbursement challenges that they didn't anticipate», и что «the rest of the field has taken note of».","text_en":"Reimbursement is a pain point: “reimbursement challenges that they didn't anticipate,” and “the rest of the field has taken note of.”","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0014","quote":"Yes, it's reimbursement challenges that they didn't anticipate— that I think the rest of the field has taken note of."}],"confidence":"high"}
{"nugget_id":"doc_2cd6f3fc87a7_chunk_0014_n3","doc_id":"doc_2cd6f3fc87a7","kind":"constraint","text_ru":"Регуляторный риск: Reuters сообщает, что FDA попросит Sarepta Therapeutics добровольно остановить все поставки (shipments) Levitas.","text_en":"Regulatory risk: Reuters notes the FDA will request Sarepta Therapeutics to voluntarily stop all shipments of Levitas.","evidence":[{"chunk_id":"doc_2cd6f3fc87a7_chunk_0014","quote":"Reuters noting that the FDA will request Sireptotherapeutics to voluntarily stop all shipments of Levitas."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0000_n1","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Смерти пациентов и связанные с этим опасения по безопасности приводят к колебаниям врачей и родителей продолжать терапию Alevitis (DMD).","text_en":"Patient deaths and resulting safety concerns are causing hesitation among physicians and parents to continue Alevitis (DMD).","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0000","quote":"there had been two deaths on Alevitis, their gene therapy for DMD"},{"chunk_id":"doc_9c939613944c_chunk_0000","quote":"This was leading to concern about what the sales of Alevitus were going to be."},{"chunk_id":"doc_9c939613944c_chunk_0000","quote":"There was definitely clear hesitation among physicians and parents to continue using."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0000_n2","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Из-за событий безопасности Sarepta остановила отгрузки для неамбулаторных пациентов, а FDA попросило добровольно остановить отгрузки и для амбулаторных (фактически — все отгрузки).","text_en":"Due to safety events, Sarepta stopped shipping to non-ambulatory patients, and FDA asked for a voluntary stop even for ambulatory patients (effectively all shipments).","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0000","quote":"they had—um— stopped shipping for non-ambulatory patients."},{"chunk_id":"doc_9c939613944c_chunk_0000","quote":"the FDA had now asked Sarepta to voluntarily stop shipping Levitas even to ambulatory patients."},{"chunk_id":"doc_9c939613944c_chunk_0000","quote":"So essentially, stopping all shipments of Levitas"}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0000_n3","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Есть конфликт/неопределённость вокруг того, что считать «материальным событием» и как Sarepta и рынок оценивают необходимость обновлений по безопасности.","text_en":"There is disagreement/uncertainty about what constitutes a “material event” and how Sarepta vs. the market view safety update obligations.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0000","quote":"where their threshold for materiality is."},{"chunk_id":"doc_9c939613944c_chunk_0000","quote":"there's certainly a disagreement on the street and with Sarepta."}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0001_n1","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Регуляторная неопределённость: после остановки поставок продукт находится в «лимбо», непонятно, что нужно, чтобы вернуться на рынок.","text_en":"Regulatory uncertainty: after halting shipments, the product is in limbo and requirements to return to market are unclear.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0001","quote":"\"And now we're in sort of this limbo phase of, you know, what will it take to get back on the market?\""}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0001_n2","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Риск «непреодолимого барьера» со стороны FDA для возвращения препарата на рынок.","text_en":"Risk of an “insurmountable hurdle” from the FDA to get the drug back on the market.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0001","quote":"\"if the FDA is really setting up an insurmountable hurdle to get this drug back on the market\""}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0001_n3","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Политическое давление/риск backlash: DMD advocacy groups «очень вокальные и очень мощные», возможна негативная реакция на снятие продукта с рынка.","text_en":"Political pressure/backlash risk: DMD advocacy groups are “very vocal and very powerful,” and may react strongly to removing the product.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0001","quote":"\"A backlash from the DMD advocacy groups who are very vocal and very powerful.\""}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0002_n1","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Регуляторный барьер: FDA одобряет препараты только при доказанной эффективности и приемлемом соотношении риск–польза; слабые сигналы эффективности усложняют/ставят под вопрос одобрение.","text_en":"Regulatory constraint: FDA approves drugs only with proven efficacy and favorable risk–benefit; weak efficacy signals complicate/undermine approval.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0002","quote":"the job of the FDA is to approve drugs with proven efficacy, and a risk-benefit profile that favors the approval."},{"chunk_id":"doc_9c939613944c_chunk_0002","quote":"the drug was approved on the back of perhaps not the most strong of efficacy signals."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0002_n2","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Проблема безопасности: сообщаются тяжёлые побочные эффекты (grade five), включая смерти; это делает решение о сохранении препарата на рынке крайне сложным.","text_en":"Safety pain: severe adverse events (grade five), including deaths, make the decision to keep the product on the market very difficult.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0002","quote":"This is a grade five. These are deaths"}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0002_n3","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Ограничение по данным/прозрачности: есть сообщения, что компания могла не делиться всеми данными по побочным эффектам с FDA; регулятор может не получать всю информацию по безопасности.","text_en":"Data/transparency constraint: reports suggest the company may not be sharing all adverse event data with FDA; the regulator may not be getting full safety information.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0002","quote":"have they been sharing all the side effect data with the FDA?"},{"chunk_id":"doc_9c939613944c_chunk_0002","quote":"they might not be getting all the safety information"}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0003_n1","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"В ситуации с безопасностью пациенты/сообщество могут не получать всю информацию о безопасности; детали «просачиваются» через медиа, что неидеально с точки зрения общественного здравоохранения.","text_en":"In a safety situation, patients/community may not be getting all safety information; details trickle out via media, which is not ideal from a public health perspective.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0003","quote":"\"a severe safety issue and they might not be getting all the safety information\""},{"chunk_id":"doc_9c939613944c_chunk_0003","quote":"\"maybe a lot of this stuff shouldn't be kind of coming out that way and trickling out that way from just a pure public health perspective\""}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0003_n2","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"В генной терапии компании получают «breakthroughs» и ускоренные пути, но последние регуляторные заголовки стали более негативными и менее гибкими.","text_en":"In gene therapy, companies are getting breakthroughs/accelerated paths, but recent regulatory headlines have been more negative and less flexible.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0003","quote":"\"In gene therapy, where we're seeing a lot of companies get breakthroughs or, you know, these accelerated paths forward.\""},{"chunk_id":"doc_9c939613944c_chunk_0003","quote":"\"some of the recent regulatory headlines... have maybe been more negative and less flexible on the margin\""}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0003_n3","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Взаимодействие компании и FDA может «сломаться»: компания может отказаться выполнять запрос FDA (например, приостановить отгрузки), что приводит к неортодоксальным коммуникациям через медиа и «messy» ситуации.","text_en":"Company–FDA communication can break down: a company may refuse an FDA request (e.g., pause shipments), leading to unorthodox media-based communication and a messy situation.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0003","quote":"\"the communication between Sarepta and the FDA has broken down\""},{"chunk_id":"doc_9c939613944c_chunk_0003","quote":"\"ask for the drug. Shipments to be paused and was refused\""},{"chunk_id":"doc_9c939613944c_chunk_0003","quote":"\"it's pretty unusual for a company to refuse to do something that the FDA requests\""}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0004_n1","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Скандальные/«грязные» ситуации вокруг компаний и препаратов могут отпугивать generalist-инвесторов от биотех-сектора.","text_en":"Messy public situations around companies/drugs can put off generalist investors from the biotech sector.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0004","quote":"the worry here is that this further puts generalist investors off from our sector."},{"chunk_id":"doc_9c939613944c_chunk_0004","quote":"It is a very, very messy situation for all involved."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0004_n2","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Снятие препарата с рынка — крайне тяжёлое решение и травматичная ситуация для пациентов/родителей, особенно когда они считают лечение эффективным или не успели его получить.","text_en":"Removing a drug from the market is a very hard decision and can be horrific for patients/parents, especially when they believe it works or can’t access it.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0004","quote":"removing things from market is a horrible, horrible decision to do."},{"chunk_id":"doc_9c939613944c_chunk_0004","quote":"parents who have kids who have been treated with the drug and they think it's enormously effective."},{"chunk_id":"doc_9c939613944c_chunk_0004","quote":"Parents who have been trying to schedule their kid to get this drug and now don't have that."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0004_n3","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Ужесточение регуляторного подхода/порогов к клиническим данным (если ключевой регулятор — primary decision maker) повышает барьер для новых одобрений и может переводить решения в плоскость общественного мнения/политики.","text_en":"A more stringent regulatory stance and higher clinical-trial hurdle (if the key regulator is the primary decision maker) raises the bar for approvals and may shift outcomes toward politics/public opinion.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0004","quote":"it's certainly a higher hurdle if he is the primary decision maker at the FDA."},{"chunk_id":"doc_9c939613944c_chunk_0004","quote":"I almost think it's going to be a political decision."},{"chunk_id":"doc_9c939613944c_chunk_0004","quote":"it's going to be a battle here and it's and it's going to be one of public opinion"}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0005_n1","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"Назначение нового директора CDER (Dr. George Tidmarsh) с выраженным индустриальным бэкграундом рассматривается как позитивный сдвиг в руководстве FDA/HHS.","text_en":"Appointment of a new CDER director (Dr. George Tidmarsh) with strong industry background is viewed as a positive shift in FDA/HHS leadership.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0005","quote":"George Tidmarsh has just been approved, put in charge of the Center for Drug Evaluation and Research."},{"chunk_id":"doc_9c939613944c_chunk_0005","quote":"Dr. Tidmarsh is coming from a very industry-centered background. He's run biotech companies."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0005_n2","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Внутри FDA есть проблема несогласованности между подразделениями (CDER и CBER): разные «пороги»/подходы к одобрению препаратов.","text_en":"FDA has an internal misalignment problem between divisions (CDER and CBER), with different bars/approaches to drug approval.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0005","quote":"one of the problems with the FDA... it wasn't immediately obvious that the two branches or two divisions actually thought the same."},{"chunk_id":"doc_9c939613944c_chunk_0005","quote":"When it came to drug approval, some had lower standards or lower bar... And others were really holding drug companies to account"}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0005_n3","doc_id":"doc_9c939613944c","kind":"opportunity","text_ru":"Есть возможность/ожидание выравнивания позиций CDER и CBER (\"alignment\"), что может повлиять на процессы одобрения и связанные политики (в т.ч. обсуждение drug advertising).","text_en":"There is an opportunity/expectation for CDER and CBER alignment, potentially affecting approval processes and related policies (incl. drug advertising discussions).","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0005","quote":"it could be interesting to see what happens when we come to discuss direct-to-consumer advertising"},{"chunk_id":"doc_9c939613944c_chunk_0005","quote":"what would be good to see is that CEDAR and CBER are getting some kind of alignment."}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0006_n1","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Сложно, став «истеблишментом» (например, в FDA), сохранять идеалы прозрачности, дебатов и открытости при управлении большой организацией.","text_en":"Once becoming the establishment (e.g., at FDA), it’s hard to maintain ideals like transparency, debate, and openness while running a large organization.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0006","quote":"it isn't necessarily easy to become the establishment and then still embrace those ideals such as transparency, debate, openness, etc., when you're running a large organization like the FDA."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0006_n2","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"В редких заболеваниях компании продолжают получать благоприятные регуляторные договорённости (например, небольшие pivotal, open-label исследования).","text_en":"In rare disease, companies continue to get favorable regulatory agreements (e.g., small pivotal, open-label trials).","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0006","quote":"we've seen a lot of companies in this rare space continue to get these regulatory agreements that you know, look very, very favorable, like small, pivotal, open-label trials"}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0006_n3","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Есть неопределённость и «парадоксы» в том, какой именно является текущая FDA (смешанные сигналы по гибкости/подходам к регуляторике).","text_en":"There’s uncertainty and perceived paradoxes about what the current FDA is (mixed signals on flexibility/regulatory approach).","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0006","quote":"we're still really figuring out, like who this FDA like actually is"}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0007_n1","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Недостаток качественных клинических данных: нет «невероятных» РКИ по антидепрессантам у беременных из‑за этических ограничений.","text_en":"Lack of strong clinical data: there haven’t been robust RCTs of antidepressants in pregnant women due to ethical issues.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0007","quote":"There haven't been like incredible randomized controlled trials of antidepressants in women who are pregnant because those studies have like ethical issues"}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0007_n2","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"В FDA решения всё чаще «сходятся» к одному лидеру/человеку, а не принимаются с участием рядовых ревьюеров; при этом рядовые сотрудники «всё чаще» уходят.","text_en":"FDA decisions are increasingly concentrated in a single leader/person rather than rank-and-file reviewers; rank-and-file staff are increasingly leaving.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0007","quote":"some of these decisions increasingly are coming down to a single person, a single leader"},{"chunk_id":"doc_9c939613944c_chunk_0007","quote":"Those rank and file review staff are increasingly heading for the exits."}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0007_n3","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Для пациентов со 2-й линией и далее при меланоме «нет хороших терапий», а стандарт лечения даёт однозначные (single-digit) проценты ответов.","text_en":"For second-line+ melanoma patients there are no good therapies, and standard-of-care response rates are in the single digits.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0007","quote":"Unfortunately, there are no good therapies for second-line plus. Melanoma patients, response rates for the standard of care, somewhere in the single-digit range."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0008_n1","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"FDA/агентство не одобрило препарат, посчитав, что single-arm study недостаточно для одобрения в онкологии; отсутствие рандомизированного контролируемого исследования стало ключевым барьером.","text_en":"FDA did not approve, stating a single-arm study was inadequate for oncology approval; lack of a randomized controlled study was a key barrier.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0008","quote":"What the drug did not have was a randomized controlled study."},{"chunk_id":"doc_9c939613944c_chunk_0008","quote":"a single arm study was not adequate to support approval in oncology"}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0008_n2","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"Стандарт лечения изменился из‑за одобрения другого препарата в промежутке времени, что повлияло на контекст рассмотрения.","text_en":"Standard of care shifted due to another approval in the interim, affecting the review context.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0008","quote":"what happened in the intervening period is that antagonism was approved."},{"chunk_id":"doc_9c939613944c_chunk_0008","quote":"the standard of care changed a little bit."}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0008_n3","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"В нишевых онкологических показаниях сложно моделировать продукт/коммерческий потенциал, потому что врачи по-разному находят подходящих пациентов и применяют терапию.","text_en":"In niche oncology settings, it’s hard to model a product because physicians variably identify the right patients and how to use it.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0008","quote":"it's so hard sometimes to model an oncology product in these kind of relatively niche settings."},{"chunk_id":"doc_9c939613944c_chunk_0008","quote":"You give them a product, they find the right patients to treat with it"}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0009_n1","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Регуляторная непредсказуемость/«последняя минута» смены тона со стороны FDA может быть разрушительной для компаний.","text_en":"Regulatory unpredictability/last-minute FDA tone shifts can be highly disruptive for companies.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0009","quote":"\"last-minute change in tone, that arbitrary nature\""},{"chunk_id":"doc_9c939613944c_chunk_0009","quote":"\"Is potentially so disruptive\""},{"chunk_id":"doc_9c939613944c_chunk_0009","quote":"\"the risk of surprises going forward, the risk of uncertainty for sure.\""}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0009_n2","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Малые биотехи могут не иметь ресурсов на рандомизированное контролируемое исследование, что блокирует вывод препарата на рынок.","text_en":"Small biotechs may lack resources to run an RCT, which can block bringing a drug to market.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0009","quote":"\"they don't have the resources to do a randomized controlled trial.\""},{"chunk_id":"doc_9c939613944c_chunk_0009","quote":"\"This drug's never coming to market. It's going to die.\""}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0009_n3","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"Восприятие, что прежние договорённости с FDA нужно «пере-согласовывать» при новом руководстве, повышает неопределённость и стоимость капитала.","text_en":"Perception that prior FDA agreements must be re-agreed under new leadership increases uncertainty and cost of capital.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0009","quote":"\"Anything that was agreed to in the past needs to be. Re-agreed to today\""},{"chunk_id":"doc_9c939613944c_chunk_0009","quote":"\"increased uncertainty in our industry, that means increased cost of capital.\""}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0010_n1","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Аналитикам/инвесторам не хватает ясности и прозрачности; присутствует информационная асимметрия, из‑за чего сложно интерпретировать решения/ситуации без переписки и протоколов.","text_en":"Analysts/investors lack clarity and transparency; informational asymmetry makes it hard to interpret situations without minutes/correspondence.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0010","quote":"But we need to see better clarity and transparency."},{"chunk_id":"doc_9c939613944c_chunk_0010","quote":"There's such a level of like informational asymmetry, right?"},{"chunk_id":"doc_9c939613944c_chunk_0010","quote":"I haven't looked at meeting minutes or correspondence, and so it's hard."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0010_n2","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Регуляторные барьеры: негативное голосование adcom против одобрения из‑за профиля побочных эффектов (особенно глазных) и вопросов к доле пациентов из США; вместо CRL FDA продлила PDUFA.","text_en":"Regulatory constraints: adcom voted against approval due to side-effect profile (especially ocular) and questions about low US patient share; FDA extended PDUFA instead of issuing a CRL.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0010","quote":"adcom uh odak basically voted against uh the approval."},{"chunk_id":"doc_9c939613944c_chunk_0010","quote":"They've extended the PDUFA."},{"chunk_id":"doc_9c939613944c_chunk_0010","quote":"The side effect profile... especially the eye side effect profiles, we don't like that."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0010_n3","doc_id":"doc_9c939613944c","kind":"opportunity","text_ru":"Возможность вернуться к регулятору с изменённым режимом дозирования (например, более низкая доза/большие интервалы) на основе других датасетов/испытаний.","text_en":"Opportunity to re-engage the regulator with a modified dosing regimen (e.g., lower dose/longer intervals) based on other datasets/trials.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0010","quote":"data sets... does show an opportunity to come back, perhaps. With a modified dosing request to the regulator"},{"chunk_id":"doc_9c939613944c_chunk_0010","quote":"they could certainly go back and talk about lower doses, longer times. Between dosing"}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Клиническая разработка ингаляционной формулы DMT в США застряла на clinical hold из‑за токсикологической находки у крыс; FDA требует обоснования, что эффект крысо-специфичен.","text_en":"US clinical development is stuck on a clinical hold due to a rat toxicity finding; FDA wants justification that it’s rat-specific.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0011","quote":"have so far been unable to get their product off clinical hold."},{"chunk_id":"doc_9c939613944c_chunk_0011","quote":"the FDA... had issues with a rat finding. That was a laryngeal toxicity finding, and they wanted the company to essentially show and justify that this is a rat-specific issue."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"Есть выраженная неопределённость/информационная асимметрия вокруг причин, почему hold не снимается, и инвесторы не понимают, что ещё FDA нужно услышать.","text_en":"There’s strong uncertainty/information asymmetry about why the hold isn’t lifted, and investors don’t know what else FDA needs.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0011","quote":"there's such a level of like informational asymmetry"},{"chunk_id":"doc_9c939613944c_chunk_0011","quote":"it's a little bit confusing, right?"},{"chunk_id":"doc_9c939613944c_chunk_0011","quote":"investors are grappling with. Do we even really know what else the FDA needs to hear"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"Описывается сигнал, что агентство может быть более «accommodating» к психоделикам и не хочет, чтобы компании делали клиническую разработку ex‑US «потому что думают, что должны».","text_en":"Signal that the agency may be more accommodating to psychedelics and doesn’t want companies to do ex‑US clinical work just because they think they have to.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0011","quote":"this agency... geared up to potentially be you know bullish for the psychedelic space right and more accommodating there"},{"chunk_id":"doc_9c939613944c_chunk_0011","quote":"they're also talking about right not wanting companies to to do clinical work ex-US just because they think they have to"}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0012_n1","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Для класса орексинов есть неопределённость/контроверсия по безопасности: наблюдались «mild visual disturbances» (светочувствительность), и рынок ждёт полного safety-апдейта.","text_en":"Orexin class has safety uncertainty: reported “mild visual disturbances” (light sensitivity) and the market is waiting for a full safety update.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0012","quote":"has seen a few cases of quote-unquote mild visual disturbances. Which largely have been described as like light sensitivity."},{"chunk_id":"doc_9c939613944c_chunk_0012","quote":"the controversy here relates to safety."},{"chunk_id":"doc_9c939613944c_chunk_0012","quote":"didn't really give us any color on this piece and sort of said, 'Wait for the full data, for the full safety update.'"}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0012_n2","doc_id":"doc_9c939613944c","kind":"buyer_signal","text_ru":"Непрозрачность по safety может сильнее наказываться рынком, чем умеренно негативная реальность (сигнал о важности раскрытия данных для инвесторов).","text_en":"Safety opacity may be penalized by the market more than mildly negative reality (investor sensitivity to disclosure).","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0012","quote":"opacity is often discounted even more than a mildly negative reality when it comes to stocks."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0012_n3","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"Abivax показал сильные Phase 3 данные в язвенном колите для перорального препарата, несмотря на неясный механизм; отмечены хорошие безопасность и эффективность, сопоставимая с инъекционными IL-23.","text_en":"Abivax reported strong Phase 3 ulcerative colitis results for an oral drug despite unclear mechanism; safety looked good and efficacy compares favorably to injectable IL-23s.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0012","quote":"read out positively in ulcerative colitis"},{"chunk_id":"doc_9c939613944c_chunk_0012","quote":"The phase three data were really solid."},{"chunk_id":"doc_9c939613944c_chunk_0012","quote":"compare relatively favorably to the injectable agents, the IL-23s."}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0013_n1","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"«Underwater» опционы сотрудников/руководства/совета после падения акции создают проблему: люди не чувствуют участия в успехе компании и это ухудшает удержание.","text_en":"Underwater employee/executive/board options after stock decline create a retention problem: people don’t feel they participate in company success.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0013","quote":"If you have underwater options, you feel like you're not participating in the success of the company... it prevents the options... which is aid employee retention."}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0013_n2","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Замена/репрайсинг опционов воспринимается инвесторами как риск рассинхронизации стимулов и потенциальный дисинцентив работать в интересах инвесторов.","text_en":"Option replacement/repricing is seen by investors as misaligning incentives and potentially creating disincentives to perform for investors.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0013","quote":"we in the investment world hate. When options are replaced, we feel like that misaligns the incentives... create some disincentives"}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0013_n3","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"Рынок изменился по сравнению с периодом «bull market» после COVID; обсуждается «коррекция» и наличие «слишком многих компаний» в разработке.","text_en":"Market conditions have shifted from the post-COVID bull market; there’s talk of a correction and too many companies in development.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0013","quote":"we are in a much different state than we were four years ago... big bull market coming off COVID... see the value to seeing a little bit of the correction"}],"confidence":"medium"}
{"nugget_id":"doc_9c939613944c_chunk_0014_n1","doc_id":"doc_9c939613944c","kind":"pain","text_ru":"После провала ключевого препарата компании рискуют потерять ключевых сотрудников; обсуждается репрайсинг опционов как способ удержания.","text_en":"After a key drug failure, companies risk losing key staff; option repricing is discussed as a retention measure.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0014","quote":"\"You can't have your drug, one of your key drugs not working, then all your key people leave.\""}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0014_n2","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"Доля лицензирования препаратов, источником которых является Китай, выросла до 14% (с ~9% в прошлом году и почти нуля несколько лет назад); большинство таких активов — биологические препараты.","text_en":"China-sourced drug licensing share rose to 14% (from ~9% last year and near zero a few years ago); most are biologics.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0014","quote":"\"The share of drug licensing for drugs sourced out of China rose to 14%.\""},{"chunk_id":"doc_9c939613944c_chunk_0014","quote":"\"the majority of the drugs. That's close to 90% of them are biologics\""}],"confidence":"high"}
{"nugget_id":"doc_9c939613944c_chunk_0014_n3","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"Крупные фармкомпании обсуждают прямые продажи лекарств потребителям в США; в центре — обсуждения с HHS и возможная необходимость изменений в законодательстве, на фоне разговоров об ограничении DTC-рекламы.","text_en":"Large pharma are discussing direct-to-consumer drug selling in the US; discussions with HHS and possible legislative changes are noted amid talk of limiting DTC advertising.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0014","quote":"\"they're all talking about this direct consumer drug selling.\""},{"chunk_id":"doc_9c939613944c_chunk_0014","quote":"\"The core of all is discussions with HHS\""},{"chunk_id":"doc_9c939613944c_chunk_0014","quote":"\"do we need any legislation changes or not\""}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_9c939613944c","kind":"constraint","text_ru":"Обсуждается потенциальное ограничение: можно продавать лекарства напрямую потребителям, но нельзя рекламировать им напрямую.","text_en":"Potential constraint discussed: you can sell direct-to-consumer, but cannot advertise to them.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0015","quote":"You can sell direct to consumers, but you can't advertise to them."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_9c939613944c","kind":"trend","text_ru":"AstraZeneca объявила о крупной пятилетней инвестиции в США ($50 млрд).","text_en":"AstraZeneca announced a large five-year investment in the US ($50B).","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0015","quote":"AstraZeneca announced, which was a $50 billion, five-year investment in the US."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_9c939613944c","kind":"opportunity","text_ru":"Озвучена идея, что снижение цен на лекарства может быть достигнуто через прямые продажи (go direct) и исключение посредников.","text_en":"Idea presented that drug prices could be reduced by going direct and cutting out the middleman.","evidence":[{"chunk_id":"doc_9c939613944c_chunk_0015","quote":"the easiest way to bring down pricing would be to go direct, cut out the middleman"}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0000_n1","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Письма администрации к фармкомпаниям с требованиями MFN не содержат описания статутных/регуляторных полномочий для их принудительного исполнения.","text_en":"Administration letters demanding MFN actions do not outline statutory or regulatory authority for enforcement.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0000","quote":"The letters do not outline any statutory or regulatory authorities."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0000_n2","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"Есть неопределённость и сложность вокруг требования гарантировать MFN-цены для новых запусков: непонятно, что будет с уже существующими продуктами при более низкой цене нового аналога (пример: новый GLP-1).","text_en":"Uncertainty/complexity around guaranteeing MFN pricing for newly launched drugs and implications for existing products if a new entrant launches cheaper (e.g., a new GLP-1).","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0000","quote":"The question then is, what happens if somebody comes with a new GLP-1 and they launch it at a lower price?"}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0000_n3","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Требование «вернуть» увеличенные доходы из-за рубежа пациентам/налогоплательщикам в США выглядит трудноисполнимым: непонятно, как это можно обеспечить и на какой правовой основе.","text_en":"The demand to return increased ex-US revenues to US patients/taxpayers appears hard to enforce, with unclear mechanism and legal basis.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0000","quote":"Well, how are you going to enforce that? And what is the point of MFN?"}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_nugget_0001","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"Агрессивные и недостаточно продуманные инициативы по реформе/переговорам цен на лекарства могут создавать «хаос» и «disturbances» для сектора.","text_en":"Aggressive, not well-thought-out drug pricing/negotiation initiatives may create chaos and disturbances across the sector.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0001","quote":"\"they're kind of so aggressive and not necessarily well thought out. They create much more chaos\""},{"chunk_id":"doc_4fb9857a2b2d_chunk_0001","quote":"\"if these are implemented in mass, it's going to create so many disturbances across the sector\""}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_nugget_0002","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Не удаётся найти простой юридический фреймворк для реализации инициативы; ожидается юридическое сопротивление со стороны компаний.","text_en":"A clear legal framework is lacking; companies are expected to resist legally.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0001","quote":"\"we've not been able to find a legal framework through which this could be easily implemented\""},{"chunk_id":"doc_4fb9857a2b2d_chunk_0001","quote":"\"companies will bring all their power to resist it from a legal perspective\""}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_nugget_0003","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Отмечается появление Китая как более низкозатратного поставщика инноваций, что влияет на глобальное ценообразование и конкуренцию.","text_en":"China is emerging as a lower-cost provider of innovation, affecting global pricing and competition.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0001","quote":"\"you have China emerging as a lower cost provider of innovation\""}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0002_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Китай рассматривается как потенциально более низкозатратный и быстро усиливающийся конкурентный источник сопоставимых терапий/фармацевтики.","text_en":"China is seen as a potential lower-cost, rapidly increasing competitor/provider of comparable therapies/pharmaceuticals.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0002","quote":"China emerging as a lower cost provider of innovation"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0002","quote":"China's changing by the minute in terms of their competitiveness."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0002_n2","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Ожидание, что компании будут подавать зарубежные данные по ценам правительству США, может столкнуться с трудностями, если за пределами США тот же препарат продаёт другая компания, не желающая раскрывать цены.","text_en":"Submitting overseas pricing data to the US government may be difficult when a different company sells the same drug ex-US and may not disclose prices.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0002","quote":"companies are expected to submit their pricing data overseas to the U. S. government."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0002","quote":"it may be difficult to get that other company to disclose their prices."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0002_n3","doc_id":"doc_4fb9857a2b2d","kind":"buyer_signal","text_ru":"Инвестсообщество, по словам спикера, «массово дисконтирует» вероятность реализации обсуждаемого сценария; позиция — «подождать и посмотреть, как это сыграет».","text_en":"The investment community is said to be heavily discounting the scenario; the stance is to wait and see how it plays out.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0002","quote":"the investment community is still massively discounting this becoming a reality"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0002","quote":"let's wait and see how it actually plays out"}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0003_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Новые препараты почти всегда сначала запускаются в США, а европейские запуски обычно происходят примерно через два года.","text_en":"New drugs almost always launch first in the US, with European launches typically about two years later.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0003","quote":"new drugs almost always launch first in the US."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0003","quote":"wait two years, which is about the sort of time it takes to get the European launches going, usually."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0003_n2","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Для некоторых высокоценовых препаратов цена в Европе становится примерно такой же, как в США, и компании фактически «сдаются» по доступу в Европе, концентрируя продажи в США.","text_en":"For some high-priced drugs, Europe pricing is roughly the same as the US, with companies effectively giving up on European access and relying heavily on US sales.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0003","quote":"the price is actually basically the same in Europe as it is here."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0003","quote":"they've just given up on European access."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0003","quote":"such a huge percentage of that's coming from the U.S."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0003_n3","doc_id":"doc_4fb9857a2b2d","kind":"buyer_signal","text_ru":"Администрация и CMS, по услышанному в Вашингтоне, хотят сотрудничать с индустрией и ждут от неё предложений; при этом CMS нацелена на борьбу с fraud/waste и неэффективностями посредников (PBMs).","text_en":"The administration and CMS reportedly want to collaborate with industry and solicit proposals; CMS is targeting fraud/waste and middlemen inefficiencies (PBMs).","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0003","quote":"the administration is actually looking to collaborate with industry. They want proposals from industry"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0003","quote":"CMS really wants to work with industry in a collaborative way"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0003","quote":"CMS is really targeting fraud, waste, and in particular, middlemen inefficiencies, so PBMs."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0004_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Китай теперь составляет около 30% глобальных стартов клинических исследований, почти сравнявшись с долей США (35%).","text_en":"China now accounts for ~30% of global clinical trial starts, nearly matching the U.S. share (35%).","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0004","quote":"it now accounts for 30% of global clinical trial starts. It's nearly matching the U. S. share, which is 35%."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0004_n2","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"Есть серьёзная обеспокоенность кражей IP со стороны Китая и угрозой лидерству США в биотехе; описывается копирование IP и ускоренная разработка.","text_en":"Major concern about China’s IP theft and threat to U.S. biotech leadership; described as copying IP and fast-tracking development.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0004","quote":"a major concern around China. and China's IP theft. and its threat to U. S. biotech leadership."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0004","quote":"Chinese companies copying IP and then moving to fast-track development."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0004_n3","doc_id":"doc_4fb9857a2b2d","kind":"opportunity","text_ru":"Обсуждаются идеи мер для защиты IP США: введение регуляторных/реимбурсных/финансовых «penalties» и стимулы для M&A, применимые к U.S.-based biotech (например, сохранение NOLs).","text_en":"Proposed ideas to protect U.S. IP: regulatory/reimbursement/funding-related penalties and M&A incentives for U.S.-based biotechs (e.g., retaining NOLs).","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0004","quote":"introducing regulatory reimbursement and funding-related penalties to protect U. S. intellectual property."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0004","quote":"incentives around M&A. That only apply to U. S.-based biotechs... allow U. S.-based biotech companies to retain their NOLs."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0005_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Генерация множества новых T cell engager’ов и получение phase 1 данных становится «commodity good», то есть больше не воспринимается как инновация.","text_en":"Generating many new T cell engagers and phase 1 data is becoming a commodity rather than innovation.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0005","quote":"\"Generating 50- CD19 T cell engagers... and generating phase one data... It just turns out that's a commodity good now.\""}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0005_n2","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Ожидается ужесточение условий ведения бизнеса с Китаем из‑за того, что политики начнут понимать, что «аутсорсится» инновационная/научная часть; это может произойти в ближайшие 2–3 года.","text_en":"Business with China may become harder as politicians react to outsourcing innovation/science, possibly within 2–3 years.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0005","quote":"\"they're going to make changes that's going to make it a lot more difficult to do business with China\""},{"chunk_id":"doc_4fb9857a2b2d_chunk_0005","quote":"\"something big is going to happen on this over the next two or three years.\""}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0005_n3","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Китайский biotech, по мнению спикера, «100% reliant on succeeding in the United States» для существования сектора, то есть сильно зависит от успеха на рынке США.","text_en":"China’s biotech sector is described as fully reliant on succeeding in the U.S., implying strong dependence on the U.S. market.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0005","quote":"\"They're on thinner ice than we are because they are 100% reliant on succeeding in the United States to even have a biotech sector.\""}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0006_n1","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"Разочарование: ожидания, что Китай будет платить за инновационные лекарства, «не материализовались» за последние 6–7 лет.","text_en":"Disappointment that China’s pharma/innovative drug pricing (what they pay for drugs) hasn’t materialized over the last 6–7 years.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0006","quote":"Disappointments of the last like six or seven years is how China's pharmaceutical and innovative like what they pay for drugs has never materialized."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0006_n2","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Часть сделок (упоминается 30%) уходит китайским компаниям, а финансирование американских стартапов в discovery/early-stage science сокращается.","text_en":"A share of deals (30% mentioned) is going to Chinese companies while funding for US discovery/early-stage startups has stopped.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0006","quote":"we've stopped funding our startups that are working on discovery and early stage science."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0006","quote":"Like, that 30% of deals, it's going to Chinese companies."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0006_n3","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Регуляторная структура и разница в издержках/скорости (в Китае «пять человек там на одного здесь») делают невозможным «выровнять поле» простым ослаблением правил FDA.","text_en":"Regulatory structure plus cost/speed differences (\"five people there for every one here\") make it impossible to level the playing field by simply loosening FDA rules.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0006","quote":"you can have five people there for every one here."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0006","quote":"it's impossible to change the regulatory structure here to level that playing field exactly."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0007_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Обсуждаются слухи о возможной реструктуризации в FDA: выделение вакцинного подразделения и объединение CBER и CDER.","text_en":"Rumors discussed about a potential FDA restructuring: spinning out the vaccines division and combining CBER and CDER.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0007","quote":"rumors of a potential restructuring. at FDA to spin out the vaccines division and combine CBER and CDER."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0007_n2","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"Индустрия и инвесторы воспринимали, что при руководстве CBER планки для программ стали существенно выше, чем раньше, что вызывало обеспокоенность.","text_en":"Industry/investors perceived a much higher bar for programs under CBER leadership than before, creating concern.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0007","quote":"Holding programs to a much higher bar than, you know, certainly we're used to for Peter Marks"}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0007_n3","doc_id":"doc_4fb9857a2b2d","kind":"buyer_signal","text_ru":"Удаление руководителя CBER инвесторы рассматривают как краткосрочно позитивное для акций, ожидая большей «лениенси» для компаний с небольшими/неоднозначными датасетами.","text_en":"Investors view the CBER leader’s removal as near-term positive for stocks, expecting more leniency for small/ambiguous datasets.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0007","quote":"His removal has been viewed by investors as at least near-term positive for stocks"}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0008_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"DMD advocacy-группы описываются как «чрезвычайно мощные» и потенциально влияющие на решения FDA по одобрениям препаратов при DMD.","text_en":"DMD advocacy groups are described as extraordinarily powerful and potentially influencing FDA decision-making on DMD drug approvals.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0008","quote":"the DMD advocacy groups are extraordinarily powerful."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0008","quote":"mothers who have had direct influence on ultimate decision makers within the FDA around DMD drug approvals."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0008_n2","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"На FDA listening session обсуждались направления: упрощение операций FDA, устранение дублирования, снижение повторного тестирования и «регуляторная гибкость».","text_en":"An FDA listening session discussed streamlining operations, eliminating redundancies, reducing duplicate testing, and regulatory flexibility.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0008","quote":"streamlining FDA operations, eliminating redundancies, reducing duplicate testing, regulatory flexibility."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0008_n3","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"В контексте тарифов отмечено, что в итоговой версии «pharmaceuticals were included», а также обсуждается неопределённость, включены ли фармпродукты в тарифы для Швейцарии.","text_en":"In the tariffs discussion, pharmaceuticals were said to be included, with uncertainty about whether Swiss tariffs include pharmaceuticals.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0008","quote":"the final bottom line was that pharmaceuticals were included."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0008","quote":"there was a question as to whether that includes pharmaceuticals or not."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0009_n1","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Многие малые и средние biotech-компании в США не имеют капитала/возможностей перенести производство; до появления достаточных и доступных мощностей CDMO в США им будет трудно соответствовать требованиям.","text_en":"Many small-to-mid US biotech companies lack capital/capability to move manufacturing; until sufficient affordable US CDMO capacity exists, compliance will be tough.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0009","quote":"most U. S. small to mid-sized biotech companies don't have the capital or capability to move their manufacturing"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0009","quote":"until there's sufficient and affordable U. S. capacity at CDMOs, it's going to be. small tough for smaller companies to comply"}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0009_n2","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Сенатский комитет по ассигнованиям отклонил предложенное администрацией сокращение финансирования NIH и продвинул меру об увеличении бюджета примерно на $400 млн (если реализуется, это позитивно для biotech-экосистемы).","text_en":"Senate Appropriations Committee rejected proposed NIH funding cut and advanced a measure to increase the budget by about $400M (potentially positive for biotech ecosystem).","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0009","quote":"the Senate Appropriations Committee rejected the administration's proposed funding cut to the NIH, advancing a measure that would increase the budget by about $400 million"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0009","quote":"it seems to be good news for the biotech ecosystem if it plays out"}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0009_n3","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Обсуждается возможная перестройка профилактической health task force (меньше врачей/медсестёр, больше диетологов/терапевтов) и «overhauling» программы компенсаций за вред от вакцин, что может привести к большему числу судебных разбирательств.","text_en":"Possible restructuring of preventive health task force and overhauling vaccine injury program, potentially leading to more litigation.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0009","quote":"he wants to restructure the preventive health task force"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0009","quote":"overhauling the vaccine injury program and wanting vaccine injury victims to be compensated quickly and fairly"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0009","quote":"which is obviously going to mean a lot of litigation"}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0010_n1","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"У крупных фармкомпаний есть давление на P&L, из‑за чего им приходится пересматривать портфели и принимать «тяжёлые решения» по активам.","text_en":"Large pharma faces P&L pressure, forcing portfolio work and tough asset decisions.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0010","quote":"they have a lot of P &L pressure. They need to work on their portfolios and they need to make tough decisions."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0010_n2","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Ожидается рост числа «креативных» партнёрских структур (spinco/опционные сделки), чтобы программы продолжали развиваться.","text_en":"More creative partnership structures (spinco/option-like deals) are expected to keep programs moving forward.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0010","quote":"expect we'll see more. And more similar things happening from them and from others in the future."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0010","quote":"creative partnership structures that allow those programs to continue to be developed."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0010_n3","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"Ранние стадии разработки (phase 1) в текущей системе выполняются медленнее и дороже, чем у некоторых игроков, что воспринимается как «структурная проблема», которую «нужно исправить».","text_en":"Early-stage (phase 1) development is slower and more expensive in the current system vs some players, seen as a structural problem to fix.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0010","quote":"they can do these phase ones and that early stage development much faster and much cheaper than currently we can."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0010","quote":"it really shines a light on what a structural problem this is."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0011_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Мейнстримные фармкомпании (упоминаются AbbVie и J&J) «идут all in» в психоделики, что воспринимается как валидация направления.","text_en":"Mainstream pharma (AbbVie and J&J mentioned) are going “all in” on psychedelics, seen as validation of the space.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0011","quote":"it reflects, you know, another player that's a mainstream player in the case of Abbey here and J &J over there going all in on on psychedelics."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0011_n2","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"У психоделиков остаются коммерческие вопросы по масштабируемости модели и практические вопросы по безопасности и масштабируемости в реальном мире.","text_en":"Psychedelics still face commercial questions about model scalability and real-world questions around safety and scalability.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0011","quote":"there were some really, really significant commercial questions around the scalability of the model with these drugs."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0011","quote":"their own questions around safety, their own questions around scalability in the real world."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0011_n3","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Малые и средние биотех-компании стали более ресурсными и более «софистицированными» при запуске препаратов по сравнению с прошлым.","text_en":"Small to mid-size biotechs are more well-resourced and sophisticated in drug launches than in the past.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0011","quote":"just midsize, small to midsize companies, are just much more well-resourced and much more sophisticated when they launch drugs."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0012_n1","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Есть «много препятствий» для прихода generalist-инвесторов/участников в сектор biotech.","text_en":"There are many impediments to bringing generalist participants/investors into the biotech sector.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0012","quote":"there's still a lot of impediments to getting generalists in the sector."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0012_n2","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"В этом году наблюдается сдвиг в пользу коммерческих историй/запусков: «short the launch» стало более опасной стратегией, а коммерческие истории выглядят лучше, чем исторически.","text_en":"This year, sentiment has shifted toward commercial launch stories; “short the launch” has become riskier and commercial stories look more favorable than historically.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0012","quote":"it feels like now that's become just a lot more dangerous for people."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0012","quote":"in my coverage universe, the commercial stories are, you know, more in favor versus how they've been historically"}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0012_n3","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Для anti-amyloid терапий есть существенные барьеры по включению пациентов в лечение, включая диагностику и подтверждение статуса (positive).","text_en":"For anti-amyloid therapies, there are major hurdles to getting patients on therapy, including diagnosis and confirming a positive status.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0012","quote":"there's certainly a lot of hurdles to getting patients on therapy."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0012","quote":"a big hurdle. is getting patients diagnosed and with a positive."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0013_n1","doc_id":"doc_4fb9857a2b2d","kind":"pain","text_ru":"Серьёзный барьер для назначения анти-амилоидной терапии — диагностика и подтверждение наличия амилоида (в т.ч. решение, кому делать PET).","text_en":"A major hurdle to anti-amyloid therapy uptake is diagnosis and confirming amyloid presence (including deciding who should get PET).","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0013","quote":"there's certainly a lot of hurdles to getting patients on therapy... getting patients diagnosed and with a positive confirmation of amyloid presence."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0013","quote":"usage of blood-based biomarkers right now to sort of... whether or not a patient... should go on for a PET or not"}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0013_n2","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Наблюдается рост использования и улучшение blood-based biomarkers для корреляции с амилоидом на PET; Biogen отмечает трёхкратный рост за год.","text_en":"Blood-based biomarkers correlating with amyloid PET are improving and seeing increased use; Biogen noted a threefold increase over the last year.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0013","quote":"we've seen an emergence of these blood-based biomarkers looking to correlate with amyloid on PET, and they're getting better and better."},{"chunk_id":"doc_4fb9857a2b2d_chunk_0013","quote":"Biogen had was, 'That they've sort of seen the blood-based biomarkers increase threefold over the last year.'"}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0013_n3","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Масштабирование терапии ограничено мощностями системы: доступом к неврологам (rate-limiting), а также высоким screen failure (85–90%) в Lilly trial.","text_en":"Scaling is constrained by system capacity: access to neurologists is rate-limiting, and Lilly trial screening failure remains 85–90%.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0013","quote":"Biogen has said over and over that one of the rate-limiting features of this launch has been... Getting people to see a neurologist"},{"chunk_id":"doc_4fb9857a2b2d_chunk_0013","quote":"if you look at the Lilly trial, the screen failure rate is still like 85% to 90%"}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Внедрение тестов в реальной практике под вопросом: непонятно, будут ли они доступны в первичном звене или всё сведётся к направлению к неврологу из‑за мониторинга ARIA.","text_en":"Real-world implementation of tests is uncertain: unclear if they can be in primary care or will still require neurologist referral due to ARIA monitoring.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0014","quote":"How are we going to implement these tests? ... are they really going to be in like primary care... referral to a neurologist, because the ARIA monitoring"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"Сложные экономические договорённости/обременения в пакте с Gilead ограничивают гибкость Galapagos и создают неопределённость до их урегулирования.","text_en":"Complex economic arrangements/encumbrances in the Gilead pact constrain Galapagos and create uncertainty until resolved.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0014","quote":"until the economic arrangement and framework with Gilead is truly sorted out. You have a box of cash that has some really complicated encumbrances"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"В последние недели/месяцы новостной поток в биотехе улучшился: много результатов клинических испытаний, отдельные компании резко выросли, некоторые запуски идут хорошо.","text_en":"Biotech news flow has improved recently: many trial readouts, some companies surged, and some launches are going well.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0014","quote":"over the last three or four weeks? We've seen companies literally quadruple or quintuple"}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0015_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"На фоне «депрессивных» оценок в секторе наблюдаются крупные движения на клинических катализаторах (200–400%).","text_en":"With depressed valuations, large moves on clinical catalysts (200–400%) are being observed.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0015","quote":"You see catalysts that can lead to 200, 300, 400 percent. moves because the valuations have been so depressed."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0015_n2","doc_id":"doc_4fb9857a2b2d","kind":"constraint","text_ru":"В секторе присутствуют регуляторные и государственные риски/опасения.","text_en":"There are regulatory and government concerns in the sector.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0015","quote":"There's a lot of regulatory concerns. Government concerns."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0015_n3","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Появляются признаки «risk-on»: больше финансирований, акции лучше торгуются на данных.","text_en":"Risk-on signs are emerging: more financings and stocks trading better on data.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0015","quote":"We're seeing more financings. Stocks have been trading better on data."}],"confidence":"high"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0016_n1","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Изменение M&A-климата приводит к тому, что биотех-компании реже покупают, и они запускают продукты как клинические компании.","text_en":"A changed M&A climate means biotech companies are less often acquired and are launching products as clinical-stage companies.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0016","quote":"Biotech companies launching products well because the M &A climate has changed, so they haven't been bought."}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0016_n2","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"В индустрии ожидается коммодитизация новых частей, что приведёт к изменениям/развитию в других сегментах.","text_en":"New parts of the industry are expected to become commoditized, driving developments in other segments.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0016","quote":"new parts of the industry are going to be commoditized and it's going to lead to like interesting developments in other parts of the industry"}],"confidence":"medium"}
{"nugget_id":"doc_4fb9857a2b2d_chunk_0016_n3","doc_id":"doc_4fb9857a2b2d","kind":"trend","text_ru":"Наблюдается «whiplashy» (рывковая) краткосрочная динамика, подпитываемая политической турбулентностью.","text_en":"There is whiplashy short-term behavior fueled by political turbulence.","evidence":[{"chunk_id":"doc_4fb9857a2b2d_chunk_0016","quote":"Getting away from some of the political turbulence... It's been so sort of whiplashy."}],"confidence":"low"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0000_n1","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Обсуждается усиление/эскалация политики по фарм-тарифам и MFN: после анонсов и писем компаниям заявлено, что тарифы могут быть объявлены в ближайшее время и достигать очень высоких уровней.","text_en":"Policy escalation around pharma tariffs and MFN: after announcements and letters to companies, tariffs may be announced soon and could reach very high levels.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0000","quote":"President Trump said pharmaceutical tariffs will be announced as soon as next week and could reach up to 250 percent."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0000_n2","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Сценарии высоких тарифов или MFN (самая низкая net price для Medicaid по группе стран) описываются как «объективно плохие» для индустрии и создают неопределённость по исходам.","text_en":"High-tariff or MFN scenarios (Medicaid getting the lowest net price across countries) are described as objectively bad for the industry and create outcome uncertainty.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0000","quote":"taken 250% or... companies have to just give Medicaid the lowest net price... this is just objectively bad for the industry."},{"chunk_id":"doc_903c28cb5ad1_chunk_0000","quote":"there's still a very, very wide range of potential outcomes here."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0000_n3","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"Тарифную составляющую сложно «встроить» в оценку компаний; при этом компании намекают на использование юридических/бухгалтерских механизмов (transfer price и т.п.) для смягчения эффекта.","text_en":"Tariffs are hard to model into company valuation; companies hint at using legal/accounting mechanisms (transfer pricing, etc.) to mitigate impact.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0000","quote":"the tariff piece... is the harder one to kind of value into companies."},{"chunk_id":"doc_903c28cb5ad1_chunk_0000","quote":"smart lawyers and accountants... working on ways... transfer price... to kind of mitigate the impact."}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0001_n1","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Для фармсектора более болезненная/страшная тема — MFN, а не тарифы; при этом исходы остаются неопределёнными.","text_en":"For pharma, MFN is seen as the scarier sore spot than tariffs, with a wide range of possible outcomes.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0001","quote":"I think that that is the far scarier thing here for the sector."},{"chunk_id":"doc_903c28cb5ad1_chunk_0001","quote":"think that it's MFN and less so tariffs that are the industry's sore spot right now."},{"chunk_id":"doc_903c28cb5ad1_chunk_0001","quote":"Uh, but still a wide range of outcomes."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0001_n2","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"Тарифные меры могут быть частично обходимы через структурирование цепочки поставок (низкая таможенная стоимость при импорте + последующие операции в США), что снижает эффективность тарифов как рычага.","text_en":"Tariffs may be partially circumvented via supply-chain structuring (low import price points plus later US fill/finish), reducing tariffs’ effectiveness as leverage.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0001","quote":"the accountants have already figured out how to game the system with regard to tariffs"},{"chunk_id":"doc_903c28cb5ad1_chunk_0001","quote":"import drugs. Price points in their supply chain that are relatively modest and low"},{"chunk_id":"doc_903c28cb5ad1_chunk_0001","quote":"subsequently either fill, finish, or do other things in the United States"}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0001_n3","doc_id":"doc_903c28cb5ad1","kind":"buyer_signal","text_ru":"Крупные фармкомпании ведут переговоры с администрацией (в т.ч. вокруг MFN/тарифов), что указывает на активную потребность в решении/сделке.","text_en":"Large pharma companies are in negotiation discussions with the administration (incl. around MFN/tariffs), indicating active demand for a deal/solution.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0001","quote":"We did hear from multiple large pharma companies... that they are having those types of negotiation discussions with the administration."},{"chunk_id":"doc_903c28cb5ad1_chunk_0001","quote":"My suspicion... would only happen if. the industry maybe comes to the table a little bit more and strikes a deal on MFN."}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0002_n1","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Обсуждается возможность возвращения Dr. Prasad в FDA/CBER: Dr. Macari говорит о почти ежедневных разговорах и приглашении вернуться.","text_en":"Possible return of Dr. Prasad to FDA/CBER is being discussed; Dr. Macari says he talks to him almost daily and invited him back.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0002","quote":"Dr. Macari went even further and said that he's in almost daily conversations with Dr. Prasad and has invited Dr. Prasad to come back to the agency."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0002_n2","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Потенциальное возвращение спорной фигуры в регулятор может стать большим «distraction» и усложнить работу аналитиков/инвесторов (например, контекст встреч с FDA).","text_en":"A controversial regulator returning could be a major distraction and complicate analysts’/investors’ work (e.g., which FDA tenure a meeting occurred under).","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0002","quote":"this would just create, I feel like a much, much. much, much bigger distraction."},{"chunk_id":"doc_903c28cb5ad1_chunk_0002","quote":"when was your meeting with the FDA? Was it during the first tenure facade or the second?"}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0002_n3","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"Сохраняется неопределённость и непредсказуемость вокруг регуляторного руководства: нет шорт-листа, кого он заменяет, и «jury» по стилю Prasad/CBER ещё не определилось.","text_en":"Uncertainty around regulatory leadership: no shortlist of who is being replaced, and the jury is still out on what Prasad/CBER would look like.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0002","quote":"I do still feel like the jury on what the Prasad-Sieber look like was still sorted out, right?"},{"chunk_id":"doc_903c28cb5ad1_chunk_0002","quote":"we haven't seen any sort of shortlist of who he's replacing."}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0003_n1","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Непредсказуемость и «драма» в руководстве CBER/FDA создают ощущение нестабильности и зависимости решений от личности.","text_en":"Unpredictability and “drama” in CBER/FDA leadership creates instability and a sense that outcomes depend on individual personalities.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0003","quote":"we did see was a little bit more drama, for sure. And a little bit more unpredictability in his 84 days at CBER."},{"chunk_id":"doc_903c28cb5ad1_chunk_0003","quote":"This day and age, where it comes down to a single personality."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0003_n2","doc_id":"doc_903c28cb5ad1","kind":"opportunity","text_ru":"Запрос на «возврат к нормальности» и стабилизацию в FDA через более сильное организационное лидерство у руководителя.","text_en":"Desire to return to normalcy and stabilize the FDA via stronger organizational leadership in leadership roles.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0003","quote":"we need to kind of return to normalcy, right? We need almost like a little bit of a healing at the FDA."},{"chunk_id":"doc_903c28cb5ad1_chunk_0003","quote":"I hope that person can bring more of a uh— an expertise in in in organizational leadership"}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0003_n3","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"CRL(ы) могут быть связаны с производственными (manufacturing) аспектами, что выступает барьером для одобрения/продвижения.","text_en":"CRLs may be driven by manufacturing considerations, acting as a barrier to approval/progress.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0003","quote":"we've had some CRLs, one issued and maybe one in the future threatening to be issued. Around. Some manufacturing considerations."}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0004_n1","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Информационная асимметрия и слабая видимость (даже у компании) того, как FDA будет трактовать/развивать CMC/CRL-ситуацию.","text_en":"Information asymmetry and limited visibility (even for the company) into how FDA will handle a CMC/CRL situation.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0004","quote":"There's like so much level of like informational asymmetry."},{"chunk_id":"doc_903c28cb5ad1_chunk_0004","quote":"they themselves at this stage, I don't think have particularly good visibility on how this is going to play out."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0004_n2","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"Проблемная CMC-площадка (бывш. Catalent, теперь Novo, Индианаполис) с давними нерешёнными наблюдениями/483; FDA может блокировать одобрение новых препаратов, произведённых/финишируемых на этой площадке.","text_en":"A troubled CMC facility (formerly Catalent, now Novo, Indianapolis) with long-standing unresolved observations/483; FDA can block approvals of new drugs finished there.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0004","quote":"CMC programs are being filled and finished by a facility that used to be owned by Catalan and now is owned by Novo."},{"chunk_id":"doc_903c28cb5ad1_chunk_0004","quote":"This facility is based in Indianapolis. And that facility has been a troublesome facility for a long time."},{"chunk_id":"doc_903c28cb5ad1_chunk_0004","quote":"one of the leverage points that the FDA has... is by not approving new drugs through that facility."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0004_n3","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Компании оказываются «между молотом и наковальней»: не контролируют контрактную площадку и зависят от владельца (Novo) в исправлении проблем, что может привести к CRL/задержкам.","text_en":"Companies are caught in the middle: they don’t control the facility and depend on the owner (Novo) to fix issues, risking CRLs/delays.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0004","quote":"They're really kind of caught in the middle. They obviously don't own and control the facility"},{"chunk_id":"doc_903c28cb5ad1_chunk_0004","quote":"completely dependent upon Novo to fix its issues."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0005_n1","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"BARDA сократила значительную часть финансирования, что снижает инвестиции в mRNA-платформу как механизм быстрого реагирования.","text_en":"BARDA cut a significant amount of funding, reducing investment in the mRNA platform as a rapid-response mechanism.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0005","quote":"the BARDA decision to basically cut the knees off of quite a bit of funding is really unfortunate"},{"chunk_id":"doc_903c28cb5ad1_chunk_0005","quote":"not need to invest in that platform as a rapid response mechanism through BARDA"}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0005_n2","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Наблюдается рост (в т.ч. глобально) вакцинной нерешительности/скепсиса, что влияет на общественное здравоохранение и меняет поведение медучреждений.","text_en":"Vaccine hesitancy is emerging and gaining traction globally, affecting public health and changing institutional behavior.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0005","quote":"global emergence of vaccine hesitancy and the implications of that on, you know, broader aspects of global public health"},{"chunk_id":"doc_903c28cb5ad1_chunk_0005","quote":"a broader sentiment that's emerging and gaining a lot of traction, and not just here in the country, but globally"}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0005_n3","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Медучреждения опасаются негативной реакции на вакцинацию и действуют более осторожно (\"are you sure\"), даже для стандартных решений вроде Hep B у новорождённых.","text_en":"Institutions are more cautious about vaccination due to fear of backlash, even for default decisions like newborn Hep B vaccination.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0005","quote":"we were checked on three times in sort of an 'are you sure' dynamic"},{"chunk_id":"doc_903c28cb5ad1_chunk_0005","quote":"they're so worried about doing something that someone then freaks out about later"}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0006_n1","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Политизация дискуссии вокруг вакцин/пандемии привела к тому, что научная повестка «ушла на второй план».","text_en":"Political polarization around vaccines/pandemic has pushed science into the background.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0006","quote":"\"it's a battle zone and the science unfortunately has taken a huge back seat\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0006_n2","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Запуск обезболивающего Vertex в госпитальном/амбулаторном сегменте идёт медленно; это рынок, который нужно «строить».","text_en":"Vertex’s pain drug launch in hospital/outpatient settings is slow; it’s a market they need to build.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0006","quote":"\"It's gone decently, but it's slow. It's a market they have to build.\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0006_n3","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"FDA не поддержала путь к широкой индикации по нейропатической боли на основе обобщения данных из нескольких конкретных индикаций.","text_en":"FDA did not support a path to a broad neuropathic pain indication based on generalizing from a couple specific indications.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0006","quote":"\"the FDA—FDA— basically said the door wasn't open for that\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0007_n1","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Разочарование из‑за того, что исследование LSR sciatica провалилось, и это отразилось в обратной связи FDA.","text_en":"Disappointment because the LSR sciatica study failed, reflected in FDA feedback.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0007","quote":"LSR sciatica, actually failed, right? So this was a disappointment on the FDA feedback."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0007_n2","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Для острого продукта в боли ключевой вопрос обсуждения — не столько эффективность, сколько возможность построить рынок.","text_en":"For the acute pain product, the debate is less about efficacy and more about whether the market can be built.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0007","quote":"the debate around the acute product and pain was less about efficacy and more about just— can you build that market?"}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0007_n3","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Инвесторы ожидают от крупных биотех-компаний «act two/act three» для поддержания будущего роста; потеря потенциального «большого победителя» усложняет историю роста.","text_en":"Investors want an “act two/act three” to fuel future growth; losing a potential big winner makes the growth story harder.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0007","quote":"investors just want to see that act two, act three that propels. Fuels future growth"}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0008_n1","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Разработка обезболивающих сложна: новые препараты часто недостаточно мощные, а запуски в pain идут медленно и могут не «взлететь».","text_en":"Pain drug development is hard: new drugs may lack potency, and pain launches are slow and may never take off.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0008","quote":"\"Pain is tough, as much as we need new pain drugs.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0008","quote":"\"there's don't seem to be that potent.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0008","quote":"\"we've seen paint launches before to know that they're very, very slow and gradual if they ever take off.\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0008_n2","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"В неврологии/боли тяжёлые конечные точки, нет биомаркеров и высокая гетерогенность пациентов, что ограничивает перенос «CF-подхода» (таргетированные PoC и ставка на ранние успехи).","text_en":"In neurology/pain, tough endpoints, lack of biomarkers, and patient heterogeneity constrain applying a CF-style targeted PoC/early-success approach.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0008","quote":"\"you can't do that in neurology.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0008","quote":"\"the endpoints are not, are really, really tough. There's no biomarkers. Patients are heterogeneous.\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0008_n3","doc_id":"doc_903c28cb5ad1","kind":"opportunity","text_ru":"Возможность улучшить R&D-стратегию в pain/нейро: параллельно вести больше Phase 2 по разным этиологиям боли/мигрени и усиливать подтверждение в Phase 3 несколькими исследованиями.","text_en":"Opportunity to revamp pain/neuro R&D strategy: run more parallel Phase 2s across pain etiologies/migraine and use multiple Phase 3 studies for confirmation.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0008","quote":"\"there'd be five phase two studies ongoing right now across a whole array of different pain etiologies and migraine.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0008","quote":"\"Any indication that was advanced to phase three would have three studies only when we need two.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0008","quote":"\"it feels like the program itself could be revamped.\""}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0009_n1","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"После «blowaway quarter» компании сталкиваются с риском разгона ожиданий рынка и последующего разочарования, поэтому приходится «dampen enthusiasm» и управлять прогнозами.","text_en":"After a blowout quarter, companies risk inflated market expectations and later disappointment, so they try to dampen enthusiasm and manage estimates.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0009","quote":"\"you definitely try to dampen enthusiasm.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0009","quote":"\"not to let expectations get too far ahead and start creating new sets of estimates that are that are not going to be met.\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0009_n2","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"FAERS (база безопасности FDA) обновляется ежеквартально и может вызывать волатильность акций из‑за сигналов безопасности (в т.ч. сообщений о потенциальных смертях).","text_en":"FDA’s FAERS safety database is updated quarterly and can drive stock volatility due to safety signals (including reports of potential deaths).","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0009","quote":"\"the FDA maintains. This gets updated on a quarterly basis.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0009","quote":"\"the stock was very volatile on on Monday.\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0009_n3","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"Сообщения в FAERS о «potential deaths» могут быть интерпретированы как потенциальная связь с препаратом и создавать регуляторно-безопасностный риск для программ в нишевых показаниях и расширении показаний.","text_en":"FAERS reports of “potential deaths” can be interpreted as a potential drug link, creating safety/regulatory risk for niche indications and label expansion.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0009","quote":"\"called out a potential link in the Fair Safety Database\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0009","quote":"\"there were four patient reports. Potential deaths linked\""}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0010_n1","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Негативные сообщения о смертях пациентов (даже при отсутствии связи с препаратом) могут вызвать «пожарную тревогу», обвал акций и риск влияния на поведение пациентов (прекращение терапии/скепсис).","text_en":"Reports of patient deaths (even if unrelated) can trigger a fire drill, hit shares, and risk influencing patient behavior (stopping therapy/skepticism).","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0010","quote":"News of that report from Southside Analyst, again, just hammered the shares."},{"chunk_id":"doc_903c28cb5ad1_chunk_0010","quote":"Would have been terrible if something like this had. Persuaded patients to come off their drug prematurely"}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0010_n2","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"Сложность/ограничение: сообщения о смертях требуют быстрого и точного разъяснения причинно-следственной связи; компания может быть «caught flat footed» и вынуждена срочно готовить ответ.","text_en":"Constraint: death reports require rapid, accurate causality clarification; companies can be caught flat-footed and scramble to respond.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0010","quote":"Really caught I think the company off guard and scrambled to kind of find a response to this."},{"chunk_id":"doc_903c28cb5ad1_chunk_0010","quote":"their response was was was very I would say. accurate in terms of trying to dispel the myth"}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0010_n3","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"У Biogen наблюдается сдвиг в сторону внешних инноваций: запуск нового venture arm и больший интерес к external innovation, включая поиск активов для in-licensing/BD.","text_en":"Biogen is shifting toward external innovation: launching a new venture arm and increased interest in external innovation, including in-licensing/BD asset search.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0010","quote":"Biogen, they put out a a release this week saying that they're going to start up a new venture arm"},{"chunk_id":"doc_903c28cb5ad1_chunk_0010","quote":"a greater interest in resourcing external innovation versus internal innovation."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Biogen проявляет больший интерес к внешним инновациям (external innovation) вместо внутренних, включая поиск активов для in-licensing/BD и инвестиции в более ранние стадии через венчурное подразделение.","text_en":"Biogen is showing greater interest in external innovation vs internal, including in-licensing/BD asset sourcing and earlier-stage investing via its venture arm.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0011","quote":"we've seen from Biogen is a greater interest in resourcing external innovation versus internal innovation."},{"chunk_id":"doc_903c28cb5ad1_chunk_0011","quote":"they've been looking for assets from an in-licensing standpoint, from a BD standpoint now."},{"chunk_id":"doc_903c28cb5ad1_chunk_0011","quote":"this venture arm now will begin to invest in earlier stage companies and assets."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"Венчурное подразделение Biogen будет инвестировать с приоритетом корпоративных задач, а не максимизации финансовой доходности (return on capital).","text_en":"Biogen’s venture arm will invest with corporate priorities rather than return-on-capital priorities.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0011","quote":"do so with an eye toward corporate priorities as opposed to return on capital priorities."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Biogen расширяет фокус за пределы неврологии, включая иммунологию и интерес к усилению присутствия в редких заболеваниях.","text_en":"Biogen is broadening beyond neurology to include immunology and is interested in augmenting its rare disease presence.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0011","quote":"They've been broadening out their effort beyond neurology to include immunology"},{"chunk_id":"doc_903c28cb5ad1_chunk_0011","quote":"also Rare Disease, they're interested. In augmenting their rare disease presence."}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0012_n1","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Разработка препаратов для болезни Альцгеймера оказалась существенно сложнее, чем ожидали, несмотря на кажущийся коммерческий потенциал.","text_en":"Alzheimer’s drug development turned out to be much harder than expected despite apparent commercial upside.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0012","quote":"\"I don't think anyone anticipated how hard it would be.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0012","quote":"\"the commercial upside always seemed like it was there.\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0012_n2","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Вокруг A-beta антител по Альцгеймеру были разные ожидания: часть врачей прогнозировала узкое применение, но большинство ожидало более широкого использования при наличии терапии.","text_en":"Expectations for A-beta antibodies varied: some physicians expected narrow use, while most expected broad use if a therapy existed.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0012","quote":"\"one-off physicians who said the A-beta antibodies would get narrow use.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0012","quote":"\"Everyone else was saying, 'Oh my God, if we had something for these patients, they'd be used more broadly.'\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0012_n3","doc_id":"doc_903c28cb5ad1","kind":"pain","text_ru":"Компания исторически испытывала сложности с M&A/сделками из‑за консервативного подхода и нежелания делать сделки, что затрудняло «второй акт» после успеха в MS.","text_en":"The company historically struggled with dealmaking due to a conservative reluctance to do deals, complicating a “second act” beyond MS.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0012","quote":"\"historically, the company has been challenged with dealmaking.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0012","quote":"\"there was just a very high level of reluctance to do.\""}],"confidence":"medium"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0013_n1","doc_id":"doc_903c28cb5ad1","kind":"constraint","text_ru":"Даже при сильных данных остаются вопросы к дизайну Phase 3 и регуляторной динамике; в DM1 присутствует клинический и регуляторный риск.","text_en":"Even with strong data, there are questions about Phase 3 design and regulatory dynamics; DM1 carries clinical and regulatory risk.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0013","quote":"\"there's still some. Questions around, I think, the phase three design and some of the regulatory dynamics\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0013","quote":"\"DM1 like is not without— either company, some level of clinical and regulatory risk.\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0013_n2","doc_id":"doc_903c28cb5ad1","kind":"trend","text_ru":"Novartis активно наращивает присутствие в RNAi через серию сделок/поглощений и позиционируется как «big believers» в этом направлении.","text_en":"Novartis is aggressively building in RNAi via multiple deals/acquisitions and is described as a big believer in the space.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0013","quote":"\"Novartis. is on a tear with RNAi, right?\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0013","quote":"\"They made the Medco acquisition back $9. 7 billion in 2019.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0013","quote":"\"So they're— They're big believers in the space.\""}],"confidence":"high"}
{"nugget_id":"doc_903c28cb5ad1_chunk_0013_n3","doc_id":"doc_903c28cb5ad1","kind":"opportunity","text_ru":"Платформа доставки RNAi в мышцу (включая потенциально гладкую и сердечную) рассматривается как способ трансформировать заболевания (FSHD, DMD, DM1) и создать крупную ценность; редкие рынки остаются «white space».","text_en":"An RNAi delivery-to-muscle platform (potentially including smooth and cardiac muscle) is seen as transformative for FSHD/DMD/DM1 and as a major value opportunity; rare disease markets remain white space.","evidence":[{"chunk_id":"doc_903c28cb5ad1_chunk_0013","quote":"\"The power of this platform, the ability to deliver RNAi to muscle\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0013","quote":"\"We're seeing potentially transform these diseases in real time, FSHD, DMD, DM1.\""},{"chunk_id":"doc_903c28cb5ad1_chunk_0013","quote":"\"Rare disease markets like that that are just white space.\""}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0000_n1","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Есть риск для процессов регулирования и одобрения лекарств в США на фоне изменений/лидерства в агентстве.","text_en":"There may be risks to U.S. drug regulation and approval processes amid agency leadership changes.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0000","quote":"\"there's a lot of things that could potentially be at risk with regard to drug regulation and approval processes in the U.S.\""}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0000_n2","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Озвучивается подход, что рандомизированные исследования не всегда нужны для одобрения медпродуктов; приводится пример полного одобрения на небольшом исследовании.","text_en":"A view is stated that randomized trials are not always needed for approvals; an example is full approval based on a small trial.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0000","quote":"\"got approved on a pretty small trial. It got full approval.\""},{"chunk_id":"doc_bac2082a6298_chunk_0000","quote":"\"randomized trials, not always needed to approve medical products.\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0000_n3","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"RA Capital расширяет фокус за пределы biotech, чтобы инвестировать в компании, связанные с planetary health (устойчивость, источники энергии, оптимизация).","text_en":"RA Capital is moving beyond biotech to invest in planetary health-related companies (sustainability, energy sources, optimization).","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0000","quote":"\"moving beyond. biotech to invest in companies that um are good for planetary health\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0001_n1","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"В обсуждении отмечается сдвиг/эволюция регуляторных путей FDA, включая идею, что рандомизированные исследования не всегда нужны для одобрения, и запрос на больше примеров/деталей.","text_en":"The discussion points to evolving FDA approval pathways, including the idea that randomized trials are not always required, and a desire for more examples/details.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0001","quote":"\"randomized trials, not always needed to approve medical products.\""},{"chunk_id":"doc_bac2082a6298_chunk_0001","quote":"\"more examples and more um, you know, more details on uh, you know, just how you know, approval pathways may be evolving and changing.\""}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0001_n2","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Есть неопределённость и риск для компаний с open-label исследованиями, небольшими выборками или несовершенным контрольным плечом из‑за регуляторной непредсказуемости.","text_en":"There is uncertainty/risk for companies with open-label trials, small sample sizes, or imperfect control arms due to regulatory unpredictability.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0001","quote":"\"the uncertainty that's being injected into any company that has an open label trial or, you know, a smaller sample size or.\""},{"chunk_id":"doc_bac2082a6298_chunk_0001","quote":"\"didn't have the perfect control arm.\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0001_n3","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"С точки зрения инвестора «бинарные» регуляторные события в биотехе имеют асимметричный риск: апсайд за одобрение часто ограничен, а не-одобрение может быть катастрофическим.","text_en":"From an investor perspective, biotech binary regulatory events can be asymmetric: limited upside on approval, but potentially catastrophic downside on non-approval.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0001","quote":"\"have always been marginal at best in terms of risk rewards\""},{"chunk_id":"doc_bac2082a6298_chunk_0001","quote":"\"in the event of a non-approval, you know, the result can be relatively catastrophic.\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0002_n1","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Сложно зарабатывать на «бинарных» событиях в biotech: риск-доходность часто неблагоприятная, инвесторы переоценивают вероятность успеха и «обжигаются».","text_en":"Hard to make money on binary biotech events: risk-reward is often unfavorable, investors overestimate success odds and get burned.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0002","quote":"\"Most likely... the risk-reward on that event itself is not going to be favorable.\""},{"chunk_id":"doc_bac2082a6298_chunk_0002","quote":"\"It often feels like moths to a flame... so oftentimes you get burned by those binary events.\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0002_n2","doc_id":"doc_bac2082a6298","kind":"opportunity","text_ru":"Стратегия/возможность: входить в позицию задолго до события (3–12 месяцев), чтобы заработать на «run-up» и снизить бинарный риск.","text_en":"Opportunity/strategy: enter 3–12 months before an event to capture the run-up while avoiding binary risk.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0002","quote":"\"buy a stock three, six, twelve months in advance of an event and get the run into the event without taking the binary risk\""},{"chunk_id":"doc_bac2082a6298_chunk_0002","quote":"\"the time to buy often is 12 months before anyone's ever even thought about that event\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0002_n3","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Для крупных фондов сложно «эффективно играть» вокруг бинарных событий: размер позиции может сам двигать акцию из‑за ликвидности/объёма торгов.","text_en":"Constraint: large funds can’t efficiently trade around binary events because their size can move the stock due to liquidity/volume dynamics.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0002","quote":"\"For bigger funds... it's hard to just... play around these events... that... would actually move the stock\""},{"chunk_id":"doc_bac2082a6298_chunk_0002","quote":"\"you might cause things to go the other way just by being a pretty substantial... percentage of that company's volume\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0003_n1","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Политические/административные решения привели к откату финансирования mRNA-вакцин и отзыву финансирования mRNA-исследований, что ограничивает развитие направления.","text_en":"Political/administrative decisions led to pullback/withdrawal of funding for mRNA vaccines/research, constraining progress in the area.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0003","quote":"\"we've had some Now, pullback in funding of mRNA vaccines.\""},{"chunk_id":"doc_bac2082a6298_chunk_0003","quote":"\"since RFK Jr. and BARDA withdrew funding for mRNA research\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0003_n2","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Решения о финансировании воспринимаются как основанные на общественном недоверии/настроениях, а не на доказательной базе, что демотивирует участников отрасли.","text_en":"Funding decisions are perceived as driven by public distrust/sentiment rather than evidence, which is discouraging for the industry.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0003","quote":"\"It's about public distrust of the technology.\""},{"chunk_id":"doc_bac2082a6298_chunk_0003","quote":"\"it's always a little bit discouraging to see a decision like that\""}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0003_n3","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Существует разрыв между управлением крупным фондом и инвестированием в небольшие, менее ликвидные биотех-активы из-за динамики ликвидности/торгов.","text_en":"There is a mismatch between running a large fund and investing in smaller, less liquid biotech names due to liquidity/trading dynamics.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0003","quote":"\"large size of funds relative to the small size of company valuations\""},{"chunk_id":"doc_bac2082a6298_chunk_0003","quote":"\"being very disconnected between running a large fund and managing an investment in in a smaller, liquid kind of name\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0004_n1","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Сложно (и возможно даже неосуществимо) иметь лучший механизм отслеживания безопасности вакцин, особенно для событий, происходящих спустя недели/месяцы/годы.","text_en":"It’s difficult (maybe infeasible) to have a strong vaccine safety capture mechanism, especially for events occurring weeks/months/years later.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0004","quote":"I'm not sure we still have the best capture mechanism for vaccine safety, I'm not sure one is even feasible. It's so hard."},{"chunk_id":"doc_bac2082a6298_chunk_0004","quote":"But if it's a week later, if it's a month later, if it's five years later, how on earth do you connect something?"},{"chunk_id":"doc_bac2082a6298_chunk_0004","quote":"it's a challenge for for science"}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0004_n2","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Наблюдается тренд: успешная динамика акций вокруг запусков продуктов встречается чаще, чем раньше.","text_en":"Trend: stock performance around product launches has been successful more often than before.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0004","quote":"One interesting trend that I think many have noticed is the successful stock performance around product launches."},{"chunk_id":"doc_bac2082a6298_chunk_0004","quote":"Not 100% of them, but far more than we've ever seen before."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0004_n3","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Тренд более агрессивного ценообразования новых препаратов «сразу на старте»: цены растут из года в год, и «всё» прайсится как потенциальный блокбастер.","text_en":"Trend toward more aggressive out-of-the-box pricing for new drugs; prices rise year over year and many are priced as blockbusters.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0004","quote":"We're just seeing more aggressive pricing out of the box than we've ever seen before."},{"chunk_id":"doc_bac2082a6298_chunk_0004","quote":"every year that passes, we price our new drugs at a higher price point. Everything is priced to be a blockbuster."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0005_n1","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Новые препараты в последние годы выводятся на рынок по всё более высоким ценам; «всё» прайсится под blockbuster, и в моделях Уолл-стрит миллиардные peak revenue стали обычным явлением.","text_en":"New drugs are being launched at increasingly higher prices; everything is priced to be a blockbuster, and $1B peak revenue estimates have become common in Wall Street models.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0005","quote":"every year that passes, we price our new drugs at a higher price point. Everything is priced to be a blockbuster."},{"chunk_id":"doc_bac2082a6298_chunk_0005","quote":"a billion-dollar peak revenue estimate was quite unusual in Wall Street models. And these days, they're all over the place."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0005_n2","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"В обсуждении отмечают, что про ограничения reimbursement (tiering, pharmacy status, co-pays) стали говорить меньше, хотя payer-барьеры «всё ещё есть»; компании и инвесторы стали более «софистицированными» в коммуникации и планировании payer-стратегии ещё на этапе Phase 3.","text_en":"They note less discussion of reimbursement restrictions, though payer barriers still exist; companies and investors have become more sophisticated in communicating and planning payer strategy as early as Phase 3.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0005","quote":"we are talking a lot less about reimbursement restrictions, about tiering... co-pays, and things like that— than we really have in the last few three, four, five years."},{"chunk_id":"doc_bac2082a6298_chunk_0005","quote":"I think it's very much still there, but I think that companies have gotten a lot better about communicating it"},{"chunk_id":"doc_bac2082a6298_chunk_0005","quote":"when they're talking about their phase three data, like they already have... how this might be positioned... how we can manage this on formulary."}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0005_n3","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Есть риск/неопределённость, что в следующем избирательном цикле цены на новые лекарства могут стать политической мишенью для любой партии.","text_en":"There is uncertainty that new drug pricing could become a political target for either party in the next election cycle.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0005","quote":"What is the probability that in the next election cycle new drug pricing becomes a target for either party?"}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0006_n1","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Политическое давление на сдерживание цен на лекарства приводит к «выдавливанию» в более высокие цены запуска новых препаратов; IRA рассматривается как фактор, стимулирующий более высокий launch price.","text_en":"Policy pressure to contain drug prices appears to push companies toward higher new-drug launch prices; IRA is cited as incentivizing higher launch pricing.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0006","quote":"the industry keeps getting squeezed by policymakers to contain drug pricing, and that balloon keeps popping out in the form of higher and higher launch drug prices."},{"chunk_id":"doc_bac2082a6298_chunk_0006","quote":"Now we have the IRA. What was the solution to the IRA? Launch at a higher price"}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0006_n2","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Высокие цены и/или рост цен могут создавать ограничения доступа, которые ощущают врачи и пациентское сообщество, вызывая «outrage».","text_en":"High launch prices/price increases can create access constraints felt by physicians and patients, triggering outrage.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0006","quote":"we have seen real outrage at certain launch prices or certain price increases over time where the patient community is feeling it."},{"chunk_id":"doc_bac2082a6298_chunk_0006","quote":"Physicians are feeling the access constraints that come as a result of that."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0006_n3","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Даже при высоких ценах запусков в последние 1–2 года, «реального outrage» не наблюдалось; это связывают с тем, что препараты «очень близко» управляются плательщиками (payers).","text_en":"Despite high-price launches in the past 1–2 years, there hasn’t been “real outrage,” attributed to close payer management of utilization.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0006","quote":"we haven't seen that for some pretty high-price launches that have happened in the past year or two years."},{"chunk_id":"doc_bac2082a6298_chunk_0006","quote":"they're actually like. Also, in many ways, like very closely managed by the payers"}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0007_n1","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Инвесторы вынуждены следить за новыми факторами (MFN, тарифы, IRA, HHS), на фоне волатильности сектора инвестиционные горизонты в biotech ещё сильнее сократились.","text_en":"With new focal points (MFN, tariffs, IRA, HHS) and sector volatility, biotech investment horizons have compressed further.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0007","quote":"there are so many new, uh, focal points for investors to follow— you know, MFN, tariffs, IRA, HHS, and all the volatility of the sector."},{"chunk_id":"doc_bac2082a6298_chunk_0007","quote":"investment horizons, which have always been short, have actually continued to compress even further."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0007_n2","doc_id":"doc_bac2082a6298","kind":"buyer_signal","text_ru":"Сейчас почти нет интереса к катализаторам 2026 года; фокус инвесторов — на ближайшие 3–4 месяца.","text_en":"There is little interest in 2026 catalysts; investors are focused on the next 3–4 months.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0007","quote":"I get almost no interest in 2026 catalysts yet."},{"chunk_id":"doc_bac2082a6298_chunk_0007","quote":"It's very much focused on the next three or four months."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0007_n3","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Инвесторы, похоже, предпочитают ближние milestones и бинарные события, чтобы «поставить больше риска», и более агрессивно/позитивно позиционируются в biotech.","text_en":"Investors appear to favor near-term milestones and binary events, taking on more risk and positioning more positively in biotech.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0007","quote":"folks seem to be looking to invest in nearer term milestones, including binary events right now. Because they want to put more risk on."},{"chunk_id":"doc_bac2082a6298_chunk_0007","quote":"They're more aggressively positioned, positively and favorably positioned in biotech in my opinion."}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0008_n1","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Инвесторы сейчас более агрессивно и позитивно позиционированы в biotech; особенно хорошо показали себя small-cap developmental stage компании за последние 3 месяца.","text_en":"Investors are more aggressively and positively positioned in biotech; small-cap developmental-stage companies performed strongly over the last three months.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0008","quote":"They're more aggressively positioned, positively and favorably positioned in biotech in my opinion."},{"chunk_id":"doc_bac2082a6298_chunk_0008","quote":"Having seen a very good last three months of performance, especially great three months of performance from smaller cap developmental stage companies."}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0008_n2","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Сильные макро-дистракции создают «слепые зоны» и мешают инвесторам фокусироваться даже на ближайшей перспективе.","text_en":"Macro distractions create blind spots and make it hard for investors to focus even on the near term.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0008","quote":"we've just gone through such an incredible macro upheaval. Where literally it's like, can you even focus on next week?"},{"chunk_id":"doc_bac2082a6298_chunk_0008","quote":"there are so many blind spots now because we have, in the way of our field of view, all these other forces that are pulling us away."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0008_n3","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Earnings calls у некоммерческих/ранних компаний часто длинные, с повторяющимися и в основном ретроспективными prepared remarks; Q&A нередко не добавляет понимания.","text_en":"Earnings calls for non-commercial/early companies are often long, redundant, backward-looking; Q&A often doesn’t add understanding.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0008","quote":"they can often be fairly lengthy in terms of the prepared remarks."},{"chunk_id":"doc_bac2082a6298_chunk_0008","quote":"The prepared remarks are generally backward-looking, not materially forward-looking, and recaps of where the company is often— you know, a fair amount of redundancy."},{"chunk_id":"doc_bac2082a6298_chunk_0008","quote":"Q&A section time that often you just hear analysts asking questions for the sake of being heard on a call"}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0009_n1","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Для ранних/девелопмент-стейдж компаний регулярные earnings calls часто воспринимаются как отвлекающие и малоценные по сравнению с data-driven апдейтами.","text_en":"For early/development-stage companies, regular earnings calls can be more distracting than beneficial versus data-driven updates.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0009","quote":"\"it is just more of a distraction than a benefit when you are, you know, early-stage\""},{"chunk_id":"doc_bac2082a6298_chunk_0009","quote":"\"very frequently it doesn't really matter\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0009_n2","doc_id":"doc_bac2082a6298","kind":"opportunity","text_ru":"Возможность сместить коммуникации ранних компаний с квартальных earnings calls на звонки/апдейты вокруг ключевых data releases, а квартальные вопросы (cash runway, статус программ) закрывать пресс-релизом.","text_en":"Opportunity to shift early-company communications from quarterly earnings calls to data-release-focused updates, covering quarterly basics (cash runway, program status) via press releases.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0009","quote":"\"why not just do calls around data?\""},{"chunk_id":"doc_bac2082a6298_chunk_0009","quote":"\"usually that can really be encompassed in the body of a press release\""}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0009_n3","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Без регулярных earnings calls компания рискует потерять внимание рынка/аналитиков и стать «non-entity», что опасно в конкурентной борьбе за капитал.","text_en":"Without regular earnings calls, a company risks losing market/analyst attention and becoming a “non-entity,” which is dangerous in the competition for capital.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0009","quote":"\"Neither voice is heard. If you don't do an earnings call.\""},{"chunk_id":"doc_bac2082a6298_chunk_0009","quote":"\"You're in danger of kind of becoming a non-entity.\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0010_n1","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Инфоперегрузка у аналитиков/инвесторов из‑за одновременных earnings calls множества компаний; сложно быстро извлечь ключевые выводы и переварить новую информацию о пайплайне.","text_en":"Information overload from many simultaneous earnings calls makes it hard to extract key takeaways and digest new pipeline information.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0010","quote":"there are certainly days where there's 100 companies reporting earnings."},{"chunk_id":"doc_bac2082a6298_chunk_0010","quote":"multiple of our companies all have their earnings calls going on at the exact same time"}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0010_n2","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Earnings calls часто тратят время на финансовые детали, которые «не важны», что воспринимается как фрустрирующее и «tone deafness».","text_en":"Earnings calls often waste time on financial minutiae that “don’t matter,” which is frustrating and perceived as tone-deaf.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0010","quote":"There's a fair amount of wasted air time in terms of reviewing financials that don't matter."},{"chunk_id":"doc_bac2082a6298_chunk_0010","quote":"that's the point of frustration because it's a point of tone deafness."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0010_n3","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"Окно IPO в biotech остаётся закрытым: прошло шесть месяцев с последнего «реального» IPO.","text_en":"The biotech IPO window remains closed: it has been six months since the last “real” biotech IPO.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0010","quote":"it's been six months since the last IPO in biotech or last real IPO in biotech."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0011_n1","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"В «очень волатильной/неровной» рыночной среде может стать больше выходов на биржу через SPAC/похожие структуры вместо классического IPO.","text_en":"In a very choppy market, there may be more public listings via SPAC-like structures rather than traditional IPOs.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0011","quote":"We may see more of these in this very choppy environment"}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0011_n2","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Отказ от IPO roadshow может снижать видимость/осведомлённость о компании и её публичный профиль.","text_en":"Skipping the IPO roadshow can reduce company visibility/awareness and public profile.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0011","quote":"having not gone through the IPO roadshow process, the visibility and knowledge that surrounds this company is a little bit lower"}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0011_n3","doc_id":"doc_bac2082a6298","kind":"opportunity","text_ru":"SPAC/обратные слияния могут быть проще в текущем рынке, потому что позволяют заранее согласовать цену и вести процесс ближе к сделке частной компании.","text_en":"SPACs/reverse mergers may be easier in the current market because they allow agreeing on price upfront and running a more private-deal-like process.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0011","quote":"what I think works really well, with that structure, is like you agree on price, right?"},{"chunk_id":"doc_bac2082a6298_chunk_0011","quote":"It's much more like a private company deal process, right? Which is what, you know, what's a little bit easier to do in this market"}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0012_n1","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"В условиях высокой волатильности сложно получить «правду» о реальном спросе и цене в IPO (инвесторы могут завышать интерес/объём).","text_en":"In volatile markets, it’s hard to find the truth about real IPO demand and pricing (investors may overstate interest/size).","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0012","quote":"\"it's such a kind of like... challenging... process to like find truth\""},{"chunk_id":"doc_bac2082a6298_chunk_0012","quote":"\"are you just putting in those numbers?\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0012_n2","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Окно IPO сложно «открывать» лучшими компаниями: самые высококлассные компании меньше нуждаются в IPO, т.к. могут привлекать частный капитал, поэтому на рынок чаще выходят компании «среднего уровня».","text_en":"It’s hard to open the IPO window with top-tier companies because they least need IPOs (can access private capital), so mid-tier companies often go public instead.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0012","quote":"\"the highest caliber companies... are the ones who least need to do it because they can still access plenty of capital\""},{"chunk_id":"doc_bac2082a6298_chunk_0012","quote":"\"we kind of probably wind up with that middle tier\""}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0012_n3","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Изменение коммуникационной практики (например, отказ от earnings call) может восприниматься рынком скептически и вызывать проблемы.","text_en":"Changing communication practices (e.g., skipping an earnings call) can be viewed skeptically by the market and cause issues.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0012","quote":"\"a company that didn't host an earnings call caused a problem\""},{"chunk_id":"doc_bac2082a6298_chunk_0012","quote":"\"that change in strategy was viewed... a little bit skeptically\""}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Отказ компании проводить earnings call создаёт «вакуум информации», что приводит к закулисным спорам/дискуссиям и росту входящих запросов.","text_en":"Skipping an earnings call creates an information vacuum, driving behind-the-scenes debate and increased inbound inquiries.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0013","quote":"\"the vacuum of information that it created, in particular, not holding a conference call, led to a lot of debate and discussion\""},{"chunk_id":"doc_bac2082a6298_chunk_0013","quote":"\"It was my number one incoming call volume stock in the last five days.\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Модель «high volume, low price» запусков сложна в исполнении, потому что требует большого числа выписывающих врачей (широкий, но неглубокий рынок).","text_en":"High-volume, low-price launches are hard to execute because they require many prescribers (a wide but shallow market).","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0013","quote":"\"high volume, low price launches, which are always hard to execute on because you just need to wait for. High volumes of prescription writers\""},{"chunk_id":"doc_bac2082a6298_chunk_0013","quote":"\"often a mile wide, inch deep type of market\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"В терапии, где важна удобство применения, появляются альтернативы инъекциям: назальный эпинефрин и растворяющийся на языке «patch».","text_en":"In convenience-sensitive therapy areas, non-injection alternatives are emerging: nasal epinephrine and a tongue-dissolving patch.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0013","quote":"\"ARS Pharma with their launch of Nefi, which is a nasal epinephrine to replace EpiPens.\""},{"chunk_id":"doc_bac2082a6298_chunk_0013","quote":"\"convenience really does matter\""},{"chunk_id":"doc_bac2082a6298_chunk_0013","quote":"\"Equestiv. And they actually have a patch. You know, therapy that you can put, you know, that dissolves into your tongue.\""}],"confidence":"medium"}
{"nugget_id":"doc_bac2082a6298_chunk_0014_n1","doc_id":"doc_bac2082a6298","kind":"trend","text_ru":"В pre-launch пространстве заметно происходит немало сделок, включая финансирование перед запуском.","text_en":"A fair number of deals are happening in the pre-launch space, including pre-launch financing.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0014","quote":"we're certainly seeing. You know, a fair bit of these deals kind of happen in the pre-launch space."}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0014_n2","doc_id":"doc_bac2082a6298","kind":"constraint","text_ru":"Стратегическое финансирование может быть поставлено в зависимость от регуляторного одобрения (approval), что делает доступ к деньгам условным.","text_en":"Strategic funding can be contingent on regulatory approval, making access to capital conditional.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0014","quote":"Having the strategic funding agreement that they provided being contingent on approval"}],"confidence":"high"}
{"nugget_id":"doc_bac2082a6298_chunk_0014_n3","doc_id":"doc_bac2082a6298","kind":"pain","text_ru":"Вопросы безопасности требуют раннего и детального раскрытия информации; важно как можно раньше публиковать данные и хорошо их характеризовать.","text_en":"Safety issues require early, detailed disclosure; it’s critical to release information as early as possible and characterize it well.","evidence":[{"chunk_id":"doc_bac2082a6298_chunk_0014","quote":"with safety, just critical to get this information out, ideally as early as possible. And just essential to have this, well, well characterized."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0000_n1","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Биотех (XBI) за последний месяц заметно опередил S&P 500, что описывается как нетипичная для сектора ситуация после нескольких лет отставания.","text_en":"Biotech (XBI) has outperformed the S&P 500 over the past month, described as unusual after years of underperformance.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0000","quote":"\"XBI, right now, 11. 9% up in the past month. And that's versus 2% up against the S &P 500.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0000","quote":"\"We've had years of... two or three years. Where we've underperformed the S &P.\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0000_n2","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Высокие процентные ставки (макрофактор) делали сложнее привлечение капитала в более рискованные (higher beta) сектора, включая биотех.","text_en":"Higher interest rates (macro) have made it harder to bring cash into higher-beta sectors like biotech.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0000","quote":"\"higher interest rates, making it tougher for people to bring in cash into... higher beta stocks and sectors such as biotech\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0000_n3","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Отмечается, что M&A в секторе есть, но премии выглядят «underwhelming», и при этом у небольших/средних компаний наблюдаются успешные запуски препаратов.","text_en":"M&A is present but premiums are described as underwhelming, while small/mid-size companies are seeing successful drug launches.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0000","quote":"\"there's been a little bit of M&A but... been maybe more underwhelming with the premiums.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0000","quote":"\"a lot of the smaller midsize companies... have a bunch of successful drug launches.\""}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0001_n1","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Сентимент инвесторов к biotech выглядит улучшающимся; с мая наблюдается крупнейший восходящий тренд в biotech за более чем десятилетие (без учета COVID-эйфории).","text_en":"Investor sentiment toward biotech appears to be improving; since May there has been the largest upward trend in biotech in over a decade (excluding COVID euphoria).","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0001","quote":"\"since May, we've had the largest upward trend in over a decade in biotech right now.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0001","quote":"\"sentiment does appear to be turning at least at this stage.\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0001_n2","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Неопределенность вокруг регуляторных/гос. факторов (FDA, HHS, CDC) и текущая процентная среда остаются негативными факторами для biotech.","text_en":"Uncertainty around regulatory/government factors (FDA, HHS, CDC) and the current interest-rate environment remain negative factors for biotech.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0001","quote":"\"the negatives that we've been dealing with and that's uncertainty—something like FDA, HHS, CDC\""},{"chunk_id":"doc_c2f93887fd12_chunk_0001","quote":"\"Certainly, we're still in the interest rate environment that we're in\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0001_n3","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"На рынке было много финансирований: IPO нет, но вторичные размещения (secondaries) проходили хорошо.","text_en":"There have been many financings: no IPOs, but secondaries seem to have performed well.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0001","quote":"\"there's been a lot of financings too. I mean, you know. No IPOs, but secondaries that seem to have done well.\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0002_n1","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Sanofi сталкивается с риском потери патентной защиты Dupixent в 2031 и нуждается в замещении значимой доли выручки.","text_en":"Sanofi faces Dupixent patent expiry in 2031 and needs to replace a significant revenue share.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0002","quote":"In 2031, based on current knowledge, the product loses patent protection. So Sanofi needs something to fill it back in."},{"chunk_id":"doc_c2f93887fd12_chunk_0002","quote":"And that's 38% of revenues in 2030."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0002_n2","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"В атопическом дерматите текущий «gold standard» (Dupixent) оптимально контролирует состояние лишь у части пациентов, что оставляет неудовлетворённую потребность и место для переключения терапии.","text_en":"In dermatitis, the current gold standard (Dupixent) optimally controls only a subset of patients, leaving unmet need and room for switching.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0002","quote":"It looks like it's trailing the gold standard, which is currently Duprixent."},{"chunk_id":"doc_c2f93887fd12_chunk_0002","quote":"And there are only one in three patients. Antepixent, which are at least, are optimally controlled, so there is room for cycling"}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0002_n3","doc_id":"doc_c2f93887fd12","kind":"opportunity","text_ru":"Бронхоэктазы: отмечено отсутствие FDA-одобренных препаратов (на момент обсуждения), что указывает на возможность для новых терапий.","text_en":"Bronchiectasis: noted lack of FDA-approved drugs (at the time), indicating opportunity for new therapies.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0002","quote":"There are no FDA-approved or there were no FDA-approved drugs for this condition."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0003_n1","doc_id":"doc_c2f93887fd12","kind":"opportunity","text_ru":"Бронхоэктазы описаны как показание, где ранее не было одобренных FDA препаратов, что указывает на незакрытую потребность/возможность для терапии.","text_en":"Bronchiectasis is described as having had no FDA-approved drugs, indicating unmet need/opportunity for therapies.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0003","quote":"There are no FDA-approved or there were no FDA-approved drugs for this condition."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0003_n2","doc_id":"doc_c2f93887fd12","kind":"buyer_signal","text_ru":"Рынок позитивно воспринял ценообразование продукта, что выступило катализатором (сигнал приемлемости цены/готовности рынка).","text_en":"Product pricing was well received by the market, acting as a catalyst (signal of market acceptance).","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0003","quote":"Product pricing was well received by the market. So that was a catalyst just last month."}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0003_n3","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Для снижения триглицеридов ключевой барьер/вопрос — удастся ли показать сигнал по снижению событий острого панкреатита; также outcome-исследование описано как сложное.","text_en":"In triglyceride lowering, a key hurdle is demonstrating an acute pancreatitis signal; an outcomes study is described as challenging.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0003","quote":"the real question in the field of triglyceride lowering... will you get a signal on acute pancreatitis?"},{"chunk_id":"doc_c2f93887fd12_chunk_0003","quote":"without having to go to an outcome study, which would be challenging."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0004_n1","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"Панкреатит описывается как очень тяжёлое и потенциально жизнеугрожающее состояние, что отражает высокую медицинскую потребность.","text_en":"Pancreatitis is described as a very severe and potentially life-threatening condition, indicating high unmet medical need.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0004","quote":"pancreatitis is a very severe condition or event and could be life-threatening as well."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0004_n2","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Проведение outcome study для разработки препарата в severe hypertriglyceridemia рассматривается как сложное (challenging).","text_en":"Running an outcome study for drug development in severe hypertriglyceridemia is described as challenging.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0004","quote":"without having to go to an outcome study, which would be challenging."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0004_n3","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"Коммерциализация препаратов в этом пространстве описывается как коммерческий вызов; для роста класса нужно выходить шире, чем KOL-аудитория.","text_en":"Commercialization is described as a challenge; to build a big class, companies likely need to go broader than KOLs.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0004","quote":"it's going to be the commercial challenge that both. That both Ionis and Arrowhead will have to face here"}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0005_n1","doc_id":"doc_c2f93887fd12","kind":"buyer_signal","text_ru":"Инвестсообщество предполагает, что наличие outcomes-бенефита по панкреатиту может существенно повысить цену (в модели обсуждался уровень около $20k, который может быть консервативным).","text_en":"The investment community assumes pancreatitis outcomes benefit could materially increase pricing (models discussed ~$20k, possibly conservative).","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0005","quote":"the investment community is. is assuming is that with this outcomes benefit on pancreatitis, maybe the price in the model goes up significantly."},{"chunk_id":"doc_c2f93887fd12_chunk_0005","quote":"I think they've been talking about the $20,000 range, but perhaps that could be really conservative."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0005_n2","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Есть компромисс: рост цены (до «пятизначного» уровня) будет связан с сужением популяции пациентов, которые будут получать лечение.","text_en":"There is a trade-off: higher (five-digit) pricing is associated with a narrower treated patient population.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0005","quote":"it's also going to be associated with the narrowing of the patient population that get treated."},{"chunk_id":"doc_c2f93887fd12_chunk_0005","quote":"if there's significant change on the pricing side of it into the five digits."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0005_n3","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"В сегменте obesity инвесторы выглядят «trigger-happy»: акции чувствительны к промаху по целевому снижению веса на 2–3%.","text_en":"In obesity, investors appear trigger-happy: stocks are sensitive to missing weight-loss targets by 2–3%.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0005","quote":"how sensitive these stocks are when a drug misses a bogey on weight loss by like two or three percent"},{"chunk_id":"doc_c2f93887fd12_chunk_0005","quote":"how trigger-happy investors seem to be on whether data hits the bogey or not"}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0006_n1","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Многие препараты в категории ограничены по поставкам (supply constrained), хотя проблему пытаются решать.","text_en":"Many drugs in the category are supply constrained, though it’s being addressed.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0006","quote":"\"There's a bunch of drugs out here that are supply constrained, most of them, although that's being addressed.\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0006_n2","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Ретроспективный анализ базы данных/«real world» исследование с коротким фоллоу-апом и неизвестным дозированием создаёт много неопределённости в выводах.","text_en":"A retrospective database analysis/“real world” study with short follow-up and unknown dosing creates significant uncertainty in conclusions.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0006","quote":"\"the follow-up was short\""},{"chunk_id":"doc_c2f93887fd12_chunk_0006","quote":"\"It was retrospective database analysis, not really a real world study.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0006","quote":"\"we really have no idea what people were dosed at\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0006_n3","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"У пероральных кандидатов есть проблема переносимости: отмечены высокие доли прекращения лечения на препарате по сравнению с плацебо.","text_en":"Oral candidates have tolerability issues, with high discontinuation rates on drug versus placebo.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0006","quote":"\"The problem for this was that the tolerability wasn't great.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0006","quote":"\"28% in the patients on the drugs stopping treatment versus 18% on placebo.\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0007_n1","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"Возмещение/реимбурсация — ключевой текущий вызов для GLP-1, особенно в ожирении; возможные сокращения Medicare/Medicaid усиливают проблему из‑за высокой стоимости препаратов.","text_en":"Reimbursement is a major current challenge for GLP-1s, especially in obesity; potential Medicare/Medicaid cuts worsen the issue given high drug costs.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0007","quote":"\"I do think that this reimbursement issue right now is probably the biggest challenge.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0007","quote":"\"potential cuts to medicare and medicaid spending here in the US and they highlighted that's going to be a particular challenge\""},{"chunk_id":"doc_c2f93887fd12_chunk_0007","quote":"\"these aren't terribly inexpensive drugs\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0007_n2","doc_id":"doc_c2f93887fd12","kind":"opportunity","text_ru":"Оральные версии GLP-1 (малые молекулы) рассматриваются как шанс снизить себестоимость/цену и расширить охват, особенно в США.","text_en":"Oral GLP-1 versions (small molecules) are positioned as a way to lower manufacturing cost/price and drive broader uptake, particularly in the US.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0007","quote":"\"the excitement and the promise of the oral versions of the drugs will come in\""},{"chunk_id":"doc_c2f93887fd12_chunk_0007","quote":"\"They are small molecules. They should be way cheaper to manufacture.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0007","quote":"\"price uh these GLP-1 ones at least the oral versions um more attractively to really drive much broader uptake\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0007_n3","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Компании продвигают direct-to-patient сервисы, чтобы снижать стоимость для пациентов.","text_en":"Companies are introducing/promoting direct-to-patient services to lower patient costs.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0007","quote":"\"each of the companies are trying to introduce or promote their own direct to patient services, and that is lowering the cost\""}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0008_n1","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"Для пероральных GLP-1 есть сомнения по эффективности и переносимости: эффективность может быть ниже инъекционных, а побочные эффекты — хуже; «вердикт» ещё не вынесен.","text_en":"Oral GLP-1s face uncertainty on efficacy and tolerability: efficacy may be lower than injectables and side effects worse; the verdict is still out.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0008","quote":"\"perhaps the efficacy isn't as great as the injectables. Interestingly, the side effects do appear worse.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0008","quote":"\"the verdict is still out on the orals vis-a-vis the tolerability and the degree of efficacy.\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0008_n2","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Ожидание, что более низкая стоимость и удобство пероральных форм приведут к более широкому назначению в первичном звене (PCP/GP) и более широкому охвату пациентов по сравнению с инъекциями.","text_en":"Expectation that lower cost and oral convenience will drive broader uptake in primary care (PCP/GP) and a broader patient population vs injections.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0008","quote":"\"it's really going to be a much lower cost. That's going to. really drive uptake.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0008","quote":"\"PCPs... like writing prescriptions for things that patients can just go pick up at their local. pharmacy\""}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0008_n3","doc_id":"doc_c2f93887fd12","kind":"opportunity","text_ru":"Есть пространство для дифференциации помимо GLP-1, в частности по «muscle sparing»; звучит тезис, что врачи ищут другие опции и «есть место для других лекарств».","text_en":"There may be room to differentiate beyond GLP-1s, particularly on muscle-sparing; doctors are said to be looking for other options and there is room for other medicines.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0008","quote":"\"doctors are looking for other things, particularly on the muscle sparing side.\""},{"chunk_id":"doc_c2f93887fd12_chunk_0008","quote":"\"there is room for other medicines. It's not just a race.\""}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0009_n1","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Растёт признание, что ASCVD — это проблема кумулятивного (пожизненного) воздействия факторов риска, а не разового измерения, и что раннее снижение LDL/АД может сильно повлиять на исходы.","text_en":"Growing recognition that ASCVD is driven by cumulative lifetime exposure, and earlier LDL/BP lowering can have a profound impact.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0009","quote":"increasing recognition that ASCVD... is really a a problem of cumulative exposure, not exposure at one point in time."},{"chunk_id":"doc_c2f93887fd12_chunk_0009","quote":"by lowering LDL and blood pressure much, much earlier in life, you can have a profound impact."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0009_n2","doc_id":"doc_c2f93887fd12","kind":"opportunity","text_ru":"Возможность: AI-инструмент на больших датасетах (например, UK Biobank) для предсказания повышенного риска + ежегодная sRNA, нацеленная на PCSK9 и ангиотензиноген, как профилактический продукт в кардиологии.","text_en":"Opportunity: AI risk prediction using large datasets (e.g., UK Biobank) paired with an annual sRNA targeting PCSK9 and angiotensinogen as a prevention approach.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0009","quote":"use a tool that we're building using AI and large datasets like UK Biobank... to predict people that are at elevated risk"},{"chunk_id":"doc_c2f93887fd12_chunk_0009","quote":"combine that predictive tool with an annual sRNA that targets both PCSK9 and angiotensinogen"}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0009_n3","doc_id":"doc_c2f93887fd12","kind":"buyer_signal","text_ru":"Ориентация на коммерциализацию через emerging consumer-based channels и профилактическое ценообразование (ориентир — пространство цен на вакцину от гриппа), что указывает на продумывание модели оплаты/вывода на рынок.","text_en":"Commercialization thinking includes consumer-based channels and prevention-style pricing (flu vaccine as reference), signaling a payment/go-to-market intent.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0009","quote":"think a lot about the emerging channels... about consumer-based channels"},{"chunk_id":"doc_c2f93887fd12_chunk_0009","quote":"pricing that is consistent with a prevention type approach... look at pricing in the flu vaccine space"}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0010_n1","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Генная редактура пока плохо подходит для относительно здоровой «превалентной» популяции из‑за необходимости внутривенной инфузии и высокой стоимости лечения.","text_en":"Gene editing is seen as a poor fit for a relatively healthy prevalent population due to IV infusion requirements and high treatment cost.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0010","quote":"\"there's just no way... somebody of that phenotype would consider a gene editing approach... which requires intravenous infusion and high cost of treatment\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0010_n2","doc_id":"doc_c2f93887fd12","kind":"opportunity","text_ru":"Есть возможность для «upstream» терапии/первичной профилактики с ценой порядка сотен долларов за годовую дозу для иначе здоровых людей с прогнозируемым риском ASCVD.","text_en":"Opportunity for an upstream primordial-prevention therapy priced at hundreds of dollars per annual dose for otherwise healthy people with predicted ASCVD risk.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0010","quote":"\"we want to go upstream with a treatment... that can cost hundreds of dollars per annual dose\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0010_n3","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Команда намеренно избегает оформления AI-инструмента как companion diagnostic и планирует коммерциализацию отдельно/заранее относительно вывода препарата на рынок.","text_en":"They want to avoid making the AI tool a companion diagnostic and consider commercializing it ahead of the drug’s market entry.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0010","quote":"\"we're certainly not looking to make it a companion diagnostic\""},{"chunk_id":"doc_c2f93887fd12_chunk_0010","quote":"\"introduce this AI tool commercially... in advance... of the drug getting to market\""}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0011_n1","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"Ограниченный доступ к COVID-вакцине (пример: в Массачусетсе спикер не может получить бустер/вакцину).","text_en":"Limited access to COVID vaccines (example: speaker cannot get a COVID vaccine yet in Massachusetts).","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0011","quote":"I can't get my COVID vaccine yet in Massachusetts, and I think that's ridiculous."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0011_n2","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"FDA запрашивает постмаркетинговые и плацебо-контролируемые исследования/тесты для бустеров, что повышает издержки и усложняет работу вакцинных компаний на фоне падения выручки.","text_en":"FDA requests post-marketing and placebo-controlled trials/tests for boosters, increasing costs and making it harder for vaccine companies amid declining revenue.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0011","quote":"the FDA, through Prasad, have put out requests for post-marketing trials and tests and placebo-controlled trials"},{"chunk_id":"doc_c2f93887fd12_chunk_0011","quote":"this, of course, makes it difficult where revenue is going down for these guys."},{"chunk_id":"doc_c2f93887fd12_chunk_0011","quote":"Costs are going to go up because they have to keep doing these trials."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0011_n3","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Нарастает общественно-политическое напряжение и злость вокруг CDC и вакцин в целом; тема «выходит на пик».","text_en":"Rising public-political anxiety/anger around the CDC and vaccines; the issue is coming to a head.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0011","quote":"you certainly get the sense of increasing anger toward what's going on at the CDC."},{"chunk_id":"doc_c2f93887fd12_chunk_0011","quote":"And what's going on with vaccines in general."},{"chunk_id":"doc_c2f93887fd12_chunk_0011","quote":"I get the sense that all of this is coming to a head in a big way."}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0012_n1","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Есть неопределённость/барьер в интерпретации данных из Китая и их переносимости на другие регионы; важна сопоставимость China vs ex-China в клиническом исследовании.","text_en":"Uncertainty/constraint around translating China trial data to other regions; similarity of China vs ex-China results is critical.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0012","quote":"the more critical element here is that split between China and ex-China data."},{"chunk_id":"doc_c2f93887fd12_chunk_0012","quote":"making us feel comfortable that you can take China data and translate directly to us."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0012_n2","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"Запуски Aβ-антител для болезни Альцгеймера от Biogen и Lilly оказались большим разочарованием.","text_en":"Aβ antibody launches for Alzheimer’s from Biogen and Lilly have been a big disappointment.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0012","quote":"the Aβ antibody launches from Biogen and Lily have been a big disappointment."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0012_n3","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Ожидается «пучок» ближайших клинических readouts осенью в неврологии и в онкологии (несколько ключевых датасетов/презентаций).","text_en":"A wave of upcoming clinical readouts in the fall across neurology and oncology (multiple key datasets/presentations).","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0012","quote":"in this fall we have a bunch of readouts coming up in the neurology space."},{"chunk_id":"doc_c2f93887fd12_chunk_0012","quote":"You've got two key datasets that we're looking at."}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0013_n1","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"Запуски Aβ-антител (Biogen и Lilly) в Альцгеймере оказались большим разочарованием.","text_en":"Aβ antibody launches (Biogen and Lilly) in Alzheimer’s have been a big disappointment.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0013","quote":"the Aβ antibody launches from Biogen and Lily have been a big disappointment."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0013_n2","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Коммерческая жизнеспособность модели лечения под вопросом: ограниченная capacity, вопросы риск–польза из‑за ARIA и сложность выявления пресимптомных пациентов (высокий screen failure).","text_en":"Commercial viability is questioned: limited treatment capacity, ARIA risk-benefit concerns, and difficulty finding pre-symptomatic patients (high screen failure).","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0013","quote":"whether this model is commercially viable. It's already hard— from a capacity perspective— to treat the patients"},{"chunk_id":"doc_c2f93887fd12_chunk_0013","quote":"There's already questions around risk-benefit with ARIA."},{"chunk_id":"doc_c2f93887fd12_chunk_0013","quote":"they're screening out almost 90% of patients."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0013_n3","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Инвесторы смотрят на prevention-исследования у пресимптомных пациентов; есть ожидание, что более раннее лечение может дать больший клинический эффект.","text_en":"Investors are watching prevention studies in pre-symptomatic patients; earlier treatment is expected to yield a bigger clinical effect.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0013","quote":"one readout that investors are looking towards... is Lilly's prevention study."},{"chunk_id":"doc_c2f93887fd12_chunk_0013","quote":"The premise being: if you treat earlier, you can have a bigger clinical effect."}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0014_n1","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"У пациентов с болезнью Альцгеймера сохраняются тяжёлые симптомы (психоз, ажитация) даже при наличии DMT; ажитация — ключевая причина перевода из дома в учреждение с уходом.","text_en":"Alzheimer’s patients still have severe symptoms (psychosis, agitation) even with DMTs; agitation is a key driver of moving patients from home to supervised care.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0014","quote":"Just because we've got now a couple of DMTs does not mean that these patients still won't have symptoms like psychosis, like agitation."},{"chunk_id":"doc_c2f93887fd12_chunk_0014","quote":"And agitation is a real- big problem in Alzheimer's patients. It's the number one reason why... family members move... loved ones... out of the home setting"}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0014_n2","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Единственная одобренная терапия ажитации при Альцгеймере — атипичный антипсихотик — имеет black box warning об увеличении смертности у пожилых с деменцией, что ограничивает применение.","text_en":"The only approved Alzheimer’s agitation therapy (an atypical antipsychotic) carries a black box warning for increased mortality in elderly with dementia, limiting use.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0014","quote":"atypical antipsychotics all have a black box warning."},{"chunk_id":"doc_c2f93887fd12_chunk_0014","quote":"increased risk of mortality in elderly with dementia... black box warning that basically is almost contraindicative of use in Alzheimer's patients."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0014_n3","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Фокус индустрии и инвесторов исторически был на DMT, но растёт внимание к симптоматическим препаратам (в т.ч. для ажитации), ожидаются клинические readouts и регуляторные шаги.","text_en":"Industry/investor focus has historically been on DMTs, but attention to symptomatic treatments (e.g., agitation) is increasing, with upcoming readouts and regulatory steps.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0014","quote":"It seems like the industry and investor focus has always been on the DMTs."},{"chunk_id":"doc_c2f93887fd12_chunk_0014","quote":"we're talking about readouts... proof of concept... readout that's expected by the end of this year."}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0015_n1","doc_id":"doc_c2f93887fd12","kind":"pain","text_ru":"В болезни Альцгеймера сохраняется большой неудовлетворённый медицинский спрос.","text_en":"There is significant unmet medical need in Alzheimer’s disease.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0015","quote":"lots of unmet medical need in Alzheimer's disease."}],"confidence":"high"}
{"nugget_id":"doc_c2f93887fd12_chunk_0015_n2","doc_id":"doc_c2f93887fd12","kind":"trend","text_ru":"Инвесторы/рынок смещают фокус с биомаркеров на клинические данные по приступам в исследовании рефрактерной эпилепсии.","text_en":"Market focus is shifting from biomarker readouts to clinical seizure data in refractory epilepsy.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0015","quote":"The street has become much more focused, I think, on the actual clinical seizure data"}],"confidence":"medium"}
{"nugget_id":"doc_c2f93887fd12_chunk_0015_n3","doc_id":"doc_c2f93887fd12","kind":"constraint","text_ru":"Неопределённость регуляторной гибкости CBER для генной терапии; предстоящие данные/подача могут прояснить позицию регулятора.","text_en":"Uncertainty around CBER flexibility for gene therapy; upcoming data/filing may clarify the regulator’s stance.","evidence":[{"chunk_id":"doc_c2f93887fd12_chunk_0015","quote":"Help us figure out where we're at with CBER as it relates to kind of flexibility"}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0000_n1","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Появились признаки оживления рынка: первый за период biotech IPO был «хорошо принят», а также прошла волна PIPE и follow-on размещений.","text_en":"Signs of market reopening: a first biotech IPO was well received, alongside multiple PIPEs and follow-on offerings.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0000","quote":"We had our first biotech IPO yesterday... It was pretty good, well-received by the market."},{"chunk_id":"doc_924f5a3029a5_chunk_0000","quote":"we saw a bunch of pipes and follow-on offerings this week"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0000_n2","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"Рынок негативно реагирует на разводнение при follow-on, а ожидания M&A могут быстро «сниматься с повестки» после привлечения капитала.","text_en":"Market can react negatively to dilution from follow-ons, and capital raises may dampen M&A expectations.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0000","quote":"the market responded not liking the dilution and feeling that M&A is off the table"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0000_n3","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"По словам банкира, за последние два года компании были в «режиме выживания», а сейчас переходят к более агрессивному росту (добавление в пайплайн, привлечение капитала под данные).","text_en":"Per a banker, companies shifted from “survival mode” over the last two years to a more aggressive growth posture (pipeline expansion, raising on data).","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0000","quote":"for the last two years. Our companies have been in survival mode. And now they're actually thriving."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0001_n1","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"Рынок для biotech остаётся «touch and go»; компании часто вынуждены делать рекапитализации, и не стоит считать, что «game on» для фандрайзинга.","text_en":"Biotech market remains touch-and-go; companies often need recapitalizations, and it’s premature to think fundraising is fully back on.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"it's still a touch and go kind of marketplace"},{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"companies that we're either recapping, which is certainly not a great thing to do"},{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"I'd be a little bit cautious in thinking that it's game on for fundraising"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0001_n2","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Высокие ставки удерживают других инвесторов от biotech; сектор воспринимается как рискованный и «mystifying» для generalist-инвесторов, а трек-рекорд (кроме COVID bubble) слабый.","text_en":"High interest rates keep other investors away; biotech is seen as risky and mystifying to generalists, with a weak track record outside the COVID bubble.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"interest rates being high, keeping, you know, other investors away from biotech"},{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"It's one that's probably most mystifying to a lot of, you know, generalist investors"},{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"the track record hasn't been great, other than the COVID bubble"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0001_n3","doc_id":"doc_924f5a3029a5","kind":"buyer_signal","text_ru":"Сделка M&A: Tourmaline приобретена Novartis за $1.4B с «healthy premium» (почти 90%), что может создавать FOMO и поддерживать сектор.","text_en":"M&A signal: Novartis acquired Tourmaline for $1.4B with a healthy premium (~90%), potentially creating FOMO and supporting the sector.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"hopefully there is at least a little bit of FOMO around this one"},{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"Tourmaline being acquired by Novartis for $1. 4 billion"},{"chunk_id":"doc_924f5a3029a5_chunk_0001","quote":"Healthy premium here and they go almost 90 percent"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0002_n1","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Крупные фармкомпании активно заключают сделки с китайскими биотехами, т.к. это позволяет дешевле получать активы и быстрее/дешевле снижать риски на ранних стадиях (discovery и early clinical).","text_en":"Large pharma is increasingly doing deals with China biotech because it enables cheaper asset access and faster/cheaper de-risking in discovery and early clinical.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0002","quote":"there's been obviously a lot more, you know, deals with Chinese companies"},{"chunk_id":"doc_924f5a3029a5_chunk_0002","quote":"how quickly Chinese companies are able to do discovery in early clinical work is hugely beneficial to large pharmaceutical companies. They're able to get assets very cheap."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0002_n2","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Потенциальный регуляторный/политический риск для сделок с китайскими биотехами: обсуждается проект executive order, который может ужесточить условия, вплоть до обязательного прохождения licensing deals через CFIUS.","text_en":"Potential regulatory/political risk for China biotech deals: a draft executive order could tighten rules, potentially requiring licensing deals to go through CFIUS.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0002","quote":"The Trump administration has been drafting an executive order. relating to China biotech"},{"chunk_id":"doc_924f5a3029a5_chunk_0002","quote":"one thing that it mentioned that could be proposed is that the licensing deals that we see it could be mandatory that they would have to go through Scythias."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0002_n3","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Идёт лоббистское противостояние вокруг China biotech: крупная фарма просит «не раскачивать лодку», а часть инвесторов — «tighten the screws», считая, что это вредит сектору и рабочим местам.","text_en":"There is lobbying conflict around China biotech: large pharma urges not to disrupt it, while some investors push to tighten restrictions, citing harm to the sector and jobs.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0002","quote":"They're lobbying the government to like not rock the boat on China biotech"},{"chunk_id":"doc_924f5a3029a5_chunk_0002","quote":"You have a handful of investors who are lobbying to basically tighten the screws and saying that it's going to hurt our biotech sector and jobs."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0003_n1","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Обсуждаются предложения сделать лицензирование обязательным через «Scythias», что может создать сильные временные и ресурсные издержки и замедлить/сорвать сделки.","text_en":"Proposals are discussed to make licensing deals mandatory through “Scythias,” potentially adding heavy time/resource burden and slowing or killing deals.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0003","quote":"\"the licensing deals that we see it could be mandatory that they would have to go through Scythias.\""},{"chunk_id":"doc_924f5a3029a5_chunk_0003","quote":"\"has the potential to like kill all of these deals\""},{"chunk_id":"doc_924f5a3029a5_chunk_0003","quote":"\"make it so time and resource burdensome to go through that process\""}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0003_n2","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"FDA не позволяет использовать данные из Китая для подачи/очень поздних стадий, и обсуждается вариант игнорировать China data на всех стадиях разработки.","text_en":"FDA doesn’t allow China data for filing/very late-stage studies, and there’s discussion of potentially ignoring China data across all development stages.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0003","quote":"\"the FDA doesn't allow China data for, like, you know, to file on or for very late stage studies\""},{"chunk_id":"doc_924f5a3029a5_chunk_0003","quote":"\"choose to basically ignore China data altogether in like all stages of drug development\""}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0003_n3","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"В Европе и Великобритании есть потребность ускорить прохождение клинических испытаний (\"getting trials through\").","text_en":"There is a need to speed up clinical trial throughput in Europe and the UK (“getting trials through”).","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0003","quote":"\"What we need is to speed things up in Europe and in the UK in terms of getting trials through.\""}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0004_n1","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Китайский онкопрепарат Serp-Lulimab (Henleus) получил регуляторные одобрения в Германии и Великобритании на основе европейских данных и фигурирует в ESMO-гайдлайнах выше некоторых конкурентов.","text_en":"A China-developed oncology drug (Serp-Lulimab, Henleus) received approvals in Germany and the UK based on European data and is ranked above some competitors in ESMO guidelines.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0004","quote":"Serp-Lulimab from Henleus. They developed it in China. They did a trial in Europe. It got approved in Germany"},{"chunk_id":"doc_924f5a3029a5_chunk_0004","quote":"It's got approved in the UK based on European data. At the ESMO guidelines, it ranks above."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0004_n2","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"Есть опасение, что геополитические/политические решения могут ограничить доступ пациентов к «лучшим» препаратам.","text_en":"Concern that geopolitical/political decisions could curb patient access to the best drugs.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0004","quote":"there has to be some control over not curbing the access of patients to the best drugs."}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0004_n3","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Барьер/ограничение: политический аргумент против финансирования научного прогресса и роста biotech-сектора в Китае, рассматриваемом как «adversary».","text_en":"Constraint: political pushback against funding scientific advancement and biotech growth in China viewed as an adversary.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0004","quote":"Do we want to fund the scientific advancement and the growth of the biotech sector? in this place that's contrary to our way of life."}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_nugget_0001","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"В биотехе наблюдается «скучивание» вокруг валидированных мишеней: слишком много продуктов против уже валидированных targets идут в разработку; VC чаще делают best-in-class/fast follower, чем first-in-class.","text_en":"Biotech is crowding around validated targets: too many products against validated targets; VCs often pursue best-in-class/fast followers over first-in-class.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0005","quote":"What we've seen in our industry... is a crowding around. Validated targets, maybe too many products against validated targets moving into development."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_nugget_0002","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"Когда IPO-окно закрыто, сектор вынужден полагаться на M&A как на ключевой путь ликвидности/выхода.","text_en":"When the IPO window is closed, the sector must rely on M&A as the main exit/liquidity path.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0005","quote":"When the IPO window is open, great... But when it's not, we have to rely on M &A."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_nugget_0003","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Фарма начинает рассматривать прямые сделки/коллаборации с Китаем, минуя US biotech, что может смещать спрос на активы и влиять на US venture-backed компании.","text_en":"Pharma is starting to consider going directly to China for deals/collaborations, bypassing US biotech, potentially shifting demand away from US venture-backed companies.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0005","quote":"Now we're starting to see deals where pharma is saying... Why don't we go straight to China?"},{"chunk_id":"doc_924f5a3029a5_chunk_0005","quote":"pharma decides if they can go right to China. We don't really need U. S. biotech"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0006_n1","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"За последний год американские венчурные инвесторы лицензировали препараты из Китая, но фарма всё чаще пытается идти напрямую к китайским разработчикам.","text_en":"Over the last year, US VCs have been licensing China-origin drugs, but pharma is increasingly going directly to Chinese developers.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0006","quote":"what we've seen in the last year is the U.S. Venture capitalists have been licensing in these China drugs. But. Then we see pharma saying, 'Well, we can go straight to them.'"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0006_n2","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"FDA описывается как «самый негибкий» регулятор в части быстрого и эффективного вывода препаратов в клинику, из‑за чего компании всё чаще проводят фазы 1–2 вне США.","text_en":"The FDA is described as the most inflexible for getting drugs into the clinic quickly/efficiently, pushing companies to run Phase 1–2 increasingly outside the US.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0006","quote":"Increasingly, going to phase two outside of the US, because the FDA is the most inflexible in getting drugs into the clinic quickly and efficiently."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0006_n3","doc_id":"doc_924f5a3029a5","kind":"opportunity","text_ru":"Возможность: реформировать процессы, чтобы быстрее заходить в клинику в США; это может вернуть больше клинических исследований в США.","text_en":"Opportunity: reform the ability to enter the clinic faster in the US, potentially bringing more clinical trials back to the US.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0006","quote":"We need to reform our ability to get into the clinic fast."},{"chunk_id":"doc_924f5a3029a5_chunk_0006","quote":"I think you may see a different scenario play out, right? And seeing more clinical trials in the US"}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0007_n1","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"Нарколепсия до недавнего времени лечилась в основном симптоматически, без воздействия на первопричину.","text_en":"Narcolepsy has largely been treated symptomatically rather than addressing the underlying cause.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0007","quote":"people have really only been able to try to help with the symptoms and not the underlying condition."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0007_n2","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Рынок нарколепсии конкурентный: несколько игроков публикуют данные (Takeda с успешными Phase 3, Alkermes с Phase 2), обсуждается гонка «первый на рынке» и удобство режима дозирования.","text_en":"The narcolepsy market is competitive with multiple data readouts (Takeda Phase 3 success, Alkermes Phase 2), with debate around first-to-market and dosing convenience.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0007","quote":"the narcolepsy market is competitive, and there's been data releases on. uh from a couple competitors"},{"chunk_id":"doc_924f5a3029a5_chunk_0007","quote":"two successful phase three trials."},{"chunk_id":"doc_924f5a3029a5_chunk_0007","quote":"Alkermes is farther behind. They presented phase two data."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0007_n3","doc_id":"doc_924f5a3029a5","kind":"opportunity","text_ru":"Потенциал коммерчески значимого препарата для нарколепсии: заболевание редкое, но в США около 150k пациентов; упоминаемые оценки пиковых продаж 1.5–3 млрд.","text_en":"Commercial opportunity for a narcolepsy drug: rare but ~150k patients in the US; cited peak sales estimates of $1.5–3B.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0007","quote":"in the U. S., it's like 150,000."},{"chunk_id":"doc_924f5a3029a5_chunk_0007","quote":"numbers that I've seen are like between 1. 5 and 3 billion."}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0008_n1","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"В раке поджелудочной железы долгое время почти ничего не работало, что подчёркивает неудовлетворённую медицинскую потребность.","text_en":"In pancreatic cancer, almost nothing has worked for a long time, highlighting unmet need.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0008","quote":"It's been 30 years of almost nothing working in pancreatic cancer."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0008_n2","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"На World Lung показали много новых/обновлённых ранних данных и новых исследований по мелкоклеточному раку лёгкого, включая ADC против B7H3 и DLL3.","text_en":"World Lung featured lots of new/updated early-stage data and new trials in SCLC, including ADCs against B7H3 and DLL3.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0008","quote":"we saw quite a lot of new early-stage, sometimes updated data, sometimes new trials for small-cell lung cancer."},{"chunk_id":"doc_924f5a3029a5_chunk_0008","quote":"there's ADCs being developed against B7H3 and DLL3."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0008_n3","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Для многих препаратов/испытаний в SCLC остаётся проблема позиционирования из‑за конкуренции с биспецификом Amgen (tarlatumab/Imdelltra), и нет данных по эффективности после терапии Imdelltra.","text_en":"Many SCLC drugs/trials face positioning challenges due to competition from Amgen’s bispecific (tarlatumab/Imdelltra), with limited post-Imdelltra data.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0008","quote":"the challenge for all of these is that you've got Amgen's bispecific. To compete with"},{"chunk_id":"doc_924f5a3029a5_chunk_0008","quote":"None of them really had data that showed how well they performed in patients. post-Indeltera therapy"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0009_n1","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"По ряду ADC нет данных, показывающих, насколько хорошо они работают у пациентов после терапии Imdeltra, т.к. многие исследования шли до её использования в 1–2 линии.","text_en":"For several ADCs, there’s a lack of data on performance in patients post-Imdeltra therapy, since many trials ran before Imdeltra was used in 1st/2nd line.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0009","quote":"None of them really had data that showed how well they performed in patients. post-Indeltera therapy"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0009_n2","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Данные по BioNTech BNT327 в 1-й линии SCLC выглядят многообещающе, но это очень ранний срез с медианой наблюдения 6,5 месяцев.","text_en":"BioNTech’s BNT327 1L SCLC data look promising but are very early, with 6.5 months median follow-up.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0009","quote":"really early readout. I mean, we had a six and a half months median follow up."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0009_n3","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Подача на регистрацию в США может быть невыгодна из‑за запуска «IRA clock», сокращающего окно эксклюзивности; поэтому компания может не хотеть подавать.","text_en":"US filing may be unattractive because it starts the “IRA clock,” shortening exclusivity; the company may prefer not to file.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0009","quote":"filing only starts the IRA clock... shortens their window. Of exclusivity"}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0010_n1","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Данные выглядят преждевременными: короткий follow-up и малое число событий делают выводы (hazard ratio) нестабильными/чувствительными к перестановке пациентов.","text_en":"Data look premature: short follow-up and small numbers make hazard ratio conclusions unstable/sensitive to patient switching.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0010","quote":"\"This is premature.\""},{"chunk_id":"doc_924f5a3029a5_chunk_0010","quote":"\"Because the follow-up is very short.\""},{"chunk_id":"doc_924f5a3029a5_chunk_0010","quote":"\"We have a 0. 7 hazard ratio on a very small number\""}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0010_n2","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"В миастении гравис появляется новый механизм: C1S ингибитор (на фоне существующих FcRN и C5 ингибиторов).","text_en":"A new mechanism is emerging in myasthenia gravis: a C1S inhibitor alongside existing FcRN and C5 inhibitors.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0010","quote":"\"there's a new mechanism in town. This is from Dianthus. They had phase two data on a C1S inhibitor.\""},{"chunk_id":"doc_924f5a3029a5_chunk_0010","quote":"\"Existing therapies for MG or FCRNs and C5 inhibitors.\""}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0010_n3","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Регуляторный риск: препарат Intercept получил accelerated approval, но был отклонён для полного одобрения и затем снят с рынка.","text_en":"Regulatory risk: Intercept’s drug had accelerated approval, was rejected for full approval, and was later pulled from the market.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0010","quote":"\"got accelerated approval. It was rejected for full approval.\""},{"chunk_id":"doc_924f5a3029a5_chunk_0010","quote":"\"they just had news this week that they pulled the drug from the market.\""}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0011_n1","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"Серьёзные риски безопасности в gene therapy: смерть первого дозированного пациента привела к остановке исследования; в целом отрасль «не вне леса» по safety concerns.","text_en":"Gene therapy safety risks: first dosed patient death led to a trial hold; the field is still not out of the woods on safety concerns.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0011","quote":"the first patient that was dosed died within a few weeks, days, I believe. And so they've basically put that trial on hold."},{"chunk_id":"doc_924f5a3029a5_chunk_0011","quote":"We still aren't out of the woods on some of the safety risks and concerns that we see in that space."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0011_n2","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"FAERS переходит к гораздо более частым релизам данных: вместо квартальных — почти ежедневные публикации adverse events.","text_en":"FAERS is moving to much more frequent data releases: from quarterly to almost daily adverse event releases.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0011","quote":"FAERS is going to much more frequent data releases. It used to be once a quarter, and now the FDA is saying that they're going to release adverse events"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0011_n3","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Ограничение FAERS: база недостаточно точна, чтобы устанавливать причинно-следственную связь (causality) между препаратом и событием; «correlation is not causation».","text_en":"Constraint of FAERS: it’s not accurate enough to establish causality between a drug and an event; correlation is not causation.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0011","quote":"Of course, correlation is not causation."},{"chunk_id":"doc_924f5a3029a5_chunk_0011","quote":"FAERS is not an accurate enough database to to come up with that potential causality link."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0012_n1","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"Высокий риск неверной интерпретации событий/сигналов при малых выборках и недостатке контекста (особенно на старте запуска препарата).","text_en":"High risk of misinterpreting events/signals with small sample sizes and limited context (especially at drug launch).","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0012","quote":"there can be a lot of misinterpretation when you're dealing with very you know, with very small n."},{"chunk_id":"doc_924f5a3029a5_chunk_0012","quote":"you can see better signals when you have more N and a larger sample size. Which... especially when a drug first launches."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0012_n2","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Одновременно растёт прозрачность (реал-тайм AE-репорты, больше фона по CRL), но наблюдается отмена adcom-ов, что снижает этот тип прозрачности.","text_en":"Transparency is increasing (real-time AE reports, more background on CRLs) while adcoms are being canceled, reducing that form of transparency.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0012","quote":"there's more transparency there's more um you know real-time uh ae reports more um background on CRLs"},{"chunk_id":"doc_924f5a3029a5_chunk_0012","quote":"we're seeing a lot of adcoms get canceled, right?"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0012_n3","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Публикация CRL/коммуникаций FDA без уведомления компании и невозможность FDA публиковать ответы компании создают дисбаланс в публичном поле и вынуждают компании публично спорить с регулятором.","text_en":"FDA posting CRLs/communications without company notice and inability to post company responses creates a public-domain imbalance and pressures companies to air disputes publicly.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0012","quote":"they were not aware that the FDA was going to post it."},{"chunk_id":"doc_924f5a3029a5_chunk_0012","quote":"the FDA doesn't have the right to post company communications"}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0013_n1","doc_id":"doc_924f5a3029a5","kind":"pain","text_ru":"Коммуникации компании с FDA могут быстро превратиться в поток публичных пресс-релизов, что воспринимается как нездоровая динамика.","text_en":"Company–FDA communications can quickly turn into a stream of public press releases, seen as an unhealthy dynamic.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0013","quote":"Every communication between the company and the FDA turns into a public press release— like, 'Is that really? Healthy.'"}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0013_n2","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Adcoms (консультативные комитеты) могут быть политизированы; формулировка вопросов и брифинг-документов может искажать процесс.","text_en":"Adcoms can be politicized; how questions and briefing documents are crafted can distort the process.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0013","quote":"adcoms can be politicized as well. And how they craft the questions and the briefing documents."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0013_n3","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"Риск регуляторно-правовых последствий (SEC) за манипуляцию/искажение данных; такие действия рассматриваются как механизм дисциплины для biotech.","text_en":"Risk of SEC enforcement for data manipulation/misrepresentation; such actions are seen as a discipline mechanism for biotech.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0013","quote":"we need these types of actions to keep. All of the biotech companies honest"}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0014_n1","doc_id":"doc_924f5a3029a5","kind":"constraint","text_ru":"На ранней стадии discovery Arena Bioworks практически ничего не раскрывает о том, над чем работает, из‑за чего сложно оценивать их направление/модальность.","text_en":"Arena Bioworks has disclosed essentially nothing about what they’re working on, making it hard to assess their direction/modality.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0014","quote":"They've disclosed essentially nothing about what they're working on and so it's hard to."},{"chunk_id":"doc_924f5a3029a5_chunk_0014","quote":"they're. Modality, agnostic, you know, so they haven't really said anything to gauge."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0014_n2","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Novo объявила масштабные сокращения (11% штата) и заявила о переходе к более performance-led культуре, при этом рынок в целом отреагировал позитивно.","text_en":"Novo announced large-scale layoffs (11% of workforce) and a shift to a more performance-led culture; shares reacted mostly positively.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0014","quote":"So 11% of it's of its workforce, 5 000 of that, 9 000 people in Denmark,"},{"chunk_id":"doc_924f5a3029a5_chunk_0014","quote":"in the press release, they said that we're going to be in a more performance-led culture"},{"chunk_id":"doc_924f5a3029a5_chunk_0014","quote":"But share prices reacted positively at least mostly."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0014_n3","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"В категории GLP наблюдается динамика «лидер был впереди, но его обогнали»: звучит мнение, что Lilly сейчас имеет более сильный препарат (zepbound) и Novo нужно «догонять».","text_en":"In GLPs, the early leader can be overtaken; Lilly is said to have the better drug (zepbound) and Novo needs to catch up.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0014","quote":"the company does need to catch up with Lilly, who currently has the better drugs."},{"chunk_id":"doc_924f5a3029a5_chunk_0014","quote":"I feel like the GLPs are going through the exact same thing that the PD1s went through."},{"chunk_id":"doc_924f5a3029a5_chunk_0014","quote":"'zep' bound seems seems to be a better drug."}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0015_n1","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"В конкурентной гонке компания, которая была впереди, может быть обогнана другим игроком.","text_en":"In a competitive race, the company that was ahead can be overtaken by another player.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0015","quote":"The company that was out in front ultimately got overtaken by somebody else."}],"confidence":"medium"}
{"nugget_id":"doc_924f5a3029a5_chunk_0015_n2","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Комбинация GLP-1 с GIP оказалась более успешной, чем ожидали многие.","text_en":"Combining GLP-1 with GIP worked better than many expected.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0015","quote":"The mechanism they used to combine GLP-1 with GIP, I don't think many people thought that was going to actually work the way it did."}],"confidence":"high"}
{"nugget_id":"doc_924f5a3029a5_chunk_0015_n3","doc_id":"doc_924f5a3029a5","kind":"trend","text_ru":"Novo долгое время инновационно работала в области GLP; GLP «вышел» из Novo.","text_en":"Novo has innovated in GLP for years; GLP originated from Novo.","evidence":[{"chunk_id":"doc_924f5a3029a5_chunk_0015","quote":"Novo has been innovating in this space for years. GLP once came out of Novo"}],"confidence":"medium"}
{"nugget_id":"doc_25081f62c841_chunk_0000_n1","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Ускоряется M&A-активность в биотехе; годовой темп M&A может стать самым сильным с 2019 года, несмотря на отсутствие мега-сделок.","text_en":"M&A activity in biotech is accelerating; annualized M&A is tracking to the strongest year since 2019 despite a lack of mega-deals.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0000","quote":"M&A activity is accelerating"},{"chunk_id":"doc_25081f62c841_chunk_0000","quote":"the annualized M&A is tracking to be around 186 billion, making it the strongest year since 2019."},{"chunk_id":"doc_25081f62c841_chunk_0000","quote":"Despite the lack of mega deals."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0000_n2","doc_id":"doc_25081f62c841","kind":"opportunity","text_ru":"У крупных фармкомпаний есть значительный «запас» средств на приобретения на фоне риска выручки из‑за patent cliffs к 2030, что создаёт окно для сделок/экзитов биотех-компаний.","text_en":"Big pharma has substantial acquisition capacity amid revenue-at-risk from patent cliffs by 2030, creating a window for biotech M&A/exits.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0000","quote":"major pharma companies are holding $1. 2 trillion in acquisition firepower."},{"chunk_id":"doc_25081f62c841_chunk_0000","quote":"As they face $180 billion in revenue at risk from patent cliffs"},{"chunk_id":"doc_25081f62c841_chunk_0000","quote":"By 2030."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0000_n3","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Сектор сталкивается с «continued policy uncertainty», обозначенной как один из headwinds.","text_en":"The sector faces continued policy uncertainty as a headwind.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0000","quote":"there's still a number of headwinds, including continued policy uncertainty"}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Сектор biotech, по словам спикеров, начинает переходить от десятилетий убыточности к более прибыльным/устойчивым бизнес-моделям, что может сделать его привлекательнее для generalist investors.","text_en":"Biotech is described as shifting from decades of unprofitability toward more profitable/sustainable business models, potentially attracting generalist investors.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0001","quote":"\"why would anyone ever want to invest in an unprofitable sector? A sector that, by the way, was unprofitable for for decades. So that's actually changing\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Сильная ориентация инвестсообщества biotech на M&A рассматривается как долгосрочно вредная: она ведёт к «crowding», «group think» и игре в угадывание ожиданий вместо построения работающего бизнеса.","text_en":"Heavy M&A focus in biotech investing is framed as long-term harmful, driving crowding/groupthink and speculation over building real businesses.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0001","quote":"\"the M&A focus of the biotech investment community is like bad long term for the sector\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Окно IPO долго было закрыто, что ограничивало выход компаний на публичный рынок; при этом это же уменьшало приток более спекулятивных имён в экосистему.","text_en":"The IPO window has been closed for a long time, constraining public listings; it also limited adding more speculative names to the ecosystem.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0001","quote":"\"the IPO window has been closed for so long that we haven't added more speculative type names to the ecosystem\""}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0002_n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Критика M&A в biotech: сделки могут «высасывать» компании, которые могли бы стать прибыльными и сделать сектор привлекательнее, что тормозит общую прибыльность/развитие сектора.","text_en":"Critique of biotech M&A: it can deplete companies that could drive profitability and make the sector more attractive, slowing overall sector profitability/development.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"we're depleting those companies that could drive profitability"},{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"the sector needs profitability."},{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"M&A that sits on the sector and prevents it from being more profitable"}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0002_n2","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Если «единственный способ выиграть — быть купленным», это делает индустрию менее интересной и ограничивает создание новых бизнесов/креативных моделей создания ценности.","text_en":"If the only way to win is to get acquired, it makes the industry less interesting and limits building new businesses/creative value creation models.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"if the only way to win is to get bought. It's just like boring."},{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"You don't get to like build fun businesses."},{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"You don't get to think about creative ways to create value."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0002_n3","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Собеседник отмечает, что сейчас «отличное время» для фандрайзинга, особенно для clinical-stage компаний; также уже видят приход generalist-инвесторов и новых фондов в публичный сектор.","text_en":"Speaker notes it’s a great time to fundraise, especially for clinical-stage companies; they’re already seeing generalist investors and new funds entering the public sector.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"we're fundraising. It's a great time to do that, especially if you're a clinical stage company."},{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"we're already seeing some generalists coming in"},{"chunk_id":"doc_25081f62c841_chunk_0002","quote":"we're also seeing some new funds that are on the public sector coming in as well."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0003_n1","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"На публичных рынках происходит «очистка», и в сектор заходят generalist-инвесторы и новые фонды, ориентированные на public.","text_en":"Public markets are seeing a cleanup, with generalist investors and new public-focused funds entering the sector.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0003","quote":"\"there's been a lot of cleanup in the public markets\""},{"chunk_id":"doc_25081f62c841_chunk_0003","quote":"\"we're already seeing some generalists coming in\""},{"chunk_id":"doc_25081f62c841_chunk_0003","quote":"\"we're also seeing some new funds that are on the public sector coming in\""}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0003_n2","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Цирротический MASH остаётся крупной неудовлетворённой медицинской потребностью (в отличие от одобренного препарата для non-cirrhotic MASH).","text_en":"Cirrhotic MASH remains a major unmet medical need (vs an approved drug for non-cirrhotic MASH).","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0003","quote":"\"it was approved for non-cirrhotic mash, so cirrhosis still remains a pretty major unmet medical need\""}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0003_n3","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Высокий execution risk: результаты фазы 3 ожидаются только в 2027 году.","text_en":"High execution risk: the phase 3 readout is not expected until 2027.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0003","quote":"\"the phase three readout is not expected until 2027. So execution risk is still high\""}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0004_n1","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Лицензионные сделки в AI drug discovery/платформенных технологиях (в т.ч. molecular glue degraders) используются как валидация значимости направления и интереса к preclinical–early clinical immunology активам.","text_en":"Licensing deals in AI drug discovery/platform technologies (incl. molecular glue degraders) are cited as validation and show interest in preclinical-to-early-clinical immunology assets.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0004","quote":"It's a further validation that AI drug discovery is meaningful. Having platform technologies is meaningful. And there's still quite a lot of interest in preclinical to early clinical. Immunology assets."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0004_n2","doc_id":"doc_25081f62c841","kind":"buyer_signal","text_ru":"Novartis платит значимый upfront за эксклюзивную лицензию на программы Monte Rosa и имеет опции на дополнительные программы, что сигнализирует о готовности покупать/лицензировать такие активы.","text_en":"Novartis is paying a meaningful upfront for an exclusive license to Monte Rosa programs and holds options for additional programs, signaling willingness to license/buy such assets.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0004","quote":"Montarosa gets $120 million, which is still pretty good. And Novartis in return gets exclusive license"},{"chunk_id":"doc_25081f62c841_chunk_0004","quote":"Novartis, in addition to this one, has an option to license two additional programs from Monterosa"}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0004_n3","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Для pharma структура сделок с относительно «скромным» upfront помогает держать риск низким и перекладывать риск discovery на партнёра до достижения preclinical milestones.","text_en":"For pharma, deal structures with relatively modest upfronts keep risk low and place discovery risk on the partner until preclinical milestones are hit.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0004","quote":"these are big numbers, but still upfront is kind of at the modest 120, 220, 250."},{"chunk_id":"doc_25081f62c841_chunk_0004","quote":"for Novartis and other pharma, it means they can keep the risk low. and really look to Monterosa to deliver on discovery."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Саркоидоз — тяжёлое заболевание с высокой заболеваемостью/смертностью и фактически без хороших вариантов лечения; пациенты в основном на стероидах/иммуносупрессантах.","text_en":"Sarcoidosis is a tough disease with high morbidity/mortality and few good treatment options; patients are mainly on steroids/immunosuppressants.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0005","quote":"\"this is a tough disease. It's a tough disease\""},{"chunk_id":"doc_25081f62c841_chunk_0005","quote":"\"High morbidity, high mortality.\""},{"chunk_id":"doc_25081f62c841_chunk_0005","quote":"\"mostly no good treatment options.\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"В аутоиммунных заболеваниях сложно проводить исследования из‑за FDA-эндпойнтов/композитных шкал с высоким плацебо-ответом и трудности измерения прогрессирования; выбор стероид-сберегающего первичного эндпойнта может быть проблемным.","text_en":"Autoimmune trials are hard due to FDA endpoints/composite scales with high placebo response and difficulty measuring progression; steroid-sparing primary endpoints can be challenging.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0005","quote":"\"FDA-established endpoints that are often these composite scales that are subject to high placebo responses.\""},{"chunk_id":"doc_25081f62c841_chunk_0005","quote":"\"it's just very hard to find a good way to study disease progression.\""},{"chunk_id":"doc_25081f62c841_chunk_0005","quote":"\"the primary endpoint, which was a true steroid sparing endpoint\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Барьером для программы может быть неясность механизма действия препарата в заболевании, даже при наличии клинических данных.","text_en":"A program barrier can be an unclear mechanism of action in the disease, even with some clinical data.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0005","quote":"\"the drug mechanistically is a little bit unclear in terms of how it was going to work in the disease\""}],"confidence":"medium"}
{"nugget_id":"doc_25081f62c841_chunk_0006_n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Агрессивные публичные short-отчёты могут вызывать путаницу среди пациентов и клиницистов из‑за смеси точной и вводящей в заблуждение информации.","text_en":"Aggressive public short reports can confuse patient and clinician groups due to a mix of accurate and misleading information.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0006","quote":"we've seen some very aggressive, very visible short reports that actually cause confusion amongst patient and clinician groups."},{"chunk_id":"doc_25081f62c841_chunk_0006","quote":"a mix of accurate information but also some misleading information."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0006_n2","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Для компаний риск от шортов ниже, если не нужно привлекать деньги до выхода данных; иначе потребность в финансировании до данных становится уязвимостью.","text_en":"Short pressure is less problematic if a company doesn’t need to raise money before data; needing pre-data financing is a vulnerability.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0006","quote":"as long as the company they're shorting doesn't need to raise money before the data."}],"confidence":"medium"}
{"nugget_id":"doc_25081f62c841_chunk_0006_n3","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Обсуждение биотех-данных и short-тезисов активно происходит в Twitter, включая публичные «back and forth» о корректности промо со стороны ведущего/гостя.","text_en":"Biotech data and short theses are actively debated on Twitter, including public back-and-forth about whether a host should promote something.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0006","quote":"there's been sort of some Twitter back and forth on whether it was appropriate"}],"confidence":"medium"}
{"nugget_id":"doc_25081f62c841_chunk_0007_n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"В дерматомиозите давно не появлялось успешно разработанной новой терапии; много провалов клинических исследований, мало альтернатив.","text_en":"Dermatomyositis has seen few successful novel therapies; many failed studies and limited options.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0007","quote":"there really hasn't been a novel therapy successfully developed in a very long time."},{"chunk_id":"doc_25081f62c841_chunk_0007","quote":"There have been probably nine or ten failed studies in the last couple of decades"}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0007_n2","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Разработка JAK-ингибиторов переживала локальный спад на фоне появления «black box» предупреждений и неопределённости в поле.","text_en":"JAK inhibitor development hit a local nadir amid black box warnings and uncertainty in the field.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0007","quote":"At a time when JAK inhibitor development was at a local nadir."},{"chunk_id":"doc_25081f62c841_chunk_0007","quote":"black box class morning showing up and people sort of weren't sure where the field was going to go."}],"confidence":"medium"}
{"nugget_id":"doc_25081f62c841_chunk_0007_n3","doc_id":"doc_25081f62c841","kind":"buyer_signal","text_ru":"Снижение стероидной нагрузки является значимым для врачей (важный критерий ценности терапии).","text_en":"Reducing steroid burden is something doctors care a lot about (a key value driver).","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0007","quote":"significantly reduced steroid burden, which, after the entire conversation, is something docs care a lot about."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0008_n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Инвесторы неохотно приписывают ценность портфелю/пайплайну за пределами первых 1–2 активов, из‑за чего перспективные компании могут иметь завышенную стоимость капитала и сложности с финансированием инноваций.","text_en":"Investors are reluctant to value portfolios beyond the first 1–2 assets, leading to higher-than-appropriate cost of capital and harder innovation funding.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0008","quote":"investors become increasingly reluctant to ascribe value beyond the first one or two assets."},{"chunk_id":"doc_25081f62c841_chunk_0008","quote":"companies that have very promising portfolios with costs of capitals that probably higher than they should be."},{"chunk_id":"doc_25081f62c841_chunk_0008","quote":"Which can make it challenging for them to fund all this incredible innovation."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0008_n2","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Из‑за длительно закрытого IPO-окна частные биотех-компании вынуждены «созревать» и генерировать данные в частном контуре, что меняет экосистему private biotech.","text_en":"With the IPO window closed for long, private biotechs are forced to mature and generate data privately, changing the private biotech ecosystem.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0008","quote":"with the IPO window having been closed for so long, the private companies are forced to mature, generate data"}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0008_n3","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Эозинофильная астма описана как очень большая неудовлетворённая медицинская потребность.","text_en":"Eosinophilic asthma is described as a very large unmet medical need.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0008","quote":"eosinophilic asthma, which remains a very large unmet medical need."}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Эозинофильная астма остаётся большой неудовлетворённой медицинской потребностью; есть спрос на пероральные опции лечения.","text_en":"Eosinophilic asthma remains a large unmet medical need; there is demand for oral treatment options.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0009","quote":"\"an oral option to treat eosinophilic asthma, which remains a very large unmet medical need.\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"В частном биотех-секторе компании вынуждены достигать вех и снижать риски до выхода на публичные рынки.","text_en":"In private biotech, companies are being forced to hit milestones and de-risk before going public.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0009","quote":"\"companies being forced to hit milestones, risk or de-risk before they come to the public markets.\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Великобритания воспринимается как сложная среда для разработки и продажи лекарств из‑за регулирования/антибизнес-политик и консервативного подхода к оплате инноваций; это может тормозить развитие биотех-хаба.","text_en":"The UK is seen as a tough environment to develop and sell drugs due to regulation/anti-business policy and conservative value-based payment; this may hinder hub formation.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0009","quote":"\"the issues have a lot to do with over-regulation and what's been pointed to as anti-business policy.\""},{"chunk_id":"doc_25081f62c841_chunk_0009","quote":"\"it's a tough place to develop and sell drugs\""},{"chunk_id":"doc_25081f62c841_chunk_0009","quote":"\"they're at the extreme end of conservatism in terms of paying for value when it comes to innovation.\""}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0010_n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Дискуссии о ценах на лекарства часто не рассматривают ключевую цель — как ценообразование должно стимулировать инновации; это вызывает фрустрацию у участников рынка.","text_en":"Drug pricing debates often ignore the key goal—how pricing should incentivize innovation—creating frustration among market participants.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0010","quote":"\"But that's not the lens that you hear these drug price discussions ever talked about, which I find a little frustrating.\""}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0010_n2","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Ограничение: UK целенаправленно ограничивает расходы на лекарства, что снижает готовность страны финансировать инновации и становится серьёзной проблемой.","text_en":"Constraint: The UK is deliberately limiting drug spending, reducing willingness to fund innovation, which is becoming a serious issue.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0010","quote":"\"Really limit the amount that they spend on drugs and, as such, the amount that they're willing to commit to innovation.\""}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0010_n3","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Тренд/сдвиг: крупные фармкомпании могут демонстративно переносить крупные инвестиции как политический сигнал США (и одновременно сигнал UK).","text_en":"Trend/shift: Big pharma may visibly shift large investments as a political signal to the US (and simultaneously to the UK).","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0010","quote":"\"nothing speaks louder in the current political moment than like shifting dollars of investment\""}],"confidence":"medium"}
{"nugget_id":"doc_25081f62c841_chunk_0011_n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"В UK (вне темы drug pricing) создана слабая среда для стимулирования построения компаний, инвестиций и формирования инновационных biotech-хабов; проблема длится годами.","text_en":"In the UK (beyond drug pricing), the environment poorly incentivizes company building, investment, and true innovation hubs; the issue has persisted for years.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"outside of drug pricing, the UK has done very minimal to understand what type of environment to create to incentivize"},{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"to build real innovation hubs"},{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"it's not a recent phenomenon. They've had issues going years, years back."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0011_n2","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Регуляторика в UK ориентирована на «protecting downside» и может мешать выстраиванию стимулов (например, отношение к долям у членов совета директоров из-за опасений конфликта интересов).","text_en":"UK regulation focuses on protecting downside and may hinder incentive alignment (e.g., frowning on board members holding shares due to conflict concerns).","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"a lot of regulation in the UK is around protecting downside. As opposed to incentivizing upside"},{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"Don't they frown upon board members having shares in the company?"},{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"they worry about conflicts of interest"}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0011_n3","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"UK takeover panel и общая «overregulation»/налоговые стимулы делают рынок менее интересным для инвесторов и, по мнению спикера, сдерживают способность строить компании; также отмечается сложность UK stock market.","text_en":"The UK takeover panel and broader overregulation/tax incentives make the market less attractive to investors and hold back company building; the UK stock market is also described as challenging.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"it really does make it less interesting for investors there"},{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"This idea of the overregulation and the tax incentives, and all of those things, I think, have really been holding back the ability to build companies there."},{"chunk_id":"doc_25081f62c841_chunk_0011","quote":"for the stock market, there is also very challenging."}],"confidence":"medium"}
{"nugget_id":"doc_25081f62c841_chunk_0012_n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"В UK не хватает подготовленных финансовых руководителей (CFO/финансовый уровень) и в целом кросс‑функционально обученного таланта для стартапов и масштабирования компаний.","text_en":"The UK lacks startup-ready finance leaders (CFO-level) and broadly cross-functional talent trained to build and scale startups.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0012","quote":"There aren't that many CFO and financial level people."},{"chunk_id":"doc_25081f62c841_chunk_0012","quote":"a lot of that talent is not actually trained to start-up companies or be in a cross-functional start-up environment"}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0012_n2","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"Регуляторная среда и отсутствие стимулов со стороны правительства UK рассматриваются как барьеры для инвестиций и развития биотех-экосистемы.","text_en":"UK regulation and lack of government incentives are described as barriers to investment and biotech ecosystem development.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0012","quote":"UK government is not really incentivizing investment in the UK."},{"chunk_id":"doc_25081f62c841_chunk_0012","quote":"tone down the regulation and incentivize investors"}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_chunk_0012_n3","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Отмечается риск/тенденция «отчуждения и потери» присутствия Big Pharma в UK-экосистеме, что может ослаблять хабы и доступ стартапов к экспертизе.","text_en":"A risk/trend is noted of the UK ecosystem alienating and losing Big Pharma presence, potentially weakening hub dynamics and startup access to expertise.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0012","quote":"for the UK, to alienate and lose, you know, presence of Big Pharma in that ecosystem"}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Даже в Массачусетсе, где сильная поддержка biotech и значимый вклад в экономический рост, индустрии сложно эффективно лоббировать и добиваться поддержки представителей; при этом на федеральном уровне продвигаются вредные для biotech/biopharma политики.","text_en":"Even in Massachusetts, despite strong biotech support and economic impact, the industry struggles to advocate effectively; harmful federal policies are being pushed against biotech/biopharma.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0013","quote":"we are still unable to advocate and to get our representatives to support us"},{"chunk_id":"doc_25081f62c841_chunk_0013","quote":"Policies at the federal level that are very harmful to to biotech and biopharma in general."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Высокая цена терапии по новому продукту J&J (TAR 200) рассматривается как сигнал направления, в котором могут продолжать двигаться цены на лекарства.","text_en":"J&J’s high first-year price for TAR 200 is framed as a signal of where drug prices may continue heading.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0013","quote":"Price pretty high, first year of therapy."},{"chunk_id":"doc_25081f62c841_chunk_0013","quote":"another signal in terms of the direction that drug prices can continue to head."}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_25081f62c841","kind":"constraint","text_ru":"В обсуждениях вакцинной политики ключевым ограничением называется недостаток «идеальных» данных для ответа на множество вопросов, из-за чего решения опираются на экспертное суждение и экстраполяции, создавая шум и неопределённость.","text_en":"A key constraint in vaccine policy discussions is the lack of perfect data, forcing reliance on expert judgment and extrapolation, creating noise and uncertainty.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0013","quote":"there's just not perfect data to answer the myriad of questions that have been raised"},{"chunk_id":"doc_25081f62c841_chunk_0013","quote":"a lot of vaccine policy comes down to expert judgment"},{"chunk_id":"doc_25081f62c841_chunk_0013","quote":"creating a lot of noise, confusion, and uncertainty."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_nugget_0014_01","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"«Экстраполяция в пользу» (favorable extrapolation) создаёт шум, путаницу и неопределённость.","text_en":"Favorable extrapolation creates noise, confusion, and uncertainty.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0014","quote":"Extrapolating favorably and that's just creating a lot of noise, confusion, and uncertainty."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_nugget_0014_02","doc_id":"doc_25081f62c841","kind":"pain","text_ru":"Качество и конфликты интересов у привлекаемых советников воспринимаются как реальная проблема.","text_en":"Advisor quality and personal conflicts of interest are seen as a real problem.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0014","quote":"the advisors that they're bringing in... they have their own personal conflicts, and I think that's a real problem."}],"confidence":"high"}
{"nugget_id":"doc_25081f62c841_nugget_0014_03","doc_id":"doc_25081f62c841","kind":"trend","text_ru":"Есть ощущение улучшения настроений в biotech: follow-on размещения сильные, но IPO пока почти нет; сентимент улучшился с минимумов апреля.","text_en":"Biotech sentiment seems to be improving: follow-ons are strong, but IPOs are still scarce; sentiment improved since April lows.","evidence":[{"chunk_id":"doc_25081f62c841_chunk_0014","quote":"the follow-ons are strong, but not really IPOs yet"},{"chunk_id":"doc_25081f62c841_chunk_0014","quote":"sentiment has improved substantially since our lows of April."}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0000_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Рынок/инвесторы восприняли новости о сделках администрации с фармой как позитивные (по реакции акций).","text_en":"Markets/investors viewed the administration–pharma deal news positively (per share price reactions).","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0000","quote":"as you can see from the share price reactions, the in general the market and investors have seen this as positive"}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0000_n2","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Непрозрачность/недоступность нетто-цен на лекарства (например, в UK) усложняет расчёты и сопоставления цен между странами.","text_en":"Lack of transparency/availability of net drug prices (e.g., in the UK) complicates cross-country price calculations and comparisons.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0000","quote":"nobody really knows what the prices are"},{"chunk_id":"doc_433066c16b44_chunk_0000","quote":"a lot of pharmacies aren't allowed to give out the net prices that they pay"}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0000_n3","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Ожидание, что фармкомпании будут чаще запускать продукты сначала в США, чтобы установить цену и затем добиваться оплаты в Европе и других странах.","text_en":"Expectation that pharma will increasingly launch products first in the US to set price, then seek higher payments in Europe/other countries.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0000","quote":"pharma companies are almost certainly going to end up launching every product... First in the US now, because you want to set the price there"}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0001_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Фармкомпании, вероятно, будут запускать продукты сначала в США, чтобы установить там цену, а затем добиваться сопоставимой нетто-цены в Европе.","text_en":"Pharma companies are likely to launch products first in the US to set price, then seek equivalent net pricing in Europe.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0001","quote":"pharma companies are almost certainly going to end up launching every product... First in the US now, because you want to set the price there"}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0001_n2","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"Европейские системы могут не увеличивать бюджеты на лекарства и вместо этого сильнее ограничивать доступ к препаратам, либо вообще отказываться от них, что бьёт по пациентам.","text_en":"European systems may not increase drug budgets and instead further restrict access or refuse drugs, harming patients.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0001","quote":"I'm not going to increase my drug budgets... I'm going to have to restrict the drug even more."},{"chunk_id":"doc_433066c16b44_chunk_0001","quote":"European setup and patients is that they go no—actually, we don't want the drug."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0001_n3","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"При появлении более удобных форм (пример: oral SIRTs) с улучшением приверженности, но конкуренцией с дженериками, возникает необходимость продумывать, как моделировать ценообразование/ценность в таких условиях.","text_en":"With more convenient forms (e.g., oral SIRTs) improving adherence but competing against generics, there’s a need to think about how to model pricing/value going forward.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0001","quote":"the competition is essentially generic, so we're going to have to be a lot higher price and... think about how do we model that going forward."}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0002_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Наблюдается ротация инвесторов в biotech/healthcare: сектор воспринимается как недооценённый, и «generalists» начинают проявлять интерес.","text_en":"There is an investor rotation into biotech/healthcare: the sector is seen as undervalued, and generalist investors are starting to show interest.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0002","quote":"I would say I think we're certainly in a rotation to biotech."},{"chunk_id":"doc_433066c16b44_chunk_0002","quote":"there's been this awakening to health care being... undervalued sector"},{"chunk_id":"doc_433066c16b44_chunk_0002","quote":"we're getting generalist inbounds, which is unusual."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0002_n2","doc_id":"doc_433066c16b44","kind":"buyer_signal","text_ru":"Появились входящие запросы от «реальных generalists», которые звонят и начинают разбираться в секторе biotech.","text_en":"There are inbound calls from 'real generalists' who are reaching out and starting to learn the biotech sector.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0002","quote":"real generalists who are calling, not knowing a lot about the sector."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0002_n3","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Часть generalist-инвесторов ожидает снижения ставок и опасается завершения tech-цикла, поэтому ищет следующий источник альфы и рассматривает biotech.","text_en":"Some generalist investors expect rates to fall and worry the tech cycle may end, so they look to biotech as the next alpha source.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0002","quote":"interest rates are going to come down."},{"chunk_id":"doc_433066c16b44_chunk_0002","quote":"they're getting a little bit worried that tech cycle is going to start ending"},{"chunk_id":"doc_433066c16b44_chunk_0002","quote":"they're rotating to the next risk level, the next alpha generator, and that, for them, is biotech."}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0003_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Генералисты начинают проявлять интерес к биотеху: участники отмечают рост звонков/контактов от generalist-инвесторов как «sea change» в оптимизме за последние 6–12 месяцев.","text_en":"Generalist investors are starting to show renewed interest in biotech, with more inbound calls seen as a sea change in optimism over the last 6–12 months.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0003","quote":"Getting any calls, I'd say, from generalists is something that we're not used to in the last six to 12 months."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0003_n2","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Неопределённость вокруг ценообразования specialty drugs и новых запусков из‑за MFN/US pricing: участник прямо говорит, что не уверен, «где specialty drugs sit».","text_en":"Uncertainty about specialty drug pricing and new launches due to MFN/US pricing; the speaker is unsure where specialty drugs fit.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0003","quote":"I'm not. Quite sure where specialty drugs sit... even the new launches having to be priced at whatever MFN will be"}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0003_n3","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Инвесторы «ротируются» в биотех как следующий уровень риска/«alpha generator» и начинают смотреть на конкретные имена (Ionis, Argenx, UCB).","text_en":"Investors are rotating into biotech as the next risk level/alpha generator and are looking at names like Ionis, Argenx, and UCB.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0003","quote":"they're rotating to the next risk level, the next alpha generator, and that, for them, is biotech."},{"chunk_id":"doc_433066c16b44_chunk_0003","quote":"starting to look at interesting names like an Ionis, like Argenix, like these UCBs."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0004_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"В FDA/CDER обсуждают пересмотр использования суррогатных конечных точек для одобрения и критикуют случаи, где не подтверждена клиническая польза (контекст accelerated approval).","text_en":"FDA/CDER is discussing re-examining surrogate endpoints for approval and criticizing cases where benefit wasn’t confirmed (accelerated approval context).","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0004","quote":"Cedar will be looking at surrogate endpoints used for FDA approval and criticizing some of the failures to confirm benefit."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0004_n2","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Публичные заявления высокопоставленного чиновника FDA могут быть отозваны как не отражающие позицию FDA/HHS, что указывает на коммуникационные/репутационные риски и неопределённость.","text_en":"Public statements by a senior FDA official can be retracted as not reflecting FDA/HHS views, indicating communication/reputational risk and uncertainty.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0004","quote":"Tidmarsh wind up deleting the post saying that it did not reflect the views of the FDA or HHS."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0004_n3","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Клинические данные могут быть ограничены дизайном/мощностью исследования: фаза 3 «немного недомощная», PFS «чуть не дотянули» (p=0.06), выживаемость также недомощная.","text_en":"Clinical results can be limited by study design/power: phase 3 described as underpowered, just missed on PFS (p=0.06), survival also underpowered.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0004","quote":"the study was a little underpowered... They just missed. It was 0. 06 on PFS. Survival obviously was underpowered"}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0005_n1","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"Фаза 3 в frontline melanoma оказалась «недостаточно мощной» и «едва не дотянула» по PFS (p=0.06), что осложняет интерпретацию и регуляторные перспективы.","text_en":"A phase 3 in frontline melanoma was seen as underpowered and narrowly missed on PFS (p=0.06), complicating interpretation and regulatory prospects.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0005","quote":"the study was a little underpowered... They just missed. It was 0. 06 on PFS."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0005_n2","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"FDA отказало в подаче/гибкости после «едва промаха» и потребовало проводить ещё одно исследование.","text_en":"FDA declined flexibility after a near-miss and required running another study.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0005","quote":"there was a question whether they'll be able to file... And the answer was from FDA was no, you need to run another study."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0005_n3","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Участники отмечают серию недавних CRL от FDA (в т.ч. в orphan pediatric indications), включая отказы по CMC, и обсуждают качество/жёсткость текущего регуляторного руководства.","text_en":"Speakers note a run of recent FDA CRLs (including in orphan pediatric indications), including CMC-based rejections, raising concerns about current FDA leadership strictness.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0005","quote":"we've had Ultragenyx, Biogen, Scholarock, and now Fortress all getting relatively recent CRLs in orphaned pediatric indications."}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0006_n1","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"В орфанных педиатрических показаниях участились CRL, причём причины часто связаны с CMC/производством, что тормозит одобрения.","text_en":"More CRLs in orphan pediatric indications, often due to CMC/manufacturing issues, slowing approvals.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0006","quote":"iogen, Scholarock, and now Fortress all getting relatively recent CRLs in orphaned pediatric indications."},{"chunk_id":"doc_433066c16b44_chunk_0006","quote":"we got three, sorry, four CRLs all due to CMC."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0006_n2","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Даже при сильных клинических данных регулятор может выдать CRL из‑за «идосинкразических» производственных/логистических требований (например, температурные пробы при доставке).","text_en":"Even with strong clinical data, a CRL can result from idiosyncratic manufacturing/logistics requirements (e.g., temperature probe requirements during shipping).","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0006","quote":"They got a CRL because of a few sort of idiosyncratic manufacturing-related numbers of temperature probes they need to do on shipping."},{"chunk_id":"doc_433066c16b44_chunk_0006","quote":"they got to work out through the manufacturing issue."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0006_n3","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Восприятие FDA как хаотичного и непоследовательного: уровень гибкости по safety/efficacy меняется, и индустрии сложно понять требуемый уровень доказательности; растёт роль отдельных лиц, подписывающих action letter.","text_en":"FDA perceived as chaotic/inconsistent: flexibility on safety/efficacy varies, making evidence expectations unclear; increasing influence of individuals who sign action letters.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0006","quote":"there just seems to be chaos and inconsistency, right?"},{"chunk_id":"doc_433066c16b44_chunk_0006","quote":"it's very hard... to kind of hone in and say, 'Oh, this is sort of the level of evidence that one needs for an approval.'"},{"chunk_id":"doc_433066c16b44_chunk_0006","quote":"There's more and more of a demand to try to characterize who is the person who has ultimate power to sign an action letter"}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0007_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"В FDA наблюдается тренд на усиление «top-down» решений, когда руководство чаще переопределяет решения/мнение старших сотрудников; возможно ускорение в последние месяцы/годы и «двухуровневость» системы.","text_en":"At the FDA, a trend toward more top-down overruling of senior staff decisions, potentially accelerating recently, creating a two-tier system.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0007","quote":"\"that trend has been ongoing for a while, but it does seem like it's potentially accelerated in the last few months\""},{"chunk_id":"doc_433066c16b44_chunk_0007","quote":"\"we're seeing more and more two-tiering of systems at the FDA\""}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0007_n2","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"Сложно «читать» агентство (FDA), и это воспринимается как часть проблемы на фоне того, что работа старших ревьюеров может не иметь значения из‑за решений сверху.","text_en":"It’s hard to “read” the FDA, and senior reviewers’ work may not matter due to top-level decisions.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0007","quote":"\"often it doesn't really matter. And that seems to be somewhat problematic.\""},{"chunk_id":"doc_433066c16b44_chunk_0007","quote":"\"how hard it is to read this agency\""}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0007_n3","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"В биотехе отмечается серия «meaningful» M&A/сделок: упоминаются «five straight weeks of meaningful deal flow».","text_en":"Biotech is seeing a run of meaningful M&A/deal flow: “five straight weeks of meaningful deal flow.”","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0007","quote":"\"it's now. five straight weeks of meaningful deal flow. in biotechnology.\""}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0008_n1","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Сложно напрямую сравнивать данные из‑за разных периодов наблюдения, что затрудняет однозначные выводы об эффективности.","text_en":"Direct comparison of data is difficult due to different follow-up periods, making firm judgments hard.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0008","quote":"They're not directly comparable, different follow-up periods, etc. It's harder to make a hard judgment on this."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0008_n2","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"Для биотех-компаний сложно компенсировать роялти‑поток после окончания успеха ключевого продукта (\"cliff\"), что вынуждает к агрессивным действиям.","text_en":"Biotech companies struggle to offset royalty streams when a key product’s success ends, pushing them to act aggressively.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0008","quote":"eventually that party will end and it's very hard to offset that royalty stream. And so they're really trying and getting aggressive."}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0008_n3","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Есть существенный клинический риск: без рандомизированного Phase 3 никто не знает точный response rate Pembro в данном сеттинге; IO может «удивить» в рандомизированных испытаниях.","text_en":"Significant clinical risk: without randomized Phase 3, Pembro response rate in this setting is unknown; IO can surprise in randomized trials.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0008","quote":"nobody knows definitively what the response rate of Pembro is in this setting."},{"chunk_id":"doc_433066c16b44_chunk_0008","quote":"until we see a randomized phase three study with this asset or other assets"}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0009_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Наблюдалась серия M&A сделок каждую неделю этой осенью (4–5 недель подряд), но участники обсуждения сомневаются, что это устойчивый тренд, и допускают случайность/кластеризацию новостей.","text_en":"There has been weekly M&A activity this fall (4–5 weeks running), but speakers doubt it’s a durable trend and suggest randomness/clustering.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0009","quote":"We have seen substantial M&A each week this fall— for now, four or five weeks running."},{"chunk_id":"doc_433066c16b44_chunk_0009","quote":"I mean, I have a tendency to think it's a little random"}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0009_n2","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Ожидания снижения ставок и удешевления стоимости капитала рассматриваются как фактор, который может подталкивать активность (в т.ч. через возможность рефинансирования).","text_en":"Expectations of lower rates and lower cost of capital are seen as a driver of activity (including refinancing opportunities).","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0009","quote":"people looking into the horizon at lower rates. right so the opportunity for refinancing down the road can be meaningful."},{"chunk_id":"doc_433066c16b44_chunk_0009","quote":"at the end of the day, the cost of capital should be getting lower."}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0009_n3","doc_id":"doc_433066c16b44","kind":"buyer_signal","text_ru":"Покупатели делают сделки на событиях де-рискинга; рынок «хорошо вознаграждает» компании, поэтому продавцам комфортнее продавать сейчас.","text_en":"Buyers transact around de-risking events; the market is remunerating companies, making sellers more comfortable selling now.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0009","quote":"Deals get done on de-risking events when the buyer is comfortable and the seller has gotten remunerated."},{"chunk_id":"doc_433066c16b44_chunk_0009","quote":"the market is fondly remunerating companies, so they're much more comfortable selling now."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"Клинический провал: препарат Moon Lake (Sotolocumab) не дифференцировался от конкурента и не достиг статистической значимости в одном из двух Phase 3, что ставит одобрение под угрозу.","text_en":"Clinical failure: Moon Lake’s Sotolocumab didn’t differentiate vs incumbent and missed statistical significance in one of two Phase 3 studies, jeopardizing approval.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0010","quote":"Sotolocumab not just failed to differentiate itself versus the incumbent UCB's Mimzelex. but also failed to achieve statistical significance on one of two phase three studies."},{"chunk_id":"doc_433066c16b44_chunk_0010","quote":"That really puts the drugs approval in jeopardy"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Барьер для ускоренного одобрения Larimar: ключевой биомаркер (frataxin в коже) является суррогатной тканью, и нет измерений в «идеальных» тканях интереса.","text_en":"Constraint for Larimar’s accelerated approval: frataxin measured in skin is a surrogate tissue, and there are no measurements in the ideal tissues of interest.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0010","quote":"skin, for taxon, it's not a direct measurement of a tissue of interest, it's a surrogate tissue."},{"chunk_id":"doc_433066c16b44_chunk_0010","quote":"we don't have measurements of the tissues that would be ideally measured for this study."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"Существенный риск безопасности у Larimar: 7 из 39 пациентов (18%) испытали анафилаксию, что усложняет интерпретацию пользы/риска и дискуссию об одобряемости.","text_en":"Material safety risk for Larimar: 7 of 39 patients (18%) experienced anaphylaxis, complicating benefit-risk and approvability debate.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0010","quote":"out of 39 patients dosed in the study, seven of them— or 18%— experienced anaphylaxis."},{"chunk_id":"doc_433066c16b44_chunk_0010","quote":"when you sort of introduce this very real risk now of anaphylaxis."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0011_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Ожидается очередная крупная дискуссия вокруг «approvability» в FDA по мере приближения финального среза данных и планов подачи BLA по subpart H во 2 квартале следующего года.","text_en":"Another major FDA approvability debate is expected as final data approach, with plans to submit a subpart H BLA in Q2 next year.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0011","quote":"fully expect this is going to be another big FDA approvability debate"},{"chunk_id":"doc_433066c16b44_chunk_0011","quote":"submitting a BLA for subpart H in the second quarter of next year"}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0011_n2","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"В респираторных вирусах сложно показать клиническую пользу, потому что многие заболевания быстро проходят; чтобы уловить эффект, нужны очень большие исследования.","text_en":"Respiratory virus indications are hard to show clinical benefit in because many diseases resolve quickly; detecting benefit may require very large studies.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0011","quote":"respiratory viruses would all all agree it's a hard indication to sort of chase"},{"chunk_id":"doc_433066c16b44_chunk_0011","quote":"so many of these diseases resolve in most people so quickly, it's hard to even ever, ever pick up a benefit unless you're running huge, huge studies"}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0011_n3","doc_id":"doc_433066c16b44","kind":"opportunity","text_ru":"Возможность: найти big pharma партнёра для разработки противовирусного лечения RSV как продукта для госпиталей/домов престарелых для вмешательства у high-risk пациентов.","text_en":"Opportunity to secure a big pharma partner to develop an RSV antiviral as a product for hospitals/elderly homes to intervene in high-risk patients.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0011","quote":"the question is, is the data good enough to find a big pharma partner"},{"chunk_id":"doc_433066c16b44_chunk_0011","quote":"developing this as sort of a product to put in the hospitals or older person homes"}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Ожидаются крупные медицинские конференции осенью (в т.ч. ESMO в Берлине) и сезон отчётности, что смещает фокус на предстоящие катализаторы/данные.","text_en":"Major fall medical conferences (incl. ESMO in Berlin) and earnings season are upcoming, shifting focus to near-term catalysts/data.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0012","quote":"\"we've, of course, got major medical conferences and kicking off for the fall\""},{"chunk_id":"doc_433066c16b44_chunk_0012","quote":"\"Going over to Berlin to see what's happening at ESMO\""},{"chunk_id":"doc_433066c16b44_chunk_0012","quote":"\"Right around the corner for better for worse is is earning season as well.\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"Неясно, что именно драйвит выживаемость в исследовании в рефрактерном раке толстой кишки; есть вопросы к обобщаемости из-за набора пациентов вне США и сравнения с устаревшим стандартом (regorafenib).","text_en":"Unclear what drives survival benefit in refractory colon cancer study; concerns about generalizability due to mostly ex-US enrollment and comparison vs an outdated standard (regorafenib).","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0012","quote":"\"we don't know what drove the benefit. Was it across all patients?\""},{"chunk_id":"doc_433066c16b44_chunk_0012","quote":"\"most patients in the study were enrolled outside the U. S.\""},{"chunk_id":"doc_433066c16b44_chunk_0012","quote":"\"you beat regorafenib, which is, you know, no longer the standard of care.\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Для FDA становится недостаточно показать выживаемость против старого стандарта лечения, особенно если исследование проведено вне США; требуется релевантное сравнение со современным стандартом.","text_en":"For FDA, survival benefit vs an old standard may be insufficient, especially for ex-US trials; comparison to current standard of care matters.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0012","quote":"\"this is important for FDA these days\""},{"chunk_id":"doc_433066c16b44_chunk_0012","quote":"\"just having a survival benefit against an old standard is not even relevant when it's conducted XUS.\""}],"confidence":"medium"}
{"nugget_id":"nugget_001","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Данные могут быть недостаточно зрелыми, чтобы показать преимущество по общей выживаемости (OS); вероятно, рано оценивать OS.","text_en":"Data may not be mature enough to show overall survival (OS) benefit; it may be too early to assess OS.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0013","quote":"\"But I'm not sure the data is mature enough.\""},{"chunk_id":"doc_433066c16b44_chunk_0013","quote":"\"I think it's going to probably be a little bit early to see overall survival.\""}],"confidence":"high"}
{"nugget_id":"nugget_002","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"В исследованиях у пациентов со squamous cell carcinoma, которые обычно избегают VEGF-ингибиторов, не наблюдается типичной проблемы гемоптизиса.","text_en":"Across studies, in squamous cell carcinoma patients who typically avoid VEGF inhibitors, the usual hemoptysis issue is not seen.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0013","quote":"\"this is a group of patients that normally would avoid a VEGF inhibitor.\""},{"chunk_id":"doc_433066c16b44_chunk_0013","quote":"\"you don't see the usual problem of haemoptysis\""}],"confidence":"high"}
{"nugget_id":"nugget_003","doc_id":"doc_433066c16b44","kind":"opportunity","text_ru":"Комбинация PD-1 + VEGF (в т.ч. с Claudin 18.2 ADC) рассматривается как интересное направление, при этом ключевой вопрос — безопасность.","text_en":"PD-1 + VEGF combinations (including with a Claudin 18.2 ADC) are viewed as an interesting direction, with safety as the biggest question.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0013","quote":"\"the target is? PD-1 VEGF. It's an interesting combination.\""},{"chunk_id":"doc_433066c16b44_chunk_0013","quote":"\"safety will be the biggest question here.\""}],"confidence":"medium"}
{"nugget_id":"doc_433066c16b44_chunk_0014_n1","doc_id":"doc_433066c16b44","kind":"pain","text_ru":"Окулярная меланома описывается как сложный тип опухоли с очень малым числом альтернативных опций лечения.","text_en":"Ocular melanoma is described as a tough tumor type with very few alternative options.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0014","quote":"In ocular melanoma, a tough tumor type with very few, very, very few alternative options."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0014_n2","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"Для G12D on-off ингибитора отмечены вопросы переносимости, которые нужно обходить/решать.","text_en":"There are tolerability considerations for the G12D on-off inhibitor that need to be worked around.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0014","quote":"They've had some tolerability considerations that need to work around."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0014_n3","doc_id":"doc_433066c16b44","kind":"constraint","text_ru":"У Legend/Corvicti упоминаются ограничения по производственным мощностям; расширение мощностей идёт медленнее, чем ожидалось.","text_en":"Legend/Corvicti has capacity constraints; capacity expansion has been slower than expected.","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0014","quote":"And there have been capacity constraints."},{"chunk_id":"doc_433066c16b44_chunk_0014","quote":"And that's been taking, probably, a little bit slower than expected."}],"confidence":"high"}
{"nugget_id":"doc_433066c16b44_chunk_0015_n1","doc_id":"doc_433066c16b44","kind":"trend","text_ru":"Внимание рынка/инвесторов сосредоточено на квартальных продажах и динамике запусков препаратов (Vertex: Jernabax; Neurocrine: Ingressive и запуск Chronicity).","text_en":"Market/investor focus is on quarterly sales and launch dynamics (Vertex: Jernabax; Neurocrine: Ingressive and Chronicity launch).","evidence":[{"chunk_id":"doc_433066c16b44_chunk_0015","quote":"Vertex will get another quarter of Jernabax sales"},{"chunk_id":"doc_433066c16b44_chunk_0015","quote":"Neurocrine obviously gets driven a lot by Ingressive sales"},{"chunk_id":"doc_433066c16b44_chunk_0015","quote":"I think a lot of eyes will be on that one."}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0000_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Рост активности M&A в biotech: year-to-date около $81B, много сделок >$1B; по числу сделок темп близок к полным годам последних лет.","text_en":"Rising biotech M&A activity: ~ $81B year-to-date with many >$1B deals; deal count tracking close to full-year levels of recent years.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0000","quote":"year-to-date M &A... Being at around 81. billion with a lot of deals over a billion dollars through September."},{"chunk_id":"doc_b88d83080b14_chunk_0000","quote":"we're looking at a about 30 deals... pretty in line with full years for many... since 2020."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0000_n2","doc_id":"doc_b88d83080b14","kind":"pain","text_ru":"Фарма нуждается в пополнении пайплайна; при неудаче внутренней разработки компании вынуждены покупать/ин-лицензировать активы.","text_en":"Pharma needs pipeline; when internal development fails, companies resort to buying or in-licensing assets.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0000","quote":"pharma needs pipeline. They hit a brick wall. There are assets out there available."},{"chunk_id":"doc_b88d83080b14_chunk_0000","quote":"Pfizer tried to develop their own asset in obesity. didn't work out, straight away, they went and buy it in."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0000_n3","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Серия M&A-сделок продолжается несколько недель подряд; упоминается, что это уже «шестая неделя подряд» с M&A deal.","text_en":"A multi-week streak of M&A deals is ongoing; described as the “sixth week in a row” with an M&A deal.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0000","quote":"this is I don't know the sixth week in a row that we've had an M&A deal."}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0001_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Наблюдается серия M&A сделок (шестая неделя подряд), включая объявление Novo Nordisk о сделке до $5.2B за Akiro; упоминается также слух о Johnson & Johnson.","text_en":"A streak of weekly M&A deals is noted, including Novo Nordisk’s announced deal up to $5.2B for Akiro; a Johnson & Johnson rumor is mentioned.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0001","quote":"\"the sixth week in a row that we've had an M&A deal\""},{"chunk_id":"doc_b88d83080b14_chunk_0001","quote":"\"Novo Nordisk announced yesterday, $5. 2 billion up to for Akiro.\""},{"chunk_id":"doc_b88d83080b14_chunk_0001","quote":"\"the rumor about Johnson and Johnson\""}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0001_n2","doc_id":"doc_b88d83080b14","kind":"constraint","text_ru":"Побочные эффекты (в т.ч. GI) и вопросы безопасности/переносимости могут ограничивать применение, особенно при потенциальной комбинации с семаглутидом; также нужно учитывать различия по включённым стадиям пациентов (F1–F4).","text_en":"Side effects (incl. GI) and safety/tolerability may constrain use, especially for potential combination with semaglutide; trial inclusion differences across fibrosis stages (F1–F4) matter.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0001","quote":"\"you have to be very careful about what patients were included, F1, F2, F3.\""},{"chunk_id":"doc_b88d83080b14_chunk_0001","quote":"\"these GI side effects do worry me a little bit if we're going to be looking at a combination with semaglutide.\""},{"chunk_id":"doc_b88d83080b14_chunk_0001","quote":"\"There are other side effects that we need to keep an eye out for, particularly bone mineral density\""}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0001_n3","doc_id":"doc_b88d83080b14","kind":"opportunity","text_ru":"В MASH вероятно потребуются комбинации терапии; GLP-1 не будут решением для всего, что поддерживает инвестиционный тезис для комбинированных/последующих препаратов.","text_en":"MASH likely requires combination therapies; GLP-1s won’t be the answer to everything, supporting an investment thesis for combination/follow-on drugs.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0001","quote":"\"this is a disease area where combinations are likely to be needed\""},{"chunk_id":"doc_b88d83080b14_chunk_0001","quote":"\"GLP-1s are not going to be the answer to everything.\""}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0002_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Рынок NASH/MASH заметно изменился за последние пару лет: независимых клинических биотехов с FGF21 стало мало, многие активы были «схвачены» (M&A), на фоне фокуса стратегов на кардиометаболике.","text_en":"The NASH/MASH landscape has shifted: few independent clinical-stage biotechs with FGF21 remain as many assets have been acquired, amid strategics’ cardiometabolic focus.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0002","quote":"I'm having a hard time thinking about another company that is like independent clinical stage biotech with you know, a clinical stage FGF21"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0002_n2","doc_id":"doc_b88d83080b14","kind":"buyer_signal","text_ru":"Озвучивается, что рынок достаточно большой и unmet need достаточно высокий, чтобы поддерживать цену, обеспечивающую «robust peak sales».","text_en":"The market is described as large with sufficient unmet need to support pricing that enables robust peak sales.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0002","quote":"it really is a big market and that there's uh, you know, a high enough unmet need to really support uh, you know, a price point"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0002_n3","doc_id":"doc_b88d83080b14","kind":"pain","text_ru":"Стандартный процесс CAR-T воспринимается как сложный: требуется аферез, кондиционирование и процессинг; поэтому ищут более простой подход (в т.ч. in vivo/off-the-shelf).","text_en":"Standard CAR-T is seen as complex (apheresis, conditioning, processing), driving interest in simpler in vivo/off-the-shelf approaches.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0002","quote":"everybody is looking for something a lot more easier and it doesn't require a phoresis and it doesn't require really, I mean, ultimately sun conditioning"}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Компании в CAR-T активно продвигают идею in vivo CAR-T, т.к. это упрощает доставку и снижает зависимость от различий между академическими и community-центрами (особенно в онкологии).","text_en":"CAR-T companies are increasingly talking up in vivo CAR-T as it simplifies delivery and reduces academic vs community site concerns (especially in oncology).","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0003","quote":"any CAR T company... is talking up the idea of in vivo... It just makes it so much easier to deliver these agents"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_b88d83080b14","kind":"pain","text_ru":"Нежелательные явления (AEs) традиционного подхода воспринимаются как неприемлемые («non-starters»).","text_en":"Adverse events of the traditional approach are viewed as unacceptable (“non-starters”).","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0003","quote":"The AEs of the traditional approach are just non-starters."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"В in vivo CAR-T наблюдается интерес к «transient» подходам; также M&A в этом году описывается как направленное на заполнение ранней части R&D-пайплайна платформами, применимыми к разным заболеваниям.","text_en":"In in vivo CAR-T there is interest in transient approaches; this year’s M&A is described as filling early R&D pipelines with platforms applicable across diseases.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0003","quote":"we're seeing a lot of... interest in really this transient... approach"},{"chunk_id":"doc_b88d83080b14_chunk_0003","quote":"a lot of the M &A this year... being about like filling out... the early side of the R &D pipeline"}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0004_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Рынок IPO в биотехе был «фронт-лоадед»: большинство IPO прошло в январе/начале февраля, затем наступила пауза, после чего появились отдельные кейсы.","text_en":"Biotech IPO activity was front-loaded: most IPOs happened in January/early February, then there was a lull, followed by a few isolated cases.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0004","quote":"there have been nine IPOs this year... almost all of those were IPOs that happened in January or very early February. And then there was nothing."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0004_n2","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"У фармы наблюдается смена отношения к AI: от интереса к платформам и попыток строить AI in-house — к осознанию необходимости партнёрств с AI-компаниями.","text_en":"Pharma’s stance on AI has shifted from platform enthusiasm and in-house builds to partnering with AI companies.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0004","quote":"Initially, everybody wanted AI platforms... Then pharma decided to build their own AI capabilities. Now they realize that they should stick to what they know. And partner with AI companies."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0004_n3","doc_id":"doc_b88d83080b14","kind":"buyer_signal","text_ru":"Сделка AstraZeneca с Algen Biotechnologies на $555M указывает на готовность фармы платить за AI-партнёрства в drug discovery (поиск новых мишеней в иммунологии).","text_en":"AstraZeneca’s $555M deal with Algen Biotechnologies signals pharma willingness to pay for AI-enabled drug discovery partnerships (new target finding in immunology).","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0004","quote":"AstraZeneca just signed with a company called Algen Biotechnologies. It's for 555 million"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0005_n1","doc_id":"doc_b88d83080b14","kind":"constraint","text_ru":"В иммунологии пока нет одобренного препарата, созданного с помощью AI drug discovery.","text_en":"In immunology, there is not yet an approved drug enabled by AI drug discovery.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0005","quote":"we haven't yet seen an AI drug discovery enabled drug that has been approved in immunology"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0005_n2","doc_id":"doc_b88d83080b14","kind":"buyer_signal","text_ru":"Фарма (Sanofi) заключает 3-летнюю лицензионную сделку на использование AI-платформы для доклинических операций/исследований.","text_en":"Pharma (Sanofi) is signing a 3-year licensing deal to use an AI platform for preclinical operations/research.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0005","quote":"they have just done a deal with Sanofi, which is a licensing deal for three years"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0005_n3","doc_id":"doc_b88d83080b14","kind":"opportunity","text_ru":"Нейро-иммунная регуляция (модуляция нейронных цепей для контроля иммунной системы/воспалительных заболеваний) описана как «сильно недофинансированная» область.","text_en":"Neuro-immune regulation (modulating neural circuits to control the immune system/inflammatory diseases) is described as a highly underfunded area.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0005","quote":"I think this is super highly unfunded area"}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0006_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Появляются новые, хорошо капитализированные биотех-фонды, ориентированные на development-stage компании (фаза 1–2) и мульти-активные пайплайны.","text_en":"New, well-capitalized biotech funds are emerging, targeting development-stage (Phase 1–2) companies with multiple assets.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0006","quote":"they just closed on a new fund... it's a $325 million fund... looking at development stage biotech... phase one, phase two... companies that have multiple assets"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0006_n2","doc_id":"doc_b88d83080b14","kind":"opportunity","text_ru":"Подход нейро-иммунной модуляции: модуляция нейронных цепей для контроля иммунной системы и воспалительных заболеваний; пока доказательства ранние и в животных моделях.","text_en":"Neuro-immune modulation approach: modulating neural circuits to control the immune system and inflammatory diseases; evidence is early and in animal models.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0006","quote":"They're modulating neural circuits to kind of control immune system and therefore inflammatory diseases."},{"chunk_id":"doc_b88d83080b14_chunk_0006","quote":"very early the evidence is in animal models"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0006_n3","doc_id":"doc_b88d83080b14","kind":"buyer_signal","text_ru":"Сигнал инвестиционного спроса: компания Nilo привлекла $101M Series A; также упоминается участие крупных инвесторов в раунде.","text_en":"Investment demand signal: Nilo raised a $101M Series A; participation of major investors is mentioned.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0006","quote":"They just raised $101 million in series A funding."},{"chunk_id":"doc_b88d83080b14_chunk_0006","quote":"Column Group, DCVC, Lux Capital, Gates Foundation all participate in this round."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0007_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"В ближайшие 6 месяцев ожидается много клинических readouts по новым механизмам лечения ожирения, потенциально применимым в нескольких заболеваниях.","text_en":"Over the next six months, many readouts are expected on new obesity mechanisms, potentially applicable across multiple disease areas.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0007","quote":"in the next six months, we're actually going to start seeing a lot of readouts on new mechanisms for obesity."},{"chunk_id":"doc_b88d83080b14_chunk_0007","quote":"new mechanisms that could actually be applicable across potentially a few different disease areas."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0007_n2","doc_id":"doc_b88d83080b14","kind":"constraint","text_ru":"Для сравнения эффективности между препаратами используются cross-trial comparisons, что ограничивает интерпретацию результатов (разные исследования и размеры выборок).","text_en":"Efficacy comparisons rely on cross-trial comparisons, limiting interpretation due to different trials and sample sizes.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0007","quote":"although obviously we're doing cross-trial comparisons, and one's 121 patients, the other is 374 patients"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0007_n3","doc_id":"doc_b88d83080b14","kind":"opportunity","text_ru":"Есть «room» для нового HIF-1-alpha препарата в почечно-клеточном раке; данные фазы 1 выглядят многообещающе относительно существующего препарата на рынке.","text_en":"There appears to be room for a new HIF-1-alpha drug in renal cell carcinoma; Phase 1 data look promising versus an on-market drug.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0007","quote":"the data looks quite good. We think that there's a room for this."},{"chunk_id":"doc_b88d83080b14_chunk_0007","quote":"there is a drug already on the market from Merc"}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0008_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Ожидается много клинических readouts по новым механизмам лечения ожирения в ближайшие месяцы.","text_en":"Many readouts on new obesity mechanisms are expected over the coming months.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0008","quote":"going to start seeing a lot of readouts on new mechanisms for obesity."},{"chunk_id":"doc_b88d83080b14_chunk_0008","quote":"Many other you know mechanisms for obesity that should be reading out over the coming months"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0008_n2","doc_id":"doc_b88d83080b14","kind":"pain","text_ru":"Механизм CB1 сталкивается с проблемами: недостаточная потеря веса и опасения по нейропсихиатрическим побочным эффектам, особенно при проникновении через ГЭБ.","text_en":"CB1 faces issues: underwhelming weight loss and concerns about neuropsychiatric side effects, especially with BBB penetration.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0008","quote":"underwhelmed a little bit in terms of weight loss. And there were also concerns about the neuropsychiatric side effects."},{"chunk_id":"doc_b88d83080b14_chunk_0008","quote":"you get these issues with your psychiatric problems when you've got an oral drug that penetrates the blood-brain barrier."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0008_n3","doc_id":"doc_b88d83080b14","kind":"opportunity","text_ru":"Возможность для CB1-подхода — периферически ограниченное антитело и/или комбинация с семаглутидом: в комбинации показана лучшая эффективность, чем у семаглутида в монорежиме, при этом без дополнительных ЖКТ-побочек от того же механизма.","text_en":"Opportunity for CB1: peripherally restricted antibody and/or combination with semaglutide; combo showed better efficacy than semaglutide alone, potentially without additive GI side effects from the same mechanism.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0008","quote":"maybe we can deal with this by using an antibody"},{"chunk_id":"doc_b88d83080b14_chunk_0008","quote":"when they combine the semaglutide, they show better efficacy than the semaglutide alone arm."},{"chunk_id":"doc_b88d83080b14_chunk_0008","quote":"you're dealing with a completely different mechanism, so you don't keep getting additional nausea and vomiting"}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0009_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"На WMS обсуждаются и показываются обновлённые данные по DM1 (Dine) и DMD генотерапии (Sarepta, Regenexx).","text_en":"At WMS, updated data are being discussed/presented for DM1 (Dine) and DMD gene therapy (Sarepta, Regenexx).","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0009","quote":"there's a lot of discussion around Sarepta, Regenexx, and the DMD gene therapy space"},{"chunk_id":"doc_b88d83080b14_chunk_0009","quote":"Dine is one of the names I cover with some updated data in their DM1 phase two study"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0009_n2","doc_id":"doc_b88d83080b14","kind":"buyer_signal","text_ru":"Dine уже набирает «pivotal cohort» в DM1 и ожидает данные примерно в середине следующего года с надеждой на последующую подачу на регистрацию.","text_en":"Dine is enrolling a pivotal cohort in DM1, expects data around mid-next year, and hopes to file afterward.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0009","quote":"they're enrolling this pivotal cohort right now uh in DM1"},{"chunk_id":"doc_b88d83080b14_chunk_0009","quote":"hopefully we'll see that data um around the middle of next year and should hopefully see a filing after that"}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0009_n3","doc_id":"doc_b88d83080b14","kind":"constraint","text_ru":"В DMD генотерапии упоминаются смерти из‑за печёночной токсичности и «back and forth» с FDA, а также попытки снизить печёночную токсичность (в т.ч. профилактический сиролимус).","text_en":"In DMD gene therapy, deaths due to liver toxicity and FDA back-and-forth are noted; mitigation attempts include prophylactic sirolimus.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0009","quote":"two deaths due to liver toxicity in non-ambulatory patients"},{"chunk_id":"doc_b88d83080b14_chunk_0009","quote":"the back and forth we've seen with the FDA over the summer"},{"chunk_id":"doc_b88d83080b14_chunk_0009","quote":"single-or experience of prophylactic use of sirolimus"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0010_n1","doc_id":"doc_b88d83080b14","kind":"pain","text_ru":"Проблема печёночной токсичности/воспаления печени в контексте DMD-терапий; обсуждается попытка контролировать это с помощью (сиро)лимуса.","text_en":"Liver toxicity/inflammation is an issue in the DMD therapy context; sirolimus is discussed as a way to control it.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0010","quote":"The liver tox that's occurring with Olavides."},{"chunk_id":"doc_b88d83080b14_chunk_0010","quote":"they also show very diminished liver inflammation as a result of serolimus."}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0010_n2","doc_id":"doc_b88d83080b14","kind":"constraint","text_ru":"Есть спор/неопределённость по общей эффективности Alevitus и генных терапий и по объёму доказательств «истинного эффекта».","text_en":"There is debate/uncertainty about Alevitus and gene therapy efficacy and the strength of evidence for a true effect.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0010","quote":"a lot of people debate the overall efficacy of Alevitus and the gene therapies in general and how much evidence there is of a true effect."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0010_n3","doc_id":"doc_b88d83080b14","kind":"buyer_signal","text_ru":"Если удастся улучшить/обезопасить профиль безопасности, есть ожидание, что продажи могут снова начать расти.","text_en":"If the safety profile can be secured/improved, there is an expectation sales could start growing again.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0010","quote":"if the safety profile can be secured a little bit more, may get back to a point where they can start growing sales again."}],"confidence":"medium"}
{"nugget_id":"doc_b88d83080b14_chunk_0011_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Ionis смещается к коммерциализации: возвращает коммерческие функции in-house и увеличивает долю wholly owned программ.","text_en":"Ionis is shifting toward commercialization: bringing commercialization back in-house and increasing wholly owned programs.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0011","quote":"Now really bringing that back in house and turning themselves into a commercial company that now has many more wholly owned programs."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0011_n2","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Ionis представила собственную siRNA-платформу и данные фазы 1; PK поддерживает более редкое дозирование (раз в 6 месяцев или раз в год).","text_en":"Ionis unveiled its own siRNA platform with Phase 1 data; PK supports less frequent dosing (every six months or once yearly).","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0011","quote":"Well, they have their own siRNA platform now, and they've unveiled now out of nowhere phase one data."},{"chunk_id":"doc_b88d83080b14_chunk_0011","quote":"it supports every six months or once annual dosing."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0011_n3","doc_id":"doc_b88d83080b14","kind":"pain","text_ru":"При Friedreich's ataxia значимая проблема — пациенты часто умирают от сердечно‑сосудистых осложнений (большой кардиальный компонент).","text_en":"In Friedreich's ataxia, a major issue is that patients often die from cardiovascular complications (large cardiac component).","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0011","quote":"Most of the patients ultimately die of cardiovascular issues. So there's a huge cardiac component to it."}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0012_n1","doc_id":"doc_b88d83080b14","kind":"constraint","text_ru":"Есть неопределённость, сохранится ли прежняя регуляторная «гибкость» CBER к генным терапиям (особенно в орфанных заболеваниях) после смены руководства.","text_en":"Uncertainty whether CBER’s prior regulatory “flexibility” toward gene therapies (especially in orphan diseases) will persist after leadership changes.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0012","quote":"with sort of the changing of the guard, there's a lot of questions: how much of that flexibility will still be applied"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0012_n2","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"FDA/CBER, по словам спикера, допускает статистическую гибкость: разрешает пулить данные из Phase 1/2 и планируемого pivotal, что может снизить размер выборки.","text_en":"FDA/CBER is allowing statistical flexibility: pooling data from Phase 1/2 and the planned pivotal study, potentially reducing pivotal sample size.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0012","quote":"The FDA is apparently letting them pull data from their phase one, two, and the planned pivotal study"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0012_n3","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Ожидаемый срок оценки LVMI может быть короче 12 месяцев; FDA «предлагает более ранний» таймфрейм анализа.","text_en":"The expected LVMI assessment timeframe may be shorter than 12 months; FDA is offering an earlier analysis timeframe.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0012","quote":"they said that it's probably going to be less than 12 months— that the FDA is offering an earlier time. timeframe for analysis"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0013_n1","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Переходы людей из госрегуляторов/госслужбы в индустрию (в т.ч. фарму) описываются как повторяющееся и «естественное» явление.","text_en":"Moves from government/regulatory roles into industry (incl. pharma) are described as recurring and a “natural extension.”","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0013","quote":"\"we see this over and over again\""},{"chunk_id":"doc_b88d83080b14_chunk_0013","quote":"\"this is just a natural extension of sort of what's next\""}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0013_n2","doc_id":"doc_b88d83080b14","kind":"constraint","text_ru":"Репутационный/общественный риск: переход регулятора в индустрию может «не выглядеть хорошо» и будет использован критиками как пример «revolving door».","text_en":"Reputational/public perception risk: a regulator moving to industry may “not look great” and be used as a “revolving door” example by critics.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0013","quote":"\"It's not going to look great.\""},{"chunk_id":"doc_b88d83080b14_chunk_0013","quote":"\"The folks who want to use this as an example of the... revolving door are going to use it.\""}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0014_n1","doc_id":"doc_b88d83080b14","kind":"pain","text_ru":"Сложно получить экспертные мнения для регуляторных/адвайзори решений, потому что профильные эксперты часто уже вовлечены в индустриальные исследования/триалы.","text_en":"It can be hard to get expert input for regulatory/advisory decisions because domain experts are often already involved in industry trials.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0014","quote":"How much are you really going to learn from an advisory committee... where you can't find a multiple myeloma expert who—uh... hasn't been involved in a trial"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0014_n2","doc_id":"doc_b88d83080b14","kind":"constraint","text_ru":"Риск конфликта интересов/«revolving door» в регуляторных ролях требует механизмов управления (disclosure, recusal), иначе возможны искажения решений.","text_en":"Conflict-of-interest/revolving-door risk in regulatory roles requires management mechanisms (disclosure, recusal) to avoid biased decisions.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0014","quote":"you don't have people making decisions in regulatory positions where they're like favoring a company"},{"chunk_id":"doc_b88d83080b14_chunk_0014","quote":"disclosure is one and... recusing yourself from like certain decisions are others"}],"confidence":"high"}
{"nugget_id":"doc_b88d83080b14_chunk_0014_n3","doc_id":"doc_b88d83080b14","kind":"trend","text_ru":"Отмечается продолжение интереса к biopharma со стороны стратегов и инвесторов.","text_en":"Continued interest in biopharma from strategics and investors is noted.","evidence":[{"chunk_id":"doc_b88d83080b14_chunk_0014","quote":"exciting week for continued interest in biopharma, both from strategics, from investors"}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0000_n1","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Сентимент в biotech сейчас описывается как очень позитивный; XBI был сильным, и инвесторы спрашивают, устойчиво ли это.","text_en":"Biotech sentiment is described as very positive; XBI has been strong and investors ask if it’s sustainable.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0000","quote":"it does of course, seem that. sentiment in biotech is very positive right now."},{"chunk_id":"doc_d031fa09e04b_chunk_0000","quote":"it feels like the XBI has been strong, and I'm sure we all get asked by people like, 'Do you think this is sustainable?'"}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0000_n2","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Отмечаются «tailwinds»: больше M&A, хорошие реакции акций на позитивные данные, и успешные запуски препаратов у небольших/средних компаний.","text_en":"Tailwinds noted: more M&A, strong stock reactions to positive data, and successful drug launches by small/mid-sized companies.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0000","quote":"we're seeing a bunch of tailwinds, right? More M&A, good stock reactions on positive data."},{"chunk_id":"doc_d031fa09e04b_chunk_0000","quote":"We've talked about smaller, mid-sized companies that are successfully launching drugs."}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0000_n3","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Сохраняется неопределённость/«noise» вокруг политики в Вашингтоне (в т.ч. drug pricing и изменения в FDA), хотя «worst case fears» у инвесторов не реализовались.","text_en":"Ongoing uncertainty/noise around Washington policy (incl. drug pricing and FDA changes), though investors’ worst-case fears haven’t materialized.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0000","quote":"Still, some noise around drug pricing"},{"chunk_id":"doc_d031fa09e04b_chunk_0000","quote":"uncertainty earlier in the year with respect to Washington DC policy... changes at FDA."},{"chunk_id":"doc_d031fa09e04b_chunk_0000","quote":"from an investor perspective, worst case fears have not materialized."}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0001_n1","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Наблюдаются положительные чистые притоки средств в biotech: вторая подряд неделя, чего не было давно; это связывают со снижением ставок/ожиданиями дальнейших снижений, снижением остроты policy-рисков в Вашингтоне и «drumbeat of M&A».","text_en":"Positive net fund flows into biotech for the second straight week after a long gap, attributed to rate cuts/expectations, reduced Washington policy risk salience, and ongoing M&A.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0001","quote":"\"This is now the second straight week of positive net. fund flows into the sector, which we haven't had that in quite a while.\""},{"chunk_id":"doc_d031fa09e04b_chunk_0001","quote":"\"It's probably driven by the interest rate cuts that we saw, and expectations for more.\""},{"chunk_id":"doc_d031fa09e04b_chunk_0001","quote":"\"the numbing of the Washington policy risks and environment, and obviously the continued drumbeat of M&A.\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0001_n2","doc_id":"doc_d031fa09e04b","kind":"buyer_signal","text_ru":"Появился/усилился интерес со стороны «generalists»: начали поступать звонки и наблюдается «deluge of interest» от инвесторов/участников, с которыми давно не общались.","text_en":"Rising inbound interest from generalist investors: more calls and a deluge of interest from parties not engaged for months/years.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0001","quote":"\"getting a few calls or maybe now starting to get more calls from generalists.\""},{"chunk_id":"doc_d031fa09e04b_chunk_0001","quote":"\"There's a deluge of interest right now from folks that we really hadn't talked to. for months or years\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0001_n3","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Есть неопределённость/риск вокруг регуляторной среды: упоминаются признаки «reduced FDA productivity» и неоднозначные сигналы (с одной стороны «rosy, flexible, sweetheart deals», с другой — проблемы/кейсы).","text_en":"Regulatory uncertainty/risk: mentions of possible reduced FDA productivity and mixed signals (rosy/flexible deals vs. problematic situations).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0001","quote":"\"we've seen other sort of signs of maybe reduced FDA productivity.\""},{"chunk_id":"doc_d031fa09e04b_chunk_0001","quote":"\"how the FDA is communicating a lot of sort of rosy, flexible, sweetheart deals\""}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0002_n1","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"FDA описывается как политизированное и испытывающее трудности агентство, что приводит к задержкам/сбоям в выполнении работы (инспекции, выпуск дат).","text_en":"The FDA is described as politicized and under distress, with issues completing work on time (inspections, issuing dates).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0002","quote":"We've still got an agency that's very politicized."},{"chunk_id":"doc_d031fa09e04b_chunk_0002","quote":"misadventures with regard to the FDA being able to get its work done on time, not just not just. inspecting facilities"}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0002_n2","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"В секторе ожидается продолжение M&A, которое может поддерживать рынок/«поднимать пол».","text_en":"M&A is seen as continuing/inevitable in the sector, potentially supporting the market/raising the floor.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0002","quote":"because it's M&A continues to seem inevitable, right? So, like, I think that's going to be there"}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0002_n3","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"По словам собеседника, на рынке IPO/капитала для биотеха наблюдаются «excitation» и активность (по отзывам инвесторов, банкиров и юристов).","text_en":"There is reported excitement and activity around the biotech IPO/capital markets (per investors, bankers, and law firm contacts).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0002","quote":"there is a lot of excitement. there is a lot of activity happening."}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0003_n1","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Ожидание, что IPO-окно для biotech может снова открыться в 1–2 квартале; отмечается «позитивная энергия» вокруг этого.","text_en":"Expectation that the biotech IPO window may reopen in Q1–Q2; described as having “positive energy” around it.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0003","quote":"\"window opening up that would be coincident with the first quarter or second quarter\""},{"chunk_id":"doc_d031fa09e04b_chunk_0003","quote":"\"lots of positive energy right now in terms of where people feel about the IPO window for biotech opening up again\""}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0003_n2","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Частные biotech-компании, пережившие «долгую зиму», стали более зрелыми: выходят не с pre-clinical, а с Phase 2/3 программами и proof of concept.","text_en":"Private biotechs that survived a long downturn are more mature: coming out with Phase 2/3 programs and proof of concept rather than pre-clinical ideas.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0003","quote":"\"they're also more mature because they've had to stay private longer\""},{"chunk_id":"doc_d031fa09e04b_chunk_0003","quote":"\"they're not coming out with you know pre-clinical ideas, but they're coming out with you know phase two, phase three\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0003_n3","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Лучшие частные компании не хотят быть первыми, кто «проверит воду» на публичном рынке, поэтому откладывают IPO.","text_en":"Top private companies don’t want to be the first to “test the waters” in public markets, so they delay IPOs.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0003","quote":"\"the best ones don't want to test the water— they don't want to be first to put a toe in\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0004_n1","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Программа CNPB нацелена на ускоренные NDA/BLA-ревью (1–2 месяца вместо обычных 9–12), и уже опубликован список из девяти программ/препаратов.","text_en":"The CNPB program targets accelerated NDA/BLA reviews (1–2 months vs typical 9–12), and a list of nine programs/drugs has been published.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0004","quote":"the CNPB program is aiming to get reviews. NDA or BLA reviews within one to two months of submission."},{"chunk_id":"doc_d031fa09e04b_chunk_0004","quote":"Compared to the normal, you know, nine to 12 months, if you're lucky, type of process."},{"chunk_id":"doc_d031fa09e04b_chunk_0004","quote":"I was delighted to see the list come out yesterday. There were nine approvals— or nine programs—"}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0004_n2","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Для компаний неясны критерии/процесс отбора в программу; ожидается большая прозрачность со стороны FDA.","text_en":"Companies find the program’s selection criteria/process unclear; there is a desire for more FDA transparency.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0004","quote":"it's unclear to most of them, if not all of them, as to what really merits you know, consideration under the program."},{"chunk_id":"doc_d031fa09e04b_chunk_0004","quote":"I do think and hope that there's more transparency around the process from FDA on this program going forward."},{"chunk_id":"doc_d031fa09e04b_chunk_0004","quote":"I would like to understand the process a little bit better and the criteria."}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0004_n3","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Есть сомнения, сможет ли FDA реально выдерживать 1–2-месячный цикл ревью и принимать правильные решения при таком ускорении.","text_en":"There is uncertainty whether FDA can meet the 1–2 month review cycle and make the right decisions under that accelerated timeline.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0004","quote":"We are not quite sure that the FDA is going to be able to hit this one or two-month review cycle"},{"chunk_id":"doc_d031fa09e04b_chunk_0004","quote":"and that they'll make the right decisions coming out of that review cycle."}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0005_n1","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"Недостаток прозрачности/видимости процесса новой программы: компании и аналитики «в темноте» по статусам заявок, отказам и будущим траншам.","text_en":"Lack of transparency/visibility in the new program: companies/analysts are “in the dark” about application status, rejections, and future tranches.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0005","quote":"“We could use a little bit more transparency to the process”"},{"chunk_id":"doc_d031fa09e04b_chunk_0005","quote":"“don't have any good visibility or knowledge as to how many other applications are in”"},{"chunk_id":"doc_d031fa09e04b_chunk_0005","quote":"“companies who applied for this were, you know, a little bit in the dark.”"}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0005_n2","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Ценообразование может быть частью «сделки» и ограничивать возврат на инновации (вплоть до очень низкой цены или бесплатной раздачи).","text_en":"Pricing may be part of the “bargain,” potentially limiting returns on innovation (down to very low price or even free).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0005","quote":"“It could be priced at a very, very low price point or even given away for free.”"},{"chunk_id":"doc_d031fa09e04b_chunk_0005","quote":"“If pricing is part and parcel or part of the bargain here.”"},{"chunk_id":"doc_d031fa09e04b_chunk_0005","quote":"“you may not be able to get the return on your innovation that you otherwise might.”"}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0005_n3","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Неясно, как «rapid approval» и программы с review voucher будут восприниматься с точки зрения доверия к безопасности/эффективности и со стороны плательщиков.","text_en":"Unclear how rapid-approval products and the review-voucher program will be perceived regarding safety/efficacy trust and by payers.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0005","quote":"“products with this rapid approval— are viewed, either from the standpoint of public trust around their safety and efficacy”"},{"chunk_id":"doc_d031fa09e04b_chunk_0005","quote":"“we'll also have to see over time how programs that are reviewed on this... review voucher program are viewed from a payer perspective”"}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0006_n1","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Есть неопределённость по стандартам/критериям отбора в программу при большом числе заявок.","text_en":"Uncertainty about program standards/selection criteria amid a large number of applications.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0006","quote":"\"There are well over 100 applications... But there was a lot of uncertainty around what the standards and criteria are.\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0006_n2","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Есть риск, что ускоренные одобрения для выбранных программ отвлекут ресурсы FDA от стандартных рассмотрений.","text_en":"Concern that rapid approvals could divert FDA resources from standard reviews.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0006","quote":"\"We just hope that the FDA has the resources to keep its eye on the ball with regard to standard review applications.\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0006_n3","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Формируется «дорожная карта» MFN-сделок между фармкомпаниями и Белым домом; ожидаются новые сделки (в т.ч. Lilly и Novo).","text_en":"A roadmap is emerging for MFN deals between pharma companies and the White House; more deals are expected (incl. Lilly and Novo).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0006","quote":"\"it gives you a pretty good roadmap for what's likely to happen for... future pharmaceutical companies\""},{"chunk_id":"doc_d031fa09e04b_chunk_0006","quote":"\"we'll all wait for Lilly and for Novo to cut their own deals with the White House\""}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_nugget_0007_01","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"Непрозрачность «истинной стоимости» лекарства позволяет компаниям выигрывать от неясности между sticker price и реальным gross-to-net.","text_en":"Opacity around the true cost of a drug lets companies benefit from the gap between sticker price and true gross-to-net impact.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0007","quote":"companies are benefiting... from the opacity around the true cost of a drug"},{"chunk_id":"doc_d031fa09e04b_chunk_0007","quote":"it's all sort of caught in the sausage making between. gross to net, and discounts, and rebates"}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_nugget_0007_02","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Сделки фармкомпаний с правительством/Белым домом по ценообразованию описываются как «benign» и «cushioned» так, чтобы минимизировать влияние на бизнес.","text_en":"Pharma-White House pricing deals are described as benign and designed to cushion/minimize business impact.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0007","quote":"these deals feel very benign to me"},{"chunk_id":"doc_d031fa09e04b_chunk_0007","quote":"they've been cushioned in their design by the pharma companies to— mitigate any meaningful impact on the business"}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_nugget_0007_03","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Консолидация в HAE/HEE: BioCryst приобретает Astrea Therapeutics; сделка значима по размеру для небольшой компании и объединяет двух игроков в пространстве профилактики приступов.","text_en":"Consolidation in the HAE/HEE space: BioCryst acquires Astrea Therapeutics, a large deal for a small company combining two players in attack prevention.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0007","quote":"the Biochrist acquisitions of Astrea therapeutics"},{"chunk_id":"doc_d031fa09e04b_chunk_0007","quote":"it's consolidation of two players in the HEE space"}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0008_n1","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"Маленьким biotech-компаниям сложно получить «полный кредит» от инвесторов за активы/рынки, которые не выглядят как blockbuster (сотни млн, а не миллиарды).","text_en":"Small biotech companies may struggle to get full investor credit for assets/markets that aren’t perceived as blockbuster-sized (hundreds of millions vs billions).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0008","quote":"investors are looking at market opportunities that are in the hundreds of millions, not the billions."},{"chunk_id":"doc_d031fa09e04b_chunk_0008","quote":"it’s hard for small companies sometimes to get full credit for an asset that might not meet that critical mass for some investors."}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0008_n2","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Сделки M&A/консолидации в HAE/HEE могут упираться в антимонопольный риск (FTC) из‑за прямого пересечения компаний.","text_en":"M&A/consolidation in the HAE/HEE space may face FTC antitrust risk due to direct overlap between companies.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0008","quote":"There’s also the FTC question, right? Because these companies are directly overlapping"}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0008_n3","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"HEE/HAE пространство стало достаточно «crowded», что усиливает неопределённость по конкуренции на горизонте 5 лет и влияет на оценку компаний.","text_en":"The HEE/HAE space has become crowded, increasing uncertainty about the 5-year competitive outlook and affecting company valuation/credit.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0008","quote":"I feel like in the HEE space, it’s become crowded enough"},{"chunk_id":"doc_d031fa09e04b_chunk_0008","quote":"the theoretical uncertainty around what the five-year competition outlook looks like."}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0009_n1","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Инвесторы считают, что в biotech слишком много компаний, и из‑за высоких потребностей в капитале не всем удастся привлечь нужное финансирование; ожидается консолидация/рост M&A.","text_en":"Investors see too many biotech companies; given high capital needs, not all will raise required financing, implying consolidation/more M&A.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0009","quote":"\"the denominator in terms of how many companies we have is. Very high\""},{"chunk_id":"doc_d031fa09e04b_chunk_0009","quote":"\"given the capital needs of all of these companies, like it's going to be very difficult for every company to raise the financing that they need\""},{"chunk_id":"doc_d031fa09e04b_chunk_0009","quote":"\"I hope we do see a lot more M&A in the space.\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0009_n2","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Регуляторное несоответствие на fill-finish заводе (OAI letter) приводит к задержкам одобрения препаратов: требуется реинспекция и восстановление compliance, что занимает месяцы.","text_en":"Regulatory non-compliance at a fill-finish plant (OAI letter) delays drug approvals; re-inspection and regaining compliance can take months.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0009","quote":"\"that plant got what's called an OAI letter earlier in the week\""},{"chunk_id":"doc_d031fa09e04b_chunk_0009","quote":"\"it's going to need to go through a re-inspection and that re-inspection is almost certainly going to take some time— number of months\""},{"chunk_id":"doc_d031fa09e04b_chunk_0009","quote":"\"according to FDA mandates, regulations they can't approve the drug\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0009_n3","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"Из‑за задержек одобрения, связанных с проблемами на производственной площадке, пациенты вынуждены ждать лекарства (в т.ч. для детей со SMA).","text_en":"Approval delays tied to manufacturing site issues force patients to wait for drugs (including for children with SMA).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0009","quote":"\"The end. Net result of all this is that patients are waiting for drugs.\""},{"chunk_id":"doc_d031fa09e04b_chunk_0009","quote":"\"they're waiting for I would say a very important drug for patients, younger patients, children with SMA\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0010_n1","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"FDA не может одобрить препарат, если производственная площадка не соответствует требованиям комплаенса.","text_en":"FDA cannot approve a drug if the manufacturing facility lacks overall compliance.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0010","quote":"\"this facility doesn't have overall compliance. Know therefore, according to FDA mandates, regulations they can't approve the drug\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0010_n2","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"Проблемы на производстве могут быть неожиданными для инвесторов/аналитиков и приводят к значимым задержкам и неопределённости по срокам.","text_en":"Manufacturing issues can be unknown until late and lead to significant delays and timeline uncertainty.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0010","quote":"\"up until August, none of us who were covering this company—Regeneron—knew. Any idea that this was an issue\""},{"chunk_id":"doc_d031fa09e04b_chunk_0010","quote":"\"we don't know what the timelines are, and that can be frustrating\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0010_n3","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Есть стремление наращивать/«доместицировать» производственные мощности в США, но на практике возникают проблемы с комплаенсом на местных площадках.","text_en":"There is a push to domesticate manufacturing capacity in the U.S., yet local facilities can still face compliance issues.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0010","quote":"\"here we are with this zeal to domesticate manufacturing capacity within the United States\""},{"chunk_id":"doc_d031fa09e04b_chunk_0010","quote":"\"here's a facility in Indiana... is running against these issues\""}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Сектор, по словам спикера, «удваивает/утраивает» усилия в GLP-категории, фокусируясь на инкрементальных улучшениях, вместо других направлений инноваций.","text_en":"The sector is doubling/tripling down on incremental innovation within the GLP category rather than other innovation areas.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0011","quote":"people are now doubling down, tripling down on different incremental aspects of that category"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Отмечаются «policy headwinds» (политико-регуляторные встречные ветры) для индустрии в этом году.","text_en":"The industry is experiencing policy headwinds this year.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0011","quote":"even with the policy headwinds that we have been experiencing this year"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_d031fa09e04b","kind":"opportunity","text_ru":"Возможность ускорить доставку лекарств пациентам в США: быстрее проводить клинические исследования и генерировать клинические доказательства дешевле.","text_en":"Opportunity to speed up getting medicines to patients in the U.S. by running clinical trials faster and generating clinical evidence for less money.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0011","quote":"accelerate getting our medicines to patients faster in this country"},{"chunk_id":"doc_d031fa09e04b_chunk_0011","quote":"getting clinical trials done quicker and generating clinical evidence for less money"}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0012_n1","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"Разработка лекарств для эссенциального тремора/двигательных расстройств исторически очень сложна: трудно селективно уменьшать тремор без седативных побочных эффектов, особенно у пожилых пациентов.","text_en":"Drug development for essential tremor/movement disorders is historically very challenging: hard to reduce tremor selectively without sedating side effects, especially in elderly patients.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0012","quote":"this space has been so, so, so challenging from a drug development perspective."},{"chunk_id":"doc_d031fa09e04b_chunk_0012","quote":"the more you attenuate the tremor, the more you have side effects like fatigue and dizziness and somnolence"}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0012_n2","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"Есть неопределённость/дискуссия о том, какой размер эффекта считать клинически значимым при этом состоянии; присутствует субъективность оценки.","text_en":"There is debate/uncertainty about what constitutes a clinically meaningful effect size in this condition; assessment is subjective.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0012","quote":"there's going to be some debate around what is a clinically significant effect size in this condition."},{"chunk_id":"doc_d031fa09e04b_chunk_0012","quote":"there's a lot of subjectivity around what even is clinically significant."}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0012_n3","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"В биотехе регулярно появляются «Phoenix from the Ashes» истории, когда отдельные акции резко растут (пример: Praxis за неделю).","text_en":"Biotech frequently sees “Phoenix from the Ashes” stories where individual stocks surge sharply (example: Praxis this week).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0012","quote":"almost every week we have one of these 'uh, I guess you know' Phoenix from the Ashes kind of stories in biotech."},{"chunk_id":"doc_d031fa09e04b_chunk_0012","quote":"that was the one stock that this week was at least up 100-plus."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"Ключевая проблема сектора последние ~4 года — недостаток финансирования/денежного runway.","text_en":"A major sector issue over the past ~4 years has been funding/cash runway constraints.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0013","quote":"\"And that has been such, such the major issue for our sector for the past four years now.\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"На хороших данных компании стали привлекать более «robust» финансирования, иногда добавляя 2–3 года runway.","text_en":"On good data, companies are seeing robust financings, sometimes adding 2–3 years of cash runway.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0013","quote":"\"we're seeing on good data... robust financings\""},{"chunk_id":"doc_d031fa09e04b_chunk_0013","quote":"\"companies are able to add cash that gives them... sometimes two, if not three years, of extra cash runway\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Инвесторы сильнее реагируют ростом акций на клинические данные, что повышает уверенность, что за клинический риск можно «получить оплату».","text_en":"Investors are showing big stock upside reactions to data, boosting confidence that taking clinical risk can be rewarded.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0013","quote":"\"big, big stock upside reactions on data\""},{"chunk_id":"doc_d031fa09e04b_chunk_0013","quote":"\"has emboldened people's confidence that you can get paid for taking on clinical risk\""}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0014_n1","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"В биотехе/медицине конкуренция чаще идёт не за долю рынка, а за расширение общего рынка (\"размер пирога\").","text_en":"In biotech/medicine, competition is often about growing the overall market (“size of the pie”) rather than taking market share.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0014","quote":"Rarely is healthcare and biotech and medicine a fight for market share. Almost always, it's a fight for the size of the pie."}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0014_n2","doc_id":"doc_d031fa09e04b","kind":"pain","text_ru":"Нейродегенеративные заболевания описываются как «очень сложная» область с высоким неудовлетворённым медицинским спросом; в случае FTD это также фатальное состояние.","text_en":"Neurodegenerative diseases are described as a very tough area with high unmet need; in FTD specifically, it is also a fatal condition.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0014","quote":"this whole neurodegenerative disease space is just so tough."},{"chunk_id":"doc_d031fa09e04b_chunk_0014","quote":"these neurodegenerative diseases, you know, high unmet medical need. In this particular case, it is a fatal condition as well."}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0014_n3","doc_id":"doc_d031fa09e04b","kind":"constraint","text_ru":"По программе Elector по FTD ранее данные были «не такими чистыми», а интерпретация осложнена: «трудно сказать многое» и мало обновлений более чем за год.","text_en":"For Elector’s FTD program, prior data were “not as clean,” and interpretation is difficult: “hard to really say much,” with few updates beyond a year.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0014","quote":"It's just hard to really say much about it. And I don't think we've seen much updates beyond a year."},{"chunk_id":"doc_d031fa09e04b_chunk_0014","quote":"the prior data. uh, was probably not as clean as perhaps those of us would want to see"}],"confidence":"medium"}
{"nugget_id":"doc_d031fa09e04b_chunk_0015_n1","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Рынок низко оценивает вероятность успеха программы (не закладывает ожиданий, что «это сработает»).","text_en":"The market is pricing in low expectations that the program will work.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0015","quote":"\"So clearly, the market is not ascribing a lot of um value or expectation that this is going to work.\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0015_n2","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"FDA (неврологическое подразделение) ранее демонстрировало регуляторную гибкость по спорным препаратам (упомянуты Alzheimer’s и ALS).","text_en":"FDA’s neurology division has shown regulatory flexibility for controversial drugs (Alzheimer’s and ALS mentioned).","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0015","quote":"\"a neurology division that in the past has shown a fair amount of regulatory flexibility when it comes to perhaps controversial drugs\""}],"confidence":"high"}
{"nugget_id":"doc_d031fa09e04b_chunk_0015_n3","doc_id":"doc_d031fa09e04b","kind":"trend","text_ru":"Генная терапия «не закончилась» и остаётся важной модальностью для некоторых ультра-редких заболеваний.","text_en":"Gene therapy is not over and remains an important modality for some ultra-rare diseases.","evidence":[{"chunk_id":"doc_d031fa09e04b_chunk_0015","quote":"\"That gene therapy is not over.\""},{"chunk_id":"doc_d031fa09e04b_chunk_0015","quote":"\"gene therapy remains an important modality for some of these ultra-rare diseases.\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0000_n1","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"В публичных биотех-рынках наблюдается улучшение настроений: XBI держится выше 100, публичные рынки и M&A выглядят хорошо.","text_en":"Public biotech markets show improved sentiment: XBI holding above 100; public markets and M&A look good.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0000","quote":"\"we've talked previously about the XBI breaking 100, staying there\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0000","quote":"\"the public markets are looking good. M&A is generally good.\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0000_n2","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Инвесторы в последнее время настроены оптимистично; рост воспринимается как «подъём без безумных оценок» после нескольких лет слабости XBI.","text_en":"Investors are upbeat; the upswing is seen as a lift-off without crazy valuations after multiple years of XBI underperformance.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0000","quote":"\"It's really an optimistic, enthusiastic public market out there right now.\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0000","quote":"\"without sort of crazy valuations\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0000","quote":"\"after multiple years of XBI underperformance\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0000_n3","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Биотех рассматривается как «catch-up trade» на фоне перегретых оценок в AI/tech; сильные реакции на катализаторы (сотни процентов апсайда) привлекают внимание.","text_en":"Biotech is viewed as a catch-up trade versus overheated AI/tech; large catalyst-driven moves (hundreds of percent upside) are drawing attention.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0000","quote":"\"people would kind of. Think of this as a catch-up trade\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0000","quote":"\"the AI trade in tech that has pushed valuations to historical extremes\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0000","quote":"\"you're seeing hundreds of percent upside on catalysts\""}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0001_n1","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Рынок стал лучше реагировать на данные: после (даже ожидаемых) датасетов акции чаще растут, а не распродаются на «хороших новостях».","text_en":"The market is reacting more constructively to data: even expected datasets are followed by better stock performance rather than sell-offs on good news.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0001","quote":"\"You're still seeing stocks perform in the aftermath of that.\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0001","quote":"\"It seems like the market's becoming more efficient.\""}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0001_n2","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Ожидается ускорение IPO-активности в ближайшие кварталы после «пустыни» IPO.","text_en":"IPO activity is expected to accelerate over the next couple of quarters after a prolonged drought.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0001","quote":"\"I think you're going to see an acceleration.\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0001","quote":"\"we went through this prolonged period where we had... a desert of IPOs\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0001_n3","doc_id":"doc_1b6dbc7c530f","kind":"buyer_signal","text_ru":"При более здоровом IPO-рынке и устойчивых оценках VC становятся более готовыми размещать капитал, писать чеки и запускать новые компании.","text_en":"With a healthier IPO market and valuations holding, VCs feel more comfortable deploying capital, writing checks, and starting new companies.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0001","quote":"\"There's definitely more of a willingness to write checks.\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0001","quote":"\"we get very encouraged and much more comfortable deploying capital\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0002_n1","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Участники рынка видят улучшение IPO-рынка/оценок и «trickle down» в виде большей готовности инвесторов выписывать чеки и активизироваться.","text_en":"Improving IPO market/valuations are seen as trickling down into greater willingness to write checks and increased VC activity.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0002","quote":"\"There's definitely more of a willingness to write checks. And I think we'll see more VCs getting more active\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0002_n2","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"M&A-окружение влияет на готовность развёртывать капитал; приводится пример многомиллиардной сделки как признак энтузиазма платить за активы.","text_en":"The M&A environment is impacting willingness to deploy capital; a multibillion acquisition is cited as evidence of enthusiasm to pay for assets.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0002","quote":"\"The M &A environment has an impact on that too.\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0002","quote":"\"adds to the bulk of evidence that you're seeing. More and more enthusiasm for paying for these assets.\""}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0002_n3","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"Есть негативное отношение к «перегреву» оценок (пример: доклинические компании по $1B), что воспринимается как нездоровая ситуация.","text_en":"There is pushback against overheated valuations (e.g., preclinical companies at $1B), viewed as unhealthy.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0002","quote":"\"Nobody wants to go back to what you were describing, preclinical companies going at a billion.\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0003_n1","doc_id":"doc_1b6dbc7c530f","kind":"buyer_signal","text_ru":"Инсайдерное участие менеджмента в финансировании (вплоть до ~50% сделки) воспринимается как «бычий» сигнал для рынка.","text_en":"Management/insider participation in financing (up to ~50% of a deal) is viewed as a bullish market signal.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0003","quote":"\"it's certainly a bullish signal when you get a management team to put effectively half of the of the deal together\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0003","quote":"\"management putting money up into their own company is a bullish signal.\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0003_n2","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"Даже при наличии meaningful phase 3 data может быть неочевидно, почему компания не привлекла больше от институциональных инвесторов (или не захотела).","text_en":"Even with meaningful phase 3 data, it may be unclear why a company didn’t (or didn’t want to) raise more from institutional investors.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0003","quote":"\"you do wonder why they couldn't go and get more from institutional investors, or did they not want to get more\""}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0003_n3","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Отмечается, что компании стремятся сохранять лидерство в конкретных показаниях.","text_en":"Companies are aiming to maintain leadership positions in specific indications.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0003","quote":"\"see companies really want to maintain a leadership position in specific indications.\""}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0004_n1","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Наблюдается сильная динамика: follow-on/PIPE/registered direct сделки закрываются, и после размещений акции часто растут (\"after-the-fact success\").","text_en":"Strong follow-on/PIPE/registered direct activity with frequent post-deal stock appreciation (“after-the-fact success”).","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0004","quote":"we're really seeing is really great performance on follow-ons. We're seeing a lot of deals get done."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0004","quote":"a deal will get done and then the stocks will appreciate immediately."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0004_n2","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"Ключевой пушбэк инвесторов в последние годы: компании не смогут профинансировать путь до катализаторов из‑за риска сильной дилюции и невозможности привлечь капитал.","text_en":"Investor pushback: companies may not be able to fund to catalysts due to dilution risk and inability to raise capital.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0004","quote":"biggest pushbacks I'd get from clients over the last couple of years is... how are they going to get to catalysts here?"},{"chunk_id":"doc_1b6dbc7c530f_chunk_0004","quote":"these companies, these are going to suffer massive dilution. They can't raise the capital."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0004_n3","doc_id":"doc_1b6dbc7c530f","kind":"buyer_signal","text_ru":"Финансирование само по себе становится триггером спроса: после закрытия раунда возникает FOMO и «robust demand/interest» со стороны инвесторов.","text_en":"Financing itself is triggering demand: post-financing FOMO and “robust demand/interest” from investors.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0004","quote":"it almost creates this FOMO where people are like, 'Oh, I always liked the story'"},{"chunk_id":"doc_1b6dbc7c530f_chunk_0004","quote":"With Alto, you saw that robust demand earlier this week."}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0005_n1","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"В сделках с китайскими компаниями появляется формат глобальной co-commercialization/co-development, где китайский партнёр сохраняет часть прав (в т.ч. по США), а не просто лицензирует актив.","text_en":"China deals increasingly use global co-commercialization/co-development where the Chinese partner retains some rights (incl. US), rather than pure out-licensing.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0005","quote":"\"It's a co-commercialization, a global co-commercialization deal and co-development.\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0005","quote":"\"I haven't seen too many examples of this where the Chinese. A partner keeps some of the rights\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0005_n2","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Отмечается рост/частота появления EGFR–B7H3 биспецификов с ADC.","text_en":"More EGFR–B7H3 bispecifics with ADC are being seen.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0005","quote":"\"We're seeing more of these EGFR3, EGFR-B7H3. Um, type of bispecifics with ADC on them\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0005_n3","doc_id":"doc_1b6dbc7c530f","kind":"buyer_signal","text_ru":"Крупные сделки/финансирования указывают на активный спрос/готовность платить за онкологические активы (пример: Takeda–Innovent с $1.2B upfront).","text_en":"Large deals/financings indicate strong buyer appetite for oncology assets (e.g., Takeda–Innovent with $1.2B upfront).","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0005","quote":"\"Takeda did a deal with Innovent. Um and it was a pretty hefty deal—$1. 2 billion dollars up front.\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0006_n1","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"В Европе много активности, но участники «ждут», пока финансовые рынки/аппетит к инвестициям улучшатся и «догонят».","text_en":"Europe shows activity but is “waiting” for financial markets/investor appetite to improve and catch up.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0006","quote":"in Europe, there's a lot of activity and there's a lot of waiting for the market to improve."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0006","quote":"waiting for the appetite for investment to stick up."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0006_n2","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"Европейским компаниям/проектам приходится конкурировать за капитал; многие не получат финансирование в желаемом объёме.","text_en":"European companies/projects must compete for capital; many won’t get funded as much as they want.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0006","quote":"Europe, they still have to compete for it, right?"},{"chunk_id":"doc_1b6dbc7c530f_chunk_0006","quote":"There's still a lot more. That are not going to get funded the way they want versus those that get selected."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0006_n3","doc_id":"doc_1b6dbc7c530f","kind":"opportunity","text_ru":"Пока рынок «ждёт», команды могут продвигать discovery/basic research (оно «не так дорого») и готовиться к будущим Series A/B раундам.","text_en":"While the market is “waiting,” teams can advance discovery/basic research (not that expensive) and prepare for future Series A/B rounds.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0006","quote":"all of the discovery research and basic research is not that expensive."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0006","quote":"they can get ready for that, you know, 30 million. Million series A round, or that, you know, 80 million, you know, series B"}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0007_n1","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"На ESMO заметно выросло присутствие китайских компаний; это связывают с эволюцией науки/ростом числа программ и частично с текущей геополитикой.","text_en":"At ESMO there was a noticeable increase in Chinese companies presenting, attributed to evolving science/more programs and partly current geopolitics.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0007","quote":"\"it was certainly quite clear that a lot of Chinese companies presenting there\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0007","quote":"\"partly is because the science is evolving and the programs are continuing to become numerous\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0007","quote":"\"perhaps a little bit to do with the geopolitics at the minute\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0007_n2","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"Ограничение/неопределённость: по Harmony 6 не представили данных по общей выживаемости (OS), что вызывает сомнения, учитывая историю VEGF, когда улучшение PFS может не переводиться в OS.","text_en":"Constraint/uncertainty: no overall survival (OS) data were provided for Harmony 6, raising concern given VEGF history where PFS gains may not translate to OS.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0007","quote":"\"We saw nothing about OS, not even a commentary about trends or anything\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0007","quote":"\"you do wonder whether the VEGF effect is on the tumor response\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0007","quote":"\"but doesn't translate to OS, which has been the case in many tumors with VEGF\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0007_n3","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"Боль/риск в разработке: в squamous NSCLC исторически опасались добавлять VEGF из‑за ранних негативных опытов.","text_en":"Pain/risk in development: in squamous NSCLC there has historically been concern about adding VEGF due to early bad experiences.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0007","quote":"\"squamous non-small cell, which has been historically something that people have worried about putting VEGF in\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0007","quote":"\"because of some early bad experiences\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0008_n1","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"В онкологии улучшение PFS/радиографической пользы может не приводить к статистически значимому улучшению OS, из‑за чего сложно интерпретировать реальную пользу для пациентов.","text_en":"In oncology, PFS/radiographic benefit may not translate into statistically significant OS benefit, making true patient benefit hard to interpret.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0008","quote":"the PFS didn't translate to a statistically significant OS benefit."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0008","quote":"Avastin sort of has this weird ability to drive radiographic benefit that hasn't necessarily correlated in long-term survival."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0008_n2","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"В исследованиях VEGF-ориентированных подходов исключают пациентов с риском кровотечения из‑за риска, что может ограничивать переносимость результатов на другие популяции/рынки.","text_en":"VEGF-focused studies exclude patients at bleeding risk due to safety concerns, which may limit generalizability/translation to other populations/markets.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0008","quote":"they did exclude patients with the risk of bleeding, as they should have, because there's a risk with VEGF in those patients."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0008","quote":"you therefore wonder whether this is going to be easily translatable and what happens to it when it comes to the US."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0008_n3","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Продолжает расти число PD-L1×VEGF би-спецификов, которые появляются в разных показаниях (например, NSCLC, gastric).","text_en":"More PD-L1×VEGF bispecifics are continuing to appear across indications (e.g., NSCLC, gastric).","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0008","quote":"we're continuing to see more and more PD-L1 VEGFs showing up."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0008","quote":"We saw a new one in non-small cell lung."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0009_n1","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"В онкологии вокруг новых таргетов часто возникает «пик хайпа» на ранних данных, после чего наступает разочарование/усиливается конкуренция.","text_en":"In oncology, new targets often see early hype peaks on initial data, followed by disappointment and/or increased competition.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0009","quote":"you get kind of peak hype early, and then there's always kind of a slow, right? Disappointment and/ or competition enters the fray."}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0009_n2","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"В биотехе есть системная проблема переоценки ранних данных: ранний энтузиазм может сменяться разочарованием по мере появления более полной картины.","text_en":"A recurring biotech problem is overexcitement about early data, which can turn disappointing as reality sets in.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0009","quote":"in biotech, you could get overexcited about early data and then. you know, as reality sets in, it could be quite disappointing."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0009_n3","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"Скепсис к небольшим single-arm исследованиям (например, 15 пациентов) и ожидание более крупных когорт/данных во времени как барьер для уверенности в раннем сигнале.","text_en":"Small single-arm studies (e.g., 15 patients) are viewed skeptically; larger cohorts and longer follow-up are needed to trust early signals.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0009","quote":"the days of looking at a single arm, you know, 15 patient study where the early signal looks good. That I think they're skeptical of"}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0010_n1","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"В 3-й линии CRC есть проблема: токсичность терапии может быть выше, чем у Stivarga, а OS/PFS не превосходят бенчмарки, что вызывает негативную реакцию.","text_en":"In 3L CRC, toxicity may be higher than Stivarga and OS/PFS don’t exceed benchmarks, triggering negative reaction.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0010","quote":"third-line CRC, you had a toxicity that seemed to be more than Stivarga."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0010","quote":"the OS benefit and PFS benefit didn't really go beyond benchmarks."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0010_n2","doc_id":"doc_1b6dbc7c530f","kind":"opportunity","text_ru":"Есть возможность/ценность в терапии 3-й линии без химиотерапии и в идентификации пациентов, которые ответят на IO, чтобы добиться durable response.","text_en":"Opportunity/value in chemo-free 3L therapy and identifying IO responders to induce durable responses.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0010","quote":"patients will most likely have had two lines of chemo already and not really be ready to take another one."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0010","quote":"Doctors are eager to really identify the sorts of patients who will respond to IO therapy."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0010","quote":"to induce a durable response, because that's what the opportunity you've got here."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0010_n3","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"G12D (KRAS) пространство «hotting up»: появляются новые игроки/агенты и ожидаются новые данные по дополнительным агентам.","text_en":"The KRAS G12D space is heating up with more players/agents and upcoming data on additional agents.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0010","quote":"the G12D space for Keras is hotting up."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0010","quote":"we'll see some more new agents that we haven't seen data for, presented."}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_001","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Наблюдается «возрождение» интереса/восприятия Insight на фоне новых активов и представленных ранних данных с управляемой токсичностью.","text_en":"A perceived resurgence of Insight driven by new assets and early data with manageable toxicity.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0011","quote":"So that's like the resurgence of insight from what we're on. seeing from these assets"}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_002","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"TGF-beta исторически воспринимался как проблемная мишень: в монотерапии/одним антителом ожидается более высокая токсичность, и прошлый проект GSK «не сработал».","text_en":"TGF-beta has been viewed as problematic: prior GSK-licensed program didn’t work out and monotherapy/single antibody is expected to be more toxic.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0011","quote":"TGF-beta, I think a lot of people remember as a drug that GlaxoSmithKline had in license that didn't work out."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0011","quote":"as this monotherapy or as a single antibody, is likely to be more toxic."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_003","doc_id":"doc_1b6dbc7c530f","kind":"buyer_signal","text_ru":"Рынок позитивно реагировал на ожидания данных Arcus: акция выросла почти на 50% за месяц и примерно удвоилась за год, что указывает на заранее заложенные ожидания/интерес инвесторов к презентациям.","text_en":"Market showed positive anticipation for Arcus data: stock up ~50% in a month and roughly doubled over a year, suggesting investor interest/expectations around presentations.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0011","quote":"The stock had run up like almost 50 percent over the last month and had grown, you know, doubled over, you know, the last year or so."}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0012_n1","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"В исследованиях по деменции возможна ситуация: биомаркерный эндпойнт достигается, но клинической пользы нет, что подчёркивает сложность принятия биомаркеров без клинической корреляции.","text_en":"In dementia trials, biomarker endpoints can be met without clinical benefit, highlighting the challenge of accepting biomarkers without clinical correlation.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0012","quote":"\"they hit their endpoint on a co-primary of the biomarker... but failed on the clinical component\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0012","quote":"\"this speaks to the challenge... like accepting biomarkers without correlative or concordance on the clinical benefit\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0012_n2","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Рынок резко наказывает за негативные клинические результаты в деменции: акция упала на 50%, компания объявила сокращения.","text_en":"The market sharply penalizes negative dementia trial results: the stock fell 50% and the company announced layoffs.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0012","quote":"\"the stock was off 50% on this news\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0012","quote":"\"they announced layoffs of half. half of their employees\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0012_n3","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"Существует неопределённость/скепсис среди врачей по поводу применения терапии против TIGIT даже при одобрении, несмотря на «хорошие» данные.","text_en":"There is physician uncertainty/skepticism about using anti-TIGIT therapy even if approved, despite data looking good.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0012","quote":"\"most physicians... 'I'm not sure if I... even if I've got approved, I would probably use it in some patients.'\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0012","quote":"\"then you look at the data and the data looks good\""}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0013_n1","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"Клинические неудачи в Alzheimer’s/BBB-shuttle программах приводят к сильным негативным последствиям для компаний (вплоть до сокращений).","text_en":"Clinical failures in Alzheimer’s/BBB-shuttle programs can have severe company impacts, including layoffs.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0013","quote":"They had another drug targeting TREM2 that was a failed study in Alzheimer's where they laid off employees."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0013","quote":"they announced layoffs of half. half of their employees while they await the results"}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0013_n2","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"Даже при механистическом эффекте (биомаркер) клинический эндпойнт (FEV) может не улучшаться, что ограничивает интерпретацию эффективности терапии.","text_en":"Even with biomarker/mechanistic activity, the clinical endpoint (FEV) may not improve, limiting efficacy interpretation.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0013","quote":"it did show restoration again on the biomarker on the CFTR protein."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0013","quote":"the clinical data on the key lung function, FEV, this is forced expiratory velocity, did not meaningfully improve."}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_chunk_0013_n3","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Растёт активность инвестиций и интерес pharma в неонкологических терапевтических областях (CNS, cardiovascular, rare pulmonary).","text_en":"Investment activity and pharma interest are increasing in non-oncology therapeutic areas (CNS, cardiovascular, rare pulmonary).","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0013","quote":"indicative of the activity in investing and also a pharma interest in just non-oncology"}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_0014_01","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Наблюдается рост активности в разработке препаратов, способных воздействовать на цели через гематоэнцефалический барьер; под это уже выходили на IPO компании с «platform hypothesis».","text_en":"Increasing activity in developing drugs that can hit targets across the blood-brain barrier; some companies have gone public on that platform hypothesis.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0014","quote":"\"we're seeing more and more. Action in in trying to get drugs to hit targets across the blood-brain barrier\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0014","quote":"\"a number of companies specifically gone public on sort of that platform hypothesis\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_0014_02","doc_id":"doc_1b6dbc7c530f","kind":"pain","text_ru":"Доставка терапий (в т.ч. mRNA) к нужной ткани/мишени остаётся сложной: CNS трудно понять и «достать» до таргета; многие попытки доставки mRNA (в лёгкие и системно) были неуспешны.","text_en":"Delivery remains hard: CNS pathophysiology/targeting is difficult; many attempts to deliver mRNA to lungs or systemically have not succeeded.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0014","quote":"\"CNS is a very hard area to really understand the pathophysiology and certainly to get to the target.\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0014","quote":"\"We've seen a lot of attempts to get delivery of mRNA, well, not just to the lungs, but even systemically... that have not been successful.\""}],"confidence":"high"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_0014_03","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"У mRNA-технологии успехи в основном отмечаются в респираторных заболеваниях (COVID, RSV, грипп); есть сомнение, что в хронических инфекциях (например, HPV) ей может быть сложнее.","text_en":"mRNA success has mainly been in respiratory diseases (COVID, RSV, flu); it may have a tougher time in chronic infections (e.g., HPV).","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0014","quote":"\"where we've seen success has been in the respiratory space... such as COVID, RSV, flu\""},{"chunk_id":"doc_1b6dbc7c530f_chunk_0014","quote":"\"in these chronic infections like HPV, et cetera, this technology might have a tougher time\""}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_001","doc_id":"doc_1b6dbc7c530f","kind":"constraint","text_ru":"Есть сомнения, что технология может хуже работать в хронических инфекциях (например, HPV), и требуется дополнительное обдумывание/обсуждение с экспертами.","text_en":"There are doubts the technology may perform worse in chronic infections (e.g., HPV), requiring further thinking and expert discussion.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0015","quote":"whether in these chronic infections like HPV, et cetera, this technology might have a tougher time."},{"chunk_id":"doc_1b6dbc7c530f_chunk_0015","quote":"I really need to see. Sit back and think it through and talk to a few."}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_002","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"Компания, о которой говорят, постепенно пытается позиционировать себя больше как онкологическую компанию.","text_en":"The discussed company is slowly trying to position itself more as a cancer company.","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0015","quote":"they're slowly trying to make themselves more of a cancer company."}],"confidence":"medium"}
{"nugget_id":"doc_1b6dbc7c530f_nugget_003","doc_id":"doc_1b6dbc7c530f","kind":"trend","text_ru":"BioNTech расширяется в разные направления помимо mRNA (антитела, ADC, биспецифики).","text_en":"BioNTech is expanding into areas beyond mRNA (antibodies, ADCs, bispecifics).","evidence":[{"chunk_id":"doc_1b6dbc7c530f_chunk_0015","quote":"BioNTech's gone into a whole variety of places with antibodies and ADCs, bispecifics, et cetera."}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0000_n1","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"В биотехе наблюдается ралли после лет недоходности; отмечаются сильные клинические данные, меньше слабых игроков, возобновление M&A и успешные коммерческие запуски.","text_en":"Biotech is rallying after years of underperformance, with strong clinical data, fewer weak players, renewed M&A, and successful commercial launches.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0000","quote":"after years of underperformance, biotech has been rallying and it looks like it may be more sustainable this time."},{"chunk_id":"doc_8911e4a8257e_chunk_0000","quote":"strong clinical data. Fewer weak players. Renewed M &A activity, and importantly, successful commercial launches by biotechs."}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0000_n2","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"IPO-рынок для биотеха по-прежнему выглядит «практически закрытым», и до конца года не ожидается большого объёма IPO из‑за длительности процесса.","text_en":"The biotech IPO market still seems largely closed, with limited IPO activity expected before year-end due to the lengthy process.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0000","quote":"The IPO market seems to still be pretty much closed."},{"chunk_id":"doc_8911e4a8257e_chunk_0000","quote":"I wouldn't anticipate a huge amount of IPO activity before the end of the year"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0000_n3","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Возвращается интерес «generalist» инвесторов (в т.ч. small-cap generalists), который воспринимается как фактор, усиливающий импульс сектора.","text_en":"Generalist investor interest is returning (including small-cap generalists), seen as a momentum builder for the sector.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0000","quote":"The generalist interest is definitely much more palpable and it's back."},{"chunk_id":"doc_8911e4a8257e_chunk_0000","quote":"as generalists come back, I think that's going to be a real momentum builder for the sector."}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0001_n1","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"Быть публичной biotech-компанией (особенно на ранней стадии R&D) тяжело: публичные рынки усиливают стресс вокруг R&D и data readouts, и CEO это даётся сложно.","text_en":"Being a public biotech (especially early-stage R&D) is difficult: public-market scrutiny makes R&D and data readouts stressful, and being a public-company CEO is hard.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0001","quote":"solving. R&D questions, especially early stage R&D questions under the glare of the public markets, is not a pleasant place."},{"chunk_id":"doc_8911e4a8257e_chunk_0001","quote":"I also agree with everything you just said about how difficult it is to be a public company CEO."},{"chunk_id":"doc_8911e4a8257e_chunk_0001","quote":"When you're managing data readouts. It's probably one of the most stressful things that you could be doing."}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0001_n2","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"IPO-процесс занимает месяцы, а статус публичной компании дорого обходится в первые годы (упоминаются комиссии, D&O и др.).","text_en":"The IPO process takes months, and being public is expensive in the first years (banker fees, D&O, etc.).","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0001","quote":"it takes you four months to sort of file, especially with a closed system."},{"chunk_id":"doc_8911e4a8257e_chunk_0001","quote":"Probably costs you $40 or $50 million to be public for your first two years when you think about bankers' fees, D&O"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0001_n3","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"В private market сейчас есть заметная активность: часто происходят раунды $100M+ (упоминается 6–7 в месяц), что позволяет дольше оставаться частными до клинической точки перегиба.","text_en":"There is notable private-market activity: frequent $100M+ financings (6–7 per month mentioned), enabling companies to stay private through a clinical inflection.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0001","quote":"the frequency of $100 million plus financings in the private market, it's like six or seven a month right now."},{"chunk_id":"doc_8911e4a8257e_chunk_0001","quote":"there is a lot of venture funding available for companies that want to get through that clinical inflection as a private company today."}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0002_n1","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"В системе IPO есть проблема отсутствия «сдержек и противовесов»/дисциплины, что ведёт к повторяющимся рыночным циклам.","text_en":"The IPO system lacks checks-and-balances/discipline, contributing to recurring market cycles.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0002","quote":"\"Yeah, who's going to exert that discipline? I mean, where is the check and balance in the system?\""},{"chunk_id":"doc_8911e4a8257e_chunk_0002","quote":"\"I mean, it is a cycle after all.\""}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0002_n2","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Решения «идти ли на IPO/продаваться» ограничены риском разводнения и необходимостью принимать разводнение на низких ценах в публичных рынках.","text_en":"Go-public/sell decisions are constrained by dilution sensitivity and the need to accept dilution at low public-market prices.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0002","quote":"\"existing investors being somewhat sensitive to dilution\""},{"chunk_id":"doc_8911e4a8257e_chunk_0002","quote":"\"Do I take the kind of dilution that might be required in the public markets at low prices?\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0002_n3","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Сделка M&A: Novartis объявила о приобретении Avidity за $12 млрд; слухи об этом ходили с лета и сопровождались ростом акций на ожиданиях.","text_en":"M&A event: Novartis announced a $12B acquisition of Avidity; rumors since summer drove a stock jump on acquisition speculation.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0002","quote":"\"Novartis will acquire Avidity. For $12 billion.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0002","quote":"\"This was speculated going back all the way into the summer.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0002","quote":"\"there's a big jump in Avidity's stock price as it was rumored to be an acquisition candidate\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0003_n1","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Крупные M&A-сделки возможны даже до публикации результатов фазы 3; это выглядит как беспрецедентный уровень оценки для компании без phase 3 readout.","text_en":"Large M&A deals can happen even before phase 3 readouts; valuation levels for companies without phase 3 results are described as unprecedented.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0003","quote":"\"this is the largest deal we've ever seen for a company that has yet to read out a phase three result\""},{"chunk_id":"doc_8911e4a8257e_chunk_0003","quote":"\"this is unprecedented in that we have a company.\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0003_n2","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"Для акционеров продажа компании на этой стадии может быть «смешанным» исходом: премия сейчас, но отказ от потенциально гораздо большей будущей стоимости.","text_en":"For shareholders, selling at this stage can be a mixed outcome: a premium now but giving up potentially much larger future value.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0003","quote":"\"it's a mixed bag for Ividi shareholders\""},{"chunk_id":"doc_8911e4a8257e_chunk_0003","quote":"\"We are giving up that potential for a $20, $30, $40 billion valuation in the future.\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0003_n3","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Покупатель (Novartis) берёт на себя существенные риски: developmental, commercial и clinical.","text_en":"The acquirer (Novartis) is taking on substantial developmental, commercial, and clinical risk.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0003","quote":"\"a company that is seeding all the developmental risk, the commercial risk, the clinical risk, Novartis.\""}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0004_n1","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Риск истечения патентов (2028–2029) приводит к плоскому росту после 2029 и требует замещения выручки новыми продуктами.","text_en":"Patent expirations (2028–2029) create post-2029 flat growth risk, driving need for replacement products.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0004","quote":"\"after that, there is a risk of patent expiration.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0004","quote":"\"The compound pattern expires in 2028 and 2029.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0004","quote":"\"growth was flat from 29 onwards, or there was no growth.\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0004_n2","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Обсуждается возможная коммодитизация платформы таргетинга (вопрос, стала ли технология «passe» и есть ли у многих игроков аналогичные подходы).","text_en":"Possible commoditization of a targeting technology platform is being questioned (whether the tech is ‘passe’ and widely available).","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0004","quote":"\"somebody on on the on Twitter saying that their technology is passe.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0004","quote":"\"Is it, is it already become commoditized\""}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0004_n3","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Отмечается сдвиг: в M&A этого года крупные сделки всё чаще возглавляют компании с женщинами-CEO; упоминается рост сообщества до 400 женщин-CEO.","text_en":"Shift noted: major M&A deals this year are increasingly led by women CEOs; a ‘sisterhood’ is cited as having 400 women CEOs.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0004","quote":"\"women CEOs have been doing on M &A this year with some of the biggest deals being women-led companies.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0004","quote":"\"There's now 400 women. CEOs in the sisterhood.\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0005_n1","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Сделка по приобретению может столкнуться с существенным антимонопольным/FTC-риском и затянуться на 6–18 месяцев.","text_en":"The acquisition deal may face significant antitrust/FTC risk and drag on for 6–18 months.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0005","quote":"there is a real uh competition, FTC risk here in terms of this not happening and going on for six months, 12 months, 18 months."}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0005_n2","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Покупатель утверждает, что цель сделки не может юридически выйти из существующего соглашения, и готов к судебным действиям.","text_en":"The buyer claims the target cannot legally exit the existing agreement and is prepared to take legal action.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0005","quote":"Pfizer also claims Mitzera cannot legally exit the existing agreement and is prepared to pursue legal actions."}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0005_n3","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"В M&A наблюдается эскалация конкурентных торгов: неожиданные контрофферы и публичные обвинения (в т.ч. в нарушении антимонопольных законов).","text_en":"M&A shows escalating competitive bidding: surprise counteroffers and public accusations (including antitrust-related).","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0005","quote":"Novo launched a surprise counteroffer of up to $9 billion"},{"chunk_id":"doc_8911e4a8257e_chunk_0005","quote":"Calling Novo's bid reckless and unprecedented, accusing it of trying to suppress competition and violate antitrust laws."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Сделка может столкнуться с антимонопольными рисками/вмешательством FTC; есть мнение, что «избежать» этого не получится, и FTC может изучать сделки даже без уведомления.","text_en":"The deal may face antitrust/FTC risk; an opinion says it can’t escape scrutiny and the FTC can review deals even without notification.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0006","quote":"\"I just can't see any way that this can escape it because the FTC doesn't have to ever be actually even notified.\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"У Novo проблемы с кандидатом Kegri/Tagrisema (GLP-1 amylin): слабее potency, не long-acting, были проблемы в клинических исследованиях (дозирование, dropouts), что подрывает конкурентное преимущество.","text_en":"Novo’s Kegri/Tagrisema (GLP-1 amylin) has issues: weaker potency, not long-acting, and clinical study problems (dosing, dropouts), undermining its edge.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0006","quote":"\"The potency of the amylin is weaker. It's not long-acting.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0006","quote":"\"They had some trouble with their clinical studies, the way the dosing worked, and dropouts.\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_8911e4a8257e","kind":"buyer_signal","text_ru":"Pfizer рассматривал Metzera как привлекательный актив/платформу с более широким toolset, чтобы «войти в obesity» и оставаться релевантным.","text_en":"Pfizer viewed Metzera as attractive due to a broader toolset to enter obesity and stay relevant.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0006","quote":"\"That Pfizer saw as attractive as a way to really get it in the size into obesity and be relevant.\""}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0007_n1","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Проблемы на крупном GMP-производстве в Индиане (Catalent) привели к жёстким регуляторным уведомлениям FDA и CMC-рискам, влияющим на одобрения препаратов.","text_en":"Issues at a large GMP facility in Indiana (Catalent) led to severe FDA notifications and CMC risks impacting drug approvals.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0007","quote":"\"over the last year, you know, they've started receiving Form 483s from the FDA.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0007","quote":"\"Two weeks ago, they got an official action indication. Classification, which is the most severe regulatory notification\""},{"chunk_id":"doc_8911e4a8257e_chunk_0007","quote":"\"both companies who have wound up receiving complete responses. Just due to the cattle in Indiana facility and the CMC issues\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0007_n2","doc_id":"doc_8911e4a8257e","kind":"buyer_signal","text_ru":"Инвесторы регулярно и массово спрашивают компании о наличии экспозиции к Catalent Indiana, что указывает на высокую значимость/боль для рынка.","text_en":"Investors repeatedly ask companies about exposure to Catalent Indiana, indicating high market concern.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0007","quote":"\"a question I get very, very frequently. From investors across all companies\""},{"chunk_id":"doc_8911e4a8257e_chunk_0007","quote":"\"literally every single meeting we had, investors asked, do you have any exposure to cattle in Indiana?\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0007_n3","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Компании начинают переходить к другим контрактным производителям, чтобы обойти проблемы на Catalent Indiana.","text_en":"Companies are starting to move to other manufacturers to work around issues at Catalent Indiana.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0007","quote":"\"companies are starting to move to other manufacturers to try to get around what's clearly a problem.\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0008_n1","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"Производственные проблемы (в т.ч. «collapse of cell manufacturing») — крупная и активно обсуждаемая на уровне бордов причина регуляторных отказов/даунсайда.","text_en":"Manufacturing issues (incl. “collapse of cell manufacturing”) are a major board-level concern and a significant driver of regulatory rejections/downside.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0008","quote":"\"the data from the 270 CRMs from the summer of FDA rejection letters and it's like 50 of them are manufacturing related\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0008_n2","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Идиосинкратическая гепатотоксичность в in vivo gene editing (ATTR) с поздним началом привела к паузе исследования и клиническому холду FDA; причина неизвестна.","text_en":"Idiosyncratic liver toxicity in an in vivo gene-editing ATTR program with late onset led to a trial pause and an FDA clinical hold; cause unknown.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0008","quote":"\"We don't know what caused it.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0008","quote":"\"required the trial to be paused for the company and then subsequently for the FDA to mandate a clinical trial hold\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0008_n3","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Информация о клинических проблемах может утекать/распространяться через X до официального анонса, что поднимает вопросы MNPI и рисков такого шаринга.","text_en":"Clinical issues may leak/spread on X before official announcements, raising MNPI and information-sharing risk questions.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0008","quote":"\"the liver tox issue was disclosed. On X\""},{"chunk_id":"doc_8911e4a8257e_chunk_0008","quote":"\"And it raises the question about an MNPI.\""}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"В TTR много сильных терапий, поэтому неудовлетворённая потребность небольшая.","text_en":"In TTR, there are many strong therapies, so the unmet need is relatively small.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0009","quote":"The one challenge with TTR is there's so many amazing therapies now."},{"chunk_id":"doc_8911e4a8257e_chunk_0009","quote":"So the unmet need is fairly kind of small."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"Набор пациентов в дерматомиозит сложно вести при IV-формате; из-за плохого набора остановили фазу 2.","text_en":"Dermatomyositis enrollment is hard with an IV format; Phase 2 was halted due to poor enrollment.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0009","quote":"enrolling patients in dermatomyositis is very hard if you have an IV"},{"chunk_id":"doc_8911e4a8257e_chunk_0009","quote":"they decided to halt enrollment in their phase two for their second pipeline product in DM because it just wasn't enrolling well with an IV."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Есть сложности экстраполировать данные из китайского датасета на глобальный.","text_en":"There are difficulties extrapolating data from a Chinese dataset to a global dataset.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0009","quote":"it was out of China, so there was some chain, some you know, difficulties extrapolating from a Chinese data set to a global data set."}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0010_n1","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Наблюдается «disconnect» между энтузиазмом врачей/пациентов/возможно big pharma к CAR‑T на конференции ACR и скепсисом инвесторов, что отражается в скромных оценках компаний.","text_en":"There is a disconnect between physician/patient (and possibly big pharma) enthusiasm for CAR-T at ACR and investor skepticism, reflected in modest company valuations.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0010","quote":"enormous disconnect between what we see and hear at a conference like ACR... and what uh investors are thinking"},{"chunk_id":"doc_8911e4a8257e_chunk_0010","quote":"these companies are trading at uh very modest valuations with a high degree of skepticism"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0010_n2","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"Склеродермия описывается как крайне трудное для лечения ревматологическое заболевание: формируется рубцовая ткань по всему телу, и «ничего» не может остановить прогрессирование активности болезни.","text_en":"Scleroderma is described as one of the hardest rheumatologic diseases to treat, with body-wide scar tissue and nothing that can stop disease activity progression.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0010","quote":"scleroderma, in particular, has probably been the most difficult rheumatologic disease to treat"},{"chunk_id":"doc_8911e4a8257e_chunk_0010","quote":"patients develop scar tissue throughout their body and there's nothing that can stop the promotion of that disease activity"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0010_n3","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"CAR‑T в тяжёлых ревматологических показаниях несут существенные барьеры: сложность и высокая стоимость.","text_en":"CAR-T in severe rheumatologic disorders faces major barriers: complexity and cost.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0010","quote":"they come with their complexity. There's no doubt they come with their cost."}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0011_n1","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"У компании быстро сокращается кэш из‑за необходимости финансировать идущие клинические испытания; возникает риск необходимости привлечения капитала.","text_en":"Cash is rapidly dwindling due to ongoing trial financing needs, creating risk of needing to raise money.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0011","quote":"a very rapidly dwindling cash and the risk that they would need to raise money."},{"chunk_id":"doc_8911e4a8257e_chunk_0011","quote":"it's got trials that are going on that it needs to finance"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0011_n2","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Есть научная/дизайнерская неопределённость: неясно, даёт ли mRNA-вакцина от рака специфическую пользу или эффект обусловлен широкой врождённой иммунной активацией; критикуется отсутствие адекватного контроля.","text_en":"Scientific/design uncertainty: unclear whether mRNA cancer vaccine benefit is antigen-specific or broad innate immune activation; lack of proper control arm is criticized.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0011","quote":"the jury's still out whether an mRNA vaccine for cancer is genuinely driving a benefit"},{"chunk_id":"doc_8911e4a8257e_chunk_0011","quote":"there should be a control arm in here or at least in the placebo group of an of an unrelated mRNA"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0011_n3","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Потенциальное M&A/покупка технологии затруднены: mRNA-технология описывается как «довольно рискованная и дорогая в поддержании», что делает приобретение «довольно трудным».","text_en":"M&A is constrained: the mRNA technology is described as risky and expensive to maintain, making acquisition difficult.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0011","quote":"technology that's still fairly risky and expensive to maintain, I think is going to be fairly tough."}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0012_n1","doc_id":"doc_8911e4a8257e","kind":"trend","text_ru":"Ожидается возобновление крупных M&A (big-to-big mergers) в фарме в ближайшие месяцы, включая сделки на десятки миллиардов.","text_en":"A resurgence of big-to-big pharma M&A is predicted in the next few months, including mid-to-high double-digit billion deals.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0012","quote":"\"my prediction is that we will see that in the next three plus months.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0012","quote":"\"You're going to see large companies in the mid to high double-digit billions being bought or merged\""}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0012_n2","doc_id":"doc_8911e4a8257e","kind":"opportunity","text_ru":"Возможность использовать «экзуберантно» оценённые акции/капитализацию для приобретения компаний и диверсификации рисков платформы (пример: mRNA).","text_en":"Opportunity to use exuberantly valued equity/market cap to acquire companies and diversify platform risk (e.g., mRNA).","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0012","quote":"\"when you have a stock price... exuberantly valued, you should take advantage of it.\""},{"chunk_id":"doc_8911e4a8257e_chunk_0012","quote":"\"leverage their let's just say exuberantly priced equity to buy some other companies.\""}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0012_n3","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Научные результаты и успешные экзиты в biotech носят стохастический характер; «тройное попадание» (талант + научный результат + exit) трудно достижимо и часто зависит от удачи.","text_en":"Biotech outcomes and exits are stochastic; hitting talent + scientific success + exit is hard and often depends on luck.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0012","quote":"\"The stochastic nature of the science that we do\""},{"chunk_id":"doc_8911e4a8257e_chunk_0012","quote":"\"that's a pretty hard thing to get the triple bullseye on\""}],"confidence":"high"}
{"nugget_id":"nugget_001","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"В biotech/наукоёмких проектах проверка, работает ли наука, занимает 6–8 лет, что усложняет оценку качества лидеров и решений.","text_en":"In biotech/science-heavy projects, it can take 6–8 years to know if the science works, complicating evaluation of leaders and decisions.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0013","quote":"it takes six to eight years to report out on whether the science works"}],"confidence":"high"}
{"nugget_id":"nugget_002","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"Смена CEO часто откладывается (особенно во время финансирования или BD), хотя признаки необходимости замены видны заранее; это может вредить компании.","text_en":"CEO changes are often delayed (especially during financing or BD) even though signals are visible earlier; this can hurt the company.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0013","quote":"The signals that you likely need a CEO change are visible far before you make the decision."},{"chunk_id":"doc_8911e4a8257e_chunk_0013","quote":"You're in the midst of financing. Don't want to change. While we're financing, or you're in the midst of a BD discussion"}],"confidence":"high"}
{"nugget_id":"nugget_003","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"Совет директоров может не иметь хорошего «пульса» происходящего в компании и не вести правильные обсуждения, что затрудняет своевременные управленческие решения.","text_en":"Boards may lack a good pulse on what’s happening and may not have the right discussions, hindering timely management decisions.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0013","quote":"Do boards do most boards really have a good pulse as to what's going on and do they really have the right discussions or not?"}],"confidence":"medium"}
{"nugget_id":"doc_8911e4a8257e_chunk_0014_n1","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"Советы директоров часто избегают «неудобных» разговоров (компенсации, цели/перформанс, cash burn, аллокация ресурсов) и не хотят «раскачивать лодку», что снижает качество надзора.","text_en":"Boards often avoid uncomfortable discussions (comp, objectives/performance, cash burn, resource allocation) and don’t want to “rock the boat,” weakening oversight.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0014","quote":"boards don't want to rock the boat. You know, that's super common."},{"chunk_id":"doc_8911e4a8257e_chunk_0014","quote":"being tough on compensation discussions, being tough on objectives, performance, digging into the details of cash burn"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0014_n2","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"В small-cap публичных биотеках проблема — потеря ролей крупных owner-director; в совете может не быть крупных владельцев, из-за чего меньше обсуждают разводнение и корректную аллокацию ресурсов.","text_en":"In small-cap public biotechs, losing large owner-director roles can leave boards without large owners, reducing discussion of dilution and proper resource allocation.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0014","quote":"you lose large owner-director roles. And I think that's a huge problem in small cap public biotechs"},{"chunk_id":"doc_8911e4a8257e_chunk_0014","quote":"there really aren't any large owners in a bunch of those companies' boardrooms"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0014_n3","doc_id":"doc_8911e4a8257e","kind":"pain","text_ru":"В ранней клинике при неожиданных данных часто начинается «hand waving» и попытки задним числом объяснить/изменить гипотезу, что мешает принятию no-go решений; truth-seeking подход помогает выравнивать ожидания.","text_en":"In early clinical stages, unexpected data can trigger “hand waving” and retroactive hypothesis shifts, hindering no-go decisions; truth-seeking helps alignment.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0014","quote":"when you're getting data that doesn't look like what you thought it would look like"},{"chunk_id":"doc_8911e4a8257e_chunk_0014","quote":"the data comes, and then the hand waving starts, and the hand waving moves really, really fast"}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0015_n1","doc_id":"doc_8911e4a8257e","kind":"opportunity","text_ru":"Есть возможность для спонсорства ежегодного офлайн-нетворкинг-ивента на J.P. Morgan; организаторы приглашают потенциальных спонсоров связаться с ними.","text_en":"Sponsorship opportunity for an annual in-person networking event at J.P. Morgan; organizers invite potential sponsors to reach out.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0015","quote":"\"if you are interested in sponsoring and have not yet reached out, please reach out to team at biotechhangout. com.\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0015_n2","doc_id":"doc_8911e4a8257e","kind":"buyer_signal","text_ru":"Сигнал готовности платить: спонсоры оплачивают напитки на мероприятии.","text_en":"Willingness-to-pay signal: sponsors cover the drinks at the event.","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0015","quote":"\"It's completely open and the sponsors pay for the drinks.\""}],"confidence":"high"}
{"nugget_id":"doc_8911e4a8257e_chunk_0015_n3","doc_id":"doc_8911e4a8257e","kind":"constraint","text_ru":"Решения по финальным спонсорским пакетам/выбору ко-спонсоров будут приняты в ближайшее время (на этой неделе/в течение следующей недели).","text_en":"Sponsorship decisions are being finalized soon (this week / next week).","evidence":[{"chunk_id":"doc_8911e4a8257e_chunk_0015","quote":"\"We're going to be making final sort of sponsorship decisions this week. In the next week or so.\""}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0000_n1","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"В биотех-секторе сохраняется волатильность на фоне earnings, новостей, клинических данных и M&A.","text_en":"Biotech remains volatile amid earnings, news, clinical data updates, and M&A.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0000","quote":"\"it's certainly been a bit of a helter-skelter week with earnings, news, clinical data news, M &A updates, but things in biotech continue to be volatile.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0000_n2","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Новости вокруг ухода главы CEDAR (George Tidmarsh) создают неопределённость на рынках и усиливают неопределённость вокруг FDA.","text_en":"News around CEDAR head George Tidmarsh’s departure creates market uncertainty and adds to FDA uncertainty.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0000","quote":"\"I think that it's created a lot of uncertainty in the markets, clearly.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0000","quote":"\"uncertainty with FDA\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0000_n3","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Среди инвесторов растёт обеспокоенность на фоне новостей о Tidmarsh и решения по Unicure.","text_en":"Investor concern is rising following Tidmarsh news and the Unicure decision.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0000","quote":"\"one of the things that I've heard a lot from investors.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0000","quote":"\"It is this elevation of concern among investors\""}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Инвесторы обеспокоены тем, что FDA становится менее предсказуемым в этой области.","text_en":"Investors are concerned the FDA is becoming more unpredictable in this area.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0001","quote":"It is this elevation of concern among investors"},{"chunk_id":"doc_bb60a3212f27_chunk_0001","quote":"it just makes the FDA seem super unpredictable in this space."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Ограничения доказательной базы: небольшой размер выборки и отсутствие отделения от плацебо на 1 году, что делает данные предметом споров.","text_en":"Evidence limitations: small sample size and no separation from placebo at one year, making the data debatable.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0001","quote":"It's not a big sample. We know the study didn't separate from placebo at one year."},{"chunk_id":"doc_bb60a3212f27_chunk_0001","quote":"it's still, I think, reasonable, no matter how bullish you are, that you can debate those data"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Непрозрачность регуляторных взаимодействий: внешние наблюдатели не видят деталей встреч/минут, что усложняет понимание решений FDA.","text_en":"Opacity of regulatory interactions: outsiders don’t see meeting details/minutes, complicating understanding of FDA decisions.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0001","quote":"none of us were in the meeting, right? ... I haven't seen meeting minutes."}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0002_n1","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"FDA, по словам спикера, считает анализ natural history «exploratory», т.к. он не был целью исследования с самого начала, и он «не может поддержать» подачу BLA.","text_en":"FDA reportedly views the natural history analysis as exploratory (not pre-specified as a study goal) and not supportive of a BLA submission.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0002","quote":"\"this natural history analysis, actually, because it wasn't the goal of the study from the outset, is actually exploratory and not something that can support a BLA submission.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0002_n2","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"В gene therapy пространстве есть компании, которые ведут single-arm Phase 3, и часть из них подчёркивает, что они «pre-specified this from the beginning».","text_en":"In gene therapy, multiple companies are running single-arm Phase 3 studies, and some emphasize they pre-specified key elements from the start.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0002","quote":"\"there's a number of other companies in this space that are running single arm phase three studies.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0002","quote":"\"we've sort of pre-specified this from the beginning.\""}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0002_n3","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Неопределённость и «динамичность» регуляторной среды: «всё меняется в реальном времени», и инвесторы спрашивают про последствия и следующий «catalyst».","text_en":"Regulatory uncertainty/dynamism: things are changing in real time, and investors are asking about implications and the next catalyst.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0002","quote":"\"all these things are changing in real time.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0002","quote":"\"investors kind of asking, OK, well, what are the implications for for everybody else?\""}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0003_n1","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Есть неопределённость из‑за отсутствия доступа к деталям встречи/данным: участники обсуждения признают, что «не были на встрече» и могут не видеть нюансы данных.","text_en":"Uncertainty due to lack of access to meeting/data details: speakers note they weren’t in the meeting and may be missing data nuances.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0003","quote":"\"none of us were in the meeting. We don't know if there's something else about this data.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0003_n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Для подачи/рассмотрения потребуется проводить sensitivity analyses и сравнивать методологии анализа с natural history (разные базы/кохорты).","text_en":"Filing/review would require sensitivity analyses and comparing analytical methods against natural history cohorts/databases.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0003","quote":"\"They're going to have to do, if this ever gets filed, sensitivity analyses\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0003_n3","doc_id":"doc_bb60a3212f27","kind":"opportunity","text_ru":"Запрос на «radical transparency»: предлагается публиковать minutes прошлых встреч/договорённости/указания FDA, чтобы прояснить ситуацию.","text_en":"Call for “radical transparency”: suggestion to publish meeting minutes/past agreements/FDA guidance to clarify the situation.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0003","quote":"\"it would be great to see all those meeting minutes\""}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0004_n1","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Смена тона/подхода руководства CBER/FDA воспринимается как сдвиг от большей гибкости к большей негибкости, что влияет на решения ревью-команд.","text_en":"A perceived leadership tone shift at CBER/FDA from flexibility to inflexibility is affecting review team behavior and decisions.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0004","quote":"\"I just wonder, is it just the tone from leadership in the FDA that's shifting things?\""},{"chunk_id":"doc_bb60a3212f27_chunk_0004","quote":"\"review teams feel emboldened one way or another, based on sort of of the leadership mentality\""}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0004_n2","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Компании сталкиваются с неожиданным изменением требований в процессе подачи/ревью: ранее согласованный план может быть пересмотрен, что приводит к внезапному CRL и требованию закрыть вопросы заранее.","text_en":"Companies face unexpected requirement changes during filing/review: previously agreed plans can shift, leading to surprise CRLs and demands to resolve issues upfront.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0004","quote":"\"the bar—of an agreement they had with the previous CBER under Peter Marks... then shifted under this new FDA\""},{"chunk_id":"doc_bb60a3212f27_chunk_0004","quote":"\"Ultimately, the carpet was pulled below them and they got a CRL out of nowhere.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0004_n3","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Есть диссонанс между публичной риторикой/гайдлайнами FDA (воспринимаются как «bullish» и гибкие) и фактическими действиями, которые выглядят более жесткими, что создает неопределенность для разработчиков.","text_en":"There is a mismatch between FDA’s public commentary/guidelines (seen as bullish/flexible) and actions that appear more stringent, creating uncertainty for developers.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0004","quote":"\"their kind of public commentary on this stuff is super flexible\""},{"chunk_id":"doc_bb60a3212f27_chunk_0004","quote":"\"It's the dissonance between the commentary... versus the actions that we're seeing\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0005_n1","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Несоответствие между публичными заявлениями руководства FDA о «гибкости» и практикой/подходом дивизионов, которые хотят применять «старую школу» и строгие требования.","text_en":"Mismatch between FDA leadership’s public messaging about “flexibility” and divisions’ practice favoring old-school rigor.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0005","quote":"there was always this disconnect between what the hierarchy was doing—rah-rah, we're flexible...— and the divisions who wanted to go old school. And apply that rigor."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0005_n2","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Наблюдался «медленный сдвиг» в сторону accelerated approval и редких заболеваний, при этом отмечается, что «маятник может качнуться обратно».","text_en":"A slow creep toward accelerated approval and rare disease, with the caveat that the pendulum can swing back.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0005","quote":"we did see this slow creep with accelerated approval, rare disease, that pendulum can always swing back."}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0005_n3","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Перевод заявленной «гибкости» регулятора в реальную практику занимает время и, по мнению некоторых, так и не был полностью реализован.","text_en":"Translating stated regulatory “flexibility” into practice takes time and may never be fully realized.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0005","quote":"translating that into practice is what. has taken time. Some would say it never fully was realized"}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0006_n1","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Крупное и длительное Phase 3 исследование в DMD провалилось; обсуждается, что метод exon-skipping/PMO может не работать.","text_en":"A large, long Phase 3 DMD study failed; discussion suggests exon-skipping/PMO may not work.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0006","quote":"\"they announced the failure of a large phase three study.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0006","quote":"\"it's kind of like a wake-up moment for me. Like, I don't think it worked.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0006_n2","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"В DMD менялись «лучшие» клинические эндпоинты (6MWT → North Star → stair), и каждый из них «проваливался», что указывает на сложности с доказательством эффективности.","text_en":"DMD trials shifted “best” endpoints (6MWT → North Star → stair) and each failed, highlighting difficulty demonstrating efficacy.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0006","quote":"\"we went from. the six-minute walk test was the most was the best endpoint.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0006","quote":"\"And then we went to the North Star. The North Star is the best endpoint. And that failed.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0006_n3","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Непредсказуемость и «flip-flopping» регулятора (FDA) воспринимаются как вредные; инвесторам сложно из‑за непредсказуемых регуляторных исходов.","text_en":"Regulatory unpredictability/flip-flopping at FDA is seen as harmful; investors struggle due to unpredictable regulatory outcomes.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0006","quote":"\"the uncertainty, the kind of flip-flopping or the, you know, just unpredictability is not helpful.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0006","quote":"\"whatever you think of the data, like that was not predictable\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0007_n1","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Инвесторам сложно доверять публичным заявлениям (например, в подкастах) и понимать, соответствуют ли они реальности.","text_en":"Investors struggle to trust public statements (e.g., podcasts) and assess whether they reflect the truth.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0007","quote":"people don't know if what's being said publicly on a podcast is really like the truth."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0007_n2","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Инвесторы сомневаются, реальна ли «согласованность» компании с FDA после встреч (что именно сказал FDA), и это воспринимается как вредное для индустрии.","text_en":"Investors doubt whether company-FDA alignment after meetings is real, which is seen as harmful for the industry.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0007","quote":"investors are asking me, like, 'Hey, the company has met with the FDA and the FDA said X or Y."},{"chunk_id":"doc_bb60a3212f27_chunk_0007","quote":"they're worried like is that alignment real?' And I just think that in itself is not good for the industry."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0007_n3","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Задержки из‑за пересогласования/переработки дизайна клинического исследования приводят к более долгому получению данных и чтению результатов.","text_en":"Trial redesign/renegotiation delays lead to longer timelines to obtain data and readouts.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0007","quote":"they renegotiated the trial design. They didn't start it until much later."},{"chunk_id":"doc_bb60a3212f27_chunk_0007","quote":"it was delayed. So we shouldn't have to take this long. To get a readout"}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0008_n1","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Разочарование из‑за отсутствия убедительной эффективности и неполноты раскрытых данных; для решения нужен полный датасет.","text_en":"Disappointment with lack of convincing efficacy and incomplete data disclosure; need the full dataset to decide.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0008","quote":"\"I thought. That the drug would show in effect. I think it hasn't.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0008","quote":"\"I would want to see the full dataset to make any decision.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0008_n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Для генной терапии есть ограничение: пациенты могут потерять возможность получить более эффективную генную терапию в будущем из‑за рисков иммуногенности.","text_en":"Gene therapy constraint: patients may be unable to receive better future gene therapy without significant immunogenicity risk.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0008","quote":"\"you may have to factor out patients who will not be able to get a better gene therapy down the road without taking significant risk with immunogenicity\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0008_n3","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Риск барьера по возмещению: страховщики могут отказаться оплачивать лечение при недостаточной доказательной базе, что ведёт к оплате из кармана семей.","text_en":"Reimbursement barrier: insurers may refuse coverage when evidence is insufficient, pushing families to pay out of pocket.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0008","quote":"\"Are the insurers having more of a position to say, 'We're not going to reimburse because the evidence isn't there?'\""},{"chunk_id":"doc_bb60a3212f27_chunk_0008","quote":"\"these poor families are going to have to pay out of pocket.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0009_n1","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"FDA и биостатистики указывают на проблемы и смещения (biases) при использовании matched natural history cohort и сравнении с open-label extension данными; это снижает доверие к эффекту.","text_en":"FDA/biostatisticians highlight problems and biases in matched natural history cohorts vs open-label extension comparisons, reducing confidence in effect size.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0009","quote":"\"just the problems with natural history and the biases that can be introduced.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0009","quote":"\"they just can't look at this three year open label natural history comparison data set and have real confidence that the effect size is real.\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0009_n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Даже при заявленном достижении первичных и вторичных конечных точек, заявка на одобрение может получить CRL из‑за статистических допущений/тестов (tipping point analyses), при которых результаты перестают быть статистически значимыми.","text_en":"Even with claimed primary/secondary endpoint hits, an approval filing can receive a CRL due to statistical assumptions/tipping point analyses where significance fails.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0009","quote":"\"Statistical analysis that they did— you know— hit on primary endpoint. It hit on all secondary endpoints.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0009","quote":"\"when you do certain tipping point analyses around. the assumptions they they wind up failing um statistically\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0009_n3","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Негативные регуляторные новости (CRL/новости по компании) приводят к резким распродажам акций в секторе.","text_en":"Negative regulatory news (e.g., CRL/company news) can trigger sharp biotech stock sell-offs.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0009","quote":"\"Well, the stock got hammered.\""},{"chunk_id":"doc_bb60a3212f27_chunk_0009","quote":"\"stoke therapeutics, which sold off on the heels of the unicure news.\""}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0010_n1","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"После выхода нового draft guidance FDA по использованию natural history/биомаркеров/real-world data для одобрений orphan без контролируемых исследований ситуация стала «train wreck» и «seesaw», что воспринимается негативно для индустрии.","text_en":"After FDA’s new draft guidance on natural history/biomarkers/RWD for orphan approvals without controlled studies, the situation became a “train wreck”/“seesaw,” seen as negative for the industry.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0010","quote":"about three months ago that FDA came out with a new draft guidance... can support an approval for orphan indications without controlled studies. Since then, it's been a little bit of a train wreck."},{"chunk_id":"doc_bb60a3212f27_chunk_0010","quote":"this kind of seesaw situation, obviously, is sort of not a positive for the industry."}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0010_n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Подача на одобрение на основе данных фазы 1–2 для ASO в DEE описывается как «очень сложная», особенно при сравнении с natural history и стремлении к более широкому лейблу с нейрокогнитивными эндпоинтами.","text_en":"Filing for approval based on Phase 1–2 data for ASOs in DEEs is described as very complicated, especially versus natural history and when seeking broader neurocognition labeling.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0010","quote":"filing based on phase one or phase two data is very complicated."},{"chunk_id":"doc_bb60a3212f27_chunk_0010","quote":"If you really want to get a broad label with neurocognition, you're going to be looking against natural history."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0010_n3","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Различия в дозировании между US/UK исследованиями и фазой 3 создают проблему выбора дозы для лейбла и «структурные» вопросы для регистрации.","text_en":"Dose differences across US/UK studies and Phase 3 create a labeling problem (which dose to put on label) and broader structural issues for approval.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0010","quote":"The dosing in the US study versus the European, the UK study was different... even different than what they were doing in the phase three."},{"chunk_id":"doc_bb60a3212f27_chunk_0010","quote":"So which dose do you even suggest to put on the label? There's some structural issues"}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0011_n1","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Несогласованность дозировок между US/UK/Европой и Phase 3 создаёт проблему выбора дозы для инструкции (label) и структурные риски для регистрации.","text_en":"Dose differences across US vs UK/Europe and Phase 3 create a labeling-dose selection problem and structural risks for approval/filing.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0011","quote":"The dosing in the US study versus the European, the UK study was different."},{"chunk_id":"doc_bb60a3212f27_chunk_0011","quote":"So which dose do you even suggest to put on the label? There's some structural issues"}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0011_n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Подача на одних ранних данных воспринимается как сложная и высокорисковая; есть неопределённость, примет ли FDA заявку и как интерпретировать «review decision».","text_en":"Filing on early data is seen as difficult and high-risk; uncertainty exists about FDA acceptance and how to interpret a 'review decision'.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0011","quote":"it's always difficult to to file on on early data like that."},{"chunk_id":"doc_bb60a3212f27_chunk_0011","quote":"You can file if you really want to. We'll see if we even accept it."},{"chunk_id":"doc_bb60a3212f27_chunk_0011","quote":"what exactly that means for Wall Street, that's completely opaque."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0011_n3","doc_id":"doc_bb60a3212f27","kind":"buyer_signal","text_ru":"Инвесторы реагировали на возможность более ранней подачи/одобрения и ожидали апдейта о встрече с FDA; была надежда на «green light».","text_en":"Investors responded to the possibility of earlier filing/approval and anticipated an update about an FDA meeting, hoping for a 'green light'.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0011","quote":"started kind of talking about this possibility of the early filing."},{"chunk_id":"doc_bb60a3212f27_chunk_0011","quote":"that really resonated with investors."},{"chunk_id":"doc_bb60a3212f27_chunk_0011","quote":"there was some hope that they've already met with FDA and had the green light."}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0012_n1","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Сдвиг рынка инвестиций в биотехе: после ~5 лет «рынка покупателя» (инвесторы диктовали условия) появляются сигналы конкуренции за качественные активы (bidding wars).","text_en":"Shift in biotech financing dynamics: after ~5 years of a buy-side market (investors dictating terms), there are signals of competition for good assets (bidding wars).","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0012","quote":"we've been five years in, you know, what was ultimately a buy-siders market for investment. Meaning that the investors would dictate the terms"}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0012_n2","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Ожидание продолжения robust M&A из‑за «patent cliffs», особенно для активов с ясным клиническим proof of concept и высокой вероятностью одобрения.","text_en":"Expectation that robust M&A will continue due to patent cliffs, especially for assets with clear clinical proof of concept and perceived path to approval.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0012","quote":"I think the patent clips are real. I think this is why we've seen some robust M&A. I think it will continue for assets that have clear clinical proof of concept."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0012_n3","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Индустрия сильнее ориентируется на решения FDA (а не на guidance), и эти решения «guiding all of us».","text_en":"Industry pays close attention to FDA decisions (more than guidance), and those decisions guide behavior.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0012","quote":"industry really looks at these decisions. Less so than guidance, right? What is the FDA calling on all of these? And that's guiding all of us."}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0013_n1","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Arena Bioworks внезапно закрылась из‑за проблем с финансированием и отсутствия «пути вперёд» на сложном рынке частного финансирования.","text_en":"Arena Bioworks shut down due to financing issues and no clear path forward in a difficult private financing market.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0013","quote":"\"shut down essentially over, you know, basically over financing\""},{"chunk_id":"doc_bb60a3212f27_chunk_0013","quote":"\"because of the difficult financing market these days, particularly for private companies, they didn't see a way forward\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0013_n2","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Seed и Series A инвестиции в этом году находятся на 10‑летнем минимуме; деньги смещаются в более поздние, data-driven раунды (Series B/C/D).","text_en":"Seed and Series A are at a 10-year low this year; capital is shifting to later-stage, data-driven Series B/C/D rounds.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0013","quote":"\"seed and Series A investments, it's been essentially at a 10-year low\""},{"chunk_id":"doc_bb60a3212f27_chunk_0013","quote":"\"most of the money has been going into de-risk later-stage clinical data-driven biotech Series Bs, Cs, and Ds\""}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0013_n3","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Модель «приватизировать лучшую академическую науку» и превращать её в прибыльную инвестиционную модель воспринимается как сомнительная, потому что drug discovery сложен и «не лёгок» для генерации доходности.","text_en":"The model of privatizing top academic science into a profitable investment engine is seen as dubious because drug discovery is hard to monetize.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0013","quote":"\"Turning it into an investment profitable model, which many of us felt that was a dubious goal, because drug discovery is not easy.\""}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0014_n1","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Рынок капитала/IPO, по мнению спикера, сейчас больше поддерживает более поздние, «de-risked» компании; ранним программам (особенно по новым невалидированным мишеням в доклинике) деньги могут начать поступать позже.","text_en":"Capital markets/IPO are seen as favoring later-stage de-risked companies; early programs (especially novel unvalidated preclinical targets) may see funding later.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0014","quote":"more of the de-risked later stage companies, maybe further in the clinic, maybe close to, you know, phase two, phase three."},{"chunk_id":"doc_bb60a3212f27_chunk_0014","quote":"best in class, I think has a better chance of getting early money than a new unvalidated novel target"}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0014_n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Есть ограничение/сомнение в доказательности: randomized withdrawal study может иметь больше потенциального bias, чем treatment initiation RCT, что влияет на уверенность в данных.","text_en":"Evidence constraint: randomized withdrawal studies may have more potential bias than treatment initiation RCTs, affecting confidence in the data.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0014","quote":"there's obviously debates about how much confidence one can have in a randomized withdrawal study."},{"chunk_id":"doc_bb60a3212f27_chunk_0014","quote":"There's more potential bias at play there than in a treatment initiation RCT."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0014_n3","doc_id":"doc_bb60a3212f27","kind":"pain","text_ru":"Для Soleno описывается проблема восприятия безопасности: в short report утверждается накопление нежелательных явлений (в т.ч. гипергликемия/отеки) с госпитализациями, из-за чего пациенты прекращают/не хотят терапию, а врачи становятся более осторожными.","text_en":"Perceived safety issue: a short report claims accumulating AEs (e.g., hyperglycemia/edema) leading to hospitalizations, reducing patient uptake and increasing physician hesitancy.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0014","quote":"claiming that you were seeing— adverse events stack up, in particular, hyperglycemia and peripheral edema and pulmonary edema, leading to hospitalizations"}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0015_n1","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Врачи становятся всё более осторожными/неохотно назначают препарат, есть ожидание, что пациенты могут прекращать приём.","text_en":"Physicians are increasingly hesitant to prescribe the drug, with expectations that patients may stop taking it.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0015","quote":"Physicians are being more and more hesitant to put patients on the drug."},{"chunk_id":"doc_bb60a3212f27_chunk_0015","quote":"patients are going to stop taking the drug, that physicians are not going to prescribe the drug."}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0015_n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Инвесторы обеспокоены риском коммерческого плато после нескольких сильных кварталов; требуется время, чтобы доказать отсутствие плато.","text_en":"Investors worry about a commercial plateau after a few strong quarters; it may take time to show the plateau won’t occur.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0015","quote":"people are are now concerned that you know is this a a drug that has a couple of good quarters and then kind of runs into a plateau."},{"chunk_id":"doc_bb60a3212f27_chunk_0015","quote":"Are a little worried that it's going to take time to really show that the plateau isn't going to occur in another quarter or two."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0015_n3","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Управленческая коммуникация на колле: инвесторов отталкивает публичное упоминание short report/шортов; это влияет на готовность брать риск по бумаге.","text_en":"On-call communications: publicly calling out shorts/short report can turn investors off and reduce willingness to take risk.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0015","quote":"one of the things I think really turned people off is they they sort of cited the short report in the call."},{"chunk_id":"doc_bb60a3212f27_chunk_0015","quote":"Management 101 recommendation would be. Do not publicly call out the shorts."}],"confidence":"medium"}
{"nugget_id":"doc_bb60a3212f27_chunk_0016_n1","doc_id":"doc_bb60a3212f27","kind":"trend","text_ru":"Оrexin-направление в терапии нарушений сна остаётся «горячим» и вызывает высокий интерес; ожидаются новые клинические датасеты (в т.ч. более крупное/длительное Phase 2 в нарколепсии типа 2).","text_en":"Orexin-focused sleep-disorder therapeutics remain a “hot” area; new clinical datasets are upcoming (incl. a larger/longer Phase 2 in narcolepsy type 2).","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0016","quote":"this orexin space has continued to be super hot and interesting."},{"chunk_id":"doc_bb60a3212f27_chunk_0016","quote":"we're going to get a bigger, longer phase two narcolepsy type two data set from Alkermes."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0016_n2","doc_id":"doc_bb60a3212f27","kind":"constraint","text_ru":"Есть неопределённость по эффективности orexin-препаратов вне нарколепсии типа 1: для типа 2 и других показаний биологическое обоснование «менее ясное», а ранние небольшие исследования могут «регрессировать к среднему» в Phase 2/3.","text_en":"Efficacy outside narcolepsy type 1 is less clear; for type 2/other indications rationale is less clear-cut, and small early studies may regress to the mean in Phase 2/3.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0016","quote":"we gonna see efficacy outside of narcolepsy type one... type two and other indications like idiopathic hyper insomnia, it's less clear-cut."},{"chunk_id":"doc_bb60a3212f27_chunk_0016","quote":"smaller phase one type studies, which regress a little bit to the mean in phase two and phase three."}],"confidence":"high"}
{"nugget_id":"doc_bb60a3212f27_chunk_0016_n3","doc_id":"doc_bb60a3212f27","kind":"buyer_signal","text_ru":"Инвесторы активно обсуждают данные по Turns Pharmaceuticals в CML; сильные ранние результаты (64% 6-месячный MMR) сопровождались резким ростом акции (более чем вдвое за неделю), при этом подчёркивается малый размер датасета и ожидание апдейта на ASH.","text_en":"Investors are actively debating Turns’ CML data; strong early results (64% 6‑month MMR) coincided with the stock more than doubling in a week, with a small dataset and an ASH update pending.","evidence":[{"chunk_id":"doc_bb60a3212f27_chunk_0016","quote":"Lots of debates amongst investors"},{"chunk_id":"doc_bb60a3212f27_chunk_0016","quote":"six-month MMR data of 64 percent"},{"chunk_id":"doc_bb60a3212f27_chunk_0016","quote":"The stock has more than doubled since the beginning of the week."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0000_n1","doc_id":"doc_4077b10d9cd7","kind":"pain","text_ru":"Есть обеспокоенность индустрии стабильностью в FDA; для успеха в выводе инноваций нужна «сильная и стабильная и последовательная» FDA.","text_en":"Industry is concerned about FDA stability; success in bringing innovation requires a strong, stable, consistent FDA.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0000","quote":"\"industry concerns around stability. At the FDA\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0000","quote":"\"We all need a strong and stable and consistent FDA for us to be able to be successful\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0000_n2","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"В последние 9–11 месяцев почти каждую неделю появляются новости по policy/FDA.","text_en":"For the last 9–11 months, there has been weekly policy/FDA news.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0000","quote":"\"Last, you know, nine, 10, 11 months, it's been every week has got some new piece of news on the policy or FDA side.\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0000_n3","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Назначение Rick Pazder директором CDER воспринимается как «хорошие новости» и «стабилизирующая сила» для индустрии.","text_en":"Rick Pazder’s selection as CDER director is viewed as good news and a stabilizing force for industry.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0000","quote":"\"the good news this week, earlier this week, was that Rick Pazder agreed to step in as the new Cedar director.\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0000","quote":"\"it's definitively good news. You know, PASDR is one that we all wanted as a stabilizing force.\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0001_n1","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"FDA обсуждает/описывает «plausible mechanism pathway» (в NEJM) как подход, ориентированный на персонализированные gene/cell терапии, с намерением расширить на антитела и малые молекулы.","text_en":"FDA discusses a “plausible mechanism pathway” (NEJM) aimed at bespoke gene/cell therapies, with intent to extend to antibodies and small molecules.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0001","quote":"It is stipulated to go into a bespoke, personalized therapies that are gene therapy and cell therapy— sort of, you know, focused."},{"chunk_id":"doc_4077b10d9cd7_chunk_0001","quote":"But it's got the intention to get brought into antibodies and small molecules."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0001_n2","doc_id":"doc_4077b10d9cd7","kind":"opportunity","text_ru":"Путь предполагает возможность использовать данные single-patient expanded access и даже «несколько последовательных успешных пациентов» как потенциальную основу для маркетингового разрешения (хотя это описано как «vague/aspirational»).","text_en":"Pathway suggests using single-patient expanded access and even several consecutive successful patients as potential basis for marketing authorization (described as vague/aspirational).","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0001","quote":"The goal is to even have single patient sort of expanded access to generate sufficient data to support marketing approvals."},{"chunk_id":"doc_4077b10d9cd7_chunk_0001","quote":"even if you can start with one patient and have several consecutive patients that are successful, that could lead to marketing authorization."}],"confidence":"medium"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0001_n3","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Описываемый pathway назван «ambitious» и «a little vague», и прямо отмечено, что значение «platform technology» для персонализированного продукта «unclear».","text_en":"The pathway is described as ambitious and a bit vague; the meaning of “platform technology” for a personalized product is stated as unclear.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0001","quote":"it's ambitious um it's a little vague which is okay at this stage"},{"chunk_id":"doc_4077b10d9cd7_chunk_0001","quote":"Then they talk about you can use that as a platform technology for a personalized product... Exactly what that means. It's unclear."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0002_n1","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Неясно, насколько широко данные от одного пациента/нескольких пациентов/платформы могут привести к регуляторному одобрению; требуется прояснение в руководствах.","text_en":"Unclear how broadly data from one patient/few patients/platform can support regulatory approval; needs clarification in guidance.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0002","quote":"\"Where it's a little confusing is exactly how broad can one patient really lead to approval?\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0002","quote":"\"It'll be probably really important to see how it gets written into guidelines ultimately\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0002_n2","doc_id":"doc_4077b10d9cd7","kind":"pain","text_ru":"Есть риск, что неправильная имплементация подхода приведёт к провалам по безопасности/эффективности и откату инициативы.","text_en":"Risk that inappropriate implementation could cause safety/efficacy failures and set back the initiative.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0002","quote":"\"if it's used inappropriately, then it could lead to.\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0002","quote":"\"safety or efficacy failures and maybe that could sort of. put a setback\""}],"confidence":"medium"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0002_n3","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Наблюдается разрыв между «громкими» регуляторными политиками и их фактическим исполнением; растёт обеспокоенность отсутствием стабильной и последовательной регуляторной линии.","text_en":"Growing gap between headline regulatory policies and actual execution; increasing concern about lack of stable, consistent regulatory approach.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0002","quote":"\"there's a headline policy that people really seem to like and are excited by.\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0002","quote":"\"the actual execution, from a regulatory standpoint, seems to run counter to that\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0003_n1","doc_id":"doc_4077b10d9cd7","kind":"pain","text_ru":"Участники индустрии ищут большей последовательности в регуляторных разъяснениях и действиях.","text_en":"Industry participants are looking for more consistency in regulatory guidance and action.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0003","quote":"we're all looking for some consistency on regulatory guidance and action."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0003_n2","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Maha Summit был закрытым мероприятием; медиа практически не приглашали, кроме пулового освещения сессии JD Vance.","text_en":"The Maha Summit was closed; essentially no media was invited except pool coverage of JD Vance’s session.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0003","quote":"It was a closed. Media events, uh, are invite-only."},{"chunk_id":"doc_4077b10d9cd7_chunk_0003","quote":"essentially no media was invited even."},{"chunk_id":"doc_4077b10d9cd7_chunk_0003","quote":"That was the only session."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0003_n3","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"На саммите обсуждали выход на рынок пероральных GLP-1; прозвучало, что это может случиться уже в марте.","text_en":"Oral GLP-1s coming to market were discussed; it was said this could happen as early as March.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0003","quote":"Some conversation about oral GLP-1s hitting the market. Dr. Oz said that this could happen as early as March."}],"confidence":"medium"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0004_n1","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Появились первые «робастные» данные по orexin-2 агонисту в популяции NT2 (нарколепсия типа 2) на выборке >90 пациентов, что поддерживает тезис о клинической пользе класса beyond NT1.","text_en":"First robust orexin-2 agonist dataset in NT2 (>90 patients) supports meaningful clinical benefit beyond NT1.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0004","quote":"this was the first robust data set in this population with data in over 90 patients."},{"chunk_id":"doc_4077b10d9cd7_chunk_0004","quote":"provide kind of a strong evidence that the orexin agonists can deliver meaningful clinical benefit beyond just NT1."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0004_n2","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Сравнение эффективности между исследованиями ограничено различиями в размере выборки и длительности лечения; также неизвестно, как проявляется тахифилаксия и сколько нужно для steady state.","text_en":"Cross-trial comparisons are constrained by sample size and treatment-duration differences; tachyphylaxis and time to steady state are not yet well understood.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0004","quote":"there are two caveats... Firstly, it's sample size."},{"chunk_id":"doc_4077b10d9cd7_chunk_0004","quote":"secondly, there's treatment duration."},{"chunk_id":"doc_4077b10d9cd7_chunk_0004","quote":"we don't fully know— how long or how much of tachyphylaxis emerges and how long it takes to reach steady state."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0004_n3","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"ESS рассматривается как более релевантная регуляторная конечная точка (особенно в ЕС) по сравнению с другими метриками, так как лучше отражает субъективный опыт сонливости пациента.","text_en":"ESS may be a more relevant regulatory endpoint (especially in the EU) as it better captures patients’ subjective sleepiness.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0004","quote":"The other key efficacy endpoint was ESS, which better captures the patient's subjective experience of sleepiness."},{"chunk_id":"doc_4077b10d9cd7_chunk_0004","quote":"probably is a more relevant regulatory endpoint, especially in the EU."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0005_n1","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Для оценки эффективности важен выбор регуляторно релевантной конечной точки: ESS может быть более релевантным регуляторным endpoint, особенно в ЕС.","text_en":"Choice of efficacy endpoint is a constraint: ESS may be a more regulatorily relevant endpoint, especially in the EU.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0005","quote":"The other key efficacy endpoint was ESS... probably is a more relevant regulatory endpoint, especially in the EU."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0005_n2","doc_id":"doc_4077b10d9cd7","kind":"opportunity","text_ru":"В NT2 потенциально можно исследовать более высокие дозы и стратегии split-dosing, так как визуальные нарушения встречались реже; обе компании обсуждают это.","text_en":"In NT2, there may be room to explore higher doses and split-dosing strategies since visual disturbances were less frequent; both companies have discussed it.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0005","quote":"visual disturbances were less frequent... perhaps in NT2, it allows these companies to continue to explore higher doses. And potentially also explore split-dosing strategies."},{"chunk_id":"doc_4077b10d9cd7_chunk_0005","quote":"we've seen both companies talk about doing that."}],"confidence":"medium"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0005_n3","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Наблюдается «heating up» M&A и случаи конкурентных торгов (bidding) вокруг сделок.","text_en":"M&A appears to be heating up, with recent cases of competitive bidding around deals.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0005","quote":"we are seeing this is sort of a second recent case... there's bidding."},{"chunk_id":"doc_4077b10d9cd7_chunk_0005","quote":"overall it's good to see M&A heating up."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0006_n1","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Конкуренция и выход дополнительных дженериков Zyrem могут ограничивать ценовую власть в рынке оксибата.","text_en":"Competition and additional Zyrem generics may limit pricing power in the oxybate market.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0006","quote":"\"There are going to be additional generic versions of. Zyrem that are going to launch early part of next year. I don't know how much pricing power\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0006_n2","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Компании активно преследуют конкретные активы в M&A, что отражает высокоинтенсивные переговоры и агрессивную конкуренцию за сделки.","text_en":"Companies are aggressively pursuing specific assets in M&A, reflecting high-intensity negotiations and competition for deals.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0006","quote":"\"I'm always interested whenever we get a look inside the boardroom and the high intensity negotiations\""}],"confidence":"medium"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0006_n3","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Неопределённость в том, как администрация Трампа будет подходить к антимонопольному регулированию в biopharma.","text_en":"Uncertainty about how the Trump administration will approach antitrust in biopharma.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0006","quote":"\"We've all been waiting for a really long time to see if we were going to get a good first look at how the Trump administration is going to approach antitrust\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0007_n1","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Риск антимонопольного иска со стороны FTC может блокировать сделки: регулятор прямо предупреждает, что подаст в суд, если сделку попытаются провести.","text_en":"FTC antitrust litigation risk can block deals: the regulator explicitly warns it will sue if a deal proceeds.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0007","quote":"It basically said, if you try to do this deal, we're going to sue."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0007_n2","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"В M&A в биотехе наблюдается сдвиг от сделок с одним покупателем и CVR к более конкурентным (иногда «жёстко конкурентным») ситуациям с несколькими претендентами.","text_en":"Biotech M&A is shifting from single-bidder/CVR deals to more competitive, sometimes aggressively competitive, multi-bidder situations.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0007","quote":"we're moving away from single bidders, CVRs to get things across the line into competitive and at times nastily competitive situations."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0007_n3","doc_id":"doc_4077b10d9cd7","kind":"buyer_signal","text_ru":"Фарма проявляет «интенсивный интерес» к биотех-активам, с ощущением срочности: «купить сейчас или потерять».","text_en":"Pharma shows intense interest in biotech assets with urgency: buy now or lose them.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0007","quote":"the intense interest from pharma in biotech assets and probably recognition that this is the time. to either buy them or lose them"}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0008_n1","doc_id":"doc_4077b10d9cd7","kind":"pain","text_ru":"Merck сталкивается с «патентным обрывом» после Keytruda и ищет способы «backfill» портфель.","text_en":"Merck faces a post-Keytruda patent cliff and is looking to backfill its portfolio.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0008","quote":"\"how is merck looking to the future, you know, kind of post Keytruda and that patent cliff that they are facing.\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0008","quote":"\"bring into the company over the next couple of years to help kind of backfill some of that patent cliff\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0008_n2","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Отмечается необычность сделок, где более мелкие биотехи приобретают другие компании; это воспринимается как заметное явление.","text_en":"It’s noted as unusual/noticeable that smaller biotechs are acquiring other companies.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0008","quote":"\"it's not usual for us to see smaller biotech acquisitions taking place.\""}],"confidence":"medium"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0008_n3","doc_id":"doc_4077b10d9cd7","kind":"opportunity","text_ru":"Структурирование M&A с низким upfront и основной стоимостью, привязанной к девелопменту/регуляторным майлстоунам, позволяет небольшим/средним биотехам наращивать пайплайн без больших авансовых платежей.","text_en":"M&A structures with low upfront and milestone-heavy payouts enable smaller/mid biotechs to build pipelines without large upfront payments.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0008","quote":"\"giving the mid-sized or the smaller biotechs the ability to acquire and build their pipeline.\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0008","quote":"\"a low upfront and you know majority of the deal value was you know is linked to development and regulatory milestones.\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_nugget_0001","doc_id":"doc_4077b10d9cd7","kind":"pain","text_ru":"Программа Neurocrine по MDD (NBI 770) в фазе 2 не достигла первичной конечной точки; механизм NMDA/депрессия имеет историю неудач и выглядит менее привлекательным.","text_en":"Neurocrine’s MDD Phase 2 (NBI 770) missed its primary endpoint; NMDA/depression has a long history of failures and the mechanism looks less attractive.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0009","quote":"It was a 73-patient study in MDD and did not reach its primary endpoint."},{"chunk_id":"doc_4077b10d9cd7_chunk_0009","quote":"You know, we've seen a long history of failures in this space."},{"chunk_id":"doc_4077b10d9cd7_chunk_0009","quote":"for the time being, I think the outlook on this mechanism is. You know, probably less attractive."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_nugget_0002","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Компания заявляет, что по датасету NBI 770 есть аспекты, требующие дополнительного анализа перед определением дальнейших шагов.","text_en":"The company says aspects of the NBI 770 dataset warrant further analysis before deciding next steps.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0009","quote":"there are some aspects of the dataset that warrant further analysis before determining next steps."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_nugget_0003","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"На American Heart Meeting представлены обнадеживающие клинические данные по in vivo CRISPR-программе против ANGPTL3 у пациентов с дислипидемией на максимальной фоновой терапии (однократная IV инфузия).","text_en":"American Heart Meeting featured encouraging clinical readouts for an in vivo CRISPR ANGPTL3 program in dyslipidemia patients on maximal background therapy (single IV infusion).","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0009","quote":"CRISPR showed data with their EngPTL3."},{"chunk_id":"doc_4077b10d9cd7_chunk_0009","quote":"15 patients with high cholesterol, high lipids, and mixed dyslipidemia on maximal background therapy, single IV infusion."},{"chunk_id":"doc_4077b10d9cd7_chunk_0009","quote":"Data looked really, really good. And it's really encouraging."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"NEJM требует длительного (15-летнего) постмаркетингового/постисследовательского наблюдения для in vivo genome editing, что повышает регуляторную/операционную нагрузку.","text_en":"NEJM calls for long-term (15-year) surveillance for in vivo genome editing, increasing regulatory/operational burden.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0010","quote":"the New England Journal is calling for a 15-year, obviously, in vivo genome editing sort of surveillance."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_4077b10d9cd7","kind":"pain","text_ru":"CRISPR-программа Intelia по ATTR кардиомиопатии получила клинический холд после тяжелого лекарственного поражения печени (grade 4 transaminitis, билирубин) и смерти пациента.","text_en":"Intellia’s CRISPR ATTR cardiomyopathy program went on clinical hold after severe liver injury (grade 4 transaminitis, bilirubin increase) and a patient death.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0010","quote":"At that point, they went on clinical hold on the 29th. and they announced that the patient sadly passed away"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_4077b10d9cd7","kind":"pain","text_ru":"LNP-подход к RNA editing для Alpha-1 antitrypsin deficiency у Coro не достиг порогов эффективности в фазе 1/2, и программу прекратили на фоне конкуренции.","text_en":"Coro’s LNP RNA-editing approach for Alpha-1 antitrypsin deficiency did not meet thresholds in a phase 1/2 study and was discontinued amid competition.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0010","quote":"it did not meet the thresholds in that study and their rewrite study, which is a phase one, two study"}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0011_n1","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Рынок начал сильнее вознаграждать компании за позитивные клинические данные: на фоне хороших readout’ов некоторые компании кратно растут по капитализации и могут привлекать капитал.","text_en":"Markets are rewarding positive clinical readouts more: some companies’ market caps are doubling and they can raise capital after good data.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0011","quote":"this fall, it seems like we're seeing several companies double their market cap at the back of positive data readouts."},{"chunk_id":"doc_4077b10d9cd7_chunk_0011","quote":"when companies can get rewarded for good data and robustly raise capital. as a result of it."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0011_n2","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"GIST описывается как «кладбище» для таргетных онкопрограмм: препараты с многообещающими ранними данными часто проваливаются в более крупных исследованиях.","text_en":"GIST is described as a 'graveyard' for targeted oncology programs: drugs with promising early data often fail in larger trials.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0011","quote":"It's sort of been a graveyard for target oncology programs where several drugs that had promising data in phase one, two ended up failing in larger trials."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0011_n3","doc_id":"doc_4077b10d9cd7","kind":"opportunity","text_ru":"Коммерческая возможность во 2-й линии GIST оценивается как «four billion plus market opportunity» при ~3,000 пациентах во 2-й линии.","text_en":"Second-line GIST is framed as a 'four billion plus' commercial opportunity with ~3,000 second-line patients.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0011","quote":"from a commercial standpoint, you know, this is sort of a four billion plus market opportunity."},{"chunk_id":"doc_4077b10d9cd7_chunk_0011","quote":"Given about 3,000 patients that are in second line."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0012_n1","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Звучит наблюдение о росте «consumerization» в здравоохранении: индустрии важно говорить не только с профессионалами, но и с потребителями/широкой публикой.","text_en":"Observation that healthcare is becoming more consumerized, implying the industry needs to speak to consumers/the broader public, not only peers.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0012","quote":"\"we are in an era where you know healthcare is becoming more and more consumerized\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0012","quote":"\"he needs to be speaking to the consumers, not just to kind of his peers\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0012_n2","doc_id":"doc_4077b10d9cd7","kind":"pain","text_ru":"Отмечается, что биофарма/научная индустрия плохо объясняет обществу, что делает и почему это важно.","text_en":"The industry is described as doing a poor job communicating to the public what it does and why it matters.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0012","quote":"\"As an industry, we've done a horrible job communicating what we do and why it matters\""}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_chunk_0012_n3","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Упоминается появление новых потенциальных модальностей лечения холестерина (эволюция от статинов к long-acting injectable PCSK9 и далее).","text_en":"Mentions emergence of new potential treatment modalities in cholesterol (from statins to long-acting injectable PCSK9 and beyond).","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0012","quote":"\"fascinating to see this. Of new potential treatment modalities in cholesterol\""},{"chunk_id":"doc_4077b10d9cd7_chunk_0012","quote":"\"we've gone from like statins to having a long-acting injectable PCSK9 biologic\""}],"confidence":"medium"}
{"nugget_id":"doc_4077b10d9cd7_nugget_001","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"В лечении гиперхолестеринемии наблюдается расширение модальностей: от статинов к длительно действующим инъекционным PCSK9-биологикам, потенциальным генным терапиям и малым молекулам PCSK9.","text_en":"Cholesterol treatment modalities are expanding: from statins to long-acting injectable PCSK9 biologics, potential gene therapies, and small-molecule PCSK9.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0013","quote":"we've gone from like statins to having a long-acting injectable PCSK9 biologic to now potentially. You know, these gene therapies."},{"chunk_id":"doc_4077b10d9cd7_chunk_0013","quote":"now from Merck, potentially, you know, a small molecule, PCSK9."}],"confidence":"high"}
{"nugget_id":"doc_4077b10d9cd7_nugget_002","doc_id":"doc_4077b10d9cd7","kind":"constraint","text_ru":"Есть напряжение между прозрачностью ценообразования и тем, чтобы не снижать усилия/стимулы к R&D по разработке новых лекарств.","text_en":"There is tension between pricing transparency and not negatively impacting R&D effort to develop new medicines.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0013","quote":"How to drive transparency in pricing. While also not adversely impacting. The amount of effort that goes into research to develop new medicines"}],"confidence":"medium"}
{"nugget_id":"doc_4077b10d9cd7_nugget_003","doc_id":"doc_4077b10d9cd7","kind":"trend","text_ru":"Отмечается рост M&A и ожидание новых участников в «bidding war» (конкурентных торгах) вокруг сделок.","text_en":"More M&A is being seen, with expectations of additional bidders in bidding wars around deals.","evidence":[{"chunk_id":"doc_4077b10d9cd7_chunk_0013","quote":"we're looking to see who the next players in a bidding war. are going to be. Because we're certainly seeing more M &A."}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0000_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"На рынке M&A в биотехе наблюдается оживление: «things heating up», появляются новые сделки и конкурирующие предложения.","text_en":"Biotech M&A is heating up, with new deals and competing bids emerging.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0000","quote":"\"Mergers and acquisitions are something we've talked a lot about on this show, but boy, are things heating up.\""}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0000_n2","doc_id":"doc_456fde1df324","kind":"buyer_signal","text_ru":"Конкурирующие покупатели повышают ставки за Evadel (с $20/акция до $23/акция), что сигнализирует о высокой готовности платить за актив.","text_en":"Competing acquirers raised bids for Evadel ($20/share to $23/share), signaling strong willingness to pay for the asset.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0000","quote":"\"Lundbeck showed up unannounced with a $23 bid up three bucks\""},{"chunk_id":"doc_456fde1df324_chunk_0000","quote":"\"ALCHEMY is actually um agreed to acquire Evadel on October 22nd for $20 a share.\""}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0000_n3","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Часть стоимости сделки завязана на условие регуляторного события: выплаты по CVR зависят от FDA approval для idiopathic hypersomnia к концу 2028.","text_en":"Part of deal value is contingent on a regulatory event: CVR payments depend on FDA approval for idiopathic hypersomnia by end of 2028.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0000","quote":"\"$1. 50 for a CVR. And if they get an FDA approval, for what's known as idiopathic hypersomnia. By the end of 28\""}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"В биотехе наблюдается «довольно горячая» M&A-среда с редкими публично конкурентными сделками/«bidding wars».","text_en":"Biotech M&A appears heated, with rare publicly competitive transactions/bidding wars.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0001","quote":"“It certainly speaks to a pretty heated M&A environment.”"},{"chunk_id":"doc_456fde1df324_chunk_0001","quote":"“these types of publicly competitive options are the things that we rarely see.”"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Озвучен крупный размер приобретения компании на стадии Phase 1 (около $3B), что подаётся как потенциально крупнейшая сделка такого типа.","text_en":"A ~$3B acquisition of a Phase 1-stage company is cited as potentially the largest of its kind.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0001","quote":"“How the therapeutics being bought by uh J & J for about $3 billion.”"},{"chunk_id":"doc_456fde1df324_chunk_0001","quote":"“Phase one, stage, company acquisition—$3 billion for a phase one company.”"}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"В области лечения (упоминается простатический рак) текущие модальности (bispecifics, radioligands, ADCs) описаны как неудобные и без убедительных доказательств высокой эффективности.","text_en":"In the mentioned treatment area (prostate cancer), current modalities (bispecifics, radioligands, ADCs) are described as inconvenient and lacking strong evidence of high effectiveness.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0001","quote":"“bispecifics, radioligands with a million different isotopes and ADCs— which are not convenient”"},{"chunk_id":"doc_456fde1df324_chunk_0001","quote":"“we haven't really seen much— evidence that that that they are particularly super effective.”"}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0002_n1","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"Множество изотопов и ADC воспринимаются как неудобные, и собеседники не видят убедительных доказательств их «суперэффективности».","text_en":"Many isotopes and ADCs are seen as inconvenient, and speakers haven’t seen strong evidence they are particularly effective.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0002","quote":"a million different isotopes and ADCs— which are not convenient and we haven't really seen much— evidence that that that they are particularly super effective."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0002_n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Отмечается сдвиг к более высокой конкуренции за сделки (в т.ч. видимой в SEC filings после закрытия).","text_en":"A shift toward heightened competition for deals is being observed, including evidence in post-deal SEC filings.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0002","quote":"we do seem to be seeing heightened competition, very publicly in a few cases"},{"chunk_id":"doc_456fde1df324_chunk_0002","quote":"But also in the SEC filings that are coming out post-deal. So. That's a real shift."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0002_n3","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Патентная экспирация по активам J&J рассматривается как фактор/ограничение, влияющее на стратегию (упоминается как «patent expiry that is coming up again»).","text_en":"Upcoming patent expiry for J&J assets is mentioned as a factor/constraint influencing strategy.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0002","quote":"it certainly helps with the um uh patent expiry that that is coming up again for another uh of JNJ assets"}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0003_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"В биофарме наблюдается высокая активность M&A, включая крупные сделки (упоминается транзакция Sedara почти на $10B).","text_en":"High M&A activity in biopharma, including very large deals (Sedara transaction mentioned at nearly $10B).","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0003","quote":"So much M &A in this space."},{"chunk_id":"doc_456fde1df324_chunk_0003","quote":"the Sedara transaction that was announced just a week ago today with Mark paying nearly $10 billion."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0003_n2","doc_id":"doc_456fde1df324","kind":"buyer_signal","text_ru":"Покупатель (Merck) публично обосновывает коммерческий потенциал: заявляет peak sales >$5B и детализирует, что поддерживает этот рынок.","text_en":"Buyer (Merck) publicly supports commercial potential: states peak sales >$5B and details what supports that market size.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0003","quote":"they came out with some pretty aggressive peak sales numbers."},{"chunk_id":"doc_456fde1df324_chunk_0003","quote":"talking about peak sales as being over $5 billion."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0003_n3","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Доступ/реимбурсация зависят от cost-effectiveness: обсуждается, что при цене до $600 за курс продукт «очень эффективен» и может не подпадать под ограничения доступа.","text_en":"Access/reimbursement depends on cost-effectiveness: at price points up to $600 per course it was described as very cost-effective and potentially not subject to access restrictions.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0003","quote":"importance of companies doing work on cost-effectiveness"},{"chunk_id":"doc_456fde1df324_chunk_0003","quote":"at price points up to $600 per course, this was very effective."},{"chunk_id":"doc_456fde1df324_chunk_0003","quote":"had the potential to not be subject to access restrictions."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0004_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"В последние месяцы в biotech M&A фиксируются рекордные суммы сделок на ранних стадиях (pre-phase 3, phase 1, preclinical).","text_en":"Biotech M&A has been setting record deal sizes at early stages (pre-phase 3, phase 1, preclinical) over the past few months.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0004","quote":"So we've been setting some records in biotech M&A left and right for the past few months."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0004_n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Стратегические покупатели стали более готовы заходить на более ранних стадиях, что создаёт пространство для платформенных и более долгосрочных сделок.","text_en":"Strategics are more willing to engage at earlier stages, creating room for platform and longer-term deals.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0004","quote":"I think that is a really positive development, because it creates space for some of these. more strategic kind of platform transactions"}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0004_n3","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Рост стоимости/цены лекарств рассматривается как один из драйверов текущей волны M&A.","text_en":"Rising drug costs/prices are cited as a driver of the current M&A wave.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0004","quote":"the cost, the price of drugs has gone up a lot, right? ... So I think that the cost of drugs is probably one of the drivers."}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0005_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Обсуждается, что крупные препараты могут быть защищены патентами значительно дольше ожидаемого срока истечения молекулярного патента, что ставит под вопрос драйвер LOE.","text_en":"Discussion suggests major drugs may be protected well beyond molecule patent expiry, calling LOE-driven narratives into question.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0005","quote":"analysis that suggests that Cosentix can be um quite i'm not going to say easily, but can be protected for way beyond this molecule patent expiry"}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0005_n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Отмечается, что рынок биотеха «привыкает» к регулярным M&A-сделкам, и поднимается вопрос о зависимости ралли от M&A.","text_en":"Biotech market is described as getting accustomed to frequent M&A deals, raising the question of rally dependence on M&A.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0005","quote":"we're almost growing accustomed to waking up on a Monday morning and having a nice splashy deal on the table"}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0005_n3","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Заявляется, что многие биотех-компании не зависят от M&A, потому что способны сами выводить препараты на рынок и относительно быстро выходить на прибыльность; этому способствует более высокая цена на лекарства.","text_en":"Many biotechs are said not to depend on M&A because they can launch drugs themselves and ramp to profitability relatively quickly, aided by higher drug pricing.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0005","quote":"many biotech companies are not dependent upon M &A because they're showing that they can launch these drugs themselves"}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0006_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Рост негативного отношения и нерешительности (hesitancy) к вакцинации из‑за обсуждений возможной связи вакцин и аутизма; проблема описана как глобальная, не только США.","text_en":"Rising negativity and vaccine hesitancy driven by autism–vaccine linkage discourse; described as a global (not US-only) issue.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0006","quote":"\"the more this happens, the more you're going to get that negativity around vaccines\""},{"chunk_id":"doc_456fde1df324_chunk_0006","quote":"\"it increases hesitancy towards vaccines\""},{"chunk_id":"doc_456fde1df324_chunk_0006","quote":"\"this is not a US issue. This is everywhere.\""}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0006_n2","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Невозможность/непрактичность «доказать отрицательное» по связи вакцин и аутизма; попытки удовлетворить критиков могут вести к трате ресурсов.","text_en":"Impracticality of “proving a negative” on vaccines–autism; attempts to satisfy critics could waste resources.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0006","quote":"\"having to prove the negative... It's impossible to do.\""},{"chunk_id":"doc_456fde1df324_chunk_0006","quote":"\"a lot of wasted resources would be spent doing so\""}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0006_n3","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Предлагаемый дизайн проспективного исследования «новорождённые без вакцин vs с вакцинами» поднимает вопросы этичности, набора участников и финансирования.","text_en":"A proposed prospective trial of newborns with no vaccines vs vaccines raises ethics, enrollment, and funding feasibility issues.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0006","quote":"\"a prospectively designed clinical trial that takes a group of newborns and gives them no vaccines\""},{"chunk_id":"doc_456fde1df324_chunk_0006","quote":"\"Who's going to fund it? How ethical is it?\""},{"chunk_id":"doc_456fde1df324_chunk_0006","quote":"\"How do they enroll these subjects\""}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0007_n1","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"Компании испытывают сложности во взаимодействии с FDA: запрашивают встречи, но не могут их получить, коммуникация сводится к письменным ответам.","text_en":"Companies report difficulties engaging with the FDA: they request meetings but can’t get them, and communication becomes written responses only.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0007","quote":"Companies had requested meetings and they couldn't get meetings. Everything was just written response only."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0007_n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"По результатам ноябрьского опроса компаний выросла обеспокоенность работоспособностью FDA: 82% респондентов заявили, что беспокоятся о способности FDA функционировать.","text_en":"In a November company survey, concern about the FDA’s ability to function is high: 82% of respondents said they were worried.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0007","quote":"in this November survey... 82% of respondents said they were worried about the FDA's ability to function."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0007_n3","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"Компании сталкиваются с несоответствием ожиданий и позиции FDA: сначала ощущение «alignment», затем FDA говорит другое.","text_en":"Companies experience misalignment with the FDA: they think there is alignment, then the FDA says something different.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0007","quote":"Unicure was like, 'We have alignment.' And then it's like, 'Oh wait, actually, the FDA said something different.'"}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0008_n1","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"Компании испытывают проблемы с взаимодействием с FDA: сложно получить встречи, ответы только письменно, возможна нехватка профильной экспертизы у ревьюеров и пропуск ключевых данных при рассмотрении пакета.","text_en":"Companies face FDA interaction issues: difficulty getting meetings, written-only responses, reviewers lacking therapeutic-area background, and missing key data in reviews.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"Companies had requested meetings and they couldn't get meetings. Everything was just written response only."},{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"none of their reviewers had any background in the therapeutic area"},{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"they didn't actually review the package properly and missed key data."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0008_n2","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"Неопределённость и трудности с получением качественной обратной связи от FDA создают путаницу по требованиям/«планке» и могут тормозить разработку, особенно для менее стандартных программ.","text_en":"Uncertainty and difficulty getting quality FDA feedback creates confusion about the bar/requirements and can hamper development, especially for less straightforward programs.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"this uncertainty and like lack of uh you know challenges getting quality feedback."},{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"confusion about what counts and where the bar is."},{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"it can hamper um you know the development path for any drug"}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0008_n3","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Есть риск задержек в рассмотрении ранних программ; задержки могут быть длительными (до 2–3 лет), что усложняет прогнозирование сроков.","text_en":"There is a risk of delays in reviewing early programs; delays could be long (2–3 years), making timelines harder to predict.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"the early programs that are not getting reviewed"},{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"it could be two or three year delays."},{"chunk_id":"doc_456fde1df324_chunk_0008","quote":"things are getting done in the meantime. Are getting a little bit harder to call"}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0009_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Обсуждается разрыв между ростом «gross» и «net» цен на брендовые препараты за последние ~10 лет: gross растут заметно быстрее, net — медленно.","text_en":"Discussion highlights a gap between branded drug gross vs net price growth over ~10 years: gross up much more than net.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0009","quote":"The gross prices went up 11. 9%. The actual net prices went up 1. 9%."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0009_n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"В FCS (ультра-орфанное показание ~1,000 пациентов в США) Ionis установила очень высокую цену ($595k) на ASO; при расширении на более широкую популяцию ожидается резкое снижение цены до ~$10k–$20k.","text_en":"In FCS (ultra-orphan ~1,000 US patients), Ionis priced an ASO at $595k; for a broader population they expect a sharp drop to ~$10k–$20k.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0009","quote":"This is an ultra, ultra orphan indication, about 1,000 patients in the U. S., and they priced it at $595,000 for an ASO."},{"chunk_id":"doc_456fde1df324_chunk_0009","quote":"they think the price will go down from 595... to let's say 10,000 to 20,000"}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0009_n3","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Novo снижает цену на семаглутид/Wegovy: стартовые дозы $200/мес до конца 1 квартала, затем ~$350/мес в среднем (против $500/мес ранее).","text_en":"Novo is cutting semaglutide/Wegovy pricing: starting doses $200/month through Q1, then ~$350/month on average (vs $500/month previously).","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0009","quote":"dropping their price again for semaglutide or Wegovy. Now starting doses of $200 per month... After which it goes up to $350 per month"}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0010_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Снижение цен на GLP-1/антиожирительные препараты для конкуренции за новых пациентов в ценочувствительном рынке; ожидается, что другие игроки тоже могут снижать цены.","text_en":"GLP-1/obesity drug prices are being cut to compete for new patient starts in a price-sensitive market; others may follow with price cuts.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0010","quote":"\"trying to compete for new patient starts... in what's clearly a price-sensitive market.\""},{"chunk_id":"doc_456fde1df324_chunk_0010","quote":"\"we could maybe also now see that lily is going to do the same thing and bring down the price.\""}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0010_n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Ожидание, что снижение цен увеличит объёмы и компенсирует падение цены; это поддерживает модели «массового потенциала» рынка.","text_en":"Belief that lower prices will drive volume that compensates for price declines, supporting models of a large market opportunity.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0010","quote":"\"the lower the prices come, the more likely you're going to get volume compensating for it.\""}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0010_n3","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Различия в дизайне исследований и сроках получения данных (у одного игрока данные позже и исследования на более высокорисковых пациентах) влияют на позиционирование/контрактацию и ценообразование для «большого» показания.","text_en":"Differences in study design and data timing (later data; higher-risk-focused studies) shape positioning/contracting and pricing for the larger indication.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0010","quote":"\"because they're behind, they're running slightly different studies... geared to inevitably looking at higher risk patients.\""},{"chunk_id":"doc_456fde1df324_chunk_0010","quote":"\"Arrowhead's not going to have their data until, let's say, Q3 or so next year.\""}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0011_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Наблюдается сдвиг: цены на лекарства скорее снижаются, а не растут, на фоне плотной конкуренции в терапевтических категориях.","text_en":"A shift is observed: drug pricing is coming down rather than up, amid dense competition in therapeutic categories.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0011","quote":"the broader theme here is that drug pricing is coming down, not up."},{"chunk_id":"doc_456fde1df324_chunk_0011","quote":"are these therapeutic categories becoming so dense and competitive."}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0011_n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Cigna планирует отменять prescription drug rebates для части частных планов с 2027 года; изменения будут постепенными и могут снижать стимул завышать цены ради «запаса под ребейты».","text_en":"Cigna plans to eliminate prescription drug rebates for some private plans starting in 2027; gradual change may reduce incentives to price high to leave room for rebates.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0011","quote":"Cigna talked about eliminating prescription drug rebates for some private health plans starting in 2027."},{"chunk_id":"doc_456fde1df324_chunk_0011","quote":"you take away one of the top reasons for pricing high, which is. Leaving room to rebate"}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0011_n3","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"List price не отражает реальную цену: значимы скидки price-to-net (в Part D «in the 30s», в «price B» — «around high 40s»), что усложняет анализ ценообразования.","text_en":"List price is not the real price: price-to-net discounts are substantial (Part D “in the 30s”, “price B” around high 40s), complicating pricing analysis.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0011","quote":"the average price to net discount right now, in part D, like dog, um, is in the 30s"},{"chunk_id":"doc_456fde1df324_chunk_0011","quote":"and in price B, like boys, around high 40s. So as you said, the list price is not the real price."}],"confidence":"medium"}
{"nugget_id":"doc_456fde1df324_chunk_0012_n1","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Новые препараты выходят на рынок с премиями по цене выше, чем раньше; в пересчёте на пациента цены, вероятно, растут.","text_en":"New products are launching at higher price premiums than before; on a per-patient basis, prices are likely increasing.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0012","quote":"new products coming in at premiums higher than what we've ever seen... the prices are probably going up."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0012_n2","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"В серповидноклеточной болезни сохраняется огромная неудовлетворённая потребность: стандарт лечения крайне плохой, пациентам нужны новые терапии.","text_en":"Sickle cell disease has huge unmet need: standard of care is extremely poor and patients need new therapies.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0012","quote":"area of huge unmet need, really, really challenging disease."},{"chunk_id":"doc_456fde1df324_chunk_0012","quote":"The standard of care for these patients is still extremely poor."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0012_n3","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Есть неопределённость в регуляторных ожиданиях FDA по редким заболеваниям: разработчики и инвесторы не понимают, где «порог» требований и что именно нужно FDA.","text_en":"Regulatory uncertainty: developers/investors don’t know where FDA sets the bar in rare disease or what it wants right now.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0012","quote":"whether anyone really knows where the FDA is going to set the bar in rare disease."},{"chunk_id":"doc_456fde1df324_chunk_0012","quote":"I don't think we have any idea what the FDA wants and needs right now."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0013_n1","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"Неясность и изменчивость ожиданий FDA: участники говорят, что не понимают, чего регулятор хочет/нужно, и что требования меняются очень часто.","text_en":"Unclear and rapidly changing FDA expectations; speakers say they don’t know what FDA wants/needs and that it changes frequently.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0013","quote":"I don't think we have any idea what the FDA wants and needs right now."},{"chunk_id":"doc_456fde1df324_chunk_0013","quote":"it seems to change on a daily basis."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0013_n2","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Биотех-компании начинают переходить от «рискованной одиночной программы» к более диверсифицированным, роялти-ориентированным моделям, включая партнерства и монетизацию будущих milestone/royalty.","text_en":"Biotech companies are shifting from single high-risk program models toward diversified, royalty-based models, including partnering and monetizing future milestones/royalties.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0013","quote":"biotech companies and how they're beginning to return cash to shareholders a little bit and the transition to royalty models as well"},{"chunk_id":"doc_456fde1df324_chunk_0013","quote":"they're increasingly going to move now to do a royalty-based business model."},{"chunk_id":"doc_456fde1df324_chunk_0013","quote":"move away from the traditional risk-heavy single sort of program business model."}],"confidence":"high"}
{"nugget_id":"doc_456fde1df324_chunk_0013_n3","doc_id":"doc_456fde1df324","kind":"buyer_signal","text_ru":"Есть сигнал «капитал-аллокейшн» спроса со стороны публичных биотехов: объявлен байбек $125 млн и обсуждается более «shareholder friendly» подход к перераспределению капитала.","text_en":"Capital-allocation buyer signal from public biotechs: a $125M buyback is announced and a more shareholder-friendly redeployment of capital is discussed.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0013","quote":"And they announced a $125 million buyback."},{"chunk_id":"doc_456fde1df324_chunk_0013","quote":"certainly seems much more shareholder friendly in terms of redeployment of capital."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_456fde1df324","kind":"constraint","text_ru":"Сложно интерпретировать данные из‑за разных подгрупп пациентов.","text_en":"Interpreting the data is difficult due to different patient subgroups.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0014","quote":"It took us a little while to get our head around the different subgroups"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_456fde1df324","kind":"pain","text_ru":"Есть опасения по поводу печёночной токсичности (liver tox) у кандидата, она выглядит выше, чем у alectinib.","text_en":"There are concerns about liver toxicity for the candidate, appearing higher than with alectinib.","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0014","quote":"the liver tox is a little bit higher than what we see with the lectinib"}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_456fde1df324","kind":"trend","text_ru":"Фарма, по словам спикера, покупает подобные активы/компании (намёк на M&A-активность в сегменте).","text_en":"Pharma appears to be buying these kinds of assets/companies (suggesting M&A activity in the segment).","evidence":[{"chunk_id":"doc_456fde1df324_chunk_0014","quote":"Pharma seems to be buying these kinds of assets and these kinds of companies"}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0000_n1","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Упоминается разворот в секторе: год начался с «боли», а к середине года перешёл в один из самых сильных бычьих ралли в биотехе.","text_en":"Sector reversal mentioned: the year started with “pain” and turned mid-year into one of the strongest biotech bull rallies.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0000","quote":"Biotech obviously started this year with a lot of pain that turned around around mid-year into one of the strongest. Bull rallies"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0000_n2","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Отмечается сдвиг: успешные запуски препаратов у small/mid-cap компаний и «взросление» молодых компаний; фаза 2/3 результаты становятся «реальными».","text_en":"Shift noted: successful launches from small/mid-sized companies; phase 2/3 drugs are becoming “real” and young companies are “growing up.”","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0000","quote":"the success of a lot of drug launches in the past year from small to mid-sized companies"},{"chunk_id":"doc_4e08bc14b958_chunk_0000","quote":"certain drugs that look great in phase two and phase three are kind of becoming real"}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0000_n3","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Есть обеспокоенность по поводу FDA: сроки, эффективность и предсказуемость (особенно в rare disease).","text_en":"Concern about FDA: timelines, efficiency, and predictability (especially in rare disease).","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0000","quote":"somewhat nervous about this FDA stuff as it relates to timelines and efficiency and also just predictability"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0001_n1","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"FDA названа основным оставшимся источником неопределённости политики для сектора.","text_en":"FDA is described as the major remaining source of policy uncertainty for the sector.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0001","quote":"\"unfortunately, FDA is now the major remaining source of policy uncertainty.\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0001_n2","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Динамика XBI сильно привязана к федеральным процентным ставкам из‑за длинного инвестиционного цикла.","text_en":"XBI is said to be strongly tied to federal interest rates due to the long investment cycle.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0001","quote":"\"the XBI is very, very much tied to. Uh, federal interest rates just because of the long investment cycle\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0001_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Отмечается сдвиг в биотехе: теперь можно быть «long» на продуктовые запуски; ранее сектор страдал, пока не «разобрался» с алгоритмом успешных запусков.","text_en":"A shift is noted: biotech can now be long product launches; the sector struggled until it figured out the algorithm for successful launches.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0001","quote":"\"the biggest divider between the old biotech and the new biotech is the idea that you can actually be long product launches.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0001","quote":"\"the sector struggled for a while up until it kind of figured out the The algorithm for successful product launches.\""}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0002_n1","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Ожидается волна IPO в 2026, и обсуждается риск, что приток более спекулятивных компаний может «размыть» качество сектора.","text_en":"A wave of IPOs is anticipated in 2026, with concern that more speculative names could dilute sector quality.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0002","quote":"as we enter 26 and anticipate a wave of IPOs, whether that wave of IPOs might impair the biotech rally"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0002_n2","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"IPO-рынок был сложным, из-за чего многие сильные частные компании смогли «созреть» и привлечь много частного капитала; также выросла роль публичных инвесторов в private-раундах.","text_en":"A tough IPO market let compelling private companies mature and raise substantial private capital; more public investors now participate in private rounds.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0002","quote":"because of how tough the IPO market has been, we've been in a world where there's been a lot of compelling private companies"},{"chunk_id":"doc_4e08bc14b958_chunk_0002","quote":"There's a lot of public investors now with deep pockets that do private investments"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0002_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Участники считают, что накопилось много «зрелых» и более де-рисковых частных biotech-компаний, которые «заслуживают» стать публичными; оценки числа IPO на следующий год варьируют (15 vs «over-under ближе к 50»).","text_en":"Participants see a large backlog of mature, de-risked private biotechs that deserve to go public; IPO count guesses vary (15 vs over/under near 50).","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0002","quote":"There are so many high-quality private companies with really de-risked products and platforms"},{"chunk_id":"doc_4e08bc14b958_chunk_0002","quote":"15."}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0003_n1","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"В текущем окне IPO на публичные рынки в основном выходят компании/активы на стадии разработки (development stage), а не preclinical.","text_en":"In the current IPO window, mostly development-stage programs/assets are reaching public markets rather than preclinical ones.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0003","quote":"\"what is coming to market are mostly development stage assets\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0003_n2","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Публичный рынок не способен устойчиво анализировать доклинические (preclinical) компании; попытки финансировать их выглядят как оппортунистическое финансирование и становятся сигналом краха.","text_en":"Public markets cannot sustainably analyze preclinical companies; financing them tends to be opportunistic and becomes a crash signal.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0003","quote":"\"I do not believe that at any point the public market has been able to sustainably sustainably analyze preclinical companies\""},{"chunk_id":"doc_4e08bc14b958_chunk_0003","quote":"\"it's opportunistic financing, and it winds up being the signal of the crash\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0003_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"В индустрии наблюдается дисциплина (расходы и аллокация капитала), и компании быстрее выходят на прибыльность, чем раньше.","text_en":"The industry is showing disciplined spending/capital allocation, and companies are reaching profitability faster than before.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0003","quote":"\"things have been very disciplined\""},{"chunk_id":"doc_4e08bc14b958_chunk_0003","quote":"\"Companies are vaulting to profitability at paces we've never seen before.\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0004_n1","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Компании быстрее, чем раньше, выходят на прибыльность и удерживают её.","text_en":"Companies are reaching profitability faster than before and sustaining it.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0004","quote":"Companies are vaulting to profitability at paces we've never seen before."},{"chunk_id":"doc_4e08bc14b958_chunk_0004","quote":"now the companies are actually hitting profitability, sustaining that momentum"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0004_n2","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Непредсказуемость и «хаос» в FDA/HHS из‑за конфликтующих сигналов и потери институциональной памяти затрудняют прогнозирование.","text_en":"Unpredictability and “chaos” at FDA/HHS due to conflicting signals and loss of institutional memory make forecasting difficult.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0004","quote":"expect chaos at the FDA through HHS. I think direction is hard to pick here."},{"chunk_id":"doc_4e08bc14b958_chunk_0004","quote":"it makes it very hard to predict a lot of things"},{"chunk_id":"doc_4e08bc14b958_chunk_0004","quote":"a pretty substantial breakdown in terms of the institutional memory here."}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0004_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"HHS, по словам спикера, «пушит» против вакцин; приводится пример негативного голосования ACIP по вакцинации Hep B при рождении.","text_en":"Speaker claims HHS is pushing back against vaccines; cites a negative ACIP vote on at-birth Hep B vaccination.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0004","quote":"this HHS is going to be pushing back against vaccines."},{"chunk_id":"doc_4e08bc14b958_chunk_0004","quote":"negative vote from ACIP on at-birth Hep B vaccination"}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0005_n1","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Непредсказуемость/сложность регуляторного пути для компаний, проводящих single-arm trials (особенно в gene therapy).","text_en":"Regulatory path is hard to predict for companies running single-arm trials (notably in gene therapy).","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0005","quote":"companies are running single arm trials. And that's the hardest thing to predict"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0005_n2","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Сигналы о «путанице» и возможном рассогласовании с FDA: компании думали, что есть alignment, но его не оказалось.","text_en":"Signals of confusion/misalignment with FDA: companies thought they had alignment but then didn’t.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0005","quote":"news that's been sort of confusing— with companies that thought they had alignment and then didn't"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0005_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Обсуждается возможное ужесточение/пересмотр со стороны FDA: «closer look» на разработки или уже одобренные продукты.","text_en":"Possible FDA tightening/review: taking a closer look at things in development or already approved.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0005","quote":"maybe we should take a closer look at some of the things that either are in development or have gotten approved"}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0006_n1","doc_id":"doc_4e08bc14b958","kind":"pain","text_ru":"Непредсказуемость/«йо-йо» в политике FDA затрудняет понимание происходящего и вызывает негативную оценку.","text_en":"Yo-yoing FDA policy makes it hard to make sense of what’s happening and is viewed negatively.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0006","quote":"\"this yo-yoing of what's happening with FDA policy, I think, is a bit ridiculous.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0006","quote":"\"it's just really hard to make sense of what's happening.\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0006_n2","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Обсуждается идея потенциально снизить число клинических испытаний, требуемых для одобрения, как возможный «net positive» для общественности.","text_en":"There’s discussion about potentially lowering the number of trials required for approval as a possible net positive for the public.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0006","quote":"\"this idea about potentially lowering the number of trials required for approval.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0006","quote":"\"I think that can be a net positive for the American public.\""}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0006_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Эволюционируют подходы пассивной иммунизации: вместо вакцин — моноклональные антитела, которые могут дать защитный иммунитет без части «багажа» вакцинного пространства.","text_en":"Passive immunity approaches are evolving: monoclonal antibodies instead of vaccines, potentially offering protective immunity without some accumulated baggage.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0006","quote":"\"one thing that's actually evolving coincidentally are passive immunity approaches.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0006","quote":"\"instead of vaccine protective immunity, monoclonal antibodies.\""}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0007_n1","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"FDA указало, что Phase 1-2 исследование не подходит как база для подачи BLA по AMT-130 (генная терапия Хантингтона), что ставит под вопрос путь к регистрации на текущем дизайне/данных.","text_en":"FDA said the Phase 1-2 study is not well suited to support a BLA filing for AMT-130, calling into question the filing path on the current study/data.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0007","quote":"their Phase 1-2 study is not is not well suited to support the basis of a BLA filing for AMT-130"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0007_n2","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"В редких заболеваниях ряд геннотерапевтических компаний ведут single-arm pivotal исследования и опираются на регуляторные диалоги/«breakthrough», но кейс Cure вызывает сомнения в устойчивости таких «регуляторных выравниваний».","text_en":"In rare disease, multiple gene therapy companies are running single-arm pivotal studies and relying on FDA dialogues/breakthroughs, but the Cure case raises doubts about the durability of such regulatory alignments.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0007","quote":"there's a number of these gene therapy companies that are running single-arm pivotal studies."},{"chunk_id":"doc_4e08bc14b958_chunk_0007","quote":"should this cure situation lead us to wonder the realness of those regulatory alignments?"}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0007_n3","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Даже при согласовании с FDA single-arm подхода остаётся неопределённость по «планке» одобрения (какая эффективность достаточна), что усложняет планирование и оценку программ.","text_en":"Even with FDA alignment on a single-arm approach, the approval bar (how much efficacy is enough) can remain unclear, complicating planning and program assessment.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0007","quote":"you can have alignment with the FDA, but that still doesn't tell you exactly what the bar is for approval."}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0008_n1","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Участники обсуждают изменения/сдвиги в подходах FDA/CBER к решениям и регуляторным перспективам на фоне смены руководства и «философских» различий.","text_en":"Participants discuss shifts in FDA/CBER decision-making and regulatory prospects amid leadership changes and philosophical differences.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0008","quote":"\"we're just seeing different interpretations of those facts, different applications and decisions around regulation.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0008","quote":"\"we've seen leadership changes at the FDA and perhaps a little bit of a philosophical difference.\""}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0008_n2","doc_id":"doc_4e08bc14b958","kind":"pain","text_ru":"Есть ощущение, что компании сложно быстро получить контакт/ясность от FDA даже при наличии статуса breakthrough; ожидание следующей встречи может растягиваться на квартал.","text_en":"It feels hard for companies to get timely access/clarity from FDA even with breakthrough status; next meetings may be delayed into the next quarter.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0008","quote":"\"Doesn't feel like that's doable though\""},{"chunk_id":"doc_4e08bc14b958_chunk_0008","quote":"\"They're hoping to have another meeting sometime in the first quarter.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0008","quote":"\"Like they have breakthrough. Like, what's breakthrough for?\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0008_n3","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Нерешительность/«раскачивание» регуляторного процесса связывают с недефинитивностью/«незрелостью» данных: при более убедительном датасете вопроса об одобрении бы не возникало.","text_en":"Regulatory uncertainty is tied to non-definitive/immature data; with a more definitive dataset, approval wouldn’t be in question.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0008","quote":"\"if the Unicure dataset were far more definitive... this wouldn't even be a discussion point.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0008","quote":"\"we're looking at a dataset that is prone to perhaps more interpretation\""},{"chunk_id":"doc_4e08bc14b958_chunk_0008","quote":"\"the immaturity of the data in the sense that it's not definitive.\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0009_n1","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Незрелые/недостаточно определённые данные могут делать событие «изолированным» и усложнять интерпретацию.","text_en":"Immature/non-definitive data can make an event seem isolated and complicate interpretation.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0009","quote":"\"this certainly seems to be more isolated an event because of the, let's call it the immaturity of the data in the sense that it's not definitive.\""}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0009_n2","doc_id":"doc_4e08bc14b958","kind":"pain","text_ru":"В медленно прогрессирующих заболеваниях с функциональными, сильно вариабельными конечными точками сравнение open-label с natural history может приводить к «overstatement» и проблемам интерпретации.","text_en":"In slowly progressive diseases with variable functional endpoints, open-label vs natural history comparisons can lead to overstatement and hard-to-interpret results.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0009","quote":"\"slowly progressive changing diseases with functional endpoints. Um, that are highly variable over time\""},{"chunk_id":"doc_4e08bc14b958_chunk_0009","quote":"\"natural history... compare our open label experience\""},{"chunk_id":"doc_4e08bc14b958_chunk_0009","quote":"\"you run into a lot of potential issues around you know certainly some level of overstatement\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0009_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Позитивные phase 3 данные могут подвергаться интенсивной публичной проверке (Twitter/инвесторы), включая разбор статистического анализа.","text_en":"Positive phase 3 data can face intense public scrutiny (Twitter/investors), including statistical analysis debates.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0009","quote":"\"positive phase three data. Now, even that data has been subject to very intense scrutiny on Twitter and amongst investors around the statistical analysis.\""}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0010_n1","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Позитивные Phase 3 данные по спорному механизму/применению вызывают интенсивную публичную и инвесторскую проверку, включая обсуждение статистического анализа в соцсетях.","text_en":"Positive Phase 3 data for a controversial mechanism/application is being intensely scrutinized publicly and by investors, including statistical analysis debates on social media.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0010","quote":"positive phase three data. Now, even that data has been subject to very intense scrutiny on Twitter and amongst investors around the statistical analysis."}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0010_n2","doc_id":"doc_4e08bc14b958","kind":"buyer_signal","text_ru":"Рынок резко отреагировал на позитивный датасет: акции выросли примерно на 400% за неделю.","text_en":"The market reacted sharply to the positive dataset: the stock rose about 400% in a week.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0010","quote":"The positive data set stocks up like 400% this week."}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0010_n3","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Неполное понимание механизма действия рассматривается как потенциальный барьер/фактор в регуляторном рассмотрении и оценке доказательности данных.","text_en":"Incomplete understanding of mechanism of action is discussed as a potential barrier/factor in regulatory review and evidentiary standards.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0010","quote":"Yeah, we don't understand the mechanism fully"}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0011_n1","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Если механизм терапии непонятен/в него не верят, регулятор может требовать более высокий порог доказательств и не быть готовым одобрять по предоставленному датасету без репликации в хорошо контролируемом клиническом исследовании.","text_en":"When a therapy’s mechanism is not understood/believed, regulators may set a higher data bar and be unwilling to approve based on the provided dataset without replication in a well-controlled trial.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0011","quote":"\"we don't necessarily understand how this works... We're not necessarily comfortable approving based on the data set that you provided.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0011","quote":"\"if you can replicate this... a well-controlled perspective— clinical trial, then yes, we will we will grant approval.\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0011_n2","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Нерегулярности/проблемы на сайтах в Phase 3 могут привести к исключению данных с «проблемных» сайтов, добору пациентов и переносу сроков чтения результатов.","text_en":"Phase 3 irregularities/site conduct issues can lead to excluding data from troubled sites, adding patients, and pushing out the readout timeline.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0011","quote":"\"with some irregularities... they elected to add more patients to the study.\""},{"chunk_id":"doc_4e08bc14b958_chunk_0011","quote":"\"They're going to exclude data from the troubled sites, and they did push out the readout until the end of next year\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0011_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Есть интерес и «excitation» вокруг расширения показаний (label expansion) для нового препарата, одобренного в шизофрении.","text_en":"There is interest and excitement around potential label expansion for a novel drug approved in schizophrenia.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0011","quote":"\"there is a fair degree of interest and excitement around the potential of expanding the label.\""}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0012_n1","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"В исследовании ADEPT2 независимая группа (DSMB/IDMC) рекомендовала увеличить выборку, чтобы исправить недостатки мощности; Bristol взаимодействовал с FDA по этому поводу.","text_en":"In ADEPT2, an independent group (DSMB/IDMC) recommended increasing sample size to address power deficiencies; Bristol engaged with the FDA about it.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0012","quote":"there was a group that, like a DSMB or IDMC... reviewed the data of ADEPT2 and recommended adding patients to it"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0012_n2","doc_id":"doc_4e08bc14b958","kind":"pain","text_ru":"В популяции ADP есть сложности с переносимостью/режимом приёма: трёхкратный приём в день, пищевой эффект и повышенная чувствительность к побочным эффектам психиатрических препаратов.","text_en":"In the ADP population, tolerability/adherence is challenging: three-times-daily dosing, a food effect, and higher sensitivity to psychiatric drug side effects.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0012","quote":"the dosing in ADP is three times a day. There's this food effect you have to navigate."},{"chunk_id":"doc_4e08bc14b958_chunk_0012","quote":"It's a population that is more sensitive to side effects, especially with psychiatry drugs."}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0012_n3","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Для Praxis по Ulexacaltamide есть регуляторный риск из‑за «нетрадиционного» хода программы (не остановили после рекомендации DMC о бесполезности), что может повлиять на готовность FDA рассматривать заявку.","text_en":"For Praxis’s Ulexacaltamide, there is regulatory risk due to a “non-traditional” program path (didn’t stop after DMC futility recommendation), potentially affecting FDA’s willingness to review.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0012","quote":"They were actually recommended to futility earlier. This year by a data monitoring committee."},{"chunk_id":"doc_4e08bc14b958_chunk_0012","quote":"the pushback has really been on this idea that... the FDA may not be open to reviewing this"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0013_n1","doc_id":"doc_4e08bc14b958","kind":"buyer_signal","text_ru":"Менеджмент сообщил о позитивной встрече с FDA и намерении подать заявку (file) в ближайшее время, ориентир — начало 2026.","text_en":"Management reported a positive FDA meeting and plans to file in the near term, targeting early 2026.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0013","quote":"they had a very positive, encouraging meeting with the FDA"},{"chunk_id":"doc_4e08bc14b958_chunk_0013","quote":"they're basically going to file in in the very near term time frame, early 2026"}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0013_n2","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Редко бывает, что у компании одновременно два разных NDA находятся на рассмотрении FDA по нейроиндикациям.","text_en":"It’s rare for a company to have two different NDAs under FDA review for neuro indications at the same time.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0013","quote":"It's pretty rare to have two totally different NDAs under review at the FDA for neuroindications."}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0013_n3","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Есть опасения/дебаты вокруг дизайна и данных исследования: высокая доля выбывших и риск «отбора респондеров» при 8-недельной конечной точке, что может создавать регуляторные риски.","text_en":"Concerns/debate about trial design/data: high dropout and potential “selecting for responders” with an 8-week endpoint, implying regulatory risk.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0013","quote":"a really substantial imbalance and dropouts between the drug and placebo"},{"chunk_id":"doc_4e08bc14b958_chunk_0013","quote":"you're basically selecting for responders because your dropout rate is so high"}],"confidence":"medium"}
{"nugget_id":"doc_4e08bc14b958_chunk_0014_n1","doc_id":"doc_4e08bc14b958","kind":"pain","text_ru":"Высокий dropout в клинических исследованиях может приводить к спору о том, что выбор endpoint (например, 8 недель) фактически «отбирает респондеров».","text_en":"High dropout in clinical trials can create debate that endpoint choice (e.g., 8 weeks) effectively selects for responders.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0014","quote":"\"an eight-week endpoint and you're basically selecting for responders because your dropout rate is so high\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0014_n2","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Из-за конкурентной динамики ожидается рост «селективного раскрытия» данных компаниями, что может оставлять инвесторов неудовлетворёнными датасетами.","text_en":"Competitive dynamics may drive more selective disclosure of data, leaving investors unsatisfied with datasets.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0014","quote":"\"prepared for more selective disclosure due to competitive dynamics\""},{"chunk_id":"doc_4e08bc14b958_chunk_0014","quote":"\"having to live with being unsatisfied with data sets\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0014_n3","doc_id":"doc_4e08bc14b958","kind":"constraint","text_ru":"Конкурентное давление (в т.ч. восприятие, что разработки в США будут быстро повторены/превзойдены Китаем) может усиливать потребность в секретности данных, продуктов, конструкций и даже патентов.","text_en":"Competitive pressure (incl. belief US work will be quickly matched/bested by China) may increase need for secrecy around data, products, constructs, and even patents.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0014","quote":"\"whatever is done in the U. S. will be matched or quickly even potentially bested by China-based biotech companies\""},{"chunk_id":"doc_4e08bc14b958_chunk_0014","quote":"\"a growing need for secrecy of data and products and constructs and even patents\""}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0015_n1","doc_id":"doc_4e08bc14b958","kind":"pain","text_ru":"Селективное раскрытие данных компаниями затрудняет инвесторам/аналитикам оценку качества датасета и принятие инвестиционных решений.","text_en":"Selective data disclosure makes it harder for investors/analysts to evaluate data quality and make investment decisions.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0015","quote":"Selective data disclosures that really don't give us a sense one way or the other, like how good the quality of the data are."}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0015_n2","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Непрозрачность (opacity) со стороны менеджмента обычно воспринимается инвесторами негативно и «дисконтируется».","text_en":"Management opacity is typically viewed negatively and discounted by investors.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0015","quote":"usually opacity is discounted as something that is negative."},{"chunk_id":"doc_4e08bc14b958_chunk_0015","quote":"opacity is not usually well received."}],"confidence":"high"}
{"nugget_id":"doc_4e08bc14b958_chunk_0015_n3","doc_id":"doc_4e08bc14b958","kind":"trend","text_ru":"Сохраняется тренд на «ультра-премиальное» ценообразование при запусках (пример: почти $400k/год), и тема высоких стартовых цен может снова стать центральной.","text_en":"Ultra-premium launch pricing persists (e.g., nearly $400k/year), and high launch prices may become a central topic again.","evidence":[{"chunk_id":"doc_4e08bc14b958_chunk_0015","quote":"Otsuka's voice act for IGA nephropathy, priced at nearly $400,000 a year."},{"chunk_id":"doc_4e08bc14b958_chunk_0015","quote":"ultra premium pricing for these rare and even some of the not so rare diseases continues."}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0000_n1","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"NDAA позиционирует biotech как национальный актив безопасности (наравне с AI/quantum и др.), что усиливает внимание государства к сектору.","text_en":"The NDAA frames biotech as a national security asset (alongside AI/quantum, etc.), increasing government focus on the sector.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0000","quote":"This is a clear statement that biotech is now moved into... fields, along with quantum hypersonics, AI... viewed as a national security asset."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0000_n2","doc_id":"doc_49833f89266a","kind":"opportunity","text_ru":"Ожидаются новые ресурсы/финансирование от DoD: создание нового biotech office и возможная программа субсидирования, похожая на SBIR/STTR, для проектов, релевантных целям DoD.","text_en":"New DoD resources/funding: a new biotech office and authorization to build an SBIR/STTR-like subsidization program for projects relevant to DoD goals.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0000","quote":"this bill is going to authorize the DOD to effectively build a similar program to subsidize things that are relevant to DOD goals."},{"chunk_id":"doc_49833f89266a_chunk_0000","quote":"the DOD is creating a new biotech office."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0000_n3","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Программа SBIR-STTR остаётся на паузе; в NDAA также есть элементы, которые могут восприниматься как ограничения (в т.ч. «watered-down version of the BioSecure Act»).","text_en":"SBIR-STTR remains paused; the NDAA also includes elements that may be seen as constraints (including a watered-down version of the BioSecure Act).","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0000","quote":"we all know that the SBIR-STTR program remains on pause."},{"chunk_id":"doc_49833f89266a_chunk_0000","quote":"Included in the bill is a watered-down version of the BioSecure Act."}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0001_n1","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"В версии законопроекта есть положения BioSecure Act: запрет федеральным агентствам покупать биотех-оборудование/услуги у «компаний, вызывающих обеспокоенность», и риск проблем при использовании таких компаний при получении федеральных денег (например, SBIR).","text_en":"BioSecure Act provisions would bar federal agencies from buying biotech equipment/services from “companies of concern,” and create issues for recipients of federal funds (e.g., SBIR) using listed companies.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0001","quote":"is going to prohibit federal agencies from buying biotech equipment or services from quote biotech companies of concern."},{"chunk_id":"doc_49833f89266a_chunk_0001","quote":"if you begin to take federal money, if you're taking SBIR money... And you're using companies that are on this list, that's going to be a problem."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0001_n2","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Появляются/существуют два списка, за которыми нужно следить: существующий «1260h list» (управляет DOIS) и новый более субъективный список из Белого дома через OMB; попадание в них усложнит ведение бизнеса/взаимодействие с федеральным финансированием.","text_en":"Two lists will matter: the existing “1260h list” managed by DOIS and a new, more subjective White House/OMB list; being listed makes doing business difficult.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0001","quote":"there are going to be two lists that everyone on this call has to pay attention to."},{"chunk_id":"doc_49833f89266a_chunk_0001","quote":"called the 1260h list. If a company shows up... it's going to be difficult to do business with them."},{"chunk_id":"doc_49833f89266a_chunk_0001","quote":"There's also going to be a new list that's a little more subjective, out of the White House, through their Office of Management and Budget."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0001_n3","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"В приоритетах финансирования DOD ожидаются фокусы на data management/защите биологических данных и на synthetic DNA/RNA.","text_en":"DOD funding priorities are expected to focus on data management/protection of biological data and on synthetic DNA/RNA.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0001","quote":"data management is gonna be a a big one."},{"chunk_id":"doc_49833f89266a_chunk_0001","quote":"I think synthetic DNA and RNA is going to be another area of focus."}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0002_n1","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"В законопроект встроен новый режим контроля outbound-инвестиций («reverse CFIUS»): пока покрывает AI/quantum/hypersonics, но biotech может быть добавлен позже, что создаёт риск требований уведомления/разрешения для инвестиций за пределами США.","text_en":"A new outbound investment regime (“reverse CFIUS”) is being implemented; biotech isn’t covered yet but could be added later, potentially requiring notification/permission for overseas investments.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0002","quote":"there is a new outbound investment regime built into this bill. And I want to be super clear: biotech as of right now is not covered."},{"chunk_id":"doc_49833f89266a_chunk_0002","quote":"The White House can add things to this list over time."},{"chunk_id":"doc_49833f89266a_chunk_0002","quote":"You might have to notify the government of your investment and at times ask for their permission."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0002_n2","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Программа SBIR/STTR заблокирована из‑за спора о допуске компаний с иностранным финансированием и «SBIR mills»; сейчас не видят пути быстро «включить» программу обратно.","text_en":"SBIR/STTR is stalled due to disputes over foreign-funded companies and “SBIR mills,” with no clear path to restart the program soon.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0002","quote":"We have a logjam over whether or not foreign funding, foreign-funded companies should be allowed to accept SBIR"},{"chunk_id":"doc_49833f89266a_chunk_0002","quote":"We do not see a path forward right now for turning the program back on."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0002_n3","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"По NIH: существенных сокращений не ожидают; бюджет остаётся «40+ млрд», но приоритеты и процесс принятия решений о финансировании находятся в переходном периоде.","text_en":"NIH is expected to remain funded at “40+ billion,” but funding priorities and decision-making are in transition.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0002","quote":"it's important to dispel the notion that NIH is facing substantial cuts."},{"chunk_id":"doc_49833f89266a_chunk_0002","quote":"We expect NIH to remain well funded to the tune of 40 plus billion dollars."},{"chunk_id":"doc_49833f89266a_chunk_0002","quote":"the priorities... and who gets to say what gets funded—certainly— is in a process of transition."}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"Наблюдаются признаки улучшения рынка: рост follow-on финансирований и повышение оценок/market cap у биотехов, но IPO-окно пока не открылось.","text_en":"Market shows improving signs: stronger follow-on financings and rising valuations/market caps, but the IPO window still hasn’t opened.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0003","quote":"follow-ons are really important. We've seen valuations start to pick up with more biotechs, uh, having more than a billion market cap."},{"chunk_id":"doc_49833f89266a_chunk_0003","quote":"The one area that we have not seen—uh, you know— yet is really the IPO window, really opening up."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"Финансирования и интерес инвесторов в биотехе связывают с «хорошими/сильными данными» и «понятным использованием средств», что воспринимается как более низкий риск.","text_en":"Biotech financings/investor interest are attributed to strong data and clear use of proceeds, seen as a lower-risk profile.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0003","quote":"most of these, like you said, Grace, are on the back of good data, right?"},{"chunk_id":"doc_49833f89266a_chunk_0003","quote":"on the back of strong data, like you know, a clear use of proceeds, right?"},{"chunk_id":"doc_49833f89266a_chunk_0003","quote":"an opportunity for more people to invest in something that has, like, a lower risk profile"}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"IPO-рынок остаётся ограниченным: даже при хорошем рынке осенью IPO было мало, и есть сомнения, сколько компаний сможет выйти на IPO.","text_en":"IPO market remains constrained: even in a strong fall market there were few IPOs, and there’s uncertainty about how many companies can IPO.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0003","quote":"it's been a great market this fall and there's been what two or three"},{"chunk_id":"doc_49833f89266a_chunk_0003","quote":"still, very, very different than opening an IPO window"}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0004_n1","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"Профиль клинической зрелости компаний, за которыми следит спикер, сместился к более поздним стадиям (фаза 2–3) по сравнению с 2020 годом, когда даже принятие IND считалось крупным событием.","text_en":"The clinical maturity profile of companies the speaker follows has shifted to later stages (Phase 2–3) versus 2020 when IND acceptance was treated as a major value event.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0004","quote":"\"the profile of that list is. Like more of a phase two, even sometimes phase three, profile than it's ever been\""},{"chunk_id":"doc_49833f89266a_chunk_0004","quote":"\"I compare that to you know, 2020, right when companies were putting in 'ind' acceptance as like a major value-creating event\""}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0004_n2","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Спикер сомневается, что на рынке есть порядка 50 mid-to-late stage компаний, способных выйти на IPO; 50 кажется завышенным числом.","text_en":"The speaker doubts there are ~50 mid-to-late stage companies that can IPO; 50 seems high.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0004","quote":"\"I don't know if there's 50 of those.\""},{"chunk_id":"doc_49833f89266a_chunk_0004","quote":"\"I feel like 50 is a high number for companies that are mid to late stage.\""}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0004_n3","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"На ASH ожидали менее насыщенную повестку, но в итоге было много данных, причём «really great data» и это выглядело обнадёживающе.","text_en":"ASH was expected to be less busy, but ended up having lots of data, including “really great” and encouraging results.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0004","quote":"\"for an Ash that was supposed to be not that busy, we all got slimed.\""},{"chunk_id":"doc_49833f89266a_chunk_0004","quote":"\"There was a lot of really great data too which was actually really encouraging.\""}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_nugget_0001","doc_id":"doc_49833f89266a","kind":"pain","text_ru":"У ведущего BCMA CAR-T (J&J/Legend) есть заметная токсичность, включая нейротоксичность/паркинсонизм, случаи энтероколита и необходимость госпитализации.","text_en":"Leading BCMA CAR-T (J&J/Legend) shows notable toxicity (neurotoxicity/parkinsonism, enterocolitis) and requires hospitalization.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0005","quote":"they do have some noticeable toxicity, and it causes low rates of Parkinsonism, let's say kind of 1% to 3% Parkinsonisms and neurotoxin."},{"chunk_id":"doc_49833f89266a_chunk_0005","quote":"The deaths have really gone down. They know how to manage it now, but it does require hospitalization."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_nugget_0002","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Ожидаемая 4L-метка для более безопасного конкурента (Gilead) ограничит использование в более ранних линиях: будет сложно применять off-label из‑за отсутствия данных и покрытия.","text_en":"A safer competitor’s expected 4L label constrains earlier-line use: off-label use will be very hard due to lack of data and coverage.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0005","quote":"It's really going to have a fourth line label and that's the issue."},{"chunk_id":"doc_49833f89266a_chunk_0005","quote":"It's going to be very hard to, if not extremely, extremely hard to use it off-label because there's no data, there's not going to be coverage."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_nugget_0003","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"У J&J/Legend по BCMA CAR-T есть ограничения по производственной мощности, которые, по словам спикера, должны закончиться в начале следующего года; продукт быстро растёт.","text_en":"J&J/Legend BCMA CAR-T is growing rapidly but faces capacity constraints expected to end early next year.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0005","quote":"Growing extremely rapidly, and had a huge benefit in second line, but their capacity constraints and that capacity constraints are going to end come early next year."}],"confidence":"medium"}
{"nugget_id":"n1","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"В CAR-T обсуждение смещается в сторону всё более быстрого производства, но спикер считает, что ключевая проблема — логистика «vein-to-vein», а не само производство.","text_en":"CAR-T discussions focus on faster manufacturing, but the speaker argues the real issue is vein-to-vein logistics, not manufacturing itself.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0006","quote":"everybody is now talking about faster and faster manufacturing."},{"chunk_id":"doc_49833f89266a_chunk_0006","quote":"manufacturing is not the issue. It's actually getting the product from vein to vein."}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_49833f89266a","kind":"opportunity","text_ru":"Возможность для решений, сокращающих/упрощающих путь «vein-to-vein» (доставка/координация), поскольку это названо узким местом.","text_en":"Opportunity for solutions that reduce/simplify vein-to-vein time (delivery/coordination), since it’s identified as the bottleneck.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0006","quote":"manufacturing is not the issue. It's actually getting the product from vein to vein."},{"chunk_id":"doc_49833f89266a_chunk_0006","quote":"about four weeks vein-to-vein or five weeks vein-to-vein."}],"confidence":"medium"}
{"nugget_id":"n3","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Ограничение интерпретации данных CAR-T: даже при «сильной эффективности» в малых исследованиях сложно понять длительность ответа.","text_en":"Constraint in interpreting CAR-T data: even with strong efficacy in small trials, duration of response is hard to assess.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0006","quote":"These are small trials, right?"},{"chunk_id":"doc_49833f89266a_chunk_0006","quote":"What you don't get is what the duration is."}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_49833f89266a","kind":"pain","text_ru":"ASCT (аутологичная трансплантация стволовых клеток) воспринимается как нежелательная/непопулярная процедура, и обсуждается возможность её вытеснения новыми терапиями.","text_en":"ASCT is viewed as an undesirable procedure, and there is discussion about new therapies potentially displacing it.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0007","quote":"\"Potentially displacing ASCT, which is Ptolemaic Stem Cell Transplantation that nobody really likes.\""}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_49833f89266a","kind":"opportunity","text_ru":"In vivo BCMA CAR-T описывается как подход без необходимости лейкафереза и кондиционирования, что может упростить лечение.","text_en":"In vivo BCMA CAR-T is described as requiring no leukapheresis or conditioning, potentially simplifying treatment.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0007","quote":"\"It's an in vivo BCMA CAR T. Early data, but so it's in vivo. There's no need for leukophoresis, no need for conditioning.\""}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Для in vivo CAR-T остаются вопросы по долговечности эффекта и настороженность из‑за того, что это по сути генная терапия; требуется больше данных на большем числе пациентов.","text_en":"For in vivo CAR-T, durability is unknown and there is caution because it is essentially gene therapy; more patient data is needed.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0007","quote":"\"you essentially have a gene therapy here. So everyone's going to just worry a little bit\""},{"chunk_id":"doc_49833f89266a_chunk_0007","quote":"\"durability is the key here, right? We don't know what the durability of these in vivo cartes are like.\""}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0008_n1","doc_id":"doc_49833f89266a","kind":"pain","text_ru":"Ранние смерти из‑за инфекций на фоне терапии, связанной с хроническим «выбиванием» B‑клеток; часть смертей была от COVID.","text_en":"Early infection-related deaths on therapy linked to chronic B-cell depletion; some deaths were from COVID.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0008","quote":"\"an early number of patients, not a lot, but a few patients died because of the infection\""},{"chunk_id":"doc_49833f89266a_chunk_0008","quote":"\"Because you're essentially chronically um getting rid of your B cells\""},{"chunk_id":"doc_49833f89266a_chunk_0008","quote":"\"A lot of the patients died of COVID.\""}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0008_n2","doc_id":"doc_49833f89266a","kind":"opportunity","text_ru":"Управление инфекционной токсичностью через IVIG (в т.ч. доступный sub-Q) рассматривается как способ снизить риск и поддержать применение терапии.","text_en":"Managing infection toxicity with IVIG (including available sub-Q) is viewed as a way to mitigate risk and support therapy use.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0008","quote":"\"IVIG wasn't necessarily part of it\""},{"chunk_id":"doc_49833f89266a_chunk_0008","quote":"\"with decent IVIG, which is now sub-QT, available as well, you should be able to manage this toxicity.\""}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0008_n3","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"После биспецифической терапии вероятность хорошего ответа на последующую CAR-T ниже из‑за «истощённых» T‑клеток, если нет большого перерыва между линиями.","text_en":"After bispecific therapy, probability of good response to subsequent CAR-T is lower due to exhausted T cells unless there is a long break.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0008","quote":"\"if you're treated by specific therapy, your probability of responding well to a CAR T afterwards is lower\""},{"chunk_id":"doc_49833f89266a_chunk_0008","quote":"\"because you end up with pretty much exhausted T cells\""}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0009_n1","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"Тренд: лечение движется в сторону меньшего использования химиотерапии (\"chemo is really going away\").","text_en":"Trend: treatment is moving toward less chemotherapy use (\"chemo is really going away\").","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0009","quote":"the innovation now is absolutely amazing and increasingly less and less chemo. I mean, chemo is really going away"}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0009_n2","doc_id":"doc_49833f89266a","kind":"opportunity","text_ru":"Возможность: перевод терапии в амбулаторный формат без необходимости первоначальной госпитализации.","text_en":"Opportunity: shifting therapy to outpatient use with no need for initial hospitalization.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0009","quote":"especially if they could move the whole thing to be outpatient and with no need for initial hospitalization"}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0009_n3","doc_id":"doc_49833f89266a","kind":"buyer_signal","text_ru":"Сигнал спроса/готовности финансировать: компания искала $400, но закрыла раунд на $650.","text_en":"Buyer signal: the company sought $400 but closed at $650.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0009","quote":"They went out looking for 400, and they closed that at 650."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0010_n1","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"В фазе 3 по CTLA-4 (BioNTech) возник частичный clinical hold от FDA, предположительно из‑за токсичности в non-squamous; программу по non-squamous решили не продвигать дальше и продолжить только в меньшей squamous популяции.","text_en":"In BioNTech’s phase 3 CTLA-4 program, there was a partial FDA clinical hold (likely toxicity in non-squamous); they agreed not to advance non-squamous and continued only in smaller squamous.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0010","quote":"They actually got into clinical hold, partial hold with FDA because we think there's probably some tox in the non-squamous"},{"chunk_id":"doc_49833f89266a_chunk_0010","quote":"With FDA, they agreed not to advance that forward further and just went with the smaller squamous."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0010_n2","doc_id":"doc_49833f89266a","kind":"pain","text_ru":"CTLA-4 имеет эффективность, но сопровождается высокой токсичностью; даже у «более мягкой» версии ожидается компромисс в виде большей токсичности.","text_en":"CTLA-4 shows efficacy but has high toxicity; even a “gentler” version is expected to come with a toxicity trade-off.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0010","quote":"CTLA-4 does have efficacy, but it's got a lot of tox."},{"chunk_id":"doc_49833f89266a_chunk_0010","quote":"you expect there is going to be a price to pay on more talk. So we are seeing more talks"}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0010_n3","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"B7-H3 как мишень для ADC даёт обнадёживающую активность в китайской когорте non-squamous NSCLC, при этом ответы в squamous и онкогенных когортах слабее.","text_en":"B7-H3 ADC shows encouraging activity in Chinese non-squamous NSCLC, while responses in squamous and oncogenic cohorts are more muted.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0010","quote":"Encouraging activity in the Chinese non-squamous, non-small cell lung cancer patients"},{"chunk_id":"doc_49833f89266a_chunk_0010","quote":"responses in the squamous and oncogenic cohorts were a bit muted"}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0011_n1","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Сложно делать кросс-триальные сравнения из‑за ранних датасетов и малого числа пациентов; особенно трудно без China-only когорты из‑за отличий биологии.","text_en":"Cross-trial comparisons are difficult due to early datasets and small patient numbers; especially hard without a China-only cohort because biology differs.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0011","quote":"\"So it's complicated and there's a lot of comparisons to be made, early data sets, small patient numbers.\""},{"chunk_id":"doc_49833f89266a_chunk_0011","quote":"\"It's even harder to do cross-trial comparisons here unless you have a China-only cohort.\""}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0011_n2","doc_id":"doc_49833f89266a","kind":"opportunity","text_ru":"Есть «возможность» в non-squamous setting, несмотря на более «приглушённые» ответы в squamous и oncogenic когортах.","text_en":"There is an opportunity in the non-squamous setting despite muted responses in squamous and oncogenic cohorts.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0011","quote":"\"responses in the squamous and oncogenic cohorts were a bit muted\""},{"chunk_id":"doc_49833f89266a_chunk_0011","quote":"\"we still have an opportunity in non-squamous.\""}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0011_n3","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"В non-muscle invasive bladder cancer формируется конкурентная ситуация: уже одобрен продукт J&J, и данные CG выглядят сопоставимыми по эффективности, с потенциально лучшим профилем побочек; выбор врачей между разными модальностями станет ключевым.","text_en":"In NMIBC, competition is emerging: J&J already has an approved product, and CG shows similar efficacy with possibly better side effects; physician choice between modalities will be key.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0011","quote":"\"non-muscle invasive bladder cancer where Johnson & Johnson's in Lexo. is already approved.\""},{"chunk_id":"doc_49833f89266a_chunk_0011","quote":"\"Similar efficacy from what we can see.\""},{"chunk_id":"doc_49833f89266a_chunk_0011","quote":"\"So what's going to be interesting is how physicians will decide between these two.\""}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0012_n1","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Инвесторы и индустрия сомневаются в статистической надёжности/робастности данных по DMD exon skippers из‑за малых выборок и ограниченной «robustness of the statistics».","text_en":"Investors/industry question statistical robustness of DMD exon-skipper data due to small sample sizes and limited statistical robustness.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0012","quote":"questions I was getting from investors were really just around the statistics and these comparisons in small sample sizes"},{"chunk_id":"doc_49833f89266a_chunk_0012","quote":"we just don't have the real robustness of the statistics"}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0012_n2","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Есть неопределённость/путаница у инвесторов относительно регуляторной позиции FDA в редких заболеваниях, что влияет на восприятие вероятности одобрения.","text_en":"Investors are confused about FDA’s regulatory stance in rare disease, affecting perceived approval likelihood.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0012","quote":"investors, I think, being a little bit confused around philosophically, what exactly does this FDA stand for from a regulatory perspective in rare disease"}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0012_n3","doc_id":"doc_49833f89266a","kind":"pain","text_ru":"Фрустрация из‑за отсутствия сильного клинического датасета, коррелирующего с биомаркером (дистрофином) в DMD, несмотря на прохождение биомаркерного «бара».","text_en":"Frustration that strong clinical datasets correlated to the dystrophin biomarker are lacking in DMD despite clearing the biomarker bar.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0012","quote":"I still struggle with the fact that we have not seen a strong clinical data set that is correlated to the biomarker"}],"confidence":"high"}
{"nugget_id":"n1","doc_id":"doc_49833f89266a","kind":"pain","text_ru":"Недостаточная статистическая надёжность данных по DMD из‑за ограничений по размеру выборки и эффекту.","text_en":"Lack of statistical robustness in DMD data due to sample size and effect size limitations.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0013","quote":"we just don't have the real robustness of the statistics."},{"chunk_id":"doc_49833f89266a_chunk_0013","quote":"Part of that is sample size, but part of it's effect size"}],"confidence":"high"}
{"nugget_id":"n2","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Неопределённость регуляторных критериев FDA: инвесторы считают, что «этот FDA» сложно прогнозировать/ставить на него.","text_en":"Uncertainty around FDA criteria; investors view this FDA as hard to bet on.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0013","quote":"are we going to see different criteria coming out of this new FDA that would throw everybody off?"},{"chunk_id":"doc_49833f89266a_chunk_0013","quote":"there's investors who throw their hands up and say this FDA is unbettable."}],"confidence":"high"}
{"nugget_id":"n3","doc_id":"doc_49833f89266a","kind":"buyer_signal","text_ru":"Сигнал спроса/готовности платить за obesity/GLP-1 активы: сделка Pfizer–Fosun по фазе 1 с $150M upfront и до $1.94B milestones.","text_en":"Buyer signal for obesity/GLP-1 assets: Pfizer–Fosun Phase 1 deal with $150M upfront and up to $1.94B milestones.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0013","quote":"Pfizer-Fosun deal for a phase one asset worth up to billion in deal value with $150 million up front."},{"chunk_id":"doc_49833f89266a_chunk_0013","quote":"$150 million upfront, and up to $1. 94 billion milestones"}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0014_n1","doc_id":"doc_49833f89266a","kind":"pain","text_ru":"У GLP-1 препаратов есть воспринимаемый недостаток: возможное негативное влияние на мышечную массу и физическую работоспособность, несмотря на пользу по жиру/исходам.","text_en":"Perceived issue with GLP-1 drugs: possible negative effects on muscle and exercise capacity despite benefits on outcomes/body fat.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0014","quote":"one of the issues people have with the glyph drugs is that... maybe a negative effect on muscle and just kind of exercise capacity"}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0014_n2","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Ранние данные по программе Wave вызывают вопросы о регуляторном пути и воспроизводимости, а также отмечаются малые выборки и «wonkiness» с плацебо.","text_en":"Early Wave data raises questions about regulatory path and replicability; small sample sizes and placebo 'wonkiness' noted.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0014","quote":"these are small sample sizes. Right? Like, also, there's certain i think wonkiness with placebo as well."},{"chunk_id":"doc_49833f89266a_chunk_0014","quote":"what is the actual regulatory path here? And, you know, is this early data set ultimately replicable?"}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0014_n3","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"В ожирении наблюдается постоянный поток новостей/данных и «massive» пайплайн.","text_en":"Obesity has a constant flow of news/data and a 'massive' pipeline.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0014","quote":"No day goes by that obesity doesn't have some news or something."},{"chunk_id":"doc_49833f89266a_chunk_0014","quote":"how it fits with the with the in the current massive uh obesity pipeline"}],"confidence":"medium"}
{"nugget_id":"doc_49833f89266a_chunk_0015_n1","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"По опросу/индексу настроений инвесторы наиболее «бычьи», затем биотех-профессионалы, а академики — самые пессимистичные из‑за сокращений NIH; в целом настроение улучшается и «движется в правильном направлении».","text_en":"Sentiment survey/index: investors are most bullish, then biotech professionals; academics are least bullish due to NIH cuts; overall sentiment is improving.","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0015","quote":"the investors are the most bullish, then followed by biotech professionals... And lastly, academics, obviously, because of the NIH cuts."},{"chunk_id":"doc_49833f89266a_chunk_0015","quote":"But overall, it's moving in the right direction"}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0015_n2","doc_id":"doc_49833f89266a","kind":"trend","text_ru":"Ожидания по биотеху на следующий год у участников панели находятся в диапазоне примерно 7–8 из 10 (7.5, 8, 7).","text_en":"Panelists’ optimism for biotech next year clusters around ~7–8/10 (7.5, 8, 7).","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0015","quote":"Seven and a half."},{"chunk_id":"doc_49833f89266a_chunk_0015","quote":"I'm going to go with eight."},{"chunk_id":"doc_49833f89266a_chunk_0015","quote":"I'm going to go with 7."}],"confidence":"high"}
{"nugget_id":"doc_49833f89266a_chunk_0015_n3","doc_id":"doc_49833f89266a","kind":"constraint","text_ru":"Сокращения NIH негативно влияют на настроения академического сегмента (академики — наименее оптимистичны).","text_en":"NIH cuts are a negative factor for academic sentiment (academics are least optimistic).","evidence":[{"chunk_id":"doc_49833f89266a_chunk_0015","quote":"academics, obviously, because of the NIH cuts."}],"confidence":"medium"}
